=== МЕТАДАННЫЕ ===
{
  "original_filename": "ehae179.pdf",
  "converted_date": "2026-01-31T14:50:23.694295",
  "file_size_bytes": 22966245,
  "original_format": "pdf",
  "document_type": "Guidelines",
  "source_folder": "Guidelines",
  "full_path": "00_RAW_CARDIOLOGY/Guidelines/ehae179.pdf"
}

=== СОДЕРЖАНИЕ ===

--- Страница 1 ---
ESC GUIDELINES
European Heart Journal (2024) 45, 3538–3700
https://doi.org/10.1093/eurheartj/ehae179
2024 ESC Guidelines for the management
of peripheral arterial and aortic diseases
Developed by the task force on the management of peripheral arterial
and aortic diseases of the European Society of Cardiology (ESC)
Endorsed by the European Association for Cardio-Thoracic Surgery
(EACTS), the European Reference Network on Rare Multisystemic
Vascular Diseases (VASCERN), and the European Society of Vascular
Medicine (ESVM)
Authors/Task Force Members: Lucia Mazzolai *†, (Chairperson) (Switzerland),
Gisela Teixido-Tura ‡, (Task Force Co-ordinator) (Spain), Stefano Lanzi ‡,
(Task Force Co-ordinator) (Switzerland), Vinko Boc (Slovenia),
Eduardo Bossone (Italy), Marianne Brodmann 1 (Austria),
Alessandra Bura-Rivière (France), Julie De Backer 2 (Belgium),
Sebastien Deglise (Switzerland), Alessandro Della Corte (Italy),
Christian Heiss (United Kingdom), Marta Kałużna-Oleksy (Poland),
Donata Kurpas (Poland), Carmel M. McEniery (United Kingdom),
Tristan Mirault (France), Agnes A. Pasquet (Belgium), Alex Pitcher
(United Kingdom), Hannah A.I. Schaubroeck (Belgium), Oliver Schlager
(Austria), Per Anton Sirnes (Norway), Muriel G. Sprynger (Belgium),
Eugenio Stabile (Italy), Françoise Steinbach (France), Matthias Thielmann
(Germany), Roland R.J. van Kimmenade (Netherlands), Maarit Venermo
(Finland), Jose F. Rodriguez-Palomares *†, (Chairperson) (Spain),
and ESC Scientific Document Group
* Corresponding authors: Lucia Mazzolai, Department of Angiology, Lausanne University Hospital (CHUV), and Medical School, Lausanne University (UNIL) Lausanne, Switzerland. Tel: +41
(0)21 314 0750. Email: Lucia.Mazzolai@chuv.ch; and Jose F. Rodriguez-Palomares, Cardiovascular Imaging Section and Aortic Diseases Unit (VASCERN), Department of Cardiology, Vall
d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Centro de Investigación Biomédica en Red de
Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain, and Department of Medicine, Universitat Autònoma de Barcelona, Spain. Tel: +34 93 882 3881. Email:
josefernando.rodriguez@vallhebron.cat
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing the European Society of Vascular Medicine (ESVM)
2 Representing the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN)
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension.
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Surgery, Thrombosis.
Patient Forum
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 2 ---
ESC Guidelines 3539
Document Reviewers: Alessia Gimelli, (CPG Review Co-ordinator) (Italy), Jean-Baptiste Ricco, (CPG Review
Co-ordinator) (France), Elena Arbelo (Spain), Christian-Alexander Behrendt (Germany), Michael Böhm
(Germany), Michael A. Borger (Germany), Margarita Brida (Croatia), Sergio Buccheri (Sweden),
Gill Louise Buchanan (United Kingdom), Christina Christersson (Sweden), Gert J. de Borst (Netherlands),
Marco De Carlo (Italy), Roman Gottardi (Austria), Lydia Hanna (United Kingdom), Lynne Hinterbuchner (Austria),
Borja Ibanez (Spain), Ignatios Ikonomidis (Greece), Stefan James (Sweden), Thomas Kahan (Sweden),
Klaus Kallenbach2 (Luxemburg), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Juraj Madaric1
(Slovakia), Blandine Maurel (France), John William McEvoy (Ireland), Gil Meltzer (Israel), Borislava Mihaylova
(United Kingdom), Richard Mindham (United Kingdom), Ioana Mozos (Romania), Jens Cosedis Nielsen (Denmark),
Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Barbara Rantner (Germany), Bianca Rocca (Italy),
Xavier Rossello (Spain), Jean Paul Schmid (Switzerland), Daniel Staub (Switzerland), Sabine Steiner (Germany),
Isabella Sudano (Switzerland), Martin Teraa (Netherlands), Ilonca Vaartjes (Netherlands), Rafael Vidal-Perez (Spain),
Christiaan Vrints (Belgium), and Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest which
are reported in a supplementary document to the guidelines. See the European Heart Journal online or
https://www.escardio.org/Guidelinesfor supplementary documents as well as evidence tables
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and
medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction,
discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant
public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged
to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated
recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s
responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC
warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational
use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written
permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of
the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
------------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Guidelines • Acute aortic syndrome • Aortic aneurysm • Aortic atherosclerosis • Aortic dissection • Aortic surgery
• Carotid artery disease • Chronic limb-threatening ischaemia • Endovascular repair • Exercise • Genetic aortic
diseases • Intramural haematoma • Lower extremity artery disease • Penetrating atherosclerotic ulcer • Peripheral
arterial disease • Polyvascular disease • Renal artery disease
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 3 ---
3540 E S C G u id e l in e s
Table of contents 8.1.1.1. Clinical presentation and diagnosis................................. 3574
8.1.1.1.1. Diagnostic tests .............................................................. 3575
1. Preamble.............................................................................................................. 3547 8.1.1.1.2. Imaging methods............................................................ 3576
2. Introduction ....................................................................................................... 3548 8.1.1.2. Medical treatment.................................................................. 3578
3. What is new....................................................................................................... 3550 8.1.1.2.1. Exercise therapy ............................................................ 3578
4. Epidemiology and risk factors..................................................................... 3558 8.1.1.2.2. Pharmacological treatment ....................................... 3582
4.1. Epidemiology............................................................................................ 3558 8.1.1.2.3. Aorto-iliac lesion revascularization........................ 3583
4.2. Risk factors................................................................................................ 3559 8.1.1.2.4. Femoro-popliteal lesion revascularization .......... 3584
5. Evaluation of peripheral arteries and aorta.......................................... 3560 8.1.1.2.5. Below-the-knee artery revascularization ........... 3584
5.1. Clinical history and examination, and laboratory assessment, 8.1.1.3. Follow-up................................................................................... 3585
in patients with peripheral arterial and aortic diseases.................. 3560 8.1.2. Chronic limb-threatening ischaemia....................................... 3585
5.2. Functional and quality of life assessment in patients with 8.1.2.1. Clinical presentation and diagnosis................................. 3585
peripheral arterial and aortic diseases ................................................... 3560 8.1.2.1.1. Definition .......................................................................... 3585
5.3. Vascular examination of peripheral arteries............................... 3561 8.1.2.1.2. Initial assessment and risk of amputation ........... 3585
5.3.1. Duplex ultrasound ......................................................................... 3562 8.1.2.1.3. Imaging ............................................................................... 3585
5.3.2. Digital subtraction angiography, computed tomography 8.1.2.1.4. Mortality risk assessment........................................... 3585
angiography, and magnetic resonance angiography ..................... 3562 8.1.2.2. Medical treatment.................................................................. 3586
5.4. Evaluation of the aorta......................................................................... 3562 8.1.2.3. Interventional treatment..................................................... 3586
5.4.1. Aortic measurements ................................................................... 3562 8.1.2.3.1. Revascularization............................................................ 3586
5.4.2. Normal aortic values..................................................................... 3565 8.1.2.3.2. Spinal cord stimulation................................................ 3587
5.4.3. Chest X-ray and electrocardiogram....................................... 3565 8.1.2.3.3. Amputation...................................................................... 3587
5.4.4. Echocardiography ........................................................................... 3565 8.1.2.4. Follow-up................................................................................... 3587
5.4.5. Duplex ultrasound imaging of the abdominal aorta........ 3566 8.1.3. Acute limb ischaemia .................................................................... 3587
5.4.6. Cardiovascular computed tomography ................................ 3566 8.1.3.1. Clinical presentation and diagnosis................................. 3587
5.4.7. Cardiovascular magnetic resonance ....................................... 3566 8.1.3.1.1. Clinical examination ..................................................... 3588
5.4.8. Positron emission tomography................................................. 3566 8.1.3.1.2. Imaging and functional tests...................................... 3588
5.4.9. Intravascular ultrasound............................................................... 3567 8.1.3.2. Medical treatment.................................................................. 3588
5.4.10. Digital subtraction aortography............................................. 3567 8.1.3.3. Surgical and interventional treatment........................... 3588
6. Screening for carotid, peripheral arterial, and aortic diseases ..... 3567 8.1.3.4. Follow-up................................................................................... 3590
6.1. Screening for carotid and peripheral arterial diseases ........... 3567 8.2. Extracranial carotid and vertebral artery disease..................... 3590
6.1.1. Lower-extremity peripheral arterial disease....................... 3567 8.2.1. Clinical presentation and diagnosis ......................................... 3590
6.1.2. Carotid artery stenosis ................................................................ 3567 8.2.1.1. Clinical presentation ............................................................. 3590
6.1.3. Multisite artery disease................................................................. 3567 8.2.1.2. Diagnosis.................................................................................... 3590
6.2. Screening for aortic diseases............................................................. 3568 8.2.2. Asymptomatic carotid artery stenosis .................................. 3591
6.2.1. Screening for abdominal aortic aneurysm ........................... 3568 8.2.2.1. Medical treatment.................................................................. 3591
6.2.2. Screening for thoracic aortic aneurysm................................ 3568 8.2.2.1.1. Lipid-lowering therapy ................................................ 3591
7. Optimal medical treatment ......................................................................... 3568 8.2.2.1.2. Antihypertensive therapy........................................... 3591
7.1. Lifestyle, exercise, patient education ............................................. 3568 8.2.2.1.3. Glucose-lowering therapy ......................................... 3591
7.1.1. Diet....................................................................................................... 3568 8.2.2.1.4. Antithrombotic therapy ............................................. 3591
7.1.2. Physical activity ................................................................................ 3569 8.2.2.2. Interventional treatment..................................................... 3592
7.1.3. Smoking............................................................................................... 3570 8.2.2.2.1. Open surgery vs. medical therapy ......................... 3592
7.1.4. Patient education............................................................................ 3570 8.2.2.2.2. Carotid revascularization: surgery vs. stenting . 3592
7.1.5. Risk scoring models in secondary prevention.................... 3570 8.2.3. Symptomatic carotid artery stenosis ..................................... 3594
7.2. Principles of pharmacological medical therapy.......................... 3571 8.2.3.1. Medical treatment.................................................................. 3594
7.2.1. Antithrombotic therapy............................................................... 3571 8.2.3.1.1. Lipid-lowering therapy ................................................ 3594
7.2.2. Antihypertensive therapy............................................................ 3571 8.2.3.1.2. Antihypertensive therapy........................................... 3594
7.2.2.1. Renovascular hypertension................................................ 3571 8.2.3.1.3. Glucose-lowering therapy ......................................... 3594
7.2.3. Lipid-lowering therapy ................................................................. 3572 8.2.3.1.4. Antithrombotic therapy ............................................. 3594
7.2.3.1. Statins.......................................................................................... 3572 8.2.3.2. Interventional treatment..................................................... 3595
7.2.3.2. Ezetimibe ................................................................................... 3572 8.2.3.2.1. Open surgery .................................................................. 3595
7.2.3.3. Proprotein convertase subtilisin/kexin type 9 8.2.3.2.2. Endovascular therapy vs. open surgery................ 3595
inhibitors.................................................................................................... 3572 8.2.3.2.3. Vertebral arteries .......................................................... 3595
7.2.3.4. Bempedoic acid....................................................................... 3572 8.2.3.3. Follow-up................................................................................... 3596
7.2.3.5. Hypertriglyceridaemia .......................................................... 3572 8.3. Other arterial locations....................................................................... 3596
7.2.4. Diabetes and pre-diabetes conditions................................... 3573 8.3.1. Subclavian artery disease............................................................. 3596
7.2.5. Other pharmacological therapy ............................................... 3574 8.3.1.1. Clinical presentation and diagnosis................................. 3596
8. Peripheral arterial disease ............................................................................ 3574 8.3.1.2. Treatment strategy (medical and interventional)..... 3597
8.1. Lower-extremity peripheral arterial disease .............................. 3574 8.3.1.3. Follow-up................................................................................... 3597
8.1.1. Peripheral arterial disease syndromes ................................... 3574 8.3.2. Renal artery disease....................................................................... 3598
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 4 ---
ESC Guidelines 3541
8.3.2.1. Clinical presentation and diagnosis................................. 3598 9.2.7.1. Follow-up after thoracic aortic aneurysm treatment 3617
8.3.2.1.1. Epidemiology ................................................................... 3598 9.2.7.2. Follow-up after abdominal aortic aneurysm
8.3.2.1.2. Clinical presentation..................................................... 3598 treatment................................................................................................... 3617
8.3.2.1.3. Diagnosis of renal artery disease............................ 3598 9.3. Acute thoracic aortic syndromes.................................................... 3618
8.3.2.1.4. Prognosis........................................................................... 3598 9.3.1. General concepts............................................................................ 3618
8.3.2.2. Treatment strategy (medical and interventional)..... 3598 9.3.1.1. Epidemiology and risk factors........................................... 3618
8.3.2.2.1. Medical therapy.............................................................. 3598 9.3.1.1.1. Sex differences................................................................ 3620
8.3.2.2.2. Revascularization............................................................ 3598 9.3.1.1.2. Chronobiology................................................................ 3621
8.3.2.3. Follow-up................................................................................... 3600 9.3.1.1.3. Outcomes......................................................................... 3621
8.3.3. Visceral artery disease .................................................................. 3600 9.3.1.2. Clinical presentation ............................................................. 3622
8.3.3.1. Acute mesenteric ischaemia.............................................. 3600 9.3.1.3. Diagnostic work-up............................................................... 3622
8.3.3.1.1. Clinical presentation and diagnosis........................ 3600 9.3.1.4. Therapeutic intervention in acute aortic dissection 3622
8.3.3.1.2. Treatment strategy....................................................... 3600 9.3.1.4.1. Initial treatment.............................................................. 3622
8.3.3.1.3. Follow-up.......................................................................... 3601 9.3.1.4.2. Type A aortic dissection interventional
8.3.3.2. Chronic mesenteric artery disease................................. 3601 treatment.............................................................................................. 3623
8.3.3.2.1. Clinical presentation and diagnosis........................ 3601 9.3.1.4.3. Acute type B aortic dissection interventional
8.3.3.2.2. Treatment strategy....................................................... 3602 treatment.............................................................................................. 3628
8.3.3.2.3. Follow-up.......................................................................... 3602 9.3.1.4.4. Chronic type B aortic dissection interventional
9. Aorta ..................................................................................................................... 3602 treatment.............................................................................................. 3629
9.1. Atheromatous disease of the aorta ............................................... 3602 9.3.1.4.5. Management during pregnancy................................ 3629
9.1.1. General concepts............................................................................ 3602 9.3.2. Intramural haematoma................................................................. 3630
9.1.2. Treatment.......................................................................................... 3602 9.3.2.1. Diagnostic work-up............................................................... 3630
9.1.2.1. Primary prevention................................................................ 3602 9.3.2.2. Clinical outcomes................................................................... 3630
9.1.2.2. Secondary prevention .......................................................... 3602 9.3.2.3. Geographical variations ....................................................... 3630
9.2. Aortic aneurysms ................................................................................... 3603 9.3.2.4. Management............................................................................. 3630
9.2.1. General concepts............................................................................ 3603 9.3.2.4.1. Type A intramural haematoma ............................... 3630
9.2.1.1. Definitions................................................................................. 3603 9.3.2.4.2. Type B intramural haematoma................................ 3630
9.2.2. Thoracic aortic aneurysms ......................................................... 3603 9.3.3. Penetrating atherosclerotic ulcer ............................................ 3631
9.2.2.1. Aetiology, risk factors, and natural history ................. 3603 9.3.3.1. Diagnosis.................................................................................... 3631
9.2.2.2. Ascending thoracic aorta and arch aneurysms ......... 3603 9.3.3.2. Treatment ................................................................................. 3631
9.2.2.3. Descending thoracic aorta and thoracoabdominal 9.3.4. Aortic pseudo-aneurysm............................................................. 3632
aorta aneurysms ..................................................................................... 3604 9.3.5. Traumatic aortic injury................................................................. 3633
9.2.2.4. Surveillance ............................................................................... 3607 9.3.5.1. Diagnosis and therapeutic interventions...................... 3633
9.2.3. Abdominal aortic aneurysms..................................................... 3607 9.3.5.2. Long-term surveillance in traumatic aortic injury .... 3633
9.2.3.1. General concepts................................................................... 3607 9.3.6. Iatrogenic aortic injuries .............................................................. 3633
9.2.3.2. Aetiology, risk factors, and natural history ................. 3607 9.3.7. Long-term follow-up of acute aortic syndrome ............... 3633
9.2.3.3. Surveillance ............................................................................... 3607 9.3.7.1. Follow-up after invasive treatment ................................ 3634
9.2.4. Optimal medical treatment of aortic aneurysms.............. 3609 9.3.7.2. Follow-up under medical treatment (chronic type B
9.2.5. Surgical management of aortic aneurysms .......................... 3609 aortic dissection, intramural haematoma, penetrating
9.2.5.1. Surgical treatment of aortic root and ascending atherosclerotic ulcer)........................................................................... 3636
aorta ............................................................................................................ 3609 10. Genetic and congenital diseases of the aorta ................................... 3637
9.2.5.2. Surgical treatment of aortic arch aneurysms............. 3611 10.1. Genetic and chromosomal diseases ............................................ 3637
9.2.5.3. Surgical treatment of the thoracic descending aorta 3612 10.1.1. Turner syndrome......................................................................... 3638
9.2.5.3.1. General considerations ............................................... 3612 10.1.1.1. Diagnosis, clinical presentation, and natural history 3638
9.2.5.3.2. Open repair ..................................................................... 3612 10.1.1.2. Medical treatment............................................................... 3640
9.2.5.3.3. Endovascular repair ...................................................... 3612 10.1.1.3. Surgery of aortic aneurysms........................................... 3640
9.2.5.4. Surgical treatment of thoracoabdominal aorta 10.1.1.4. Pregnancy and physical exercise ................................... 3640
aneurysms ................................................................................................. 3612 10.1.2. Vascular Ehlers–Danlos syndrome ....................................... 3641
9.2.5.4.1. General considerations ............................................... 3612 10.1.2.1. Diagnosis, clinical presentation, and natural history 3641
9.2.5.4.2. Open repair ..................................................................... 3612 10.1.2.2. Surveillance and imaging ................................................... 3641
9.2.5.4.3. Endovascular repair ...................................................... 3612 10.1.2.3. Medical treatment............................................................... 3641
9.2.5.5. Surgical treatment of abdominal aorta aneurysms.. 3613 10.1.2.4. Surgical treatment............................................................... 3641
9.2.5.5.1. General considerations ............................................... 3613 10.1.2.5. Pregnancy................................................................................ 3641
9.2.5.5.2. Pre-operative cardiovascular evaluation and 10.1.3. Marfan syndrome......................................................................... 3641
choice of treatment ......................................................................... 3613 10.1.3.1. Diagnosis, clinical presentation, and natural history 3641
9.2.5.5.3. Open abdominal aorta aneurysm repair............. 3615 10.1.3.2. Imaging surveillance ............................................................ 3641
9.2.5.5.4. Endovascular abdominal aorta aneurysm repair 3615 10.1.3.3. Medical treatment............................................................... 3642
9.2.6. Endoleaks ........................................................................................... 3615 10.1.3.4. Aortic surgery....................................................................... 3642
9.2.7. Long-term follow-up after aortic repair............................... 3617 10.1.3.5. Pregnancy and physical exercise ................................... 3643
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 5 ---
3542 E S C G u id e l in e s
10.1.4. Other syndromic and non-syndromic heritable thoracic Recommendation Table 7 — Recommendations for lifestyle,
aortic diseases and/or arterial disorders........................................... 3643 physical activity, and patient education (see also Evidence Table 4) 3570
10.1.4.1. Loeys–Dietz syndrome..................................................... 3643 Recommendation Table 8 — Recommendations for
10.1.4.1.1. Diagnosis, clinical presentation, and natural antihypertensive therapy in patients with peripheral and aortic
evolution............................................................................................... 3643 disease........................................................................................................................ 3571
10.1.4.2. ACTA2-related heritable thoracic aortic disease .... 3645 Recommendation Table 9 — Recommendations for lipid-lowering
10.2. Aortic disease associated with bicuspid aortic valves.......... 3646 therapy in patients with peripheral arterial and aortic diseases....... 3572
Recommendation Table 10 — Recommendations for the medical
10.3. Coarctation of the aorta and aortic arch variants ................ 3648
management of patients with peripheral arterial and aortic diseases
10.3.1. Coarctation of the aorta........................................................... 3648
and diabetes ............................................................................................................ 3573
10.3.1.1. Diagnostic work-up............................................................ 3648
Recommendation Table 11 — Recommendations for diagnostic
10.3.1.2. Treatment and follow-up................................................. 3648
tests in patients with peripheral arterial disease and diabetes, renal
10.3.2. Aortic arch anatomic variants ................................................ 3650
failure, and wounds .............................................................................................. 3577
10.3.3. Aberrant subclavian artery and Kommerell’s
Recommendation Table 12 — Recommendations for imaging in
diverticulum................................................................................................... 3650
patients with peripheral arterial disease ..................................................... 3577
11. Polyvascular peripheral arterial disease and peripheral arterial
Recommendation Table 13 — Recommendations for exercise
disease in patients with cardiac diseases..................................................... 3650
therapy in patients with peripheral arterial disease (see also Evidence
11.1. Polyvascular disease............................................................................ 3650
Table 5) ..................................................................................................................... 3582
11.1.1. Epidemiology and prognosis.................................................... 3650 Recommendation Table 14 — Recommendations for
11.1.2. Screening for atherosclerosis in other arterial antithrombotic therapy in patients with peripheral arterial disease
territories ....................................................................................................... 3650 (see also Evidence Table 6) .............................................................................. 3582
11.1.2.1. Screening for coronary artery disease in patients Recommendation Table 15 — Recommendations for interventional
with symptomatic peripheral arterial disease............................ 3651 treatment of asymptomatic and symptomatic peripheral arterial
11.1.2.2. Screening for peripheral arterial disease in patients disease (general) .................................................................................................... 3584
with coronary artery disease............................................................ 3651 Recommendation Table 16 — Recommendations for interventional
11.1.2.3. Screening for coronary artery disease in patients treatment of patients with symptomatic peripheral arterial disease
with carotid stenosis ............................................................................ 3651 (per arterial bed)................................................................................................... 3585
11.1.2.4. Screening for carotid stenosis in patients with Recommendation Table 17 — Recommendations in patients with
coronary artery disease....................................................................... 3651 peripheral arterial disease: follow-up of patients with peripheral
11.1.3. Management of patients with polyvascular disease....... 3651 arterial disease........................................................................................................ 3585
11.2. Peripheral arterial disease and heart failure............................. 3651 Recommendation Table 18 — Recommendations for the
management of chronic limb-threatening ischaemia ............................. 3586
11.3. Peripheral arterial disease and AF................................................ 3652
Recommendation Table 19 — Recommendations for medical
11.4. Peripheral arterial disease and aortic stenosis ........................ 3652
treatment in patients with chronic limb-threatening ischaemia (see
12. Key messages .................................................................................................. 3652
also Evidence Table 7) ........................................................................................ 3586
13. Gaps in evidence............................................................................................ 3653
Recommendation Table 20 — Recommendations for interventional
14. Sex differences ............................................................................................... 3653
treatment of chronic limb-threatening ischaemia................................... 3587
15. ‘What to do’ and ‘What not to do’ messages from the
Recommendation Table 21 — Recommendations for follow-up in
guidelines .................................................................................................................. 3653
patients with chronic limb-threatening ischaemia .................................. 3587
16. Evidence tables ............................................................................................... 3661
Recommendation Table 22 — Recommendations for the
17. Data availability statement......................................................................... 3661
management of patients presenting with acute limb ischaemia (see
18. Author information...................................................................................... 3661
also Evidence Table 8) ........................................................................................ 3590
19. Appendix........................................................................................................... 3662
Recommendation Table 23 — Recommendations for carotid artery
20. References........................................................................................................ 3663 stenosis assessment ............................................................................................. 3590
Recommendation Table 24 — Recommendations for
Tables of Recommendations antithrombotic treatment in patients with carotid stenosis .............. 3592
Recommendation Table 25 — Recommendations for interventional
Recommendation Table 1 — Recommendations for clinical and treatment in patients with asymptomatic carotid artery stenosis... 3594
laboratory, and for functional and quality of life, assessment in patients Recommendation Table 26 — Recommendations for evaluation and
with peripheral arterial and aortic disease (see also Evidence Table 1) 3560 medical treatment in patients with symptomatic carotid artery
Recommendation Table 2 — Recommendations for diagnostic tests stenosis...................................................................................................................... 3594
in patients with peripheral arterial disease ................................................ 3562 Recommendation Table 27 — Recommendations for interventions
Recommendation Table 3 — Recommendations for imaging of the in patients with symptomatic carotid artery stenosis........................... 3596
aorta (see also Evidence Table 2).................................................................. 3565 Recommendation Table 28 — Recommendations for follow-up in
Recommendation Table 4 — Recommendations for thoracic aortic patients with carotid artery stenosis............................................................ 3596
measurements........................................................................................................ 3566 Recommendation Table 29 — Recommendations for the
Recommendation Table 5 — Recommendations for peripheral management of subclavian artery stenosis (see also Evidence
arterial disease screening (see also Evidence Table 3).......................... 3568 Table 9) ..................................................................................................................... 3597
Recommendation Table 6 — Recommendations for abdominal Recommendation Table 30 — Recommendations for diagnostic
aortic aneurysm screening ................................................................................ 3568 strategies for renal artery disease.................................................................. 3600
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 6 ---
ESC Guidelines 3543
Recommendation Table 31 — Recommendations for treatment Recommendation Table 57 — Recommendations for imaging in
strategies for renal artery disease (see also Evidence Table 10)...... 3600 women with Turner syndrome ...................................................................... 3638
Recommendation Table 32 — Recommendations in patients with Recommendation Table 58 — Recommendations for aortic surgery
visceral artery stenosis........................................................................................ 3602 in women with Turner syndrome................................................................. 3640
Recommendation Table 33 — Recommendations for primary and Recommendation Table 59 — Recommendations for medical
secondary prevention in aortic atheromatous plaques........................ 3602 treatment in patients with vascular Ehlers–Danlos syndrome (see
Recommendation Table 34 — Recommendations for initial also Evidence Table 13)...................................................................................... 3641
evaluation of thoracic aortic aneurysm and abdominal aortic Recommendation Table 60 — Recommendations for vascular
aneurysm .................................................................................................................. 3603 imaging in Marfan syndrome ............................................................................ 3642
Recommendation Table 35 — Recommendation for the surveillance Recommendation Table 61 — Recommendations for medical
of patients with thoracic aortic aneurysms (non-heritable thoracic treatment in Marfan syndrome (see also Evidence Table 14)........... 3642
aortic disease)......................................................................................................... 3607 Recommendation Table 62 — Recommendations for aortic surgery
Recommendation Table 36 — Recommendations for surveillance of in Marfan syndrome............................................................................................. 3642
patients with abdominal aortic aneurysm .................................................. 3609 Recommendation Table 63 — Recommendations for pregnancy in
Recommendation Table 37 — Recommendations for medical women with Marfan syndrome ...................................................................... 3643
treatment in patients with thoracic aorta or abdominal aortic Recommendation Table 64 — Recommendations for physical
aneurysms ................................................................................................................ 3609 exercise in patients with Marfan syndrome .............................................. 3643
Recommendation Table 38 — Recommendations for surgery in Recommendation Table 65 — Recommendations for imaging
aortic root and ascending aorta dilatation associated with tricuspid follow-up in Loeys–Dietz syndrome ............................................................ 3644
aortic valve (see also Evidence Table 11)................................................... 3611 Recommendation Table 66 — Recommendations for aortic root
Recommendation Table 39 — Recommendations for surgery in surgery in Loeys–Dietz syndrome................................................................. 3644
aortic arch aneurysms......................................................................................... 3611 Recommendation Table 67 — Recommendations for imaging and
Recommendation Table 40 — Recommendations for the surgery in ACTA2-related heritable thoracic aortic disease (see also
management of patients presenting with descending thoracic aortic Evidence Table 11)............................................................................................... 3645
and thoracoabdominal aortic aneurysms ................................................... 3613 Recommendation Table 68 — Recommendations for bicuspid aortic
Recommendation Table 41 — Recommendations for the valve-associated aortopathy management........................................................ 3647
management of patients presenting with abdominal aortic Recommendation Table 69 — Recommendations for evaluation and
aneurysm .................................................................................................................. 3615 medical treatment of patients with coarctation of the aorta............ 3648
Recommendation Table 42 — Recommendations for the Recommendation Table 70 — Recommendations for screening and
management of patients presenting with endoleaks ............................. 3617 management of polyvascular disease and peripheral arterial disease
Recommendation Table 43 — Recommendations for follow-up with cardiac diseases (see also Evidence Table 15) ............................... 3652
after treatment of aortic aneurysms (see also Evidence Table 12) 3618
Recommendation Table 44 — Recommendations for diagnostic
List of tables
work-up of acute aortic syndromes............................................................. 3622
Recommendation Table 45 — Recommendation for medical
Table 1 Classes of recommendations.......................................................... 3547
treatment in acute aortic syndromes........................................................... 3623
Table 2 Levels of evidence................................................................................ 3548
Recommendation Table 46 — Recommendations for intervention
Table 3 New recommendations .................................................................... 3550
in type A acute aortic dissection.................................................................... 3624
Table 4 Revised recommendations............................................................... 3555
Recommendation Table 47 — Recommendations for aortic repair
Table 5 Main aortic imaging techniques...................................................... 3564
strategies in type A acute aortic dissection............................................... 3624
Table 6 High-risk populations for carotid artery stenosis .................. 3567
Recommendation Table 48 — Recommendations for the
Table 7 Peripheral arterial disease categorized according to clinical
management of malperfusion in the setting of acute aortic presentation ............................................................................................................ 3574
dissection.................................................................................................................. 3628 Table 8 Assessment of the risk of amputation: the Wound,
Recommendation Table 49 — Recommendations for the
Ischaemia, and foot Infection classification ................................................ 3577
management of patients presenting with acute type B aortic
Table 9 Clinical categories of acute limb ischaemia............................... 3588
dissection.................................................................................................................. 3629
Table 10 Peak systolic velocity criteria for grading internal carotid
Recommendation Table 50 — Recommendations for the
artery stenosis........................................................................................................ 3591
management of patients presenting with chronic type B aortic
Table 11 High-risk features associated with increased risk of stroke
dissection.................................................................................................................. 3629
in patients with asymptomatic internal carotid artery stenosis on
Recommendation Table 51 — Recommendations for the
optimal medical treatment................................................................................ 3592
management of intramural haematoma...................................................... 3631
Table 12 High-risk peri-operative features for carotid
Recommendation Table 52 — Recommendations for the
endarterectomy..................................................................................................... 3595
management of penetrating atherosclerotic ulcer ................................. 3631
Table 13 Clinical signs suggestive of renal artery disease.................... 3598
Recommendation Table 53 — Recommendations for traumatic
Table 14 Grading of atherosclerotic aortic plaques .............................. 3603
aortic injury.............................................................................................................. 3633
Table 15 Overview of factors favouring open vs. endovascular repair
Recommendation Table 54 — Recommendations for follow-up
in thoracoabdominal aortic aneurysm......................................................... 3613
after treatment of acute aortic syndrome................................................. 3637
Table 16 High-risk features of intramural haematoma type A and B 3630
Recommendation Table 55 — Recommendations for the
Table 17 Need for assessment of associated atherosclerotic disease in
management of patients with heritable thoracic aortic disease ....... 3637
additional vascular territories in symptomatic patients with coronary
Recommendation Table 56 — Recommendations for genetic testing
artery disease, peripheral arterial disease, or carotid stenosis............... 3651
and aortic screening in aortic disease .......................................................... 3638
Table 18 ‘What to do’ and ‘What not to do’ .......................................... 3654
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 7 ---
3544 E S C G u id e l in e s
List of figures Figure 32 Complications in acute aortic syndromes, clinical evidence
associated with malperfusion syndrome, and in-hospital mortality
Figure 1 Central illustration: from diagnosis to treatment, a holistic associated with these complications ............................................................ 3625
multidisciplinary peripheral arterial and aortic diseases approach .. 3549 Figure 33 Interventional treatment algorithm in acute aortic
Figure 2 Estimated specific prevalence of peripheral arterial disease, dissection.................................................................................................................. 3626
by sex, in people aged 40 years and older................................................. 3558 Figure 34 Mechanisms and clinical management of aortic branch
Figure 3 Main risk factors associated with atherosclerosis in obstruction in acute aortic dissection.......................................................... 3627
peripheral arterial and aortic diseases ......................................................... 3559 Figure 35 High-risk features in penetrating atherosclerotic ulcer and
Figure 4 Haemodynamic assessment of peripheral arterial disease 3561 management of patients with type B penetrating atherosclerotic
Figure 5 Anatomy and aortic segments and upper normal values for ulcer............................................................................................................................ 3632
aortic dimensions.................................................................................................. 3563 Figure 36 Classification and treatment of traumatic aortic injuries 3634
Figure 6 Conventional measurements of the aorta at different Figure 37 Aetiology, risk factors, and classification of iatrogenic
levels by echocardiography or duplex ultrasound (A, B, C), aortic injuries .......................................................................................................... 3635
cardiovascular computed tomography or cardiovascular magnetic Figure 38 Algorithm for follow-up after acute aortic syndrome ..... 3636
resonance (D, E, F) ......................................................................................... 3564 Figure 39 Algorithm for genetic and imaging screening in patients
Figure 7 Cardiovascular risk modification and healthy lifestyle with thoracic aortic disease.............................................................................. 3639
interventions and targets in patients with peripheral arterial and Figure 40 Algorithm for surveillance in women (≥15 years) with
aortic diseases ........................................................................................................ 3569 Turner syndrome.................................................................................................. 3640
Figure 8 Cardiovascular risk in patients with peripheral arterial disease 3575 Figure 41 Algorithm for imaging surveillance in patients with
Figure 9 Diagnostic algorithm for peripheral arterial disease............ 3576 syndromic and non-syndromic heritable thoracic aortic disease..... 3644
Figure 10 Optimal medical treatment in patients with peripheral Figure 42 Suggested thresholds for prophylactic aortic root/
arterial disease........................................................................................................ 3578 ascending replacement in Loeys–Dietz syndrome ................................. 3645
Figure 11 Treatment algorithm in peripheral arterial disease without Figure 43 Bicuspid aortic valve, valvulo-aortopathy nomenclature. 3646
wounds................................................................................................................................ 3579 Figure 44 Criteria for significant coarctation/re-coarctation of the
Figure 12 Treatment algorithm in peripheral arterial disease with aorta and management algorithm.................................................................. 3649
wounds...................................................................................................................... 3580 Figure 45 Reported rate ranges of other localizations of
Figure 13 Exercise training characteristics and benefits in patients atherosclerosis in patients with a specific arterial disease.................. 3650
with peripheral arterial disease....................................................................... 3581
Figure 14 Long-term antithrombotic therapy in patients with
symptomatic peripheral arterial disease.......................................................... 3583 Abbreviations and acronyms
Figure 15 Patients with chronic symptomatic PAD after
endovascular revascularization........................................................................ 3584 18F–NaF Fluorine-18–sodium fluoride
Figure 16 Management of acute limb ischaemia...................................... 3589 6MWD Six-minute walking distance
Figure 17 North American Symptomatic Carotid Endarterectomy 6MWT Six-minute walk test
Trial/European Carotid Surgery Trial methods....................................... 3591 AA Abdominal aorta
Figure 18 Algorithm of carotid artery stenosis management............ 3593 AAA Abdominal aortic aneurysm
Figure 19 Diagnostic and treatment algorithm for renal artery AAD Acute aortic dissection
stenosis...................................................................................................................... 3599 AAE Aortic adverse events
Figure 20 Algorithm of chronic mesenteric ischaemia management 3601 AAL Ascending aortic length
Figure 21 Thoracic and abdominal aortic aneurysms: aetiology, AAS Acute aortic syndrome
screening and diagnostic methods................................................................. 3604 ABI Ankle–brachial index
Figure 22 Classification of thoracoabdominal and abdominal aortic ACAS Asymptomatic Carotid Atherosclerosis Study
aneurysms ................................................................................................................ 3605 ACB Asymptomatic Cervical Bruit Study
Figure 23 Risk factors for thoracic and abdominal aneurysm rupture 3606 ACC/AHA American College of Cardiology and American
Figure 24 Surveillance of patients with non-heritable thoracic Heart Association
aortic disease and abdominal aortic aneurysms ...................................... 3608 ACEI Angiotensin-converting enzyme inhibitor
Figure 25 Peri-operative algorithm for the management of patients ACS Acute coronary syndrome
with surgically treated aortic root and ascending aortic aneurysm 3610 ACST Asymptomatic Carotid Surgery Trial
Figure 26 Algorithm for individual decision-making process in the ACTA2 Alpha-actin gene
treatment of patients with abdominal aortic aneurysm ...................... 3614 AD Aortic dissection
Figure 27 Algorithm for follow-up after thoracic endovascular aortic ADAM American Aneurysm Detection and Management
aneurysm repair, and management of endoleaks and their classification 3616 ADD-RS Aortic dissection detection-risk score
Figure 28 Anatomical and temporal classification of acute aortic AF Atrial fibrillation
syndrome.................................................................................................................. 3619 AHI Aortic height index
Figure 29 Aortic dissection classification system based on the 2020 ALI Acute limb ischaemia
Society for Vascular Surgery/Society of Thoracic Surgeons AMI Acute mesenteric ischaemia
Reporting Standards and the European update of the Stanford AP Antero-posterior
classification—Type Entry Malperfusion classification.......................... 3620 ARB Angiotensin receptor blocker
Figure 30 Multiparametric diagnostic work-up of acute aortic ARR Absolute risk reduction
syndrome.................................................................................................................. 3621 ASCVD Atherosclerotic cardiovascular disease
Figure 31 Medical management of acute aortic syndrome................. 3623 ASE American Society of Echocardiography
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 8 ---
ESC Guidelines 3545
ASI Aortic size index DTA Descending thoracic aorta
BASIL Bypass versus Angioplasty in Severe Ischaemia of DUS Duplex ultrasound
the Leg trial DWI Diffusion-weighted imaging
BAV Bicuspid aortic valve ECG Electrocardiogram
BB Beta-blocker ECST European Carotid Surgery Trial
BEST-CLI Best Endovascular versus Best Surgical Therapy for eGFR Estimated glomerular filtration rate
Patients with Critical Limb Ischemia trial EMPA-REG (Empagliflozin) Cardiovascular Outcome Event
b.i.d. Bis in die (twice daily) OUTCOME Trial in Type 2 Diabetes Mellitus Patients
BMI Body mass index ESC European Society of Cardiology
BP Blood pressure ESH European Society of Hypertension
b.p.m. Beats per minute ESRD End-stage renal disease
BSA Body surface area EUCLID Examining Use of tiCagreLor In peripheral artery
BTK Below-the-knee Disease
CABG Coronary artery bypass grafting FDA (United States) Food and Drug Administration
CAD Coronary artery disease FDG Fluorodeoxyglucose
CANTOS Canakinumab Anti-Inflammatory Thrombosis FDR First-degree relative
Outcomes Study FET Frozen elephant trunk
CANVAS Canagliflozin Cardiovascular Assessment Study FID Focal intimal disruption
CAS Carotid artery stenting FL False lumen
CCA Common carotid artery GERAADA German Registry of Acute Aortic Dissection Type
CCB Calcium channel blocker A
CCT Cardiovascular computed tomography GFR Glomerular filtration rate
CDT Catheter-based thrombectomy GLP-1RA Glucagon-like peptide-1 receptor agonist
cdTLR Clinically driven target lesion revascularization GSV Great saphenous vein
CEA Carotid endarterectomy HADS Hospital anxiety and depression score
CEUS Contrast-enhanced ultrasound HbA1c Glycated haemoglobin
CHA DS -VASc Congestive heart failure, hypertension, age ≥75 HBET Home-based exercise training
2 2
(doubled), diabetes, stroke (doubled), vascular HF Heart failure
disease, age 65 to 74 and sex category (female) HITS High-intensity transient signal
CI Confidence interval HOME Hyperinsulinaemia: the Outcomes of its Metabolic
cIMT Carotid intima media thickness Effects
CK Creatinine kinase HR Hazard ratio
CKD Chronic kidney disease HRQoL Health-related quality of life
CLTI Chronic limb-threatening ischaemia hs-CRP High-sensitivity C-reactive protein
CMI Chronic mesenteric ischaemia HSR High surgical risk
CMR Cardiovascular magnetic resonance HTAD Heritable thoracic aortic disease
CoA Coarctation of the aorta IC Intermittent claudication
COMPASS Cardiovascular Outcomes for People Using ICA Internal carotid artery
Anticoagulation Strategies ID Intimal disruption
COPD Chronic obstructive pulmonary disease IL Interleukin
CP Carotid plaque ILT Intensive lipid-lowering therapy
CREDENCE Canagliflozin and Renal Events in Diabetes with IMA Inferior mesenteric artery
Established Nephropathy Clinical Evaluation IMH Intramural haematoma
CREST-2 Carotid Revascularization Endartectomy vs. IMPROVE-AD The Improving outcomes in vascular disease—
Stenting Trial 2 aortic dissection trial
CRP C-reactive protein IMPROVE-IT IMProved Reduction of Outcomes: Vytorin
CS Carotid artery stenosis Efficacy International Trial
CSA/h Cross-sectional area-to-height ratio IPE Icosapent ethyl
CT Computed tomography IRAD International Registry of Acute Aortic Dissection
CTA Computed tomography angiography ISTH International Society on Thrombosis and
CV Cardiovascular Haemostasis
CVD Cardiovascular disease i.v. Intravenous
CVRF Cardiovascular risk factor IVUS Intravascular ultrasound
DAPT Dual antiplatelet therapy LDL-C Low-density lipoprotein cholesterol
DBP Diastolic blood pressure LEADER Liraglutide Effect and Action in Diabetes:
DD D-dimer Evaluation of Cardiovascular Outcome Results
DISSECT Duration, Intimal tear, Size, Segmental Extent, trial
Clinical complications, Thrombosis LSA Left subclavian artery
DPI Dual pathway inhibition LV Left ventricular
DSA Digital subtraction angiography MACE Major adverse cardiac event
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 9 ---
3546 E S C G u id e l in e s
MAD Multisite artery disease SCORE2 Systematic Coronary Risk Evaluation 2
MALE Major adverse limb event SCORE2-Diabetes Systematic Coronary Risk Evaluation 2 - diabetes
MAP Mean arterial pressure SCORE2-OP Systematic Coronary Risk Evaluation 2–Older
MESA Multi-Ethnic Study of Atherosclerosis Persons
MFS Marfan syndrome SPACE-2 Stent Protected Angioplasty versus Carotid
MHV Mechanical heart valve Endarterectomy study
MI Myocardial infarction SPPB Short physical performance battery
MRA Magnetic resonance angiography SRUCC Society of Radiologists in Ultrasound
MRI Magnetic resonance imaging SS Subclavian stenosis
MWD Maximal walking distance SSFP Steady-state free precession
NASCET North American Symptomatic Carotid STJ Sinotubular junction
Endarterectomy Trial STS/AATS Society of Thoracic Surgeons/American
OAC Oral anticoagulation Association for Thoracic Surgery
o.d. Once daily SUSTAIN-6 Trial to Evaluate Cardiovascular and Other
OMT Optimal medical treatment Long-term Outcomes with Semaglutide in
OR Odds ratio Subjects with Type 2 Diabetes
PAAD Peripheral arterial and aortic diseases SVS Society for Vascular Surgery
PA Popliteal aneurysm T1DM Type 1 diabetes mellitus
PAD Peripheral arterial disease T2DM Type 2 diabetes mellitus
PAU Penetrating atherosclerotic ulcer TAA Thoracic aortic aneurysm
PC-AKI Post-contrast acute kidney injury TAAA Thoracoabdominal aortic aneurysm
PCSK9 Proprotein convertase subtilisin/kexin type 9 TAAD Type A aortic dissection
PET Positron emission tomography TAD Thoracic aortic disease
PET-CT PET-computed tomography TAI Traumatic aortic injury
PFWD Pain-free walking distance TAV Tricuspid aortic valve
PROM Patient-reported outcome measure TAVI Transcatheter aortic valve implantation
PSV Peak systolic velocity TBAD Type B aortic dissection
PSVr Peak systolic velocity ratio TBI Toe–brachial index
PVD Polyvascular disease TCAR Transcarotid artery revascularization
QoL Quality of life TcPO Transcutaneous oxygen pressure
2
RAR Renal-aortic peak flow velocity ratio TOE Transoesophageal echocardiography
RAS Renal artery stenosis TEM Type entry malperfusion classification
RCT Randomized controlled trial TEVAR/EVAR Thoracic endovascular aortic aneurysm
REACH The REduction of Atherothrombosis for repair
Continued Health TFCAS Transfemoral carotid artery stenting
REDUCE-IT Reduction of Cardiovascular Events With THALES Acute Stroke or Transient Ischaemic Attack
Icosapent Ethyl–Intervention Trial Treated with Ticagrelor and acetylsalicylic acid for
ROMS Retrograde open mesenteric stenting Prevention of Stroke and Death trial
ROPAC Registry Of Pregnancy And Cardiac disease TIA Transient ischaemic attack
RPE Rate of perceived exertion TIMI Thrombolysis in myocardial infarction
RR Relative risk TP Toe pressure
SAMMPRIS Stenting and Aggressive Medical Management for TS Turner syndrome
Preventing Recurrent Stroke in Intracranial TTE Transthoracic echocardiography
Stenosis trial UEAD Upper-limb artery disease
SAPPHIRE Stenting and Angioplasty with Protection in UKPDS United Kingdom Prospective Diabetes Study:
Patients at High Risk for Endarterectomy trial clinical and therapeutic implications for type 2
SAPT Single antiplatelet therapy diabetes
SBP Systolic blood pressure uTBAD Uncomplicated type B aortic dissection
SCI Spinal cord ischaemia VascuQoL Vascular quality of life questionnaire
SCS Spinal cord stimulation VAST Vertebral Artery Stenting Trial
SET Supervised exercise training vEDS Vascular Ehlers–Danlos syndrome
SF-36 Short-form 36-item health questionnaire VIST Vertebral Artery Ischaemia Stenting Trial
SGLT2i Sodium-glucose co-transporter-2 inhibitor VKA Vitamin K antagonist
SMA Superior mesenteric artery WELCH Walking Estimated Limitation Calculated by
SMART Secondary Manifestation of ARTerial disease History
SOCRATES Acute Stroke or Transient Ischaemic Attack WIfI Wound, Ischaemia, foot Infection classification
Treated with Aspirin or Ticagrelor and Patient WIQ Walking Impairment Questionnaire
Outcomes trial
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 10 ---
ESC Guidelines 3547
1. Preamble The task force performed a critical review and evaluation of the pub-
lished literature on diagnostic and therapeutic approaches including as-
Guidelines evaluate and summarize available evidence with the aim of as- sessment of the risk–benefit ratio. The strength of every
sisting health professionals in proposing the best diagnostic or therapeutic recommendation and the level of evidence supporting them were
approach for an individual patient with a given condition. Guidelines are weighed and scored according to pre-defined scales as outlined in
intended for use by health professionals and the European Society of Tables 1and 2below. Patient-reported outcome measures (PROMs)
Cardiology (ESC) makes its guidelines freely available. and patient-reported experience measures (PREMs) were also evalu-
ESC Guidelines do not override the individual responsibility of health ated as the basis for recommendations and/or discussion in these
professionals to make appropriate and accurate decisions in consider- guidelines. The task force followed ESC voting procedures and all ap-
ation of each patient’s health condition and in consultation with that pa- proved recommendations were subject to a vote and achieved at least
tient or the patient’s caregiver where appropriate and/or necessary. It is 75% agreement among voting members. Members of the task force
also the health professional’s responsibility to verify the rules and reg- with declared interests on specific topics were asked to abstain from
ulations applicable in each country to drugs and devices at the time of voting on related recommendations.
prescription and to respect the ethical rules of their profession. The experts of the writing and reviewing panels provided declaration
ESC Guidelines represent the official position of the ESC on a given of interest forms for all relationships that might be perceived as real or
topic and are regularly updated when warranted by new evidence. ESC potential sources of conflicts of interest. Their declarations of interest
Policies and Procedures for formulating and issuing ESC Guidelines can were reviewed according to the ESC declaration of interest rules which
be found on the ESC website (https://www.escardio.org/Guidelines/ can be found on the ESC website (http://www.escardio.org/guidelines)
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC- and have been compiled in a report published in a supplementary docu-
Guidelines). This guideline updates and replaces the previous periph- ment with the guidelines. Funding for the development of ESC
eral arterial disease and aortic disease guidelines from 2017 and Guidelines is derived entirely from the ESC with no involvement of
2014, respectively. the healthcare industry.
The Members of this task force were selected by the ESC to include The ESC Clinical Practice Guidelines (CPG) Committee supervises
professionals involved with the medical care of patients with this path- and co-ordinates the preparation of new guidelines and is responsible
ology as well as patient representatives and methodologists. The selec- for the approval process. In addition to review by the CPG
tion procedure included an open call for authors and aimed to include Committee, ESC Guidelines undergo multiple rounds of double-blind
members from across the whole of the ESC region and from relevant peer review by external experts, including members from across the
ESC Subspecialty Communities. Consideration was given to diversity whole of the ESC region, all National Cardiac Societies of the ESC
and inclusion, notably with respect to gender and country of origin. and from relevant ESC Subspecialty Communities. After appropriate
Table 1 Classes of recommendations
Definition Wording to use
Class I Evidence and/or general agreement Is recommended or is indicated
that a given treatment or procedure is
beneficial, useful, effective.
Class II Conflicting evidence and/or a divergence of opinion about the usefulness/
efficacy of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in Should be considered
favour of usefulness/efficacy.
Class IIb Usefulness/efficacy is less well May be considered
established by evidence/opinion.
Class III Evidence or general agreement that the Is not recommended
given treatment or procedure is not
useful/effective, and in some cases
may be harmful.
snoitadnemmocer
fo
sessalC
4202
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 11 ---
3548 E S C G u id e l in e s
Table 2 Levels of evidence
Level of Data derived from multiple randomized clinical trials
evidence A or meta-analyses.
Level of Data derived from a single randomized clinical trial
evidence B or large non-randomized studies.
Level of Consensus of opinion of the experts and/or small studies,
evidence C retrospective studies, registries.
revisions, the guidelines are signed off by all the experts in the task morbidity in the general population,1,2consequently, intensive pre-
force. The finalized document is signed off by the CPG Committee ventive strategies are needed. However, patients with PAAD are
for publication in the European Heart Journal. generally underdiagnosed and undertreated3,4 compared with pa-
ESC Guidelines are based on analyses of published evidence, chiefly tients with coronary artery disease (CAD).5Common risk factors
on clinical trials and meta-analyses of trials, but potentially including in PAAD often coexist, requiring a multidisciplinary approach for ef-
other types of studies. Evidence tables summarizing key information fective management.5Early diagnosis is crucial for better outcomes.
from relevant studies are generated early in the guideline development These guidelines address PAAD, updating and merging the 2017
process to facilitate the formulation of recommendations, to enhance peripheral arterial diseases and 2014 aortic diseases guidelines.
comprehension of recommendations after publication, and reinforce The focus is primarily on atherosclerotic arterial diseases, but
transparency in the guidelines development process. The tables are they also address some non-atherosclerotic genetic conditions.
published in their own section of ESC Guidelines and reference specific While not exhaustive, these 2024 guidelines offer guidance on
recommendation tables. diagnosis, surveillance, and treatment. A number of new and revised
Off-label use of medication may be presented in this guideline if a recommendations are summarized in Tables 3 and 4, respectively.
sufficient level of evidence shows that it can be considered medically ap- Readers should consider non-atherosclerotic conditions and refer
propriate for a given condition. However, the final decisions concerning to specific documents.6–9
an individual patient must be made by the responsible health profes- A general approach to PAAD is provided in the central illustration
sional giving special consideration to: (Figure 1).
In the management of PAAD, the following aspects must be • The specific situation of the patient. Unless otherwise provided for
highlighted:
by national regulations, off-label use of medication should be limited
to situations where it is in the patient’s interest with regard to the • Shared decision-making to involve patients, explore
quality, safety, and efficacy of care, and only after the patient has treatment options, assess patient values, and reach decisions
been informed and has provided consent. collaboratively.
• Country-specific health regulations, indications by governmental • Multidisciplinary approach (Figure 1) in expert and high-volume
drug regulatory agencies, and the ethical rules to which health profes- PAAD centres for complex patients or procedures. These centres
sionals are subject, where applicable. provide diverse services, including diagnosis, treatment planning,
minimally invasive procedures, open surgery, post-operative and out-
patient care, and ideally, research and innovation. They should provide
2. Introduction continuous clinical service (24/7) and have access to digital imaging.
These guidelines recognize variations in healthcare systems, population
Peripheral arterial and aortic diseases (PAAD) are highly prevalent sizes, and needs, impacting the definition of ‘high volume’ in PAAD care
and significantly increase cardiovascular (CV) mortality and across countries.
4202
CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 12 ---
ESC Guidelines 3549
Cardiologist
Angiologist Cardiac
surgeon
Diagnosis
Vascular
Increase awareness Clinical assessment
surgeon
CVRFs management Functional assessment CV radiologist
Screening QoL assessment
Genetic counselling Use of non-invasive tools
Imaging, if appropriate
Prevention Treatment
Geneticist
CV intensive
care specialist
Regular follow-up
Optimal medical
Optimal medical
treatment
treatment
Patient education
CVRFs management
CVRFs control
Patient education
Exercise/rehabilitation
Patient’s tailored
programmes
Exercise targets and goals Need for intervention/
therapist Family screening, if surgery?
appropriate Anaesthetist
Follow-up
Neurologist
Nephrologist
Nurse
Goals Initial steps
Prevent development of peripheral and Screen patients at risk of PAAD
aortic atherosclerosis Enable early access to treatment
Prevent aortic dilation or lesions Ensure optimal medical treatment
Improve patients’ QoL and functioning
Reduce risk of MACE and MALE
Improve survival
Reduce the risk of hospitalization
Reduce the need for intervention/surgery
Figure 1 Central illustration: from diagnosis to treatment, a holistic multidisciplinary peripheral arterial and aortic diseases approach. CV, cardiovas-
cular; CVRFs, cardiovascular risk factors; MACE, major adverse cardiac event; MALE, major adverse limb event; PAAD, peripheral arterial and aortic
diseases; QoL, quality of life.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 13 ---
3550 E S C G u id e l in e s
3. What is new
Table 3 New recommendations
Recommendations Class Level
Recommendations for clinical and laboratory, and for functional quality of life, assessment in patients with peripheral arterial and aortic
disease
When managing PAAD, it is recommended to adopt a comprehensive approach that addresses the entirety of arterial circulation. I B
Recommendations for peripheral arterial disease screening
In patients with AAA, femoro-popliteal aneurysm screening with DUS should be considered. IIa C
In patients needing intervention with transfemoral access, screening for iliofemoral artery disease may be considered. IIb C
In patients with two or more CVRFs, screening for asymptomatic CS may be considered. IIb C
Recommendations for abdominal aortic aneurysm screening
Opportunistic AAA screening with DUS should be considered in symptomatic/asymptomatic PAD patients. IIa B
Recommendations for lifestyle, physical activity, and patient education
Use of web- or app-based secondary prevention risk calculators should be considered in the shared decision-making to improve patient
IIa C
adherence to treatment and lifestyle changes.
E-cigarettes may be considered as an aid to quitting tobacco smoking, but it is advisable to limit their use and avoid simultaneous use with
IIb C
conventional cigarettes due to unknown long-term effects.
Recommendations for lipid-lowering therapy in patients with peripheral arterial and aortic diseases
In patients with atherosclerotic PAAD, lipid-lowering therapy is recommended. I A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50% reduction in LDL-C vs. baseline are recommended in patients with
I A
atherosclerotic PAAD.
If the target LDL-C level is not achieved on maximally tolerated statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended in
I A
patients with atherosclerotic PAAD, to achieve target values.
If the target LDL-C level is not achieved, a combination of statins and ezetimibe is indicated in patients with atherosclerotic PAAD, to achieve
I B
the given target values.
For statin-intolerant patients with atherosclerotic PAAD, at high CV risk, who do not achieve their LDL-C goal on ezetimibe, it is
I B
recommended to add bempedoic acid either alone or in combination with a PCSK9 inhibitor.
Statins for the reduction of growth and rupture of AAA should be considered. IIa B
Statins for the reduction of growth and rupture of TAA may be considered. IIb B
In high-risk patients with PAAD and triglycerides >1.5 mmol/L despite lifestyle measures and statin therapy, icosapent ethyl 2 g b.i.d. may be
IIb B
considered in addition to a statin.
Fibrates are not recommended for cholesterol lowering. III B
Recommendations for exercise therapy in patients with peripheral arterial disease
In patients with symptomatic PAD, SET is recommended. I A
In those patients undergoing endovascular revascularization, SET is recommended as an adjuvant therapy. I A
When SET is not available or feasible, a structured and monitored (calls, logbooks, connected devices) HBET programme should be
IIa A
considered.
Walking should be considered as the first-line training modality. When walking exercise is not an option, alternative exercise modes (strength
IIa A
training, arm cranking, cycling, and combinations of different training modes) should also be considered.
Walking training performed at high intensity (77%–95% of maximal heart rate or 14–17 self-perceived exertion on Borg’s scale) should be
considered to improve walking performance, and high-intensity exercise training (various aerobic training modes) should be considered to IIa A
improve cardiorespiratory fitness.
Training frequency of at least three times per week, training session duration of at least 30 min, and training programme duration of at least 12
IIa B
weeks should be considered.
In patients with PAD, exercise training to moderate-severe claudication pain may be considered to improve walking performance. However,
IIb B
improvements are also achievable with lesser claudication pain severities (low-mild pain or pain-free).
Based on patient’s tolerance, a progressive increase (every 1–2 weeks) in exercise training load may be considered. IIb C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 14 ---
ESC Guidelines 3551
Recommendations for antithrombotic therapy in patients with peripheral arterial disease
Treatment with combination rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered for patients with PAD and high
IIa A
ischaemic risk, and non-high bleeding risk.
Treatment with combination rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered for patients with PAD and non-high
IIa B
bleeding risk following lower-limb revascularization.
Aspirin (75–100 mg) for primary prevention may be considered in patients with asymptomatic PAD and DM, in the absence of
IIb A
contraindications.
Recommendations for interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)
In patients with symptomatic PAD, after a 3 month period of OMT and exercise therapy, PAD-related QoL assessment is recommended. I B
It is recommended to adapt the mode and type of revascularization options to anatomical lesion location, lesion morphology, and general
I C
patient condition.
In patients with symptomatic PAD and impaired PAD-related QoL after a 3 month period of OMT and exercise therapy, revascularization
IIb B
may be considered.
In patients with PAD, revascularization is not recommended if the reason is to solely prevent progression to CLTI. III B
In patients with asymptomatic PAD, revascularization is not recommended. III C
Recommendations for interventional treatment of patients with symptomatic peripheral arterial disease (per arterial bed)
In femoro-popliteal lesions, drug-eluting treatment should be considered as the first-choice strategy. IIa A
In femoro-popliteal lesions, if revascularization is indicated, an open surgical approach should be considered when an autologous vein (e.g.
IIa C
GSV) is available in patients with low surgical risk.
In patients with severe IC undergoing endovascular femoro-popliteal revascularization, treatment of BTK arteries may be considered in the
IIb C
same intervention.
Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease
It is recommended to regularly, at least once a year, follow-up patients with PAD, assessing clinical and functional status, medication
I C
adherence, limb symptoms, and CVRFs, with DUS assessment as needed.
Recommendations for the management of chronic limb-threatening ischaemia
Early recognition of CLTI and referral to the vascular team are recommended for limb salvage. I C
Recommendations for medical treatment in patients with chronic limb-threatening ischaemia
It is recommended that patients with CLTI are managed by a vascular team. I C
In patients with CLTI and ulcers, offloading mechanical tissue stress is indicated to allow wound healing. I C
Lower-limb exercise training is not recommended in patients with CLTI and wounds. III C
Recommendations for interventional treatment of chronic limb-threatening ischaemia
In CLTI patients, it is recommended to perform revascularization as soon as possible. I B
In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery. I B
In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions. I C
In CLTI patients with good autologous veins and low surgical risk (<5% peri-operative mortality, >50% 2 year survival), infra-inguinal bypass
IIb B
may be considered.
In CLTI patients, endovascular treatment may be considered as first-line therapy, especially in patients with increased surgical risk or
IIb B
inadequate autologous veins.
Recommendations for follow-up in patients with chronic limb-threatening ischaemia
In patients with CLTI, following revascularization it is recommended to follow-up patients on a regular basis. I C
At follow-up, it is recommended to assess clinical, haemodynamic and functional status, limb symptoms, treatment adherence, and CVRFs. I C
Recommendations for carotid artery stenosis assessment
It is recommended to use the NASCET method or its non-invasive equivalent to assess ICA stenosis. I B
It is not recommended to use the ECST method for ICA stenosis assessment. III C
Recommendations for the management of subclavian artery stenosis
Bilateral arm BP measurement is recommended for all patients with PAAD. I B
Endovascular revascularization may be considered over surgery, despite similar long-term outcomes, due to lower complication rates. IIb B
Routine revascularization in patients with atherosclerotic subclavian artery disease is not recommended. III C
Recommendations for diagnostic strategies for renal artery disease
DUS is recommended as the first-line imaging modality in patients with suspicion of RAS. I B
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 15 ---
3552 E S C G u id e l in e s
Recommendations for treatment strategies for renal artery disease
Revascularization
In patients with atherosclerotic unilateral >70% RAS, concomitant high-risk features, and signs of kidney viability, renal artery revascularization
IIa B
should be considered after OMT has been established.
In patients with atherosclerotic bilateral (>70%) RAS or RAS in a solitary kidney, concomitant high risk features, and signs of kidney viability,
IIa B
renal artery revascularization should be considered.
In patients with hypertension and/or signs of renal dysfunction due to RAS caused by fibromuscular dysplasia, concomitant high-risk features,
IIa B
and signs of kidney viability, revascularization with primary balloon angioplasty and bailout stenting should be considered.
In patients with an indication for renal artery revascularization and complex anatomy, or after failed endovascular revascularization, open
IIa B
surgical revascularization should be considered.
In patients with atherosclerotic unilateral RAS, routine revascularization is not recommended. III A
Recommendations in patients with visceral artery stenosis
In patients with acute or chronic mesenteric ischaemia, assessment by a vascular team is recommended. I C
Revascularization of asymptomatic atherosclerotic visceral artery stenosis is not recommended. III C
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
In patients with dilatation of the tubular ascending aorta who can be offered surgery with low predicted risk, ascending aortic replacement
IIa B
should be considered at a maximum diameter >52 mm.
In patients undergoing surgery for tricuspid aortic valve disease who have concomitant dilatation of the aortic root or ascending tubular aorta,
and low predicted surgical risk, ascending aorta or root replacement should be considered at a maximum diameter ≥45 mm, otherwise IIa B
≥50 mm.
SAPT with low-dose aspirin (75–100 mg/day) should be considered for the first 3 months after valve-sparing aortic surgery when there are no
IIa C
other baseline indications for OAC.
In patients undergoing non-aortic-valve cardiac surgery who have concomitant dilatation of the ascending aorta or aortic root with a
IIa C
maximum diameter ≥50 mm, concomitant aortic surgery should be considered.
Recommendations for surgery in aortic arch aneurysms
In patients with low or intermediate operative risk with an aortic arch aneurysm and recurrent episodes of chest pain not attributable to
I C
non-aortic causes, open surgical replacement of the arch is recommended.
In patients undergoing open surgical repair of an aortic arch aneurysm, an elephant trunk or frozen elephant trunk procedure should be
IIa C
considered if the aneurysmal disease extends into the proximal descending thoracic aorta.
Recommendations for follow-up after treatment of aortic aneurysms
After open repair of TAA, an early CCT is recommended within 1 month, and then yearly CCT follow-up for the first 2 post-operative years
I B
and every 5 years thereafter is recommended if findings are stable.
After 5 post-operative years without complications, continuing long-term follow-up of TEVAR by CCT every 5 years should be considered. IIa B
If growth of the excluded aneurysm is observed, without evidence of type I or III endoleak, repeating CCT every 6–12 months, depending on
IIa C
the growth rate observed, should be considered.
In low-risk patients, from 1 year post-operatively after EVAR, repeating DUS/CEUS every 2 years should be considered. IIa B
If any abnormality during DUS/CEUS is found, confirmation should be considered using additional CCT or CMR (based on potential artefacts). IIa B
Recommendations for diagnostic work-up of acute aortic syndrome
CCT from neck to pelvis is recommended as the first-line imaging technique in patients with suspected AAS since it is widely available,
I C
accurate, and provides information about the entry tear, extension, and possible complications (malperfusion, dilatation, or rupture).
In patients with suspected AAS, TOE is recommended to guide peri-operative management and detect complications. I C
Recommendations for medical treatment in acute aortic syndromes
In patients with AAS who can be managed conservatively and who achieved haemodynamic targets with i.v. anti-impulse therapy, switching to
I B
oral BBs and, if necessary, up-titration of other BP-lowering agents is recommended after 24 h if gastrointestinal transit is preserved.
If the patient has a contraindication for BBs, a non-dihydropyridine calcium blocker should be considered. IIa B
Recommendations for intervention in type A acute aortic dissection
In patients with acute TAAD who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aortic disorder, aortic
I B
root replacement is recommended with a mechanical or biological valved conduit.
In patients presenting with acute TAAD, transfer from a low- to a high-volume aortic centre with the presence of a multidisciplinary team
IIa B
should be considered to improve survival if transfer can be accomplished without significant delay in surgery.
In selected patients, a valve-sparing root repair may be considered, when performed by experienced surgeons. IIb B
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 16 ---
ESC Guidelines 3553
Recommendations for aortic repair strategies in type A acute aortic dissection
In patients with acute TAAD and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is
I B
recommended over valve replacement.
In patients with acute TAAD undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase FL
I B
thrombosis rates.
In patients with acute TAAD without an intimal tear in the arch or a significant arch aneurysm, hemi-arch repair is recommended over more
I B
extensive arch replacement.
In patients with acute TAAD and a secondary intimal tear in the arch or proximal DTA, extended aortic repair with stenting of the proximal
DTA (e.g. by the frozen elephant technique) may be considered to reduce late distal aortic complications (e.g. aneurysm evolution of the IIb C
remaining dissected descending aorta).
Recommendations for the management of malperfusion in the setting of acute aortic dissection
In patients with acute TAAD presenting with malperfusion (cerebral, mesenteric, lower limb, or renal), immediate aortic surgery is
I B
recommended.
In patients with acute TAAD presenting with cerebral malperfusion or non-haemorrhagic stroke, immediate aortic surgery should be
IIa B
considered to improve neurological outcome and reduce mortality.
In patients with acute TAAD presenting with clinically significant mesenteric malperfusion syndrome, immediate invasive angiographic
diagnostics to evaluate percutaneous malperfusion repair before or directly after aortic surgery, in aortic centres with expertise, should be IIa C
considered.
Recommendations for the management of patients presenting with acute type B aortic dissection
In patients with uncomplicated acute TBAD, TEVAR in the subacute phase (between 14 and 90 days) should be considered in selected
IIa B
patients with high-risk features to prevent aortic complications.
Recommendations for the management of patients presenting with chronic type B aortic dissection
In chronic TBAD and with a descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable surgical risk. I B
In patients with chronic TBAD and a descending thoracic aortic diameter ≥55 mm, an indication for intervention should be considered in
IIa C
patients with low procedural risk.
In patients with chronic post-dissection thoracoabdominal aortic aneurysms, the use of fenestrated/branched stent grafts may be considered,
IIb C
when treatment is indicated.
Recommendations for the management of penetrating atherosclerotic ulcer
In uncomplicated type B PAU with high-risk imaging features, endovascular treatment should be considered. IIa C
Recommendations for traumatic aortic injury
In cases of severe aortic injury (grade 4), immediate repair is recommended. I A
In minimal aortic injury (grades 1 or 2), initial medical therapy under careful clinical and imaging surveillance should be considered. IIa C
In cases of progression of the IMH (grade 2), semi-elective repair (within 24–72 h) should be considered. IIa C
Recommendations for follow-up after treatment of acute aortic syndrome
In medically treated type B AAS or IMH, follow-up imaging is recommended at 1, 3, 6, and 12 months after onset, then yearly if imaging findings
I C
are stable.
In medically treated PAU, follow-up imaging is recommended at 1 month after diagnosis, then every 6 months if imaging findings are stable. I C
After open surgery for AAS, follow-up imaging by CCT and TTE within 6 months, then CCT at 12 months and then yearly if findings are stable,
IIa B
should be considered.
If no complications occur within the first 5 years, CCT every 2 years thereafter should be considered. IIa B
If no residual patent FL is documented for 3 post-operative years, subsequent surveillance by CCT every 2–3 years should be considered. IIa C
In the follow-up of medically treated PAU, after 2 years of imaging stability, larger intervals should be considered in low-risk patients. IIa C
Recommendations for the management of patients with heritable thoracic aortic disease
It is recommended that medical management of patients with HTAD is individualized and based on shared decision-making. I C
It is recommended that patients with known or suspected syndromic or non-syndromic HTAD are evaluated in a centre with experience in
I C
the care of this patient group.
Recommendations for genetic testing and aortic screening in aortic disease
In patients with HTAD, guidance of clinical management by the underlying gene/variant, when known, should be considered. IIa B
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 17 ---
3554 E S C G u id e l in e s
Recommendations for imaging in women with Turner syndrome
To take the smaller body size of women (≥15 years) with TS into account, the use of the ascending ASI (ratio of aortic diameter [mm] to BSA
[m2]), AHI (ratio of aortic diameter [mm] to height [m]), or aortic z-score is recommended to define the degree of aortic dilatation and assess I C
the risk of aortic dissection.
It is recommended to define imaging and clinical surveillance intervals according to the estimated risk for dissection, based on the ascending
I C
ASI and concomitant lesions.
Recommendations for aortic surgery in women with Turner syndrome
Elective surgery for aneurysms of the aortic root and/or ascending aorta should be considered in women with TS who are ≥15 years of age,
have an ascending ASI >23 mm/m2, an AHI >23 mm/m, a z-score >3.5, and have associated risk factors for aortic dissection or are planning IIa C
pregnancy.
Elective surgery for aneurysms of the aortic root and/or ascending aorta may be considered for women with TS who are ≥15 years of age,
IIb C
have an ascending ASI >25 mm/m2, an AHI >25 mm/m, a z-score >4, and who do not have associated risk factors for aortic dissection.
Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome
In patients with vEDS, regular vascular surveillance of the aorta and peripheral arteries by DUS, CCT, or CMR is recommended. I C
Treatment with celiprolol should be considered in patients with vEDS. IIa B
Recommendations for vascular imaging in Marfan syndrome
In patients with MFS, TTE is recommended:
• At least annually in patients with an aortic root diameter <45 mm in the absence of additional risk factors
I C
• At least every 6 months in patients with an aortic root diameter <45 mm in the presence of additional risk factors
• At least every 6–12 months in patients with an aortic root diameter ≥45 mm in the absence of additional risk factors
In patients without previous aortic surgery, complete peripheral vascular and thoracoabdominal aortic imaging by CMR or CCT and DUS is
I C
recommended at the first evaluation, and subsequently every 3–5 years if stable.
Recommendations for medical treatment in Marfan syndrome
In patients with MFS, treatment with either a BB or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to reduce
I A
the rate of aortic dilatation.
In patients with MFS, the use of both a BB and an ARB, in maximally tolerated doses (unless contraindicated), should be considered to reduce
IIa A
the rate of aortic dilatation.
Recommendations for pregnancy in women with Marfan syndrome
It is recommended that all women with MFS:
• Have a pre-conception evaluation to address the risks of maternal CV and other complications I C
• Have follow-up in a centre with access to a pregnancy heart and vessel team
It is recommended that couples in which a partner has or is at risk of HTAD be offered pre-conception genetic counselling. I C
Imaging of the whole aorta (by CMR/CCT) is recommended prior to pregnancy. I C
Follow-up during pregnancy is recommended with a frequency determined by aortic diameter and growth. I C
Intake of BBs during pregnancy is recommended. I C
Prophylactic aortic root surgery is recommended in women desiring pregnancy with aortic diameters >45 mm. I C
Prophylactic aortic root surgery may be considered in women desiring pregnancy with aortic diameters of 40–45 mm. IIb C
Recommendations for physical exercise in patients with Marfan syndrome
It is recommended to individualize physical activity in patients with MFS based on aortic diameter, family history of aortic dissection, and
I C
pre-existing fitness.
Regular moderate aerobic exercise with a level of intensity informed by aortic diameter is recommended in most patients with MFS. I C
For patients who present with aortic dissection and/or have undergone aortic surgery, post-operative cardiac rehabilitation aiming at
IIa B
improving both physical and mental health should be considered.
Recommendations for imaging follow-up in Loeys–Dietz syndrome
In patients with Loeys–Dietz syndrome, TTE at baseline and subsequently every 6–12 months, depending on aortic diameter and growth, is
I C
recommended.
In patients with Loeys–Dietz syndrome, a baseline arterial imaging study from head to pelvis with CMR or CCT and subsequent surveillance
I C
with CMR or CCT or DUS every 1–3 years is recommended.
Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease
Annual monitoring of the aortic root/ascending aorta with TTE to evaluate for aortic root/ascending aorta enlargement is recommended. I C
Imaging of the aorta with CMR/CCT every 3–5 years is recommended. I C
Prophylactic aortic root surgery should be considered with a diameter ≥45 mm, or lower in cases with other risk factors. IIa C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 18 ---
ESC Guidelines 3555
Recommendations for bicuspid aortic valve-associated aortopathy management
Surgery for bicuspid aortopathy of the root phenotype is recommended when the maximum aortic diameter is ≥50 mm. I B
Screening by TTE in FDRs of BAV patients with root phenotype aortopathy and/or isolated aortic regurgitation is recommended. I C
In patients with low surgical risk, surgery for bicuspid aortopathy of ascending phenotype should be considered when the maximum aortic
IIa B
diameter is >52 mm.
Recommendations for evaluation and medical treatment of patients with coarctation of the aorta
In patients with native or repaired coarctation, lifelong follow-up is recommended, including regular imaging of the aorta with CCT/CMR
I B
every 3–5 years (adapted to clinical status and previous imaging findings).
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients with PVD, an LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended. I A
In patients with stable PVD who are symptomatic in at least one territory and without high bleeding risk, treatment with a combination of
IIa A
rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) should be considered.
AAA, abdominal aortic aneurysm; AAD, acute aortic dissection; AAS, acute aortic syndrome; AHI, aortic height index; ARB, angiotensin receptor blocker; ASI, aortic size index; BAV, bicuspid
aortic valve; BB, beta-blocker; b.i.d., twice daily; BP, blood pressure; BTK, below-the-knee; BSA, body surface area; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced
ultrasound; CLTI, chronic limb-threatening ischaemia; CMR, cardiovascular magnetic resonance; CS, carotid artery stenosis; CV, cardiovascular; CVRFs, cardiovascular risk factors; DM,
diabetes mellitus; DTA, descending thoracic aorta; DUS, duplex ultrasound; ECST, European Carotid Surgery Trial; FDR, first-degree relative; FL, false lumen; GSV, great saphenous vein;
HBET, home-based exercise training; HTAD, heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; IC, intermittent claudication; i.v., intravenous;
LDL-C, low-density lipoprotein cholesterol; MFS, Marfan syndrome; NASCET, North American Symptomatic Carotid Endarterectomy Trial; OAC, oral anticoagulation; o.d., once daily;
OMT, optimal medical treatment; PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; PVD, polyvascular disease;
QoL, quality of life; RAS, renal artery stenosis; SAPT, single antiplatelet therapy; SET, supervised exercise training; TAA, thoracic aortic aneurysm; TAAD, type A aortic dissection;
TBAD, type B aortic dissection; TOE, transoesophageal echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TS, Turner syndrome; TTE, transthoracic
echocardiography; vEDS, vascular Ehlers–Danlos syndrome.
Table 4 Revised recommendations
Recommendations in 2017 (PAD) and 2014 Class Level Recommendations in 2024 Class Level
(Aortic)
Recommendations for abdominal aortic aneurysm screening
Screening for AAA with DUS
Is recommended in all men >65 years of age. Is recommended in men aged ≥65 years with a history of
I A I A
smoking to reduce the risk of death from ruptured AAA.
(i) May be considered in women >65 years of age with May be considered in men aged ≥75 years (irrespective of
IIb C
history of current/past smoking. smoking history) or in women aged ≥75 years who are
IIb C
(ii) Is not recommended in female non-smokers without current smokers, hypertensive, or both.
III C
familial history.
Family AAA screening with DUS
Targeted screening for AAA with ultrasound should be Is recommended for FDRs of patients with AAA aged
IIa B I C
considered in first-degree siblings of a patient with AAA. ≥50, unless an acquired cause can be clearly identified.
Opportunistic AAA screening with DUS
Targeted screening for AAA with ultrasound should be Should be considered in men ≥65 years and in women
IIa B IIa B
considered in first-degree siblings of patients with AAA. aged ≥75 years during TTE.
Recommendations for antihypertensive therapy in patients with peripheral and aortic disease
In patients with PAD and hypertension, it is recommended In patients with PAAD and hypertension an SBP target
I A I A
to control blood pressure at <140/90 mmHg towards 120–129 mmHg, if tolerated, is recommended.
ACEIs or ARBs should be considered as first-line therapy ACEIs/ARBs may be considered in all patients with PAD,
IIa B IIb B
in patients with PAD and hypertension. regardless of BP levels, in the absence of contraindications.
Recommendations for lipid-lowering therapy for patients with peripheral arterial and aortic diseases
In patients with PAD, it is recommended to reduce LDL-C An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a
to <1.8 mmol/L (70 mg/dL) or decrease it by >50% if I C >50% reduction in LDL-C vs. baseline are recommended I A
baseline values are 1.8–3.5 mmol/L (70–135 mg/dL). in patients with atherosclerotic PAAD.
Recommendations for carotid artery stenosis assessment
DUS (as first-line imaging), CTA, and/or MRA are It is recommended to use DUS as first-line imaging to
recommended for evaluating the extent and severity of I B diagnose ICA stenosis. I C
extracranial carotid stenosis.
Continued
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 19 ---
3556 E S C G u id e l in e s
Recommendations in patients with visceral artery stenosis
In patients with acute embolic occlusion of the SMA, both In patients with acute mesenteric ischaemia due to acute
endovascular and open surgery therapy should be IIa B occlusion of the SMA, endovascular revascularization is I B
considered. recommended.
Recommendations for surveillance of patients with abdominal aorta aneurysm
In patients with small (30–55 mm) AAA, the following DUS surveillance should be considered annually in women
time interval should be considered: with AAA of 40–45 mm and in men with AAA of 40–
• Every 3 years for AAA of 30–39 mm diameter IIa B 49 mm. IIa B
• Every 2 years for AAA of 40–44 mm diameter
• Every year for AAA >45 mm diameter.
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
Surgery should be considered in patients who have Surgery is recommended in patients with dilatation of the
isolated aortic arch aneurysm with a maximal diameter IIa C aortic root or ascending aorta with a tricuspid aortic valve I B
≥55 mm. and a maximum diameter of ≥55 mm.
Aortic valve repair using the reimplantation technique or Valve-sparing aortic root replacement is recommended in
remodelling with aortic annuloplasty is recommended in patients with aortic root dilatation if performed in
I C I B
young patients with aortic root dilation and tricuspid experienced centres and durable results are expected.
aortic valves.
Lower thresholds for intervention may be considered Ascending aortic or root replacement may be considered
according to BSA in patients with small stature or in the at a maximum diameter of ≥50 mm in patients with
case of rapid progression, aortic valve regurgitation, proximal aorta dilatation who can be offered surgery with
planned pregnancy, and patient’s preference. low predicted risk and present with any of the following:
• Growth of the aortic diameter ≥3 mm per year
• Resistant hypertension
IIb C IIb B
• Short stature (<1.69 m)
• Root phenotype
• Aortic length >11 cm
• Age <50 years
• Desire for pregnancy
• Aortic coarctation.
Recommendations for surgery in aortic arch aneurysms
Aortic arch repair may be considered in patients with In patients undergoing open surgical repair of an ascending
aortic arch aneurysm who already have an indication for aortic aneurysm, concomitant hemi-arch replacement
IIb C IIa C
surgery of an adjacent aneurysm located in the ascending should be considered if the dilatation extends into the
or descending aorta. proximal aortic arch (>50 mm).
Recommendations for follow-up after treatment of aortic aneurysms
After TEVAR or EVAR, surveillance is recommended after After TEVAR, follow-up imaging is recommended at 1 and
1, 6, and 12 months and then yearly. Shorter intervals can 12 months post-operatively, then yearly until the fifth
I C I B
be proposed in the event of abnormal findings requiring post-operative year if no abnormalities are documented.
closer surveillance.
Long-term surveillance of open abdominal aortic repair After open repair of AAA, first follow-up imaging is
may be considered at loose (5 year) intervals using colour IIb C recommended within 1 post-operative year, and every 5 I A
DUS or CCT imaging. years thereafter if findings are stable.
If neither endoleak nor AAA sac enlargement is After EVAR, follow-up imaging is recommended with CCT
documented during first year after EVAR, then colour (or CMR) and DUS/CEUS at 1 month and 12 months
DUS, with or without contrast agents, should be IIa C post-operatively, then, if no abnormalities are documented, I A
considered for annual post-operative surveillance, with DUS/CEUS is recommended every year, repeating CCT or
non-contrast CT imaging every 5 years. CMR (based on potential artefacts) every 5 years.
Recommendations for diagnostic work-up of acute aortic syndrome
TTE is recommended as an initial imaging investigation. In patients with suspected AAS, focused TTE (with use of
In stable patients with a suspicion of AAS, the following contrast if feasible) is recommended during the initial
I C I C
imaging modalities are recommended (or should be evaluation.
considered according to local availability and expertise):
MRI In patients with suspected AAS, CMR should be
I C considered as an alternative imaging technique if CCT is IIa C
not available.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 20 ---
ESC Guidelines 3557
TOE In patients with suspected AAS, TOE is recommended to
IIa C guide peri-operative management and detect I C
complications.
Recommendations for medical treatment in acute aortic syndromes
In all patients with AD, medical therapy, including pain Invasive monitoring with an arterial line and continuous
relief and blood pressure control, is recommended. I C three-lead ECG recording, as well as admission to an I B
intensive care unit, is recommended.
Recommendations for the management of patients presenting with acute type B aortic dissection
In complicated TBAD, TEVAR is recommended. I C In patients with complicated acute TBAD, emergency
I B
In complicated TBAD, surgery may be considered. IIb C intervention is recommended.
In complicated TBAD, TEVAR may be recommended. IIb C In patients with complicated acute TBAD, TEVAR is
I B
In complicated TBAD, surgery may be considered. IIb C recommended as the first-line therapy.
Recommendations for the management of intramural haematoma
In complicated type B IMH, TEVAR should be considered. IIa C In complicated type B IMH, TEVAR is recommended. I C
Recommendations for the management of penetrating atherosclerotic ulcer
In the case of type A PAU, surgery should be considered. IIa C In the case of type A PAU, surgery is recommended. I C
In complicated type B PAU, TEVAR should be considered. In complicated type B PAU, endovascular treatment is
IIa C I C
recommended.
Recommendations for traumatic aortic injury
In cases of TAI with suitable anatomy requiring In cases of TAI with suitable anatomy requiring
IIa C I A
intervention, TEVAR should be preferred to surgery. intervention, TEVAR is recommended over open surgery.
Recommendations for genetic testing and aortic screening in aortic disease
It is recommended to investigate FDRs (siblings and Imaging screening of family members of patients with
parents) of a subject with TAAD to identify a familial form TAD with risk factors for HTAD in whom no (likely)
in which relatives all have a 50% chance of carrying the pathogenic variant is identified should be considered
family mutation/disease. I C starting at age 25, or 10 years below the youngest case, IIa C
whichever is younger. If the initial screening is normal,
continued screening every 5 years until the age of 60
should be considered.
Recommendations for bicuspid aortic valve-associated aortopathy management
Cardiac MRI or CT is indicated in patients with BAV when CCT or CMR of the entire thoracic aorta is
the morphology of the aortic root and the ascending aorta I C recommended at first diagnosis and when important
cannot be accurately assessed by TTE. discrepancies in measurements are found between
In the case of aortic diameter >50 mm or an increase of subsequent TTE controls during surveillance, or when the I C
>3 mm per year measured by echocardiography, diameter of the aorta exceeds 45 mm.
I C
confirmation of the measurement is indicated, using
another imaging modality (CT or MRI).
In the case of a diameter of the aortic root or the Surveillance serial imaging by TTE is recommended in BAV
ascending aorta >45 mm or an increase of >3 mm per patients with a maximum aortic diameter >40 mm, either
year measured by echocardiography, annual I C with no indication for surgery or after isolated aortic valve I C
measurement of aortic diameter is indicated. surgery, after 1 year, then if stability is observed, every 2–3
years.
In cases of BAV, surgery of the ascending aorta is indicated In patients with low surgical risk and ascending phenotype
in the case of: bicuspid aortopathy, surgery should be considered at a
• Aortic root or ascending aortic diameter >50 mm in the maximum diameter ≥50 mm if any of the following is the
presence of other risk factors (coarctation of the aorta, case:
systemic hypertension, family history of dissection, or • Age <50 years
increase in aortic diameter of >3 mm per year). • Short stature
I C • Ascending aortic length ≥11 cm IIa C
• Aortic diameter growth rate >3 mm per year
• Family history of acute aortic syndrome
• Aortic coarctation
• Resistant hypertension
• Concomitant non-aortic-valve cardiac surgery
• Desire for pregnancy
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 21 ---
3558 E S C G u id e l in e s
In cases of BAV, surgery of the ascending aorta is indicated Surgery for bicuspid aortopathy in patients undergoing
in the case of: aortic valve surgery should be considered at a root or
I C IIa C
• Aortic root or ascending aortic diameter >45 mm ascending diameter ≥45 mm.
when surgical aortic valve replacement is scheduled.
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients undergoing CABG, DUS is recommended in Carotid DUS should be considered for stable patients
patients with a recent (<6 months) history of TIA/stroke. I B scheduled for CABG with TIA/stroke within the past 6 IIa B
months without carotid revascularization.
AAA, abdominal aortic aneurysm; AAS, acute aortic syndrome; ACEI, angiotensin-converting enzyme inhibitor; AD, aortic dissection; ARB, angiotensin receptor blocker; BAV, bicuspid aortic
valve; BP, blood pressure; BSA, body surface area; CABG, coronary artery bypass grafting; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced ultrasound; CMR,
cardiovascular magnetic resonance; CT, computed tomography; CTA, computed tomography angiography; DUS, duplex ultrasound; ECG, electrocardiogram; FDR, first-degree relative;
HTAD, heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; LDL-C, low-density lipoprotein cholesterol; MRA, magnetic resonance angiography;
MRI, magnetic resonance imaging; PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; SBP, systolic blood pressure;
SMA, superior mesenteric artery; TAAD, type A aortic dissection; TAD, thoracic aortic disease; TAI, traumatic aortic injury; TBAD, type B aortic dissection; TOE, transoesophageal
echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TIA, transient ischaemic attack; TTE, transthoracic echocardiography.
4. Epidemiology and risk factors Ischaemic cerebral disease, mainly linked to carotid stenosis (65% of
cases), has a prevalence of 77.19 million, marking a 95% increase from
4.1. Epidemiology 1990 to 2019.15
Peripheral arterial disease (PAD) is prevalent worldwide and affects 113 The overall prevalence of aortic disease including aneurysm and
million people aged 40 and older, of which 42.6% are in countries with a dissections is estimated at around 1% to 3% in the general population,
low-to-middle sociodemographic index. Global prevalence is 1.52%, in- with up to 10% prevalence in older age groups. European studies show
creases with age (14.91% in those aged 80–84 years), and is higher in a decrease in abdominal aortic aneurysm (AAA) prevalence in screened
females than in males (18.03% vs. 10.56%, in the same age group).10–13 men >65 years of age, at 1.3%–3.3%,16,17contrasting with the United
PAD prevalence rose by 72% from 1990 to 2019, considering a States of America’s 5% found in screened male smokers.16,17
45% growth rate in the world population.10,11,14 The overall global Globally, in 2019, there were 172 000 aortic aneurysm-related deaths
age-standardized prevalence is about 1470 per 100 000 persons (Figure 2).14 (82.1% increase from 1990).10
Prevalence rate (per 100 000 population)
30 000
Female Male
25 000
20 000
15 000
10 000
5000
0
40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89 90–94
Age (years)
Figure 2 Estimated specific prevalence of peripheral arterial disease, by sex, in people aged 40 years and older. Adapted from12under the terms of the
Open access Creative Commons CC-BY license.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 22 ---
ESC Guidelines 3559
4.2. Risk factors SCORE2-OP (Systematic Coronary Risk Evaluation 2–Older Persons)
(Europe)18also contribute to PAAD’s pathophysiology and development.
Main PAAD risk factors are summarized in Figure 3. Traditional risk factors
in tools like Framingham, Reynolds, Atherosclerotic Cardiovascular Disease More details are available in Supplementary data online, Section 1.1, and the
(ASCVD) risk estimator Plus (United States of America), SCORE2 2021 ESC Guidelines on CV disease prevention in clinical practice.19
(Systematic Coronary Risk Evaluation 2, age 40–69 years), SCORE2- Low-density lipoprotein cholesterol (LDL-C) is a pivotal factor in
Diabetes (Systematic Coronary Risk Evaluation 2 - diabetes), and atherosclerosis,19 with diabetes and tobacco exposure significantly
Traditional risk factors
Non-modifiable risk factors Modifiable risk factors
Tobacco
Age Diabetes
Sex Lipids
Polygenic and
family inheritance h e r o
sclerotic
P A
Hypertension
At A
D
Pregnancy-induced
hypertension/ Overweight
diabetes
Menopause
Sedentary lifestyle
Female-specific
risk factors
Sleep disorders
Socio-economic status
Environmental pollution Stressful lifestyle
Inflammation
Autoimmune disease Alcohol
Apolipoproteins Diet
Non-traditional risk factors
Figure 3 Main risk factors associated with atherosclerosis in peripheral arterial and aortic diseases. PAAD, peripheral arterial and aortic diseases.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 23 ---
3560 E S C G u id e l in e s
amplifying PAD risk by 2–4 times each.20Both men and women face a generic questionnaire in PAD.35,36,38 The Edinburgh Claudication
similar risk of PAD, but women have distinct risk factors (Figure 3).21 Questionnaire is a modified version of the initially developed Rose ques-
Hypertension and male sex are major risk factors for AAA, whereas dia- tionnaire and has a sensitivity of 91% and a specificity of 99% in compari-
betes mellitus lowers its incidence by 25%.22–24Thoracic aortic aneurysm son with a physician-based diagnosis.55,56 The Walking Impairment
(TAA) or dissection share atherosclerotic risk factors, yet monogenic or Questionnaire (WIQ), the Walking Estimated Limitation Calculated by
polygenic diseases like Marfan syndrome (MFS), more prevalent in young- History (WELCH), and the Vascular quality of life (VascuQoL) question-
er individuals, also contribute.24,25Inflammation as a risk factor can be ob- naire are the most used PAD-specific questionnaires.34–36,38
served in PAAD26and the potential for inflammation to be a modifiable Treadmill testing, using standardized criteria, is the gold standard to as-
risk factor is indicated by research related to colchicine and the effects sess walking performance.37,57–62Patients are asked to walk until max-
demonstrated by canakinumab (a monoclonal antibody that reduces in- imal pain levels, defining the maximal walking distance (MWD).
flammation by inhibiting interleukin-1 beta).27,28 Patients are also asked to indicate the point at which pain begins, defining
the pain-free walking distance (PFWD). Constant-load protocols have
poorer reliability than graded protocols.60–64Additionally, the six-minute
5. Evaluation of peripheral arteries
walk test (6MWT) should be performed to assess functional walking per-
and aorta formance.62,65For muscular lower-limb strength assessment,66isokinetic
dynamometry has good test–retest reliability.67Alternatively, the Short
To be consistent with existing literature, the term PAD is used to refer physical performance battery (SPPB) test should be used.62,64,68,69The
to lower-extremity atherosclerotic arterial disease. SPPB has good test–retest reliability.64
Few data exist on HRQoL, functional assessment, and exercise cap-
5.1. Clinical history and examination, and acity in patients with aortic diseases.70,71Those with acute aortic dis-
section (AAD), as well as patients who had aortic valve or thoracic
laboratory assessment, in patients with
aortic surgery, may present with depression and anxiety, leading to
peripheral arterial and aortic diseases mental health issues72,73that can also be assessed with the SF-36 ques-
Clinical evaluation encompassing history (including family history), tionnaire or the hospital anxiety and depression score (HADS).72
review of symptoms, and physical examination are the first steps Patients with MFS have reduced HRQoL and a significant decline
in diagnosing and assessing patients with PAAD. Pulse palpation, over time in physical HRQoL.74,75Assessing HRQoL in aortic disease
femoral, carotid, and abdominal bruit auscultation, heart ausculta- patients is crucial for understanding well-being, disease impact, and
tion, and observation of the legs and feet need to be part of the vas- treatment effects. This involves PROMs, including surveys, symptom
cular examination. assessment, functional evaluation, psychological well-being (HADS),
Clinical signs, beyond aiding diagnosis, offer prognostic insights. social and occupational function, and medication/treatment side effects.
Carotid bruits double the risk of myocardial infarction (MI) and CV It also covers healthcare utilization and patient satisfaction, informing
death,29,30while a brachial systolic blood pressure (SBP) difference of care and enhancing aortic disease management.
more than 15 mmHg raises CV death risk by 50%.31Hence, bilateral
arm blood pressure (BP) measurement is recommended.32Lab assess-
ments should include lipid profile (including lipoprotein[a] at least once
Recommendation Table 1 — Recommendations for clin-
in a lifetime),33fasting glycaemia, glycated haemoglobin (HbA1c), renal
ical and laboratory, and for functional and quality of life, as-
function, blood count, coagulation studies, liver function, electrolytes, sessment in patients with peripheral arterial and aortic
and inflammatory markers (C-reactive protein [CRP] and erythrocyte disease (see also Evidence Table 1)
sedimentation rate). Additional evaluations, like thyroid function tests,
are advised as needed. Recommendations Classa Levelb
When managing PAAD, it is recommended to adopt
5.2. Functional and quality of life a comprehensive approach that addresses the I B
assessment in patients with peripheral entirety of the arterial circulation.76
arterial and aortic diseases To assess PAAD, it is recommended to perform
thorough clinical, vascular, and CVRFs laboratory I C Patients with PAD have decreased walking performance and self-
evaluation.77
reported physical and mental health-related quality of life
(HRQoL).34–40 Muscle strength and balance are also impaired,41–45 Overall evaluation of functional (physical functioning)
leading to a faster decline in functional (physical functioning) perform- performance with objective tests should be
IIa B
ance in both symptomatic and asymptomatic patients.46,47Depression considered in patients with symptomatic and
is associated with greater impairment in functional performance.48,49 asymptomatic chronic PAD.57,61,63
Impaired functional status is related to decreased self-reported Overall evaluation of self-reported (i.e. by
HRQoL,50,51and predicts further mobility loss and CV mortality.52,53 questionnaire) physical and mental/social HRQoL
IIa B
Very poor HRQoL has been found in patients with chronic limb- should be considered in patients with
threatening ischaemia (CLTI).54 PAAD.34–36,38,72
Different questionnaires are available assessing different facets (func-
tional, mental, and social status) of patient-reported outcome measures CVRFs, cardiovascular risk factors; HRQoL, health-related quality of life; PAAD, peripheral
arterial and aortic diseases; PAD, peripheral arterial disease.
(PROMs).34–36,38The Short-form 36-item health questionnaire (SF-36) aClass of recommendation.
(including physical- and mental health-related items) is the most used bLevel of evidence.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 24 ---
ESC Guidelines 3561
5.3. Vascular examination of peripheral diagnosis.79,85–87For values >1.40, the term ‘non-compressible arteries’
arteries should be used.
Ankle–brachial index >1.40, seen in arterial stiffness (diabetes,
The ankle-brachial index (ABI)78,79is a low-cost, easy, and largely used severe kidney failure, or advanced age), correlates with increased CV
tool, used both at rest or after exercise80–84for PAD diagnosis and sur- events and mortality risk.88,89 For ABI >1.40, assessing resting toe–
veillance (Figure 4). Both oscillometric and Doppler methods have brachial index (TBI) is recommended.79,90–95
shown good concordance.78 Toe–brachial index addresses medium-calibre artery rigidity96measur-
Resting ABI has a 68%–84% sensitivity and an 84%–99% specificity ing pressure on the hallux, second, or third toe using laser Doppler probe
for PAD diagnosis (Figure 4).79 An ABI ≤0.90 confirms PAD or plethysmography.97,98 Sensitivity and specificity for PAD diagnosis
Ankle-brachial index (ABI) Toe-brachial index (TBI)
Haemodynamic criteria for PAD
Higher systolic ankle pressure of target leg
(posterior tibial or dorsalis pedis artery) Toe pressure of target leg
Higher systolic brachial pressure, Higher systolic brachial pressure,
irrespective of target leg irrespective of target leg
Borderline ABI
Normal Normal
1.0 0.70
0.90 ABI TBI
Abnormal Abnormal
low ABI low TBI
1.40
Abnormal
high ABI
Haemodynamic criteria for CLTI
Ankle pressure <50 mmHg Toe pressure <30 mmHg
Transcutaneous oxygen partial pressure (TcPO )
2
TcPO <30 mmHg
2
How to measure
In supine position, 5–10 min resting, constant room temperature
ABI and ankle pressure: cuffs on upper arms and lower limbs (just above the ankle)
TBI and toe pressure: cuffs on upper arms and photoplethysmography probe on distal pulp of first or second toe
TcPO : preferred position of measurement electrode at first intermetatarsal position
2
Figure 4 Haemodynamic assessment of peripheral arterial disease. ABI, ankle–brachial index; CLTI, chronic limb-threatening ischaemia; PAD,
peripheral arterial disease; TBI, toe–brachial index; TcPO , transcutaneous oxygen pressure.
2
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 25 ---
3562 E S C G u id e l in e s
range from 45% to 100% and 17% to 100%, respectively.91 The usual 5.3.2. Digital subtraction angiography, computed
pathological threshold for TBI is ≤0.70 (Figure 4).99 tomography angiography, and magnetic resonance
Used within the Framingham risk score, ABI enables the upgrading of angiography
risk estimation in ‘low-risk’ women and men,77,88it allows CV risk as-
Detailed information about these techniques can be found in the
sessment in diverse ethnic groups independently of risk factors,77,89
Supplementary data online, Section 1.2 (Table S1). Digital subtraction
and is inexpensive and minimally time-consuming.100Trained physicians
angiography (DSA) remains mostly limited to revascularization proce-
have better reproducibility than inexperienced ones.101,102
dures. Computed tomography angiography (CTA) offers better spatial
In patients with exertional limb pain relieved by rest and a resting
resolution than magnetic resonance angiography (MRA) and better cal-
ABI >0.90, exercise testing with post-exercise ABI measurements
cification visualization; however, it can also overestimate stenosis sever-
or exercise oximetry has been proposed to diagnose lower-limb ar-
ity due to the blooming effect. MRA allows arterial wall and lumen
terial stenoses.103–105
assessment as well as tissue and organ perfusion distal to or surround-
The post-exercise ABI is determined 1 min after the cessation of
ing the explored arterial territory.
a standardized treadmill exercise.106The physician measures bilat-
eral ankle BP, starting with the symptomatic leg, using the ankle ar-
tery used for the reference resting ABI measurement. Brachial SBP Recommendation Table 2 — Recommendations for
should simultaneously be measured to enable calculation of the diagnostic tests in patients with peripheral arterial
post-exercise ABI.104 disease
Discrepancies in PAD diagnosis exist between exercise criteria, such
Recommendations Classa Levelb as a fall in absolute ankle BP >30 mmHg or a drop of >20% in the post-
exercise ABI.104Recent studies identified numerous false positives in a
Measurement of the ABI is recommended as the
healthy population when using a post-exercise ABI drop of >20% as the
first-line non-invasive test for screening and diagnosis
diagnostic threshold, as commonly proposed.103 I B
of PAD, using an ABI ≤0.90 as a diagnostic
Measurement of transcutaneous oxygen pressure (TcPO ) is a
2 criterion.79,90,130,131
means of evaluating tissue viability and is proposed as a diagnostic cri-
In the case of non-compressible ankle arteries or ABI
terion of CLTI (Figure 4).107TcPO is affected by local and general fac-
2 >1.40, additional methods such as TP, TBI or
tors such as skin thickness, probe temperature, inflammation, and I B
oedema,108,109resulting in misleading values. Doppler waveform analysis are
recommended.90,91,124,132,133
Resting TcPO >30 mmHg is a favourable indicator of wound heal-
2
ing;110–112however, resting TcPO 2 <10 mmHg is associated with bad ABI, ankle–brachial index; PAD, peripheral arterial disease; TBI, toe–brachial index; TP, toe
prognosis for wound healing and amputation in CLTI patients treated pressure.
with bone marrow-derived stem cells.107When performed at succes- aClass of recommendation.
bLevel of evidence.
sive levels on an ischaemic limb, TcPO measurement may help to de-
2
termine amputation level.113–115
Exercise transcutaneous oximetry has also been proposed.116,117
5.4. Evaluation of the aorta
This seems of interest to detect proximal (buttock) claudication105
or unsuspected exercise-induced hypoxaemia118in patients with inter- The aorta can be divided into different anatomical regions (from prox-
mittent claudication (IC).117 imal to distal) for reporting purposes. The main anatomical aortic re-
gions are the aortic root, ascending aorta, aortic arch, descending
thoracic aorta (DTA), abdominal aorta (AA), infrarenal aorta, and the
5.3.1. Duplex ultrasound iliac arteries (Figure 5).134,135
Duplex ultrasound (DUS) is a first step in the vascular work-up for PAD
screening and diagnosis, allowing a dynamic, non-invasive, radiation- and
contrast-free examination. It localizes vascular lesions and quantifies 5.4.1. Aortic measurements
their extent and severity through velocity criteria.119–121 In combin- The main imaging techniques used for aortic evaluation are illustrated in
ation with ABI or TBI, DUS permits determining the haemodynamic Table 5.
relevance of arterial lesions122,123 and estimation of ABI.124 DUS has Evaluating aortic dilation and progression depends on standardized
a sensitivity of 88% and specificity of 95% for >50% stenosis detec- measurements. In echocardiography, aortic diameters should be mea-
tion.125Post-exercise DUS can reveal borderline arterial lesions if initial sured using the leading-to-leading edge method during end-diastole
findings are inconclusive.122,126,127 (as systole sees about a 2 mm aortic expansion) in all segments
Duplex ultrasound distinguishes atherosclerotic (even subclinical dis- (Figure 6).137,138
ease) from non-atherosclerotic lesions, but its reliability relies on the Most studies supporting prophylactic surgery have used this ap-
sonographer’s expertise.122Cross-sectional imaging is advisable for re- proach. Furthermore, better agreement exists between echo’s
vascularization planning. ABI and DUS are recommended for PAD pa- leading-to-leading edge and cardiovascular computed tomography
tient follow-up post-revascularization.128 (CCT)/cardiovascular magnetic resonance (CMR)’s inner-to-inner
More recent techniques, such as flow imaging, 3D echography, ultra- edge during end-diastole.137,139,140 However, when the aortic wall
fast ultrasound, and shear wave elastography, as well as the use of thickens (e.g. atheroma, thrombus, intramural haematoma [IMH], or
contrast-enhanced ultrasound (CEUS), could further improve DUS aortitis) or in cases of aortic dissection (AD), also report the
performance.129 outer-to-outer diameter (Figure 6).
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 26 ---
ESC Guidelines 3563
Aortic arch
Mid
aortic
34 mm 31 mm arch
1 2
3
Proximal aortic arch 37 mm 34 mm 0 Proximal
descending
Ascending aorta 40 mm 36 mm 29 mm 26 mm aorta
4
Thoracic
descending
Sinotubular junction 38 mm 33 mm aorta
Sinus of Valsalva 40 mm 34 mm Distal
(<22 mm/m2) descending
5
23 mm 20 mm
aorta
6
7
8
Abdominal
aorta
9 23 mm 19 mm
10
11
Figure 5 Anatomy and aortic segments and upper normal values for aortic dimensions. Numbers represent the 11 aortic segments based on the
Society for Vascular Surgery/Society of Thoracic Surgeons (SVS/STS) classification for surgical and endovascular purposes.136Z-scores can be calcu-
lated for aortic root and ascending aorta. Calculation of z-scores can be performed following these links: https://www.marfan.fr/accueil/z-score-calculus/
or https://marfan.org/dx/z-score-adults.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 27 ---
3564 E S C G u id e l in e s
Table 5 Main aortic imaging techniques
TTE/DUS TOE CCT CMR
Availability ++++ +++ ++ +
Cost + ++ +++ ++++
Time requirement + +++ +++ ++++
Radiation 0 0 +++ 0
Spatial resolution 1 mm 1 mm 0.6 mm 1–2 mm
Temporal resolution 20 msec 20 msec 80 msec 30 msec
Nephrotoxicity 0 0 +++ +
Accuracy ++ ++++ ++++ ++++
Serial examination ++++ ++ ++ ++++
Aortic wall visualization ++ +++ ++++ ++++
Aortic valve function +++ ++++ + ++++
RV/LV function +++ +++ +++a ++++
Aortic root assessment +++ +++ ++++ ++++
Aortic arch assessment ++ +++ ++++ ++++
Thoracic aorta assessment + ++ ++++ ++++
Abdominal aorta assessment +++ - ++++ ++++
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; LV, left ventricle; RV right ventricle; TOE, transoesophageal echocardiography; TTE, transthoracic
echocardiography.
aCCT can be used to evaluate left and right ventricular function only if retrospective gating is used.
A B C
ASC
AoR
D E F
Figure 6 Conventional measurements of the aorta at different levels by echocardiography or duplex ultrasound (A, B, C), cardiovascular computed
tomography or cardiovascular magnetic resonance (D, E, F). (A) Echocardiographic measurements of the aortic root and ascending aorta using the
leading-to-leading edge methodology. (B) The outer-to-outer convention in the abdominal aorta in cases with aortic wall disease in a longitudinal
view. This method can be used in a non-circular section as an alternative. (C) The outer-to-outer antero-posterior diameter of the abdominal aorta
in a cross-sectional view. Evaluation of the aortic root using the cusp-to-cusp diameter (D) and the cusp-to-commissure convention (E); (F) meas-
urement of the ascending aorta and the descending aorta with the double-oblique technique. AoR, aortic root; ASC, proximal ascending aorta.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 28 ---
ESC Guidelines 3565
Given the high incidence of atherosclerotic plaques/thrombi in the Moreover, with ageing and loss of elastic properties, the aorta tends
AA, the outer-to-outer convention should be preferred (also present- to enlarge. Aortic growth in adults is about 0.9 mm per 10 years in
ing the best agreement with CCT and CMR) (Figure 6).141,142 males and 0.7 mm per 10 years in females, which may be influenced
Regarding CCT and CMR, measurements must be performed using by BP, physical activity, and genetic factors.
the inner-to-inner edge method (Figure 6) in end-diastole (fewer mo-
tion artefacts).137,143,144
The aortic root is measured in the parasternal long axis by transthor- Recommendation Table 3 — Recommendations for
acic echocardiography (TTE),137,139,140,145since the short axis underesti- imaging of the aorta (see also Evidence Table 2)
mates the diameter due to possible plane obliquity. By CMR or CCT, the
cusp-to-cusp diameter best correlates with echocardiography (Figure 6). Recommendations Classa Levelb
A diameter difference >5 mm (among root diameters within the same
It is recommended that aortic diameters are
imaging modality) indicates root asymmetry, frequent in bicuspid aortic
measured at pre-specified anatomical landmarks, and
valve (BAV) or genetic aortopathies, which is important to be determined I C
the largest diameter of the section be perpendicular
since it generates underestimations.146While 3D echocardiography is a
to the longitudinal axis.134,135
potential surveillance alternative in these cases (especially if CMR/CCT
is limited for serial follow-up), validation studies are lacking.147 It is recommended in cases of serial imaging of the
aorta over time to use the same imaging modality I C
In end-diastole, measure the ascending aorta by moving the transducer
1–2 intercostal spaces up in the parasternal long axis. Echocardiography with the same measurement method.159
provides information on aortic arch or DTA enlargement, but diagnostic It is recommended to consider renal function,
certainty (precise measurement of the diameters) is lacking. CCT or pregnancy, age, and history of allergy to contrast
CMR uses the double-oblique technique to measure aortic diameters, re- media to select the optimal imaging modality with I C
porting antero-posterior and perpendicular dimensions for accurate as- minimal radiation exposure and lowest iatrogenic
sessment.148 It is recommended to report aortic measurements by risk, except for emergency cases.159–161
specific segments based on anatomical landmarks and to relate the largest Indexing aortic diameters to BSA, along with the use
diameter to a nearby anatomical structure for reference. of nomograms, z-scores, or other indexing methods,
Changes in aortic diameter require a ≥3 mm increase in echocardi- should be considered for more accurate assessment IIa B
ography, which should be confirmed with CCT/CMR and compared
of aortic size, especially for body sizes at the lower
with baseline measurements. For accurate assessment, stick to the end of the normal distribution.156–158
same imaging technique, centre, methodology, and side-by-side
comparisons.137,140 BSA, body surface area.
aClass of recommendation.
bLevel of evidence.
5.4.2. Normal aortic values
When evaluating aortic dimensions and clinical relevance, consider fac- 5.4.3. Chest X-ray and electrocardiogram
tors like aortic region, anthropometric measurements, patient history, Chest X-ray obtained for other indications in asymptomatic patients or
and underlying medical conditions. Factors influencing aortic and per- in cases of acute aortic syndrome (AAS) suspicion may detect abnor-
ipheral artery size in the normal population include age, sex, ethnicity, malities of aortic size/contour that need to be confirmed by another im-
body surface area (BSA), and, particularly, height.149 aging technique. It presents limited sensitivity (64%) and specificity
Body surface area is the most used method to normalize aortic dimen- (86%) in the diagnosis of aortic diseases;162 thus, a normal chest
sions based on an individual’s body size, thus an ascending thoracic aorta X-ray may not rule out the diagnosis of AAS.162–164On the contrary,
>22 mm/m2 or a DTA >16 mm/m2 is considered aortic dilatation.150–152 chest X-ray may identify other causes of chest pain (e.g. pleural effusion
However, extremes of low or high body weight pose limitations. In such or pneumothorax).
cases, surgical thresholds may involve indexing aortic diameter by height Electrocardiogram (ECG) might be useful to rule out other causes of
(an aorta height index >32.1 mm/m is associated with a 12% yearly risk chest pain (e.g. MI) or AAS complications (coronary occlusion/dissec-
of aortic adverse events [AAE]),153aortic cross-sectional area to patient tion) but it is not useful for AAS diagnosis.
height (a ratio ≥10 cm2/m implies reduced long-term survival),154or aor-
tic length (from the aortic annulus to the innominate artery, considering a
length >11 cm a threshold for surgery).155 5.4.4. Echocardiography
To correlate measured diameter with the expected one based on It is considered the first-line imaging technique in the evaluation of aor-
age, sex, and body surface, use nomograms or z-score calculation for- tic disease, assessing all echocardiographic windows and the aortic
mulas, especially in heritable thoracic aortic disease (HTAD). valve. It provides key anatomic information (i.e. dilatation, atheroscler-
Supplementary data online, Figure S1 and Table S2, presents nomo- otic lesions, or dissection) for the ascending aorta, arch, and AA; how-
grams developed for echocardiography, applicable also to CCT ever, it is not useful to assess the exact diameters of the aortic arch and
and CMR.156,157Calculation of z-scores can be performed following DTA (requiring confirmation with CCT/CMR). Also, the distal ascend-
these links: https://www.marfan.fr/accueil/z-score-calculus/or https:// ing aorta and proximal arch (blind spot) are inadequately visualized due
marfan.org/dx/z-score-adults/; reference values used for their esti- to left mainstem bronchus interposition.
mation may vary depending on age and other factors. However, Transthoracic echocardiography can identify AAS complications (e.g.
z-scores are limited by the fact that not all ethnic groups are equally aortic regurgitation, tamponade, or wall motion abnormalities), but its
represented (mostly white) and over- or underweight can lead to an diagnostic accuracy for AAS is limited (sensitivity: 78%–100% for type
over- or underestimation.158 A, 31%–55% for type B). Contrast enhancement improves diagnosis.165
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 29 ---
3566 E S C G u id e l in e s
Transoesophageal echocardiography (TOE) is highly accurate (sensitiv- recommended by the American Institute of Ultrasound in Medicine,
ity: up to 99%, specificity: 89% for AAS), except with absolute contra- the American College of Cardiology/American Heart Association
indications like oesophageal issues, bleeding, recent gastro-oesophageal (ACC/AHA), and the European Society of Cardiology (ESC), since it
surgery, or respiratory distress. TOE is convenient for bedside and in- is more reliable in cases of atherosclerotic plaque or intravascular
traoperative use but less suitable for long-term surveillance, which re- thrombus and best correlates with CCT and CMR. However, the
quires evaluation with CCT/CMR. most effective methodology is under debate and further studies are
needed to determine the best convention.169
Normal diameters of the AA are reported in Figure 5 and
Recommendation Table 4 — Recommendations for Supplementary data online, Section 1.3.
thoracic aortic measurements
5.4.6. Cardiovascular computed tomography
Recommendations Classa Levelb
Cardiovascular computed tomography, due to its quick acquisition,
TTE is recommended as the first-line imaging wide availability, high reproducibility, and suitability for emergency de-
I B
technique in evaluating thoracic aortic diseases.159,165 partments, is the primary imaging method for aortic disease diagnosis,
It is recommended to report aortic diameters using prognosis, and therapy planning (sensitivity 100%, specificity 98% for
the leading-to-leading edge convention in I C AAS).170–172‘Double or triple rule-out’ protocols concurrently assess
end-diastole by echocardiography.137,139,140,159 the aorta, pulmonary, and coronary arteries.173,174
It is recommended to report aortic diameters using Electrocardiogram triggering is crucial to prevent motion artefacts
the inner-to-inner edge convention in end-diastole I C (especially in the aortic root and ascending aorta), which can distort
by CCT or CMR.137,143,144,159 measurements or resemble dissection flaps, facilitating coronary artery
assessment. The standard protocol comprises non-enhanced scans (for
It is recommended to report aortic diameters from
calcification, IMH, or surgical material), contrast-enhanced CCT angiog-
images obtained with the double-oblique technique I C
raphy, and a late scan (to visualize contrast leakage or aortic wall late
(not axial images) by CCT or CMR.148
enhancement suggestive of inflammation or infection).175
ECG-triggered CCT is recommended for
Iodinated contrast agents carry potential allergic reactions and post-
comprehensive diagnosis, follow-up, and pre-invasive I C contrast acute kidney injury (PC-AKI) risks.176In these cases, opt for
treatment assessment of the entire aorta, particularly
contrast-free CCT for accurate aortic diameter measurement (also
the root and ascending aorta.159 for CMR-intolerant patients). Moreover, excessive radiation caution
CMR is recommended for diagnosis and follow-up of is crucial, particularly in young females, when performing CCT for mon-
thoracic aortic diseases, especially when chronic I C itoring chronic aortic diseases.177
follow-up is required.166–168
The aortic root should be measured using the 5.4.7. Cardiovascular magnetic resonance
cusp-to-cusp distance. Also, the presence of Cardiovascular magnetic resonance comprehensively evaluates the
IIa C
asymmetry (>5 mm) among distances should be aorta, including shape, diameter, tissue characteristics (inflammation, in-
reported.137,146 fection, atheroma, bleeding),178lesion extent, side branches, adjacent
If an increase of ≥3 mm per year in aortic diameters structures, and mural thrombus. It assesses ventricular and valve func-
by TTE is observed, confirmation by CCT/CMR IIa C tion, quantifies flow, and employs cine steady-state free precession
should be considered.137,159 (SSFP) or ECG-gated angio-CMR for the aortic root, while non-gated
sequences suffice for the rest. Recently, 4D flow sequences179 have
Chest X-ray may be considered in cases of low
been developed to evaluate complex intravascular flows,180,181 com-
clinical probability of AAS; however, a negative
IIb C plex flow parameters (wall shear stress, pulse wave velocity, or kinetic
exploration should not delay dedicated aortic
imaging in high-risk patients.162–164 energy), or flow quantification at different levels in one unique acquisi-
tion (useful in AD or congenital diseases).182,183
AAS, acute aortic syndrome; CCT, cardiovascular computed tomography; CMR, Cardiovascular magnetic resonance obviates ionizing radiation and
cardiovascular magnetic resonance; ECG, electrocardiogram; TTE, transthoracic
iodinated contrast (3D contrast CMR), making it ideal for young pa-
echocardiography.
aClass of recommendation. tients, women, and pregnancy. Caution is warranted, especially with
bLevel of evidence. non-macrocyclic gadolinium, for estimated glomerular filtration
rate (eGFR) <30 mL/min/1.73 m² (Supplementary data online,
Section 1.2). CMR is increasingly used in patients with intracardiac de-
5.4.5. Duplex ultrasound imaging of the abdominal vices (pacemakers/implantable cardioverter defibrillators, CMR- and
aorta non-CMR-compatible devices) with proper monitoring, but not for
those with cochlear implants or intracranial clips.184,185
After scanning both transversally and longitudinally, the antero-
In the acute setting, CMR use is limited because of low availability, dif-
posterior (AP) diameter in a cross-sectional view of the AA should
ficulties in monitoring unstable patients, and longer acquisition
be measured. Ensure the DUS beam is perpendicular to the AA axis,
times.166,186
forming a circular vessel section. If the AA is sinuous or dilated, achiev-
ing equal AP and transverse diameters may be challenging. In such in-
stances, calculate the mean ellipse diameter or measure the AA 5.4.8. Positron emission tomography
diameter in a clear longitudinal view with a perpendicular diameter Positron emission tomography (PET) usually uses 18F-fluorodeoxyglucose
(Figure 6).122 The outer-to-outer (Figure 6) method is the one (FDG), allowing non-invasive assessments of metabolic activity
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 30 ---
ESC Guidelines 3567
(inflammation/infection) and treatment response.187,188Although differ- 6.1.2. Carotid artery stenosis
ent tracers have been tested to identify calcification, fibrosis and/or Due to the low prevalence of ≥70% asymptomatic carotid artery
thrombus formation, most PET studies have focused on vasculitis. stenosis (CS) in the general population (0%–3.1%), widespread
The relationship between FDG-PET images and AAA progression is screening is not recommended since it does not reduce stroke
controversial. However, fluorine-18–sodium fluoride (18F–NaF) risk and might lead to inappropriate stress and invasive proce-
PET-computed tomography (PET-CT), a marker of active vascular cal- dures.199,200Conversely, screening for significant CS in a highly se-
cification and high-risk plaques, has shown a correlation between in- lected population might be cost-effective, especially if prevalence is
creased tracer uptake, AAA growth, and CV events.189 ≥20% (Table 6).201When the degree of asymptomatic CS is ≥70%,
PET-CT has shown better diagnostic accuracy in identifying lesions the 5 year ipsilateral stroke risk is significantly increased (14.6%) and
and detecting graft infection or infectious aortic diseases.190–193High revascularization may be beneficial.202 Selective screening aims to
radiation exposure, high costs, and limited availability are the main lim- prevent CV events, rather than identifying candidates for an
itations of PET. intervention.203
5.4.9. Intravascular ultrasound
Intravascular ultrasound (IVUS) provides high-resolution imaging for ar- Table 6 High-risk populations for carotid artery
stenosis
tery and vein diseases, aiding complex aortic disease management by
distinguishing true and false lumens and guiding stent placement. It is
Population Prevalence of carotid stenosis
operator-dependent, costly, and less accessible, but seems to provide
(%)
better measurements for acute aortic syndromes.194
>60 years + CVRFs (hypertension, Two CVRFs: 14%
5.4.10. Digital subtraction aortography CAD, current smoking, Three CVRFs: 16%
Non-invasive imaging modalities have replaced DSA in first-line first-degree family history of Four CVRFs: 67%
diagnostic testing, both in suspected AAS or known chronic AD;
stroke)210
however, DSA might be useful if findings in non-invasive techniques Hypertension + cardiac disease211 22%
are ambiguous or incomplete. It is primarily used for the percutan- HD212 • In HD patients, prevalence of
eous treatment of CAD, aortic visceral branches, or for monitoring carotid stenosis is high, and is
thoracic endovascular aortic aneurysm repair (TEVAR/EVAR) associated with high
implantation. peri-operative and long-term
stroke or death rates
6. Screening for carotid, • Carotid stenosis is a predictor of
death in patients with long-term
peripheral arterial, and aortic
dialysis and aged ≥70 years at time
diseases of surgery
• Lower risk if previous renal
6.1. Screening for carotid and peripheral transplant.
arterial diseases PAD213 23.2%
6.1.1. Lower-extremity peripheral arterial disease Severe CAD (before CABG) • Almost 20%214
• Carotid bruit and T2DM:
Due to elevated CV risk in chronic PAD, early diagnosis, preven-
increased predictive value215
tion, and robust cardiovascular risk factor (CVRF) control are es-
• Carotid stenosis = risk factors for
sential, even in asymptomatic cases. ‘Intermediary CV risk’
individuals may be reclassified as ‘high or very high risk’, prompting peri-operative stroke.215
adapted prevention. ABI is the preferred first-line test for asymp- Carotid bruit216 31%
tomatic individuals aged ≥65 years,14,195 especially women.196 Previous neck irradiation217 21.7% (70%–99% stenosis)
Screening might also be beneficial at a younger age in case of
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CVRFs,
CVRFs, but data are still lacking. Clinical examination, functional
cardiovascular risk factors; HD, haemodialysis; PAD, peripheral arterial disease; T2DM,
status, and walking capacity assessment are recommended to de- type 2 diabetes mellitus.
tect ‘masked PAD’.77
In diabetes, early PAD (and foot neuropathy) diagnosis is crucial.
Effective CVRF management and treatment can prevent CV disease, 6.1.3. Multisite artery disease
foot wounds, and amputation.197In patients with diabetes and normal Multisite artery disease (MAD) is defined as the presence of athero-
resting ABI, TBI measurement should be considered. sclerosis in two or more vascular beds.204This is a common condition
The prevalence of popliteal aneurysms (PAs) is high in patients with in patients with atherosclerotic diseases. Although associated with
AAA and subaneurysmal aortic dilatation, warranting screening. PAs worse clinical outcomes, screening for asymptomatic disease in add-
are correlated with iliac and femoral artery diameters.76 In patients itional vascular sites did not seem to improve outcomes.77 More re-
needing transfemoral access, screening for iliofemoral artery disease cently, screening for coronary calcifications (coronary artery calcium
may be considered.198 [CAC] score) and screening for carotid and femoral plaques have
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 31 ---
3568 E S C G u id e l in e s
been shown to be of potential assistance in CV risk reclassification of Recommendation Table 6 — Recommendations for
‘presumed moderate-risk patients’ into a higher-risk category, leading abdominal aortic aneurysm screening
to more aggressive prevention strategies.205–209
Recommendations Classa Levelb
Recommendation Table 5 — Recommendations for
Screening for AAA with DUS:
peripheral arterial disease screening (see also Evidence
Table 3) Is recommended in men aged ≥65 years with a
history of smoking to reduce the risk of death from I A
Recommendations Classa Levelb ruptured AAA.221–224,234
In patients with diabetes or chronic kidney disease, May be considered in men aged ≥75 years
and normal resting ABI, TBI measurement should be IIa B (irrespective of smoking history) or in women aged
IIb C
considered. ≥75 years who are current smokers, hypertensive,
In patients ≥65 years of age with CVRFs, screening or both.227,228,235–237
IIa C
for PAD by ABI or TBI should be considered.77,218,219 Family AAA screening with DUS:
In patients with AAA, femoro-popliteal aneurysm Is recommended for FDRs of patients with AAA aged
IIa C
screening with DUS should be considered.76 ≥50, unless an acquired cause can be clearly I C
In patients ≥65 years without CVRFs, screening for identified.231
IIb C
PAD by ABI or TBI may be considered.220 Opportunistic AAA screening with DUS:
In patients needing intervention with transfemoral
Should be considered in symptomatic/asymptomatic
access, screening for iliofemoral artery disease may IIb C PAD patients.233 IIa B
be considered.198
Should be considered in men aged ≥65 years and in
In patients with two or more CVRFs, screening for IIb C women aged ≥75 years during TTE.232 IIa B
CS may be considered.201,203,210
AAA, abdominal aortic aneurysm; FDR, first-degree relative; DUS, duplex ultrasound; PAD,
AAA, abdominal aortic aneurysm; ABI, ankle–brachial index; CS, carotid artery stenosis; peripheral arterial disease; TTE, transthoracic echocardiography.
CVRFs, cardiovascular risk factors; DUS, duplex ultrasound; PAD, peripheral arterial Smoking is defined as lifetime smoking of >100 cigarettes or equivalent. This threshold is
disease; TBI, toe–brachial index. used to distinguish between substantial exposure and occasional use.
aClass of recommendation. aClass of recommendation.
bLevel of evidence. bLevel of evidence.
6.2. Screening for aortic diseases
6.2.1. Screening for abdominal aortic aneurysm 6.2.2. Screening for thoracic aortic aneurysm
Abdominal aortic aneurysm screening by DUS is effective in reducing Screening for TAA is described in detail in Section 10.1and Section 10.2.
rupture-related mortality in populations with high AAA prevalence (es-
pecially male smokers aged ≥65 years).221–224However, no such effect
7. Optimal medical treatment
has been found in a single large study in which AAA prevalence was low
(current or former smoking women aged 65–74 years, or with a history
Optimal medical treatment (OMT), including lifestyle measures and
of CAD).225
pharmacological treatment, is recommended for all patients with
Screening for AAA by non-contrast computed tomography (CT)
PAAD (Figure 7).
was not found to be effective over 5 years in males aged 65–74 years
in a Danish trial.226Longer-term follow-up is planned, and as the tech-
7.1. Lifestyle, exercise, patient education
nique involves ionizing radiation, no recommendation is made in rela-
Apart from genetic-related TAA, hypertension and ASCVD are the
tion to CT at present.
main causative factors for PAAD. As lifestyle factors are strongly re-
Screening may be considered in populations at intermediate risk,
lated to ASCVD,11 patients with PAAD should strive to maintain a
such as men aged >75 years, or women aged >75 years who are hyper-
healthy lifestyle. The 2021 ESC Guidelines on cardiovascular prevention19 tensive, smokers, or both, since almost all women in a contemporary
give comprehensive guidance on risk factors for ASCVD and their
population-based study who had ruptured AAA and were aged
>75 years were either smokers or hypertensive.227,228 treatment.
Screening for AAA is recommended in first-degree relatives (FDRs) of
patients with AAA (especially siblings), as they are at increased risk of 7.1.1. Diet
AAA when >50 years of age.229The risk associated with family history A Mediterranean diet rich in legumes, dietary fibre, nuts, fruits, and
is uncertain, but a population-based study estimated a relative risk of vegetables proves crucial and efficacious for primary and CV pre-
around 2.230Screening should be repeated periodically if initial assessment vention in PAAD.238It has demonstrated notable reductions in chol-
is reassuring and performed at a relatively young age.231 esterol and BP,239–247and holds potential protective benefits against
Opportunistic screening (during TTE) identified AAA in about 2% of PAAD development.248,249 In a large cohort with 17.5 years of
subjects, thus it may be considered in high-prevalence populations follow-up, adherence to a Mediterranean diet was associated with
(males ≥65 or women ≥75 years of age).232Additionally, opportunistic reduced AAA risk in current and ex-smokers.249,250 Malnutrition
screening detects AAA in patients with symptomatic/asymptomatic and metabolic disorders can complicate post-invasive procedure re-
PAD (with a 12% cumulative incidence in symptomatic PAD), making covery and nutritional support may improve nutritional status and
it worthwhile in this population.233 HRQoL.251
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 32 ---
ESC Guidelines 3569
7.1.2. Physical activity physical activity is also relevant in patients with aortic diseases70,71,256–259
Few patients with chronic symptomatic PAD meet the physical activity guide- and lowers resting heart rate and BP, thus decreasing the risk of aortic com-
lines252for reducing the risk of major adverse cardiac events (MACE).253,254 plications.256,259Few data exist on the practice of exercise and sports in pa-
Better ambulation, HRQoL, and vascular outcomes have been observed in tients with aortic diseases.70,71,256–259 Recommendations should be
patients meeting the physical activity time-intensity guidelines.19,255Regular individualized and based on risk stratification.71
Targets
Systolic blood pressure
≤120–129 mmHg
Diastolic blood pressure
Beta-blockers ≤70–79 mmHg
ACEi or ARB
Calcium channel blockers
Reducing risk of atherothrombosis
Medications
Antiplatelet therapy
Anticoagulants
Statins
Optimal glucose control (HbA1c <7%)
Ezetimibe
PCSK9i
Bempedoic acid
Glucose-lowering agents LDL <55 mg/dL (<1.4 mmol/L)
Targets
Healthy diet
BMI 20–25 kg/m2
Waist: <94 cm men; <80 cm women
Educational programmes Lifestyle Low-to-moderate exercise training
Psychological support
Genetic counselling
Supervised exercise training Avoid smoking/smoking cessation
Avoid excessive alcohol intake
Limit isometric exercise in
aortic diseases
Avoid cocaine and stimulating drugs
Figure 7 Cardiovascular risk modification and healthy lifestyle interventions and targets in patients with peripheral arterial and aortic diseases. ACEi,
angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; LDL, low-density lipoprotein; PCSK9i, proprotein
convertase subtilisin/kexin type 9 inhibitor; HbA1c, glycated haemoglobin.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 33 ---
3570 E S C G u id e l in e s
7.1.3. Smoking smartphone apps on the ESC website (https://www.escardio.org/
Patients with PAAD who smoke should strongly be advised to quit (see Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/SMART-
Supplementary data online, Section 1.1.5). Complete smoking cessation Risk-Score).
and avoiding second-hand smoke or environmental particle air pollu-
tion are crucial in patients with PAAD to reduce the risk of death,
Recommendation Table 7 — Recommendations for
AD, acute mesenteric ischaemia (AMI), AAA, and PAD.119,260–267 lifestyle, physical activity, and patient education (see
Smokers should be offered structural follow-up support, including nico- also Evidence Table 4)
tine replacement therapy, varenicline, and bupropion, individually or in
combination.19,268,269Smoking avoidance also includes cannabis, asso- Recommendations Classa Levelb
ciated with premature ASCVD.266
In patients with PAAD, cessation and abstinence from
Vaping and e-cigarette use has surged in the past decade, viewed by
smoking of any kind is recommended to reduce the I A
some as a healthier option than smoked tobacco, though long-term
health effects remain unknown.270E-cigarettes may be considered as risk of AD, MI, death, and limb ischaemia.119,261–267
an aid to quit tobacco smoking, as a recent Cochrane review found A healthy diet rich in legumes, dietary fibre, nuts,
that they increase quit rates as compared with nicotine replacement fruits, and vegetables, with a high flavonoid intake
therapy,271but their use has been associated with adverse effects on (Mediterranean diet), is recommended for CV I A
CV, respiratory, immunological, and periodontal health compared with disease prevention in patients with PAAD.239–
non-users, but with a milder impact than smoked cigarettes.272–274 241,249,290–293
However, their use should be brief and preferably not concurrent with Low- to moderate-intensity (or high if tolerated)c
traditional cigarettes.271,275 aerobic activities are recommended in patients with
I A
The main limitation of the evidence base remains imprecision due to PAD to increase overall and pain-free walking
the small number of randomized controlled trials (RCTs), often with distance.37,294
low event rates and follow-up limited to 2 years.
In patients with PAAD, behavioural counselling to
promote healthy diet, smoking cessation, and
I B
7.1.4. Patient education physical activity is recommended to improve the CV
risk profile.241,249,253,295
While detailed explanations of CVRFs might not always inspire lifestyle
changes,276providing plain language and visual aids is essential for pa- It is recommended to promote patient and
tient understanding.277Structured programmes, incorporating psycho- caregivers’ education and empowerment through
I C
logical and behavioural aspects, are pivotal in fostering desired tailored guidance on lifestyle adjustments and the
changes.276 Engaging patients’ families, friends, and support networks importance of regular physical activity.276,277,283
significantly contributes to perpetuating these changes (particularly in In patients with PAAD, avoidance of exposure to
self-care),276and increases treatment compliance and self-efficacy, re- second-hand smoke and air pollution should be IIa C
ducing hospitalization risk and enriching patient HRQoL.278,279When considered.261
caregivers disconnect from healthcare professionals, they should be re- Physical exercise and sports activities should be
cognised to receive better support systems.280,281Psychosocial inter-
considered in patients with aortic diseases based on
ventions are crucial to navigating complexities with resilience.282 IIa C
prior risk stratification (based on the extent of the
Advocating active involvement, education, clear communication, and aneurysm, risk of dissection, and BP control).71
shared decision-making is key for achieving optimal patient out-
Use of web- or app-based secondary prevention risk
comes.276–283
calculators should be considered in the shared
IIa C
decision-making to improve patient adherence to
7.1.5. Risk scoring models in secondary prevention treatment and lifestyle changes.288,289
Recent ESC CV prevention guidelines discuss risk models for develop- E-cigarettes may be considered as an aid to quit
ing vascular disease in healthy individuals and ASCVD patients.19 tobacco smoking, but it is advisable to limit their use
Several registries enabling risk prediction in ASCVD have been and avoid simultaneous use with conventional IIb C
developed: REACH (The REduction of Atherothrombosis for cigarettes due to unknown long-term
Continued Health)284 and SMART (Secondary Manifestation of effects.119,271,296,297
ARTerial disease)285which use clinical parameters such as medical his-
AD, aortic dissection; BP, blood pressure; CV, cardiovascular; MI, myocardial infarction;
tory, SBP, and common biomarkers. Addition of carotid ultrasound
PAAD, peripheral arterial and aortic diseases; PAD, peripheral arterial disease.
did not improve the model.286 A new algorithm combining the aClass of recommendation.
SMART and REACH models287 enables calculation of lifetime risk bLevel of evidence.
and treatment effects. The SMART model has recently been updated cLow intensity refers to an exercising heart rate (HR) of 57%–63% HRmax or a rate of
perceived exertion (RPE) on the Borg’s scale of 9–11. Moderate intensity refers to an
and validated288,289with the SMART-2 algorithm. These tools are avail-
exercising heart rate of 64%–76% HRmax or RPE of 12–13. Vigorous intensity refers to
able online as clinical risk calculators (see www.u-preveotnt.com) and an exercising heart rate of 77%–95% HRmax or RPE of 14–17.298
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 34 ---
ESC Guidelines 3571
7.2. Principles of pharmacological medical rate315 or increased rate of re-intervention316 in patients with CLTI
therapy treated with ACEIs, although in one smaller study no effect on
limb-related outcomes was observed.317Thus, they remain a treatment
7.2.1. Antithrombotic therapy
option in hypertensive patients with PAD, especially in those with con-
Antithrombotic therapy is crucial for patients with symptomatic PAAD at comitant CAD.318BBs were not associated with worsened clinical out-
high CV risk. While trials are fewer than in CAD, recent evidence should comes in a retrospective study319 on CLTI patients, but it seems
guide practice. In the absence of specific indications for chronic oral antic- prudent to avoid excessively low heart rates in these patients.
oagulation (OAC) in concomitant CV disease, a single antiplatelet agent is
the primary long-term treatment for patients with symptomatic PAAD.
7.2.2.1. Renovascular hypertension
Combining it with another antiplatelet agent or low-dose anticoagulants
Angiotensin-converting enzyme inhibitors and ARBs effectively manage
depends on the patient’s ischaemic and bleeding risk, as well as therapeutic
unilateral renal artery stenosis (RAS) by blocking the renin–angiotensin
paths (e.g. endovascular therapy). Recent guidelines299propose a tool for
system, potentially reducing renal capillary perfusion pressure.320–322
bleeding risk assessment in PAD patients (OAC3PAD score).
This transiently lowers glomerular filtration rate (GFR) and raises ser-
Antithrombotic strategy is detailed in Sections 8and 9for each arter-
um creatinine. For bilateral RAS, regular follow-up assessments of renal
ial territory.
function and kidney perfusion are advised.
Angiotensin-converting enzyme inhibitors and ARBs additionally
7.2.2. Antihypertensive therapy
(combined with hydrochlorothiazide and/or CCBs if needed) contrib-
New 2024 ESC Guidelines on hypertension are currently published and ute to CV risk reduction in patients with atherosclerotic disease and re-
should be reviewed for further details.300 Patients with hypertension duced eGFR.307,323,324
and PAAD are considered to have target organ damage and are at
high CV risk.300
Different meta-analyses showed that systolic BP treatments reduce
CV risk in all ages up to 85 years down to a level of 120– Recommendation Table 8 — Recommendations for
129 mmHg.301,302There is no need to increase the BP target in healthy antihypertensive therapy in patients with peripheral
and aortic disease
patients up to the age of 85 years.303,304To reduce cardiovascular disease
(CVD) risk, it is recommended that treated SBP values in most adults be
Recommendations Classa Levelb
targeted to 120–129 mmHg, provided the treatment is well tolerated.
However, in cases where BP-lowering treatment is poorly tolerated In patients with PAAD and hypertension an SBP
and achieving an SBP of 120–129 mmHg is not possible, it is recom- target towards 120–129 mmHg, if tolerated, is I A
mended to target an SBP level that is ‘as low as reasonably achievable’ recommended.301–305,325
(ALARA principle).301,302,305 To avoid overtreatment, out-of-office BP In unilateral RAS patients, it is recommended that
measurements may be helpful when pursuing this target.
antihypertensive medication include ACEIs/ I B
If on-treatment SBP is on target, but diastolic blood pressure (DBP) ARBs.307,320–323
is ≥80 mmHg, intensified treatment may be considered to further re-
In patients with PAAD and hypertension, ACEIs or
duce the CV risk.306
ARBs should be considered as first-line IIa B
Because the CVD benefit of an on-treatment BP target of 120–
antihypertensive therapy.307,312
129 mmHg may not generalize to some groups, setting personalized
In RAS-related hypertension, the combination of
and more lenient BP targets (e.g. <140/90 mmHg) has to be considered
ACEIs/ARBs with diuretics and/or calcium channel IIa B
in patients with pre-treatment orthostatic hypotension, age ≥85 years,
clinically significant frailty at any age, or a limited lifespan (<3 years).301 blockers should be considered.324
Patients with both PAAD and hypertension face a high or very high An individualized, more lenient BP goal (e.g. <140/
CV risk. Antihypertensive medications such as diuretics, beta-blockers 90 mmHg) should be considered in:301
(BBs), calcium channel blockers (CCBs), angiotensin-converting en- • Age ≥85 years IIa C
zyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) • Residential care
are all appropriate options for managing hypertension in PAAD. • Symptomatic orthostatic hypotension
These agents can be used as monotherapy or in various combinations An individualized, more lenient BP goal (e.g. <140/
(excluding ARBs+ACEIs), considering individual patients’ conditions. It 90 mmHg) may be considered in:301
is often necessary to implement combination therapy, preferably in IIb C
• Clinically severe frailty at any age
the form of a single pill, to effectively achieve the recommended treat-
• Limited life expectancy (<3 years)
ment goals. However, ACEIs or ARBs should be considered as first-line
In patients with bilateral RAS, antihypertensive
antihypertensive therapy to reduce CV events.300,307–312
medication including ACEIs/ARBs may be considered
Regardless of BP levels and in the absence of contraindications, IIb B
if close patient monitoring (renal function) is
ACEIs/ARBs may be considered in all patients with PAD to reduce car-
diovascular events.312,313A meta-analysis suggests that antihypertensive
feasible.321
treatment may improve mean walking distance in patients with PAD.310 ACEIs/ARBs may be considered in all patients with
Beta-blockers can be prescribed, if necessary, to patients with inter- PAD, regardless of BP levels, in the absence of IIb B
mittent claudication, since they do not worsen walking capacity or limb
contraindications.312,313
events.314 There is some evidence suggesting a higher amputation Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 35 ---
3572 E S C G u id e l in e s
In cases where on-treatment SBP is at or below 7.2.3.4. Bempedoic acid
target (120–129 mmHg) but DBP is not at target Bempedoic acid, acting upstream of statins in cholesterol metabolism,
(≥80 mmHg), intensifying BP-lowering treatment to IIb C has been shown to reduce cholesterol levels by 17%–28%359,360and
achieve an on-treatment DBP of 70–79 mmHg may demonstrated a decrease in the incidence of MACE in statin-intolerant
be considered to reduce CVD risk.306 PAD patients.361However, its impact on aortic diseases and AAA still
requires further research.
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BP,
blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; PAAD,
peripheral arterial and aortic diseases; PAD, peripheral arterial disease; RAS, renal artery 7.2.3.5. Hypertriglyceridaemia
stenosis; SBP, systolic blood pressure.
aClass of recommendation. Beyond LDL-C, evidence shows insulin resistance, elevated triglycer-
bLevel of evidence. ides, and remnant lipoproteins are associated with ASCVD, particularly
in PAD.362–365 However, in a meta-analysis and an RCT, fibrates
7.2.3. Lipid-lowering therapy
showed no benefit over placebo in reducing MACE in patients with
Patients with symptomatic PAAD are at very high CV risk but are usually PAD for a composite outcome of non-fatal stroke, non-fatal MI, and
inadequately managed compared with patients with CAD.5,247,326–332 vascular death.366Fibrates showed no benefit over placebo in reducing
Both LDL-C reduction by ≥50% from baseline and an LDL-C goal of coronary and cerebrovascular events in patients with PAD in an
<1.4 mmol/L (<55 mg/dL) are recommended to obtain a reduction in RCT.367 While the relationship between triglycerides and aortic dis-
CV death, MI, and stroke, and to improve walking distance.242,333–336 eases is complex and not fully understood, some evidence suggests
that triglyceride levels may contribute to the development and progres-
7.2.3.1. Statins sion of aortic diseases.
Statins demonstrate mortality and CV event reduction in RCTs for In contrast, icosapent ethyl (IPE) demonstrated a reduction
PAD, CS, and severe aortic arch plaques.243–245Even in advanced dis- in mortality and morbidity among individuals with hypertrigly-
ease stages, they are linked to lower MACE and mortality.246 ceridaemia in the Reduction of Cardiovascular Events With
Statins significantly improve CV outcomes in patients with PAD, redu- Icosapent Ethyl–Intervention Trial (REDUCE-IT).368 Its impact
cing major adverse limb events (MALE).244,327–329,337,338 Meta-analyses on patients with PAAD is unexplored,369 although a small pilot
show enhanced walking distances.244,338,339 RCT suggested an improved ABI in hyperglycaemic haemodialysis
For CS, statin pre-treatment lowers recurrent stroke risk post- patients.370
transient ischaemic attack (TIA).19,340–343While lacking RCTs in reno-
vascular or visceral artery disease, statins benefit cardiorenal events and
post-RAS stenting prognosis.344–346
Recommendation Table 9 — Recommendations for
Mixed evidence suggests statins may mitigate AAA and TAA
lipid-lowering therapy in patients with peripheral
growth.347–352However, since most patients with AAA or TAA pre-
arterial and aortic diseases
sent with associated CVRFs, liberal use of lipid-lowering treatment19
should be considered, using an individualized approach with shared Recommendations Classa Levelb
decision-making and considering residual CV risk.353Pre-operative sta-
tin use links to increased 5 year survival after TEVAR.19 In patients with atherosclerotic PAAD, lipid-lowering
I A
Statin use was associated with a mean AAA growth rate reduction therapy is recommended.242,334–336
and a lower rupture risk.347–349,352,354 An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL)
Some evidence suggests that statins may reduce TAA growth rate and a >50% reduction in LDL-C vs. baseline are
and risk of rupture.350,351,355 recommended in patients with atherosclerotic I A
No benefit on AAA or TAA growth rate was shown with fenofibrate PAAD.19,242,246,300,335
therapy.356,357
Statins are recommended in all patients with
I A
PAD.328,329,337,371
7.2.3.2. Ezetimibe
If the target LDL-C level is not achieved on maximally
Ezetimibe combined with statins benefits selected patients with
tolerated statins and ezetimibe, treatment with a
PAAD, particularly when the target LDL-C level is not met.335 In
PCSK9 inhibitor is recommended in patients with I A
an IMProved Reduction of Outcomes: Vytorin Efficacy International
atherosclerotic PAAD, to achieve target
Trial (IMPROVE-IT) subanalysis, involving acute coronary syndrome
values.372,373
(ACS) patients with PAD, ezetimibe consistently reduced CV risk, espe-
cially in high-risk subgroups.247,331 If the target LDL-C level is not achieved, a
combination of statins and ezetimibe is indicated in
I B
patients with atherosclerotic PAAD, to achieve the
7.2.3.3. Proprotein convertase subtilisin/kexin type 9 inhibitors
given target values.247
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, in addition
For statin-intolerant patients with atherosclerotic
to statins, reduce CV events in symptomatic atherosclerotic disease patients
PAAD, at high CV risk, who do not achieve their
with LDL-C ≥1.8 mmol/L.336Adding them to statins further reduces MACE
and MALE risk in patients with PAD and improves walking distance;333how- LDL-C goal on ezetimibe, it is recommended to add I B
ever, their potential in TAA/AAA is an emerging area of research.247 bempedoic acid either alone or in combination with a
PCSK9 inhibitor.361
Inclisiran, administered semi-annually, has proved a notable 26%
MACE risk reduction in a pooled phase III analysis,358 but its role in Statins for the reduction of growth and rupture of
IIa B
PAAD is not firmly established and ongoing RCTs including PAD parti- AAA should be considered.347–349,352,354
cipants (e.g. ClinicalTrials.govNCT05030428) aim to provide insights. Continued
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 36 ---
ESC Guidelines 3573
Statins for the reduction of growth and rupture of (CREDENCE) trial investigating canagliflozin in patients with T2DM
TAA may be considered.350,351,355 IIb B and chronic kidney disease (CKD).386 Still, the use of other SLGT2is
seems reasonable in PAD patients.
In high-risk patients with PAAD and triglycerides
Patients with carotid stenosis were included in trials testing GLP-1RA
>1.5 mmol/L despite lifestyle measures and statin
IIb B and SGLT2i, but no analysis on this subpopulation was performed. A
therapy, icosapent ethyl 2 g b.i.d. may be considered
meta-analysis of eight trials investigating GLP-1RAs vs. placebo in pa-
in addition to a statin.368
tients with T2DM reported a reduction in all strokes (HR, 0.84; 95%
Fibrates are not recommended for cholesterol III B CI, 0.75–0.93).387Among patients with T2DM and prior history of MI
lowering.367
or non-fatal stroke, GLP-1RAs reduced the incidence of recurrent
AAA, abdominal aortic aneurysm; b.i.d., twice daily; CV, cardiovascular; LDL-C, low-density MACE (HR, 0.86; 95% CI, 0.8–0.92).388SGLT2is do not appear to re-
lipoprotein cholesterol; PAAD, peripheral arterial and aortic diseases; PAD, peripheral duce stroke in patients with T2DM, but patients with a stroke history
arterial disease; PCSK9, proprotein convertase subtilisin/kexin type 9; TAA, thoracic experienced similar cardiorenal benefits as the rest of the population.389
aortic aneurysm.
aClass of recommendation. Before the era of GLP-1RAs and SGLT2is, different studies (United
bLevel of evidence. Kingdom Prospective Diabetes Study [UKPDS] 34390 and
Hyperinsulinaemia: the Outcomes of its Metabolic Effects [HOME]
7.2.4. Diabetes and pre-diabetes conditions trials391) showed that metformin reduced the risk of MALE and
Screening for diabetes or pre-diabetes is recommended in PAAD. Recent MACE in patients with PAD.391,392But a recent study with GLP-1RA
ESC Guidelines on diabetes and CVD374provide detailed diagnostic cri- dulaglutide found the same risk reduction in MACE between patients
teria and underscore the importance of diagnosing diabetes in ASCVD pa- with and without baseline metformin, calling into question its add-on
tients and vice versa. Both Type 1 (T1DM) and Type 2 (T2DM) diabetes value.384,393 However, there are studies suggesting that metformin
mellitus imply significantly increased risk of PAD, carotid stenosis, and may reduce AAA growth (see Section 9.2.4).
polyvascular disease, depending on disease duration and the status
of other CVRFs. Diabetes is present in 30% of patients with IC and Recommendation Table 10 — Recommendations for
50%–70% of those with CLTI.375,376 Although the prevalence of PAD the medical management of patients with peripheral
arterial and aortic diseases and diabetes
in patients with diabetes is 20%–30%, only half of them are symptomatic
because of peripheral neuropathy with decreased pain sensitivity.377As
Recommendations Classa Levelb
already detailed in Section 4, diabetes implies reduced risk of TAA,
AAA, or aortic dissection. However, patients with T2DM and PAAD It is recommended to apply tight glycaemic control
are in the very high-risk group for stroke, MI, and CV death,374and for (HbA1c <53 mmol/mol [7%]) to reduce microvascular I A
T1DM, an online risk prediction tool has recently been developed.377–380 complications in patients with PAAD.374,394–397
For non-pregnant PAAD patients, aiming for an HbA1c level of SGLT2i with proven CV benefit are recommended
<53 mmol/mol (7%) to avoid significant hypoglycaemia is appropriate. in patients with T2DM and PAAD to reduce CV
Consider a higher threshold (<69 mmol/mol [8.5%]) for limited life ex- events, independent of baseline or target HbA1c I A
pectancy or when treatment risks outweigh benefits.374
and concomitant glucose-lowering
In PAAD, it is recommended to aim for tight glycaemic control, pref- medication.382,386,398–402
erably with agents with proven CV benefits such as sodium-glucose
GLP-1RAs with proven CV benefit are
co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 re-
recommended in patients with T2DM and PAAD to
ceptor agonists (GLP-1RA), adding metformin and other glucose-
lowering agents as necessary.374,381–384 reduce CV events, independent of baseline or target I A
HbA1c and concomitant glucose-lowering
The Liraglutide Effect and Action in Diabetes: Evaluation of
medication.381,403–407
Cardiovascular Outcome Results (LEADER) trial and Trial to Evaluate
Cardiovascular and Other Long-term Outcomes with Semaglutide It is recommended to avoid hypoglycaemia in I B
in Subjects with Type 2 Diabetes (SUSTAIN-6) investigated subcutane- patients with PAAD.374,408–412
ous GLP-1RAs liraglutide (≤1.8 mg/day) and semaglutide (0.5 or It is recommended to individualize HbA1c targets
1.0 mg/week), respectively, vs. placebo in T2DM patients with high CV according to comorbidities, diabetes duration, and I C
risk. Overall, 12.7% of patients in LEADER and 14.0% in SUSTAIN-6 pre- life expectancy.408,411
sented with PAD at baseline. Although non-statistically significant due to It is recommended to prioritize the use of
a lack of power, the effects on MACE showed a consistently beneficial glucose-lowering agents with proven CV benefits,c,d
trend in PAD: liraglutide (hazard ratio (HR), 0.77; 95% confidence interval followed by agents with proven CV safety,e over I C
(CI), 0.58–1.01) and semaglutide (HR, 0.61; 95% CI, 0.33–1.13).381 agents without proven CV benefit or safety.374
The (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2
If additional glucose control is needed, metformin
Diabetes Mellitus Patients (EMPA-REG OUTCOME) investigated the
should be considered in patients with T2DM and IIa B
SGLT2i empagliflozin (10 mg or 25 mg per day) vs. placebo in patients
PAAD.374,384,393
with T2DM and high CV risk. Overall, 20.8% of patients presented
with PAD at baseline. In these patients, empagliflozin reduced CV death CV, cardiovascular; GLP-1RAs, glucagon-like peptide-1 receptor agonists; HbA1c, glycated
(HR, 0.57; 95% CI, 0.37–0.88) and all-cause mortality (HR, 0.62; 95% CI, haemoglobin; PAAD, peripheral arterial and aortic diseases; SGLT2i, sodium-glucose
co-transporter-2 inhibitors; T2DM, type 2 diabetes mellitus.
0.44–0.88), and there was a non-significant reduction in limb amputa-
aClass of recommendation.
tion: 5.5% with empagliflozin vs. 6.3% with placebo (HR, 0.84; 95% CI, bLevel of evidence.
0.54–1.32).382 In the Canagliflozin Cardiovascular Assessment Study cEmpagliflozin, canagliflozin, dapagliflozin, sotagliflozin.
(CANVAS)385investigating canagliflozin, there was an increased risk of dLiraglutide, semaglutide subcutaneous, dulaglutide, efpeglenatide.
eMetformin, pioglitazone, dipeptidyl peptidase 4 (DPP-4) inhibitor (sitagliptin, alogliptin,
amputation, but this was not confirmed in the Canagliflozin and Renal
linagliptin), glimepiride, gliclazide, insulin glargine, insulin degludec, ertugliflozin,
Events in Diabetes with Established Nephropathy Clinical Evaluation lixisenatide, exenatide (extended release), oral semaglutide.
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 37 ---
3574 E S C G u id e l in e s
7.2.5. Other pharmacological therapy • Symptomatic (effort-related) PAD: patients with pathological ABI or
Increased attention is focused on inflammation in ASCVD,413 sup- TBI, presenting with IC, atypical effort-related symptoms, or chronic
ported by the Canakinumab Anti-Inflammatory Thrombosis lower-limb wounds (diabetic foot or non-healing ulceration/gangrene
Outcomes Study (CANTOS),414 which showed that canakinumab, ≥2 weeks) without critically reduced limb perfusion.417,421In these
a monoclonal antibody targeting interleukin (IL)-1β, reduced MACE patients, IC is characterized by exertional muscle pain and dysfunc-
in high-risk patients with previous MI and increased high-sensitivity tion in the supply area of the obstructed arterial segment, which is
(hs)-CRP. Data for patients with PAAD are not reported. relieved at rest.422 Some patients may present with atypical
Furthermore, low-dose colchicine (0.5 mg/day) has been shown to symptoms or with ‘masked PAD’.420,423 In women, the prevalence
reduce MACE among those with stable atherosclerosis after recent of IC is lower than in men, while atypical symptoms are more
MI.415However, the effect of colchicine and other anti-inflammatory common.424
drugs in PAAD remains unproven.416 • CLTI represents the more severe chronic PAD presentation and un-
derlies poor limb outcomes without intervention. In addition to com-
mon signs of chronic PAD, patients with CLTI present with a critical
8. Peripheral arterial disease haemodynamic status (ankle pressure <50 mmHg, toe pressure [TP]
<30 mmHg, or TcPO <30 mmHg) responsible for ischaemic rest
2
8.1. Lower-extremity peripheral arterial pain, non-healing chronic (>2 weeks of duration) ulceration, or
foot gangrene.425,426 disease
8.1.1. Peripheral arterial disease syndromes
PAD syndromes can be categorized according to their clinical presen-
8.1.1.1. Clinical presentation and diagnosis
tation (Table 7).
Atheromatous lower-extremity PAD is a chronic disease with different
clinical manifestations. PAD may be symptomatic or asymptomatic and
The 5 year cumulative incidence of clinical deterioration from
may or may not be associated with limb wounds. Wound healing and
asymptomatic PAD to IC is 7%, and 21% from IC to CLTI.427All pa-
amputation risk may be affected by the concomitant presence of
tients with PAD are at high risk of MACE, cerebrovascular disease,
PAD, diabetes, and/or infection;417therefore, amputation risk assess-
and MALE (Figure 8).428–430 The 5 year cumulative incidence of CV
ment should be systematically performed using the Wound,
mortality is 9% in asymptomatic PAD and 13% in symptomatic pa-
Ischaemia, and foot Infection (WIfI) classification.
tients. In comparison with symptomatic PAD, CLTI further increases
PAD presents as: all-cause mortality risk (relative risk [RR] 2.26) and the risk of MACE
• Asymptomatic PAD: suspected by lower-limb pulse abolition or im- (RR 1.73).431Health insurance data reveal a major amputation rate of
aging studies performed for other purposes and detected by patho- 9% in patients with CLTI and 1% in patients with IC, while consider-
logical ABI or TBI.418,419These patients do not present with IC or ably higher amputation rates were reported in trials and registries
atypical effort-related symptoms. However, attention should be data focusing on patients with CLTI.432–435 Among patients with
paid to those with wounds, with masked effort-related symptoms PAD, development of MALE is associated with poor prognosis,
due to reduced walking capacity (for reasons other than PAD), or re- with a three-fold increase in death and a 200-fold increase in subse-
duced pain sensitivity. ‘Masked PAD’ is defined as PAD without pro- quent lower-extremity amputation.429
voked leg pain because of reduced walking capacity for other reasons Prevention of MALE is crucial, and the risk of MACE/MALE increases
or reduced pain sensitivity.420 with the increased number of arterial beds involved.
Table 7 Peripheral arterial disease categorized according to clinical presentation
Clinical characteristics of PAD Rutherford classification Fontaine classification
Category Signs and symptoms Stage Signs and symptoms
Asymptomatic PAD 0 Asymptomatic I Asymptomatic
Symptomatic (effort-related) PAD 1 Mild claudication IIa Non-disabling intermittent claudication
2 Moderate claudication IIb Disabling intermittent claudication
3 Severe claudication
Chronic limb-threatening Ischaemia 4 Ischaemic rest pain III Ischaemic rest pain
5 Minor tissue loss IV Ischaemic ulceration or gangrene
6 Major tissue loss
PAD, peripheral arterial disease.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 38 ---
ESC Guidelines 3575
Cardiac disease (MACE):
CV mortality
Myocardial infarction
4–5x increased risk of
Coronary revascularization
CV events compared with
Hospitalization for heart failure
patients without PAD
Cerebrovascular disease
Lower limb disease (MALE):
Amputation
Chronic or acute Increased death and
lower limb ischaemia vascular amputation
Lower limb risk
revascularization
Figure 8 Cardiovascular risk in patients with peripheral arterial disease. CV, cardiovascular; MACE, major adverse cardiac event; MALE, major adverse limb
event; PAD, peripheral arterial disease.
8.1.1.1.1. Diagnostic tests. Vascular assessment: ABI, TBI, TcPO In cases of abnormally high ABI values (ABI >1.4; see
2
measurements (refer to Section 5.3) Recommendation Table 2) and patients with CLTI and diabetes440
Ankle–brachial index is the proposed initial non-invasive diagnostic (see Recommendation Table 11), TP measurements, the calculation
test to confirm lower-limb decreased perfusion status90,436,437 and of TBI and TcPO , as well as pulse volume recordings or analysis of dis-
2
needs to be reported separately for each leg (see Recommendation tal arterial Doppler waveforms, should be considered,90,91,132,133,441
Table 2). An ABI ≤0.90 confirms PAD diagnosis.90,436,437 In cases of and ABI can be estimated from distal Doppler waveforms independent
an ABI >0.90 and clinical suspicion of PAD, post-exercise ABI measure- of diabetes and media sclerosis.124
ments should be considered, along with imaging studies (preferably by Apart from the assessment of limb perfusion, ABI serves as a surro-
treadmill). A post-exercise ABI decrease of >20% may serve as a PAD gate marker for CV and all-cause mortality.88,442,443A diagnostic PAD
diagnostic criterion.438,439 algorithm is depicted in Figure 9.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 39 ---
3576 E S C G u id e l in e s
Suspicion of PAD
Clinical assessment (personal history, physical examination),
walking impairment assessment (questionnaire, treadmill),
and functional assessment (6MWT, SPPB)
Haemodynamic/vascular assessment
(ABI, AP, TP, TcPO , DUS),
2
wound assessment (WIfl)
Other diagnosis N PAD
Y
Asymptomatic PAD
Typical symptoms N Masked PAD N
with or without wound
Y
Ischaemic rest pain or gangrene
Symptomatic PAD
or non-healing chronic wound and critical limb perfusion N
with or without wound
(AP <50 mmHg, TP <30 mmHg or TcPO <30 mmHg)
2
Y
Chronic limb-threatening ischaemia
Figure 9 Diagnostic algorithm for peripheral arterial disease. 6MWT, six-minute walk test; ABI, ankle–brachial index; AP, ankle pressure; DUS, duplex
ultrasound; PAD, peripheral arterial disease; SPPB, short physical performance battery; TcPO , transcutaneous oxygen pressure; TP, toe pressure; WIfI, 2
Wound, Ischaemia, and foot Infection classification.
Walking impairment questionnaires, assessment of functional and increased risk of amputation. The WIfI classification system takes
walking capacity the patients’ limb perfusion, wound size, and the extent of foot
Determining walking impairment, capacity, and functional status in all infection into account to determine the amputation risk
patients with PAD is mandatory (refer to Section 5.2). (Table 8).417,444–446
Assessment of amputation risk
In patients with PAD and chronic lower-limb wounds (diabetic
foot ulcer, non-healing lower-limb ulceration, or gangrene of ≥2 8.1.1.1.2. Imaging methods. Duplex ultrasound is recommended as
weeks of duration), even without haemodynamic parameters of the first-line imaging method for PAD screening and diagnosis. CTA
critical limb perfusion, the additional presence of comorbidities and/or MRA are recommended as adjuvant imaging. For details refer
such as diabetes and/or wound infection may contribute to an to Supplementary data online, Section 1.4.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 40 ---
ESC Guidelines 3577
Table 8 Assessment of the risk of amputation: the Wound, Ischaemia, and foot Infection classification
Component Score Description
W (Wound) 0 No ulcer (ischaemic rest pain)
1 Small, shallow ulcer on distal leg or foot without gangrene
2 Deeper ulcer with exposed bone, joint or tendon ± gangrenous changes limited to toes
3 Extensive deep ulcer, full thickness heel ulcer ± calcaneal involvement ± extensive gangrene
I (Ischaemia) ABI Ankle pressure (mmHg) Toe pressure or TcPO
2
0 ≥0.80 >100 ≥60
1 0.60–0.79 70–100 40–59
2 0.40–0.59 50–70 30–39
3 <0.40 <50 <30
fl (foot infection) 0 No symptoms/signs of infection
1 Local infection involving only skin and subcutaneous tissue
2 Local infection involving deeper than skin/subcutaneous tissue
3 Systemic inflammatory response syndrome
Ischaemia – 0 Ischaemia – 1 Ischaemia – 2 Ischaemia – 3
W–0 VL VL VL VL VL L L M L L M M M H H H
W–1 VL VL VL VL L M M M M H H H H H H H
W–2 VL VL VL VL M M H H H H H H H H H H
W–3 VL VL VL VL M M M H H H H H H H H H
fl–0 fl–1 fl–2 fl–3 fl–0 fl–1 fl–2 fl–3 fl–0 fl–1 fl–2 fl–3 fl–0 fl–1 fl–2 fl–3
Very low (green) = VL = clinical stage 1; low (yellow) = L = clinical stage 2; moderate (orange) = M = clinical stage 3; high (red) = H = clinical stage 4.
ABI, ankle–brachial index; TcPO2, transcutaneous oxygen pressure.
The Wound, Ischaemia and foot Infection (WIfI) classification allows the assessment of the individual risk of amputation in PAD patients: it comprises scores for wound size (W), degree of
ischaemia (I), as assessed by the ABI, ankle pressure, and toe pressure or TcPO2, and extent of foot infection (fI) as depicted in the respective table. The combination of all three components
results in the amputation risk stratification (VL = very low, L = low, M = moderate, H = high). Table reproduced with permission from.417
Recommendation Table 11 — Recommendations for Recommendation Table 12 — Recommendations for
diagnostic tests in patients with peripheral arterial dis- imaging in patients with peripheral arterial disease
ease and diabetes, renal failure, and wounds
Recommendations Classa Levelb
Recommendations Classa Levelb
DUS is recommended as the first-line imaging
I C Measuring TP or TBI is recommended in patients method to confirm PAD lesions.122,123,447
with diabetes or renal failure if resting ABI is I C
In symptomatic patients with aorto-iliac or
normal.90,91,94,440
multisegmental/complex disease, CTA and/or MRA
I C
In patients with PAD and chronic wounds, the WIfI are recommended as adjuvant imaging techniques for
classification system should be considered to IIa C preparation of revascularization procedures.448,449
estimate individual risk of amputation.417,444–446
Analysis of anatomical imaging tests in conjunction
ABI, ankle–brachial index; PAD, peripheral arterial disease; TBI, toe–brachial index; TP, toe with symptoms and haemodynamic tests prior to an I C
pressure; WIfI, Wound, Ischaemia, and foot Infection classification. invasive procedure is recommended.426
aClass of recommendation.
bLevel of evidence. CTA, computed tomography angiography; DUS, duplex ultrasound; MRA, magnetic
resonance angiography; PAD, peripheral arterial disease.
aClass of recommendation.
bLevel of evidence.
4202CSE©
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 41 ---
3578 E S C G u id e l in e s
Address lower limbs-related
Address general CV risk + symptoms
prevention
Improve quality of life
Optimal
medical
treatment
Smoking cessation Antihypertensive drugs
Healthy diet Cholesterol-lowering drugs
Weight loss Optimal glucose control in diabetics
Supervised exercise training Antithrombotic drugs
Figure 10 Optimal medical treatment in patients with peripheral arterial disease. CV, cardiovascular.
8.1.1.2. Medical treatment improve ABI.457,458 Ideally, SET should be co-ordinated by vascular
Patients with PAD should receive comprehensive OMT, including physicians, and training sessions supervised by clinical exercise
supervised exercise training and lifestyle modification (Figures 10– physiologists or physiotherapists.62 In Europe, SET is usually
12). A personalized programme of guidelines-guided pharmacother-
underused.464,465
apy to reduce MACE and MALE should be prescribed and tightly When SET is not available, home-based exercise training (HBET)
followed. should be proposed (Figure 13), although it is inferior with regard to im-
Patients with PAD are less likely to receive OMT than patients with proving walking performance.466–469HBET is safe and its inferiority is
CAD.450–452 For general lifestyle and pharmacological therapy see reduced if monitoring is implemented.469,470Compared with no exer-
Section 7. cise, HBET improves walking performance.471SET training frequency
should be at least three times per week, for 30–60 min, and the pro-
8.1.1.2.1. Exercise therapy. A consensus document on exercise and gramme last for at least 12 weeks.37,58,59,454,472,473Patients should ex-
PAD has been published recently.62 Symptomatic patients should be ercise to moderate-severe claudication pain to improve walking
medically screened before any supervised exercise training (SET) pro- performance.37,294,453,454,456–458,474 However, prescribing high-pain
gramme initiation.37,62In patients with symptomatic PAD, SET is safe exercise may hinder programme uptake and adherence. Additionally,
and improves treadmill PFWD, MWD, functional walking as measured it has been reported that improvements in walking performance may
by six-minute walking distance (6MWD), HRQoL, and cardiorespira- be obtained with less severe claudication pain.455,460 Therefore, a
tory fitness (Figure 13).294,453–463 Exercise has not been found to flexible approach is recommended, considering the patient’s needs
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 42 ---
ESC Guidelines 3579
Chronic PAD syndromes (without wounds)
Asymptomatic PAD Symptomatic PAD CLTI
Optimal medical treatment Optimal medical treatment Optimal medical treatment
Supervised or structured
home-based Vascular team assessment
exercise training
Improved PAD-related Revascularization indicated
Y
symptoms and reasonable
N
N Y
Vascular team assessment
Revascularization indicated
N Revascularization feasible
and reasonable
N
Y
Y
Revascularization
Revascularization feasible
Y N
Evaluate
Revascularization and alternative
Supervised or structured
supervised or structured treatment
home-based
home-based strategy
exercise training
exercise training (pharmacological,
amputation)
Vascular follow-up (clinical, physical, functional, vascular assessment)
Figure 11 Treatment algorithm in peripheral arterial disease without wounds. CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.
and preferences.62 Alternative training modalities, such as strength rate or 14–17 on the rate of perceived exertion on Borg’s scale) has
training, arm cranking, cycling, and combinations of different modes, been shown to induce the best walking and cardiorespiratory fitness
have proven effective in improving walking performance compared improvements.294,457 Training programmes should begin at
with traditional walking training, with limited evidence for HRQoL.475 low-to-moderate intensity, gradually advancing to vigorous exercise if
However, this evidence is low due to small sample size and risk of well tolerated.62 This approach assesses patient response and mini-
bias.475Vigorous intensity exercise training (77%–95% of maximal heart mizes complications.37,62
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 43 ---
3580 E S C G u id e l in e s
Chronic PAD syndromes (with wounds)
Asymptomatic PAD Symptomatic PAD CLTI
Optimal medical treatment Optimal medical treatment Optimal medical treatment
Wound care Wound care
Healing Healing
Y N N Y
Supervised or structured
Vascular team assessment home-based Vascular team assessment
exercise training
Revascularization indicated Improved PAD-related Revascularization indicated
N Y
and reasonable symptoms and reasonable
Y N Y N
Revascularization feasible Vascular team assessment
Y N
Revascularization indicated
Revascularization feasible
and reasonable
Revascularization
N
and supervised
Y N
or structured Y
home-based
exercise training Revascularization and
Revascularization feasible
Wound care
Y N
Supervised Evaluate
or structured alternative
home-based Revascularization and Wound care treatment
exercise training Wound care strategy
(pharmacological,
amputation)
Vascular follow-up (clinical, physical, functional, vascular assessment)
Figure 12 Treatment algorithm in peripheral arterial disease with wounds. CLTI, chronic limb-threatening ischaemia; PAD, peripheral arterial disease.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 44 ---
ESC Guidelines 3581
Training characteristics
Supervised hospital-based Supervised home-based
exercise programmes exercise programmes
At least three times per week
Session duration of at least
30 min. Programmes duration
of at least 12 weeks.
Supervised group sessions Low-to-moderate exercise Remote monitoring,
intensity (or high if tolerated) logbook and connected devices
Different training modes
Different levels of elicited pain
Training benefits
Symptoms Quality Walking Patient CVR Functional
of life performance awareness status
Potential involved mechanisms
Mitochondrial Endothelial
A rteriogenesis Myofibre size Inflammation
content/function function
Figure 13 Exercise training characteristics and benefits in patients with peripheral arterial disease. CVR, cardiovascular risk.
Data on the efficacy of exercise therapy in women compared with SET combined with endovascular revascularization significantly improves
men are scarce. Women may respond less well than men,476,477 al- walking performance, HRQoL, and reduces future revascularization.482,483
though discrepancies among studies exist.478–481 An exercise therapy algorithm in PAD has been recently described.62
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 45 ---
3582 E S C G u id e l in e s
Recommendation Table 13 — Recommendations for CV risk factors) has not been evaluated in randomized trials.
exercise therapy in patients with peripheral arterial Antithrombotic therapy should not be systematically administered in
disease (see also Evidence Table 5) patients with asymptomatic PAD.
Symptomatic PAD
Recommendations Classa Levelb
In patients with symptomatic PAD, antithrombotic therapy improves
In patients with symptomatic PAD, SET is CV prognosis.488–492Clopidogrel may have a modest advantage over
recommended.294,453,456–458,462 I A aspirin (Figure 14).493,494In the Examining Use of tiCagreLor In periph-
eral artery Disease (EUCLID) trial, single antiplatelet therapy (SAPT)
In those patients undergoing endovascular
with ticagrelor showed no superior benefit in the reduction of
revascularization, SET is recommended as an I A
MACE or major bleeding compared with clopidogrel.495–497
adjuvant therapy.482,483
Dual antithrombotic therapy with aspirin and vascular-dose rivarox-
When SET is not available or feasible, a structured
aban (2.5 mg b.i.d.) in patients with PAD is more effective than aspirin
and monitored (calls, logbooks, connected devices) IIa A
alone, reducing MACE, MALE, and preventing acute limb ischaemia
HBET programme should be considered.468,469,471 (ALI), but with increased major bleeding risk.429,430,498,499 Patients
Walking should be considered as a first-line training with high-risk limb presentation (CLTI, previous amputation, or revas-
modality. When walking exercise is not an option, cularization) or high-risk comorbidities (heart failure [HF], diabetes, or
alternative exercise modes (strength training, arm IIa A polyvascular disease [PVD]) benefit the most.498
cranking, cycling, and combinations of different After endovascular therapy, dual antiplatelet therapy (DAPT) for 1–3
training modes) should also be considered.475 months is supported by rare randomized studies.500,501DAPT is not asso-
Walking training performed at high intensity (77%– ciated with reduced CV mortality or MACE,501 but seems to improve
95% of maximal heart rate or 14–17 self-perceived patency without increasing bleeding (Figure 15).502–504The combination
exertion on Borg’s scale) should be considered to of aspirin 100 mg and vascular-dose rivaroxaban (2.5 mg b.i.d.), started
improve walking performance,294and high-intensity IIa A post-revascularization, showed a moderate but significantly lower incidence
of MALE and MACE compared with aspirin alone,490,505without an increase
exercise training (various aerobic training modes)
in thrombolysis in myocardial infarction (TIMI) major bleedings, but with an
should be considered to improve cardiorespiratory
increase in International Society on Thrombosis and Haemostasis (ISTH)
fitness.294,457
major bleedings, especially when clopidogrel was given for >1 month.506
Training frequency of at least three times per week,
Patients with CLTI are at high risk of MACE and MALE.429,431,507
training session duration of at least 30 min, and
IIa B Among CLTI patients, there is no robust evidence favouring a specific an-
training programme duration of at least 12 weeks
tithrombotic strategy for vein graft maintenance. DAPT with clopidogrel
should be considered.472
and aspirin is not superior to aspirin alone in below-the-knee (BTK) by-
In patients with PAD, exercise training to pass grafts.508–510Vitamin K antagonists (VKAs) may be considered for
moderate-severe claudication pain may be high-risk conduits with low bleeding risk.509
considered to improve walking Dual antiplatelet therapy could confer benefit for prosthetic conduit
IIb B
performance.37,454,456,458However, improvements (occlusion, revascularization, amputation, or death), without increasing
are also achievable with lesser claudication pain major bleeding.510VKAs with an international normalized ratio (INR) of
severities (low-mild pain or pain-free).455,460 3–4.5 are slightly beneficial in venous conduits, but with a 1.9-fold and
Based on patient’s tolerance, a progressive increase 1.3-fold increase in major and fatal bleedings, respectively.509A study
(every 1–2 weeks) in exercise training load may be IIb C suggested that VKAs could be associated with prolonged patency of
considered.37,62 at-risk prosthetic grafts due to poor run-off.511
In patients with another indication for OAC (such as atrial fibrillation
HBET, home-based exercise training; PAD, peripheral arterial disease; SET, supervised [AF] or mechanic valve replacement) and PAD, anticoagulation is war-
exercise training.
aClass of recommendation. ranted.512Additional SAPT post-endovascular therapy should be brief.
bLevel of evidence.
8.1.1.2.2. Pharmacological treatment. Antithrombotic therapy
Recommendation Table 14 — Recommendations for
Asymptomatic PAD antithrombotic therapy in patients with peripheral
Although patients with PAD are at very high CV risk,404,484 a trial arterial disease (see also Evidence Table 6)
evaluating the effect of antiplatelet agents in asymptomatic patients
with an ABI ≤0.95 did not show an effect on MACE or revasculariza- Recommendations Classa Levelb
tion.485Another trial on patients with an ABI ≤0.99 and diabetes also
Use of antiplatelet therapy with aspirin alone (range
failed to show any difference in MACE or amputation.486 However,
75–160 mg o.d.) or clopidogrel alone (75 mg o.d.) is
these data were not powered to analyse subgroups and do not rule I A
recommended for the reduction of MACE in patients
out the possibility that aspirin could provide a benefit in subjects at in-
with symptomatic PAD.488–490
creased risk of CV events. In a randomized trial evaluating aspirin in the
Treatment with combination rivaroxaban (2.5 mg
prevention of cancer and CVD in patients with diabetes without known
arterial disease, MACE occurred in a significantly lower percentage of b.i.d.) and aspirin (100 mg o.d.) should be considered
IIa A
participants in the aspirin group than in the placebo group, with for patients with PAD, high ischaemic risk,c and
more major bleeding events in the aspirin group.487The effect of antith- non-high bleeding risk.d,429,498,499
rombotics in patients with higher-risk PAD (i.e. ABI <0.90 and other Continued
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 46 ---
ESC Guidelines 3583
Treatment with combination rivaroxaban (2.5 mg Pharmacotherapy to decrease walking impairment
b.i.d.) and aspirin (100 mg o.d.) should be considered Verapamil,516 statins,517,518 antiplatelet agents, and prostanoids
IIa B (prostaglandins I and E )519can alleviate walking impairment in patients
for patients with PAD and non-high bleeding risk 2 1
following lower-limb revascularization.490,505 with symptomatic PAD. However, drugs like cilostazol, naftidrofuryl,
pentoxifylline, buflomedil, carnitine, and propionyl-L-carnitine are sug-
Use of antiplatelet therapy with clopidogrel alone
gested to increase walking distance in patients with IC without impact-
(75 mg o.d.) may be considered over aspirin to IIb B
ing CV health.339,520Their objective benefit is generally limited, ranging
reduce MI, stroke, and vascular death.493,494
from mild to moderate, with considerable variability.339The additional
Aspirin (75–100 mg) for primary prevention may be
benefit of these drugs alongside antithrombotics, antihypertensives, and
considered in patients with asymptomatic PAD and IIb A
statins remains unknown.
DM, in the absence of contraindications.419,487 Cilostazol, a phosphodiesterase type III inhibitor, improved MWD
DAPT for at least 1 month after revascularization compared with placebo and pentoxifylline.520–522In a Cochrane analysis,
may be considered to reduce limb IIb B 100 mg twice daily increased MWD by 76%,521while another review re-
events.500,501,503,513,514 ported a 25% average improvement.520Cilostazol also has antiplatelet ef-
Long-term DAPT in patients with PAD is not fects, requiring cautious combination with other anticoagulant and
recommended.489 III A antiplatelet treatments.522Notably, it increases bleeding complications.523
Naftidrofuryl oxalate, tested for IC,524demonstrated a 74% average Oral anticoagulant monotherapy for PAD (unless for
another indication) is not recommended.515 III A increase in MWD and improved HRQoL.524,525In a systematic review,
the average MWD improvement was 60% compared with placebo.520
The routine use of ticagrelor in patients with PAD is
III A However, inconsistent results for other medications, such as prosta-
not recommended.495
noids, pentoxifylline, L-arginine, buflomedil, or Gingko biloba, preclude
It is not recommended to systematically treat their recommendation for patients with IC.519,526,527
patients with asymptomatic PAD without any sign of III B
clinically relevant ASCVD with antiplatelet drugs.485 8.1.1.2.3. Aorto-iliac lesion revascularization. Aorto-iliac lesions can
be treated by either an endovascular or a surgical approach according
ASCVD, atherosclerotic cardiovascular disease; DAPT, dual antiplatelet therapy; DM,
diabetes mellitus; MACE, major adverse cardiovascular events; MI, myocardial infarction; to the lesion morphology and patient risk. Long-term patency with a
o.d., once daily; PAD, peripheral arterial disease. low risk of complications can be achieved by balloon angioplasty with
aClass of recommendation.
or without stenting in external iliac arteries or primary stenting in com-
bLevel of evidence.
cHigh ischaemic risk: previous amputation, critical limb threatening ischaemia, previous mon iliac arteries.528A meta-analysis evaluated outcomes of open surgery
revascularization, high-risk comorbidities (heart failure, diabetes, vascular disease in two vs. an endovascular approach in aorto-iliac lesions (TASC II C-D) and
or more vascular beds), eGFR <60 mL/min/1.73 m2.498 found that short-term morbidity and mortality favours the endovascular
dHigh bleeding risk: dialysis or renal impairment GFR <15 mL/min/1.73 m2, acute coronary
approach, but early and mid-term primary patency favours open surgery;
syndrome <30 days, history of intracranial haemorrhage, stroke or TIA, active or clinically
significant bleeding. however, secondary patency is comparable in all groups.
Patients with chronic symptomatic PAD
Assess risk level at every follow-up
High-risk limb presentation
Non high-risk limb presentation Patients requiring or high-risk comorbiditiesa
or high-risk comorbiditiesa long-term anticoagulation
without high bleeding risk
Single antiplatelet therapy ASA Single OAC
(ASA or clopidogrel) and 2.5 mg rivaroxaban b.i.d. monotherapy
(Class I) (Class IIa) (Class IIb)
Figure 14 Long-term antithrombotic therapy in patients with symptomatic peripheral arterial disease. b.i.d., twice daily; OAC, oral anticoagulant; PAD,
peripheral arterial disease; ASA, aspirin aHigh-risk limb presentation: previous amputation, chronic limb-threatening ischaemia, previous revascularization,
high-risk comorbidities: heart failure, diabetes, vascular disease in two or more vascular beds, moderate kidney dysfunction; eGFR <60 mL/min/1.73 m2.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 47 ---
3584 E S C G u id e l in e s
Patients with chronic symptomatic PAD after endovascular revascularization
Long-term anticoagulation required
N Y
Bleeding risk Bleeding risk
No high bleeding risk High bleeding riska No high bleeding risk High bleeding riska
ASA and 2.5 mg rivaroxaban
DAPT SAPT 1–3 months
b.i.d. +/- clopidogrel
1–3 months and OAC
for 1 month
(Class IIa) (Class IIa)
(Class IIa)
ASA + 2.5 mg SAPT OAC OAC
rivaroxaban b.i.d. (ASA or clopidogrel) monotherapy monotherapy
(Class IIa) (Class I) (Class IIa) (Class IIa)
Figure 15 Patients with chronic symptomatic PAD after endovascular revascularization. b.i.d., twice daily; DAPT, dual antiplatelet therapy; OAC, oral
anticoagulant; PAD, peripheral arterial disease; ASA, aspirin; SAPT, single antiplatelet therapy aHigh bleeding risk: dialysis or a renal impairment glom-
erular filtration rate <15 mL/min/1.73 m2, acute coronary syndrome <30 days, history of intracranial haemorrhage, stroke or TIA, active or clinically
significant bleeding.
8.1.1.2.4. Femoro-popliteal lesion revascularization. If revasculariza- Recommendation Table 15 — Recommendations for
tion is indicated, endovascular therapy should be the first choice interventional treatment of asymptomatic and symp-
even for complex lesions, especially in surgical high-risk pa- tomatic peripheral arterial disease (general)
tients.119,529–531
Recommendations Classa Levelb
Endovascular therapy faces the challenge of sustaining long-term
patency and durability in the femoro-popliteal region, particularly In patients with symptomatic PAD, after a 3 month
post-stent placement in a highly mobile artery. Drug-eluting balloons period of OMT and exercise therapy, PAD-related I B
have improved long-term patency in complex patient cohorts and le- QoL assessment is recommended.119
sions.532 With regard to paclitaxel-coated devices, a meta-analysis
It is recommended to adapt the mode and type of
caused a decline in their usage, especially as the United States
revascularization options to anatomical lesion location, I C
Food and Drug Administration (FDA) reacted and restricted their
lesion morphology, and general patient condition.119
use.533Consequently, data from large national databases were eval-
In patients with symptomatic PAD and impaired
uated and the mortality signal could not be confirmed. The FDA re-
PAD-related quality of life after a 3 month period of
vised its position, and drug-eluting treatment is now deemed to be IIb B
a safe and efficient treatment strategy for femoro-popliteal OMT and exercise therapy, revascularization may be
lesions.534–538 considered.465,540
An open surgical approach in femoro-popliteal lesions should be In patients with PAD, revascularization is not
considered when an autologous vein (e.g. great saphenous vein recommended if the reason is to solely prevent III B
[GSV]) is available and the patient shows low surgical risk, and in com- progression to CLTI.541–544
plex lesions after an interdisciplinary team discussion. In patients with asymptomatic PAD,
III C
revascularization is not recommended.119,529
8.1.1.2.5. Below-the-knee artery revascularization. In patients with
severe IC in whom endovascular femoro-popliteal treatment is per- CLTI, chronic limb-threatening ischaemia; OMT, optimal medical treatment; PAD,
peripheral arterial disease; QoL, quality of life.
formed, BTK arteries can be treated in the same intervention if there aClass of recommendation.
is substantially impaired outflow.539 bLevel of evidence.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 48 ---
ESC Guidelines 3585
Recommendation Table 16 — Recommendations for or gangrene (typically in distal segments).555,556Ischaemic rest pain pri-
interventional treatment of patients with symptomatic marily affects the patient’s forefoot and aggravates in a supine position,
peripheral arterial disease (per arterial bed) while lowering of the affected leg eases ischaemic symptoms.
Recommendations Classa Levelb
8.1.2.1.1. Definition. Chronic limb-thretening ischaemia should be
In femoro-popliteal lesions, drug-eluting treatment considered in the presence of one of the following lower-limb clinical
IIa A
should be considered as the first-choice strategy.534–537 signs or symptoms:
In iliac lesions, balloon angioplasty with or without
• Ischaemic rest pain
stenting in external iliac arteries, or primary stenting in IIa B
• Non-healing lower-limb wound of ≥2 weeks’ duration
common iliac arteries, should be considered.545–548
• Lower-limb gangrene
In femoro-popliteal lesions, if revascularization is
indicated, endovascular therapy should be IIa B The following haemodynamic criteria may be used to guide diagnosis
considered.119,529–531 in patients with suspicion of CLTI:
In femoro-popliteal lesions, if revascularization is
• Ankle pressure <50 mmHg
indicated, an open surgical approach should be
IIa C • TP <30 mmHg
considered when an autologous vein (e.g. GSV) is
• TcPO <30 mmHg
available in patients with low surgical risk.119,529 2
In patients with severe IC undergoing endovascular
8.1.2.1.2. Initial assessment and risk of amputation. For patients
femoro-popliteal revascularization, treatment of
IIb C with CLTI, initial diagnostic steps involve clinical examination and limb
BTK arteries may be considered in the same
perfusion assessment through haemodynamic measurements.
intervention.549,550
Regarding haemodynamic assessment in CLTI, standard ABI may be
normal or falsely elevated due to non-compressible arteries related
BTK, below-the-knee; GSV, great saphenous vein; IC, intermittent claudication.
aClass of recommendation. to medial sclerosis (common in diabetes or CKD),557 which can be
bLevel of evidence. overcome by estimation of ABI based on Doppler waveforms.124
Therefore, standard ankle pressure alone may not be reliable in esti-
mating limb loss risk.441,558In addition, a large proportion of patients
8.1.1.3. Follow-up
with ulcers may have below-the-ankle lesions.440 In patients with
Asymptomatic and symptomatic PAD are at increased risk of leg symp-
CLTI, TP, TBI, or TcPO should additionally be obtained.90,441,559
tom worsening427 and of CV mortality and morbidity.419,431,551 2
Particularly in patients with CLTI, the WIfI classification system
Follow-up post-revascularization is crucial to ensure perfusion improve-
should be applied. In addition to patients’ limb perfusion, the WIfI clas-
ment, address CVRFs, optimize pharmacological treatment adherence,
sification considers the wound size and the extent of foot infection to
identify disease progression, and evaluate mental health and functional
determine the individual risk of amputation.417,444–446
capacity. Experienced vascular care physicians should conduct follow-up,
although specific protocols are currently undefined.128,552Data on asymp-
tomatic PAD follow-up are limited.553 For symptomatic PAD or post- 8.1.2.1.3. Imaging. In all patients with CLTI, comprehensive vascular
imaging is mandatory to evaluate revascularization options. CLTI com-
intervention, annual follow-up are advised, including ABI/TBI measure-
monly affects more than one arterial segment of the lower limbs, involving
ment and DUS for new or worsening symptoms.
infra-popliteal arteries (BTK and below-the-ankle arteries) in most cases.
While non-invasive imaging (DUS, CTA, MRA) provides reliable results
Recommendation Table 17 — Recommendations in for above-the-knee arteries, imaging of BTK arteries, especially below
patients with peripheral arterial disease: follow-up of the ankle, may be hampered by severe calcification.448,560,561Therefore,
patients with peripheral arterial disease in CLTI additional DSA with dedicated views of the foot should be con-
sidered for the assessment of BTK arteries.560Even in patients who are
Recommendations Classa Levelb not candidates for revascularization, DSA should be obtained to prevent
unnecessary amputation or to minimize amputation extent.560,562
It is recommended to regularly, at least once a year,
follow up patients with PAD, assessing clinical and
functional status, medication adherence, limb I C 8.1.2.1.4. Mortality risk assessment. All-cause mortality and event
rates of MI are more than two-fold higher in CLTI patients than in un-
symptoms, and CVRFs, with DUS assessment as
needed.553,554 selected patients with an ABI ≤0.90.431
In CLTI patients undergoing revascularization, the post-revascularization
CVRFs, cardiovascular risk factors; DUS, duplex ultrasound; PAD, peripheral arterial period is particularly associated with an increased risk of MALE and
disease. MACE.563 The management of patients with CLTI should therefore in-
aClass of recommendation.
bLevel of evidence. clude an individual peri-procedural risk assessment. Referring to the peri-
procedural risk patients can be categorized as average procedural risk
(peri-procedural mortality <5% and 2 year survival >50%) or high proced-
8.1.2. Chronic limb-threatening ischaemia ural risk (peri-procedural mortality ≥5% and 2 year survival ≤50%).564,565
8.1.2.1. Clinical presentation and diagnosis Besides revascularization, it also needs to be considered that lower-
Chronic limb-thretening ischaemia describes chronic lower-limb hypo- limb amputation is associated with 30 day mortality rates of up to
perfusion responsible for ischaemic rest pain, or non-healing ulceration 22%.566
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 49 ---
3586 E S C G u id e l in e s
Recommendation Table 18 — Recommendations for 8.1.2.3. Interventional treatment
the management of chronic limb-threatening ischaemia 8.1.2.3.1. Revascularization. In CLTI, revascularization should be at-
tempted to rapidly restore an inline direct blood flow to the
Recommendations Classa Levelb foot.585–588 Three RCTs compared endovascular therapy with open
For limb salvage in patients with CLTI, surgery in infra-inguinal arteries. In the Bypass versus Angioplasty in
revascularization is recommended.564,567 I B Severe Ischaemia of the Leg (BASIL) trial, no significant difference
was found regarding mortality or amputation-free survival at 2 years.589
Early recognition of CLTI and referral to the vascular
I C However, surgery was associated with a significantly reduced risk of
team are recommended for limb salvage.417,560
amputation, death, or both after 2 years.564,589 In the Best
In patients with CLTI, imaging of the entire affected
IIa C Endovascular versus Best Surgical Therapy for Patients with Critical
limb should be considered.560
Limb Ischemia (BEST-CLI) trial (median follow-up of 2.7 years), the in-
CLTI, chronic limb-threatening ischaemia. cidence of MALE or death was lower in patients in which one segment
aClass of recommendation. of the GSV was available for surgical revascularization than in patients
bLevel of evidence. who underwent endovascular revascularization. In the same trial, out-
comes of patients for whom an alternative bypass conduit was needed
8.1.2.2. Medical treatment for surgical revascularization were similar to those of patients who
Chronic limb-thretening ischaemia is associated with a high risk of is- underwent endovascular revascularization.567
chaemic events,429,431thus management of patients with CLTI must in- In the BASIL-2 trial, which included patients requiring infra-popliteal,
clude OMT. with or without additional further proximal infra-inguinal, revasculariza-
In addition, rest pain, optimal wound care, and infection control should tion procedures, endovascular revascularization was associated with
be managed. A vascular team, including at least a vascular physician, a vas- better amputation-free survival than surgical revascularization, which
cular surgeon, and a radiologist, should be involved to prevent amputa- was primarily due to fewer deaths in this group.590It is important to
tion.568Lower-limb exercise training is contraindicated until ulcers are consider591both revascularization options individually in each patient,
healed and aggressive offloading should be ensured to allow healing. considering the complexity of the diseased anatomical region.
Depending on infection extent, oral antibiotics may suffice, however, if Multilevel disease
extensive with systemic signs of inflammation, admission for intravenous Patients with CLTI commonly present with multilevel disease.592
(i.v.) antibiotic administration may be required.569,570 Especially for complex lesions, comprehensive patient assessment, in-
Good-quality evidence on the advantages of one type of wound cluding the individual patient’s clinical presentation, the lesion morph-
dressing over others is lacking, while in selected patients individualized ology, and the peri-procedural risk, needs to be undertaken by a
treatments with antimicrobial dressing,571 silver dressing,572 collagen multidisciplinary vascular team to weigh the risks against the benefits
dressing,573honey- or iodine-based dressings,574 platelet-rich plasma, of the respective methods of revascularization (endovascular vs. surgi-
or negative pressure therapy575,576 may accelerate wound healing, cal).590,593–596A structured approach is essential to achieve rapid and
shorten hospital stay, and prevent amputations. If deep-seated infection durable restoration of an inline flow to the foot. When possible, the an-
is suspected, X-ray or MRA are required to diagnose osteomyelitis, in giosome concept can be considered, targeting the most affected ischae-
which case a longer course of antibiotics may be necessary.577 mic area.597 When CLTI leaves no viable revascularization options,
Antibiotics for osteomyelitis treatment may be empirical, however, transcatheter arterialization of deep veins may be considered.598
they should be adapted according to (preferably tissue) cultures.578–581 Aorto-iliac disease
Ulcers require assessment of venous aetiology and potential for en- An endovascular approach is the first choice, commonly employing
dovenous therapy, while mixed ulcers require compression therapy bare metal or covered stents.599–603Surgery is reserved for extensive
after revascularization.582 obstructions and lesions treated unsuccessfully with an endovascular
procedure.604Hybrid revascularization should be considered in occlu-
Recommendation Table 19 — Recommendations for sion of the common femoral artery or profunda femoris artery requir-
medical treatment in patients with chronic limb- ing endarterectomy, in addition to inflow and/or outflow disease
threatening ischaemia (see also Evidence Table 7) amenable to endovascular therapy. Hybrid procedures should be en-
couraged in a one-step modality.605
Recommendations Classa Levelb Femoro-popliteal disease
Chronic limb-threatening ischaemia is unlikely to be related to iso-
It is recommended that patients with CLTI are
I C lated superficial femoral artery lesions; femoro-popliteal involvement
managed by a vascular team.568
in combination with aorto-iliac or infra-popliteal disease is frequently
In patients with CLTI and ulcers, offloading
found. In 40% of cases, inflow treatment of femoro-popliteal disease
mechanical tissue stress is recommended to allow I C is necessary.606 The revascularization strategy should be selected ac-
wound healing.583,584 cording to lesion complexity.422If endovascular therapy is chosen, land-
It is recommended to treat infection with ing zones for potential bypass grafts should be preserved. When bypass
I C
antibiotics.569,570
surgery is decided, the bypass should be as short as possible, using the
Lower-limb exercise training is not recommended in saphenous veins.567
III C
patients with CLTI and wounds.584 Infra-popliteal disease
Extended infra-popliteal disease is mainly seen in patients with dia-
CLTI, chronic limb-threatening ischaemia.
aClass of recommendation. betes607–610 and CKD,611,612 often being associated with superficial
bLevel of evidence. femoral artery lesions. In short infra-popliteal lesions, endovascular
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 50 ---
ESC Guidelines 3587
therapy is the first choice.593Drug-eluting balloons607and bare metal of revascularization failure, wound healing, and contralateral limb status.
stent implantation613 have shown no superiority over plain balloon After revascularization, at least an annual appointment with a vascular
angioplasty, although drug-eluting stents may be used for relatively physician expert in CLTI management is warranted. Due to the lack of
short proximal lesions.614–616 evidence, recommendations are largely based on consensus and expert
opinions.128
First-year incidence of vein graft stenosis is 20%;621however, if un-
8.1.2.3.2. Spinal cord stimulation. Spinal cord stimulation (SCS) may
eventful for 12 months, late issues are scarce.622Clinical examination,
be considered in treating patients with CLTI and no viable revascular-
ABI (or TBI) measurement, and DUS should be performed within 4–
ization options. SCS offers modest pain relief and an 11% reduction
6 weeks and thereafter at 3, 6, 12, and 24 months after bypass
in amputation rate compared with conservative management at 1
surgery.128
year. No effect was seen in ulcer healing and benefits should be weighed
against the high cost and possible complications.617Recent technologic- After endovascular treatment, restenosis and occlusion ranges from
5% in the pelvic region to >50% in the infra-popliteal arteries.623,624
al advances in neuromodulation may improve the treatment value of
this modality.618 Unlike after surgery, no plateau phase is seen, and the failure rate is con-
stant for at least 5 years. Surveillance includes clinical assessment looking
for recurrent symptoms or signs, ABI measurement, and DUS based on
8.1.2.3.3. Amputation. Minor amputation, usually up to the forefoot,
the first check-up: if normal, DUS is recommended if symptoms reappear;
is often needed for necrotic tissue removal with minor impact on patient
if abnormal, initial DUS, re-intervention, or closer DUS follow-up on a
mobility. Pre-amputation revascularization enhances wound healing. In case-by-case basis are recommended.128Post-procedural ankle duplex-
cases of extensive necrosis or infectious gangrene, primary major ampu- based estimated ABI of <0.90 predicts suboptimal wound healing, clinic-
tation without revascularization may be preferable to avoid complica- ally driven target lesion revascularization (cdTLR), and MALE.625
tions. Secondary amputation is indicated when revascularization fails,
After revascularization, closer follow-up and wound care are recom-
re-intervention is not possible, or limb deterioration persists despite a
mended until healing. Thereafter, annual appointments with vascular
patent graft and optimal management. BTK amputation allows better
physicians with expertise in CLTI management should be scheduled
mobility with a prosthesis. For bedridden patients, above-the-knee am-
to check for symptoms, foot condition, ABI, and CVRFs, including avail-
putation may be the preferred choice.
ability for TP and TcPO if needed. Recurrence of symptoms may also
2
be due to the progression of atherosclerotic disease above or below
Recommendation Table 20 — Recommendations for the bypass or angioplasty site.427
interventional treatment of chronic limb-threatening
ischaemia
Recommendation Table 21 — Recommendations for
Recommendation Classa Levelb follow-up in patients with chronic limb-threatening
ischaemia
In CLTI patients, it is recommended to perform
I B
revascularization as soon as possible.564 Recommendations Classa Levelb
In CLTI, it is recommended to use autologous veins
In patients with CLTI, following revascularization it is
as the preferred conduit for infra-inguinal bypass I B
surgery.567,593 recommended to follow up patients on a regular I C
basis.552,626,627
In multilevel vascular disease, it is recommended to
At follow-up, it is recommended to assess clinical,
eliminate inflow obstructions when treating I C
haemodynamic and functional status, limb symptoms, I C downstream lesions.
treatment adherence, and CVRFs.552,625–628
An individual risk assessment (weighing the patient’s
individual procedural risk of endovascular vs. surgical CLTI, chronic limb-threatening ischaemia; CVRFs, cardiovascular risk factors.
revascularization) by a multidisciplinary vascular team I C aClass of recommendation.
bLevel of evidence.
is recommended.
In CLTI patients with good autologous veins and low
surgical risk (<5% peri-operative mortality, >50% 2 8.1.3. Acute limb ischaemia
IIb B
year survival), infra-inguinal bypass may be 8.1.3.1. Clinical presentation and diagnosis
considered.564,567,590 Acute limb ischaemia is caused by an abrupt decrease in arterial limb per-
In CLTI patients, endovascular treatment may be fusion. Potential causes are PAD progression, cardiac/aortic embolization,
considered as first-line therapy, especially in patients AD, graft thrombosis, aneurysm thrombosis, popliteal artery entrapment
IIb B
syndrome, trauma, phlegmasia cerulea dolens, ergotism, hypercoagulable
with increased surgical risk or inadequate autologous
veins.564,567,590 states, and iatrogenic complications related to vascular procedures. ALI is
a medical emergency and timely recognition is crucial to successful treat-
CLTI, chronic limb-threatening ischaemia. ment.629–632Patients should be rapidly evaluated by a vascular specialist633
aClass of recommendation.
or rapidly transferred to a facility with such resources.
bLevel of evidence.
The time constraint is due to the period that skeletal muscle and
nerves will tolerate ischaemia—roughly 4–6 h.634 Lower-extremity
8.1.2.4. Follow-up symptoms can include both pain and loss of function. The longer and
In patients with CLTI, the incidence of CV events is increased.619,620 the stronger these symptoms are, the less likely the possibility of limb
Follow-up should focus on general clinical CV condition, prevention salvage.
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 51 ---
3588 E S C G u id e l in e s
Table 9 Clinical categories of acute limb ischaemia
Grade Category Sensory Motor deficit Arterial Venous Capillary Biomarkers Prognosis
loss Doppler Doppler refill
signal signal
I Viable None None Yes Yes Yes Not elevated No immediate
threat
IIA Marginally None or None No Yes Salvageable if
threatened minimal promptly treated
(toes)
IIB Immediately More than Mild-moderate No Yes Salvageable if
threatened toes promptly
revascularized
III Irreversible Profound, Profound No No No Massively Major tissue loss,
anaesthetic paralysis (rigor) elevated permanent nerve
damage inevitable
Adapted with permission from.641
8.1.3.1.1. Clinical examination. The emergency level and the choice If the limb is deemed unsalvageable, primary amputation or comfort
of therapeutic strategy depend on the clinical presentation, mainly ac- care is indicated.
cording to neurological deficits. Clinical assessment must include symp- Different revascularization modalities can be applied, including per-
tom duration as well as sensory and motor deficit severity to distinguish cutaneous catheter-directed thrombolytic therapy, percutaneous
a threatened from a non-viable extremity. Neurological deficits (sen- mechanical thrombus extraction or thrombo-aspiration (with or with-
sory loss or especially motor deficit) are signs of limb threat and require out thrombolytic therapy), or surgical thrombectomy, bypass, and/or
emergency imaging and revascularization.635Severe sensory deficit and arterial repair.642 Moreover, these modalities can be combined, with
paralysis suggest the limb may be unsalvageable. Clinical ALI categories the strategy determined by factors such as neurological deficit, ischae-
are presented in Table 9. mia duration, localization, size, aetiology, comorbidities, type of conduit
(artery or graft), and therapy-related risks and outcomes. Current en-
8.1.3.1.2. Imaging and functional tests. The imaging method de- dovascular approaches to ALI boast high technical success rates.626To
reduce morbidity and mortality, an endovascular-first approach is often
pends on availability and aims to diagnose clot presence and assess
preferred, especially in patients with severe comorbidities. Thrombus
haemodynamic severity. DSA, CTA, DUS, and contrast-enhanced
extraction, thrombo-aspiration, and surgical thrombectomy are indi-
(CE)-MRA are options based on local expertise, availability, and prefer-
ence.636 DUS helps determine treatment urgency when assessing cated in cases of neurological deficit, while catheter-directed thrombo-
lytic therapy is more appropriate in less severe cases without
neurological deficit is challenging. Loss of arterial signal suggests limb
neurological deficit. Modern catheter-based thrombectomy (CDT) is
threat, while a present signal may indicate the limb is not immediately
associated with 12-month amputation rates of <10% in Rutherford
threatened, allowing for ABI measurement. The absence of both arter-
IIB.643 A meta-analysis showed that although CDT in the treatment
ial and venous Doppler signals, coupled with extensive motor deficit,
suggests the limb may be irreversibly damaged (non-salvageable).637 of not immediately threatening ALI showed high angiographic success,
the long-term outcomes were relatively poor, with low patency and a
In addition, biomarkers of muscle damage such as creatinine kinase
substantial risk of major amputation.644Systemic thrombolysis has no
(CK) or myoglobin may be useful as high levels indicate rhabdomyolysis,
risk of amputation,638kidney failure, and mortality.639In limb ischaemia, role in the treatment of patients with ALI.
A meta-analysis showed that CDT and surgery have similar limb sal-
CK and myoglobin elevations may be lower in chronic cases, possibly
due to ischaemic pre-conditioning and collateral development.640 vage rates.645 Recent analyses indicate benefits of endovascular ap-
proaches in terms of mortality at similar amputation rates.646,647
A comparison of percutaneous thrombectomy vs. ultrasound-
8.1.3.2. Medical treatment
accelerated thrombolysis for the initial management of ALI showed
Upon clinical diagnosis, initiate analgesia, anticoagulation, and i.v. fluids.
no difference in terms of amputation, bleeding, clinical success, and ad-
Addressing acidosis and hyperkalaemia may be necessary. Administer
verse events, with primary patency at 30 days of 82% and 71%,
i.v. unfractionated heparin (bolus 5000 IU or 70–100 IU per kg body respectively.629,648,649
weight, followed by continuous infusion with dose adjustment based
After thrombus removal, in cases of pre-existing arterial lesions,
on patient response, monitored by activated clotting time or activated
these should be treated by endovascular therapy or open surgery. If
partial thromboplastin time) or subcutaneous low molecular weight
surgical treatment is required, it should be ideally performed in a hybrid
heparin (e.g. enoxaparin 1 mg per kg twice daily) to prevent further em-
room with capacity to allow sufficient completion angiographic imaging
bolization and thrombus propagation.
and initiation of local lysis if any remaining clot is visualized.
Lower-extremity four-compartment fasciotomies should be per-
8.1.3.3. Surgical and interventional treatment formed in patients with long-lasting ischaemia to prevent post-
For a salvageable limb, urgent revascularization is essential. Diagnostic reperfusion compartment syndrome.637 The management of ALI is
imaging, if it will not delay treatment, is recommended to guide therapy. summarized in Figure 16.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 52 ---
ESC Guidelines 3589
Acutely cold and painful leg
Suspected ALI
Pain management
Clinical evaluation by experienced clinician
Neurological function
Sensory loss more than
No sensory loss Sensory loss limited to toes toes and rest pain Complete sensory loss
Normal motor function No muscle weakness Mild-to-moderate muscle and loss of motor function
weakness
Capillary refill
Intact Slow-intact Slow-absent Absent
Arterial Doppler
Audible Inaudible
Venous Doppler
Audible Inaudible
Muscle biomarkers
Elevated
I: Viable IIA: Marginally threatened IIB: Immediately threatened III: Irreversible
Imaging Imaginga
(DUS, CTA, DSA, MRA) (DUS, CTA, DSA, MRA)
Urgent revascularization Emergency revascularization
Primary amputation
AND anticoagulation AND anticoagulation
or palliative care
unless contraindicated unless contraindicated
Medical management and follow-up
Figure 16 Management of acute limb ischaemia. ALI, acute limb ischaemia; CTA, computed tomography angiography; DSA, digital subtraction angi-
ography; DUS, duplex ultrasound; MRA, magnetic resonance angiography. aShould not delay treatment.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 53 ---
3590 E S C G u id e l in e s
8.1.3.4. Follow-up 8.2. Extracranial carotid and vertebral
After revascularization or amputation, haemodynamic success should artery disease
be established, aetiology of ALI investigated, and OMT ensured.
8.2.1. Clinical presentation and diagnosis
Statins improve outcomes after revascularization.552,630 Since ALI is
8.2.1.1. Clinical presentation
frequently caused by thrombo-embolism, Holter-ECG, echocardio-
Atherosclerotic CS represents one of the major causes of acute ischae-
gram, and aortic imaging are useful to allow initiation of appropriate
therapy, in particular anticoagulation.650Additionally, consider other mic stroke (20%).657
CS may be revealed by a cervical bruit, but also by a TIA or stroke.
prothrombotic syndromes, such as antiphospholipid syndromes and
vasculitis, if clinically suspected. While there is only sparse evidence,
the inclusion of PAD patients after revascularization into structured 8.2.1.2. Diagnosis
follow-up may improve their functional outcomes.627 Atherosclerotic lesions are primarily located in specific arterial segments,
including the carotid bifurcation, siphon, M1 segment of the middle cere-
bral artery, brachiocephalic trunk, subclavian artery, first and fourth seg-
ments of the vertebral artery, or first segment of the basilar artery.
Carotid plaques (CP), originating in the intima, offer a better representa-
Recommendation Table 22 — Recommendations for tion of the atherosclerotic process than carotid intima-media thickness
the management of patients presenting with acute (cIMT). CP may be diffuse or focal (protuberant). According to the
limb ischaemia (see also Evidence Table 8)
Mannheim carotid plaque consensus, a CP is defined as a focal structure
encroaching into the arterial lumen by ≥0.5 mm or ≥50% of the sur-
Recommendations Classa Levelb
rounding vessel.658The American Society of Echocardiography (ASE) re-
In patients with ALI, it is recommended that an cently proposed a definition that includes any focal thickening considered
urgent evaluation is performed by a vascular clinician atherosclerotic in origin and encroaching into the lumen of any carotid
I C
with sufficient experience to assess limb viability and artery segment (protuberant-type plaque) or, in the case of diffuse vessel
implement appropriate therapy.635 wall atherosclerosis, when cIMT measures ≥1.5 mm in any carotid artery
segment.659Plaques can progress to CS, defined as ≥50% narrowing of
In cases of neurological deficit, urgent
the extracranial internal carotid artery (ICA), with stenosis severity esti-
revascularization is recommended; diagnostic
mated using the North American Symptomatic Carotid Endarterectomy
imaging is recommended to guide treatment, I C
Trial (NASCET) method or its non-invasive equivalent assessed by DUS
provided it does not delay treatment, or if the need
(Figure 17).122,660 Other methods are described in the Supplementary
for primary amputation is obvious.422,635,651,652
data online, Section 1.5. The European Carotid Surgery Trial (ECST)
In the absence of severe neurological deficit,
and the area methods overestimate the severity of the CS and are not
revascularization is recommended within hours of I C recommended.77
initial imaging in a case-by-case decision.422,635,652 Carotid DUS is safe, accurate, and reliable if performed by a skilled vas-
Treatment with analgesics is recommended as soon cular specialist. It is the first-line imaging modality for screening, diagnosis,
I C
as possible for pain control. and surveillance of extracranial carotid arteries.77The degree of stenosis
It is recommended to monitor for compartment is mostly based on Doppler analysis of blood flow in the common carotid
syndrome after revascularization and treat I C artery (CCA), ICA, and external carotid artery (Table 10).661,662
(fasciotomy).637,652 Vertebral and subclavian arteries must also be checked. In some cases,
indirect signs of severe stenosis have to be evaluated by transcranial It is recommended to assess clinical and
and/or ophthalmic artery Doppler. Severe arterial calcification can de-
haemodynamic success following I C
revascularization.627 crease DUS accuracy.122
In patients with ALI, it is recommended to obtain a
comprehensive medical history and determine the I C Recommendation Table 23 — Recommendations for
cause of thrombosis and/or embolization.650 carotid artery stenosis assessment
In patients with ALI, following revascularization if not
Recommendations Classa Levelb
on anticoagulation for other reasons, DAPT or
IIa C
rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) It is recommended to use the NASCET method or its
should be considered.514,653 non-invasive equivalent to assess ICA I B
Upon confirmation of ALI diagnosis, treatment with stenosis.77,122,660
IIb C
heparin may be considered.635,654–656 It is recommended to use DUS as first-line imaging to
I C
diagnose ICA stenosis.77,663
ALI, acute limb ischaemia; b.i.d., twice daily; DAPT, dual antiplatelet therapy; DPI, dual
pathway inhibition; o.d., once daily. It is not recommended to use the ECST method for
aClass of recommendation. ICA stenosis assessment.77,122,660 III C
bLevel of evidence.
DUS, duplex ultrasound; ECST, European Carotid Surgery Trial; ICA, internal carotid
artery; NASCET, North American Symptomatic Carotid Endarterectomy Trial.
aClass of recommendation.
bLevel of evidence.
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 54 ---
ESC Guidelines 3591
Carotid artery stenosis
B ECST method
equivalents between
(C-A)
x 100% NASCET and ECST criteria
C
NASCET ECST
(% stenosis) (% stenosis)
A
C
50 75
60 80
70 85
NASCET method 80 91
(B-A)
x 100% 90 97
B
Figure 17 North American Symptomatic Carotid Endarterectomy Trial/European Carotid Surgery Trial methods. ECST, European Carotid Surgery
Trial; NASCET, North American Symptomatic Carotid Endarterectomy trial.
Table 10 Peak systolic velocity criteria for grading internal carotid artery stenosis
% stenosis Reference 50%–69% (moderate stenosis) ≥70% (severe stenosis)
PSV threshold SRUCC662 125–230 cm/s >230 cm/s
-------------------------
Gornik et al.661 ------------------------- -------------------------
≥180 cm/s Overestimation with SRUCC criteria but no consensus
or
≥125 cm/s + PSV ICA/CCA ≥2
CCA, common carotid artery; ICA, internal carotid artery; PSV, peak systolic velocity; SRUCC, Society of Radiologists in Ultrasound.
8.2.2. Asymptomatic carotid artery stenosis unproven.664 The only RCT (the Asymptomatic Cervical Bruit
8.2.2.1. Medical treatment Study [ACB]) addressing the issue enrolled only 188 patients per
Optimal medical treatment is based on CVRF correction through arm, and failed to show superiority of aspirin vs. placebo in reducing
lifestyle intervention and pharmacological treatment, with the goal of TIA, stroke, MI, or death.665In observational studies, SAPT (mainly
reducing cerebrovascular and global CV events.19 Concerning hyper- low-dose aspirin) was associated with reduced risk of MACE,
tension, similar target values as those presented in the general section although data were conflicting for moderate stenosis (i.e. 50%–
are recommended for patients with asymptomatic CS. 75%);664 DAPT, combining aspirin and clopidogrel, has no benefit
over SAPT.496,497
8.2.2.1.1. Lipid-lowering therapy. See Section 7. The Cardiovascular Outcomes for People Using Anticoagulation
8.2.2.1.2. Antihypertensive therapy. See Section 7. Strategies (COMPASS) trial reported a non-significant decrease in
8.2.2.1.3. Glucose-lowering therapy. See Section 7. MACE in patients with either history of carotid revascularization or
8.2.2.1.4. Antithrombotic therapy. The clinical benefit of antithrom- asymptomatic patients with >50% CS and CVRFs allocated to dual an-
botic treatment in patients with asymptomatic CS remains tithrombotic therapy (aspirin 100 mg o.d. and rivaroxaban 2.5 mg b.i.d.)
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 55 ---
3592 E S C G u id e l in e s
vs. aspirin alone or rivaroxaban 5 mg b.i.d. alone. However, specific data Table 11 High-risk features associated with increased
on asymptomatic CS were not reported. risk of stroke in patients with asymptomatic internal ca-
Since these patients present a two times higher risk of MI,30lifelong rotid artery stenosis on optimal medical treatment
low-dose aspirin should be considered in asymptomatic CS patients at Clinicala Contralateral TIA/stroke681,682
increased risk for CV events (i.e. diabetic patients) and low bleeding Cerebral imaging Ipsilateral silent infarction683–685
risk497to reduce stroke and CV risk.19,299,488,666
Ultrasound/CT Stenosis progression (>20%)340,684,685
imaging Spontaneous embolization on transcranial Doppler
(HITS)341,686
Recommendation Table 24 — Recommendations for
Impaired cerebral vascular reserve687,688
antithrombotic treatment in patients with carotid
Large plaques689,690
stenosis
Echolucent plaques136,691
Recommendations Classa Levelb Increased juxta-luminal black (hypoechogenic)
area689,690
Carotid artery disease
MRAb Intraplaque haemorrhage692,693
In patients with symptomatic CS, not undergoing Lipid-rich necrotic core694,695
carotid endarterectomy or stenting, DAPT with
CT, computed tomography; HITS, high-intensity transient signal; MRA, magnetic resonance
low-dose aspirin and clopidogrel (75 mg) is
I A angiography; TIA, transient ischaemic attack.
recommended for the first 21 days or longer, aAge is not a predictor of poorer outcome.
followed by clopidogrel 75 mg or long-term aspirin bMore than 40 mm2 on digital analysis.
to reduce the risk of stroke.667–669
In patients with asymptomatic >50% CS, long-term
The ARR in stroke favouring surgery over OMT was only 4.6% at 10
antiplatelet therapy (commonly low-dose aspirin)
IIa C years in ACST-1, indicating that 95% of asymptomatic patients ultim-
should be considered if bleeding risk is
ately underwent unnecessary interventions.674,678
low.488,497,670,671
A recent meta-analysis confirmed the role of modern OMT in redu-
CS, carotid artery stenosis; DAPT, dual antiplatelet therapy. cing major stroke, combined stroke, and mortality in asymptomatic pa-
aClass of recommendation. tients, suggesting that OMT has the potential to reduce the
bLevel of evidence.
requirement for surgical intervention in patients with asymptomatic
carotis stenosis.679
In conclusion, for invasive treatment of asymptomatic carotid sten-
8.2.2.2. Interventional treatment osis, the overall risk reduction is low compared with OMT. Current
8.2.2.2.1. Open surgery vs. medical therapy. The rationale for carotid data are not available to assess subgroups that may still benefit from
endarterectomy (CEA) in asymptomatic CS stems from two trials that intervention. However, there is a need to target revascularization in a
were published some time ago. The Asymptomatic Carotid subgroup of patients with clinical and/or imaging features that increase
Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery the risk for stroke on OMT (Table 11).678,680
Trial 1 (ACST-1) compared CEA with medical therapy in asymptomatic Importantly, ACST-1 found no evidence that age >75 years at base-
patients with 60%–99% CS.672–674In ACAS, 5 year rates of ipsilateral line was associated with any ipsilateral stroke reduction at 5–10
stroke/death under CEA vs. medical therapy were 5.1% vs. 11.0%. years.676–678,696Neither the ACAS nor ACST-1 studies found any evi-
ACST-1 reported 5 year rates of any stroke of 6.4% vs. 11.8%, respect- dence that stenosis severity or contralateral occlusion increased late
ively. In a combined analysis of both trials, CEA conferred less benefit in stroke risk.672,674,697In a recent meta-analysis, increasing stenosis was
women at 5 years.675At 10 years, however, ACST-1674reported that associated with late ipsilateral stroke only in the presence of concomi-
females benefit following CEA (absolute risk reduction [ARR] 5.8%) tant high-risk features.698The general algorithm of CS management is
to the same extent as men (ARR 5.5%). presented in Figure 18.552
Medical treatment has advanced following the recruitment of patients
in these trials.672–676A 60%–70% decline in annual stroke rates was also 8.2.2.2.2. Carotid revascularization: surgery vs. stenting. In a recent
observed in medically treated patients in both trials over 1995 to 2010.676 meta-analysis update on RCTs in asymptomatic patients comparing
This reduction was attributed to better medical treatment and lower CEA vs. CAS, including altogether 7092 patients, CAS was associated
smoking incidence. The Stent Protected Angioplasty versus Carotid with significantly higher rates of 30 day ‘any’ stroke and 30 day death/
Endarterectomy study (SPACE-2) compared OMT alone against OMT any stroke, while CEA was associated with significantly higher rates
plus CEA/carotid artery stenting (CAS) in asymptomatic patients with of 30 day MI. No significant differences were seen in 30 day death,
CS ≥70% according to ECST criteria. Due to slow recruitment, the study 30 day disabling stroke, 30 day death/disabling stroke, or 30 day
was underpowered. The 1 year rate of the major secondary endpoint was death/any stroke/MI when CAS was compared with CEA.699In the lar-
2.5% after CEA, 3.0% after CAS, and 0.9% after OMT.677Incidence of any gest RCT, ACST-2, post-operative death and major stroke were similar
stroke or death from any cause within 30 days or any ipsilateral ischaemic (1.0%) between groups.700,701
stroke within 5 years (primary efficacy endpoint) was 2.5% with CEA plus No significant difference was found in the 5 and 10 year incidence of
OMT, 4.4% with CAS plus OMT, and 3.1% with OMT alone. Results from ipsilateral stroke and any stroke between CEA and CAS.696,702,703The
the Carotid Revascularization Endartectomy vs. Stenting Trial 2 5 year non-procedural stroke rate in ACST-2 was 2.5% in each group
(CREST-2) are awaited to clarify whether intervention is beneficial in for fatal/disabling stroke, and 5.3% with CAS vs. 4.5% with CEA for any
the treatment of asymptomatic CS compared with modern OMT. stroke.700,701
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 56 ---
ESC Guidelines 3593
Asymptomatic patient
Duplex ultrasound
<60% carotid stenosis 60–99% carotid stenosis 100% carotid occlusion
OMT OMT OMT
(Class I) (Class I) (Class I)
Revascularization Vascular team Revascularization
(Class III) and neurologist (Class III)
Individual risk assessmenta
Average-to-high surgical risk Y
N
Revascularization Routine revascularization
(Class IIb) (Class III)
CTA and/or MRA
(incl. aortic arch)
CEA
or CAS/TCAR decision by vascular team based on an individual patient approach
Symptomatic patient
Duplex ultrasound
CTA and/or MRA
(incl. aortic arch)
<50% carotid stenosis 50–69% carotid stenosis 70–99% carotid stenosis 100% carotid occlusion
OMT OMT OMT OMT
(Class I) (Class I) (Class I) (Class I)
Routine
Revascularization Revascularization Revascularization
revascularization
(Class IIa) (Class I) (Class III)
(Class III)
Surgical/endovascular risk assessmenta
CEA
or CAS/TCAR decision by vascular team based on an individual patient approach
Figure 18 Algorithm of carotid artery stenosis management. CAS, carotid artery stenting; CEA, carotid endarterectomy; CTA, computed tomog-
raphy angiography; MRA, magnetic resonance angiography; OMT, optimal medical treatment; TCAR, transcarotid artery revascularization; TIA, tran-
sient ischaemic attack. aAssess presence of high-risk features according to Table 11. If surgery/revascularization is considered, assess the overall risk
related to surgery according to Table 12.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 57 ---
3594 E S C G u id e l in e s
The Stenting and Angioplasty with Protection in Patients at High Risk 8.2.3. Symptomatic carotid artery stenosis
for Endarterectomy (SAPPHIRE) trial randomized symptomatic and 8.2.3.1. Medical treatment
asymptomatic patients deemed ‘high-risk for surgery’ to either CEA
8.2.3.1.1. Lipid-lowering therapy. See Section 7.
or CAS (using embolic protection devices).704 Overall, 71% of
SAPPHIRE patients were asymptomatic, and in these patients the 30 8.2.3.1.2. Antihypertensive therapy. See Section 7.
day rate of death/stroke after CAS was 5.8% vs. 6.1% after CEA704— 8.2.3.1.3. Glucose-lowering therapy. See Section 7.
both beyond the recommended 3%. If these procedural risk levels re-
8.2.3.1.4. Antithrombotic therapy. Symptomatic CS is associated
flect contemporary practice, most ‘high-risk for surgery’ asymptomatic
with a high risk of early recurrence of cerebrovascular ischaemic
patients would be better treated medically.
events.667–669,683 DAPT with low-dose aspirin and clopidogrel is re-
A small sample size RCT has provided evidence that the use of a
commended for all patients with symptomatic CS for at least
double-layer mesh stent can reduce the occurrence of peri-procedural
3 months.669Those undergoing surgical revascularization can stop clo-
diffusion-weighted imaging (DWI)-detected ischaemic lesion after ca-
pidogrel after surgery.711Those undergoing endovascular revasculari-
rotid stents, when compared with conventional stents. At 1 year follow-
zation should continue DAPT with clopidogrel and low-dose aspirin
up the use of a double-layer mesh stent was associated with a significant
for 4 weeks after the procedure.488,666,711,712In patients with stroke re-
reduction in the composite endpoint of MACE and in-stent restenosis or
lated to extracranial arterial disease, aspirin was more effective than
occlusion. The clinical benefit of these findings has to be proven.705,706
VKAs in reducing recurrencies.687,713 Subgroup analysis from the
Transcarotid artery revascularization (TCAR) has been introduced
Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or
recently. Although no RCTs are available, large registry-based analyses
Ticagrelor and Patient Outcomes (SOCRATES) trial suggested a lower report a 99.7% technical success rate and low 30 day complication rates
rate of MACE in patients receiving ticagrelor vs. aspirin;689 however,
(<3% in 30 day stroke/death and <1% MI).681
this analysis was underpowered to make any conclusions regarding
In a large-scale registry the 1 year rate of stroke or death was 6.4%
the benefit of ticagrelor.
for TCAR, 5.2% for CEA, and 9.7% for transfemoral carotid artery
A combination of aspirin and clopidogrel in the early phase of symp-
stenting (TFCAS).707
tomatic carotid stenosis reduces asymptomatic cerebral embolization
Properly conducted RCTs comparing TCAR with CEA in asymp-
and stroke.692,694,714 It also reduces stroke recurrence after a minor
tomatic patients are required to establish the true place of TCAR in ca-
stroke/TIA.667,668
rotid revascularization.708
Recently, the Acute Stroke or Transient Ischaemic Attack Treated
Recommendation Table 25 — Recommendations for with Ticagrelor and acetylsalicylic acid for Prevention of Stroke and
interventional treatment in patients with asymptomatic Death (THALES) trial showed a 17% reduction in the risk of death
carotid artery stenosis or stroke when using ticagrelor and aspirin vs. aspirin alone in patients
with minor stroke or high-risk TIA;715 however, bleeding events oc-
Recommendations Classa Levelb curred more frequently in the ticagrelor plus aspirin group.700,716Of
note, COMPASS data cannot be applied to symptomatic carotid sten-
When ICA revascularization is considered,
osis since these patients were excluded because of intracranial bleeding
documented peri-operative stroke/death rates
risk.499
should be <3% and the patient’s life expectancy
IIa B
should be considered >5 years after careful
consideration of the risks and benefits by a vascular Recommendation Table 26 — Recommendations for
team. 674,709 evaluation and medical treatment in patients with
symptomatic carotid artery stenosis
In ‘average surgical risk’ patients over 75 years of age
with a CS of 60%–99%, in the presence of high-risk
IIa B Recommendations Classa Levelb
features, CEA, in addition to OMT, should be
considered.674,709 DAPT is recommended in the early phase of minor
In ‘high surgical risk’ patients with a CS of 60%–99%, strokes in patients with ICA stenosis, if not
I A
in the presence of high-risk features, CAS, in addition IIb B revascularized, for at least 21 days, considering the
to OMT, may be considered.699,701,704 bleeding risk.667,668
In ‘average surgical risk’ patients with a CS of 60%– It is recommended that symptomatic ICA stenosis
99%, in the presence of high-risk features, CAS, in patients are assessed by a vascular team including a I C
IIb B
addition to OMT, may be considered as an neurologist.667,668
alternative to CEA.696,701,702,710 Long-term treatment with SAPT should be
IIa C
In asymptomatic patients with ICA stenosis, in the considered following ICA revascularization.667,668
absence of high-risk features and with a life DAPT may be considered in the early phase of minor
III A
expectancy <5 years, routine revascularization is not stroke in patients with ICA stenosis for up to 90 days, IIb B
recommended.674 considering the bleeding risk.667,668
CAS, carotid artery stenting; CEA, carotid endarterectomy; CS, carotid artery stenosis; DAPT, dual antiplatelet therapy (aspirin and clopidogrel); ICA, internal carotid artery;
ICA, internal carotid artery; OMT, optimal medical treatment. SAPT, single antiplatelet therapy.
aClass of recommendation. aClass of recommendation.
bLevel of evidence. bLevel of evidence.
4202CSE© 4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 58 ---
ESC Guidelines 3595
8.2.3.2. Interventional treatment Table 12 High-risk peri-operative features for carotid
8.2.3.2.1. Open surgery. Optimal medical treatment is recommended endarterectomy
for all symptomatic patients with CS. In recently symptomatic patients
Clinical
with <50% stenosis, CEA (plus OMT) did not prevent stroke.
Congestive heart failure (NYHA functional class III/IV)
However, surgery reduced stroke risk in patients with moderate
(50%–69%) and severe (70%–99%) stenosis. The benefit from surgery Unstable angina (CCS III/IV)
increased with increasing severity of stenosis, except for ‘near- CAD with LM or >1 vessel with 70% stenosis
occlusion’ lesions (95%–99% stenosis with distal ICA collapse or a nar- Recent MI (<30 days)
row calibre lumen with ‘trickle flow’).660,717–720 Planned open heart surgery (<30 days)
Some features are associated with a higher increase of stroke in symp-
LVEF <30%
tomatic patients (50%–99% stenosis) medically treated: age (>75 years),
Severe pulmonary disease
symptoms within 14 days, male sex, hemispheric (vs. retinal) symptoms,
Severe renal disease
cortical (vs. lacunar) stroke, increasing comorbidities, irregular stenosis,
stenosis severity, contralateral occlusion, tandem intracranial stenosis, Anatomical
and failure to recruit intracranial collaterals.721 Surgically inaccessible lesions
Large-scale registries suggest that CEA can be performed safely in • At or above C2
the first 7 days after TIA/minor stroke.722–724However, not all patients • Below the clavicle
benefit from urgent revascularization, and controversy exists over the
Ipsilateral neck irradiation
safety of performing CEA within the first 48 h after symptom onset due
Spinal immobility of the neck
to an increased risk of haemorrhagic transformation. Higher-risk pa-
Contralateral carotid artery occlusion (increases risk for stroke)
tients include those with acute carotid occlusion, a persisting major
Contralateral laryngeal palsy
neurological deficit, an area of middle cerebral artery infarction exceed-
ing one-third, evidence of pre-existing parenchymal haemorrhage, and Tracheostomy
signs of impaired consciousness.724,725
CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; LM, left main; LVEF,
The choice to perform carotid revascularization within 48 h from left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart
symptom onset is still debatable.726 Association.
OMT. Initially designed as an alternative for high surgical risk (HSR) pa-
8.2.3.2.2. Endovascular therapy vs. open surgery. Contemporary tients,704,736carotid stenting’s efficacy needs consideration in contem-
RCTs comparing CEA with CAS in symptomatic patients reported a porary practice (Table 12).735
significantly higher risk of 30 day ‘any stroke’ and ‘death/stroke’ follow-
In conclusion, CEA is still the treatment choice for patients with
ing CAS. This is mainly due to higher rates of minor stroke, which were
symptomatic carotid stenosis. However, in patients eligible for ca-
non-disabling and resolved within 6 months.711,727
rotid revascularization but deemed high surgical risk by a multidiscli-
However, the occurrence of a peri-operative stroke is associated
plinary team, CAS may be preferred over CEA—the patient must be
with three-fold poorer long-term survival,727 similar to a post-
a suitable candidate for CAS, and the complication rate should not
procedural MI (which was more frequent after CEA).728
surpass 6%.
In CAS patients, the risk increased in those aged >60 years, especially
At present, TCAR results have been analysed in registries only. In
for those aged >80 years, who are four times more likely to experience
these studies, in-hospital stroke/death has been significantly lower after
a procedural stroke/death. When comparing CAS with CEA, the TCAR compared with transfemoral CAS.707,737Similar to the previous
age-related effect became apparent in patients aged 60–65 years, and
results established for CEA, symptomatic patients undergoing TCAR
CEA is superior to CAS in patients aged >70 years.729,730
demonstrate similar outcomes if the procedure is performed >48 h
Elderly CAS patients may experience more peri-operative strokes, after the neurological event.738However, TCAR has not yet been eval-
mainly minor ipsilateral strokes, possibly due to a higher burden of aor- uated in RCTs and has not been compared with CEA or OMT.
tic arch disease. In these cases, operator/institution experience may
play a role in determining peri-procedural outcomes. CAS is associated
with significantly lower risks for MI, transient cranial nerve injury, and 8.2.3.2.3. Vertebral arteries. The evidence on the use of lifestyle
haematoma.731,732 modifications and medical therapy in cases of symptomatic vertebral ar-
Beyond the 30 day peri-operative period, long-term data suggest that tery stenosis is lacking, but their use is reasonable given the overall CV
outcomes after CAS are similar to those with CEA.703,733 The pre- risk in these patients.
dicted magnitude of 30 day risk (according to clinical/anatomical char- Evidence on the use of preventive strategies and antithrombotic
acteristics and operator/centre experience) will thus largely agents is lacking, but their use is reasonable in the presence of other
determine whether CEA or CAS is preferable in individual patients. CVRFs.
Post-hoc trial analysis revealed enhanced benefits of CEA when per- Surgery on extracranial vertebral stenosis (with transposition to CCA,
formed within 2 weeks of the ischaemic event,734with reduced compli- trans-subclavian vertebral endarterectomy, distal venous bypass) can be
cations compared with CAS performed within 1 week of stroke/TIA. performed with low stroke/death rates in experienced centres.739,740
The Carotid Stenosis Trialists’ Collaboration found a higher stroke/ However, with limited expertise in complex vertebral artery reconstruc-
death rate (8.3% with CAS vs. 1.3% with CEA) for CAS in patients trea- tions, open surgery has been mostly replaced by endovascular interventions.
ted within 1 week of the last symptomatic event.735These findings sup- In a combined analysis of the the Vertebral Artery Ischaemia Stenting
port a preference for early CEA in symptomatic patients. However, Trial (VIST), the Vertebral Artery Stenting Trial (VAST), and the
these trials, initiated over 30 years ago, lack evaluation of current Stenting and Aggressive Medical Management for Preventing
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 59 ---
3596 E S C G u id e l in e s
Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial,741no clear Duplex ultrasound is the first-line technique to evaluate patients
benefit was shown for extracranial vertebral artery stenting. after CEA or CAS. CTA and MRA are alternative methods for deter-
Randomized controlled trials have not assessed surgical techniques mining restenosis.749,754
like vertebral artery endarterectomy or transposition. While case ser- After CEA or CAS, DUS is recommended at baseline (<3 months)
ies exist, they often lack a control group following a consistent medical and annually thereafter until the patient is stable (i.e. until no restenosis
treatment protocol.742 As a result, the effectiveness of these proce- is observed in two consecutive annual scans). Regular surveillance (e.g.
dures remains uncertain. every 2 years) can be performed based on the stenosis of the contra-
lateral ICA, risk profile, and patient’s life expectancy.749,754
Recommendation Table 27 — Recommendations for For patients combining multiple CVRFs after the procedure, DUS
interventions in patients with symptomatic carotid may be beneficial every 6 months until a stable clinical pattern is estab-
artery stenosis lished, and annually thereafter.749,754
Early surveillance, especially within 1–3 months and particularly in
Recommendations Classa Levelb cases where intraoperative completion imaging is absent (e.g. after
CEA), aids in detecting technical errors and setting a baseline for future
It is recommended to perform CEA of symptomatic
comparisons.
70%–99% ICA stenosis provided a documented 30 I A
Follow-up enables the identification of ipsilateral carotid restenosis
day risk of procedural death/stroke is <6%.660,719
and contralateral disease progression, offering a chance for timely inter-
If indicated, it is recommended to perform CEA
vention to minimize the risk of stroke. Nevertheless, this concept is fa-
within 14 days in symptomatic ICA stenosis I B cing growing challenges due to a reduced and selective role for
patients.734
intervention in asymptomatic patients. A surveillance protocol holds
OMT is recommended for all symptomatic ICA significance when anticipated outcomes are expected to cost-
I A
stenosis patients.19 effectively influence a medical or interventional treatment plan.749,754
CEA of symptomatic 50%–69% ICA stenosis should
be considered provided a documented 30 day risk of IIa A
procedural death/stroke is <6%.660,719 Recommendation Table 28 — Recommendations for
follow-up in patients with carotid artery stenosis
For symptomatic patients at high risk for CEA with a
70%–99% ICA stenosis, CAS should be considered
IIa B Recommendations Classa Levelb
provided a documented 30 day risk of procedural
death/stroke is <6%.703 Once-yearly follow-up is recommended to check for
I A
For symptomatic patients <70 years of age with a CVRFs and treatment compliance.754
70%–99% ICA stenosis, CAS may be considered After ICA stent implantation, DAPT with aspirin and
IIb A
provided a documented 30 day risk of procedural clopidogrel is recommended for at least 1 I A
death/stroke is <6%.703 month.77,749,750
Revascularization is not recommended in patients After ICA revascularization, long-term aspirin or
III A I B
with ICA lesions <50%.660,719 clopidogrel is recommended.746,747
During follow-up, it is recommended to assess
CAS, carotid artery stenting; CEA, carotid endarterectomy; ICA, internal carotid artery;
OMT, optimal medical treatment. neurological symptoms, CVRFs, and treatment I C
aClass of recommendation. adherence at least yearly in patients with CS.754
bLevel of evidence.
After ICA revascularization, surveillance with DUS is
I C
recommended within the first month.749,754
8.2.3.3. Follow-up
CS, carotid artery stenosis; CVRFs, cardiovascular risk factors; DAPT, dual antiplatelet
Peri-operative and post-procedural medical management after carotid therapy; DUS, duplex ultrasound; ICA, internal carotid artery.
revascularization should include OMT. Post-operative hypertension is a aClass of recommendation.
risk factor for stroke and TIAs, wound bleeding, and intracranial haem- bLevel of evidence.
orrhage.743Therefore, proper pharmacological BP control is important
in optimizing outcomes.744
8.3. Other arterial locations
Fluctuations of hypertension and hypotension are not uncommon
and should be treated promptly.744,745 8.3.1. Subclavian artery disease
An intensive lipid-lowering therapy (ILT) aiming at >50% LDL-C re- 8.3.1.1. Clinical presentation and diagnosis
duction and LDL-C <1.4 mmol/L (55 mg/dL) is also recommended.19 Atherosclerotic upper-limb artery disease (UEAD) is most frequently
Antiplatelet therapy should be tailored according to type of interven- located in the subclavian artery.755,756 Digital ischaemia is most fre-
tion. In CEA, the reduction in peri-procedural and long-term ischaemic quently caused by non-atherosclerotic aetiologies, including thrombo-
events under low-dose aspirin has been demonstrated.746,747After ca- embolism, systemic sclerosis, idiopathic, thromboangiitis obliterans,
rotid stenting, DAPT (aspirin and clopidogrel) is recommended, while iatrogenic, or cancer.757 Isolated subclavian stenosis (SS) is often
optimal duration is debated.748 In the peri-operative period after asymptomatic and may be suspected because of an absolute inter-arm
CAS, DAPT should be prescribed and continued for at least 30 days SBP difference >10–15 mmHg.758 In the Multi-Ethnic Study of
post-procedure.77,749,750Ticagrelor, when included in DAPT following Atherosclerosis (MESA), prevalence of asymptomatic SS was approxi-
CAS/TCAR, presents a drawback due to its elevated bleeding risk com- mately 4.5% (male: 5.1%, female: 3.9%) in adults and more frequent in
pared with clopidogrel.751–753 patients with PAD (11.4%).759 In patients attending CV clinics, a
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 60 ---
ESC Guidelines 3597
>25 mmHg SBP difference doubles prevalence and independently pre- or re-occlusion after stenting (5 year patency 97%).770Other options
dicts mortality.32,758As obstructive disease progresses, particularly af- are extrathoracic extra-anatomic bypass procedures (axillo-axillary, ca-
fecting vertebral vessels, the risk of ischaemia or steal symptoms rotid–axillary, or carotid–carotid bypass);771,772however, axillo-axillary
significantly rises. Visual disturbances, syncope, ataxia, vertigo, dyspha- bypasses may occlude at 1 year in 14% of cases.773The transthoracic ap-
sia, dysarthria, and facial sensory deficits during arm movements may proach is an option in patients with multivessel disease involving the aor-
indicate subclavian steal syndrome, correlating with inter-arm BP differ- tic arch and several supra-aortic vessels.767
ence.760Brachiocephalic occlusive disease can lead to stroke or TIA in While critical hand ischaemia owing to below-the-elbow atherosclerot-
carotid and vertebral territories, manifesting as exercise-induced fa- ic occlusive disease is relatively uncommon, interventions are associated
tigue, pain, and arm claudication. Severe cases, especially with distal dis- with a high rate of success, major amputations are rare, and many can
ease, may result in rest pain and digital ischaemia with necrosis. be treated non-operatively.756In appropriately selected patients, both en-
Duplex ultrasound assessment of subclavian arteries enables the de- dovascular and open interventions have a high rate of success.755,756
tection of SS via intrastenotic high-velocity flows (50% stenosis: peak In symptomatic patients with contraindications for endovascular ther-
systolic velocity [PSV] ≥230 cm/s, PSV ratio [PSVr] ≥2.2; 70% stenosis apy or open surgery, prostanoid infusion or thoracic sympathectomy
PSV ≥340 cm/s and PSVr ≥3.0) or monophasic post-stenotic wave- may be considered.774
forms.761The majority of patients (>90%) with at least 50% proximal
SS have either intermittent or continuous flow reversal in the vertebral 8.3.1.3. Follow-up
artery, though not all will be symptomatic.760,762When subclavian steal Patients with UEAD should be followed up to ensure optimal CV
syndrome is suspected, flow reversal should be assessed in the ipsilat-
prevention. Tighter follow-up is required in symptomatic patients to re-
eral extracranial vertebral artery by hyperaemia testing and if available
assess indication for revascularization as a large proportion of symptoms
transcranial Doppler.762Severe stenosis or occlusion of the right bra- resolve spontaneously.775After revascularization, patients should be fol-
chiocephalic trunk is associated with reduced flow velocities in the ip-
lowed up to allow early detection and treatment of impending late proced-
silateral subclavian artery and the CCA. Abnormal or doubtful DUS
ural failure.
should lead to anatomic imaging (CTA/MRA).763CTA is excellent for
supra-aortic lesions and can provide extravascular information, espe- Recommendation Table 29 — Recommendations for
cially when thoracic outlet syndrome is a differential diagnosis. MRA the management of subclavian artery stenosis (see also
Evidence Table 9)
provides both functional and morphological information useful to dis-
tinguish antegrade from retrograde perfusion and to estimate stenosis
Recommendations Classa Levelb
severity.764DSA is performed if endovascular therapy is indicated. PET
is useful for the diagnosis of arteritis but not for assessment of athero- Bilateral arm BP measurement is recommended for
I B
sclerotic lesions in clinical practice. all patients with PAAD.32,758
In symptomatic patients with atherosclerotic
8.3.1.2. Treatment strategy (medical and interventional)
subclavian artery disease (TIA/stroke, coronary
Optimal medical treatment is recommended in all patients with symptom-
subclavian steal syndrome, ipsilateral haemodialysis
atic UEAD to reduce CV risk.32Revascularization is indicated in symptom-
access dysfunction, severe ischaemia), both IIa B
atic patients with TIA/stroke, coronary subclavian steal syndrome,
revascularization options (endovascular ± stenting
ipsilateral haemodialysis access dysfunction, or impaired HRQoL.
or surgery) should be considered and discussed case
Revascularization should be considered in asymptomatic patients with
by case by a vascular team.776
planned coronary artery bypass grafting (CABG) using the internal mam-
Endovascular revascularization may be considered
mary artery and those with ipsilateral haemodialysis access, as well as
over surgery, despite similar long-term outcomes, IIb B
asymptomatic patients with significant bilateral SS/occlusion for adequate
BP surveillance. For revascularization, both endovascular and surgical pro- due to lower complication rates.765
cedures are available. There are no RCTs comparing endovascular vs. open In patients with atherosclerotic subclavian artery disease,
repair but individual studies, including the Danish Vascular Registry, indicate revascularization:
similar long-term symptom resolution but higher general complication
Should be considered in cases of proximal stenosis in
rates and hospital length of stay for open surgery.765The risk of severe
patients undergoing CABG using the ipsilateral IIa C
complications, including vertebrobasilar stroke, is low with both ap-
internal mammary artery.777–781
proaches. The post-procedural stroke rate is reported at 1.3% for endo-
Should be considered in cases of proximal stenosis in
vascular therapy765and 0.9%–2.4% after open surgery.765–767
patients who already have the ipsilateral internal
Percutaneous angioplasty for subclavian arterial stenosis is often used IIa C
mammary artery grafted to coronary arteries with
with stenting. There is no conclusive evidence to determine whether
stenting is more effective than balloon angioplasty.768 Similar results evidence of myocardial ischaemia.777,778,780
were reported for endovascular therapy of the innominate artery.769 Should be considered in cases of ipsilateral
IIa C
In heavily calcified ostial lesions, balloon-expandable stents give more ra- haemodialysis arteriovenous access.778
dial force than nitinol stents. An endovascular approach is often the de- Routine revascularization in patients with
fault strategy. However, in selected patients with low operative risk, atherosclerotic subclavian artery disease is not III C
with subclavian artery occlusion or after endovascular therapy failure, recommended.776
surgical subclavian–carotid transposition is safe with excellent long-term
patency results (5 year patency 96%).766Carotid–subclavian bypass sur- BP, blood pressure; CABG, coronary artery bypass grafting; PAAD, peripheral arterial and
aortic diseases; TIA, transient ischaemic attack.
gery with a prosthetic graft showed long-term benefit with low opera- aClass of recommendation.
tive mortality and morbidity, especially in patients with extensive disease bLevel of evidence.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 61 ---
3598 E S C G u id e l in e s
8.3.2. Renal artery disease Table 13 Clinical signs suggestive of renal artery
8.3.2.1. Clinical presentation and diagnosis disease
8.3.2.1.1. Epidemiology. In >90% of cases, RAS is caused by athero-
Hypertension onset before 30 years of age
sclerosis and typically involves the ostial renal arterial segment
(Table 13).782Above 65 years of age, overall prevalence of ≥60% RAS Severe hypertension after the age of 55 years, when associated with CKD or
heart failure
is 6.8%, with a higher prevalence in men (9.1%) than in women
(5.5%).783 In patients with PAD, RAS prevalence ranges between 7% Hypertension and abdominal bruit
and 42%, influenced by diagnostic criteria.784 Rapid and persistent worsening of previously controlled hypertension
Resistant hypertension
8.3.2.1.2. Clinical presentation. Clinical presentation comprises reno- • Three antihypertensive drugs including a diuretic agent
vascular hypertension, renal function impairment and eventually, flash pul- or
monary oedema (Table 13). RAS reduces the filtration capacity of the • ≥4 antihypertensive drugs
affected kidney, which activates the renin–angiotensin–aldosterone path- and
way, potentially resulting in renovascular hypertension.782,785In unilateral
• Other secondary form unlikely
RAS, the functioning contralateral kidney may increase sodium excretion
to prevent sodium retention and volume overload. In high-grade bilateral
Hypertensive crisis (i.e. acute renal failure, acute heart failure, hypertensive
RAS or in unilateral RAS without a functioning second kidney, the risk of
encephalopathy, or grade 3–4 retinopathy)
cardiorenal deterioration is higher than in unilateral disease.786
New azotaemia or worsening of renal function after treatment with RAAS
8.3.2.1.3. Diagnosis of renal artery disease. First diagnostic steps in- blockers
clude laboratory tests to examine renal function, analysis of office and Unexplained atrophic kidney or discrepancy in kidney size, or unexplained
out-of-office BP recordings (ambulatory BP monitoring or home BP renal failure
monitoring, as recommended by [upcoming] ESC/European Society Flash pulmonary oedema
of Hypertension [ESH] Guidelines for arterial hypertension), and non-
invasive haemodynamic assessment of renal arteries by DUS.787 CKD, chronic kidney disease; RAAS, renin–angiotensin–aldosterone system.
Renal artery PSV >200 cm/s measured by DUS allows the diagnosis of
a >50% RAS (sensitivity 95%, specificity 90%).788A renal-aortic peak flow development of end-stage renal disease (ESRD).795 The risk of RAS-
velocity ratio (RAR = renal artery PSV/aortic PSV) >3.5 has 84%–91% related ESRD is higher in men than in women and increases with age.795
sensitivity and 95%–97% specificity for the detection of ≥60% RAS.789
A side-to-side difference of the intrarenal resistance index ≥0.5 between
8.3.2.2. Treatment strategy (medical and interventional)
both kidneys may serve as an additional haemodynamic criterion for
haemodynamically relevant RAS.787,790Other DUS criteria (acceleration 8.3.2.2.1. Medical therapy. Optimal medical treatment is recom-
time, acceleration index) have lower diagnostic accuracy.791 mended in RAS patients.785Data on antithrombotic therapy in patients
with atherosclerotic RAS are scarce and retrospective.796 However,
Sensitivity and specificity of contrast-enhanced MRA in the diagnosis
of RAS is 88% and 100%, respectively;789however, MRA overestimates the use of an antiplatelet agent is reasonable in atherosclerotic RAS.
the degree of RAS by 26%–32%.789 The advantages of MRA are the No prospective study has specifically examined antithrombotic ther-
apy post-RAS stenting, and information from existing RAS stenting
possibility of assessing renal parenchymal blood flow and freedom
trials is limited.797 Following the antithrombotic treatment approach
from radiation and iodinated contrast agents.
in non-coronary arterial beds, it is suggested to use DAPT for at least
Spiral multidetector CTA allows renal artery diameter measure-
1 month after RAS stent implantation.666
ments and provides information on vessel wall calcification and mural
plaques. RAS diagnosis by CTA presents 64%–100% sensitivity and
92%–98% specificity.789 CTA drawbacks include radiation exposure, 8.3.2.2.2. Revascularization. Revascularization in atherosclerotic RAS
the need for contrast media in patients with impaired renal function, Prospective RCTs comparing endovascular revascularization with
and limited haemodynamic assessment of RAS. OMT in atherosclerotic RAS favoured renal artery stenting over bal-
Catheter angiography is the gold standard for diagnosing RAS, enab- loon angioplasty.792
ling additional haemodynamic measures (Figure 19).792Considering the However, renal artery stenting showed no superiority over OMT in
potential risks of invasive procedures, DUS and other non-invasive mo- reducing BP, CV events, renal events, or mortality in unilateral athero-
dalities (CTA or MRA) should precede catheter angiography and inva- sclerotic RAS.788,798,799A trial suggested a potential benefit of renal ar-
sive haemodynamic measurements (Figure 19). tery angioplasty for BP in bilateral RAS, but subsequent RCTs did not
Renal scintigraphy, plasma renin measurements before and after confirm this.800–802Data on the benefit of renal artery stenting in spar-
ACEI provocation, and venous renin measurements are not considered ing antihypertensive drugs are inconsistent.324,800,801,803,804
for RAS evaluation. In specific circumstances or RAS aetiologies, revascularization should
be considered (Figure 19). Open surgical renal artery revascularization
8.3.2.1.4. Prognosis. Atherosclerotic RAS progresses with respect to appears comparable to endovascular treatment regarding BP and renal
the degree of stenosis, while total renal artery occlusions occur less function.805,806Thus, open surgery can be an alternative approach in
frequently.793The presence of significant RAS is a strong predictor for cases with a revascularization indication and complex anatomy or failed
mortality794and renovascular disease is an important risk factor for the endovascular repair.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 62 ---
ESC Guidelines 3599
Patient with suspicion of RAS
Duplex ultrasound
PSV ≥200 cm/s (>50% RAS), RAR >3.5 (≥60%)
side-to-side difference of intrarenal resistance index ≥0.5
Inconclusive DUS or RAS exclusion
suspicion of haemodynamically
significant RAS
MRA/CTA
(Class I)
Diagnostic RAS exclusion No RAS
Morphologically significant RAS
Unilateral atherosclerotic Bilateral high-grade atherosclerotic Non-atherosclerotic RAS and
RAS (>70%) RAS (>70%) special populations
OMT OMT OMT
(Class I) (Class I) (Class I)
N Kidney viablea N Kidney viablea Kidney viablea N
Renal artery
Y revascularization Y Y
(Class III)
Presence of high-risk featuresb
Y N
Evaluation of high-risk
features after Y Catheter-based angiography
confirmed OMTb
>70% RAS or
N Y haemodynamically
relevant 50–70% RASc
Renal artery
revascularization
N (Class IIa)
Renal artery revascularization
(Class III)
Figure 19 Diagnostic and treatment algorithm for renal artery stenosis. CTA, computed tomography angiography; MRA, magnetic resonance angi-
ography; OMT, optimal medical treatment; Pd/Pa, distal coronary pressure to aortic pressure ratio; PSV, peak systolic velocity; RAR, renal-aortic peak
flow velocity ratio; RAS, renal artery stenosis.
asee table below
aKidney viability in RAS
Signs of viability Signs of non-viability
Renal size >8 cm <7 cm
Renal cortex Distinct cortex (>0.5 cm) Loss of corticomedullar differentiation
Proteinuria Albumin-creatinine ratio <20 mg/mmol Albumin-creatinine ratio >30 mg/mmol
Renal resistance index <0.8 >0.8
bRapidly progressive, treatment-resistant arterial hypertension; rapidly declining renal function; flash pulmonary oedema; solitary kidney.
cResting mean pressure gradient >10 mmHg; systolic hyperaemic pressure gradient >20 mmHg; renal PdPa ≤ 0.9 (or 0.8).
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 63 ---
3600 E S C G u id e l in e s
8.3.2.3. Follow-up In patients with hypertension and/or signs of renal
Following the diagnosis of significant RAS and the implementation of dysfunction due to RAS caused by fibromuscular
OMT and/or renal artery revascularization, regular follow-up exams dysplasia, concomitant high-risk features, and signs of
IIa B
are crucial. Monitoring should encompass laboratory tests to assess re- kidney viability, revascularization with primary
nal function, analysis of office and out-of-office BP recordings (ambula- balloon angioplasty and bailout stenting should be
tory or home BP monitoring per upcoming ESC/ESH Guidelines for considered.812,813
arterial hypertension), and renal artery DUS. DUS, comprising renal
In patients with an indication for renal artery
PSV, RAR, side-to-side difference of the resistance index, and kidney
revascularization and complex anatomy, or after
size, is the preferred imaging modality during follow-up.787 IIa B
failed endovascular revascularization, open surgical
In conservatively managed RAS patients, follow-up assessment
revascularization should be considered.805,806
should re-evaluate potential indications for renal artery revasculariza-
In patients with atherosclerotic unilateral RAS,
tion (Figure 19).
routine revascularization is not III A
After renal artery stenting, the initial follow-up is recommended at 1
recommended.324,800–804,814
month and subsequently every 12 months or when new signs or symp-
toms arise.807Re-intervention may be considered for in-stent resten- RAS, renal artery stenosis.
osis ≥60% detected by DUS, recurrent signs and symptoms (diastolic aClass of recommendation.
BP >90 mmHg on >3 antihypertensive drugs, or a >20% increase in bLevel of evidence.
serum creatinine).787,808
Recommendation Table 30 — Recommendations for 8.3.3. Visceral artery disease
diagnostic strategies for renal artery disease 8.3.3.1. Acute mesenteric ischaemia
Acute mesenteric ischaemia can be caused by arterial embolism or
Recommendations Classa Levelb thrombosis in situ, non-occlusive mesenteric ischaemia (usually due
to superior mesenteric artery [SMA] vasoconstriction), and venous
DUS is recommended as the first-line imaging
modality in patients with suspicion of RAS.787,789–791 I B thrombosis. In recent decades, embolism decreased from 46% to
35%, while arterial thrombosis increased from 20% to 35%.815–817
In cases of DUS-based suspicion of RAS or
Acute thrombo-embolic occlusion most frequently affects the SMA.
inconclusive DUS, MRA, or CTA are I B
Due to extensive collaterals, it infrequently leads to intestinal infarction.
recommended.789,791
In patients with atherosclerotic RAS, it is
recommended to assess clinical high-risk features and 8.3.3.1.1. Clinical presentation and diagnosis. Clinical examination
I B
kidney viability when evaluating renal artery Early diagnosis of AMI is based on high clinical suspicion. Embolic AMI
revascularization.809,810 typically manifests as sudden onset intense abdominal pain, accompan-
ied by minimal physical findings, bowel emptying (vomiting, diarrhoea),
CTA, computed tomography angiography; DUS, duplex ultrasound; MRA, magnetic and a common embolic source (primarily AF).818–820Emboli may also
resonance angiography; RAS, renal artery stenosis.
lodge in other locations, aiding diagnosis. Acute arterial thrombosis
aClass of recommendation.
bLevel of evidence. tends to occur in areas with pre-existing atherosclerotic disease, result-
ing in a less dramatic clinical presentation. Patients may have previous
symptoms of chronic mesenteric ischaemia (CMI) or other atheroscler-
otic manifestations.821
Recommendation Table 31 — Recommendations for
treatment strategies for renal artery disease (see also Laboratory tests are unreliable for the diagnosis of AMI, although ele-
Evidence Table 10) vated levels of l-lactate, leucocytosis, and D-dimer (DD) may exist.822–825
Imaging
Recommendations Classa Levelb
Computed tomography angiography is the gold standard for diagno-
Medical therapy sis,826,827allowing the detection of thrombi and/or emboli in the SMA
trunk or its branches together with the recognition of intestinal ischae-
In patients with atherosclerotic RAS the use of
IIb C mic signs. A plain abdominal X-ray lacks specificity. A normal result does
low-dose aspirin may be considered.811
not rule out the diagnosis.828
Revascularization
In patients with atherosclerotic unilateral >70% RAS,
8.3.3.1.2. Treatment strategy. Most patients require immediate re-
concomitant high-risk features, and signs of kidney
vascularization to survive. There are no RCTs comparing surgical vs. en-
viability, renal artery revascularization should be IIa B
dovascular intervention in AMI. Two meta-analyses found endovascular
considered after OMT has been
revascularization to be superior to surgical intervention in terms of in-
established.798,809,810
hospital mortality and rates of bowel resection.829,830An open surgical
In patients with atherosclerotic bilateral (>70%) RAS
approach is most appropriate in centres where endovascular interven-
or RAS in a solitary kidney, concomitant high risk IIa B tions are less available and in patients with peritonitis.831 Retrograde
features, and signs of kidney viability, renal artery open mesenteric stenting (ROMS) is an alternative that offers shorter
revascularization should be considered.800–802 operative time; the SMA is punctured in the open abdomen, followed
Continued by stenting.832
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 64 ---
ESC Guidelines 3601
Patient with suspected CMI
Exclude other causes
Confirmed
CTA
(Class I)
Diagnosis
No stenosis Isolated CA or SMA stenosis Multi-vessel stenosis
Functional test
Chronic NOMI MALS Atherosclerosis
Multidisciplinary meeting for
consensus treatment
Endovascular or
surgical revascularization
Secondary prevention
Therapy of underlying condition
of atherosclerosis
Figure 20 Algorithm of chronic mesenteric ischaemia management. CA, coeliac artery; CMI, chronic mesenteric ischaemia; CTA, computed tom-
ography angiography; MALS, median arcuate ligament syndrome; NOMI, non-occlusive mesenteric ischaemia; SMA, superior mesenteric artery.
8.3.3.1.3. Follow-up. Most patients treated for AMI require lifelong least two mesenteric vessels are involved due to extensive collaterals.
anticoagulant/antiplatelet therapy to prevent recurrence. Patients Prevalence of asymptomatic coeliac artery and/or SMA stenosis is 3%
undergoing revascularization should have surveillance with CTA or in patients under 65 years of age and 18% in those aged >65.837
DUS within 6 months,833as recurrent AMI after mesenteric revascular- However, inadequate anastomoses can result in symptomatic ischae-
ization accounts for 6%–8% of late deaths.834 Current Society for mia even with a single-vessel atherosclerotic occlusion.838,839
Vascular Surgery (SVS) Guidelines recommend DUS at 1, 6, and 12
months after the intervention, and then annually thereafter.754
8.3.3.2.1. Clinical presentation and diagnosis. Clinical examination
Like AMI, early diagnosis of CMI relies on clinical suspicion. Classic
8.3.3.2. Chronic mesenteric artery disease symptoms include post-prandial abdominal pain, weight loss, and
Occlusive CMI is mostly caused by atherosclerosis and more frequently gastrointestinal disturbances like diarrhoea or constipation. Patients
affects females (65%–72%).835,836Symptoms typically manifest when at may develop food aversion to avoid pain, but their appetite remains
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 65 ---
3602 E S C G u id e l in e s
unaffected, distinguishing them from individuals with malignancies. An on plaque thickness and the presence of ulceration or mobile components
abdominal examination might reveal a bruit. (Table 14).159,171,854This classification is crucial because severe or complex
Lactate, lactate dehydrogenase, and/or leucocyte count are unhelpful atherosclerotic plaques in the aortic arch or ascending aorta are strongly
in CMI diagnosis.840,841Functional testing (tonometry, visible light spec- linked to cerebrovascular events (odds ratio [OR] 4–9.1 for plaques
troscopy) is applicable in patients with symptomatic mesenteric sten- ≥4 mm).855–860Additionally, the annual incidence of stroke recurrence re-
osis and single-vessel disease.842 mains high (up to 16%) despite antiplatelet or anticoagulant therapy.855,861
Imaging
Duplex ultrasound is valuable due to its low costs, absence of the 9.1.2. Treatment
need for contrast agents, and no radiation. However, skilled investiga-
9.1.2.1. Primary prevention
tors in specialized centres are required for the examination. Despite
Asymptomatic non-severe/non-complex aortic plaques (Table 14) should
suggested diagnostic criteria, consensus is lacking.843,844 Anatomical
not mandate antiplatelet therapy. Nonetheless, in severe/complex plaques,
mapping for treatment planning typically involves CTA or MRA,
statins should be indicated to decrease plaque progression or CV
845,846with DSA reserved only for therapeutic purposes (Figure 20). events,862and SAPT with clopidogrel or low-dose aspirin should be con-
sidered after risk/benefit evaluation.493,666,861,863However, in this scenario,
8.3.3.2.2. Treatment strategy. Optimal medical treatment is the basis anticoagulation861or DAPT (low-dose aspirin and clopidogrel) are not in-
of CMI management. Prophylactic revascularization is not recom- dicated.666,863 Floating aortic thrombi and complex mobile plaques are
mended for asymptomatic CMI. In symptomatic cases, a meta-analysis rare, with limited large-scale trials on their management. Guidance relies
favoured endovascular over open surgery due to fewer complications on case reports, observational studies, and expert opinions, yet there is evi-
and a trend towards lower 30 day mortality.835However, open surgery dence favouring anticoagulation, particularly for symptomatic cases.864
showed superior long-term results, with fewer symptom recurrences
and higher 1 and 5 year primary patency rates in two additional
9.1.2.2. Secondary prevention
meta-analyses.847,848Despite the growing use of endovascular therapy,
Secondary prevention with antiplatelet therapy after an embolic event is
open surgery remains indicated after failed endovascular therapy with-
recommended to prevent recurrences.666,865,866 While the value of
out the option for repeat intervention, and in cases with extensive oc-
DAPT vs. SAPT remains uncertain, recent studies indicate that prolonged
clusions, calcifications, or technical challenges.
DAPT raises bleeding risk without added antithrombotic bene-
fits.667,863,867Treatment duration is unclear and must strike a balance be-
8.3.3.2.3. Follow-up. Following CMI revascularization, lifelong medical
tween early benefit (notably within 7 days post-emboli) and steady
treatment, including lifestyle changes and OMT for atherosclerosis, is
bleeding risk. Statins (LDL target below 1.4 mmol/L [55 mg/dL]) prove ef-
recommended. SVS guidelines propose mesenteric DUS surveillance
fective in preventing strokes regardless of the aetiology.862,865,868
for recurrent stenosis. A potential follow-up schedule involves controls
Additionally, a healthy lifestyle is crucial for improving CV health and redu-
within 1 month post-procedure, biannually for the first 2 years, and an-
cing complications.
nually thereafter.849
Recommendation Table 33 — Recommendations for
Recommendation Table 32 — Recommendations in
primary and secondary prevention in aortic atheroma-
patients with visceral artery stenosis
tous plaques
Recommendations Classa Levelb
Recommendations Classa Levelb
In patients with acute mesenteric ischaemia due to
Primary prevention acute occlusion of the SMA, endovascular I B
revascularization is recommended.829–831 In patients with severe/complex aortic atheromatous
In patients with suspected acute or chronic plaques, statins should be considered to decrease IIa C
mesenteric ischaemia, CTA is I C progression and risk of CV events.862
recommended.826,827,845,846 SAPT with clopidogrel or low-dose aspirin should be
IIa C
In patients with acute or chronic mesenteric considered in severe/complex plaques.493,666,861,863
ischaemia, assessment by a vascular team is I C Anticoagulation861or DAPT863are not
recommended. recommended in aortic plaques since they present III C
Revascularization of asymptomatic atherosclerotic no benefit and increase bleeding risk.666
III C
visceral artery stenosis is not recommended. Secondary prevention after an embolic event related to aortic
atherosclerosis
CTA, computed tomography angiography; SMA, superior mesenteric artery.
aClass of recommendation. In patients with an embolic event and evidence of an
bLevel of evidence. aortic arch atheroma, intensive lipid management to
I A
an LDL-C target <1.4 mmol/L (<55 mg/dL) is
9. Aorta
recommended to prevent recurrences.242,862,865,868
In patients with an embolic event and evidence of an
9.1. Atheromatous disease of the aorta
aortic arch atheroma, SAPT is recommended to I C
9.1.1. General concepts
prevent recurrences.666,865,866
Atheromatous disease of the aorta has an estimated incidence of
40%–51.3%, being complicated in 7.6% of cases.850–853Earlier stages of ath- CV, cardiovascular; DAPT, dual antiplatelet therapy; LDL-C, low-density lipoprotein
cholesterol; SAPT, single antiplatelet therapy.
erosclerosis, presenting as plaque inflammation, can be present in 48% of aClass of recommendation.
asymptomatic individuals.850 Atherosclerotic plaque classification is based bLevel of evidence.
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 66 ---
ESC Guidelines 3603
Table 14 Grading of atherosclerotic aortic plaques in femoro-popliteal segments, is less clear compared with AAA.
However, cerebral aneurysms, notably prevalent in women and those
Grade Severity (atheroma Description with HTAD, warrant thorough screening, particularly in symptomatic
thickness) cases.876–878
1 Normal Intimal thickness <2 mm
Recommendation Table 34 — Recommendations for
2 Mild Intimal thickening of 2 to <3 mm
initial evaluation of thoracic aortic aneurysm and
3 Moderate Atheroma ≥3 to <4 mm (no
abdominal aortic aneurysm
mobile/ulcerated components)
4 Severe Atheroma ≥4 mm (no mobile/ Recommendations Classa Levelb
ulcerated components)
When an aortic aneurysm is identified at any
5 Complex Grade 2, 3, or 4 atheroma plus
location, assessment of the entire aorta is
mobile/ulcerated components I C
recommended at baseline and during
follow-up.874,875
When a TAA is identified, assessment of the aortic
9.2. Aortic aneurysms I C
valve (especially for BAV) is recommended.879,880
9.2.1. General concepts When an AAA is identified, evaluation of the
9.2.1.1. Definitions presence of aneurysm in the femoro-popliteal IIa C
Aortic dilatation, the second most frequent aortic disease after athero- arterial segment should be considered.876–878,881
sclerosis, is defined as an aortic diameter >2 standard deviations of Patients with aortic aneurysm are at increased risk of
the predicted mean diameter depending on age, sex, and body size CVD, thus general CV prevention should be IIa C
(z-score >2). However, in clinical practice, aortic root dilatation considered.26,882,883
can be suspected in male adults when aortic diameter is >40 mm and
in females at >36 mm,138,149,869 or with an indexed diameter/BSA AAA, abdominal aortic aneurysm; BAV, bicuspid aortic valve; CV, cardiovascular; CVD,
(aortic size index [ASI]) >22 mm/m2. In extreme BSA and age values, cardiovascular disease; TAA, thoracic aortic aneurysm.
aClass of recommendation.
use of z-scores is recommended (see Section 5.4for their calculation). bLevel of evidence.
Arterial aneurysm is defined as a diameter >1.5 times (>50%) lar-
ger than the predicted one. This definition, as well as the use of
z-scores, introduces the need for normal values and correction for 9.2.2. Thoracic aortic aneurysms
age, sex, and body size. However, correcting for BSA can lead to 9.2.2.1. Aetiology, risk factors, and natural history
underestimation in overweight patients,870 therefore a correction Thoracic aortic aneurysms occur in 5–10/100 000 person-years,884
for height (aortic height index [AHI]) is becoming more popular.153
with an approximate predominance of root and/or ascending aorta
In terms of clinical risk, both ASI and AHI have been shown to improve of ∼60%, arch of ∼10%, and descending aorta of ∼30%.885,886
risk stratification for AAE.153,871Since in many cases of aortic dilata-
Hypertension is the main risk factor (80%); however, genetics may be
tion the surgical indication is established before achieving this aneur- involved in 20% of cases.887The decision to refer patients for genetic
ysmal diameter, we strongly recommend the use of significant aortic
evaluation should consider age, family history, and presence of syn-
dilation specifying the diameter or the indexed diameter value rather dromic features,25,888as reported in more detail in Section 10.1.
than the term ‘aneurysm’.
Thoracic aortic aneurysms (TAAs) are more prevalent in men than in
women (ratio 4:1);872however, the growth rate is greater in women 9.2.2.2. Ascending thoracic aorta and arch aneurysms
(0.96 ± 1.00 mm per year) than in men (0.45 ± 0.58 mm per year), (1) Aortic root aneurysms (including sinuses of Valsalva: annulo-
and thus the risk of AAE.873 aortic ectasia). They can be idiopathic, associated with HTAD (syn-
Aneurysms can be fusiform or saccular based on morphology. dromic/non-syndromic), or found in 20%–30% of BAV patients
Saccular aneurysms relate to infection, penetrating atherosclerotic (see Section 10).879,880 Patients are usually younger (30–50 years
ulcer (PAU), trauma, or inflammatory diseases, while fusiform aneur- of age), with aortic regurgitation, and with a 1:1 sex ratio.
ysms connect with degenerative and connective tissue conditions. (2) Supra-coronary aortic aneurysms (above sinuses of
Although evidence about their natural course is limited, saccular aneur- Valsalva). Caused by atherosclerosis in relation to hypertension af-
ysms are considered more malignant in terms of AAE. Based on loca- fecting older patients (59–69 years) and males (ratio 3:1),880or re-
tion, aortic aneurysms are classified into TAA and abdominal aortic lated to medial degeneration (isolated or associated with aortic
aneurysm (AAA) (Figure 21). They differ in treating specialists, causes, valve disease, including BAV) (see Section 10). Primary bacterial in-
age at onset, risk factors, and complications. However, this binary clas- fection or syphilis are uncommon. Arteritis is rare, but Takayasu’s
sification is artificial due to the prevalence of thoracoabdominal aortic and giant cell arteritis can lead to aneurysm formation.
aneurysms (TAAA) and tandem lesions (20%–30% of AAA patients (3) Aortic arch aneurysms. Often accompanying adjacent ascend-
also have TAA),874,875emphasizing the importance of comprehensive ing or descending aorta aneurysms, aortic arch aneurysms present
aortic and vascular assessments at diagnosis. When detecting an aortic surgical challenges due to potential neurological and CV risks. They
aneurysm at any site, it is advisable to conduct a thorough evaluation of are typically linked to atherosclerosis, with cystic medial degener-
the entire aorta initially and during subsequent follow-ups. Specifically, ation primarily affecting ascending aorta-related arch aneurysms.
when diagnosing a TAA, it is crucial to assess the aortic valve, particu- Deceleration injuries or coarctation may extend into the aortic
larly in cases of BAV. Data on peripheral aneurysms in TAA, particularly arch.889
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 67 ---
3604 E S C G u id e l in e s
Thoracic aortic aneurysm (TAA)
Aetiology
Root and ascending aorta
HTAD
BAV
Sporadic TAA
Atherosclerosis
Descending aorta
Atherosclerosis
Aortitis (infectious or not)
Trauma
Coarctation
Screening TTE
Diagnostic TTE or TOE plus CCT or CMR
Abdominal aortic aneurysm (AAA)
Aetiology
Media degeneration
Inflammation
Genetic disorders
Infection
Atherosclerosis
Screening DUS
Diagnostic DUS or CEUS, CCT or CMR
Figure 21 Thoracic and abdominal aortic aneurysms: aetiology, screening and diagnostic methods. AAA, abdominal aortic aneurysm; BAV, bicuspid
aortic valve; CCT, cardiovascular computed tomography; CEUS, contrast-enhanced Doppler ultrasound; CMR, cardiovascular magnetic resonance;
DUS, Doppler ultrasound; HTAD, heritable thoracic aortic disease; TAA, thoracic aortic aneurysm; TOE, transoesophageal echocardiography; TTE,
transthoracic echocardiography.
Thoracic aortic aneurysm patients are usually asymptomatic, diagnosed 9.2.2.3. Descending thoracic aorta and thoracoabdominal aorta
incidentally during unrelated imaging or screenings. Symptoms such as aneurysms
chest pain, aortic regurgitation, and compression-related issues may oc- They can involve different parts of the DTA and may extend to the AA:
cur.890 Patients with aortic root involvement (as seen in HTAD) are TAAA. TAAAs are divided into five groups900according to the modi-
more prone to suffer from AAE.891,892 fied TAAA classification scheme (Figure 22), which is crucial for risk stra-
Thoracic aortic aneurysm growth rate is variable, associated with tification. By classifying aneurysm extent, surgeons can anticipate
aetiology, location, and baseline aortic diameter.893–895 Degenerative procedure complexity, select suitable techniques, and reduce risks dur-
TAAs grow faster in women than men and are associated with a three- ing surgical planning.
fold higher risk of AAE.24,873,896When the aorta reaches 57.5 mm in Most DTA aneurysms and TAAA are degenerative with calcification,
size, reported yearly rates of rupture, dissection, and death are 3.6%, although other causes include trauma, infection, inflammation, or gen-
3.7%, and 10.8%, respectively.897–899 etic factors901,902 (Figure 21). Patients with HTAD rarely develop
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 68 ---
ESC Guidelines 3605
Classification of thoracoabdominal aortic aneurysms
Innominate
artery Left carotid artery
Left subclavian
artery
Coeliac trunk
SMA
Left renal
artery
IMA
Type I Type II Type III Type IV Type V
Classification of abdominal aortic aneurysms
Suprarenal AAA Pararenal AAA Juxtarenal AAA Infrarenal AAA
Figure 22 Classification of thoracoabdominal900and abdominal aortic aneurysms. AAA, abdominal aortic aneurysm; IMA, inferior mesenteric artery;
SMA, superior mesenteric artery.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 69 ---
3606 E S C G u id e l in e s
High-risk features for TAAA rupture beyond aortic diameter
Aortic root and ascending aorta Descending thoracic aorta
Relation with Upper normal limits of Saccular aneurysm Uncontrolled resistant
patient’s height aortic diameter by age associated to PAU hypertension
COPD
Thoracoabdominal aorta
Uncontrolled resistant Aortic length
hypertension measurement
Aortic growth rate:
Ascending aorta and arch ≥ 3mm/year
DTAA ≥ 10mm/year (or ≥ 5mm/6 months)
AAA ≥ 10mm/year (or ≥ 5mm/6 months)
Yearly rate of Root vs
diameter growth ascending phenotype
Radiological signs of AAA rupture
Genetic predisposition
Retroperitoneal haematoma Contrast extravasation
High crescent sign Paraortic fat stranding
Tangential calcification Calcification discontinuity Symptoms
Thrombus fissuration Draped aorta sign
Figure 23 Risk factors for thoracic and abdominal aneurysm rupture. AAA, abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease;
DTAA, descending thoracic aorta aneurysm; PAU, penetrating atherosclerotic ulcer; TAAA, thoracoabdominal aortic aneurysm.905–908
thoracoabdominal aortic aneurysms without dissection. Mean age at For untreated DTA aneurysm patients, 5 year survival is about 54%,
diagnosis is 59–69, with a male predominance of 2–4:1. Aneurysm with aortic rupture as the leading cause of death.904Rupture risk factors
growth rate is 1.9–3.4 mm per year,902,903but tends to increase notably include HTAD, a diameter over 50 mm, hypertension, smoking, chronic
with diameters over 50 mm or post-proximal aorta surgery in patients obstructive pulmonary disease (COPD), symptoms, chronic aortic dis-
with MFS. In this population, debate continues as to whether this re- section, and age. A significant rise in AAE risk occurs at a 60 mm diam-
flects a more vulnerable aorta associated to the genetic disease or eter. Although dissection can occur in smaller aortas, the individual risk
haemodynamic changes post-surgery. is low.899High-risk features for rupture are represented in Figure 23.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 70 ---
ESC Guidelines 3607
9.2.2.4. Surveillance Follow-up imaging with TTE, CCT, or CMR (based
Patients with TAA who do not meet surgical criteria require chronic on aneurysm location) should be considered annually
follow-up that includes clinical evaluation and imaging techniques. if there is no expansion/extension or customized IIa C
The best imaging modality depends on aneurysm location: TTE, according to baseline aortic diameter and the
CCT, or CMR when affecting the aortic root and the ascending aorta; underlying condition.70,159,172
CMR and CCT when involving the distal ascending aorta, the aortic
TTE is not recommended for the surveillance of
arch, or the DTA.159,171 Follow-up should be conducted with the
aneurysms in the distal ascending aorta, aortic arch, III C
same imaging technique and in the same centre.909If a TAA is only or DTA.159,171
moderate in size and remains relatively stable over time, CMR rather
than CCT is reasonable to minimize radiation exposure.172,910 CCT, Cardiovascular computed tomography; CMR, cardiovascular magnetic resonance;
DTA, descending thoracic aorta; TAAA, thoracoabdominal aortic aneurysm; TTE,
Follow-up for aortic aneurysms associated with HTAD is described
transthoracic echocardiography.
in Section 10.1.3.2.
See proposed algorithm in Figure 24.
Figure 24proposes a follow-up algorithm for patients with TAA. In aClass of recommendation.
cases of aortic root or proximal ascending aorta dilatation, after ini- bLevel of evidence.
tial diagnosis by TTE the basal diameter and extension must be con-
firmed by CMR or CCT. If there is agreement between techniques,
TTE can be used for follow-up; however, if there is a difference of
9.2.3. Abdominal aortic aneurysms
≥3 mm, surveillance must be performed by CMR or CCT. After
9.2.3.1. General concepts
the initial diagnosis, imaging is required at 6–12 months, depending
An AAA is defined as a focal dilation at least 1.5 times its normal diam-
on aetiology and baseline diameter (Figure 24); see Sections 5.4.2
eter, generally ≥30 mm. Most AAAs are fusiform, and many are lined
and 9.2.1 about indexed values of aortic dimensions, to ensure sta-
bility.159,911Subsequently, imaging can be performed annually if there with laminated thrombi.916 Their prevalence increases with age, with
a 4:1 male/female ratio.872They are commonly classified based on their
is no expansion/extension or customized according to the underlying
relation to renal arteries (Figure 22) because of the complexity of sur-
condition. If the aorta shows rapid expansion (≥3 mm per year) or
gical treatment. AAA extends to the common iliac arteries in 25% of
approaches the surgery/endovascular repair threshold, a closer evalu-
cases and in up to 20% of patients is associated with peripheral femoral
ation is recommended every 6 months. In contrast, stability in aortic
and/or popliteal artery aneurysm.876–878
diameters over years could lengthen these intervals (especially in
non-genetic aneurysms and those <45 mm). In cases of dilatation
of aortic arch or DTA, diameters obtained by TTE are deemed 9.2.3.2. Aetiology, risk factors, and natural history
less precise and need confirmation by CMR or CCT. In those types Smoking, age, male sex, and familial history of aneurysmal disease are ma-
of aneurysms, follow-up frequency will depend on the baseline diam- jor risk factors,917–921whereas diabetes is associated with a decreased
eter and aetiology and will follow the same criteria established in the risk922,923 and slower growth rate924 (Figure 21, see also Section 5).
algorithm in Figure 24 for the 40–49 mm range. However, for the Other aetiologies include inflammation (5%–10% of all AAA),925genetic
50–55 mm range, the aorta should be re-imaged every 6 months un- disorders, and infection. The mean growth rate is around 3 mm per year
til the threshold for intervention is reached (see Sections 9.2.5.3 and (1–6 mm)906,926and depends on sac diameter, presence of genetic disor-
9.2.5.4). ders, continuous smoking, metabolism (presence of inflammation), and
aortic wall calcification.927–929 Risk of rupture rises exponentially de-
pending on diameter, being higher in women.930,931
AAAs are asymptomatic in two-thirds of cases and if they become
symptomatic, rupture is the main manifestation. They often represent
Recommendation Table 35 — Recommendation
incidental imaging findings, as the sensitivity of clinical examination—
for the surveillance of patients with thoracic aortic an-
eurysms (non-heritable thoracic aortic disease) especially palpation of an abdominal mass—is generally poor.
Symptoms may include acute abdominal or back pain, and in some
Recommendations Classa Levelb cases, hypovolaemic shock. However, contained rupture may present
with atypical low flank or abdominal pain (see Figure 23for high-risk fac-
In thoracic aortic dilatation, TTE is recommended at tors and radiological signs or AAA rupture).932–935 Independently of
diagnosis to assess aortic valve anatomy and function,
risk of rupture, patients with AAA have impaired survival: the 5 year
aortic root, and ascending aorta diameters. I C mortality rate is higher (×4 in women, ×2 in men) despite AAA repair,
Additionally, a global aortic evaluation using all likely due to the presence of cardiovascular disease in other areas.936
echocardiographic views is recommended.159
CMR or CCT is recommended for surveillance of
9.2.3.3. Surveillance
patients with aneurysm at the distal ascending aorta, I C
Those with an aortic diameter <25 mm present low risk of developing
aortic arch, DTA, or TAAA.70,159,172,912–915
large AAA in 10 years, whereas a diameter of 25–29 mm deserves re-
In thoracic aortic dilatation, CCT or CMR is assessment after 4 years.937,938DUS is the standard imaging technique
recommended to confirm TTE measurements, rule I C for surveillance; however, CCT provides superior visualization of the
out aortic asymmetry, and determine baseline AA and its branches, especially for pre-operative planning. CMR is rea-
diameters for follow-up.137,143,144 sonable in selected patients (young and female) when a long follow-up is
Continued considered, to avoid radiation.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 71 ---
3608 E S C G u id e l in e s
Root or ascending dilatation with TAV or BAV (and normal valve function)
at first or susbsequent echocardiography
Aortic diameter
40–44 mmª 45–49 mm 50–52 mm 53–54 mm ≥55 mm
Baseline CCT/CMR Confirm by Confirm by Confirm by
and reimage by CCT or CMR CCT or CMR CCT or CMR
TTE in one year
Phenotype Root Phenotype
Growth rate
Ascending Ascending
≥3 mm/y
Confirm by High-risk
<3 mm/y CCT or CMR featuresb
N
Y
Reimage by CCT/
CMR 6 months TAV TAV/BAV
later to define
projected
growth rate BAV
Growth rate
≥3 mm/y
<3 mm/y
Surgery if low Surgery if low
operative risk operative risk
Surgery Surgery
(Class IIb) (Class IIa)
(Class I) (Class I)
Reimage by TTE Reimage by TTE yearly Otherwise Otherwise
every (or every 6 months if
2 or 3 years growth rate ≥3 mm/y)
Reimage every 6 months
Surveillance of AAA
AAA size 25 30 35 40 45 50 55
(mm)
Every Every Every 12 Every 6 Consider intervention
Women
4 years 3 years months months (Class I)
Every Every Every 6 Consider intervention
Men Every 12 months
4 years 3 years months (Class I)
Consider follow-up Follow-up
Figure 24 Surveillance of patients with non-heritable thoracic aortic disease and abdominal aortic aneurysms. AAA, abdominal aortic aneurysm,
BAV, bicuspid aortic valve; CCT, cardiovascular computed tomography; HTAD, heritable thoracic aortic disease; CMR, cardiovascular magnetic res-
onance; TAV, tricuspid aortic valve; TTE, transthoracic echocardiography. a36–44 mm in women. bFor TAV and BAV: age <50 years; height
<1.69 m; ascending length >11 cm; uncontrolled hypertension; and, for BAV: coarctation; family history of acute aortic events.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 72 ---
ESC Guidelines 3609
A meta-analysis advises follow-up intervals for AAAs based on size: 3 Furthermore, reduced AAA growth by the antidiabetic drug metformin
years for 30–39 mm, 1 year for 40–44 mm, and 6 months for 45– has been suggested in several meta-analyses352,948,949and there are sev-
54 mm in men, with <1% rupture risk.938Women have similar growth eral ongoing RCTs to explore this. For BP, follow general hypertension
rates but a four-fold higher rupture risk.938A proposed follow-up algo- guidelines. Aim for BP below 140/90 mmHg, with a target of 120/80
rithm is displayed in Figure 24. Consider shorter intervals for rapid mmHg, if tolerated.300,302,305 Data on the specific positive effects of
growth (≥10 mm per year or ≥5 mm per 6 months), in which case re- beta-blockers and ARBs in TAA and AAA are limited (mostly derived
pair may be considered. from MFS populations). However, it is reasonable to use BBs and/or
ARBs as first-line antihypertensive drugs in TAA and AAA.
Consider moderate/high-intensity statins in TAA patients but skip
Recommendation Table 36 — Recommendations for
for those with low CV risk and non-atherosclerotic (HTAD). In
surveillance of patients with abdominal aortic aneurysm
AAA, consider statins to reduce aneurysm risks, including growth, rup-
ture, and peri-operative mortality.330,347,348 Low-dose aspirin is de-
Recommendations Classa Levelb
bated but may be reasonable given elevated CV risk factors in TAA
DUS surveillance is recommended every 6 months in and AAA patients.666,950Additionally, apply all CVD secondary preven-
men with AAA of 50–55 mm and in women with I B tion measures to these patients (see Section 7).
AAA of 45–50 mm.938 Some evidence suggests that fluoroquinolones could be associated
CCT or CMR is recommended if DUS does not with an increased risk for aneurysm progression and dissection,951–956
allow adequate measurement of AAA I B but conflicting analyses do not support this association. The cautious
diameter.148,939–942 use of fluoroquinolones should not be discouraged when there is a clin-
ical indication, even considering concerns regarding aortic aneurysm
DUS is recommended for AAA surveillance.943 I C
and dissection (AA/AD). Note that AA/AD risk (both thoracic and ab-
DUS surveillance every 3 years should be considered
IIa B dominal) may increase due to infection itself, regardless of the antibiotic
in patients with AAA of 30–<40 mm.938
chosen. Infectious disease specialists discourage routine fluoroquino-
DUS surveillance should be considered annually in lone use as a first-line antibiotic if equally effective alternatives exist.
women with AAA of 40–<45 mm and in men with IIa B Hence, do not withhold this therapy in aortic disease cases when clin-
AAA of 40–<50 mm.938 ically necessary. All medical and lifestyle recommendations are summar-
DUS surveillance should be considered every 4 years ized in Figure 7.
in patients with aortic diameter ≥25 mm and IIa C
<30 mm and life expectancy >2 years.937,938
Recommendation Table 37 — Recommendations for
AAA, abdominal aortic aneurysm; CCT, Cardiovascular computed tomography; CMR, medical treatment in patients with thoracic aorta or
cardiovascular magnetic resonance; DUS, duplex ultrasound. abdominal aortic aneurysms
aClass of recommendation.
bLevel of evidence. Recommendations Classa Levelb
In patients with aortic aneurysm (TAA and/or AAA),
9.2.4. Optimal medical treatment of aortic aneurysms optimal implementation of CV risk management and
In patients with aortic aneurysms, the role of antithrombotic therapy is medical treatment (see detailed recommendations in I C
uncertain. In complicated aortic atherosclerotic plaques, concomitant dedicated Tables of Recommendationsc) are
CAD is common (OR 2.99) and SAPT should be considered (see recommended to reduce MACE.936
Section 9.1). In patients with AAA, results of observational studies Fluoroquinolones, while generally discouraged for
are conflicting in relation to aneurysm growth. Low-dose aspirin is patients with aortic aneurysms, may be considered if
IIb B
not associated with a higher risk of AAA rupture but could worsen there is a compelling clinical indication and no other
prognosis in cases of rupture.944 In an RCT of patients with AAA reasonable alternative.951–960
(35–44 mm), ticagrelor did not reduce growth rate.945
AAA, abdominal aortic aneurysm; CV, cardiovascular; MACE, major adverse cardiovascular
Optimal medical treatment for aortic aneurysms aims to lower CV
events; TAA, thoracic aortic aneurysm.
morbidity, slow growth rate, delay surgery, reduce peri-operative aClass of recommendation.
risk, and prevent AAE. Aneurysm patients face elevated CV risk due bLevel of evidence.
to common CVRFs, and the 10 year CV event mortality risk (heart at- csee Tables of Recommendations 7 to 10.
tacks or strokes) is 15 times higher than AAE risk, even after re-
pair.882,883 According to the SMART risk score algorithm, optimal
implementation of risk management guidelines would reduce the 10 9.2.5. Surgical management of aortic aneurysms
year risk of MACE from 43% to 14% in patients with AAA.936Thus, life- 9.2.5.1. Surgical treatment of aortic root and ascending aorta
style modification, exercise, smoking cessation, and treatment of risk In isolated dilatation of the ascending tubular (supra-coronary) aorta, a
factors are crucial (see Section 7). supra-commissural tubular graft is inserted with the distal anastomosis
Risk factors and possible drug treatment to reduce AAA growth and/ just before the aortic arch. For aneurysms extending proximally below
or the risk of rupture have been thoroughly discussed in a recent review the sinotubular junction (STJ) with involvement of aortic sinuses, the
paper.946Their meta-analysis suggested a possible effect of ACEIs (but surgical approach depends on the aortic annulus and valve condition.
not ARBs) on the risk of rupture, whereas another meta-analysis947did If the aortic valve cusps are pliable, experienced centres may recom-
not indicate an effect of ACEIs on AAA growth. A reduction of AAA mend aortic valve-sparing techniques,961–965such as David’s procedure
growth by statins is indicated in a recent meta-analysis.352 (reimplantation) or the Yacoub technique (remodelling).890,966–968
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 73 ---
3610 E S C G u id e l in e s
STJ dilatation STJ and aortic root Annulus dilatation Aortic valve
TTE and TOE
(Ia) dilatation (Ib) (Ic) disease
Aortic valve
assessment
Pre-surgery
CCT or CMR
Annulus/root/
Supracommisural Aortic valve Bentall
ascending aorta Annuloplasty
tubular graft sparing procedure
assessment
TTE
Before CCT or CMR
Immediate cardiac complications
discharge Rule out aortic complications
(i.e. pericardial effusion...)
TTE
Aortic valve function and gradients
1 month
Aortic root and proximal
ascending aorta assessment
TTE CCT or CMR
Aortic valve function and gradients Evaluation of aortic disease
Aortic root and proximal progression and
ascending aorta assessment rule out complications
From
1 year
Mechanical prosthesis Aorta totally Aorta not fully
Bioprosthesis: or native valve: repaired: repaired:
TTE/year TTE based on gradients, Follow-up at 2 years link with aneurysm
symptoms or residual AR and then every 5 years follow-up algorithm
Figure 25 Peri-operative algorithm for the management of patients with surgically treated aortic root and ascending aortic aneurysm. AR, aortic
regurgitation; CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; STJ, sinotubular junction; TOE, transoesophageal
echocardiography; TTE, transthoracic echocardiography.
Otherwise, composite replacement of the aortic root and valve with dose aspirin (75–100 mg per day) should be considered for the first
the Bentall procedure is indicated. 3 months after conservative aortic valve surgery if there are no indica-
Pre-operative evaluation890and initial follow-up of patients is defined tions for OAC. Lifelong OAC with a VKA is recommended for all pa-
in Figure 25. Patients with a bioprosthetic valve should be monitored by tients with a Bentall mechanical prosthesis.970,971 However, in
TTE annually. However, in patients with mechanical prosthesis or na- patients with no baseline indications for OAC, low-dose aspirin (75–
tive aortic valve, clinical evaluation and TTE should be performed as 100 mg/day) or OAC using a VKA should be considered for the first
soon as possible if new heart symptoms develop.969SAPT with low- 3 months after Bentall surgery with a bioprosthesis.972,973
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 74 ---
ESC Guidelines 3611
Although many risk factors associated with AAE have been described SAPT with low-dose aspirin (75–100 mg per day)
(such as elongation, angulation, and unfavourable biomechanics), aortic should be considered for the first 3 months after
IIa C
diameter is still the main determinant of aortic complications and
valve-sparing aortic surgery when there are no other
death.974–976 AAE rates decreased with prophylactic aortic surgery
baseline indications for OAC.
over a decade,977and additionally, surgical risk for ascending aortic/aor-
In patients undergoing non-aortic-valve cardiac
tic root surgery dropped significantly.978–980Now, experienced cardiac
surgery who have concomitant dilatation of the
surgery centres report <1% mortality with elective surgery.980,981
ascending aorta or aortic root with a maximum IIa C
Most acute type A aortic dissections (acute TAAD) occur at diameters
below 55 mm. However, the risk exceeds 1% between 50 and 54 mm,982 diameter ≥50 mm, concomitant aortic surgery
with a critical point at 52–53 mm.153,981,983Pre-dissection aortic diam- should be considered.70,990,991
eter at the tubular level is 25%–30% smaller than post-dissection. Ascending aortic or root replacement may be
Over 60% of non-MFS, non-BAV acute TAAD patients have a non- considered at a maximum diameter of ≥50 mm in
dilated ascending aorta before dissection.984,985 Additionally, the ‘root patients with proximal aorta dilatation who can be
phenotype’ has been reported to be more malignant than those with as- offered surgery with low predicted riskc and present
cending phenotype, with higher velocity of progression and AAE with any of the following:153–155,891,892
risk.154,891,892,986 • Growth of the aortic diameter ≥3 mm per year
Novel parameters, like ascending aortic length (AAL) and the • Resistant hypertensiond IIb B
ascending-arch angle, correlate with acute TAAD risk.155,976 AAL • Short stature <1.69 m
≥13 cm links to nearly five-fold higher yearly AAE rates compared • Root phenotype
with AAL <9 cm, with a threshold of >11 cm as a risk indicator.155 • Aortic lengthe >11 cm
Indexing aortic diameters to anthropometric parameters has been sug- • Age <50 years
gested and a proportional increase in the risk of AAE has been retro- • Desire for pregnancy
spectively demonstrated for increasing diameter indexed to BSA,904
• Aortic coarctation
diameter indexed to patient height,153or cross-sectional area indexed
to patient height.154However, these diameter-based indexing methods MHV, mechanical heart valve; OAC, oral anticoagulation; SAPT, single antiplatelet therapy;
VKA, vitamin K antagonist.
share the same limitations in risk prediction as the absolute diameter in
For heritable thoracic aortic disease and bicuspid aortic valve-related thoracic aortic
the general population,984,985whereas they can be advantageous in pa- aneurysm refer to Section 10.
tients with small body size.153,154These additional risk factors (beyond aClass of recommendation.
bLevel of evidence.
the diameter) are summarized in Figure 23.
cIndividual patient’s risk <3%.
dHypertension that cannot be adequately controlled despite use of three or more agents
recommended by a physician with expertise in the management of hypertension.
Recommendation Table 38 — Recommendations for eCurvilinear distance at aortic centreline between the ventriculo-aortic junction and the
surgery in aortic root and ascending aorta dilatation origin of the innominate artery.
associated with tricuspid aortic valve (see also
Evidence Table 11) 9.2.5.2. Surgical treatment of aortic arch aneurysms
Surgery for arch aneurysms is challenging, primarily due to risks like
Recommendations Classa Levelb
hypothermic circulatory arrest and the need for brain protection, re-
Surgery is recommended in patients with dilatation sulting in higher mortality and stroke rates. Isolated aortic arch surgery
of the aortic root or ascending aorta with a tricuspid is appropriate for asymptomatic degenerative aortic arch aneurysms
I B ≥55 mm in diameter or symptoms or signs of local compression.
aortic valve and a maximum diameter of
≥55 mm.172,894,899,904 Hemi-arch or total arch replacement are frequently required in patients
who have an indication for surgery on an adjacent aneurysm of the as-
Valve-sparing aortic root replacement is
cending aorta. In specific cases, supra-aortic vessel transposition via off-
recommended in patients with aortic root dilatation
I B pump debranching followed by TEVAR of the arch can be an alternative
if performed in experienced centres and durable
to traditional surgery, particularly when avoiding hypothermic circula-
results are expected.961–965
tory arrest is a concern.992–996When the disease involves the proximal
VKAs are recommended lifelong for all patients with
I B descending aorta or future need for treatment of the descending aorta
a Bentall procedure with an MHV prosthesis.970,971 is anticipated, the frozen elephant trunk (FET) technique is a good op-
In patients with dilatation of the tubular ascending tion.997Assessment of patency and morphology of the circle of Willis is
aorta who can be offered surgery with low predicted recommended when treatment involves the aortic arch.998,999
risk,c ascending aortic replacement should be IIa B
considered at a maximum diameter Recommendation Table 39 — Recommendations for
>52 mm.153,981,983 surgery in aortic arch aneurysms
In patients undergoing surgery for tricuspid aortic
Recommendations Classa Levelb
valve disease who have concomitant dilatation of the
aortic root or ascending tubular aorta, and low In patients with low or intermediate operative risk with
IIa B
predicted surgical risk, ascending aorta or root an aortic arch aneurysm and recurrent episodes of
I C
replacement should be considered at a maximum chest pain not attributable to non-aortic causes, open
diameter ≥45 mm, otherwise ≥50 mm.70,987–989 surgical replacement of the arch is recommended.70,172
Continued Continued
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 75 ---
3612 E S C G u id e l in e s
In patients with an isolated aortic arch aneurysm who minimal improvement in recent years, with mortality rates around
are asymptomatic and have low operative risk, open 10% and spinal cord ischaemia rates at 11%–15%.1016,1018
IIa B
surgical replacement should be considered at an arch
diameter of ≥55 mm.70,172,899 9.2.5.3.3. Endovascular repair. Comparative studies favour TEVAR
In patients undergoing open surgical repair of an over open repair, showing lower mortality (6%) and morbid-
ascending aortic aneurysm, concomitant hemi-arch ity.1006,1019,1020 However, TEVAR’s survival advantage is balanced by
replacement should be considered if the dilatation IIa C an increased risk of follow-up re-intervention. It reduces spinal cord in-
extends into the proximal aortic arch jury risk (3%).1021–1024 Left subclavian artery (LSA) coverage during
(>50 mm).70,172,1000 TEVAR for proximal sealing is required in up to 50% of cases.1025
This is associated with an increased risk of cerebrovascular events,
In patients undergoing open surgical repair of an
spinal cord ischaemia (SCI), and upper-limb ischaemia,1026,1027justifying
aortic arch aneurysm, an elephant trunk or frozen
previous surgical or concomitant endovascular (with branched or fene-
elephant trunk procedure should be considered if the IIa C
strated grafts) revascularization of the LSA in an elective set-
aneurysmal disease extends into the proximal
ting.1026,1028,1029 In cases of inadequate distal zone sealing, safe
descending thoracic aorta.70,172,997,1001
coverage of the coeliac artery has been proposed when sufficient col-
In patients undergoing open surgical repair of an lateral circulation exists,1030,1031but results are controversial.1032
ascending aortic aneurysm, concomitant hemi-arch
or arch replacement may be considered in IIb C
9.2.5.4. Surgical treatment of thoracoabdominal aorta aneurysms
experienced centres if the dilatation extends into the
9.2.5.4.1. General considerations. Since AAEs increase when TAAA
aortic arch (>45 mm).70,172,1001
diameter exceeds 60 mm,902,1002,1033and there are more technical sur-
In patients with an aortic arch aneurysm who meet
gical challenges in TAAA repair (compared with DTA aneurysm or
criteria for intervention but have high surgical risk, a
IIb C AAA), TAAA repair, in low-moderate surgical risk patients, is proposed
hybrid or endovascular approach may be if the aortic diameter is ≥60 mm. However, surgical repair should be
considered.70,172
considered at diameters ≥55 mm if patients present with high-risk fea-
tures (Figure 24) or are at very low risk and under the care of experi-
For heritable thoracic aortic disease refer to Section 10.
aClass of recommendation. enced surgeons in a multidisciplinary aorta team.1004,1033,1034 HTAD,
bLevel of evidence. distal location, chronic dissection, and BAV903are associated with rapid
growth rate and will require closer follow-up.
9.2.5.3. Surgical treatment of the thoracic descending aorta
9.2.5.3.1. General considerations. At 60 mm diameter, a DTA aneur- 9.2.5.4.2. Open repair. Open TAAA repair is a complex aortic pro-
ysm has a 10% annual rupture risk, justifying intervention at cedure. Post-operative mortality risk increases with left ventricular
≥55 mm.902,1002 Intervention at a diameter <55 mm may not bring (LV) dysfunction, renal insufficiency, and advanced age.1035–1037 Since
any further survival benefit except for women,904,1003 patients with organs and tissues distal to the aortic clamp will suffer from prolonged
connective tissue disorders,904or rapid growth (≥10 mm per year or ischaemia, extracorporeal circulation is mandatory to reduce complica-
≥5 mm every 6 months),1004 (for high-risk factors see Figure 23). tions,1011,1038 especially SCI (2.5%–15%).1011,1039–1044 The mortality
This threshold may be increased in high surgical risk patients.1005It is rate after open TAAA repair varies between 6% and 8% in high-volume
advisable to centralize complex procedures in centres with expertise centres1006,1011,1039vs. 30% in less experienced centres,1045,1046raising
in aortic diseases and a multidisciplinary team for effective patient the recommendation to perform these complex procedures only in
management. specialized institutions.
9.2.5.3.2. Open repair. Thoracic endovascular aortic aneurysm 9.2.5.4.3. Endovascular repair. Endovascular repair is a promising al-
repair is recommended as first-choice intervention for DTA aneur- ternative for treating challenging aortic anatomy like juxta-renal AAA
ysms,1006–1010 thus open repair is limited to patients with unsuitable (Figure 22).1047,1048 The use of fenestrated and branched endografts
anatomy for TEVAR1011or connective tissue disorders.1012The early has shown excellent results, allowing perfusion of visceral ves-
mortality benefit of TEVAR seems to decrease after 1 year, and there- sels.1049–1053While direct comparison studies with open TAAA repair
after long-term survival (10 years) seems better with open repair.1013 are lacking,1054the increasing adoption of endovascular procedures is
Therefore, open repair is advisable for young, healthy patients with un- notable, especially for high-risk patients, with low post-operative mor-
suitable TEVAR anatomy and prolonged life expectancy, particularly tality rates (<10%).1051,1052,1055–1058 A recent meta-analysis confirms
when symptoms from aneurysm rupture or compression arise. these excellent outcomes, endorsing endovascular repair for
However, open repair involves significant post-operative risks, ne- TAAA.1059The incidence of post-operative SCI (around 5%) is similar
cessitating thorough pre-operative evaluations for cardiac, pulmonary, between endovascular and open repair.1052,1057,1060,1061 Thus, at
renal function, carotid, and peripheral arterial diseases. Risks include mid-term follow-up, endovascular repair is durable with acceptable
stroke, mesenteric and renal ischaemia due to clamping dur- secondary re-intervention rates, which remain one of the major limita-
ation,1014,1015 and paraplegia tied to the extent of aneurysmal dis- tions.1052,1057,1058,1060,1061Factors favouring endovascular vs. open re-
ease.1016,1017 Outside experienced centres, outcomes have shown pair in TAAA are presented in Table 15.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 76 ---
ESC Guidelines 3613
Recommendation Table 40 — Recommendations for In patients with unruptured DTA aneurysm (without
the management of patients presenting with descending HTAD) and high-risk features,c elective repair may
thoracic aortic and thoracoabdominal aortic aneurysms IIb B
be considered if the diameter is
Recommendations Classa Levelb <55 mm.904,1003,1004,1033,1034
DTA, descending thoracic aorta; HTAD, heritable thoracic aortic disease; LSA, left
In patients with unruptured DTA aneurysm (without
subclavian artery; SCI, spinal cord ischaemia; TAAA, thoracoabdominal aortic aneurysm;
HTAD), elective repair is recommended if diameter I B TEVAR, thoracic endovascular aortic aneurysm repair.
≥55 mm.902,1002 For heritable thoracic aortic disease refer to Section 10.
aClass of recommendation.
In patients without HTAD with unruptured DTA bLevel of evidence.
aneurysm, when elective repair is indicated and cSee Figure 23for high-risk features.
I B
anatomy is suitable, TEVAR is recommended over
open repair.1006,1019,1020
In patients with DTA aneurysm who undergo 9.2.5.5. Surgical treatment of abdominal aorta aneurysms
TEVAR with planned LSA coverage, it is 9.2.5.5.1. General considerations. Rupture remains the most feared
recommended to revascularize the LSA before I B AAA complication, and is associated with the maximum diameter,1063
TEVAR to reduce the risk of SCI and as well as other risk factors (Figure 23). Different studies1064–1071(in-
stroke.1026,1028,1029 cluding the United Kingdom Small Aneurysm Trial [UKSAT] and
American Aneurysm Detection and Management [ADAM] trial) re- In patients with unruptured degenerative TAAA,
ported no benefits from open or endovascular interventions (despite
elective repair is recommended when the diameter is I B
lower peri-operative complication rates) in asymptomatic AAA pa-
≥60 mm.902,1002,1033
tients with a maximal diameter <55 mm in men and <50 mm in wo-
In patients without significant comorbidities and with
men. Evidence that women are more likely to rupture under
unruptured DTA aneurysm, when elective repair is
surveillance and at a smaller aortic diameter justified a lower
indicated and anatomy is unsuitable for TEVAR, open IIa B
(50 mm) threshold. Another interesting method to quantify the risk
repair should be considered if life expectancy
of rupture based on body size, which seems a better predictor in wo-
exceeds 2 years.1013 men, has been proposed.1072However, in the absence of recent stud-
In TAAA, surgical repair should be considered at ies, thresholds for intervention have not changed in recent years.
diameters ≥55 mm if patients present with high-risk Considering the complexity of patient management, it is advisable to
features, are at very low risk, and are under the care IIa B centralize complex procedures in centres with a high level of expertise
of experienced surgeons in a multidisciplinary aorta in aortic diseases and a multidisciplinary team.
team.1004,1033,1034
In patients with unruptured degenerative TAAA and 9.2.5.5.2. Pre-operative cardiovascular evaluation and choice of
suitable anatomy, when elective repair is indicated, treatment. Coronary artery disease is the leading cause of early mor-
endovascular repair using fenestrated and/or IIa B tality after AAA repair,937,1073and is associated with a 5%–10% rate of
branched endografts should be considered in peri-operative CV complications such as death, MI, or stroke.1074,1075
experienced centres.1051,1052,1055–1059 Since endovascular repair is associated with lower mortality (<1%)
Continued and CV complications,1076–1079 the need for pre-operative cardiac
Table 15 Overview of factors favouring open vs. endovascular repair in thoracoabdominal aortic aneurysm
Characteristic Favours open repair Favours endovascular repair
Biological age and life • Younger age • Older age
expectancy • Considerable life expectancy with acceptable • Limited life expectancy
quality of life
Anatomical considerations • If aortic and branch anatomy preclude endovascular • Suitable proximal and distal landing zones
approach • Favourable visceral and renal configuration
• Poor vascular access • Vascular access obtainable
Pathological • Chronic dissection • Acute dissection
Background/causal factor • Hereditary aortic disease • Degenerative aortic disease
Cardiopulmonary condition • Good cardiopulmonary reserve • Poor cardiopulmonary reserve
Fitness • No significant comorbidities • Severe organ impairment (renal, kidney, pulmonary)
• Successful rehabilitation likely • Obesity
• Limited mobility, unlikely to rehabilitate successfully
Urgency • Elective repair • Elective repair
• Emergency repair without a viable endovascular • Emergency repair with time for custom-made graft or suitable for
solution standard grafts
Adapted from Ouzounian et al. with permission.1062
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 77 ---
3614 E S C G u id e l in e s
A B
Aortic aneurysm Aortic aneurysm
Graft Stent graft
Patients with abdominal aortic aneurysm
Either of the following:
Fusiform AAA ≥55 mm (men), ≥50 mm (women) N
Saccular aneurysm �45 mm
Surveillance
Y (See aneurysm
follow-up algorithm)
Life expectancy �2 years N
Y
Operative mortality risk Prohibitive
Low/medium High
Anatomy
Elective repair N
appropriate for EVAR
Y
EVAR
Open repair Optimal medical
(Class IIa)
(Class I) treatment
If suitable anatomy, Elective repair
EVAR (Class IIa) (Class III)
Figure 26 Algorithm for individual decision-making process in the treatment of patients with abdominal aortic aneurysm. (A) Illustration of open
repair (graft). (B) Illustration of endovascular treatment (EVAR). AAA, abdominal aortic aneurysm; EVAR, endovascular aortic aneurysm repair.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 78 ---
ESC Guidelines 3615
work-up will depend on procedure risk, symptoms, and patient-specific A percutaneous femoral approach is suitable since it provides quick-
CVRFs (see Sections 4and 12, and the 2022 ESC Guidelines on cardiovas- er access, reduced invasiveness, and allows local anaesthesia. Some evi-
cular assessment and management of patients undergoing non-cardiac sur- dence supports the use of ultrasound-guided percutaneous access for
gery).1080Coronary revascularization before elective aortic surgery in EVAR due to a lower rate of access-related complications and a shorter
patients with stable cardiac symptoms cannot be recommended, since operation time.1132–1135
there is evidence that this strategy does not improve outcomes or re- As patients treated by EVAR are more prone to late complications
duce the 30 day MI rate.1080,1081 (endoleaks, migration, or rupture) and re-interventions, lifelong surveil-
A complete vascular evaluation (that includes not only the AA but lance is currently mandatory.1096,1136–1140
also the entire aorta: ascending, arch, and descending aorta) is manda-
tory to determine the best strategy in AAA management, CCT being,
by consensus, the optimal pre-operative imaging modality.1082,1083 Recommendation Table 41 — Recommendations for
the management of patients presenting with abdominal
When CCT is contraindicated, consider CMR, though calcification as-
aortic aneurysm
sessment is challenging. Pre-operative planning should determine
EVAR feasibility by sizing the aorto-iliac system, yet adherence to Recommendations Classa Levelb
device-specific instructions remains uncertain.1084–1090 DUS assess-
ment of the femoro-popliteal segment is advocated since femoro- Elective repair is recommended if AAA diameter is
I A
popliteal aneurysms are commonly associated with AAA.1091,1092 ≥55 mm in men or ≥50 mm in women.1064–1067
Additionally, the technique of choice should be discussed between In ruptured AAA with suitable anatomy,
the treating physician and the patient based on the patient’s life expect- endovascular repair is recommended over open
I B
ancy and preferences, operator and hospital volumes, and surveillance repair to reduce peri-operative morbidity and
compliance.910,1093–1097 Elective AAA repair is not recommended in mortality.1116–1118
frail patients or those with life expectancy <2 years.1098,1099The indi-
Prior to AAA repair, DUS assessment of the
vidual decision-making process in AAA patients is displayed in Figure 26.
femoro-popliteal segment, to detect concomitant IIa B
Different studies have demonstrated a significant short-term survival
aneurysms, should be considered.1091,1092
benefit for EVAR, but with similar long-term outcomes compared with
open repair (up to 15 years)1100–1103 also reported in females.1104 In patients with AAA with suitable anatomy and
reasonable life expectancy (>2 years), EVAR should
However, loss of early benefit is associated with an increased rate of IIa B
late complications occurring after 8 years, especially late ruptures.1079 be considered as the preferred therapy, based on
shared decision-making.910,1096,1141–1143
These trials used earlier-generation EVAR devices, so the durability
of the latest-generation devices remains uncertain. Recent data, how- In patients with unruptured AAA and aneurysm
ever, suggest a reduced risk of late complications and fewer re- growth ≥5 mm in 6 months or ≥10 mm per year, IIb C
interventions.1105–1108 repair may be considered.1064,1065
Elective repair for patients presenting with a saccular
IIb C
aneurysm ≥45 mm may be considered.1144
9.2.5.5.3. Open abdominal aorta aneurysm repair. Open AAA re-
pair through mid-line laparotomy (with <30 min clamping time) In patients with AAA and limited life expectancy
with a Dacron graft has been the preferred choice for years, despite (<2 years), elective AAA repair is not III B
notable CV morbidity1078,1100,1109–1113 and a 2%–5% mortality recommended.1098,1099
rate.1110,1111,1113,1114In ruptured AAA, open repair results are worse Prior to AAA repair, routine evaluation with
than those of elective surgery, with an unchanged complication rate coronary angiography and systematic
III C
of around 48%.1115Thus, endovascular repair is recommended to re- revascularization in patients with chronic coronary
duce peri-operative morbidity and mortality.1116–1118 syndromes is not recommended.1080,1081
Open AAA repair raises incisional hernia risk, particularly in obese
patients, suggesting prophylactic mesh use in high-risk cases.1119–1121 AAA, abdominal aortic aneurysm; DUS, duplex ultrasound; EVAR, endovascular aortic
aneurysm repair; TAA, thoracic aortic aneurysm.
See also Figure 23.
aClass of recommendation.
9.2.5.5.4. Endovascular abdominal aorta aneurysm repair. bLevel of evidence.
Endovascular abdominal aorta aneurysm repair reduces peri-operative
mortality to <1%, although it implies higher risk of re-intervention in
the long term.1122–1124 Current devices offer features like active fix- 9.2.6. Endoleaks
ation, repositioning ability, low-profile design, and polymer-filled rings Endoleaks are defined as the persistence of blood flow outside the graft
for improved sealing.1106,1125–1128 New devices demonstrate similar but inside the aneurysm sac, preventing complete thrombosis
long-term outcomes with reduced re-intervention risk,1090expanding (Figure 27). They are the most common complication, with an incidence
treatment possibilities to 60%–70% of infrarenal AAA cases.1129,1130 up to one-third of either early or late procedures (those appearing after
In cases of juxta- or para-renal AAA (Figure 22), both open and en- 1 year).1145 Chronic anticoagulation constitutes a risk factor for
dovascular treatment can be proposed in high-volume centres, with re-intervention, late conversion surgery, or mortality.1146 Endoleaks
similar short- and long-term results. The choice between open surgical exposing the aneurysm sac to systemic pressure and expansion will
repair and endovascular repair depends on various factors, including the require re-intervention to prevent rupture.
patient’s anatomy, overall health, and the extent of the aneurysm Five types of endoleaks have been described, as detailed in Figure 27.
(see Table 15). In cases of complex endovascular treatment, a fene- Type I and type III require correction with a new (endovascular) pro-
strated or branch stent endograft should be considered.1096,1131 cedure. Type II is present in about 25% of patients but may seal
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 79 ---
3616 E S C G u id e l in e s
Classification of endoleak types
Type Ia Type Ib Type II Type III Type IV Type V
Surveillance after TEVAR/EVAR and management of endoleaks
CCT and DUS/CEUSa at 1 month and 1 year post-op
No new endoleak Type II endoleak Type I or type III endoleak
Detected at
Consider re-intervention
1 month post-op
(Class I)
CCT re-evaluation
at 6–12 months
Growing aneurysm sac ≥10 mm
<10 mm or shrinking
CCT or DUS/CEUSa Consider embolization,
surveillance every 6 months if feasible
for 24 months (Class IIa)
New endoleak or N CCT or DUS/CEUSa
growing aneurysm sac
Annual surveillance with surveillance at 6–12 months
CCT or DUS/CEUSa
for the first 5 years Consider open surgery,
if growing aneurysm sac
New endoleak
N CCT
CCT, or
non-contrast CCT with
DUS/CEUS every 5 yearsa Proceed to endoleak type
Figure 27 Algorithm for follow-up after thoracic endovascular aortic aneurysm repair, and management of endoleaks and their classification. CEUS,
contrast-enhanced ultrasound; CCT, cardiovascular computed tomography; DUS, duplex ultrasound; TEVAR, thoracic endovascular aortic aneurysm repair;
EVAR: Endovascular aortic repair. aIn cases of TEVAR, CCT is the preferred imaging technique since DUS/CEUS does not permit the correct evaluation of the
thoracic aorta. In cases of renal failure, non-contrast CCT is a good alternative to monitor aneurysm sac growing and is associated to DUS/CEUS for EVAR
monitoring. Endoleaks are classified into five types: Type Ia, proximal attachment site endoleak; Type Ib, distal attachment site endoleak; Type II, backfilling of
the aneurysm sac through branch vessels of the aorta; Type III, graft defect or component misalignment; Type IV, leakage through the graft wall attributable to
endograft porosity; and Type V; caused by ‘endotension’, possibly resulting from aortic pressure transmitted through the graft/thrombus to the aneurysm sac.
Adapted from Rokosh et al. with permission.1147
Y
Y
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 80 ---
ESC Guidelines 3617
spontaneously in approximately 50% of cases. Risk factors for type II for both endovascular and surgical treatments.1150–1152After interven-
endoleaks include patent collaterals, presence of accessory arteries, tion on the AA, CCT, CMR, and DUS/CEUS are used. DUS/CEUS can
and anticoagulation. In cases of significant sac expansion (≥10 mm), detect the most common drawbacks of EVAR, except for graft struc-
re-intervention should be considered, preferably by vessel or sac em- tural issues. For chronic and periodic monitoring, the use of CMR, es-
bolization. Type IV, attributed to device porosity, is rare with modern pecially in young women, should be considered (to reduce radiation
devices and no intervention is needed. Type V induces sac expansion exposure). However, the choice between these modalities should con-
without any visible endoleak. Treatment may be considered for signifi- sider patient factors, potential artefacts, and local imaging expertise and
cant sac growth (≥10 mm) and consists of stent graft relining or defini- availability. Both for the thoracic and abdominal aorta, due to the lack of
tive endograft explant and open surgical repair. studies systematically comparing different surveillance time intervals,
Cardiovascular computed tomography with(out) contrast, and DUS recommendations are mostly based on consensus or evidence from
and/or CEUS, are the main imaging modalities for TEVAR/EVAR follow- single-centre observational studies.70,1153
up. Imaging within the first 30 days is recommended to assess treat-
ment success and/or complications. For TEVAR, contrast-enhanced 9.2.7.1. Follow-up after thoracic aortic aneurysm treatment
CCT is the preferred imaging technique for follow-up and should be
Complications after ascending aorta graft replacement, though rare,
performed regularly (shorter or longer intervals are based on the ex-
include pseudo-aneurysms and graft infections. Pseudo-aneurysms,
pansion rate). In renally impaired patients, combined follow-up using
occurring in roughly 5% of cases, are most common within the first 2
DUS and non-contrast enhanced CCT is a suitable alternative (see
post-operative years, linked to aortic dissection surgery, HTAD, and
follow-up algorithm, Figure 27). For EVAR, CCT and DUS/CEUS are re-
synthetic glues.1154 CMR studies systematically following peri-
commended at 1 month following repair. Thereafter, surveillance
anastomotic haematomas have reported higher rates (15%).1155
should be based on the risk of late complications and includes DUS
Graft infections can occur in 0.5%–6% of surgical patients with high
and/or CEUS (Figure 27).
morbidity and mortality rates, requiring rapid diagnosis. Treatment typ-
ically involves surgery and antibiotics, tailored to factors like overall
health, infection severity, and underlying conditions.1156Residual aortic
Recommendation Table 42 — Recommendations for
disease progression depends on the underlying condition, such as
the management of patients presenting with endoleaks
HTAD, and requires individualized surveillance.
Recommendations Classa Levelb After TEVAR for DTA aneurysm, late complications are higher
than with surgery (up to 38%), leading to re-operation in 24% of
It is recommended to perform 30 day imaging after cases.1150 However, over 80% of TEVAR complications arise within
TEVAR/EVAR, by CCT and DUS/CEUS, to assess the I B the initial post-operative years.1157Notably, FET results in fewer stent
success of intervention.1096 graft-related complications: 2% stent-induced intimal tear, 3% endo-
It is recommended to re-intervene to achieve a seal leak, and 7% need for additional TEVAR.1158
in patients with type I endoleak after TEVAR/ I B After surgical treatment of TAAs, the protocol is a first CCT scan at
EVAR.1137,1148 discharge or 1 month, then another in the first post-operative year (at
6, 9, or 12 months), followed by a 2 year scan, and if no issues arise,
It is recommended to re-intervene, principally by
scans every 5 years thereafter (Figure 25).1062,1159Stricter lifelong sur-
endovascular means, to achieve a seal in patients with I B
type III endoleak after TEVAR/EVAR.1139 veillance is recommended after TEVAR: after first imaging at 1 month,
yearly controls are recommended for at least the first 5 post-operative
Re-intervention, principally with an endovascular
years, then less frequently if no complications are detected (Figure 27).
approach or embolization, should be considered in
Cardiovascular risk profile modification, cardiac rehabilitation, and
patients with type II or V endoleak and significant sac IIa C
lifestyle adjustments are an integral part of post-aneurysm repair
expansion ≥10 mm or significantly decreasing follow-up (Figure 7).24
proximal or distal seal.1096,1149
CCT, cardiovascular computed tomography; CEUS, contrast-enhanced ultrasound; DUS, 9.2.7.2. Follow-up after abdominal aortic aneurysm treatment
Duplex ultrasound; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair.
aClass of recommendation. Evidence for follow-up after AAA is more robust than after TAA re-
bLevel of evidence. pair.70,1096 Post-surgery, anastomotic or para-anastomotic complica-
tions are rare (2%–4%).1160 In contrast, EVAR has higher
complication rates (16%–30%), necessitating lifelong surveil-
9.2.7. Long-term follow-up after aortic repair lance.1079,1150EVAR’s survival advantage over surgery diminishes after
Long-term success in the management of aortic aneurysms depends 8 years, with higher aneurysm-related mortality risk for EVAR.1079
also on strict post-treatment surveillance, for both secondary preven- However, most failures are detectable early, and complications seldom
tion of the aortic disease and early identification of post-repair occur later in patients with normal early controls.1161,1162CCT effect-
complications. ively detects early EVAR abnormalities,1163but DUS/CEUS surveillance
In endovascularly treated patients, surveillance aims to detect endo- proves accurate, reducing the need for radiation and nephrotoxic
leaks, aneurysmal sac dilatation, and graft structural failure or migra- agents, and lowering costs (Figure 27).1164–1167
tion.1150 Surgical treatments, while carrying higher operative risks, Interestingly, a meta-analysis found low compliance of patients to
often yield more durable results with rarer late complications mostly post-operative surveillance without differences in all-cause mortality,
related to laparotomy.1151 aneurysm-related mortality, and re-intervention between compliant
After intervention on the thoracic aorta, TTE, TOE, CCT, and CMR and non-compliant patients.1168Altogether, the above-mentioned evi-
are used for follow-up, CCT being the most used and available method dence supports stratified methods of surveillance,1096 with
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 81 ---
3618 E S C G u id e l in e s
identification of high-risk situations (e.g. older patients, inadequate seal- If any abnormality during DUS/CEUS is found,
ing, type II endoleaks, no early post-procedural shrinkage of the aneur- confirmation should be considered using additional IIa B
ysmal sac) for which more frequent evaluation should be CCT or CMR (based on potential artefacts).1163,1166
planned.1161,1169,1170
In post-treatment surveillance, administration of
Follow-up of OMT is highly important in AAA patients (Figure 7).24
OMT (see 8.1.2.2 and 8.2.4) and assessment of
Statin use after AAA repair (surgical or EVAR) is associated with de- IIa C
aneurysm development/growth in other arterial
creased short- and long-term mortality.1171 In addition, surveillance
segments should be considered.
for aneurysm development in other arterial locations is recommended.
AAA, abdominal aortic aneurysm; CCT, cardiovascular computed tomography; CEUS,
Recommendation Table 43 — Recommendations for contrast-enhanced ultrasound; CMR, cardiovascular magnetic resonance; DUS, Duplex
follow-up after treatment of aortic aneurysms (see ultrasound; EVAR, endovascular aortic repair; OMT, optimal medical treatment; TAA,
thoracic aortic aneurysm; TEVAR, thoracic endovascular aortic repair.
also Evidence Table 12)
aClass of recommendation.
bLevel of evidence.
Recommendations Classa Levelb cBoth at the level of the treated segment and in the residual native aorta.
dIncluding: endoleak (any type), enlargement of the excluded aneurysm, and stent graft
Thoracic aortic aneurysm migration/separation/fracture.
After open repair of TAA, an early CCT is ee.g. imaging every 6 months during the first year, thereafter every 2–3 years.
fLow-risk: early sac shrinkage >10 mm, relatively younger age (<70 years), proximal and
recommended within 1 month, and then yearly CCT
distal sealing >10 mm, no endoleak.
follow-up for the first 2 post-operative years and I B
every 5 years thereafter is recommended if findings
are stable.c,70,1153,1159 9.3. Acute thoracic aortic syndromes
After TEVAR, follow-up imaging is recommended at 9.3.1. General concepts
1 and 12 months post-operatively, then yearly until Acute aortic syndromes are life-threatening emergencies, including classic
I B
the fifth post-operative year if no abnormalitiesd are AAD, IMH, PAU, aortic pseudo-aneurysm, and traumatic aortic injuries
documented.70,1153,1158 (TAI). They involve aortic wall damage and share a dynamic, overlapping
After 5 post-operative years without complications, pathophysiology, clinical presentation, and diagnostic and therapeutic ap-
continuing long-term follow-up of TEVAR by CCT IIa B proaches.24,172,174,910AAS may also be iatrogenic following open or endo-
every 5 years should be considered.70,1153,1158 vascular/percutaneous procedures, or cardiac surgery.1172
To guide AAS management, several anatomical classifications have
If growth of the excluded aneurysm is observed,
been developed, the Stanford and the DeBakey systems being the
without evidence of type I or III endoleak, repeating
IIa C most widely used. The Stanford system classifies AAS according to
CCT every 6–12 months, depending on the growth
whether the ascending aorta is involved (type A or DeBakey type I
rate observed, should be considered.1150
and type II) or not (type B or DeBakey type IIIa and type IIIb) regardless
When frequent controls are required in TAA of the site of origin of the intimal tear.172,174,910,1173This classification
patients treated either by open or endovascular
considers not only anatomical and treatment aspects, but also prognos-
repair, CMR should be considered instead of CCT
tic implications, since patients with DeBakey type II AAS will probably
after the first year of follow-up. However, the choice IIa C be left without structural aortic wall lesions after surgery (Figure 28).
between these imaging modalities should be based Furthermore, if time elapsed from symptom onset to diagnosis is con-
on individual patient factors, the potential for sidered, AAS can be divided into hyperacute (<24 h), acute (1–14 days),
artefacts, and the local availability and expertise in subacute (15–90 days), and chronic (>90 days) (Figure 28).1174–1176
specific imaging techniques.1155 A new classification considers the intimal tear’s entry site and dissec-
Abdominal aortic aneurysm tion extension (Figure 29).136 Subscript P describes the proximal in-
After open repair of AAA, first follow-up imaging is volved aorta, and subscript D indicates the distal zone. This
recommended within 1 post-operative year, and I A classification guides treatment decisions for sealing the entry tear.
every 5 years thereafter if findings are stable.1079,1096 AADs limited to the aortic arch or originating as retrograde dissections
from the descending aorta that extend into the arch and stop before After EVAR, follow-up imaging is recommended with
the ascending aorta are termed as non-A non-B AD.1177–1179
CCT (or CMR) and DUS/CEUS at 1 month and 12
Recently, a European update of the Stanford classification—Type
months post-operatively, then, if no abnormalitiesd
I A Entry Malperfusion (TEM) classification—has been proposed.1180This
are documented, DUS/CEUS is recommended every
combines information about the type of dissection, its extent, and
year, repeating CCT or CMR (based on potential
the presence of complications (malperfusion), thus providing greater
artefacts) every 5 years.70,1079,1100,1163–1165,1167
prognostic insights (Figure 29). This classification is recommended by
In higher-risk patients, i.e. with inadequate sealing or the European Association for Cardio-Thoracic Surgery. The TEM and
type II endoleak at first CCT control, more frequent other classifications are described in the Supplementary data online,
IIa B
DUS/CEUS imaging should be Section 1.6.
considered.e,1096,1161,1164,1165,1167
In low-riskf patients, from 1 year post-operatively 9.3.1.1. Epidemiology and risk factors
after EVAR, repeating DUS/CEUS every 2 years IIa B Classic AAD (comprising 80%–90% of AAS; incidence of 2.6–3.5 cases
should be considered.1096 per 100 000 person-years)24,1181is characterized by the presence of an
Continued intimal flap separating the true from the false lumen (FL).24,172,910
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 82 ---
ESC Guidelines 3619
Classification of acute aortic syndromes
Stanford A Stanford B
DeBakey I DeBakey II DeBakey IIIa DeBakey IIIb
Frequency of acute aortic syndrome
60% 10–15% 25–30%
Classification of timing
Hyperacute Acute Subacute Chronic
AAS AAS AAS AAS
Time
AAS 24 hours 14 days 90 days
onset post-AAS post-AAS post-AAS
Figure 28 Anatomical and temporal classification of acute aortic syndrome. AAS, acute aortic syndrome.
Acute aortic dissection occurs mostly in males (∼65%) and in the including syndromic and non-syndromic genetic diseases. HTAD,
seventh decade of life (∼63 years).1175,1182Multiple risk factors often BAV, prior aortic surgery, and larger aortic dimensions are more fre-
coexist directly linked to factors like wall stress (with systemic hyper- quent among young patients (<40 years).24,1182,1183Systemic hyperten-
tension being the most common) and/or aortic media abnormalities, sion and cocaine abuse are more common among African-American
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 83 ---
3620 E S C G u id e l in e s
Proximal Distal
Type
extent extent
1 0 0
2 A
3 D 1 1
0
Entry tear: 2 2
Zone 0
4 3 3
4 4
B PD 5 5
5 Entry tear: 6 6
≥Zone 1 7 7
6 8 8
7
8 I D 9 9
10 10 9 Unidentified entry
10 10 tear involving 11 11
11 11 Zone 0 12 12
TEM aortic dissection classification
T
Type
A B Non-A non-B
E
E E E E E
E
Entry
E0 E1 E2 E3 E0 E3 E0 E2 E3
M M0 - no malperfusion
M1 - coronary (-) no clinical symptoms
M2 - supra-aortic (+) clinical symptoms
Malperfusion M3 - spinal, visceral, iliac
Figure 29 Aortic dissection classification system based on the 2020 Society for Vascular Surgery/Society of Thoracic Surgeons Reporting Standards
and the European update of the Stanford classification—Type Entry Malperfusion classification. A, type A aortic dissection; B, type B aortic dissection;
non-A, non-B, aortic dissection limited to the aortic arch or retrograde dissection extending into the arch (but not in the ascending aorta). Upper panel:
Classification of AAD considering the intimal tear’s entry site and dissection extension. Subscript P describes the proximal involved aorta, and subscript
D indicates the distal zone. Lower panel: The TEM classification is the European update of the Stanford classification combining information about the
Type of dissection (T), the Entry site (E), and the presence of Malperfusion (M). Also refer to Supplementary data online, Section 1.6. Society for Vascular
Surgery/Society of Thoracic Surgeons (SVS/STS). Reproduced with permission from.136,1180
than among white patients.1184,1185Of note, the incidence of iatrogenic 9.3.1.1.1. Sex differences. A specific female sex phenotype appears to
AD during cardiac catheterization is very low (around 0.01%–0.02%) be evident in acute TAAD. At admission, acute TAAD female patients
and during cardiac surgery is 0.06%–0.23%, with favourable in-hospital are usually older but have lower body mass index (BMI), BSA, and cre-
and long-term prognosis.1186,1187 atinine plasma levels. They present less frequently with active smoking,
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 84 ---
ESC Guidelines 3621
Clinical suspicion of AAS: determine ADD-RSa
Aortic dissection detection-risk score (ADD-RS)a
High-risk condition High-risk pain feature High-risk examination feature
Marfan syndrome Chest, back, or abdominal Haemodynamic instability
Family history of aortic disease pain described as abrupt (hypotension/shock)
Known aortic valve disease onset, severe intensity, or Perfusion deficit (pulse deficit,
Recent aortic manipulation ripping/tearing differential systolic blood pressure)
Known aortic aneurysm Focal neurological deficit
New AR murmur
If one present = 1 ADD-RS point If present = 1 ADD-RS point If one present = 1 ADD-RS point
High risk: ADD-RS ≥2 Low risk: ADD-RS <2
CCT neck-pelvis without delay ECG: exclude STEMI (2023 ESC ACS Guidelines)
and/or focused TTEa + ECG
Chest X-Ray and laboratory test and POCUS (if available)
D-dimer and
POCUS Chest X-Ray D-dimer
chest X-Ray
+ + + –
CCT
Consider
+ – alternative
diagnosis
AAS confirmed AAS excluded
Figure 30 Multiparametric diagnostic work-up of acute aortic syndrome. AAS, acute aortic syndrome; ADD-RS, aortic dissection detection-risk
score; CCT, cardiovascular computed tomography; ECG, electrocardiogram; POCUS, point-of-care ultrasound; STEMI, ST elevation myocardial infarc-
tion; TOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; +, findings compatible with AAS. aIn haemodynamically unstable
patients: consider TTE and/or TOE as first-line imaging technique depending on local expertise and availability.
BAV, and previous cardiac surgery,1188 but diabetes mellitus is more 9.3.1.1.2. Chronobiology. Acute aortic dissection presents chrono-
common in women than in men. In-hospital surgical mortality does biological patterns, with a higher incidence in morning hours (peak be-
not differ between sexes, although 10 year survival appears to be higher tween 8 am and 9 am) and winter (peak in January in the Northern
in men. Among only medically treated acute TAAD patients, prohibitive Hemisphere).24,1175
high in-hospital mortality has been equally registered for both sexes
(men 58.6% vs. women 53.8%).1188 However, further studies are 9.3.1.1.3. Outcomes. For acute TAAD, in-hospital mortality has de-
needed to explore AAD sex differences to design appropriate diagnos- creased from 31% to 22% due to better surgical outcomes; for acute
tic and therapeutic interventions and preventive strategies.1189 type B aortic dissection (acute TBAD), in-hospital mortality has remained
Pregnancy increases the risk of AAS, more often in the last trimester stable over the years (14%).1175,1182Including deaths before admission, 30
(50%) or post-partum (33%).1190 day mortality for AAD ranges from 23% to 55.8% in Western Europe.1181
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 85 ---
3622 E S C G u id e l in e s
Non-A, non-B dissection patients tend to be younger (median age 59 Recommendation Table 44 — Recommendations for
years) and have a lower mortality than acute TAAD patients.1180,1191 diagnostic work-up of acute aortic syndromes
The 30 day mortality in patients medically treated is around 14%,1179
and 4.4% for those successfully treated surgically.1177 Recommendations Classa Levelb
In unstable patients who cannot be transferred to CCT,
9.3.1.2. Clinical presentation TOE is recommended for diagnosis1204,1208,1209and I B
Acute TAAD typically presents with sudden, severe chest/back pain, evaluation of the coeliac trunk and mesenteric artery.1210
often described as ‘sharp’, alongside a history of arterial hypertension. In patients presenting with clinical features compatible
However, around 6.4% of patients do not experience pain.1182,1192,1193 with possible AAS, a multiparametric algorithm for
I B
Hypotension and shock are frequent. Unique clinical features specific to ruling in or out AAS using the ADD-RS is
acute TAAD include pericardial effusion, aortic regurgitation, and cor- recommended.1196–1200
onary artery involvement leading to ACS (particularly the right coron- ECG-gated CCT from neck to pelvis is recommended
ary artery).1194 Stroke may occur when supra-aortic branches are as the first-line imaging technique in patients with a
involved. Additional complications encompass paraplegia (resulting suspected AAS since it is widely available, accurate,
I C
from spinal ischaemia), acute kidney injury, intestinal ischaemia, or and provides information about the entry tear,
limb ischaemia. Isolated abdominal aortic dissection occurs in about extension, and possible complications (malperfusion,
1.3% of acute TBAD cases when the intimal flap originates below or dilatation, or rupture).170
at the renal arteries.1195 In patients with suspected AAS, focused TTE (with
A complete clinical evaluation is mandatory, consisting of a central use of contrast if feasible) is recommended during the I C
neurological evaluation, heart and lung auscultation (aortic diastolic initial evaluation.170
murmur, pericardial rubbing, etc.), abdominal palpation (tenderness,
In patients with suspected AAS, TOE is
etc.), and assessment of peripheral pulsations as well as mobility and
recommended to guide peri-operative management I C
sensibility in upper and lower limbs. SBP differences (pulse deficit) and detect complications.170
should be sought.
In patients with suspected AAS, CMR should be
considered as an alternative imaging technique if CCT IIa C
9.3.1.3. Diagnostic work-up is not available.170
Early diagnosis is still a major pitfall in managing AAD patients, there-
AAS, acute aortic syndrome; ADD-RS, aortic dissection detection-risk score; CCT,
fore, a diagnostic multiparametric algorithm is proposed (Figure 30).
cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; ECG,
It combines the aortic dissection detection-risk score (ADD-RS) with electrocardiogram; TOE, transoesophageal echocardiography; TTE, transthoracic
D-dimer (DD) and has been validated with an excellent capacity to echocardiography.
rule out AAS.1196–1200 See also Figure 30.
aClass of recommendation.
In patients presenting with chest pain, a routine chest radiography bLevel of evidence.
and ECG are recommended to exclude other aetiologies; however,
9.3.1.4. Therapeutic intervention in acute aortic dissection
the absence of these findings should not delay further investigations.163
9.3.1.4.1. Initial treatment. Acute aortic syndrome care should be
Laboratory tests should be obtained, but awaiting results should not
centralized in experienced centres and managed by aorta teams.1211
delay imaging if there is a high probability of AAD. The most common
The cornerstone in AAS is initial reduction of the pulse pressure by low-
finding is an increase in DD level, which is the case in several other con-
ering SBP below 120 mmHg and heart rhythm ≤60 beats per minute
ditions such as pulmonary embolism or infections. When DD levels are
(b.p.m.). The aim is to decrease aortic wall stress to avoid further exten- below 500 ng/mL, AAD is unlikely.172,1201
sion of dissection with possible rupture or malperfusion.174,1212–1216
A focused TTE at the emergency department, if available, is recom-
Intravenous beta blockade (labetalol as a first choice due to its alpha-
mended1202,1203to assess pericardial effusion, wall motion abnormal-
and beta-blocking properties) is generally accepted as the best option.
ities, aortic regurgitation, and aortic diameters. Sometimes a
Also, esmolol, an ultra-short-acting beta-blocker, can be titrated quickly
dissection flap can be visualized, especially when using contrast.165
and easily, making it particularly useful in the acute setting. If contraindi-
When AAD is suspected, ECG-gated CCT from neck to pelvis is the
cated, i.v. non-dihydropyridine CCBs could be used for heart rate control.
preferred imaging technique, with 100% sensitivity and 98% specificity, If the BP target is not reached after initiating beta-blockers, i.v. vasodilators
and should be performed as soon as possible to confirm diagnosis, lo-
such as nitrates or dihydropyridine CCBs (e.g. nicardipine) can be adminis-
calize entry tear, extension (type A vs. type B), and malperfu-
tered concomitantly with rate-controlling agents first to avoid reflex
sion.170,172,1182,1204 When ACS or pulmonary embolism are still in tachycardia. In cases of malperfusion, higher BP could be tolerated to op-
the differential diagnosis, a triple rule-out ECG-gated CCT scan proto- timize perfusion to the threatened region. Early placement of an arterial
col can be performed be performed to avoid motion artefacts mimick- line to monitor BP invasively is mandatory and admission to an intensive
ing acute TAAD.170,1205,1206However, this strategy is associated with care unit is advisable (including ECG and urine output monitor-
higher contrast and radiation doses, might be less accurate for AAS, ing).1205,1217,1218 Antihypertensive treatment can be gradually switched
and does not reduce the need for additional imaging tests.170,1207 If to oral therapy once BP and heart rate targets are reached and the patient
CCT is not available or in haemodynamically unstable patients, TOE has normal gastrointestinal transit. Adequate pain control is necessary to
can confirm diagnosis. TOE is especially useful pre-, intra, and post- help reach these haemodynamic goals. Intravenous morphine can be cau-
operatively to monitor changes in the anatomical AAD configuration tiously titrated to induce pain relief (Figure 31).
or surgical complications. CMR could be a valuable alternative for In-hospital mortality, reaching 60%, correlates with AAS type, loca-
CCT, however, it is less available, requires a longer examination time, tion, patient comorbidities, and treatment. Risk rises with complications
relies on patient collaboration, and consequently, is less frequently like pericardial tamponade, coronary involvement, or malperfusion.
used in the acute setting. CCT, CMR, and TOE all provide good diagnos- Figure 32describes the main signs and symptoms of complications and
tic accuracy172,1204(See Supplementary data online, Table S4). the mortality rate associated with them.1219–1223
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 86 ---
ESC Guidelines 3623
Recommendation Table 45 — Recommendation for Interventional treatment in acute TAAD and acute TBAD is de-
medical treatment in acute aortic syndromes scribed in the next sections and summarized in Figure 33.
Recommendations Classa Levelb
9.3.1.4.2. Type A aortic dissection interventional treatment.
In patients with AAS, immediate anti-impulse Immediate surgical repair is recommended for acute TAAD, however,
treatment targeting SBP <120 mmHg and heart rate a high mortality rate (∼50% and 1%–2% per hour) within the first 48 h
≤60 b.p.m. is recommended. In cases of spinal I B is described if managed medically only.1232Despite advances in surgi-
ischaemia or concomitant brain injury, maintaining cal and anaesthetic techniques, there is still a high risk of peri-
higher MAP is recommended.1214–1216 operative mortality (17%–25%) and neurological complications
Intravenous BBs (e.g. labetalol or esmolol) are (18%).1233 In recent reports from the International Registry of
recommended as first-line agents. If necessary, i.v. Acute Aortic Dissection (IRAD), medically managed patients had a
I B
vasodilators (e.g. dihydropyridine calcium blockers or 23.7% mortality rate (0.5% per hour) compared with 4.4% (0.09%
nitrates) could be added.174,1224 per hour) for those undergoing surgery.1234 Analyses of pre- and
Invasive monitoring with an arterial line and continuous post-July 2007 IRAD data showed no difference in 48 h mortality
three-lead ECG recording, as well as admission to an I B for medically treated patients, but surgical mortality decreased
intensive care unit, is recommended.1205,1217,1218,1225 (from 5.5% to 3.9%).1234As surgical techniques have improved, data
In patients with AAS who can be managed have shown improved post-operative survival rates.1235 The use of
conservatively and who achieved haemodynamic the GERAADA (German Registry of Acute Aortic Dissection Type
targets with i.v. anti-impulse therapy, switching to A) score1236should be considered in patients undergoing surgery to
I B
oral BBs and, if necessary, up-titration of other determine 30 day mortality (https://www.dgthg.de/de/GERAADA_
BP-lowering agents, is recommended after 24 h if Score).
gastrointestinal transit is preserved.174,1216 Surgical intervention surpasses conservative therapy in long-term
Adequate pain control to achieve haemodynamic follow-up,1237even for challenging cases. Thus, all acute TAAD pa-
I C
targets is recommended.174 tients should receive surgical treatment; however, cardiogenic shock
If the patient has a contraindication for BBs, a secondary to pericardial tamponade, malperfusion of coronary arter-
non-dihydropyridine calcium blocker should be IIa B ies, mesenteric circulation, lower extremities, kidneys, or brain, and/
considered.174,1224 or coma are major predictors for post-operative mortality
(Figure 32).1234,1238 Among octogenarians, in-hospital mortality
AAS, acute aortic syndrome; BB, beta-blocker; BP, blood pressure; b.p.m., beats per minute; ECG, was lower after surgery than with conservative treatment
electrocardiogram; i.v., intravenous; MAP, mean arterial pressure; SBP, systolic blood
(37.9% vs. 55.2%), but with a non-significant difference due to small
pressure.
aClass of recommendation. sample size.1239 While some have reported excellent surgical and
bLevel of evidence. quality of life (QoL) outcomes in elderly patients,1239others found
1 Rate/pressure control
Intravenous labetalol or esmolol
(if contraindication to beta-blockade,
substitute with diltiazem or verapamil)
3 Pressure control
Titrate to heart rate ≤60 b.p.m. Continue to step 3
if systolic
Intravenous vasodilator (nitroprusside
(Class I)
BP ≥ 120mmHg
or angiotensin-converting enzyme inhibitor)
+ Titrate to BP <120 mmHg
(Goal is lowest possible BP that maintains
2 Pain control
adequate organ perfusion)
Intravenous opiates
(Class I)
Titrate to pain control
(Class I)
Figure 31 Medical management of acute aortic syndrome. BP, blood pressure; b.p.m: beats per minute.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 87 ---
3624 E S C G u id e l in e s
a higher rate of post-operative neurological complications.1240Based The frozen elephant trunk technique
on the current evidence, age per se should not be considered an ex- The FET technique addresses complex aortic and aortic arch
clusion criterion for surgery. issues in a single operation,1260–1263 creating a secure landing zone
For optimal repair of acute TAAD regarding long-term outcomes, for future interventions. Recent advances involve ‘proximalization’—
including risk of late death and late re-operation, the following points placing the FET in the aortic arch’s zone 0 or 1, treating proximal
need to be addressed. First, in most cases of aortic regurgitation as- arch aortic issues, and enhancing the landing zone for downstream
sociated with acute TAAD, the aortic valve is essentially normal and procedures—which surpasses the standard elephant trunk
can be preserved.1241–1243 Alternatively, valve replacement can be technique.1264,1265
performed in cases of pre-existent structural valve disease. The de-
cision whether to replace the aortic root is based on the presence of
tears in the sinuses, extensive dissection of sinuses/coronary ostia,
Recommendation Table 47 — Recommendations for
or significant dilatation of the root. The risk of late dilatation of
aortic repair strategies in type A acute aortic dissection
the aortic sinuses when spared should be considered.1242,1244
Additionally, the distal extent of aortic repair is a topic of debate. Recommendations Classa Levelb
Ascending aortic replacement or hemi-arch replacement alone is technic-
ally easier and effectively closes the entry site but leaves a large part of the In patients with acute TAAD and a partially dissected
diseased aorta untreated. In acute TAAD with visceral or renal malperfu- aortic root but no significant aortic valve leaflet I B
sion, the primary entry tear is often in the descending aorta. Consider ex- pathology, aortic valve resuspension is
tended therapies like FET repair for these patients, offering a complete recommended over valve replacement.1251–1255
repair with a low chance of late re-intervention despite increased tech- In patients with acute TAAD undergoing aortic
nical complexity.1245–1247 repair, an open distal anastomosis is recommended
I B
For potential cardiac arrest from pericardial tamponade, consider an
to improve survival and increase FL thrombosis rates.
emergency pericardial puncture as a temporary life-saving measure be- 1266–1269
fore transferring to the operating room.1248,1249
In patients with acute TAAD without an intimal tear
in the arch or a significant arch aneurysm, hemi-arch
I B
repair is recommended over more extensive arch
replacement.1270–1272
Recommendation Table 46 — Recommendations for
In patients with acute TAAD and a secondary intimal
intervention in type A acute aortic dissection
tear in the arch or proximal DTA, an extended aortic
Recommendations Classa Levelb repair with stenting of the proximal DTA (e.g. by
using the frozen elephant trunk technique) may be IIb C
In patients with acute TAAD, emergency
considered to reduce late distal aortic complications
surgical consultation and evaluation
I B (e.g. aneurysm evolution of the remaining dissected
and immediate surgical intervention
descending aorta).1273,1274
is recommended.1182,1250
In patients with acute TAAD who have DTA, descending thoracic aorta; FL, false lumen; TAAD, type A aortic dissection.
aClass of recommendation.
extensive destruction of the aortic root, a bLevel of evidence.
root aneurysm, or a known genetic aortic
I B
disorder, aortic root replacement is
recommended with a mechanical or
biological valved conduit.1251–1255 Malperfusion in type A aortic dissection
In patients presenting with acute TAAD, transfer In acute TAAD with malperfusion, operative mortality correlates
from a low- to a high-volume aortic centre with the with the number of affected organs. Around 30% of patients develop
presence of a multidisciplinary team should be malperfusion syndrome due to elevated pressure in the FL caused by
IIa B considered to improve survival if transfer can be substantial proximal inflow and insufficient distal outflow, leading to
visceral organ and limb ischaemia.1175 The intimal flap may extend
accomplished without significant delay in
surgery.1256,1257 into peripheral arteries, causing a static ‘stenosis-like’ blockage.
Malperfusion typically combines dynamic and static obstructions, ne-
In selected patients, a valve-sparing root repair may
cessitating surgical and hybrid interventions for affected patients
be considered, when performed by experienced IIb B
(Figure 34).
surgeons.1251,1258,1259
Mesenteric malperfusion, a life-threatening complication with a
TAAD, type A aortic dissection. mortality rate of 65%–95%, leads to diverse treatment approaches.
aClass of recommendation. Some centres prefer early direct reperfusion before aortic surgery,
bLevel of evidence.
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 88 ---
ESC Guidelines 3625
Hypotension/shock N
Cardiogenic shock related to:
Tamponade (pulsus paradoxus)
Aortic regurgitation (diastolic murmur)
Major coronary occlusion by
compression or dissection flap
Hypovolaemic shock (aortic rupture)
Branch vessel involvement N
Bowel ischaemia
Lactic acidosis
Elevation liver function test
Hemiplegia, hemiparesis or paraplegia
Stroke, coma or altered mental status
Acute kidney injury or oliguria
Peri-aortic haematoma
Y Y Y N
Mortality 56% 28.6% 10.5% 4.4%
Figure 32 Complications in acute aortic syndromes, clinical evidence associated with malperfusion syndrome, and in-hospital mortality associated
with these complications.
while others favour conventional central aortic repair.1275 for renal malperfusion, extremity malperfusion, uncomplicated
The IRAD registry highlights the superiority of a surgical and hybrid mesenteric malperfusion, or combinations.
approach over medical or endovascular therapy alone. Central aor- Cerebral malperfusion, equally grave, triggers treatment debates ne-
tic repair effectively restores perfusion, showing promising results cessitating a multidisciplinary strategy. Evidence supports surgical
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 89 ---
3626 E S C G u id e l in e s
Initial diagnosis based on CCT
Type A AAD Type B AAD
Open cardiac surgery One of the following:
(Class I)
Contained or free aortic rupture
Organ malperfusion
Extension of the dissectionª
Progressive aortic enlargementª
Refractory hypertensionb
Refractory pain >12 h
Y N
Complicated type B AAD Uncomplicated type B AAD
Favourable TEVAR anatomyc One of the following:
High-risk features at CCT or CMR
Y N Ao diameter >40 mm
FL diameter >20–22 mm
Endovascular repair Open surgical repair
Entry tear >10 mm
(Class I) (Class I)
Entry tear at lesser curvature
Total Ao diameter >5 mmª
Haemorrhagic pleural effusion
Evidence of malperfusion
High-risk clinical features
Need for readmission
Reappearance of pain/symptoms
Y N
Favourable TEVAR anatomyc
OMT + surveillance
+ life expectancy >5 years
Y N
Endovascular repair
OMT + more frequent
in the subacute phased
surveillance
(Class IIa)
Figure 33 Interventional treatment algorithm in acute aortic dissection. AAD, acute aortic dissection; Ao, aorta; CCT, cardiovascular computed tom-
ography; OMT, optimal medical treatment; TEVAR, thoracic endovascular aortic repair. aOn serial imaging in the acute phase during the hospital stay.
bOngoing hypertension despite more than three classes of antihypertensive drugs. cDefined as the presence of adequate proximal and distal landing
zones for the prosthesis and adequate iliac/femoral vessels for vascular access. dBetween 14 and 90 days after dissection onset.172,1226–1231
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 90 ---
ESC Guidelines 3627
Static Dynamic Static + dynamic
thrombus
F T
thrombus
thrombus
Acute type A aortic dissection
Check for presence of acute type A aortic dissection complications
Aortic rupture Cerebral malperfusion Mesenteric Lower extremity
Tamponade
or CPR or stroke malperfusion malperfusion
Consider pericardial drainage
Invasive diagnostics and/or percutaneous
malperfusion repair or TEVAR/EVAR
(Class IIa)
Direct admission to hybrid-OR with onsite aortic team
Anaesthesiological monitoring and intraoperative TOE (if feasible) and preparation for surgery
Immediate aortic surgery (ascending and consider aortic arch or FET based on extension)
(Class I)
If not performed before aortic surgery and malperfusion persists, optional
angiographic control and/or percutaneous malperfusion repair/TEVAR/EVAR
(Class IIa)
Acute type B aortic dissection
Check for presence of acute type B aortic dissection complications
Aortic rupture/ Cerebral Mesenteric Lower extremity
tamponadea malperfusion/strokea malperfusion malperfusion
Consider pericardial
drainage
TEVAR or EVAR and/or percutaneous malperfusion repair
In case of retrograde aortic dissection, immediate aortic surgery (ascending aorta, aortic arch or
FET, based on extension)
(Class I)
If malperfusion persists
Angiographic control and/or percutaneous malperfusion repair or TEVAR or EVAR
Consider extra-anatomic bypass if lower extremity malperfusion persists
Figure 34 Mechanisms and clinical management of aortic branch obstruction in acute aortic dissection. CPR, cardiopulmonary resuscitation; F, false
lumen; FET, frozen elephant trunk; OR, operating room; T, true lumen; TOE, transoesophageal echocardiography; TEVAR/EVAR, thoracic endovascular
aortic aneurysm repair. aDevelops only in retrograde type A dissection.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 91 ---
3628 E S C G u id e l in e s
intervention, reducing mortality rates to 25%–27%, compared with below 50%.1286,1287Compliance increases with previous aortic sur-
76% with medical management alone.1255,1276Close monitoring and ra- gery, severity of hypertension, and understanding of the disease pro-
pid intervention are essential to achieve optimal outcomes and minim- cess. Thus, surveillance and disease awareness are imperative for
ize the risk of permanent neurological damage. A recommended these patients.
algorithm for malperfusion management is displayed in Figure 34. Endovascular therapy for complicated acute TBAD is now the first-
line treatment, provided there is favourable anatomy, due to positive
short- and long-term outcomes.1288–1294 Open surgery is reserved
Recommendation Table 48 — Recommendations for for unsuitable cases, and fenestration could be considered as an ultima
the management of malperfusion in the setting of acute
ratio. In selected instances, correcting side branch compression before
aortic dissection
proximal sealing may be considered.136
In recent years, the ADSORB (Acute Dissection Stentgraft OR Best
Recommendations Classa Levelb
Medical Treatment) and INSTEAD-XL (Investigation of Stent Grafts in
In patients with acute TAAD presenting with Aortic Dissection with extended length of follow-up) trials1219,1226,1295
malperfusion (cerebral, mesenteric, lower limb, or have reported that early intervention for uncomplicated acute and sub-
I B
renal), immediate aortic surgery is acute TBAD is beneficial compared with medical management, and there
recommended.1275,1277 is important debate on whether to treat patients with uncomplicated
In patients with acute TAAD presenting with acute TBAD to improve their life expectancy.1296–1298Intervention is con-
sidered early within 90 days after onset of symptoms and may be safer
cerebral malperfusion or non-haemorrhagic stroke,
when performed in the subacute phase (>14 days after onset of symp-
immediate aortic surgery should be considered to IIa B
toms), but data are scarce.1298–1300The Society of Thoracic Surgeons/
improve neurological outcome and reduce
American Association for Thoracic Surgery (STS/AATS) 2022
mortality.1255,1276,1278
guidelines1294state that prophylactic TEVAR may be considered also in pa-
In patients with acute TAAD presenting with clinically
tients with suitable anatomy and high-risk features (Figure 33) to reduce
significant mesenteric malperfusion syndrome,
late aortic-related adverse events. However, this matter is not entirely
immediate invasive angiographic diagnostics to evaluate
IIa C settled, and the Improving outcomes in vascular disease—aortic dissection
percutaneous malperfusion repair before or directly
(IMPROVE-AD trial) is currently underway. This trial aims to evaluate clin-
after aortic surgery, in aortic centres with expertise,
ical outcomes in patients with subacute (from 48 h to 6 weeks) uncompli-
should be considered.1278–1280 cated type B aortic dissection (uTBAD), comparing upfront TEVAR plus
medical therapy against medical therapy with surveillance for deterioration.
TAAD, type A aortic dissection.
aClass of recommendation. Aortic characteristics change over time, and endovascular treatment in
bLevel of evidence. the chronic phase offers limited potential for aortic remodelling.
Identifying specific characteristics at the time of acute TBAD diagnosis
that predict a complicated course has been attempted. Independent pre-
Endovascular treatment in type A aortic dissection
dictors of TBAD outcomes include a primary entry tear >10 mm located
Endovascular therapy alone has been attempted in highly selected
at the inner aortic curvature,1301initial aortic diameter >40 mm,1301,1302
cases and the concept of a single endovascular valve-carrying conduit
was suggested recently but has not yet been validated.1281,1282 initial FL diameter >20 mm,1301number/size of fenestrations between the
true lumen and FL,1303 stent graft-induced new entry tear,1304,1305and
Treatment in non-A non-B aortic dissection partial FL thrombosis.1306,1307 These parameters are summarized in a
Conservative management leads to high mortality (malperfusion, new system for the categorization of AD, DISSECT (Duration from onset
aortic rupture); thus, surgery or endovascular therapy is favoured of symptoms, Intimal tear location, Size of the aorta based on maximum
within 14 days of symptom onset. For complicated non-A non-B trans-aortic diameter, Segmental Extent, Clinical complications related to
aortic dissection with an arch tear, consider FET repair, though if the dissection, Thrombosis of the FL),1308which serves as a guide to sup-
feasible, stent-graft implantation for primary tear coverage is an port a therapeutic decision (Figure 33).1308A recent meta-analysis found
alternative.1179,1283
TEVAR to be superior to best medical therapy in uncomplicated acute
TBAD. Early outcomes were similar, but TEVAR was associated with few-
9.3.1.4.3. Acute type B aortic dissection interventional treatment. er long-term events and better aortic remodelling.1297,1298,1309Thus, in
Acute TBAD presents without complications (uncomplicated) in stable TBAD with suitable anatomy and high-risk features, pre-emptive
around 50% of cases.1250Complicated acute TBAD includes aortic rup- TEVAR to improve the late outcome should be considered.
ture, malperfusion-related issues, rapid aortic expansion, paraplegia/ Accurate endograft sizing is vital for TEVAR success, as errors may lead
paraparesis, aortic haematoma, refractory pain, and hypertension des- to complications. Disease-specific factors, such as acute thoracic aortic
pite optimal therapy, which associates with an approximately 50% mor- syndromes, pose challenges due to fluctuations in aorta diameter from
tality risk with conservative treatment.1193,1250,1284,1285 haemorrhagic shock and resuscitation. Sizing decisions must account
Open surgery used to be the sole option for complicated acute for these changes. Measuring the thoracic aorta based on admission
TBAD but carried a mortality rate of 25%–50%. Consequently, CCT may be imprecise, even with proper centreline measurements.
medical management, now considered the standard for uncompli- Real-time imaging, especially IVUS, enhances accuracy, particularly in
cated cases, significantly reduces mortality. Goals include lowering hypovolaemic cases. However, further research is required to clarify
SBP and heart rate with BBs (see Section 9.3.1.4.1). However, adher- the role of intraoperative imaging methods (e.g. IVUS, TOE, 3D CCT)
ence is the main limitation of chronic medical treatment, with a rate in endograft sizing and long-term outcomes for optimal patient care.194
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 92 ---
ESC Guidelines 3629
Recommendation Table 49 — Recommendations for mortality (<5%), with stroke and SCI rates below 3%. It is also suitable
the management of patients presenting with acute for high-risk patients who are not candidates for open repair. The pri-
type B aortic dissection mary goal is to close the entry tear, induce FL thrombosis, and promote
aortic remodelling to mitigate growth and rupture risk.1322,1323A sys-
Recommendations Classa Levelb
tematic review showed 90% immediate technical success and 86%
Medical therapy including pain relief and blood complete FL thrombosis. However, FL thrombosis usually occurs
pressure control is recommended in all patients with I B above the coeliac trunk, necessitating lifelong distal FL surveillance.1324
acute TBAD.1215,1219,1310,1311 Coverage of the LSA is often necessary and should be associated with
revascularization. In a recent meta-analysis1325 comparing TEVAR to
In patients with complicated acute TBAD,
open repair in chronic TBAD, TEVAR showed lower early mortality,
emergency intervention is I B
stroke rates, SCI, and respiratory complications but a higher re-
recommended.1193,1250,1284,1285,1288,1289,1291–1293
intervention rate. Long-term survival rates were similar, but open re-
In patients with complicated acute TBAD, TEVAR is I B pair offered greater durability.1326
recommended as the first-line therapy.c,910,1288–1293
Adequate distal sealing poses a challenge due to the dissection extend-
In patients with acute TBAD, BBs should be ing to the iliac artery, with additional re-entries, allowing retrograde flow
IIa B
considered as the first-line medical therapy.1216,1312 into the thoracic aneurysm. In chronic TBAD patients with AA enlarge-
In patients with uncomplicated acute TBAD, TEVAR ment, insufficient distal landing, or large re-entry tears, TEVAR alone is
in the subacute phase (between 14 and 90 days) discouraged. Instead, a comprehensive repair involving the visceral aorta,
should be considered in selected patients with IIa B infra-renal aorta, and iliac artery is needed. Recent studies have shown
high-risk featuresd to prevent aortic favourable results using custom or improvized fenestrated/branched en-
complications.1219,1226,1295,1297,1298,1308,1309 dografts with careful patient selection.1062,1327–1329 A multidisciplinary
team-based approach in experienced centres is necessary for good
BBs, beta-blockers; HTAD, heritable thoracic aortic disease; TBAD, type B aortic outcomes.1330
dissection; TEVAR, thoracic endovascular aortic repair.
See also Figure 33.
aClass of recommendation.
Recommendation Table 50 — Recommendations for
bLevel of evidence.
the management of patients presenting with chronic
cExcept in patients with known or suspected HTAD.
dFor high-risk features see Figure 33. type B aortic dissection
9.3.1.4.4. Chronic type B aortic dissection interventional treatment. Recommendations Classa Levelb
Type B aortic dissection is considered as chronic 3 months after the onset
Antihypertensive therapy is recommended in all
of symptoms, but it also includes residual type B dissection after repair of I B
patients with chronic TBAD.1331–1333
TAAD. Aortic complications, especially aneurysmal degeneration, will oc-
cur in up to 50% of these patients.1302,1313Therefore, in chronic TBAD, In chronic TBAD with acute symptoms of
indications for treatment include the onset of new aortic symptoms such malperfusion, rupture, or progression of disease,
I C
as rapid expansion, malperfusion, or rupture.1314 In asymptomatic pa- emergency intervention is
tients, aneurysmal dilatation is the most important risk factor for rupture, recommended.1302,1313,1314
reaching 20% when the diameter exceeds 55 mm.1302,1315Risk of rupture In patients with chronic TBAD and a descending
increases with diameter; it has been reported a risk of 15.3% and 18.8% thoracic aortic diameter ≥60 mm, treatment is
I B
between 50–55 mm and 54–56 mm, respectively, thus suggesting recommended in patients at reasonable surgical
50–55 mm as a threshold for elective surgery.1316 However, smaller risk.1302,1315,1334
diameters should be considered in patients with HTAD. According to sev-
In patients with chronic TBAD and a descending
eral studies, mortality in the chronic phase is high (40%–70%) and it is
thoracic aortic diameter ≥55 mm, an indication for
mainly related to patients’ comorbidities, such as heart disease and stroke. IIa C
intervention should be considered in patients with
Open repair low procedural risk.1302,1316
Despite the lack of data comparing open repair vs. TEVAR in chronic In patients with chronic post-dissection
TBAD, open surgery remains the first-line treatment in low-risk pa- thoracoabdominal aortic aneurysms, the use of
tients or those with HTAD. The STS/AATS guidelines1294 state that fenestrated/branched stent grafts may be considered, IIb C
open repair should be considered in chronic TBAD patients with indi- when treatment is indicated.1062,1327–1329
cation for intervention, unless comorbidities are prohibitive or anatomy
TBAD, type B aortic dissection.
is not suitable for TEVAR. The surgical technique for chronic TBAD is
aClass of recommendation.
like those for degenerative aneurysms, but repair is more complex due bLevel of evidence.
to the dissection flap.1317Surgical mortality rates between 6% and 11%
and SCI rates between 3% and 11% have been reported.1317–1321
9.3.1.4.5. Management during pregnancy. Management of AD dur-
Patients treated in low-volume centres present higher mortality rates
ing pregnancy requires a multidisciplinary team and specialized centres.
(up to 20%), which reinforces the recommendation for centralization
Initial care should consider general medical recommendations (as pre-
in experienced centres.
viously described), using drugs with the lowest teratogenic impact.
Endovascular repair In cases of type A dissection, if the foetus is viable, caesarean delivery
Thoracic endovascular aortic aneurysm repair (TEVAR) is the pre- will be performed before aortic repair. If the foetus is not viable, surgery
ferred treatment for eligible chronic TBAD patients, offering low early will be done with the foetus in place.1335,1336In uncomplicated type B
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 93 ---
3630 E S C G u id e l in e s
dissections, strict control of the pregnant patient and foetus with con- Table 16 High-risk features of intramural haematoma
servative medical management is recommended.1224,1335Although lim- type A and B
ited to selected cases, successful TEVAR has been described in
complicated TBAD.1227More information is detailed in the 2018 ESC Ascending aorta involvement
Guidelines for the management of cardiovascular diseases during Difficult BP control
pregnancy.1337 Persistent/recurrent pain despite aggressive BP control
Maximum aortic diameter:
9.3.2. Intramural haematoma • Type A: >45–50 mm
• Type B: >47–50 mm
Intramural haematoma, constituting 5%–25% of AAS cases, involves
vasa vasorum haemorrhage within the aortic media, with or without in- Progression to aortic dissection
timal disruption (ID).70,172,1338Most cases (60%–70%) involve the DTA Focal intimal disruption with ulcer-like projection
(ascending aorta ∼30%, aortic arch ∼10%).70,172,1192Although it usually Haematoma thickness >10 mm (type A) or >13 mm (type B)
occurs at an older age than AAD, risk factors and symptoms are simi- Enlarging haematoma thickness
lar;70,172,1192,1338 however, aortic regurgitation, malperfusion syn-
Enlarging aortic diameter
drome, and pulse deficits are less frequent in type A IMH than in
Pericardial effusion at admission (type A)
TAAD.70,172
Recurrent pleural effusion
Detection of organ malperfusion
9.3.2.1. Diagnostic work-up
Diagnostic IMH work-up should be similar to that proposed for AAS BP, blood pressure.
Adapted with permission from.172
(Figure 30), but with different morphological features in the imaging
techniques.
9.3.2.4. Management
CCT and CMR (followed by TOE) are the leading techniques for
diagnosis.70,159,171–173 Unenhanced followed by contrast-enhanced Current IMH therapeutic interventions are similar to AAD, with the
first step consisting mainly of pain and BP control regardless of the ana-
CCT represents the most used tool in the acute setting (hyperin-
tense signal of aortic wall before contrast administration).70,171,172 tomopathological features (Figure 31).
The IMH diagnostic hallmark consists of crescentic or circular aortic
wall thickening in the absence of an intimal flap or aortic wall en- 9.3.2.4.1. Type A intramural haematoma. As in AAD, type A IMH
hancement following contrast administration.70,171,172CMR is an ex-
involves the ascending aorta. Surgery (emergency or urgent depend-
cellent imaging technique to detect small IMHs and for the
ing on clinical status) is recommended. In selected patients with in-
differentiation of IMH (hyperenhanced images in T1-weighted
creased operative risk (i.e. multiple comorbidities) and uncomplicated
images) from atherosclerotic thickening of the aorta, thrombus, or
type A IMH without high-risk imaging features (Table 16) a
thrombosed dissection.172 TTE yields low sensitivity (<40% for
‘wait-and-see strategy’ in a reference/experienced centre may be
IMH cut-off limit of 5 mm).171 reasonable.70,172,1348,1349
9.3.2.2. Clinical outcomes
9.3.2.4.2. Type B intramural haematoma. In type B IMH, the disease
Intramural haematoma may evolve into AAD (12% of patients), saccu-
is in the descending aorta, distal to the left subclavian artery. For un-
lar (8%) or fusiform aneurysm (22%), and/or ID (54%).1192,1339–1342
complicated type B IMH, initial management involves medical treat-
Partial or total regression is reported in 34% of patients.70,1192,1343
ment and thorough clinical and imaging monitoring.70,172 If
Outcomes are comparable to those in AAD. In-hospital mortality for
uncomplicated type B IMH presents high-risk imaging characteristics
type A IMH is 26.6% (surgical 24.1% and medical 40.0%). In this regard,
(see Table 16), the multidisciplinary team should consider endovascu-
higher mortality for IMH involving the aortic valvular complex has been
lar repair as an option. In contrast, complicated type B IMH warrants
observed.1175In-hospital mortality for type B IMH is 4.4% but worsens
consideration of TEVAR.1350,1351 However, in unfavourable anat-
once surgery is indicated (surgical 20.0% vs. medical 3.8%).1175,1344
omy, open surgery remains an alternative.
ID has been described in 54% of type B IMH cases.1192,1339–1342
9.3.2.3. Geographical variations Approximately 28% of them are tiny intimal disruptions (≤3 mm)
Reports from South Korea and Japan reveal notable disparities with that are not related to AAEs. However, 14% of them evolve into focal
Western nations in IMH incidence (28.9% vs. 5.7% of overall AAD as intimal disruptions (FID) (>3 mm), with prognostic implications; thus,
reported by IRAD), treatment strategies, and outcomes. In Eastern all patients with ID require close follow-up with imaging techniques.
regions, the majority (80.8%) of type A IMH patients received med- In the acute phase, FID has a poor prognosis owing to the high risk
ical treatment, resulting in significantly improved clinical outcomes of aortic rupture and should be treated early and invasively, especially
(in-hospital mortality 6.6% [5.9% for medical and 9.4% for surgi- large FID (≥10 mm length and ≥5 mm depth).1342,1352 However, in
cal]).1345These results may be partially explained by the detection the chronic phase, most FIDs evolve with slow aortic dilatation and
of early-stage IMH (mild, uncomplicated cases) at primary cen- without complications, and they can be managed with medical treat-
tres.1345–1347 ment and close imaging surveillance.1352
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 94 ---
ESC Guidelines 3631
Recommendation Table 51 — Recommendations for activity and inflammation, which has been associated with major ad-
the management of intramural haematoma verse events.1358,1359This information may be used to guide treatment
decisions, such as the selection of patients who may benefit from endo-
Recommendations Classa Levelb vascular or surgical intervention.1360
In patients with IMH, medical therapy including pain
relief and blood pressure control is I C 9.3.3.2. Treatment
recommended.24,172 Medical treatment as described for AD is recommended (Figure 31).
In type A IMH, urgent surgery is Management of incidental cases is not clearly defined.174 Small series
I C
recommended.172,1175,1192 suggest that isolated, asymptomatic, small PAUs may be safely managed
conservatively with regular surveillance.1361,1362
In type B IMH, initial medical therapy under careful
I C Surgery is recommended in type A PAU with the option of a
surveillance is recommended.1175,1192,1347,1350,1353
‘wait-and-see strategy’ in highly selected high-risk patients with no high-
In uncomplicatedc type B IMH, repetitive imaging I C risk features (Figure 35). However, in uncomplicated type B PAU, med-
(CCT or CMR) is indicated.1175,1192,1347,1350,1353
ical treatment along with careful clinical and imaging surveillance is re-
In complicatedc type B IMH, TEVAR is I C commended.174,1350 When intervention is needed, endovascular
recommended.1175,1192,1347,1350,1353
treatment (early and 3 year aortic mortality 7.2% and 10.4%, respect-
In uncomplicatedc type B IMH but with high-risk ively)1350should be preferred to open surgery (early and 3 year aortic
imaging featuresd, TEVAR should be IIa C mortality of 15.9% and 25.0%, respectively).174,1350In cases of uncom-
considered.1347,1350 plicated PAU with high-risk imaging features1363–1365(Figure 35), endo-
In complicatedc type B IMH, surgery may be vascular treatment should also be considered. The natural history of
considered in patients with anatomy unfavourable IIb C PAU of the abdominal aorta (AA) with associated IMH is less known.
for TEVAR.1175,1192,1347,1350,1353 In a review of PAU of the AA, endovascular stenting was the preferred
treatment of choice (62%), followed by open surgical repair (35%) and
In selected patients with increased operative risk and
uncomplicatedc type A IMH without high-risk conservative therapy (3%).1366
IIb C
imaging featuresd, a ‘wait and see’ strategy may be
considered.1348,1354–1356
Recommendation Table 52 — Recommendations for
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; the management of penetrating atherosclerotic ulcer
IMH, intramural haematoma; TEVAR, thoracic endovascular aortic repair.
aClass of recommendation. Recommendations Classa Levelb
bLevel of evidence.
cUncomplicated/complicated IMH refers to the absence or presence of recurrent pain, In all patients with PAU, medical therapy including
expansion of the IMH, periaortic haematoma, and intimal disruption.
dHigh-risk features of intramural hematoma type A and B are described in Table 16. pain relief and blood pressure control is I C
recommended.24,172
9.3.3. Penetrating atherosclerotic ulcer In cases of type A PAU, surgery is recommended.172 I C
Penetrating atherosclerotic ulcer (2%–7% of all AAS cases) is character- In cases of type B PAU, initial medical therapy under
I C
ized by localized ulceration of an aortic atherosclerotic plaque penetrat- careful surveillance is recommended.1347,1350
ing through the internal elastic lamina into the media, frequently In uncomplicated type B PAU, repetitive imaging
I C
associated with IMH and diffuse atherosclerosis.70,172,174,910,1338,1343 (CMR, CCT, or TOE) is recommended.1347,1350
Often, multiple PAUs are present, ranging from 5 to 25 mm in diam- In complicated type B PAU, endovascular treatment
eter and 4 to 30 mm in depth.70,172,174,1338 They occur mostly in the (TEVAR) is recommended.1347,1350,1357 I C
middle and lower DTA, with the aortic arch and AA less involved.
In uncomplicated type B PAU with high-risk imaging
The ascending aorta is rarely affected,70,172,910,1192but when this occurs,
features,c endovascular treatment should be IIa C
especially complicated with IMH, the risk of rupture is 33%–75% and
considered.1347,1350
progression to dissection is associated with a high mortality rate.
In selected patients with increased operative risk and
Most patients are older males, smokers, aged >65, with multiple co-
uncomplicated type A PAU without high-risk imaging
morbidities like systemic hypertension, CAD, COPD, renal insuffi- IIb C
ciency, and concurrent abdominal aneurysm.24,172,910,1357 features,c a ‘wait-and-see’ strategy may be
considered.1367
Symptoms are like those in AAD and may manifest in older age after a
long asymptomatic phase (often PAU is diagnosed as an incidental finding In complicated type B PAU, surgery may be
during an imaging examination).24,172,910,1357It should be highlighted that considered based on anatomy and medical IIb C
symptom onset may indicate PAU expansion (tunica adventitia involve- comorbidities.1347,1350
ment); thus, urgent imaging (CCT or CMR) and appropriate therapeutic In isolated, asymptomatic, small PAUs with no
intervention are needed to prevent aortic rupture.70,171,172,174 high-risk features,c conservative management with
IIb C
regular surveillance and medical treatment may be
9.3.3.1. Diagnosis
considered.24,1361
Diagnostic work-up is described in Figure 30. CCT represents the tech- CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance;
nique of choice for diagnosis. TOE and CMR represent possible valid PAU, penetrating atherosclerotic ulcer; TOE, transoesophageal echocardiography;
alternatives considering availability and local expertise.70,159,171–173Of TEVAR, thoracic endovascular aortic repair.
aClass of recommendation.
note, 18FDG-PET-CT is a promising technique since it can detect in- bLevel of evidence.
creased glucose uptake in PAUs as a marker of increased metabolic cSee Figure 35for high-risk imaging features of PAU.
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 95 ---
3632 E S C G u id e l in e s
Type B PAU
Acute or symptomatic PAU Chronic or asymptomatic PAU
Follow-up
Presence of any of the following
Haemodynamic instability
Rupture, contained rupture or signs
Appearance of symptoms or
of impending rupture
signs of impending rupture
Refractory pain
Aortic diameter �55 mm (C)
Large pseudoaneurysm Y
Presence of IMH or high-risk N
imaging features (see box below)
Presence of any of the following
Y N Significant growth of PAU width
(A) or depth (B) >5 mm/yr
Aortic diameter �55 mm (C)
Endovascular treatment
High-risk imaging features
(Class I)
(see box below)
Y N
Endovascular Optimal medical
treatment treatment
(Class IIa) (Class I)
High-risk imaging features of PAUs
Maximum PAU width (A) �13–20 mm
A
Maximum PAU depth (B) �10 mm
Significant growth of PAU width C
B
(A) or depth (B) >5 mm/year
PAU associated with a saccular aneurysm
PAU with an increasing pleural effusion
Figure 35 High-risk features in penetrating atherosclerotic ulcer and management of patients with type B penetrating atherosclerotic ulcer. IMH,
intramural haematoma; PAU, penetrating atherosclerotic ulcer; TEVAR, thoracic endovascular aortic repair. (A) Maximum PAU width. (B)
Maximum PAU depth; (C) Maximal aortic diameter at the site of the PAU.910
9.3.4. Aortic pseudo-aneurysm are often symptomless, detected incidentally during post-aortic procedure
Aortic pseudo-aneurysms, or false aneurysms, result from aortic wall disrup- imaging. Symptoms may include chest pain, compression, and if untreated,
tion, typically caused by factors like trauma,1368surgery, or infections. They they can lead to fatal rupture or other severe complications.1369,1370
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 96 ---
ESC Guidelines 3633
Pseudo-aneurysm repair seems always indicated regardless of size or Recommendation Table 53 — Recommendations for
position to prevent progression and rupture. Nevertheless, in some cir- traumatic aortic injury
cumstances and under close follow-up, patients could be moni-
Recommendations Classa Levelb
tored by CCT, CMR, or TOE and intervention could be
postponed unless size expansion, symptoms, or compression of
In cases of severe aortic injury (grade 4), immediate
surrounding structures occur.1371 Pseudo-aneurysms could be repair is recommended.24,1373,1374 I A
treated by open surgery or endovascular treatment (occluders,
In cases of TAI with suitable anatomy requiring
stent grafts, or coils). There is no randomized study comparing
intervention, TEVAR is recommended over open I A
open surgery vs. TEVAR; however, treatment of choice is com-
surgery.24,1373,1374
monly based on anatomical features, clinical presentation, and
In all TAI patients, medical therapy including pain
the patient’s comorbidities and decided by a multidisciplinary
team in specialized centres.1045,1371 relief, and blood pressure and heart rate control, is I C
recommended.24,172
In cases of TAI suspicion, CCT is
I C
9.3.5. Traumatic aortic injury recommended.159,172
Traumatic aortic injury (TAI), commonly from high-speed motor In cases of moderate aortic injury (grade 3), repair is
I C
accidents or falls, involves partial or complete aorta transection. It recommended.24,1373
results from rapid deceleration causing torsion and shearing forces, If CCT is not available, TOE should be
often affecting relatively immobile aorta segments like the aortic isth- considered.159,172 IIa C
mus (90%), aortic root (5%), or diaphragmatic hiatus (5%).24,70,172
In minimal aortic injury (grades 1 or 2), initial medical
Traumatic aortic injury is classified based on the degree of lesion
therapy under careful clinical and imaging surveillance IIa C
in the aortic wall (Figure 36): grade I (intimal tear), grade II (IMH),
should be considered.24,1374
grade III (pseudo-aneurysm), and grade IV (aortic rupture). In the
In cases of progression of the IMH (grade 2),
Crash Injury Study, 130/613 deaths (21%) were associated with TAI
semi-elective repair (within 24–72 h) should be IIa C
(mortality associated with aortic rupture 91%; at-scene survival
9%).1372 considered.24,1374
CCT, cardiovascular computed tomography; IMH, intramural haematoma; TAI, traumatic
aortic injury; TOE, transoesophageal echocardiography; TEVAR, thoracic endovascular
9.3.5.1. Diagnosis and therapeutic interventions aortic repair.
aClass of recommendation.
Due to non-specific symptoms and signs (often obscured by con-
bLevel of evidence.
comitant multiple organ injury) a timely diagnosis relies on a high level
of clinical suspicion.70,172CCT (accuracy close to 100%) represents
the technique of choice, acting as a ‘one-stop shop’ to rapidly assess 9.3.6. Iatrogenic aortic injuries
the entire skeletal system and internal organs.70,171,172TOE may be
Iatrogenic aortic lesions are those associated with invasive procedures
an alternative, although limited by availability, local expertise, and po-
(cardiac surgery, most commonly dissection type A, or coronary angi-
tentially a patient’s multiple traumas.24,70,172 Therapeutic interven-
ography, with a similar proportion of type A and B dissections) (see
tions are dependent on the extent of aorta lesion and patient
Section 9.3.2.1). Incidence is low and ADs are the most common lesions.
clinical status as assessed by a multidisciplinary team. Generally, ag-
Main risk factors are advanced age, presence of CVRFs, atherosclerosis,
gressive fluid administration should be avoided because it may ex-
aortic aneurysms, or PAD (Figure 37). Patients with iatrogenic AAS are
acerbate bleeding, coagulopathy, and hypertension. To reduce risk often painless with correspondingly less chest or back pain.1375
of rupture, mean BP should not exceed 80 mmHg.172Minimal aortic While historically associated with high mortality,1375recent registries
injury (grades 1 and 2) may be managed medically along with strict like the German GERAADA indicate a mortality rate similar to that for
clinical and imaging surveillance; moderate aortic injury (grade 3) spontaneous dissections.1186
with semi-elective repair (within 24–72 h) to allow patient stabiliza-
Clinical management is based on the underlying lesion (AAD, IMH)
tion (though in some patients urgent repair is needed);24,1373and se-
and location; however, conservative management has been described
vere aortic injury (grade 4) with immediate repair.1374 If there is
with good results in type A iatrogenic dissection if the coronary flow
progression of the IMH (grade 2), semi-elective repair (within is preserved and the dissection is small.1376Iatrogenic lesion classifica-
24–72 h) may be considered. TEVAR is preferred (if feasible) to tion is depicted in Figure 37.1377Although scarce, data support a conser-
open surgery (in-hospital mortality 7.9% vs. 20% and 1 year mortality
vative approach based on evolution in type 1 and 2 lesions (Dunning
8.7% vs. 17%). In semi-elective repair, if the LSA needs to be covered, classification), and surgery in type 3.1377In cases of coronary involve-
prior LSA revascularization before TEVAR is suggested to reduce the ment, stent implantation sealing the flap may be proposed.1376,1377
risk of paraplegia 172,1373,1374
9.3.7. Long-term follow-up of acute aortic syndrome
9.3.5.2. Long-term surveillance in traumatic aortic injury Imaging modalities and time intervals for surveillance vary according to le-
In addition to clinical assessment, CCT is the imaging choice for follow- sion location (ascending/descending aorta), type of treatment (medical, en-
up.70,171,172Cumulative exposure to radiation and iodinated contrast dovascular, surgical), and underlying disease (HTAD).70,1062,1153Compared
medium remains the major limitation in young patients, especially in with the chronic disease setting, follow-up of AAS patients is characterized
women. A combination of a chest X-ray and CMR (if no graft artefacts) by a higher risk of complications and need for re-operation.1378Patients re-
would be a valid alternative.24,171,172 ceiving TEVAR for AAS involving the descending aorta are more prone
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 97 ---
3634 E S C G u id e l in e s
MACE
GRADE MedTX
Intimal tear
I (Class IIa)
Med
GRADE Intramural
TX/TEVAR
II haematoma
(Class IIa)
GRADE Pseudo- TEVAR/OR
III aneurysm (Class I)
TEVAR/OR
GRADE
Rupture (Emergent)
IV
(Class I)
Figure 36 Classification and treatment of traumatic aortic injuries. Med, medical; OR, open surgery repair; TEVAR, thoracic endovascular aortic re-
pair; Tx, treatment.
(27%–49%) to requiring a second intervention than patients undergoing graft infection. CCT is the most used modality, but in patients requiring
surgical repair.1379,1380 However, need for re-intervention at follow-up frequent examinations CMR can be considered to reduce radiation.
(after initial treatment of AAD) seems to have a significant impact on sur- Compared with outcomes of open surgery for aortic aneurysms, time
vival for TAAD1381but not for TBAD.1380 to re-intervention in patients developing complications is significantly
shorter,1159also due to the faster average growth of the dissected aorta
(about 1 mm per year).70 Considering the reported incidence rates
9.3.7.1. Follow-up after invasive treatment (around 10%) of complications requiring re-operation, it is reasonable
Following surgery for AAS, imaging surveillance will focus on persist- to follow patients every 6 months in the first year (including an
ence/obliteration of the FL, anastomotic dehiscence, progressive dilata- early—within 1 month—echocardiography to follow native or pros-
tion of residual native aorta (with or without residual dissection), or thetic aortic valve function), then yearly up to the third post-operative
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 98 ---
ESC Guidelines 3635
Risk factors
Cardiovascular Aortic
Older age Atherosclerosis PAD
risk factors aneurysm
Aetiology
Aortic canulation Coronary angiography
Dunning classification
4 cm 4 cm 4 cm
Grade 1 Grade 2 Grade 3
Figure 37 Aetiology, risk factors, and classification of iatrogenic aortic injuries. PAD, peripheral arterial disease. Dunning classification of iatrogenic
aortic dissection:1377: type 1, dissection limited to the sinuses of Valsalva; type 2, dissection of the ascending aorta outside the sinuses but < 40 mm from
the aortic annulus. type 3, dissection > 40 mm from the annulus.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 99 ---
3636 E S C G u id e l in e s
months
1 2 3 4 5 6
1 3 6 year years years years years years
No false
lumen
Stable
Treated AAS
Pre-discharge
(open or
(1 month)
endovascular Residual
repair) false lumen
Concerning
findings
Stable
(AD or IMH)
Pre-discharge
Medically
treated AAS
PAU or
concerning
findings
Recommendation for CCT or CMR
From this point on, extend the time intervals for monitoring according to the clinical context
Figure 38 Algorithm for follow-up after acute aortic syndrome. AAS, acute aortic syndrome; AD, aortic dissection; CMR, cardiovascular magnetic
resonance; CCT, cardiovascular computed tomography IMH, intramural haematoma; PAU, penetrating atherosclerotic ulcer.
year and then every 2–3 years if there are no complications 9.3.7.2. Follow-up under medical treatment (chronic type B aortic
(Figure 38).1153,1159 dissection, intramural haematoma, penetrating atherosclerotic ulcer)
TEVAR implies a higher risk for late re-interventions,1159,1378and a Around 70% of TBAD patients survive the hyperacute phase. If there is
sequence of imaging intervals at 1, 6, 12, 24, 36, 48, and 60 months is no malperfusion, uncontrolled hypertension, or impending rupture, ini-
recommended if no abnormality is detected (shorter intervals should tiate anti-impulse therapy alongside surveillance.
be considered in high-risk patients). Thereafter, controls can be per- Chronic aortic dilatation, reaching 55 mm, is the leading cause (about
formed every 2–3 years. Compared with the time points after surgery, 40%) of intervention, while acute complications necessitating immediate
an adjunctive early control at 1 month is necessary to exclude asymp- treatment are rare.1301,1383Imaging controls should be performed at least
tomatic retrograde type A dissection induced by TEVAR (70% of cases at 1, 6, and 12 months after discharge and yearly thereafter; however, one
occurring within 30 post-operative days).1382 additional earlier scan, e.g. within 3 months, may reveal important changes
Besides imaging surveillance, clinical follow-up is aimed at achieving occurring in the subacute phase, when the dissected aorta remains suc-
strict BP control, limiting the burden of CVRFs, and providing patients cessfully amenable to early TEVAR.1383During surveillance, late complica-
with counselling for lifestyle modifications and prescriptions for sport tions may be predicted by imaging features, including the number and
activity.24There is evidence that statin treatment may improve survival location of the entry tear(s), and dimensions of the FL, total (true + false)
in AAS patients under medical treatment, whereas BBs may improve lumen, or entry tear.1383This might help in risk stratification to modulate
survival in surgically treated patients.1333 the stringency of surveillance in the individual patient (Figure 33).1213
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 100 ---
ESC Guidelines 3637
Type B IMH and PAU are usually conservatively treated with antihyper- 10. Genetic and congenital diseases
tensive therapy and watchful monitoring. Most of the medically treated
of the aorta
IMHs have a favourable course, whereas PAUs are less predictable in terms
of risk of acute TBAD or rupture.1350Therefore, for IMH the same surveil-
10.1. Genetic and chromosomal diseases
lance criteria as for medically treated uncomplicated TBAD can be em-
ployed; for PAU more frequent controls are advisable, i.e. one every 6 This section discusses genetic and congenital aortic diseases.
months instead of every year. Selectively, in asymptomatic patients with Aortic root and ascending aortic disease is commonly linked to
2 year growth-rate stabilization and no high-risk features, intervals be- congenital or hereditary factors, while descending aortic pro-
tween controls can be longer (every 1–2 years) (Figures 35and 38).70,1384 blems, especially in the AA, often result from atherosclerosis.1385
Unless noted otherwise, recommendations provided herein are
intended for adults.
Recommendation Table 54 — Recommendations for Genetic diseases affecting the thoracic aorta are grouped under
follow-up after treatment of acute aortic syndrome the broader term of HTAD. HTAD comprises a clinically and genet-
ically heterogeneous group of disorders sharing the common de-
Recommendations Classa Levelb nominator of aneurysm or dissection of the thoracic aorta.
Familial forms (thoracic aortic disease [TAD] affecting ≥2 individuals
After TEVAR for AAS, follow-up imaging is
in one family) or confirmed genetic entities (familial or sporadic) as
recommended at 1, 6, and 12 months
well as syndromes conferring a risk for TAD fall under the definition
post-operatively, then yearly until the fifth I B of HTAD.70Due to the rarity of these conditions, robust evidence
post-operative year if no abnormalitiesc are
for many scenarios, such as intervention thresholds, surgical meth-
documented.1159,1378,1382
ods, open surgery vs. endovascular approaches, and pregnancy plan-
In medically treated type B AAS or IMH, follow-up ning, is lacking. Thus, a multidisciplinary and individualized approach
imaging is recommended at 1, 3, 6, and 12 months is advisable.70,1386,1387
I C
after onset, then yearly if imaging findings are
stable.1301,1383
In medically treated PAU, follow-up imaging is
Recommendation Table 55 — Recommendations for
recommended at 1 month after diagnosis, then every I C the management of patients with heritable thoracic aor-
6 months if imaging findings are stable.70,1350,1384 tic disease
After open surgery for AAS, follow-up imaging by
Recommendations Classa Levelb
CCT and TTE within 6 months, then CCT at 12
IIa B
months and then yearly if findings are stable,d should It is recommended that medical management of
be considered.1153,1159,1383 patients with HTAD is individualized and based on I C
If no complicationsc occur within the first 5 years, shared decision-making.1386
CCT every 2 years thereafter should be IIa B It is recommended that patients with known or
considered.1159,1378
suspected syndromic or non-syndromic HTAD are
I C
If no residual patent FL is documented for 3 evaluated in a centre with experience in the care of
post-operative years, subsequent surveillance by this patient group.888
IIa C
CCT every 2–3 years should be
HTAD, heritable thoracic aortic disease. considered.1153,1159,1383
aClass of recommendation.
If abnormalitiesc are documented at any time of bLevel of evidence.
follow-up after TEVAR for AAS, then CCT should be IIa C
considered every 3–6 months.1159,1378,1382
When frequent controls are required in AAS Clinically, HTADs can manifest as either syndromic or non-
patients treated either by open or endovascular syndromic entities. The genes identified to date may underly both
IIa C
entities and predominantly show autosomal dominant inheritance
repair, CMR should be considered instead of CCT
after the first-year follow-up.70,1153 patterns. While TAD is the primary feature in HTAD, extra-aortic
features (skeletal/ocular) may be key to diagnosing certain syndrom-
In the follow-up of medically treated PAU, after 2
ic cases. In some cases, the presence of extra-aortic manifestations
years of imaging stability, larger intervals should be IIa C
may aid in risk stratification and hence in defining optimal manage-
considered in low-risk patientse.70,1350,1384
ment.1388–1390 The main clinical and genetic data on syndromic
AAS, acute aortic syndrome; CCT, cardiovascular computed tomography; CMR, and non-syndromic HTADs are summarized in the Supplementary
cardiovascular magnetic resonance; FL, false lumen; IMH, intramural haematoma; PAU, data online, Table S5.
penetrating atherosclerotic ulcer; TEVAR, thoracic endovascular aortic repair; TTE,
Numerous underlying gene defects have been discovered in both
transthoracic echocardiography.
aClass of recommendation. syndromic and non-syndromic cases, leading to the constitution of
bLevel of evidence. three major molecular groups: genes encoding components of: (i) the
cIncluding: pseudo-aneurysm, graft infection, endoleak (any type), enlargement of the extracellular matrix; (ii) the transforming growth factor-beta (TGF-ß)
excluded aneurysm, and stent graft migration/separation/fracture.
dBoth in terms of extent of residual FL and of aortic diameters at any level. signalling pathway; and (iii) the smooth muscle cell contractile appar-
eLow-risk: based on width and depth of PAU (See Figure 35for high-risk features). atus. Clinical and CV outcomes vary between these groups and will
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 101 ---
3638 E S C G u id e l in e s
help pave the way to precision medicine in HTAD.1391Extensive clinical Imaging screening of family members of patients with
and imaging studies in HTAD revealed arterial vasculature involvement TAD with risk factors for HTADc in whom no (likely)
beyond the thoracic aorta. Patients may develop aneurysms and/or dis-
pathogenic variant is identified should be considered
sections beyond the aorta in diseases such as MFS, Loeys–Dietz or vas-
starting at age 25, or 10 years below the youngest IIa C
cular Ehlers–Danlos syndrome (vEDS),1390,1392,1393or can be prone to
case, whichever is younger. If the initial screening is
occlusive vascular disease in the setting of alpha-actin gene (ACTA2) var-
normal, continued screening every 5 years until the
iants.1394Large clinical variability is observed within families carrying an
age of 60 should be considered.25
identical variant and instances of incomplete penetrance (a ‘skipped
generation’) are observed. All HTAD entities display cystic medial de- CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance;
generation, hindering precise diagnosis using pathology. FDR, first-degree relative; HTAD, heritable thoracic aortic disease; TAD, thoracic aortic
disease; TTE, transthoracic echocardiography.
Both genetic testing and imaging (mainly by TTE, but also consider aClass of recommendation.
CMR or CCT if the aortic root/ascending aorta are not properly visua- bLevel of evidence.
lized) in patients and family members are important in the diagnosis of cSee Figure 39.
dCMR/CCT may be indicated if the aortic root/ascending aorta cannot be visualized
HTAD. In those patients in whom no genetic cause is identified, but in
adequately.
whom there is a high suspicion of an underlying genetic defect, genetic eParents, siblings, children.
re-evaluation needs to be considered after 3–5 years. Genetic testing
should always be accompanied with appropriate counselling. 10.1.1. Turner syndrome
Furthermore, appropriate assessment of HRQoL and psychological
10.1.1.1. Diagnosis, clinical presentation, and natural history
support should be offered to patients and families.1395Indications for
Turner syndrome (TS), resulting from partial or complete monosomy
genetic testing and aortic screening in HTAD are illustrated in the algo-
of the X-chromosome, affects 1 in 2500 live-born females.
rithm in Figure 39.
About 50% of patients experience CV issues like ascending aortic dila-
Although isolated AAA is less frequently associated with a genetic ba-
tation, BAV, aortic coarctation, elongated aortic arch, and partial abnormal
sis, patients with high-risk features (syndromic features, early onset of
pulmonary venous return.1417–1419All women present with generalized ar-
disease, absence of CVRFs, and/or family history of TAD or AAA)
teriopathy and TS itself is an independent risk factor for thoracic aortic dila-
should be evaluated in centres with experience in HTAD to evaluate
tation. AD risk (type A in 85% and type B in 15%) is elevated in this
the need for genetic testing and specific surveillance, including active
population,1420–1422 although recent studies indicate that this risk may
clinical screening in family members.
be lower with proper treatment guidelines.1423–1426Risk factors include
aortic dilatation, BAV, coarctation, and arterial hypertension. Defining aor-
tic dilatation in TS requires adjustment for anthropometric parameters and
Recommendation Table 56 — Recommendations for aortic growth data for dissection risk estimation.1427Z-scores used in the
genetic testing and aortic screening in aortic disease
general population are equivalent to Turner-specific z-scores.1428
Recommendations Classa Levelb Imaging surveillance
In newly diagnosed TS, TTE and CMR are recommended at baseline for
Genetic testing
the evaluation of congenital heart defects and aortic anatomy/diameters.
In patients with aortic root/ascending aneurysms or For women aged 15 years and older with TS, adjusting for their smaller
thoracic aortic dissection, gathering family history body size is essential when assessing aortic dimensions. Utilize metrics
information for at least three generations about like the ascending aortic size index (ASI), aortic height index (AHI), or aor-
I B
TAD, unexplained sudden deaths, and peripheral tic z-scores to gauge aortic dilation and dissection risk. Further follow-up
and intracranial aneurysms is is dictated by baseline aortic diameters, age, and risk factors (Figure 40).
recommended.880,1396–1402
In patients with aortic root/ascending aortic Recommendation Table 57 — Recommendations for
aneurysms or thoracic aortic dissection and risk imaging in women with Turner syndrome
factors for HTAD,c genetic counselling at an expert I B
Recommendations Classa Levelb
centre and subsequent testing, if indicated, is
recommended.1399,1403–1408
To take the smaller body size of women (≥15 years)
In patients with HTAD who have a pathogenic/likely with TS into account, the use of the ascending ASI
pathogenic variant, genetic testing of at-risk biological (ratio of aortic diameter [mm] to BSA [m2]), AHI
I C
relatives (i.e. cascade testing) is recommended, (ratio of aortic diameter [mm] to height [m]), or I C
irrespective of age.70,1407,1409 aortic z-score is recommended to define the degree
In patients with HTAD, guidance of clinical of aortic dilatation and assess the risk of aortic
management by the underlying gene/variant, when IIa B dissection.153,1417,1421,1423,1428,1429
known, should be considered.70,1391,1410–1416 It is recommended to define imaging and clinical
Aortic imaging screening surveillance intervals according to the estimated risk
I C
In patients with TAD with risk factors for HTAD,c for dissection, based on the ascending ASI and
concomitant lesions.c,1420,1421
with a negative family history of TAD and in whom
no (likely) pathogenic variant is identified, TTEd I B AHI, aortic height index; ASI, aortic size index; BSA, body surface area; TS, Turner
screening aortic imaging of FDRse is syndrome.
recommended.1396,1402 aClass of recommendation.
bLevel of evidence.
Continued cConcomitant lesions: hypertension, aortic coarctation, bicuspid aortic valve (Figure 40).
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 102 ---
ESC Guidelines 3639
Patient with TAD
≤ 60 years
N Y
Aortic root/ascending z-score ≥3 Aortic dissection Aortic dilatation
or aortic dissection
HTN HTN
Y N N Y
Any additional Aortic root/ascending
risk feature z-score ≥3 or
(see box below) any additional
risk feature
(see box below)
N Y
Y N
No further
investigation
for HTAD No further
investigation
for HTAD
Referral to a centre with
experience in the care of this patient group
(Class I)
Genetic testing Aortic imaginga screening of FDRs
(Class I) (Class I)
Negative
Positive
or VUS
Cascade screening Re-evaluate genetic testing
(Class I) in the proband (after 3–5 years)
Gene-based management Reimaging of FDRs (after 5 years)
(Class IIa) (Class IIa)
Any additional risk feature
Syndromic features of: Family history of (either one):
Marfan syndrome TAD
Loeys-Dietz syndrome Peripheral/intracranial artery aneurysm
Vascular Ehlers-Danlos syndrome Unexplained Sudden death <60 years
Figure 39 Algorithm for genetic and imaging screening in patients with thoracic aortic disease. CCT, cardiovascular computed tomography; CMR,
cardiovascular magnetic resonance; FDR, first-degree relative; HTAD, heritable thoracic aortic disease; HTN, arterial hypertension; TAD, thoracic aor-
tic disease; TTE, transthoracic echocardiography; VUS, variant of uncertain significance. amainly by TTE, but also consider CMR or CCT if the aortic
root/ascending aorta are not properly visualized.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 103 ---
3640 E S C G u id e l in e s
CoA, BAV, HTNa or
None of CoA, BAV, HTNa
aortic growth ≥3 mm/year
ASI <20 mm/m2 ≥20–<23 mm/m2 ≥23–25 mm/m2 >25 mm/m2 �23 mm/m2 >23 mm/m2
AHI <20 mm/m ≥20–<23 mm/m ≥23–25 mm/m >25 mm/m �23 mm/m >23 mm/m
Z-score - - 3.5–4 >4 - >3.5
Risk
Low Moderate Moderate High Moderate High
group
Every 5–10 Every 3–5 Every Every 2–3
years: years: year: Consider years: Consider
Cardiology Cardiology Cardiology surgery Cardiology surgery
evaluation and evaluation and evaluation and (Class IIb) evaluation and (Class IIa)
TTEb TTEb TTEb TTEb
Figure 40 Algorithm for surveillance in women (≥15 years) with Turner syndrome. AHI, aortic height index (ratio of aortic diameter [mm] to height
[m]); ASI, aortic size index (ratio of aortic diameter [mm] to BSA [m2]); BAV, bicuspid aortic valve; BSA, body surface area; CCT, Cardiovascular
Computed Tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; HTN, arterial hypertension; TTE, transthoracic
echocardiography. aHTN: arterial hypertension, not under control despite more than three classes of antihypertensive drugs. bCMR (preferably) or
CCT if inadequate visualization of the ascending aorta.
10.1.1.2. Medical treatment
Elective surgery for aneurysms of the aortic root and/
In the absence of clinical trials, a pragmatic approach in a shared-decision
or ascending aorta may be considered for women
model is adopted regarding TS medical treatment. Adoption of the
with TS who are ≥15 years of age, have an ascending
strategy for inhibition of aortic growth with BBs and/or ARBs as in IIb C ASI >25 mm/m2, an AHI >25 mm/m, a z-score >4,
MFS may be considered. Hypertension should be treated according
and who do not have associated risk factors for
to general guidelines.300
aortic dissectionc.70,1417,1421
Hormonal treatment with growth hormone (in childhood), sex (oestro-
gen and/or progesterone), and thyroid hormones needs to be discussed in a AHI, aortic height index (ratio of aortic diameter [mm] to height [m]); ASI, aortic size index
multidisciplinary team with the paediatrician and endocrinologist.1430–1434 (ratio of aortic diameter [mm] to BSA [m2]); TS, Turner syndrome.
aClass of recommendation.
bLevel of evidence.
10.1.1.3. Surgery of aortic aneurysms cBicuspid aortic valve, elongation of the transverse aorta, coarctation of the aorta, and/or
uncontrolled hypertension (despite more than three classes of antihypertensive drugs). See
Aortic aneurysm surgery in TS should be informed, individualized, and
Figure 40.
consider factors beyond aortic diameter (indexed). These include BAV,
coarctation, uncontrolled hypertension (despite more than three
classes of antihypertensive drugs), rapid aortic growth (≥3 mm per
year) and planned pregnancy. 10.1.1.4. Pregnancy and physical exercise
Turner syndrome often involves fertility challenges, but assisted
Recommendation Table 58 — Recommendations for
aortic surgery in women with Turner syndrome reproductive therapy has increased pregnancy rates. However, preg-
nancy in TS can elevate the risk of AD, particularly with additional
Recommendations Classa Levelb risk factors (Figure 40). Recent studies suggest improved pregnancy out-
comes due to better guideline adherence.1435,1436Prophylactic aortic
Elective surgery for aneurysms of the aortic root and/
root surgery in women with TS contemplating pregnancy is recom-
or ascending aorta should be considered in women mended when the ASI reaches 25 mm/m2.1337These decisions should
with TS who are ≥15 years of age, have an ascending
IIa C be made by an expert team in a shared-decision process.
ASI >23 mm/m2, an AHI >23 mm/m, a z-score >3.5, Physical exercise has a beneficial impact on CVD risk and HRQoL
and have associated risk factors for aortic dissectionc in TS.1437 Structural congenital heart defects and aortic diameters
or are planning pregnancy.70,1417,1421 (ASI, AHI and z-score) (Figure 40) need to be considered in the recom-
Continued mendations on the level of sports practice.1418
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 104 ---
ESC Guidelines 3641
10.1.2. Vascular Ehlers–Danlos syndrome 10.1.2.4. Surgical treatment
10.1.2.1. Diagnosis, clinical presentation, and natural history Acute, unexplained pain requires urgent imaging to exclude arterial
Vascular Ehlers–Danlos syndrome is a rare (prevalence of 1/50 000 to rupture. Acute arterial complications usually require hospitalization
1/200 000) autosomal dominant disease caused by pathogenic variants and a conservative approach in most cases. Interventional vascular or
in the COL3A1 gene, which encodes the pro-alpha1 chains of type III intestinal procedures are limited to vital risk. Procedures requiring or-
procollagen. The most common COL3A1 variants provoke a disruption gan inflation should be avoided or performed with extreme caution.
in the assembly of type III collagen fibrils, causing an important loss of There are no clear recommendations regarding aortic/arterial dia-
mechanical strength of arteries and other hollow organs, especially meters at which to intervene in patients with vEDS. Thus, decisions
the bowel and uterus.1438Identification of a causal COL3A1 variant is need to be made on a case-by-case basis.
a requirement for the diagnosis of vEDS.1439
vEDS is the most severe form of Ehlers–Danlos syndrome because 10.1.2.5. Pregnancy
of its clinical life-threatening vascular complications, making early iden- Pregnancy in vEDS incurs a risk of (fatal) arterial and uterine complica-
tification and a thorough family inquiry particularly crucial. tions. Pregnancy does not appear to affect overall mortality compared
Clinical complications may start during adolescence and repeat at un- with nulliparous vEDS women.1446However, patients need to be en-
predictable time intervals. The most common complications involve gaged in a shared-decision process, informed by vascular status and
medium-sized arteries: dissections, aneurysms, arterial ruptures, and underlying variant type.
arteriovenous fistulas. AD (both type A and B) occurs in up to 10%
of patients.1440
10.1.3. Marfan syndrome
Prognosis depends on the type of COL3A1 variant, with null variants
10.1.3.1. Diagnosis, clinical presentation, and natural history
(no gene product or absence of function) showing a better out-
Marfan syndrome, the most common syndromic HTAD condition
come.1441The rate of recurrence of organic complications in patients
(prevalence of 1/5000–1/10 000), arises from pathogenic fibrillin-1
with vEDS is 1.6 events per 5 year period. Life expectancy is reduced
gene (FBN1) variants. Beyond the CV system, multiple organ systems
to an average of 51 years.1442
are often affected, including the eyes and skeleton. Diagnosis relies
on recognizing clinical features in line with the revised Ghent nosology,
10.1.2.2. Surveillance and imaging which includes genetic testing.1447
Management of vEDS is complex and requires a multidisciplinary ap- Aortic aneurysm and dissection involving the aortic root are a
proach. Recommendations include: lifestyle modification to minimize hallmark of the disease. Less commonly, the descending thoracic
injury and risk of vessel/organ rupture, identification of a care team, in- and abdominal aorta may be involved. With increasing survival
dividualized emergency care plans, maintaining BP in the normal range, and age in MFS, the prevalence of TBAD seems to be increasing, ex-
aggressive hypertension treatment, and annual surveillance of the vas- ceeding type A dissection rates in recent reports.1448,1449 TBAD
cular tree by DUS, CCT (low radiation alternatives), or CMR (if feas- will often occur at diameters below surgical thresholds. Previous
ible).1439 A recent survey among European expert centres indicated aortic root replacement, mitral valve surgery, and a longer life
that arterial monitoring is standard clinical practice and that frequency span are associated with TBAD. Additional CV features include mi-
of follow-up should be adapted individually.1443 The prognosis im- tral valve prolapse, extra-aortic arterial involvement, myocardial
proves when patients are properly managed.1441 dysfunction, and arrhythmias.1393,1450–1452 Thanks to improved
diagnosis in earlier stages, proper management including surveil-
10.1.2.3. Medical treatment lance, medical treatment, and timely prophylactic aortic surgery,
life expectancy in MFS patients is now approaching that of the gen-
Medical management is based on optimal BP control. Celiprolol, a BB eral population.1416,1453
with vasodilatory properties, has been shown to reduce vascular mor-
bidity in two retrospective studies1441,1444and one randomized, open- The major determinant of TAAD is the aortic root diameter, with
label trial.1445There is no consensus about the age at which to start increased risk of rupture when it exceeds 50 mm.1454Other risk fac-
tors include family history of AAS at low diameter, aortic root growth
treatment, but starting after 10 years of age is considered reasonable
rate (annualized growth rate ≥3 mm or more in adults), pregnancy, and
by many experts.
hypertension (hypertension persisting notwithstanding three or more
antihypertensive medications prescribed by a physician with experience
Recommendation Table 59 — Recommendations for in hypertension treatment). Increasing evidence for variant-based dif-
medical treatment in patients with vascular Ehlers– ferences in aortic risk is emerging and may be considered.1413,1416
Danlos syndrome (see also Evidence Table 13)
10.1.3.2. Imaging surveillance
Recommendations Classa Levelb
Transthoracic echocardiography is the appropriate imaging modality
In patients with vEDS, regular vascular surveillance of for initial evaluation and follow-up of the aortic root in most patients
the aorta and peripheral arteries by DUS, CCT, or I C and allows evaluation of the distal segments of the aorta in many.
CMR is recommended.1439,1443 Also, TTE is useful for assessing mitral and aortic valve regurgitation, mi-
Treatment with celiprolol should be considered in tral valve prolapse with/out annular disjunction, and LV dysfunction. In
IIa B
patients with vEDS.1441,1444,1445 some cases (especially when pectus abnormalities are present) TTE
windows may be suboptimal, and CMR (preferably)/CCT may be pre-
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; ferred. Periodical evaluation of the global aorta and peripheral arteries
DUS, duplex ultrasound; vEDS, vascular Ehlers–Danlos syndrome.
aClass of recommendation. with CMR/CCT and DUS (every 3–5 years based on the patient’s evo-
bLevel of evidence. lution) is indicated since they also present a higher incidence of
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 105 ---
3642 E S C G u id e l in e s
peripheral aneurysms,1455which are associated with more aggressive Recommendation Table 61 — Recommendations for
forms of the disease.1393CMR is preferred over CCT to avoid radiation medical treatment in Marfan syndrome (see also
exposure; however, its use should be adapted to local availability/ex- Evidence Table 14)
pertise. Additionally, CMR allows evaluation of biomechanical and
Recommendations Classa Levelb
haemodynamic parameters that can be useful in risk stratifica-
tion.181,1456,1457Given its superior spatial resolution, CCT may be re- In patients with MFS, treatment with either a BB or
commended for pre-operative planning and in cases of measurement
an ARB, in maximally tolerated doses (unless
inconsistency. Imaging of intracerebral vessels is indicated in cases of I A
contraindicated), is recommended to reduce the rate
symptoms and/or clinical manifestations of aneurysms/rupture. of aortic dilatation.1461,1462
Recommendations for imaging surveillance are illustrated in Figure 41
In patients with MFS, the use of both a BB and an
and should be adjusted to the individual patient, taking the history
ARB, in maximally tolerated doses (unless
and presence of abnormalities during preceding studies into account. IIa A
contraindicated), should be considered to reduce the
rate of aortic dilatation.1463,1464
Recommendation Table 60 — Recommendations for ARB, angiotensin receptor blocker; BB, beta-blocker; MFS, Marfan syndrome.
vascular imaging in Marfan syndrome aClass of recommendation.
bLevel of evidence.
Recommendations Classa Levelb
In patients with MFS, TTE is 10.1.3.4. Aortic surgery
recommended:70,171,1458,1459 Open surgery is preferred over endovascular procedures in patients
• At least annually in patients with an aortic root with MFS. Endovascular procedures may be considered in selected
diameter <45 mm in the absence of additional risk cases in emergency settings and/or in centres with a high level of ex-
factorsc pertise.1465The thresholds for aortic root surgery need to take add-
• At least every 6 months in patients with an aortic I C itional risk factors, as well as the expertise of the team, into account.1466
root diameter <45 mm in the presence of
additional risk factorsc
Recommendation Table 62 — Recommendations for
• At least every 6–12 months in patients with an
aortic surgery in Marfan syndrome
aortic root diameter ≥45 mm in the absence of
additional risk factorsc Recommendations Classa Levelb
In patients without previous aortic surgery, complete
Surgery is indicated in patients with MFS who have
peripheral vascular and thoracoabdominal aorta
aortic root disease with a maximal aortic sinus I B
imaging by CMR or CCT and DUS is recommended I C
diameter ≥50 mm.70,172,1466–1468
at the first evaluation, and subsequently every 3–5
Surgery to replace the aortic root and ascending
years if stable.70,1455,1459
aorta, using the valve-sparing surgery technique, is
In patients with MFS who have undergone aortic root
recommended in patients with MFS or related
replacement, surveillance imaging of the thoracic I B
I C HTAD with aortic root dilatation when anatomical
aorta by CMR (or CCT) is recommended at least
features of the valve allow its preservation and the
every 3 years.70,1458
surgeon has specific expertise.70,1466,1469
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; Surgery should be considered in patients with MFS
DUS, duplex ultrasound; MFS, Marfan syndrome; TTE, transthoracic echocardiography.
who have an aortic root aneurysm with a maximal aClass of recommendation. IIa C
bLevel of evidence. aortic sinus diameter ≥45 mm and additional risk
cRisk factors: aortic root diameter >40 to ≤45 mm and family history of aortic dissection at factors.c,1467,1469
small aortic dimensions (i.e. <50 mm); resistant hypertension (hypertension persisting
In patients with MFS and an aneurysm of the
notwithstanding three or more antihypertensive medications prescribed by a physician
with experience in hypertension treatment); and rapid growth of the aorta (annualized ascending aorta, aortic arch, descending thoracic
growth rate ≥3 mm or more in adults). aorta, or abdominal aorta of ≥50 mm, surgical IIa C
replacement of the aneurysmal segment by a surgeon
with specific expertise should be considered.1467,1469
10.1.3.3. Medical treatment
Medical treatment is described in Recommendation Table 61. Some HTAD, heritable thoracic aortic disease; MFS, Marfan syndrome.
aClass of recommendation.
caution may be warranted with the use of CCBs: these have shown an bLevel of evidence.
increased aortic risk in a mouse model and in retrospective case con- cFamily history of aortic dissection at small aortic dimensions (i.e. <50 mm); resistant
trol studies,1460 and alternatives are preferred for hypertension hypertension (hypertension persisting notwithstanding three or more antihypertensive
medications prescribed by a physician with experience in hypertension treatment); and
treatment.
rapid growth of the aorta (annualized growth rate ≥3 mm or more in adults).
4202CSE©
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 106 ---
ESC Guidelines 3643
10.1.3.5. Pregnancy and physical exercise programmes, two studies1484,1485 evidenced that physical activity, up
In pregnant MFS women, the risk of AD increases up to eight times to a moderate specific intensity, may be recommended. Thus, although
relative to the general population.1470The risk for TAAD is deter- physical activity poses a dilemma, individualized adapted programmes
mined by the aortic diameter, but type B dissections tend to occur are most likely successful in encouraging exercise in MFS.
even more commonly and may occur without prior dilata-
tion.1470,1471 Patients should be aware of the persisting risk of
Recommendation Table 64 — Recommendations for
TBAD after aortic root replacement.1471 Women unaware of the
physical exercise in patients with Marfan syndrome
diagnosis are at the highest risk of dissection.1470–1472
The Registry Of Pregnancy And Cardiac disease (ROPAC) indicates Recommendations Classa Levelb
that women managed according to guidelines are at low risk of
pregnancy-related complications and major effects of BBs on foetal It is recommended to individualize physical activity in
growth were not shown, although this needs to be carefully patients with MFS based on aortic diameter, family I C
monitored.70,1337,1435,1471,1472 history of aortic dissection, and pre-existing fitness.
Regular moderate aerobic exercise with a level of
Recommendation Table 63 — Recommendations for intensity informed by aortic diameter is I C
pregnancy in women with Marfan syndrome recommended in most patients with MFS.
For patients who present with aortic dissection and/
Recommendations Classa Levelb
or have undergone aortic surgery, post-operative
It is recommended that all women with MFS: cardiac rehabilitation aiming at improving both IIa B
• Have a pre-conception evaluation to address the physical and mental health should be
risks of maternal CV and other complications I C considered.73,1483,1484,1486
• Have follow-up in a centre with access to a
MFS, Marfan syndrome.
pregnancy heart and vessel team.1473 aClass of recommendation.
It is recommended that couples in which a partner bLevel of evidence.
has or is at risk for HTAD be offered pre-conception I C
genetic counselling. 10.1.4. Other syndromic and non-syndromic
Imaging of the whole aorta (by CMR/CCT) is heritable thoracic aortic diseases and/or arterial
I C
recommended prior to pregnancy. disorders
Follow-up during pregnancy is recommended with a Main clinical and genetic data of known syndromic and non-syndromic
frequency determined by aortic diameter and I C HTAD entities are summarized in the Supplementary data online,
growth.1337,1474,1475
Table S5. The two most prevalent diseases for each entity include
Intake of BBs during pregnancy is recommended.1476 I C Loeys–Dietz syndrome and ACTA2-related HTAD, respectively. Given
Prophylactic aortic root surgery is recommended in the rarity of these entities, specific recommendations regarding surveillance
women desiring pregnancy with aortic diameters I C and treatment are lacking and largely adopted from the recommendations
>45 mm.1435,1472 for MFS. Some disease-specific recommendations are mentioned below.
Prophylactic aortic root surgery may be considered
in women desiring pregnancy with aortic diameters IIb C
10.1.4.1. Loeys–Dietz syndrome
of 40–45 mm.1472,1475,1477
10.1.4.1.1. Diagnosis, clinical presentation, and natural evolution.
ARBs are not recommended during pregnancy.1478–1480 III B
The spectrum of clinical presentations in Loeys–Dietz syndrome is very
ARBs, angiotensin receptor blockers; BBs, beta-blockers; CCT, cardiovascular computed wide. Some patients fulfil criteria for MFS,1447while some features such
tomography; CMR, cardiovascular magnetic resonance; CV, cardiovascular; HTAD, as bifid uvula and hypertelorism are very specific to the disease. Clinical
heritable thoracic aortic disease; MFS, Marfan syndrome.
manifestations are listed in the Supplementary data online, Table S5.
aClass of recommendation.
bLevel of evidence. There is a tendency for AD and rupture at lower vessel dimensions
than is typically seen in other similar conditions.1390,1487Pathogenic var-
Exercise is potentially associated with an increased risk of aortic dila- iants in six genes (TGFBR1 and TGFBR2, TGFB2 and TGFB3, SMAD2 and
tation and AAD. It is recommended to individualize physical activity in SMAD3), all encoding components of the TGF-ß signalling pathway, cause
MFS based on aortic diameter, family history of dissection or sudden Loeys–Dietz syndrome. Differences in clinical manifestations and aortic
death, and pre-existing fitness status.71 Although competitive sports outcome according to the underlying gene and the extent of extra-aortic
are contraindicated, moderate aerobic exercise is recommended features have been reported and need to be considered in surveillance
with a level of intensity based on aortic diameters.71 and defining thresholds for surgery.1388,1390,1391
Two studies1481,1482 showed that mild-moderate dynamic exercise Surveillance in Loeys–Dietz syndrome is described in
improved aortic wall structure and function and reduced aortic growth Recommendation Table 65 and Figure 41. Although the indication for
rate in MFS mouse models. Recent data in MFS children and young adults surgery must be considered according to the underlying genetic defect
indicate that adhering to daily physical exercise (10 000 steps a day) had and the presence of risk factors (Recommendation Table 66 and
a beneficial effect on aortic root growth.1483Although a limited number Figure 42), a 45 mm aortic diameter threshold should be considered
of clinical studies have evaluated physical activity rehabilitation (≥40 mm in cases of associated high-risk features).
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 107 ---
3644 E S C G u id e l in e s
Aortic root/
ascending 35 mm 40 mm 42 mm 45 mm 50 mm
diameter (mm)
Baseline CMR/CCT
Every 6–12 months
Marfan/FBN1 TTE yearly Surgery if
CCTa risk factorsb
(Class IIa)
Surgery
CCTa
(Class I)
CMR/CCT every 3–5 years
Baseline CMR/CCT
Every 6–12 months
Loeys-Dietz/
TTE yearly Surgery if
TGF-ß genes
CCTa risk factorsb
(Class IIb)
Surgery
CCTa
(Class IIa)
CMR/CCT head-to-pelvis every 1–3 years
Baseline CMR/CCT
ACTA2/
TTE yearly Surgery
SMC genes CCTa
(Class IIa)
CMR/CCT every 3–5 years
TTE Follow-up
Figure 41 Algorithm for imaging surveillance in patients with syndromic and non-syndromic heritable thoracic aortic disease. CCT, cardiovascular
computed tomography; CMR, cardiovascular magnetic resonance; DUS, duplex ultrasound; HTAD, heritable thoracic aortic disease; SMC, smoth mus-
cle cell; TTE, transthoracic echocardiography. aPre-surgical CCT. bSee respective tables of recommendations for aortic surgery in Marfan (Table 62) and
Loeys-Dietz syndrome (Table 66).
Recommendation Table 65 — Recommendations for Recommendation Table 66 — Recommendations for
imaging follow-up in Loeys–Dietz syndrome aortic root surgery in Loeys–Dietz syndrome
Recommendations Classa Levelb Recommendations Classa Levelb
In patients with Loeys–Dietz syndrome, TTE at baseline Aortic root replacement should be considered
and subsequently every 6–12 months, depending on I C for patients with Loeys–Dietz syndrome if the
IIa C
aortic diameter and growth,c is recommended.70,1390,1488 aortic root diameter exceeds
In patients with Loeys–Dietz syndrome, a baseline 45 mm.1388,1390,1489–1492
arterial imaging study from head to pelvis with CMR or It may be considered to adjust the threshold for
I C
CCT and subsequent surveillance with CMR or CCT or surgery according to the underlying gene, taking IIb C
DUS every 1–3 years is recommended.70,1488 associated risk featuresc into account.1391
CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance; aClass of recommendation.
DUS, duplex ultrasound; TTE, transthoracic echocardiography. bLevel of evidence.
aClass of recommendation. cHigh-risk features include certain specific pathogenic variants; women with TGFBR2
bLevel of evidence. variants and small body size; severe extra-aortic features; family history of aortic
cMore frequent imaging if aortic root/ascending diameter >42 mm and aortic growth rate dissection (especially at young age or relatively small aortic diameter); and aortic growth
≥3 mm per year. rate ≥3 mm per year.
4202CSE© 4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 108 ---
ESC Guidelines 3645
Aortic root Aortic root
surgery if surgery
risk factors
(see box
below)
TGFBR2a,b TGFBR2a
TGFBR1a TGFBR1a
35 mm 40 mm 45 mm 50 mm 55 mm
SMAD3c,d TGFB3h,i
TGFB2e,f,g
Consider Consider
aortic root aortic root
surgery surgery
High risk features include:
Known high risk genetic variants (R528H/C in TGFBR2) Family history of aortic dissection (especially at
Women with TGFBR2 variants and small body size young age or relatively small aortic diameter)
Severe extra-aortic features Aortic growth rate ≥3mm per year
Figure 42 Suggested thresholds for prophylactic aortic root/ascending replacement in Loeys–Dietz syndrome. From a1388, b1391, c1492, d1491, e1490,
f1489, g1493, h1494, i1495.
10.1.4.2. ACTA2-related heritable thoracic aortic disease Recommendation Table 67 — Recommendations for
imaging and surgery in ACTA2-related heritable thoracic
Pathogenic variants in the ACTA2 gene, encoding for smooth muscle-
aortic disease (see also Evidence Table 11)
specific alpha-actin (a critical component of the vascular smooth
muscle cell contractile apparatus), lead to aortic aneurysms and dis- Recommendations Classa Levelb
sections in non-syndromic patients.1496 Patients primarily present
with type A or B aortic dissection, and with aneurysms that involve Annual monitoring of the aortic root/ascending aorta
the root and/or ascending aorta. A subset of pathogenic variants pre- with TTE to evaluate aortic root/ascending aorta I C
disposes to occlusive vascular diseases.1497Surveillance is summarized enlargement is recommended.1498
in Recommendation Table 67 and Figure 41. TAAD may occur at Imaging of the aorta with CMR/CCT every 3–5 years
I C
aortic diameters <45 mm, and consideration of surgery at diameters is recommended.1498
<45 mm should be informed by the presence of additional clinical and
Prophylactic aortic root surgery should be
genetic risk factors.1410 Genetic and imaging cascade screening of
considered with an aortic diameter ≥45 mm, or IIa C
first-degree family members is an essential element of care, as treat-
lower in cases with other risk factors.c,1499
able disease may otherwise be missed in family members—with fatal
consequences. CCT, cardiovascular computed tomography; CMR, cardiovascular magnetic resonance;
TTE, transthoracic echocardiography.
aClass of recommendation.
bLevel of evidence.
cRisk factors for aortic dissection: family history of dissection with no or minimal dilatation
or young age; rapid growth ≥3 mm per year.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 109 ---
3646 E S C G u id e l in e s
10.2. Aortic disease associated with morphological and clinical heterogeneity (bicuspid valvulo-aortopathy).
bicuspid aortic valves Its inheritance is high, with autosomal dominant transmission of BAV in
a minority of cases, but no single-gene model clearly explaining BAV
Bicuspid aortic valves, the most common congenital heart defect inheritance.1500–1502Several genes, generally implicated in embryogenesis
(0.5%–2% of live births), besides being a risk factor for aortic valve dis-
and cell differentiation, have been associated with BAV/BAV-related aor-
ease, is associated with a peculiar form of aortopathy, characterized by topathy, but each of them explained <5% of cases.1503–1507Therefore,
Aortic phenotypes
Ascending phenotype
BAV morphologies
(70–75%)
Fused BAV (90–95% of BAV) 3 phenotypes
Right - left cusp fusion Right - non cusp fusion Left - non cusp fusion
(70–80%) (20–30%) (3–6%)
Root phenotype
(15–20%)
2-sinus BAV (5–7% of BAV) 2 phenotypes
Laterolateral Anteroposterior
1 2a 2b
A A
L
L
P P
Extended phenotype
(5–10%)
Partial-fusion BAV - short fusion of 1 commisure
Figure 43 Bicuspid aortic valve, valvulo-aortopathy nomenclature. Modified from Michelena et al.1510A, anterior; BAV, bicuspid aortic valve; L, lateral;
P, posterior. Although preferential associations exist, each of the three valve types—‘fused BAV’, ‘2-sinus BAV’, and ‘partial-fusion BAV’—can be vari-
ably associated with dilatation predominantly located at the sinuses of Valsalva (‘root phenotype’, 15%–20%) or at the tubular (supra-coronary) tract
(‘ascending phenotype’, 70%–75%). A minor proportion of patients present with equal dilatation of the sinusal and tubular segments or ascending dila-
tation extending into the proximal arch (‘extended phenotype’, 5%–10%).
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 110 ---
ESC Guidelines 3647
genetic testing is not indicated for isolated BAV disease, but reserved 50 mm faced a 1% risk of AAEs within 5 years, compared with
for patients with syndromic features, family history of aortic disease, 0.1% for those with 40 mm diameters, explaining the 10-fold differ-
or aneurysms/dissections of medium-sized arteries other than the ence; however, this study did not exclusively involve BAV patients.894
thoracic aorta, and may be considered in patients with the root Another recent study1520specifically focused on BAV patients found
phenotype.1389,1508,1509 a 0.4% incidence of AAEs per patient-year for diameters above
We recommend adopting a new international consensus nomencla- 50 mm, in contrast to the general BAV population’s 0.03% inci-
ture and classification, established by a panel of experts, to replace the dence.1521 Previous guidelines also suggested aortic repair for a
previous various concurrent nomenclatures used1510 (Figure 43). cross-sectional area-to-height ratio (CSA/h) >10 cm2/m;70neverthe-
Aneurysm prevalence reaches 40% in clinical series and 0.85 per 100 less, more recently, it has been suggested that the CSA/h threshold
patient-years in population studies. AAEs are rare, but 8- to 10-fold for the ascending tract in BAV should be 13 cm2/m.981For the aver-
more frequent than in the general population.1001,1511 The longest age height of male and female Europeans (1.8 m and 1.67 m, respect-
available follow-up of BAV subjects was recently reported,1512showing ively), a CSA/h of 10 cm2/m would correspond to a diameter of
a total lifetime morbidity burden as high as 86%, a predominant part of 48 mm or 46 mm, respectively, whereas 13 cm2/m means 54 mm
which was driven by valve-related complications (aortic stenosis, endo- or 53 mm. It is reasonable to refer to the 13 cm2/m CSA/h cut-off
carditis, HF). for ascending aortic repair, especially in individuals ≤1.69 m in height
When a BAV is first detected, a complete study of the thoracic aorta (since 13 cm2/m corresponds to ≤52 mm diameter). Recently, be-
is necessary; vice versa, in every patient with ascending aortic dilatation, sides dilatation, aortic elongation is also considered a risk factor,974
valve morphology should be ascertained.70,969 When TTE detects and a curvilinear length >11.5 cm at the vessel’s centreline increases
BAV-associated aortic dilatation, CCT or CMR is recommended to the yearly risk of AAEs.155Age is another factor to consider: at 50
confirm measurements, exclude coarctation, and record baseline dia- years, a 40 mm ascending aorta corresponds to the upper normal
meters at different levels for subsequent periodic assessments.137,1001 limit for patients with large body size,149 and therefore the same
Surveillance by TTE becomes necessary when the maximum diameter diameter at a higher age could imply a lower risk of AAEs.
exceeds 40 mm. In mixed tricuspid aortic valve (TAV) and BAV series,
AAEs occurred in 2/10 000 patient-years with a diameter >40 mm (vs. Recommendation Table 68 — Recommendations for
0.1–0.3/10 000 patient-years in the general population)894(Figure 43). bicuspid aortic valve-associated aortopathy management
Considering average aortic diameter growth of 0.2–0.6 mm per
year,893,1513once fast progression is excluded, follow-up can be sched- Recommendations Classa Levelb
uled every 2–3 years (according to risk profile). In 5%–15% of cases,
When a BAV is first diagnosed, initial TTE to assess
BAV patients have at least one FDR with either BAV or ascending aortic diameters of the aorta at several levels is I B
dilatation; root phenotype and aortic regurgitation in the proband pre- recommended.1001,1510,1522
dict ascending dilatation in FDRs.1514FDR screening is considered cost- Surgery for bicuspid aortopathy is recommended
effective, but the age at which relatives should undergo TTE remains to when the maximum aortic diameter is I B
be determined.1515,1516 ≥55 mm.70,172,899,969,1001
A diameter exceeding 55 mm at any level mandates sur- Surgery for bicuspid aortopathy of the root
gery.70,969,1001However, the historically known relation between diam- phenotypec is recommended when the maximum I B
eter and acute complications has been recently reappraised. Both in aortic diameter is ≥50 mm.70,893,981,986,1001,1519,1523
large mixed153 and purely BAV series,981 an ascending diameter of CCT or CMR of the entire thoracic aorta is
about 52 mm already marked an AAE risk increase from ∼1% to recommended at first diagnosis and when important
4%–5%. Additionally, early post-operative mortality for elective surgery discrepancies in measurements are found between I C
of the proximal aorta ranges today between 0.25% and 2%.980,981 subsequent TTE controls during surveillance, or when
Therefore, aortic surgery in low surgical risk (<3%) patients with an as- the diameter of the aorta exceeds 45 mm.1001,1510
cending diameter >52 mm implies a lower risk than observed in the Screening by TTE in FDRs of BAV patients with root
natural history of the disease. For aortic root dilatation in BAV patients, phenotypec aortopathy and/or isolated aortic I C
the ‘hinge point’ was at 50 mm;981this phenotype is associated with fas- regurgitation is recommended.1001,1510,1514
ter growth rate,893higher risk of events following isolated aortic valve Surveillance serial imaging by TTE is recommended in
replacement,1517worse survival if not operated,1518and higher risk of BAV patients with a maximum aortic diameter
acute TAAD.976,1519 >40 mm, either with no indication for surgery or I C
Surgery should be considered when the diameter is ≥50 mm in se- after isolated aortic valve surgery, after 1 year, then if
lected ascending phenotype patients (Figures 23, 24 and 43).70,1001 stability is observed, every 2–3 years.70,1001
Among those factors, family history of AAEs, poorly controlled hyper- Screening by TTE in FDRs of all BAV patients should
IIa B
tension, aortic coarctation, and rapid (≥3 mm per year) diameter be considered.70,1001,1500,1510,1515
growth should be noted. Surgery at >50 mm may also be considered In patients with low surgical risk, surgery for bicuspid
in a shared decision with the patient, taking lifestyle and psychological aortopathy of ascending phenotyped should be
IIa B
factors into consideration,70,1001 since 50 mm should correspond to considered when the maximum aortic diameter is
an approximately 10-fold increase in the risk of AAEs.894In a study >52 mm.153,172,981
of patients with aortic diameter ≥40 mm, those with diameters of Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 111 ---
3648 E S C G u id e l in e s
In patients with low surgical risk and ascending significant CoA. In the presence of collaterals or decreased LV function, gra-
phenotype bicuspid aortopathy, surgery should be dients or ABI may underestimate severity. A diastolic tail in the DTA or ab-
dominal diastolic antegrade flow by TTE is suggestive of significant
considered at a maximum diameter ≥50 mm if any of
the following is the case:70,153,155,981,1001 narrowing. Criteria to consider significant CoA are listed in Figure 44. TTE
is also useful to detect LV hypertrophy, which is a marker of disease.
• Age <50 years
CMR and CCT are the preferred imaging techniques, depicting the narrow-
• Shorter staturee
ing as well as the surrounding anatomy, necessary for interventional
• Ascending aortic length ≥11 cmf IIa C
decision-making.
• Aortic diameter growth rate ≥3 mm per yearg
• Family history of acute aortic syndrome
• Aortic coarctation 10.3.1.2. Treatment and follow-up
• Resistant hypertensionh In native CoA and re-coarctation (Figure 44) covered stenting is the first-
• Concomitant non-aortic-valve cardiac surgery choice treatment. Interposition of a tube graft is the preferred surgical
• Desire for pregnancy therapy if stenting is less suitable.1529Hypertension remains an important
Surgery for bicuspid aortopathy in patients complication, even after successful treatment, and is more common when
undergoing aortic valve surgery should be considered IIa C the initial repair is performed in adulthood.1528Right arm 24 h ambulatory
at a root or ascending diameter ≥45 mm.70,172,969 BP measurement or exercise tests better detect hypertension.1530,1531
All CoA patients require lifelong follow-up.1532Imaging of the aorta with
BAV, bicuspid aortic valve; BP, blood pressure; CCT, cardiovascular computed tomography;
CMR/CCT every 3–5 years, adjusted to previous imaging findings and type
CMR, cardiovascular magnetic resonance; CSA/h, cross-sectional area-to-height ratio; FDRs,
of intervention, is required to document post-repair or post-interventional
first-degree relatives; TTE, transthoracic echocardiography.
aClass of recommendation. complications (such as re-coarctation). Patch repairs are at particular risk
bLevel of evidence. of repair-site para-anastomotic aneurysms or pseudo-aneurysms, the lat-
cRoot phenotype = aortic dilatation with sinus diameter > tubular diameter. ter possibly occurring following interposition grafts as well.1533
dAscending phenotype = aortic dilatation with tubular diameter > sinus diameter.
ePatient height between 1.50 and 1.69 m (yielding a CSA/h ratio >13 cm2/m).
fCurvilinear distance at aortic centreline between the ventriculo-aortic junction and the origin
of the innominate artery.
gIn order to ascertain real rapid growth, side-by-side re-evaluation of images obtained with the Recommendation Table 69 — Recommendations for
evaluation and medical treatment of patients with
same modality and technique should be performed.
hHypertension persisting notwithstanding three or more antihypertensive medications coarctation of the aorta
prescribed by a physician with experience in hypertension treatment, including diuretics.
Recommendations Classa Levelb
In patients with native or repaired coarctation, lifelong
follow-up is recommended, including regular imaging
I B
of the aorta with CCT/CMR every 3–5 years (adapted
10.3. Coarctation of the aorta and aortic
to clinical status and previous imaging findings).1534,1535
arch variants
Coarctation or re-coarctation repair (either surgical or
10.3.1. Coarctation of the aorta endovascular) is indicated in patients with hypertension
with an increased non-invasive gradient between the
This topic is extensively discussed in the ESC 2020 Guidelines for the man- I C
agement of adult congenital heart disease.1468 Coarctation of the aorta upper and lower limbs (decreased ABI) confirmed with
invasive measurement (peak-to-peak >20 mmHg), with
(CoA) manifests as a discrete stenosis or a hypoplastic segment typically a preference for stenting when technically feasible.1536
located at the insertion of the ductus arteriosus. More distal locations
In patients with coarctation, BP measurements at both
are known as mid-aortic syndrome and require dedicated manage- I C
arms and one lower extremity are recommended.
ment.1524Associated lesions include BAV (up to 50%–85%), intracereb-
ral aneurysms (10%), and ascending aortic aneurysms.1525,1526CoA may It is recommended to treat hypertension in patients
with coarctation according to ESC hypertension I C
be associated with syndromes such as TS. Research indicates that up to
guidelines.300
12.6% of females diagnosed with CoA also have TS, and coarctation is
Endovascular treatment should be considered in observed in 7%–18% of patients with TS.1417,1468,1527
patients with hypertension with >50% narrowing
relative to the aortic diameter at the diaphragm, even IIa C
10.3.1.1. Diagnostic work-up
if the invasive peak-to-peak gradient is <20 mmHg,
Mild cases of CoA may only become evident in adulthood. Symptoms when technically feasible.1537
reflect pre-stenotic hypertension (e.g. headache, nosebleeds) and post-
Endovascular treatment should be considered in
stenotic hypoperfusion (e.g. abdominal angina and claudication). The
normotensive patients with an increased non-invasive
natural course is largely driven by hypertension-related complications, in- IIa C
gradient confirmed with invasive peak-to-peak gradient
cluding HF, intracranial haemorrhage, premature coronary/cerebral artery >20 mmHg, when technically feasible.1468
disease, and aortic rupture/dissection.1528Presently, there is no evidence
supporting screening for intracerebral aneurysms in asymptomatic patients. ABI, ankle–brachial index; BP, blood pressure; CCT, cardiovascular computed tomography;
CMR, cardiovascular magnetic resonance; ESC, European Society of Cardiology.
A systolic non-invasive gradient between upper and lower extremities, an aClass of recommendation.
abnormal ABI, or an invasive peak-to-peak gradient ≥20 mmHg indicates bLevel of evidence.
4202CSE©
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 112 ---
ESC Guidelines 3649
Suspicion of significant (re)coarctation: any of the following:
A N BPo n gr i an dv ia es niv t e > ( 2r 0ig mht m a Hrm g-to-leg) A C E > >3 25 0 m mm mH Hg g p me ea ak n g gr ra ad die ien nt t
>50% narrowing on any
B
imaging modality
Abdominal antegrade
C
diastolic flow on DUS
Diastolic run off in the
D B D F
descending thoracic aorta on DUS
Mean gradient >20 mmHg D mL/s Post CoAo
E
across the CoA region on DUS
Pre CoAo
Collateral flow >30% >30% increase F
on phase contrast CMR
Y N
Perform (Re)coarctation
catheterization not likely
≥20 mmHg <20 mmHg
BP measurement BP measurement
and investigationa and investigationa
HTN HTN
N Y N
Intervention Intervention ≥50% narrowing
(Class IIa) (Class I) on any imaging modality
N
Intervention Surveillance: TTE every year
(Class IIa) and CMR or CCT 3–5 years
Figure 44 Criteria for significant coarctation/re-coarctation of the aorta and management algorithm. BP, blood pressure; CCT, cardiovascular com-
puted tomography; CMR, cardiovascular magnetic resonance; CoA, coarctation of the aorta; DUS, duplex ultrasound; HTN, hypertension; TTE, trans-
thoracic echocardiography. aDiagnosis of hypertension may require confirmation with ambulatory BP measurement and should also be considered in
cases of exercise-induced hypertension and/or left ventricular hypertrophy on TTE.
Y
Y
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 113 ---
3650 E S C G u id e l in e s
10.3.2. Aortic arch anatomic variants 11. Polyvascular peripheral arterial
A type I arch, where the three great vessels directly arise from the aor- disease and peripheral arterial
ta, is the most common form, occurring in about 70% of the population.
disease in patients with
The type II (bovine) arch is the most frequent variant: type II-A (9% of
the population) has the left common carotid artery arising from the in- cardiac diseases
nominate artery, and type II-B (13% of the population) has both the in-
nominate and left common carotid arteries originating from a common 11.1. Polyvascular disease
point on the aortic arch.1538,1539Limited data suggest that a bovine arch
Polyvascular disease is defined as the simultaneous presence of clinically
is associated with a higher risk of aortic dilation and aortic events/com-
relevant obstructive atherosclerotic lesions in at least two major arter-
plications.1540,1541These variations are important to report as they can
ial territories.
impact specific medical procedures and diagnostic interpretations.
10.3.3. Aberrant subclavian artery and Kommerell’s 11.1.1. Epidemiology and prognosis
diverticulum Approximately 1 in 4–6 patients with atherosclerosis have PVD
The most common variant is the aberrant right subclavian artery, where (Figure 45).620,1545 According to the REACH registry, patients with
the right subclavian artery arises as the last branch of the aortic arch, PAD were most likely both to have PVD at baseline and to develop
usually after the left subclavian artery, and often passes behind the PVD over the observational period.1546,1547
oesophagus through the mediastinum, potentially causing dysphagia PVD independently increases major CV event risk, roughly doubling
lusoria, respiratory symptoms, or recurrent laryngeal nerve palsy. it compared with single arterial bed symptoms.1547–1549Event rates rise
The less common variant, the aberrant left subclavian artery, is typically with the number of affected arterial beds.1546,1550
associated with congenital heart defects, such as a right aortic arch.
However, in adulthood, both variations are often incidental findings.1542
Kommerell’s diverticulum is a remnant of the fourth dorsal aortic 11.1.2. Screening for atherosclerosis in other arterial
arch due to incomplete regression, found in 20%–60% of those with territories
an aberrant subclavian artery.1543 Surgical intervention is advised for Screening for PVD in atherosclerotic patients relies on medical
a diverticulum orifice >30 mm or combined diverticulum and adjacent history, clinical exam, and ABI measurement. If suspected, start with
descending aorta diameter >50 mm, or both.1544Successful repair has non-invasive DUS, followed by CTA/MRA if needed.1557 Assessing
been described using open, endovascular, or hybrid approaches de- concurrent atherosclerosis in other vascular regions is detailed in
pending on anatomy, comorbidities, and expertise.1543 Table 17.
70%
61%
60%
40%
39%
22% 23%
25%
20% 16% 19%
15%
18%
9%
14%
10%
0% 5% 7% 4%
CAD Carotid stenosis >70% PAD (ABI ≤0.90)
CAD Carotid stenosis >70% PAD (ABI ≤0.90) RAS >70%
Figure 45 Reported rate ranges of other localizations of atherosclerosis in patients with a specific arterial disease. The graph reports the rates of
concomitant arterial diseases in patients presenting an arterial disease in one territory (e.g. in patients with CAD, 5%–9% of cases have concomitant
carotid stenosis >70%). Adapted from 2017 ESC Guidelines on PAD.77,493,784,1549,1551–1556ABI, ankle–brachial index; CAD, coronary artery disease;
PAD, peripheral arterial disease; RAS, renal artery stenosis.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 114 ---
ESC Guidelines 3651
Table 17 Need for assessment of associated atherosclerotic disease in additional vascular territories in symptomatic pa-
tients with coronary artery disease, peripheral arterial disease, or carotid stenosis
Leading disease
Assessment in CAD PAD Carotid stenosis
other vascular
territories
CAD May be helpful to optimize medical treatment431and Consider in patients scheduled for
to be considered in patients scheduled for open carotid endarterectomy and
vascular surgery with poor functional capacity or suspected CAD.1558
significant risk factors or symptoms. 1080
PAD Potential benefits in identifying
high-risk patients and guiding
treatment decisions.429,1559–1561
Carotid stenosis Useful in patients undergoing elective
CABG.1555,1562
CABG, coronary artery bypass grafting; CAD, coronary artery disease; PAD, peripheral arterial disease.
11.1.2.1. Screening for coronary artery disease in patients with recently symptomatic patients with unstable neurological symptoms
symptomatic peripheral arterial disease in whom carotid revascularization should be prioritized.680
The morbidity and mortality of patients with PAD is high due to CV
complications. Given high CAD event rates in patients with PAD, 11.1.2.4. Screening for carotid stenosis in patients with coronary
CAD screening may be helpful to optimize medical treatment and is artery disease
not intended to increase the rate of coronary interventions.431 Carotid artery stenosis screening may be useful in patients undergoing
Evaluation can be performed by stress testing or CCT; however, there elective CABG. Ischaemic stroke after CABG is multifactorial,1567but
is no evidence that systematic screening for CAD in stable PAD im- also depends on the degree of carotid disease.1556Two studies suggest
proves outcomes. Coronary angiography is less suitable due to invasive- that limiting DUS to patients with at least one risk factor (age >65
ness. In patients requiring lower-limb revascularization, CAD years, history of cerebrovascular disease, presence of a carotid bruit,
management should be based on the 2022 ESC Guidelines on cardiovas- multivessel CAD or PAD) identifies most patients with significant
cular assessment and management of patients undergoing non-cardiac (≥70%) CS.1555,1562Nevertheless, addition of CEA to CABG is unlikely
surgery.1080 to provide significant stroke reduction. In a study in patients with CAD
with >80% CS undergoing staged or synchronous carotid procedures
11.1.2.2. Screening for peripheral arterial disease in patients with (two-thirds were neurologically asymptomatic and 73% had unilateral
coronary artery disease asymptomatic carotid stenosis), in-hospital stroke rates and 30 day
mortality were similar in patients treated with CABG + CEA and in In high-risk CAD patients with three-vessel disease or recent ACS, sys-
those treated with isolated CABG.1568Another study suggests that se- tematic screening for multisite atherosclerotic disease through ABI and
lective use of DUS should be considered before CABG in patients with
DUS of carotids, lower-extremity, and renal arteries did not improve
outcomes.1563 However, a subgroup analysis of the COMPASS trial a history of neurological events or PAD.1569
suggests potential benefits when adding vascular-dose rivaroxaban to
11.1.3. Management of patients with polyvascular
aspirin in stable patients with CAD and PAD, raising the question of
disease
whether identifying PAD in stable CAD patients could be advanta-
geous.429,1559In patients undergoing CABG, the presence of concomi- Polyvascular disease requires proactive management of all modifiable
tant PAD is associated with a three-fold risk of subsequent CV events risk factors through lifestyle changes and drug therapy. Scientific evi-
after CABG.1560,1561 The GSV should be spared whenever possible, dence suggests the benefit of intensified antithrombotic therapy, with
since the success of peripheral arterial revascularization in complex le- no increase in risk of bleeding.1570ILT offers comparable benefits for
sions is strongly associated with the availability of sufficient autologous PVD patients and those with single arterial territory disease.
venous segments.567,1564 However, the benefits of ILT in patients with PVD are not dependent
on baseline LDL-C.1571
11.1.2.3. Screening for coronary artery disease in patients with Revascularization should be reserved for symptomatic arterial terri-
tories, using the least invasive strategy in a multidisciplinary vascular
carotid stenosis
team approach.
Due to the high prevalence of CAD among patients scheduled for elect-
ive CEA,1565,1566 pre-operative CAD screening, including coronary
11.2. Peripheral arterial disease and heart
angiography, may be considered in suspected patients.1558 CAD re-
failure
quires prioritization of revascularization according to the patient’s clin-
ical status and the severity of carotid disease and CAD. Coronary Left ventricular (LV) dysfunction is observed in 20%–30% of PAD pa-
revascularization should generally be performed first; the exception is tients,1572,1573 mostly associated with CAD.1574 High aortic stiffness
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 115 ---
3652 E S C G u id e l in e s
can increase LV afterload and impair coronary blood flow, resulting in In patients with stable PVD who are symptomatic in
hypertension, LV hypertrophy, LV diastolic dysfunction, and at least one territory and without high bleeding risk,c
HF.1575,1576 Skeletal muscle involvement and deconditioning due to treatment with a combination of rivaroxaban (2.5 mg IIa A
PAD may aggravate HF severity.1577,1578
b.i.d.) and aspirin (100 mg o.d.) should be
Peripheral arterial disease and HF are independently associated with considered.429,1559
poor outcomes and those with concomitant HF have a 30% higher risk
Carotid DUS may be considered for stable patients
of MACE and 40% higher risk of all-cause mortality.1574Evaluation of
scheduled for CABG without TIA/stroke within the IIb C
LV function in patients with PAD may be useful for better CV risk strati-
fication and comprehensive management of their CV disease.1579This is past 6 months.1555,1562
of particular importance when an intermediate- or high-risk vascular AF, atrial fibrillation; b.i.d., twice daily; CABG, coronary artery bypass grafting;
intervention is planned. Expectedly, the presence of PAD in patients CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes,
with HF is also associated with poor outcomes.1580–1584These patients stroke (doubled), vascular disease, age 65 to 74 and sex category (female); DUS, duplex
ultrasound; eGFR, estimated glomerular filtration rate; LDL-C, low-density lipoprotein
represent a high-risk group in which intense risk-factor modification cholesterol; o.d., once daily; PAD, peripheral arterial disease; PVD, polyvascular disease;
strategies and optimization of HF therapy are warranted. TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
cPrior history of intracerebral haemorrhage or ischaemic stroke, history of other
11.3. Peripheral arterial disease and AF
intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible
The prevalence of AF among patients with PAD is around 12%.1585–1590 gastrointestinal blood loss, other gastrointestinal pathology associated with increased
bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty,
A meta-analysis revealed that in patients with AF and PAD, risk of all-
or renal failure requiring dialysis or with eGFR <15 mL/min/1.73 m2.
cause mortality, CV mortality, and MACE is 40%, over 60%, and over
70% higher, respectively compared with patients with AF without
PAD.1591PAD is included in the CHA DS -VASc (congestive heart fail-
2 2
ure, hypertension, age ≥75 [doubled], diabetes, stroke [doubled], vas- 12. Key messages
cular disease, age 65 to 74 and sex category [female]) risk score, which
underlies the prognostic importance of PAD in patients with AF.1592 Peripheral arterial and aortic diseases are highly prevalent, often asymp-
tomatic, and linked to increased morbidity and mortality. Early diagnosis
is crucial for better outcomes and management requires a multidiscip-
11.4. Peripheral arterial disease and aortic linary team. CVRF control is crucial to prevent progression and compli-
stenosis cations. Despite the benefit of medical therapy, lifestyle changes,
healthy diet, abstinence from smoking, exercise/rehabilitation, and edu-
Peripheral arterial disease frequently accompanies symptomatic aortic
cation are essential for effective management. Patient empowerment is
stenosis, especially among patients not eligible for surgical aortic valve
replacement (20%–30%).198,1593–1595In these patients, pre-procedural essential to improve adherence and close/regular monitoring is essen-
CCT/CTA or CMR1596 of the aorta and major peripheral arteries is tial to improve prognosis. Use of web- or app-based calculators for es-
timation of CV risk in the secondary prevention of ASCVD may aid
mandatory to evaluate the access site for transcatheter aortic valve im-
patient motivation for lifestyle changes and adherence to medication.
plantation (TAVI) and plan a closure strategy for the access site.
Peripheral arteries
Patients with PAD have increased risk of all-cause mortality and vascu-
lar complications after TAVI,198thus, screening for PAD in these pa- Atherosclerotic lower-extremity PAD is a chronic disease needing
lifelong follow-up.
tients may be helpful.
Assessment of walking impairment, functional status, and amputation
risk is crucial in PAD management.
Recommendation Table 70 — Recommendations for Ankle–brachial index should be the initial diagnostic test for screen-
screening and management of polyvascular disease and ing and diagnosing PAD, and serves as a surrogate marker for CV and
peripheral arterial disease with cardiac diseases (see all-cause mortality. DUS is the first-line imaging method to confirm
also Evidence Table 15)
PAD lesions.
Supervised exercise training or, if not available, HBET, improves
Recommendations Classa Levelb
walking and functional performances, and reduces CV risk. Exercise
In patients with PVD, an LDL-C reduction by ≥50% training remains underused and increased awareness is warranted.
from baseline and an LDL-C goal of <1.4 mmol/L I A In asymptomatic PAD patient revascularization is not recommended.
(<55 mg/dL) are recommended.242,1571 In symptomatic PAD patient need for interventional treatment, follow-
ing a period of optimal medical treatment and exercise, should be dis-
In patients with PAD and newly diagnosed AF with a
cussed in a multidisciplinary setting.
CHADS -VASc score ≥2, full oral anticoagulation is I C
2 2
Chronic limb-threatening ischaemia increases the risk of CV events,
recommended.1597
needs early diagnosis, rapid referral to a multidisciplinary vascular team,
Screening for ilio-femoral PAD is recommended in
I B and revascularization for limb salvage.
patients undergoing TAVI.198,1598
Acute limb ischaemia warrants rapid clinical assessment by a vascular
Carotid DUS should be considered for stable
team and urgent revascularization.
patients scheduled for CABG with TIA/stroke within Duplex ultrasound is the first-line diagnostic modality for carotid
IIa B
the past 6 months without carotid stenosis. Routine revascularization is not recommended if asymp-
revascularization.1556,1569
tomatic. In symptomatic patients multidisciplinary assessment is
Continued recommended.
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 116 ---
ESC Guidelines 3653
Atherosclerotic UEAD is most frequently located in the subclavian (c) Inflammation biomarkers, metabolomics, and proteomics may
artery and may be suspected because of an absolute inter-arm SBP dif- have prognostic value in PAAD.
ference >10–15 mmHg. DUS is first-line imaging and routine revascu- (2) Evaluation of peripheral arteries and aorta:
larization is not recommended. (a) Follow-up algorithms can assist PAAD patient management
The key to early diagnosis of acute and chronic mesenteric ischae- but have limitations and evidence on cost-effectiveness is
mia is a high level of clinical suspicion—laboratory tests are unreli- needed.
able for the diagnosis. Acute SMA occlusion requires immediate (b) The best methodology for aortic measurements remains to be
revascularization. elucidated.
Aorta (3) Screening for carotid, peripheral arterial, and aortic diseases:
Aortic aneurysms are managed based on size, location, and growth (a) Screening in specific populations: research is needed to under-
rate. Small aneurysms are monitored regularly (Guidelines provide stand the nuances of screening in particular populations and
disease-specific follow-up algorithms), while larger ones may require whether modifications to current guidelines are necessary.
surgical/endovascular repair to prevent rupture. (b) Patient outcomes and benefits of screening: impact of screen-
In aortic root aneurysms, aortic replacement may be considered at ing on patient outcome should be assessed.
>52 mm in low-risk patients and at experienced centres. (4) OMT and PAAD:
Aortic diameter is the primary risk factor for aortic events. However, (a) Research needed on QoL and workability.
evidence supports diameter indexation (especially in extreme BSA po- (b) Research needed for optimal preventive strategies.
pulations) and the use of aortic length (>11 cm), the AHI (>32.1 mm/m), (c) Exercise therapy and rehabilitation for PAAD should be more
growth rate (≥3 mm per year for ascending aorta and arch or >5 mm accessible and employed.
per 6 months in the thoracoabdominall aorta), and age/sex for risk (d) Anti-inflammatory therapy should be investigated.
assessment. (e) Antithrombotic therapies in specific risk groups of PAAD and
Multidisciplinary collaboration, hybrid operating rooms, and ad- patients undergoing revascularization should be addressed.
vanced stent technology have increased the adoption of hybrid ap- (5) Aortic aneurysms:
proaches and endovascular therapies for different thoracoabdominal (a) Discovering novel individualized risk stratification parameters
aortic diseases. beyond well-established markers.
Acute aortic syndrome management involves medical treatment in (b) Assessing the safety of fluoroquinolone use in patients with
critical care units and selective surgical intervention based on location aortic aneurysm.
and complications. The main problem in these conditions continues (6) Acute aortic syndromes:
to be a delay in diagnosing patients or transferring them to an aortic (a) Assess the management of pregnancy-related AAS.
centre. Improved diagnostic algorithms and reduced surgical complica- (b) Identify diagnostic biomarkers other than D-dimer.
tions have lowered mortality rates. Surgical/endovascular treatment in (c) Management in uncomplicated TBAD and IMH should be
the subacute phase is advised for high-risk patients with type B aortic assessed.
syndrome. (7) Genetic aortic diseases:
Suspected genetic aortic conditions require evaluation at experi- (a) Need to refine risk estimation in AD, particularly in HTAD, es-
enced centres to assess both the patient and their FDRs for genetic pecially the risk of type B aortic dissection.
studies. Genetic aortic conditions should be considered based on family (b) There is insufficient evidence to support the efficacy of any
history, syndromic features, age <60 years, and no CVRFs (Guidelines medication in reducing the risk of AD.
offer a screening algorithm for thoracic aorta disease). A comprehen- (8) Sex differences in PAAD:
sive evaluation of the entire aorta and other vascular territories is re- (a) Investigate sex and age differences.
commended in HTAD. Recent advances in genetics are enabling (b) Assess the optimal parameter or indexed parameter to guide
personalized and patient-centred assessment. This includes using differ- intervention decisions in women with aortic and PAD diseases.
ent aortic diameter thresholds to indicate surgery and implementing di-
verse surveillance algorithms. 14. Sex differences
Sex differences have been evaluated and discussed in the specific
13. Gaps in evidence sections.
There are several areas where robust evidence is still lacking and which 15. ‘What to do’ and ‘What not to
deserve to be addressed in future clinical research.
do’ messages from the guidelines
(1) Epidemiology and risk factors in PAAD:
(a) Improve PAAD risk definition. Table 18‘What to do’ and ’What not to do’. ‘What to do and What not
(b) Provide contemporary data on PAAD prevalence in Europe. to do’ lists all Class I and Class III recommendations from the text.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 117 ---
3654 E S C G u id e l in e s
Table 18 ‘What to do’ and ‘What not to do’
Recommendations Classa Levelb
Recommendations for clinical and laboratory, and for functional and quality of life, assessment in patients with peripheral arterial and
aortic disease
When managing PAAD, it is recommended to adopt a comprehensive approach that addresses the entirety of arterial circulation. I B
To assess PAAD, it is recommended to perform thorough clinical, vascular, and CVRF laboratory evaluation. I C
Recommendations for diagnostic tests in patients with peripheral arterial disease
Measurement of the ABI is recommended as the first-line non-invasive test for screening and diagnosis of PAD, using an ABI ≤0.90 as a
I B
diagnostic criterion.
In the case of non-compressible ankle arteries or ABI >1.40, additional methods such as TP, TBI or Doppler waveform analysis are
I B
recommended.
Recommendations for imaging of the aorta
It is recommended that aortic diameters are measured at prespecified anatomical landmarks, and the largest diameter of the section be
I C
perpendicular to the longitudinal axis.
It is recommended in cases of serial imaging of the aorta over time to use the same imaging modality with the same measurement method. I C
It is recommended to consider renal function, pregnancy, age, and history of allergy to contrast media to select the optimal imaging modality
I C
with minimal radiation exposure and lowest iatrogenic risk, except for emergency cases.
Recommendations for thoracic aortic measurements
TTE is recommended as the first-line imaging technique in evaluating thoracic aortic diseases. I B
It is recommended to report aortic diameters using the leading-to-leading edge convention in end-diastole by echocardiography. I C
It is recommended to report aortic diameters using the inner-to-inner edge convention in end-diastole by CCT or CMR. I C
It is recommended to report aortic diameters from images obtained with the double-oblique technique (not axial images) by CCT or CMR. I C
ECG-triggered CCT is recommended for comprehensive diagnosis, follow-up, and pre-invasive treatment assessment of the entire aorta,
I C
particularly the root and ascending aorta.
CMR is recommended for diagnosis and follow-up of thoracic aortic diseases, especially when chronic follow-up is required. I C
Recommendations for abdominal aortic aneurysm screening
Screening is recommended in men aged ≥65 years and with a history of smoking to reduce the risk of death from ruptured AAA. I A
Screening is recommended in FDRs of patients with AAA aged ≥50, unless an acquired cause can be clearly identified. I C
Recommendations for lifestyle, physical activity, and patient education
In patients with PAAD, cessation and abstinence from smoking of any kind is recommended to reduce the risk of AD, MI, death, and limb
I A
ischaemia.
A healthy diet rich in legumes, dietary fibre, nuts, fruits, and vegetables, with a high flavonoid intake (Mediterranean diet), is recommended
I A
for CV disease prevention in patients with PAAD.
Low- to moderate-intensity (or high if tolerated) aerobic activities are recommended in patients with PAD to increase overall and pain-free
I A
walking distance.
In patients with PAAD, behavioural counselling to promote healthy diet, smoking cessation, and physical activity is recommended to
I B
improve the CV risk profile.
It is recommended to promote patient and caregivers’ education and empowerment through tailored guidance on lifestyle adjustments and
I C
the importance of regular physical activity.
Recommendations for antihypertensive therapy in patients with peripheral and aortic disease
In patients with PAAD and hypertension an SBP target towards 120–129 mmHg, if tolerated, is recommended. I A
In unilateral RAS patients, it is recommended that antihypertensive medication include ACEIs/ARBs. I B
Recommendations for lipid-lowering therapy for patients with peripheral arterial and aortic diseases
In patients with atherosclerotic PAAD, lipid-lowering therapy is recommended. I A
An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50% reduction in LDL-C vs. baseline are recommended in patients with
I A
atherosclerotic PAAD.
Statins are recommended in all patients with PAD. I A
If the target LDL-C level is not achieved, a combination of statins and ezetimibe is indicated in patients with atherosclerotic PAAD, to
I B
achieve the given target values.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 118 ---
ESC Guidelines 3655
If the target LDL-C level is not achieved on maximally tolerated statins and ezetimibe, treatment with a PCSK9 inhibitor is recommended in
I A
patients with atherosclerotic PAAD, to achieve target values.
For statin-intolerant patients with atherosclerotic PAAD, at high CV risk, who do not achieve their LDL-C goal on ezetimibe, it is
I B
recommended to add bempedoic acid either alone or in combination with a PCSK9 inhibitor.
Fibrates are not recommended for cholesterol lowering. III B
Recommendations for the medical management of patients with peripheral arterial and aortic diseases and diabetes
It is recommended to apply tight glycaemic control (HbA1c <53 mmol/mol [7%]) to reduce microvascular complications in patients with
I A
PAAD.
SGLT2i with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or
I A
target HbA1c and concomitant glucose-lowering medication.
GLP-1RAs with proven CV benefit are recommended in patients with T2DM and PAAD to reduce CV events, independent of baseline or
I A
target HbA1c and concomitant glucose-lowering medication.
It is recommended to avoid hypoglycaemia in patients with PAAD. I B
It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy. I C
It is recommended to prioritize the use of glucose-lowering agents with proven CV benefits, followed by agents with proven CV safety, over
I C
agents without proven CV benefit or safety.
Recommendations for diagnostic tests in patients with peripheral arterial disease and diabetes, renal failure and wounds
Measuring TP or TBI is recommended in patients with diabetes or renal failure if resting ABI is normal. I C
Recommendations for imaging in patients with peripheral arterial disease
DUS is recommended as first-line imaging method to confirm PAD lesions. I C
In symptomatic patients with aorto-iliac or multisegmental/complex disease, CTA and/or MRA are recommended as adjuvant imaging
I C
techniques for preparation of revascularization procedures.
Analysis of anatomical imaging tests in conjunction with symptoms and haemodynamic tests prior to an invasive procedure is
I C
recommended.
Recommendations for exercise therapy in patients with peripheral arterial disease
In patients with symptomatic PAD, SET is recommended. I A
In those patients undergoing endovascular revascularization, SET is recommended as an adjuvant therapy. I A
Recommendations for antithrombotic therapy in patients with peripheral arterial disease
Use of antiplatelet therapy with aspirin alone (range 75–160 mg o.d.) or clopidogrel alone (75 mg o.d.) is recommended for the reduction of
I A
MACE in patients with symptomatic PAD.
Long-term DAPT in patients with PAD is not recommended. III A
Oral anticoagulant monotherapy for PAD (unless for another indication) is not recommended. III A
The routine use of ticagrelor in patients with PAD is not recommended. III A
It is not recommended to systematically treat patients with asymptomatic PAD without any sign of clinically relevant ASCVD with
III B
antiplatelet drugs.
Recommendations on interventional treatment of asymptomatic and symptomatic peripheral arterial disease (general)
In patients with symptomatic PAD, after a 3 month period of OMT and exercise therapy, PAD-related QoL assessment is recommended. I B
It is recommended to adapt the mode and type of revascularization options to anatomical lesion location, lesion morphology, and general
I C
patient condition.
In patients with PAD, revascularization is not recommended if the reason is to solely prevent progression to CLTI. III B
In patients with asymptomatic PAD, revascularization is not recommended. III C
Recommendations in patients with peripheral arterial disease: follow-up of patients with peripheral arterial disease
It is recommended to regularly, at least once a year, follow-up patients with PAD, assessing clinical and functional status, medication
I C
adherence, limb symptoms, and CVRFs, with DUS assessment as needed.
Recommendations for the management of chronic limb-threatening ischaemia
For limb salvage in patients with CLTI, revascularization is recommended. I B
Early recognition of CLTI and referral to the vascular team are recommended for limb salvage. I C
Recommendations for medical treatment in patients with chronic limb-threatening ischaemia
It is recommended that patients with CLTI are managed by a vascular team. I C
In patients with CLTI and ulcers, offloading mechanical tissue stress is recommended to allow wound healing. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 119 ---
3656 E S C G u id e l in e s
It is recommended to treat infection with antibiotics. I C
Lower-limb exercise training is not recommended in patients with CLTI and wounds. III C
Recommendations for interventional treatment of chronic limb-threatening ischaemia
In CLTI patients, it is recommended to perform revascularization as soon as possible. I B
In CLTI, it is recommended to use autologous veins as the preferred conduit for infra-inguinal bypass surgery. I B
In multilevel vascular disease, it is recommended to eliminate inflow obstructions when treating downstream lesions. I C
An individual risk assessment (weighing the patient’s individual procedural risk of endovascular vs. surgical revascularization) by a
I C
multidisciplinary vascular team is recommended.
Recommendations for follow-up in patients with chronic limb-threatening ischaemia
In patients with CLTI, following revascularization it is recommended to follow-up patients on a regular basis. I C
At follow-up, it is recommended to assess clinical, haemodynamic and functional status, limb symptoms, treatment adherence, and CVRFs. I C
Recommendations for the management of patients presenting with acute limb ischaemia
In patients with ALI, it is recommended that an urgent evaluation is performed by a vascular clinician with sufficient experience to assess limb
I C
viability and implement appropriate therapy.
In cases of neurological deficit, urgent revascularization is recommended; diagnostic imaging is recommended to guide treatment, provided
I C
it does not delay treatment, or if the need for primary amputation is obvious.
In the absence of severe neurological deficit, revascularization is recommended within hours of initial imaging in a case-by-case decision. I C
Treatment with analgesics is recommended as soon as possible for pain control. I C
It is recommended to monitor for compartment syndrome after revascularization and treat (fasciotomy). I C
It is recommended to assess clinical and haemodynamic success following revascularization. I C
In patients with ALI, it is recommended to obtain a comprehensive medical history and determine the cause of thrombosis and/or
I C
embolization.
Recommendations for carotid artery stenosis assessment
It is recommended to use the NASCET method or its non-invasive equivalent to assess ICA stenosis. I B
It is recommended to use DUS as first-line imaging to diagnose ICA stenosis. I C
It is not recommended to use the ECST method for ICA stenosis assessment. III C
Recommendations for antithrombotic treatment in patients with carotid stenosis
In patients with symptomatic CS, not undergoing carotid endarterectomy or stenting, DAPT with low-dose aspirin and clopidogrel (75 mg)
I A
is recommended for the first 21 days or longer, followed by clopidogrel 75 mg or long-term aspirin to reduce the risk of stroke.
Recommendations for interventional treatment in patients with asymptomatic carotid artery stenosis
In asymptomatic patients with ICA stenosis, in the absence of high-risk features and with a life expectancy <5 years, routine
III A
revascularization is not recommended.
Recommendations for evaluation and medical treatment in patients with symptomatic carotid artery stenosis
DAPT is recommended in the early phase of minor strokes in patients with ICA stenosis, if not revascularized, for at least 21 days,
I A
considering the bleeding risk.
It is recommended that symptomatic ICA stenosis patients are assessed by a vascular team including a neurologist. I C
Recommendations for interventions in patients with symptomatic carotid artery stenosis
It is recommended to perform CEA of symptomatic 70%–99% ICA stenosis provided a documented 30 day risk of procedural death/stroke
I A
is <6%.
If indicated, it is recommended to perform CEA within 14 days in symptomatic ICA stenosis patients. I B
OMT is recommended for all symptomatic ICA stenosis patients. I A
Revascularization is not recommended in patients with ICA lesions <50%. III A
Recommendations for follow-up in patients with carotid artery stenosis
Once-yearly follow-up is recommended to check for CVRFs and treatment compliance. I A
After ICA stent implantation, DAPT with aspirin and clopidogrel is recommended for at least 1 month. I A
After ICA revascularization, long-term aspirin or clopidogrel is recommended. I B
During follow-up, it is recommended to assess neurological symptoms, CVRFs, and treatment adherence at least yearly in patients with CS. I C
After ICA revascularization, surveillance with DUS is recommended within the first month. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 120 ---
ESC Guidelines 3657
Recommendations for the management of subclavian artery stenosis
Bilateral arm BP measurement is recommended for all patients with PAAD. I B
Routine revascularization in patients with atherosclerotic subclavian artery disease is not recommended. III C
Recommendations for diagnostic strategies for renal artery disease
DUS is recommended as the first-line imaging modality in patients with suspicion of RAS. I B
In cases of DUS-based suspicion of RAS or in inconclusive DUS, MRA or CTA are recommended. I B
In patients with atherosclerotic RAS, it is recommended to assess clinical high-risk features and kidney viability when evaluating renal artery
I B
revascularization.
Recommendations for treatment strategies for renal artery disease
In patients with atherosclerotic unilateral RAS, routine revascularization is not recommended. III A
Recommendations in patients with visceral artery stenosis
In patients with acute mesenteric ischaemia due to acute occlusion of the SMA, endovascular revascularization is recommended. I B
In patients with suspected acute or chronic mesenteric ischaemia, CTA is recommended. I C
In patients with acute or chronic mesenteric ischaemia, assessment by a vascular team is recommended. I C
Revascularization of asymptomatic atherosclerotic visceral artery stenosis is not recommended. III C
Recommendations for primary and secondary prevention in aortic atheromatous plaques
Anticoagulation or DAPT are not recommended in aortic plaques since they present no benefit and increase bleeding risk. III C
In patients with an embolic event and evidence of an aortic arch atheroma, intensive lipid management to an LDL-C target <1.4 mmol/L
I A
(<55 mg/dL) is recommended to prevent recurrences.
In patients with an embolic event and evidence of an aortic arch atheroma, SAPT is recommended to prevent recurrences. I C
Recommendations for initial evaluation of thoracic aorta aneurysm and abdominal aortic aneurysm
When an aortic aneurysm is identified at any location, assessment of the entire aorta is recommended at baseline and during follow-up. I C
When a TAA is identified, assessment of the aortic valve (especially for BAV) is recommended. I C
Recommendation for the surveillance of patients with thoracic aortic aneurysms (non-heritable thoracic aortic disease)
In thoracic aortic dilatation, TTE is recommended at diagnosis to assess aortic valve anatomy and function, aortic root, and ascending aorta
I C
diameters. Additionally, a global aortic evaluation using all echocardiographic views is recommended.
CMR or CCT is recommended for surveillance of patients with aneurysm at the distal ascending aorta, aortic arch, DTA, or TAAA. I C
In thoracic aortic dilatation, CCT or CMR is recommended to confirm TTE measurements, rule out aortic asymmetry, and determine
I C
baseline diameters for follow-up.
TTE is not recommended for the surveillance of aneurysms in the distal ascending aorta, aortic arch, or DTA. III C
Recommendations for surveillance of patients with abdominal aortic aneurysm
DUS surveillance is recommended every 6 months in men with AAA of 50–55 mm and in women with AAA of 45–50 mm. I B
DUS is recommended for AAA surveillance. I C
CCT or CMR is recommended if DUS does not allow adequate measurement of AAA diameter. I B
Recommendations for medical treatment in patients with thoracic aorta or abdominal aortic aneurysms
In patients with aortic aneurysm (TAA and/or AAA), optimal implementation of CV risk management and medical treatment (see detailed
I C
recommendations in dedicated Tables of Recommendations) are recommended to reduce MACE.
Recommendations for surgery in aortic root and ascending aorta dilatation associated with tricuspid aortic valve
Surgery is recommended in patients with dilatation of the aortic root or ascending aorta with a tricuspid aortic valve and a maximum
I B
diameter of ≥55 mm.
Valve-sparing aortic root replacement is recommended in patients with aortic root dilatation if performed in experienced centres and
I B
durable results are expected.
VKAs are recommended lifelong for all patients with a Bentall procedure with an MHV prosthesis. I B
Recommendations for surgery in aortic arch aneurysms
In patients with low or intermediate operative risk with an aortic arch aneurysm and recurrent episodes of chest pain not attributable to
I C
non-aortic causes, open surgical replacement of the arch is recommended.
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 121 ---
3658 E S C G u id e l in e s
Recommendations for the management of patients presenting with descending thoracic aortic and thoracoabdominal aortic
aneurysms
In patients with unruptured DTA aneurysm (without HTAD), elective repair is recommended if diameter ≥55 mm. I B
In patients without HTAD with unruptured DTA aneurysm, when elective repair is indicated and anatomy is suitable, TEVAR is
I B
recommended over open repair.
In patients with DTA aneurysm who undergo TEVAR with planned LSA coverage, it is recommended to revascularize the LSA before
I B
TEVAR to reduce the risk of SCI and stroke.
In patients with unruptured degenerative TAAA, elective repair is recommended when the diameter is ≥60 mm. I B
Recommendations for the management of patients presenting with abdominal aortic aneurysm
Elective repair is recommended if AAA diameter is ≥55 mm in men or ≥50 mm in women. I A
In ruptured AAA with suitable anatomy, endovascular repair is recommended over open repair to reduce peri-operative morbidity and
I B
mortality.
In patients with AAA and limited life expectancy (<2 years), elective AAA repair is not recommended. III B
Prior to AAA repair, routine evaluation with coronary angiography and systematic revascularization in patients with chronic coronary
III C
syndromes is not recommended.
Recommendations for the management of patients presenting with endoleaks
It is recommended to perform 30 day imaging after TEVAR/EVAR, by CCT + DUS/CEUS, to assess the success of intervention. I B
It is recommended to re-intervene to achieve a seal in patients with type I endoleak after TEVAR/EVAR. I B
It is recommended to re-intervene, principally by endovascular means, to achieve a seal in patients with type III endoleak after TEVAR/EVAR. I B
Recommendations for follow-up after treatment of aortic aneurysms
After open repair of TAA, early CCT is recommended within 1 month, and then yearly CCT follow-up for the first 2 post-operative years
I B
and every 5 years thereafter is recommended if findings are stable.
After TEVAR, follow-up imaging is recommended at 1 and 12 months post-operatively, then yearly until the fifth post-operative year if no
I B
abnormalities are documented.
After open repair of AAA, first follow-up imaging is recommended within 1 post-operative year, and then every 5 years thereafter if findings
I A
are stable.
After EVAR, follow-up imaging is recommended with CCT (or CMR) and DUS/CEUS at 1 month and 12 months post-operatively, then, if
no abnormalities are documented, DUS/CEUS is recommended every year, repeating CCT or CMR (based on potential artefacts) every 5 I A
years.
Recommendations for diagnostic work-up of acute aortic syndrome
In unstable patients who cannot be transferred to CCT, TOE is recommended for diagnosis and evaluation of the coeliac trunk and
I B
mesenteric artery.
In patients presenting with clinical features compatible with possible AAS, a multiparametric algorithm for ruling in or out AAS using the
I B
ADD-RS is recommended.
ECG-gated CCT from neck to pelvis is recommended as the first-line imaging technique in patients with a suspected AAS since it is widely
I C
available, accurate, and provides information about the entry tear, extension, and possible complications (malperfusion, dilatation, or rupture).
In patients with suspected AAS, focused TTE (with use of contrast if feasible) is recommended during the initial evaluation. I C
In patients with suspected AAS, TOE is recommended to guide peri-operative management and detect complications. I C
Recommendation for medical treatment in acute aortic syndromes
In patients with AAS, immediate anti-impulse treatment targeting SBP <120 mmHg and heart rate ≤60 b.p.m. is recommended. In cases of
I B
spinal ischaemia or concomitant brain injury, maintaining higher MAP is recommended.
Intravenous BBs (e.g. labetalol) are recommended as first-line agents. If necessary, i.v. vasodilators (e.g. dihydropyridine calcium blockers or
I B
nitrates) could be added.
Invasive monitoring with an arterial line and continuous three-lead ECG recording, as well as admission to an intensive care unit, is
I B
recommended.
In patients with AAS who can be managed conservatively and who achieved haemodynamic targets with i.v. anti-impulse therapy, switching
I B
to oral BBs and, if necessary, up-titration of other BP-lowering agents, is recommended after 24 h if gastrointestinal transit is preserved.
Adequate pain control to achieve haemodynamic targets is recommended. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 122 ---
ESC Guidelines 3659
Recommendations for intervention in type A acute aortic dissection
In patients with acute TAAD, emergency surgical consultation and evaluation and immediate surgical intervention is recommended. I B
In patients with acute TAAD who have extensive destruction of the aortic root, a root aneurysm, or a known genetic aortic disorder, aortic
I B
root replacement is recommended with a mechanical or biological valved conduit.
Recommendations for aortic repair strategies in type A acute aortic dissection
In patients with acute TAAD and a partially dissected aortic root but no significant aortic valve leaflet pathology, aortic valve resuspension is
I B
recommended over valve replacement.
In patients with acute TAAD undergoing aortic repair, an open distal anastomosis is recommended to improve survival and increase FL
I B
thrombosis rates.
In patients with acute TAAD without an intimal tear in the arch or a significant arch aneurysm, hemi-arch repair is recommended over more
I B
extensive arch replacement.
Recommendations for the management of malperfusion in the setting of acute aortic dissection
In patients with acute TAAD presenting with malperfusion (cerebral, mesenteric, lower limb, or renal), immediate aortic surgery is
I B
recommended.
Recommendations for the management of patients presenting with acute type B aortic dissection
Medical therapy including pain relief and blood pressure control is recommended in all patients with acute TBAD. I B
In patients with complicated acute TBAD, emergency intervention is recommended. I B
In patients with complicated acute TBAD, TEVAR is recommended as the first-line therapy. I B
Recommendations for the management of patients presenting with chronic type B aortic dissection
Antihypertensive therapy is recommended in all patients with chronic TBAD. I B
In chronic TBAD with acute symptoms of malperfusion, rupture, or progression of disease, emergency intervention is recommended. I C
In patients with chronic TBAD and a descending thoracic aortic diameter ≥60 mm, treatment is recommended in patients at reasonable
I B
surgical risk.
Recommendations for the management of intramural haematoma
In patients with IMH, medical therapy including pain relief and blood pressure control is recommended. I C
In type A IMH, urgent surgery is recommended. I C
In type B IMH, initial medical therapy under careful surveillance is recommended. I C
In uncomplicated type B IMH, repetitive imaging (CCT or CMR) is indicated. I C
In complicated type B IMH, TEVAR is recommended. I C
Recommendations for the management of penetrating atherosclerotic ulcer
In all patients with PAU, medical therapy including pain relief and blood pressure control is recommended. I C
In cases of type A PAU, surgery is recommended. I C
In cases of type B PAU, initial medical therapy under careful surveillance is recommended. I C
In uncomplicated type B PAU, repetitive imaging (CMR, CCT, or TOE) is recommended. I C
In complicated type B PAU, endovascular treatment (TEVAR) is recommended. I C
Recommendations for traumatic aortic injury
In cases of severe aortic injury (grade 4), immediate repair is recommended. I A
In cases of TAI with suitable anatomy requiring intervention, TEVAR is recommended over open surgery. I A
In all TAI patients, medical therapy including pain relief, and blood pressure and heart rate control, is recommended. I C
In cases of TAI suspicion, CCT is recommended. I C
In cases of moderate aortic injury (grade 3), repair is recommended. I C
Recommendations for follow-up after treatment of acute aortic syndrome
After TEVAR for AAS, follow-up imaging is recommended at 1, 6, and 12 months post-operatively, then yearly until the fifth post-operative
I B
year if no abnormalities are documented.
In medically treated type B AAD or IMH, follow-up imaging is recommended at 1, 3, 6, and 12 months after onset, then yearly if imaging
I C
findings are stable.
In medically treated PAU, follow-up imaging is recommended at 1 month after diagnosis, then every 6 months if imaging findings are stable. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 123 ---
3660 E S C G u id e l in e s
Recommendations for the management of patients with heritable thoracic aortic disease
It is recommended that medical management of patients with HTAD is individualized and based on shared decision-making. I C
It is recommended that patients with known or suspected syndromic or non-syndromic HTAD are evaluated in a centre with experience in
I C
the care of this patient group.
Recommendations for genetic testing and aortic screening in aortic disease
In patients with aortic root/ascending aneurysms or thoracic aortic dissection, gathering family history information for at least three
I B
generations about TAD, unexplained sudden deaths, and peripheral and intracranial aneurysms is recommended.
In patients with aortic root/ascending aortic aneurysms or thoracic aortic dissection and risk factors for HTAD, genetic counselling at an
I B
expert centre and subsequent testing, if indicated, is recommended.
In patients with HTAD who have a pathogenic/likely pathogenic variant, genetic testing of at-risk biological relatives (i.e. cascade testing) is
I C
recommended, irrespective of age.
In patients with TAD with risk factors for HTAD, with a negative family history of TAD and in whom no (likely) pathogenic variant is
I B
identified, TTE screening aortic imaging of FDRs is recommended.
Recommendations for imaging in women with Turner syndrome
To take the smaller body size of women (≥15 years) with TS into account, the use of the ascending ASI (ratio of aortic diameter [mm] to
BSA [m2]), AHI (ratio of aortic diameter [mm] to height [m]), or aortic z-score is recommended to define the degree of aortic dilatation and I C
assess the risk of aortic dissection.
It is recommended to define imaging and clinical surveillance intervals according to the estimated risk for dissection, based on the ascending
I C
ASI and concomitant lesions.
Recommendations for medical treatment in patients with vascular Ehlers–Danlos syndrome
In patients with vEDS, regular vascular surveillance of the aorta and peripheral arteries by DUS, CCT, or CMR is recommended. I C
Recommendations for vascular imaging in Marfan syndrome
In patients with MFS, TTE is recommended:
• At least annually in patients with an aortic root diameter <45 mm in the absence of additional risk factors
I C
• At least every 6 months in patients with an aortic root diameter <45 mm in the presence of additional risk factors
• At least every 6–12 months in patients with an aortic root diameter ≥45 mm in the absence of additional risk factors
In patients without previous aortic surgery, complete peripheral vascular and thoracoabdominal aorta imaging by CMR or CCT and DUS is
I C
recommended at the first evaluation, and subsequently every 3–5 years if stable.
In patients with MFS who have undergone aortic root replacement, surveillance imaging of the thoracic aorta by CMR (or CCT) is
I C
recommended at least every 3 years.
Recommendations for medical treatment in Marfan syndrome
In patients with MFS, treatment with either a BB or an ARB, in maximally tolerated doses (unless contraindicated), is recommended to
I A
reduce the rate of aortic dilatation.
Recommendations for aortic surgery in Marfan syndrome
Surgery is indicated in patients with MFS who have aortic root disease with a maximal aortic sinus diameter ≥50 mm. I B
Surgery to replace the aortic root and ascending aorta, using the valve-sparing surgery technique, is recommended in patients with MFS or
I B
related HTAD with aortic root dilatation when anatomical features of the valve allow its preservation and the surgeon has specific expertise.
Recommendations for pregnancy in women with Marfan syndrome
It is recommended that all women with MFS:
• Have a pre-conception evaluation to address the risks of maternal CV and other complications I C
• Have follow-up in a centre with access to a pregnancy heart and vessel team
It is recommended that couples in which a partner has or is at risk of HTAD be offered pre-conception genetic counselling. I C
Imaging of the whole aorta (by CMR/CCT) is recommended prior to pregnancy. I C
Follow-up during pregnancy is recommended with a frequency determined by aortic diameter and growth. I C
Intake of BBs during pregnancy is recommended. I C
Prophylactic aortic root surgery is recommended in women desiring pregnancy with aortic diameters >45 mm. I C
ARBs are not recommended during pregnancy. III B
Recommendations for physical exercise in patients with Marfan syndrome
It is recommended to individualize physical activity in patients with MFS based on aortic diameter, family history of aortic dissection, and
I C
pre-existing fitness.
Regular moderate aerobic exercise with a level of intensity informed by aortic diameter is recommended in most patients with MFS. I C
Continued
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 124 ---
ESC Guidelines 3661
Recommendations for imaging follow-up in Loeys–Dietz syndrome
In patients with Loeys–Dietz syndrome, TTE at baseline and subsequently every 6–12 months, depending on aortic diameter and growth, is
I C
recommended.
In patients with Loeys–Dietz syndrome, a baseline arterial imaging study from head to pelvis with CMR or CCT and subsequent surveillance
I C
with CMR or CCT or DUS every 1–3 years is recommended.
Recommendations for imaging and surgery in ACTA2-related heritable thoracic aortic disease
Annual monitoring of the aortic root/ascending aorta with TTE to evaluate aortic root/ascending aorta enlargement is recommended. I C
Imaging of the aorta with CMR/CCT every 3–5 years is recommended. I C
Recommendations for bicuspid aortic valve-associated aortopathy management
When a BAV is first diagnosed, initial TTE to assess diameters of the aorta at several levels is recommended. I B
Surgery for bicuspid aortopathy is recommended when the maximum aortic diameter is ≥55 mm. I B
Surgery for bicuspid aortopathy of the root phenotype is recommended when the maximum aortic diameter is ≥50 mm. I B
CCT or CMR of the entire thoracic aorta is recommended at first diagnosis and when important discrepancies in measurements are found
I C
between subsequent TTE controls during surveillance, or when the diameter of the aorta exceeds 45 mm.
Screening by TTE in FDRs of BAV patients with root phenotype aortopathy and/or isolated aortic regurgitation is recommended. I C
Surveillance serial imaging by TTE is recommended in BAV patients with a maximum aortic diameter >40 mm, either with no indication for
I C
surgery or after isolated aortic valve surgery, after 1 year, then if stability is observed, every 2–3 years.
Recommendations for evaluation and medical treatment of patients with coarctation of the aorta
In patients with native or repaired coarctation, lifelong follow-up is recommended, including regular imaging of the aorta with CCT/CMR
I B
every 3–5 years (adapted to clinical status and previous imaging findings).
Coarctation or re-coarctation repair (either surgical or endovascular) is indicated in patients with hypertension with an increased
non-invasive gradient between the upper and lower limbs (decreased ABI) confirmed with invasive measurement (peak-to-peak I C
>20 mmHg), with a preference for stenting when technically feasible.
In patients with coarctation, BP measurements at both arms and one lower extremity are recommended. I C
It is recommended to treat hypertension in patients with coarctation according to ESC hypertension guidelines. I C
Recommendations for screening and management of polyvascular disease and peripheral arterial disease with cardiac diseases
In patients with PVD, an LDL-C reduction by ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended. I A
In patients with PAD and newly diagnosed AF with a CHA DS-VASc score ≥2, full oral anticoagulation is recommended. I C
2 2
Screening for ilio-femoral PAD is recommended in patients undergoing TAVI. I B
AAA, abdominal aortic aneurysm; AAS, acute aortic syndrome; ABI, ankle–brachial index; ACEI, angiotensin-converting enzyme inhibitor; AD, aortic dissection; ADD-RS, aortic dissection
detection-risk score; AF, atrial fibrillation; AHI, aortic height index; ALI, acute limb ischaemia; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; ASI, aortic
size index; BAV, bicuspid aortic valve; BB, beta-blocker; BP, blood pressure; b.p.m., beats per minute; CCT, cardiovascular computed tomography; CEA, carotid endarterectomy; CEUS,
contrast-enhanced ultrasound; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 and sex category
(female); CLTI, chronic limb-threatening ischaemia; CMR, cardiovascular magnetic resonance; CS, carotid artery stenosis; CTA, computed tomography angiography; CV, cardiovascular;
CVRF, cardiovascular risk factor; DAPT, dual antiplatelet therapy; DTA, descending thoracic aorta; DUS, duplex ultrasound; ECG, electrocardiogram; ECST, European Carotid Surgery
Trial; ESC, European Society of Cardiology; FDR, first-degree relative; FL, false lumen; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HTAD,
heritable thoracic aortic disease; ICA, internal carotid artery; IMH, intramural haematoma; i.v., intravenous; LDL-C, low-density lipoprotein cholesterol; LSA, left subclavian artery;
MACE, major adverse cardiac event; MAP, mean arterial pressure; MFS, Marfan syndrome; MHV, mechanical heart valve; MI, myocardial infarction; MRA, magnetic resonance
angiography; NASCET, North American Symptomatic Carotid Endarterectomy Trial; o.d., once daily; OMT, optimal medical treatment; PAAD, peripheral arterial and aortic diseases;
PAD, peripheral arterial disease; PAU, penetrating atherosclerotic ulcer; PCSK9, proprotein convertase subtilisin/kexin type 9; PVD, polyvascular disease; RAS, renal artery stenosis;
QoL, quality of life; SAPT, single antiplatelet therapy; SBP, systolic blood pressure; SCI, spinal cord ischaemia; SET, supervised exercise training; SGLT2i, sodium-glucose co-transporter-2
inhibitor; SMA, superior mesenteric artery; T2DM, type 2 diabetes mellitus; TAA, thoracic aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm; TAAD, type A aortic dissection;
TAD, thoracic aortic disease; TAI, traumatic aortic injury; TAVI, transcatheter aortic valve implantation; TBAD, type B aortic dissection; TBI, toe–brachial index; TOE, transoesophageal
echocardiography; TEVAR/EVAR, thoracic endovascular aortic aneurysm repair; TP, toe pressure; TS, Turner syndrome; TTE, transthoracic echocardiography; vEDS, vascular Ehlers–
Danlos syndrome; VKA, vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
16. Evidence tables Unit (VASCERN), Department of Cardiology, Vall d’Hebron Hospital
Universitari, Vall d’Hebron Barcelona Hospital Campus, Vall d′
Evidence tablesare available on the European Heart Journal website. Hebron Institut de Recerca (VHIR), Barcelona, Spain, Centro de
Investigación Biomédica en Red de Enfermedades Cardiovasculares,
17. Data availability statement Instituto de Salud Carlos III, Madrid, Spain; Stefano Lanzi,
Department of Angiology, Lausanne University Hospital, University of
No new data were generated or analysed in support of this research. Lausanne, Lausanne, Switzerland; Vinko Boc, Department of
Vascular Diseases, University Medical Centre Ljubljana, Ljubljana,
18. Author information Slovenia; Eduardo Bossone, Department of Public Health,
University of Naples “Federico II”, Naples, Italy, Department of
Author/task force Member Affiliations: Gisela Translational Medical Sciences, University of Naples “Federico II”,
Teixido-Tura, Cardiovascular Imaging section and Aortic diseases Naples, Italy; Marianne Brodmann, Division of Angiology, Medical
4202CSE©
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 125 ---
3662 E S C G u id e l in e s
University Graz, Graz, Austria; Alessandra Bura-Rivière, Vascular (Sweden), Klaus Kallenbach2 (Luxemburg), Lars Køber (Denmark),
Medicine Department, Toulouse University Hospital, Toulouse, France, Konstantinos C. Koskinas (Switzerland), Juraj Madaric1 (Slovakia),
Faculty of Medicine, University Toulouse 3, Toulouse, France; Julie De Blandine Maurel (France), John William McEvoy (Ireland), Gil Meltzer
Backer, Cardiology and Center for Medical Genetics, Ghent (Israel), Borislava Mihaylova (United Kingdom), Richard Mindham
University Hospital, Ghent, Belgium; Sebastien Deglise, (United Kingdom), Ioana Mozos (Romania), Jens Cosedis Nielsen
Department of Vascular Surgery, University Hospital Lausanne (Denmark), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan),
(CHUV), Lausanne, Switzerland; Alessandro Della Corte, Barbara Rantner (Germany), Bianca Rocca (Italy), Xavier Rossello
Department of Translational Medical Sciences, University of (Spain), Jean Paul Schmid (Switzerland), Daniel Staub (Switzerland),
Campania “Luigi Vanvitelli”, Naples, Italy, Unit of Cardiac Surgery, Sabine Steiner (Germany), Isabella Sudano (Switzerland), Martin
Monaldi Hospital, Naples, Italy; Christian Heiss, Department of Teraa (Netherlands), Ilonca Vaartjes (Netherlands), Rafael
Clinical and Experimental Medicine, University of Surrey, Guildford, Vidal-Perez (Spain), Christiaan Vrints (Belgium), and Katja Zeppenfeld
United Kingdom, Vascular Medicine Department, Surrey and Sussex (Netherlands).
Healthcare NHS Trust, Redhill, United Kingdom; Marta ESC National Cardiac Societies actively involved in the review
Kałużna-Oleksy, 1st Department of Cardiology, Poznan University process of the 2024 ESC Guidelines for the management of peripheral ar-
of Medical Sciences, Poznan, Poland; Donata Kurpas, Division of terial and aortic diseases:
Research Methodology, Department of Nursing, Faculty of Nursing Algeria: Algerian Society of Cardiology, Mohammed El Amine
and Midwifery, Wroclaw Medical University, Poland; Carmel Bouzid; Armenia: Armenian Cardiologists Association, Arsen
M. McEniery, Medicine, University of Cambridge, Cambridge, A. Tsaturyan; Austria: Austrian Society of Cardiology, Georg Delle
United Kingdom; Tristan Mirault, Vascular Medicine Department, Karth; Azerbaijan: Azerbaijan Society of Cardiology, Fuad Samadov;
Université Paris Cité, Paris, France, Vascular Medicine Department, Belgium: Belgian Society of Cardiology, Antoine Bondue; Bosnia
Assistance Publique Hôpitaux de Paris-APHP, Hôpital Européen and Herzegovina: Association of Cardiologists of Bosnia and
Georges-Pompidou, Paris, PARCC U970 team 5 Innate and Herzegovina, Alden Begić; Bulgaria: Bulgarian Society of Cardiology,
Adaptative Immunity in Vascular Diseases, INSERM, Paris, France; Ivo Petrov; Croatia: Croatian Cardiac Society, Majda Vrkic
Agnes A. Pasquet, Department of Cardiovascular Diseases, Kirhmajer; Cyprus: Cyprus Society of Cardiology, Georgios
Cliniques Universitaires Saint Luc, Brussels, Belgium, IREC/CARD, P. Georghiou; Czechia: Czech Society of Cardiology, Pavel
UCLouvain, Brussels, Belgium; Alex Pitcher, The Heart Centre, Procházka; Denmark: Danish Society of Cardiology, Torsten
Oxford University NHS Foundation Trust, Oxford, United Kingdom; B. Rasmussen; Egypt: Egyptian Society of Cardiology, Yasser
Hannah A.I. Schaubroeck, Department of Intensive Care A. Sadek; Estonia: Estonian Society of Cardiology, Jaagup Truusalu;
Medicine, Ghent University Hospital, Ghent, Belgium; Oliver Finland: Finnish Cardiac Society, Petri Saari; France: French Society
Schlager, Division of Angiology, Department of Medicine II, Medical of Cardiology, Guillaume Jondeau; Germany: German Cardiac
University of Vienna, Vienna, Austria; Per Anton Sirnes, Society, Christiane Tiefenbacher; Greece: Hellenic Society of
Cardiology Practice, Kardiokonsult, Son, Norway, Cardiology section, Cardiology, Kimon Stamatelopoulos; Hungary: Hungarian Society
Volvat Medical Centre, Moss, Norway; Muriel G. Sprynger, of Cardiology, Endre Kolossváry; Iceland: Icelandic Society of
Cardiology, University Hospital of Liège, Liège, Belgium; Eugenio Cardiology, Elín Hanna Laxdal; Ireland: Irish Cardiac Society, Monica
Stabile, Division of Cardiology, Health Science Department, Monaghan; Israel: Israel Heart Society, Jonathan Koslowsky; Italy:
Università della Basilicata, Potenza, Italy; Françoise Steinbach Italian Federation of Cardiology, Ciro Indolfi; Kazakhstan:
(France), ESC Patient Forum, Sophia Antipolis, France; Matthias Association of Cardiologists of Kazakhstan, Nursultan Kospanov;
Thielmann, Department of Thoracic and Cardiovascular Surgery, Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera
West-German Heart and Vascular Center, University Hospital Essen, Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Olga Lunegova;
University Duisburg-Essen, Essen, Germany; Roland R.J. van Latvia: Latvian Society of Cardiology, Ainars Rudzitis; Lithuania:
Kimmenade, Department of Cardiology, Radboud University Lithuanian Society of Cardiology, Andrius Berūkštis; Luxembourg:
Medical Center, Nijmegen, Netherlands; and Maarit Venermo, Luxembourg Society of Cardiology, Katja Lottermoser; Malta:
Department of Vascular Surgery, University of Helsinki and Helsinki Maltese Cardiac Society, Maryanne Caruana; Morocco: Moroccan
University Hospital, Helsinki, Finland. Society of Cardiology, Raissuni Zainab; North Macedonia:
National Society of Cardiology of North Macedonia, Marijan
Bosevski; Norway: Norwegian Society of Cardiology, Stein Samstad;
19. Appendix Portugal: Portuguese Society of Cardiology, Ana Teresa Timoteo;
Romania: Romanian Society of Cardiology, Ovidiu Dragomir
ESC Scientific Document Group Chioncel; San Marino: San Marino Society of Cardiology, Pier
Includes Document Reviewers and ESC National Cardiac Societies. Camillo Pavesi; Slovakia: Slovak Society of Cardiology, Maria
Document Reviewers: Rasiova; Slovenia: Slovenian Society of Cardiology, Borut Jug;
Alessia Gimelli (CPG Review Co-ordinator) (Italy), Jean-Baptiste Spain: Spanish Society of Cardiology, Ariana González Gomez;
Ricco (CPG Review Co-ordinator) (France), Elena Arbelo (Spain), Sweden: Swedish Society of Cardiology, Stefan James;
Christian-Alexander Behrendt (Germany), Michael Böhm (Germany), Switzerland: Swiss Society of Cardiology, Marc Righini; Tunisia:
Michael A. Borger (Germany), Margarita Brida (Croatia), Sergio Tunisian Society of Cardiology and Cardio-Vascular Surgery, Amine
Buccheri (Sweden), Gill Louise Buchanan (United Kingdom), Christina Tarmiz; Turkey: Turkish Society of Cardiology, Eralp Tutar; and
Christersson (Sweden), Gert J. de Borst (Netherlands), Marco De Ukraine: Ukrainian Association of Cardiology, Maksym Sokolov.
Carlo (Italy), Roman Gottardi (Austria), Lydia Hanna (United ESC Clinical Practice Guidelines (CPG) Committee: Eva
Kingdom), Lynne Hinterbuchner (Austria), Borja Ibanez (Spain), Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson)
Ignatios Ikonomidis (Greece), Stefan James (Sweden), Thomas Kahan (Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom),
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 126 ---
ESC Guidelines 3663
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja Ibanez 18.Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M,
(Spain), Lars Køber (Denmark), Konstantinos C. Koskinas Bonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease prevention:
a report from the ESC Prevention of CVD programme led by the European
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova
Association of Preventive Cardiology (EAPC) in collaboration with the Acute
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck Cardiovascular Care Association (ACCA) and the Association of Cardiovascular
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes Nursing and Allied Professions (ACNAP). Eur Heart J Acute Cardiovasc Care 2020;9:
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 522–32. https://doi.org/10.1177/2048872619858285
19.Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands),
Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 42:3227–337. https://doi.org/10.1093/eurheartj/ehab484
Zeppenfeld (Netherlands). 20.Aday AW, Matsushita K. Epidemiology of peripheral artery disease and polyvascular
disease. Circ Res 2021;128:1818–32. https://doi.org/10.1161/CIRCRESAHA.121.
318535
21.Pabon M, Cheng S, Altin SE, Sethi SS, Nelson MD, Moreau KL, et al. Sex differences in
20. References peripheral artery disease. Circ Res 2022;130:496–511. https://doi.org/10.1161/
CIRCRESAHA.121.320702
22.Khawaja T, Janus SE, Tashtish N, Janko M, Baeza C, Gilkeson R, et al. Prevalence of
1.van Kuijk JP, Flu WJ, Welten GM, Hoeks SE, Chonchol M, Vidakovic R, et al. Long-term
thoracic aortic aneurysm in patients referred for no/low-charge coronary artery cal-
prognosis of patients with peripheral arterial disease with or without polyvascular ath-
cium scoring: insights from the CLARIFY registry. Am J Prev Cardiol 2022;12:100378.
erosclerotic disease. Eur Heart J 2010;31:992–9. https://doi.org/10.1093/eurheartj/
https://doi.org/10.1016/j.ajpc.2022.100378
ehp553
23.Obel LM, Diederichsen AC, Steffensen FH, Frost L, Lambrechtsen J, Busk M, et al.
2.Dolmaci OB, El Mathari S, Driessen AHG, Klautz RJM, Poelmann RE, Lindeman JHN,
Population-based risk factors for ascending, arch, descending, and abdominal aortic di-
et al. Are thoracic aortic aneurysm patients at increased risk for cardiovascular dis-
lations for 60-74-year-old individuals. J Am Coll Cardiol 2021;78:201–11. https://doi.org/
eases? J Clin Med 2023;12:272. https://doi.org/10.3390/jcm12010272
3.Tully L, Gianos E, Vani A, Guo Y, Balakrishnan R, Schwartzbard A, et al. Suboptimal risk 10.1016/j.jacc.2021.04.094
factor control in patients undergoing elective coronary or peripheral percutaneous 24.Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneur-
intervention. Am Heart J 2014;168:310–6.e3. https://doi.org/10.1016/j.ahj.2014.05.011 ysms and acute aortic syndromes. Nat Rev Cardiol 2021;18:331–48. https://doi.org/
4.Saratzis A, Jaspers NEM, Gwilym B, Thomas O, Tsui A, Lefroy R, et al. Observational 10.1038/s41569-020-00472-6
study of the medical management of patients with peripheral artery disease. Br J Surg 25.Verhagen JMA, Kempers M, Cozijnsen L, Bouma BJ, Duijnhouwer AL, Post JG, et al.
2019;106:1168–77. https://doi.org/10.1002/bjs.11214 Expert consensus recommendations on the cardiogenetic care for patients with thor-
5.McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, et al. Knowledge acic aortic disease and their first-degree relatives. Int J Cardiol 2018;258:243–8. https://
and attitudes regarding cardiovascular disease risk and prevention in patients with cor- doi.org/10.1016/j.ijcard.2018.01.145
onary or peripheral arterial disease. Arch Intern Med 2003;163:2157–62. https://doi. 26.Burger PM, Pradhan AD, Dorresteijn JAN, Koudstaal S, Teraa M, de Borst GJ, et al.
org/10.1001/archinte.163.18.2157 C-reactive protein and risk of cardiovascular events and mortality in patients with vari-
6.Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022 ous cardiovascular disease locations. Am J Cardiol 2023;197:13–23. https://doi.org/10.
American College of Rheumatology/EULAR classification criteria for Takayasu arter- 1016/j.amjcard.2023.03.025
itis. Ann Rheum Dis 2022;81:1654–60. https://doi.org/10.1136/ard-2022-223482 27.Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine
7.Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 up- in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47. https://doi.
date of the EULAR recommendations for the management of large vessel vasculitis. org/10.1056/NEJMoa2021372
Ann Rheum Dis 2020;79:19–30. https://doi.org/10.1136/annrheumdis-2019-215672 28.Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and
8.Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:
American College of Rheumatology/EULAR classification criteria for giant cell arteritis. 2497–505. https://doi.org/10.1056/NEJMoa1912388
Ann Rheum Dis 2022;81:1647–53. https://doi.org/10.1136/ard-2022-223480 29.Parkkila K, Kiviniemi A, Tulppo M, Perkiömäki J, Kesäniemi YA, Ukkola O. Carotid and
9.Stone JR, Bruneval P, Angelini A, Bartoloni G, Basso C, Batoroeva L, et al. Consensus femoral bruits as cardiovascular risk indicators in a middle-aged Finnish population: a
statement on surgical pathology of the aorta from the Society for Cardiovascular 20-year prospective study. PLoS One 2022;17:e0278901. https://doi.org/10.1371/
Pathology and the Association for European Cardiovascular Pathology: journal.pone.0278901
I. Inflammatory diseases. Cardiovasc Pathol 2015;24:267–78. https://doi.org/10. 30.Pickett CA, Jackson JL, Hemann BA, Atwood JE. Carotid bruits as a prognostic indica-
1016/j.carpath.2015.05.001 tor of cardiovascular death and myocardial infarction: a meta-analysis. Lancet 2008;
10.Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 coun- 371:1587–94. https://doi.org/10.1016/s0140-6736(08)60691-1
tries and territories, 1990-2019: a systematic analysis for the Global Burden of 31.Charry D, Gouskova N, Meyer ML, Ring K, Nambi V, Heiss G, et al. Arterial stiffness
Disease study 2019. Lancet 2020;396:1204–22. https://doi.org/10.1016/S0140- and contralateral differences in blood pressure: the Atherosclerosis Risk in
6736(20)30925-9 Communities (ARIC) study. J Clin Hypertens (Greenwich) 2022;24:878–84. https://doi.
11.Lin J, Chen Y, Jiang N, Li Z, Xu S. Burden of peripheral artery disease and its attributable org/10.1111/jch.14493
risk factors in 204 countries and territories from 1990 to 2019. Front Cardiovasc Med 32.Aboyans V, Criqui MH, McDermott MM, Allison MA, Denenberg JO, Shadman R, et al.
2022;9:868370. https://doi.org/10.3389/fcvm.2022.868370 The vital prognosis of subclavian stenosis. J Am Coll Cardiol 2007;49:1540–5. https://doi.
12.GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral ar- org/10.1016/j.jacc.2006.09.055
tery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden 33.Marcovina SM, Shapiro MD. Measurement of lipoprotein(a): a once in a lifetime op-
of Disease study 2019. Lancet Glob Health 2023;11:e1553–65. https://doi.org/10.1016/ portunity. J Am Coll Cardiol 2022;79:629–31. https://doi.org/10.1016/j.jacc.2021.11.
S2214-109X(23)00355-8 053
13.Liu W, Yang C, Chen, Lei F, Qin J-J, Liu H, et al. Global death burden and attributable 34.Arndt H, Nordanstig J, Bertges DJ, Budtz-Lilly J, Venermo M, Espada CL, et al. A Delphi
risk factors of peripheral artery disease by age, sex, SDI regions, and countries from consensus on patient reported outcomes for registries and trials including patients
1990 to 2030: results from the Global Burden of Disease study 2019. Atherosclerosis with intermittent claudication: recommendations and reporting standard. Eur J Vasc
2022;347:17–27. https://doi.org/10.1016/j.atherosclerosis.2022.03.002 Endovasc Surg 2022;64:526–33. https://doi.org/10.1016/j.ejvs.2022.08.011
14.Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. 35.Rymer JA, Narcisse D, Cosiano M, Tanaka J, McDermott MM, Treat-Jacobson DJ, et al.
Global burden of cardiovascular diseases and risk factors, 1990–2019: update from Patient-reported outcome measures in symptomatic, non-limb-threatening peripheral
the GBD 2019 study. J Am Coll Cardiol 2020;76:2982–3021. https://doi.org/10.1016/j. artery disease: a state-of-the-art review. Circ Cardiovasc Interv 2022;15:e011320.
jacc.2020.11.010 https://doi.org/10.1161/circinterventions.121.011320
15.Pu L, Wang L, Zhang R, Zhao T, Jiang Y, Han L. Projected global trends in ischemic 36.Raja A, Spertus J, Yeh RW, Secemsky EA. Assessing health-related quality of life among
stroke incidence, deaths and disability-adjusted life years from 2020 to 2030. Stroke patients with peripheral artery disease: a review of the literature and focus on patient-
2023;54:1330–9. https://doi.org/10.1161/STROKEAHA.122.040073 reported outcome measures. Vasc Med 2021;26:317–25. https://doi.org/10.1177/
16.Summers KL, Kerut EK, Sheahan CM, Sheahan MG, III. Evaluating the prevalence of ab- 1358863x20977016
dominal aortic aneurysms in the United States through a national screening database. 37.Treat-Jacobson D, McDermott MM, Bronas UG, Campia U, Collins TC, Criqui MH,
J Vasc Surg 2021;73:61–8. https://doi.org10.1016/j.jvs.2020.03.046 et al. Optimal exercise programs for patients with peripheral artery disease: a scientific
17.Behrendt CA, Thomalla G, Rimmele DL, Petersen EL, Twerenbold R, Debus ES, et al. statement from the American Heart Association. Circulation 2019;139:e10–33. https://
Editor’s choice—prevalence of peripheral arterial disease, abdominal aortic aneurysm, doi.org/10.1161/cir.0000000000000623
and risk factors in the Hamburg city health study: a cross sectional analysis. Eur J Vasc 38.Poku E, Duncan R, Keetharuth A, Essat M, Phillips P, Woods HB, et al. Patient-reported
Endovasc Surg 2023;65:590–8. https://doi.org/10.1016/j.ejvs.2023.01.002 outcome measures in patients with peripheral arterial disease: a systematic review of
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 127 ---
3664 E S C G u id e l in e s
psychometric properties. Health Qual Life Outcomes 2016;14:161. https://doi.org/10. 61.Nicolaï SP, Viechtbauer W, Kruidenier LM, Candel MJJM, Prins MH, Teijink JAW.
1186/s12955-016-0563-y Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis.
39.Mays RJ, Casserly IP, Kohrt WM, Ho PM, Hiatt WR, Nehler MR, et al. Assessment of J Vasc Surg 2009;50:322–9. https://doi.org/10.1016/j.jvs.2009.01.042
functional status and quality of life in claudication. J Vasc Surg 2011;53:1410–21. https:// 62.Mazzolai L, Belch J, Venermo M, Aboyans V, Brodmann M, Bura-Rivière A, et al.
doi.org/10.1016/j.jvs.2010.11.092 Exercise therapy for chronic symptomatic peripheral artery disease. Eur Heart J
40.Regensteiner JG, Hiatt WR, Coll JR, Criqui MH, Treat-Jacobson D, McDermott MM, 2024;45:1303–21. https://doi.org/10.1093/eurheartj/ehad734
et al. The impact of peripheral arterial disease on health-related quality of life in the 63.McDermott MM, Guralnik JM, Criqui MH, Liu K, Kibbe MR, Ferrucci L. Six-minute walk
peripheral arterial disease awareness, risk, and treatment: new resources for sur- is a better outcome measure than treadmill walking tests in therapeutic trials of pa-
vival (PARTNERS) program. Vasc Med 2008;13:15–24. https://doi.org/10.1177/ tients with peripheral artery disease. Circulation 2014;130:61–8. https://doi.org/10.
1358863x07084911 1161/circulationaha.114.007002
41.Harwood AE, King S, Totty J, Smith GE, Vanicek N, Chetter IC. A systematic review of 64.McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based
muscle morphology and function in intermittent claudication. J Vasc Surg 2017;66: functional performance measures correlate better with physical activity during daily life
1241–57. https://doi.org/10.1016/j.jvs.2017.05.106 than treadmill measures in persons with peripheral arterial disease. J Vasc Surg 2008;
42.Schieber MN, Hasenkamp RM, Pipinos II, Johanning JM, Stergiou N, DeSpiegelaere HK, 48:1231–7.e1. https://doi.org/10.1016/j.jvs.2008.06.050
et al. Muscle strength and control characteristics are altered by peripheral artery dis- 65.ATS Committee on Proficiency Standards for Clinical Pulmonary Function
ease. J Vasc Surg 2017;66:178–86.e12. https://doi.org/10.1016/j.jvs.2017.01.051 Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit
43.Gohil RA, Mockford KA, Mazari F, Khan J, Vanicek N, Chetter IC, et al. Balance impair- Care Med 2002;166:111–7. https://doi.org/10.1164/ajrccm.166.1.at1102
ment, physical ability, and its link with disease severity in patients with intermittent 66.Verdijk LB, van Loon L, Meijer K, Savelberg HH. One-repetition maximum strength
claudication. Ann Vasc Surg 2013;27:68–74. https://doi.org/10.1016/j.avsg.2012.05.005 test represents a valid means to assess leg strength in vivo in humans. J Sports Sci
44.Mockford KA, Mazari FA, Jordan AR, Vanicek N, Chetter IC, Coughlin PA. 2009;27:59–68. https://doi.org/10.1080/02640410802428089
Computerized dynamic posturography in the objective assessment of balance in pa- 67.Ritti-Dias RM, Basyches M, Câmara L, Puech-Leao P, Battistella L, Wolosker N.
tients with intermittent claudication. Ann Vasc Surg 2011;25:182–90. https://doi.org/ Test-retest reliability of isokinetic strength and endurance tests in patients with
10.1016/j.avsg.2010.07.021 intermittent claudication. Vasc Med 2010;15:275–8. https://doi.org/10.1177/
45.Gardner AW, Montgomery PS. Impaired balance and higher prevalence of falls in sub- 1358863x10371415
68.Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short
jects with intermittent claudication. J Gerontol A Biol Sci Med Sci 2001;56:M454–8.
physical performance battery assessing lower extremity function: association with self-
https://doi.org/10.1093/gerona/56.7.m454
reported disability and prediction of mortality and nursing home admission. J Gerontol
46.McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian Lu, Liao Y, et al. Leg symptom
1994;49:M85–94. https://doi.org/10.1093/geronj/49.2.m85
categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr
69.Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity func-
Soc 2010;58:1256–62. https://doi.org/10.1111/j.1532-5415.2010.02941.x
tion in persons over the age of 70 years as a predictor of subsequent disability. N Engl J
47.McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional
Med 1995;332:556–62. https://doi.org/10.1056/nejm199503023320902
decline in peripheral arterial disease: associations with the ankle brachial index and leg
70.Isselbacher EM, Preventza O, Hamilton Black J III, Augoustides JG, Beck AW, Bolen
symptoms. JAMA 2004;292:453–61. https://doi.org/10.1001/jama.292.4.453
MA, et al. 2022 ACC/AHA Guideline for the diagnosis and management of aortic dis-
48.McDermott MM, Greenland P, Guralnik JM, Guralnik JM, Criqui MH, Chan C, et al.
ease: a report of the American Heart Association/American College of Cardiology
Depressive symptoms and lower extremity functioning in men and women with per-
Joint Committee on clinical practice guidelines. J Am Coll Cardiol 2022;80:e223–393.
ipheral arterial disease. J Gen Intern Med 2003;18:461–7. https://doi.org/10.1046/j.
https://doi.org/10.1016/j.jacc.2022.08.004
1525-1497.2003.20527.x
71.Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines
49.Ramirez JL, Drudi LM, Grenon SM. Review of biologic and behavioral risk factors link-
on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J
ing depression and peripheral artery disease. Vasc Med 2018;23:478–88. https://doi.
2021;42:17–96. https://doi.org/10.1093/eurheartj/ehaa605
org/10.1177/1358863X18773161
72.de Heer F, Gökalp AL, Kluin J, Takkenberg JJM. Measuring what matters to the patient:
50.Golledge J, Leicht AS, Yip L, Rowbotham SE, Pinchbeck J, Jenkins JS, et al. Relationship
health related quality of life after aortic valve and thoracic aortic surgery. Gen Thorac
between disease specific quality of life measures, physical performance, and activity in
Cardiovasc Surg 2019;67:37–43. https://doi.org/10.1007/s11748-017-0830-9
people with intermittent claudication caused by peripheral artery disease. Eur J Vasc
73.Chaddha A, Kline-Rogers E, Braverman AC, Erickson SR, Jackson EA, Franklin BA, et al.
Endovasc Surg 2020;59:957–64. https://doi.org/10.1016/j.ejvs.2020.02.006
Survivors of aortic dissection: activity, mental health, and sexual function. Clin Cardiol
51.Gardner AW, Montgomery PS, Wang M, Xu C. Predictors of health-related quality of
2015;38:652–9. https://doi.org/10.1002/clc.22418
life in patients with symptomatic peripheral artery disease. J Vasc Surg 2018;68:
74.Andonian C, Freilinger S, Achenbach S, Ewert P, Gundlach U, Kaemmerer H, et al.
1126–34. https://doi.org/10.1016/j.jvs.2017.12.074
Quality of life in patients with Marfan syndrome: a cross-sectional study of 102 adult
52.McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, et al. Prognostic value of
patients. Cardiovasc Diagn Ther 2021;11:602–10. https://doi.org/10.21037/cdt-20-692
functional performance for mortality in patients with peripheral artery disease. J Am
75.Vanem TT, Rand-Hendriksen S, Brunborg C, Geiran OR, Røe C. Health-related quality
Coll Cardiol 2008;51:1482–9. https://doi.org/10.1016/j.jacc.2007.12.034 of life in Marfan syndrome: a 10-year follow-up. Health Qual Life Outcomes 2020;18:
53.McDermott MM, Guralnik JM, Tian L, Ferrucci L, Liu K, Liao Y, et al. Baseline functional
376. https://doi.org/10.1186/s12955-020-01633-4
performance predicts the rate of mobility loss in persons with peripheral arterial dis- 76.Cervin A, Wanhainen A, Björck M. Popliteal aneurysms are common among men with
ease. J Am Coll Cardiol 2007;50:974–82. https://doi.org/10.1016/j.jacc.2007.05.030 screening detected abdominal aortic aneurysms, and prevalence correlates with the
54.Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC. Quality of diameters of the common iliac arteries. Eur J Vasc Endovasc Surg 2020;59:67–72.
life in patients with no-option critical limb ischemia underlines the need for new effect- https://doi.org/10.1016/j.ejvs.2019.07.042
ive treatment. J Vasc Surg 2010;52:843–9.e1. https://doi.org/10.1016/j.jvs.2010.04.057 77.Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017
55.Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in col-
surveys. Bull World Health Organ 1962;27:645–58 . laboration with the European Society for Vascular Surgery (ESVS): document cov-
56.Leng GC, Fowkes FG. The Edinburgh claudication questionnaire: an improved version ering atherosclerotic disease of extracranial carotid and vertebral, mesenteric,
of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol renal, upper and lower extremity arteries. Endorsed by: the European Stroke
1992;45:1101–9. https://doi.org/10.1016/0895-4356(92)90150-l Organization (ESO), the task force for the diagnosis and treatment of peripheral ar-
57.Birkett ST, Harwood AE, Caldow E, Ibeggazene S, Ingle L, Pymer S. A systematic review terial diseases of the European Society of Cardiology (ESC) and of the European
of exercise testing in patients with intermittent claudication: a focus on test standard- Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816. https://doi.org/
isation and reporting quality in randomised controlled trials of exercise interventions. 10.1093/eurheartj/ehx095
PLoS One 2021;16:e0249277. https://doi.org/10.1371/journal.pone.0249277 78.Ichihashi S, Desormais I, Hashimoto T, Magne J, Kichikawa K, Aboyans V. Accuracy and
58.Harwood AE, Pymer S, Ingle L, Doherty P, Chetter IC, Parmenter B. Exercise training reliability of the ankle brachial index measurement using a multicuff oscillometric de-
for intermittent claudication: a narrative review and summary of guidelines for practi- vice versus the Doppler method. Eur J Vasc Endovasc Surg 2020;60:462–8. https://doi.
tioners. BMJ Open Sport Exerc Med 2020;6:e000897. https://doi.org/10.1136/bmjsem- org/10.1016/j.ejvs.2020.06.013
2020-000897 79.Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al.
59.Treat-Jacobson D, McDermott MM, Beckman JA, Burt MA, Creager MA, Ehrman JK, Measurement and interpretation of the ankle-brachial index: a scientific statement
et al. Implementation of supervised exercise therapy for patients with symptomatic from the American Heart Association. Circulation 2012;126:2890–909. https://doi.
peripheral artery disease: a science advisory from the American Heart Association. org/10.1161/CIR.0b013e318276fbcb
Circulation 2019;140:e700–10. https://doi.org/10.1161/cir.0000000000000727 80.Høyer C, Strandberg J, Overvad Jordansen MK, Zacho HD. The ability of the
60.Hiatt WR, Rogers RK, Brass EP. The treadmill is a better functional test than the 6-mi- toe-brachial index to predict the outcome of treadmill exercise testing in patients
nute walk test in therapeutic trials of patients with peripheral artery disease. Circulation with a normal resting ankle-brachial index. Ann Vasc Surg 2020;64:263–9. https://doi.
2014;130:69–78. https://doi.org/10.1161/circulationaha.113.007003 org/10.1016/j.avsg.2019.10.041
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 128 ---
ESC Guidelines 3665
81.Godet R, Bruneau A, Vielle B, Vincent F, Le Tourneau T, Carre F, et al. Post-exercise 104. Stivalet O, Paisant A, Belabbas D, Omarjee L, Le Faucheur A, Landreau P, et al. Exercise
ankle blood pressure and ankle to brachial index after heavy load bicycle exercise. testing criteria to diagnose lower extremity peripheral artery disease assessed by
Scand J Med Sci Sports 2018;28:2144–52. https://doi.org/10.1111/sms.13234 computed-tomography angiography. PLoS One 2019;14:e0219082. https://doi.org/10.
82.van Langen H, van Gurp J, Rubbens L. Interobserver variability of ankle-brachial index 1371/journal.pone.0219082
measurements at rest and post exercise in patients with intermittent claudication. Vasc 105. Abraham P, Picquet J, Vielle B, Sigaudo-Roussel D, Paisant-Thouveny F, Enon B, et al.
Med 2009;14:221–6. https://doi.org/10.1177/1358863x08101017 Transcutaneous oxygen pressure measurements on the buttocks during exercise to
83.Stein R, Hriljac I, Halperin JL, Gustavson SM, Teodorescu V, Olin JW, Limitation of the detect proximal arterial ischemia: comparison with arteriography. Circulation 2003;
resting ankle-brachial index in symptomatic patients with peripheral arterial disease. 107:1896–900. https://doi.org/10.1161/01.Cir.0000060500.60646.E0
Vasc Med 2006;11:29–33. https://doi.org/10.1191/1358863x06vm663oa 106. Yamamoto K, Miyata T, Onozuka A, Koyama H, Ohtsu H, Nagawa H. Plantar flexion
84.Abraham P, Desvaux B, Saumet JL. Ankle-brachial index after maximum exercise in as an alternative to treadmill exercise for evaluating patients with intermittent clau-
treadmill and cycle ergometers in athletes. Clin Physiol 1998;18:321–6. https://doi. dication. Eur J Vasc Endovasc Surg 2007;33:325–9. https://doi.org/10.1016/j.ejvs.
org/10.1046/j.1365-2281.1998.00100.x 2006.10.012
85.Stoffers HE, Kester AD, Kaiser V, Rinkens PELM, Kitslaar PJEHM, Knottnerus JA, The 107. Maufus M, Sevestre-Pietri MA, Sessa C, Pignon B, Egelhofer H, Dupas S, et al. Critical
diagnostic value of the measurement of the ankle-brachial systolic pressure index in limb ischaemia and the response to bone marrow-derived cell therapy according to
primary health care. J Clin Epidemiol 1996;49:1401–5. https://doi.org/10.1016/s0895- tcPO(2) measurement. Vasa 2017;46:23–8. https://doi.org/10.1024/0301-1526/
4356(96)00275-2 a000590
86.Ouriel K, McDonnell AE, Metz CE, Zarins CK. Critical evaluation of stress testing in the 108. Leenstra B, Wijnand J, Verhoeven B, Koning O, Teraa M, Verhaar MC, et al.
diagnosis of peripheral vascular disease. Surgery 1982;91:686–93 . Applicability of transcutaneous oxygen tension measurement in the assessment of
87.Laing S, Greenhalgh RM. The detection and progression of asymptomatic peripheral chronic limb-threatening ischemia. Angiology 2020;71:208–16. https://doi.org/10.
arterial disease. Br J Surg 2005;70:628–30. https://doi.org/10.1002/bjs.1800701017 1177/0003319719866958
88.Ankle Brachial Index Collaboration; Fowkes FG, Murray GD, Butcher I, Heald CL, Lee 109. Ott A. Inflammation and transcutaneous measurement of oxygen pressure in
RJ, et al. Ankle brachial index combined with Framingham risk score to predict cardio- dermatology. Adv Exp Med Biol 1987;220:79–82. https://doi.org/10.1007/978-1-
vascular events and mortality: a meta-analysis. JAMA 2008;300:197–208. https://doi. 4613-1927-6_14
org/10.1001/jama.300.2.197 110. Woo Y, Suh YJ, Lee H, Jeong E, Park SC, Yun SS, et al. TcPO2 value can predict wound
89.Criqui MH, McClelland RL, McDermott MM, McDermott MM, Allison MA, Blumenthal healing time in clinical practice of CLTI patients. Ann Vasc Surg 2023;91:249–56. https://
RS, et al. The ankle-brachial index and incident cardiovascular events in the MESA doi.org/10.1016/j.avsg.2022.11.020
111. Wang Z, Hasan R, Firwana B, Elraiyah T, Tsapas A, Prokop L, et al. A systematic review
(multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2010;56:1506–12. https://
and meta-analysis of tests to predict wound healing in diabetic foot. J Vasc Surg 2016;
doi.org/10.1016/j.jacc.2010.04.060
63:29S–36S.e2. https://doi.org/10.1016/j.jvs.2015.10.004
90.Herraiz-Adillo Á, Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP,
112. Yamada T, Ohta T, Ishibashi H, Sugimoto I, Iwata H, Takahashi M, et al. Clinical reliabil-
Solera-Martínez M. The accuracy of toe brachial index and ankle brachial index in
ity and utility of skin perfusion pressure measurement in ischemic limbs—comparison
the diagnosis of lower limb peripheral arterial disease: a systematic review and
with other noninvasive diagnostic methods. J Vasc Surg 2008;47:318–23. https://doi.
meta-analysis. Atherosclerosis 2020;315:81–92. https://doi.org/10.1016/j.
org/10.1016/j.jvs.2007.10.045
atherosclerosis.2020.09.026
113. Noori N, Haruno L, Schroeder I, Vrahas M, Little M, Moon C, et al. Preoperative trans-
91.Tehan PE, Santos D, Chuter VH. A systematic review of the sensitivity and specificity of
cutaneous oxygen perfusion measurements in predicting atraumatic wound healing
the toe-brachial index for detecting peripheral artery disease. Vasc Med 2016;21:
after major lower extremity amputation. Orthopedics 2022;45:174–80. https://doi.
382–9. https://doi.org/10.1177/1358863x16645854
org/10.3928/01477447-20220128-05
92.Fukui M, Tanaka M, Hamaguchi M, Senmaru T, Sakabe K, Asano M, et al. Toe-brachial
114. Nishio H, Minakata K, Kawaguchi A, Kumagai M, Ikeda T, Shimizu A, et al.
index is associated more strongly with albuminuria or glomerular filtration rate than
Transcutaneous oxygen pressure as a surrogate index of lower limb amputation. Int
ankle-brachial index in patients with type 2 diabetes. Hypertens Res 2012;35:745–9.
Angiol 2016;35:565–72.
https://doi.org/10.1038/hr.2012.16
115. Sarin S, Shami S, Shields DA, Scurr JH, Smith PD. Selection of amputation level: a re-
93.Dachun X, Jue L, Liling Z, Xu Y, Hu D, Pagoto SL, et al. Sensitivity and specificity of the
view. Eur J Vasc Surg 1991;5:611–20. https://doi.org/10.1016/s0950-821x(05)80894-1
ankle—brachial index to diagnose peripheral artery disease: a structured review. Vasc
116. Abraham P, Ramondou P, Hersant J, Sempore WY, Feuilloy M, Henni S.
Med 2010;15:361–9. https://doi.org/10.1177/1358863x10378376
Investigation of arterial claudication with transcutaneous oxygen pressure at exer-
94.Morimoto S, Nakajima F, Yurugi T, Morita T, Jo F, Nishikawa M, et al. Risk factors of
cise: interests and limits. Trends Cardiovasc Med 2021;31:218–23. https://doi.org/10.
normal ankle-brachial index and low toe-brachial index in hemodialysis patients.
1016/j.tcm.2020.03.003
Ther Apher Dial 2009;13:103–7. https://doi.org/10.1111/j.1744-9987.2009.00663.x
117. Abraham P, Gu Y, Guo L, Kroeger K, Ouedraogo N, Wennberg P, et al. Clinical ap-
95.Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcifica-
plication of transcutaneous oxygen pressure measurements during exercise.
tion in the feet of diabetic patients and matched non-diabetic control subjects.
Atherosclerosis 2018;276:117–23. https://doi.org/10.1016/j.atherosclerosis.2018.
Diabetologia 1993;36:615–21. https://doi.org/10.1007/bf00404070 07.023
96.Carter SA, Lezack JD. Digital systolic pressures in the lower limb in arterial disease.
118. Colas-Ribas C, Signolet I, Henni S, Feuillloy M, Gagnadoux F, Abraham P. High preva-
Circulation 1971;43:905–14. https://doi.org/10.1161/01.cir.43.6.905 lence of known and unknown pulmonary diseases in patients with claudication during
97.Watanabe Y, Masaki H, Kojima K, Tanemoto K. Toe-brachial index in the second toe: exercise oximetry: a retrospective analysis. Medicine (Baltimore) 2016;95:e4888.
substitutability to toe-brachial index in the great toe and ankle-brachial index. Ann Vasc https://doi.org/10.1097/md.0000000000004888
Dis 2016;9:300–6. https://doi.org/10.3400/avd.oa.16-00078 119. Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. ESVM guideline on
98.Pérez-Martin A, Meyer G, Demattei C, Böge G, Laroche J-P, Quéré I, et al. Validation of peripheral arterial disease. Vasa 2019;48:1–79. https://doi.org/10.1024/0301-1526/
a fully automatic photoplethysmographic device for toe blood pressure measurement. a000834
Eur J Vasc Endovasc Surg 2010;40:515–20. https://doi.org/10.1016/j.ejvs.2010.06.008 120. Schlager O, Francesconi M, Haumer M, Dick P, Sabeti S, Amighi J, et al. Duplex son-
99.Hoyer C, Sandermann J, Petersen LJ. The toe-brachial index in the diagnosis of periph- ography versus angiography for assessment of femoropopliteal arterial disease in a
eral arterial disease. J Vasc Surg 2013;58:231–8. https://doi.org/10.1016/j.jvs.2013.03. ‘real-world’ setting. J Endovasc Ther 2007;14:452–9. https://doi.org/10.1177/
044 152660280701400404
100. Monti M, Calanca L, Alatri A, Mazzolai L. Accuracy of in-patients ankle-brachial index 121. Collins R, Burch J, Cranny G, Aguiar-Ibáñez R, Craig D, Wright K, et al. Duplex ultra-
measurement by medical students. Vasa 2016;45:43–8. https://doi.org/10.1024/0301- sonography, magnetic resonance angiography, and computed tomography angiog-
1526/a000494 raphy for diagnosis and assessment of symptomatic, lower limb peripheral arterial
101. Kaiser V, Kester AD, Stoffers HE, Kitslaar PJ, Knottnerus JA. The influence of experi- disease: systematic review. BMJ 2007;334:1257. https://doi.org/10.1136/bmj.39217.
ence on the reproducibility of the ankle-brachial systolic pressure ratio in peripheral 473275.55
arterial occlusive disease. Eur J Vasc Endovasc Surg 1999;18:25–9. https://doi.org/10. 122. Sprynger M, Rigo F, Moonen M, Aboyans V, Edvardsen T, de Alcantara ML, et al. Focus
1053/ejvs.1999.0843 on echovascular imaging assessment of arterial disease: complement to the ESC
102. Ray SA, Srodon PD, Taylor RS, Dormandy JA. Reliability of ankle:brachial pressure in- Guidelines (PARTIM 1) in collaboration with the working group on aorta and periph-
dex measurement by junior doctors. Br J Surg 1994;81:188–90. https://doi.org/10. eral vascular diseases. Eur Heart J Cardiovasc Imaging 2018;19:1195–221. https://doi.
1002/bjs.1800810208 org/10.1093/ehjci/jey103
103. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman 123. Collins R, Cranny G, Burch J, Aguiar-Ibáñez R, Craig D, Wright K, et al. A systematic
DE, et al. 2016 AHA/ACC Guideline on the management of patients with lower ex- review of duplex ultrasound, magnetic resonance angiography and computed tomog-
tremity peripheral artery disease: a report of the American College of Cardiology/ raphy angiography for the diagnosis and assessment of symptomatic, lower limb per-
American Heart Association task force on clinical practice guidelines. Circulation ipheral arterial disease. Health Technol Assess 2007;11:iii–iv, xi-xiii, 1–184. https://doi.
2017;135:e726–79. https://doi.org/10.1161/CIR.0000000000000471 org/10.3310/hta11200
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 129 ---
3666 E S C G u id e l in e s
124. Rodway AD, Cheal D, Allan C, Pazos-Casal F, Hanna L, Field BCT, et al. Ankle Doppler edge and inner edge-to-inner edge conventions in healthy volunteers. Eur Heart J
for cuffless ankle brachial index estimation and peripheral artery disease diagno- Cardiovasc Imaging 2014;15:415–22. https://doi.org/10.1093/ehjci/jet173
sis independent of diabetes. J Clin Med 2022;12:97. https://doi.org/10.3390/ 146. Vis JC, Rodríguez-Palomares JF, Teixidó-Tura G, Galian-Gay L, Granato C, Guala A,
jcm12010097 et al. Implications of asymmetry and valvular morphotype on echocardiographic mea-
125. Katsanos K, Tepe G, Tsetis D, Fanelli F. Standards of practice for superficial femoral surements of the aortic root in bicuspid aortic valve. J Am Soc Echocardiogr 2019;32:
and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol 2014;37: 105–12. https://doi.org/10.1016/j.echo.2018.08.004
592–603. https://doi.org/10.1007/s00270-014-0876-3 147. Ghulam Ali S, Fusini L, Dalla Cia A, Tamborini G, Gripari P, Muratori M, et al.
126. Coffi SB, Ubbink DT, Zwiers I, van Gurp JA, Legemate DA. Improved assessment of Technological advancements in echocardiographic assessment of thoracic aortic dila-
the hemodynamic significance of borderline iliac stenoses with use of hyperemic du- tation: head to head comparison among multidetector computed tomography, 2-di-
plex scanning. J Vasc Surg 2002;36:575–80. https://doi.org/10.1067/mva.2002.126086 mensional, and 3-dimensional echocardiography measurements. J Thorac Imaging
127. Elsman BH, Legemate DA, de Vos HJ, Mali WP, Eikelboom BC. Hyperaemic colour du- 2018;33:232–9. https://doi.org/10.1097/rti.0000000000000330
plex scanning for the detection of aortoiliac stenoses. a comparative study with 148. Mendoza DD, Kochar M, Devereux RB, Basson CT, Min JK, Holmes K, et al. Impact of
intra-arterial pressure measurement. Eur J Vasc Endovasc Surg 1997;14:462–7. image analysis methodology on diagnostic and surgical classification of patients with
https://doi.org/10.1016/s1078-5884(97)80125-6 thoracic aortic aneurysms. Ann Thorac Surg 2011;92:904–12. https://doi.org/10.1016/
128. Venermo M, Sprynger M, Desormais I, Björck M, Brodmann M, Cohnert T, et al. j.athoracsur.2011.03.130
Follow-up of patients after revascularisation for peripheral arterial diseases: a consen- 149. Campens L, Demulier L, De Groote K, Vandekerckhove K, De Wolf D, Roman MJ,
sus document from the European Society of Cardiology working group on aorta and et al. Reference values for echocardiographic assessment of the diameter of the aortic
peripheral vascular diseases and the European Society for Vascular Surgery. Eur J Prev root and ascending aorta spanning all age categories. Am J Cardiol 2014;114:914–20.
Cardiol 2019;26:1971–84. https://doi.org/10.1177/2047487319846999 https://doi.org/10.1016/j.amjcard.2014.06.024
129. Golemati S, Cokkinos DD. Recent advances in vascular ultrasound imaging technology 150. Pedersen OM, Aslaksen A, Vik-Mo H. Ultrasound measurement of the luminal diam-
and their clinical implications. Ultrasonics 2022;119:106599. https://doi.org/10.1016/j. eter of the abdominal aorta and iliac arteries in patients without vascular disease. J Vasc
ultras.2021.106599 Surg 1993;17:596–601. https://doi.org/10.1067/mva.1993.39525
130. Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E, et al. 151. Kim H, Kwon TW, Choi E, Jeong S, Kim H-K, Han Y, et al. Aortoiliac diameter and
Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with length in a healthy cohort. PLoS One 2022;17:e0268077. https://doi.org/10.1371/
the ABI test. Vasc Med 2018;23:97–106. https://doi.org/10.1177/1358863X17745371
journal.pone.0268077
131. Xu D, Zou L, Xing Y, Hou L, Wei Y, Zhang J, et al. Diagnostic value of ankle-brachial
152. Evangelista A, Flachskampf FA, Erbel R, Antonini-Canterin F, Vlachopoulos C, Rocchi
index in peripheral arterial disease: a meta-analysis. Can J Cardiol 2013;29:492–8.
G, et al. Echocardiography in aortic diseases: EAE recommendations for clinical prac-
https://doi.org/10.1016/j.cjca.2012.06.014
tice. Eur J Echocardiogr 2010;11:645–58. https://doi.org/10.1093/ejechocard/jeq056
132. Hashimoto T, Ichihashi S, Iwakoshi S, Kichikawa K. Combination of pulse volume re-
153. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, et al. Height alone,
cording (PVR) parameters and ankle-brachial index (ABI) improves diagnostic accuracy
rather than body surface area, suffices for risk estimation in ascending aortic aneurysm.
for peripheral arterial disease compared with ABI alone. Hypertens Res 2016;39:430–4.
J Thorac Cardiovasc Surg 2018;155:1938–50. https://doi.org/10.1016/j.jtcvs.2017.10.140
https://doi.org/10.1038/hr.2016.13
154. Masri A, Kalahasti V, Svensson LG, Roselli EE, Johnston D, Hammer D, et al. Aortic
133. Tehan PE, Bray A, Chuter VH. Non-invasive vascular assessment in the foot with dia-
cross-sectional area/height ratio and outcomes in patients with a trileaflet aortic valve
betes: sensitivity and specificity of the ankle brachial index, toe brachial index and con-
and a dilated aorta. Circulation 2016;134:1724–37. https://doi.org/10.1161/
tinuous wave Doppler for detecting peripheral arterial disease. J Diabetes Complications
circulationaha.116.022995
2016;30:155–60. https://doi.org/10.1016/j.jdiacomp.2015.07.019
155. Wu J, Zafar MA, Li Y, Saeyeldin A, Huang Y, Zhao R, et al. Ascending aortic length and
134. Loukas M, Bilinsky E, Bilinsky S, Blaak C, Tubbs RS, Anderson RH. The anatomy of the
risk of aortic adverse events: the neglected dimension. J Am Coll Cardiol 2019;74:
aortic root. Clin Anat 2014;27:748–56. https://doi.org/10.1002/ca.22295
1883–94. https://doi.org/10.1016/j.jacc.2019.07.078
135. Dagenais F. Anatomy of the thoracic aorta and of its branches. Thorac Surg Clin 2011;
156. Pham MHC, Ballegaard C, de Knegt MC, Sigvardsen PE, Sørgaard MH, Fuchs A, et al.
21:219–27, viii. https://doi.org/10.1016/j.thorsurg.2010.12.004
Normal values of aortic dimensions assessed by multidetector computed tomography
136. Lombardi JV, Hughes GC, Appoo JJ, Bavaria JE, Beck AW, Cambria RP, et al. Society for
in the Copenhagen general population study. Eur Heart J Cardiovasc Imaging 2019;20:
Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) reporting standards for
939–48. https://doi.org/10.1093/ehjci/jez012
type B aortic dissections. Ann Thorac Surg 2020;109:959–81. https://doi.org/10.1016/j.
157. Davis AE, Lewandowski AJ, Holloway CJ, Ntusi NAB, Banerjee R, Nethononda R, et al.
athoracsur.2019.10.005
Observational study of regional aortic size referenced to body size: production of a
137. Rodríguez-Palomares JF, Teixidó-Tura G, Galuppo V, Cuéllar H, Laynez A, Gutiérrez L,
cardiovascular magnetic resonance nomogram. J Cardiovasc Magn Reson 2014;16:9.
et al. Multimodality assessment of ascending aortic diameters: comparison of different
https://doi.org/10.1186/1532-429x-16-9
measurement methods. J Am Soc Echocardiogr 2016;29:819–26.e4. https://doi.org/10.
158. Braley KT, Tang X, Makil ES, Borroughs-Ray D, Collins RT. The impact of body weight
1016/j.echo.2016.04.006
on the diagnosis of aortic dilation—misdiagnosis in overweight and underweight
138. Saura D, Dulgheru R, Caballero L, Bernard A, Kou S, Gonjilashvili N, et al.
groups. Echocardiography 2017;34:1029–34. https://doi.org/10.1111/echo.13565 Two-dimensional transthoracic echocardiographic normal reference ranges for prox-
159. Evangelista A, Sitges M, Jondeau G, Nijveldt R, Pepi M, Cuellar H, et al. Multimodality
imal aorta dimensions: results from the EACVI NORRE study. Eur Heart J Cardiovasc
imaging in thoracic aortic diseases: a clinical consensus statement from the European
Imaging 2017;18:167–79. https://doi.org/10.1093/ehjci/jew053
139. Bons LR, Duijnhouwer AL, Boccalini S, van den Hoven AT, van der Vlugt MJ, Chelu RG, Association of Cardiovascular Imaging and the European Society of Cardiology work-
et al. Intermodality variation of aortic dimensions: how, where and when to measure ing group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging
the ascending aorta. Int J Cardiol 2019;276:230–5. https://doi.org/10.1016/j.ijcard.2018. 2023;24:e65–85. https://doi.org/10.1093/ehjci/jead024
08.067 160. Macdonald DB, Hurrell C, Costa AF, McInnes MDF, O’Malley ME, Barrett B, et al.
140. Amsallem M, Ou P, Milleron O, Henry-Feugeas M-C, Detaint D, Arnoult F, et al. Canadian Association of Radiologists Guidance on contrast associated acute kid-
Comparative assessment of ascending aortic aneurysms in Marfan patients using ney injury. Can Assoc Radiol J 2022;73:499–514. https://doi.org/10.1177/
ECG-gated computerized tomographic angiography versus trans-thoracic echocardi- 08465371221083970
ography. Int J Cardiol 2015;184:22–7. https://doi.org/10.1016/j.ijcard.2015.01.086 161. Committee opinion no. 723: guidelines for diagnostic imaging during pregnancy and
141. Matthews EO, Pinchbeck J, Elmore K, Jones RE, Moxon JV, Golledge J. The reprodu- lactation. Obstet Gynecol 2017;130:e210–6. https://doi.org/10.1097/AOG.000000000
cibility of measuring maximum abdominal aortic aneurysm diameter from ultrasound 0002355
images. Ultrasound J 2021;13:13. https://doi.org/10.1186/s13089-021-00211-z 162. von Kodolitsch Y, Nienaber CA, Dieckmann C, Schwartz AG, Hofmann T, Brekenfeld
142. Bonnafy T, Lacroix P, Desormais I, Labrunie A, Marin B, Leclerc A, et al. Reliability of C, et al. Chest radiography for the diagnosis of acute aortic syndrome. Am J Med 2004;
the measurement of the abdominal aortic diameter by novice operators using a 116:73–7. https://doi.org/10.1016/j.amjmed.2003.08.030
pocket-sized ultrasound system. Arch Cardiovasc Dis 2013;106:644–50. https://doi. 163. Nazerian P, Pivetta E, Veglia S, Cavigli E, Mueller C, de Matos Soeiro A, et al. Integrated
org/10.1016/j.acvd.2013.08.004 use of conventional chest radiography cannot rule out acute aortic syndromes in
143. Fitzgerald BT, Kwon A, Scalia GM. The new dimension in aortic measurements—use emergency department patients at low clinical probability. Acad Emerg Med 2019;
of the inner edge measurement for the thoracic aorta in Australian patients. Heart Lung 26:1255–65. https://doi.org/10.1111/acem.13819
Circ 2015;24:1104–10. https://doi.org/10.1016/j.hlc.2015.05.001 164. Hartnell GG, Wakeley CJ, Tottle A, Papouchado M, Wilde RP. Limitations of chest
144. Burman ED, Keegan J, Kilner PJ. Aortic root measurement by cardiovascular magnetic radiography in discriminating between aortic dissection and myocardial infarction: im-
resonance: specification of planes and lines of measurement and corresponding nor- plications for thrombolysis. J Thorac Imaging 1993;8:152–5. https://doi.org/10.1097/
mal values. Circ Cardiovasc Imaging 2008;1:104–13. https://doi.org/10.1161/ 00005382-199321000-00008
circimaging.108.768911 165. Evangelista A, Avegliano G, Aguilar R, Cuellar H, Igual A, Gonzalez-Alujas T, et al.
145. Muraru D, Maffessanti F, Kocabay G, Peluso D, Bianco LD, Piasentini E, et al. Ascending Impact of contrast-enhanced echocardiography on the diagnostic algorithm of acute
aorta diameters measured by echocardiography using both leading edge-to-leading aortic dissection. Eur Heart J 2010;31:472–9. https://doi.org/10.1093/eurheartj/ehp505
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 130 ---
ESC Guidelines 3667
166. Litmanovich D, Bankier AA, Cantin L, Raptopoulos V, Boiselle PM. CT and MRI in dis- 188. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR re-
eases of the aorta. AJR Am J Roentgenol 2009;193:928–40. https://doi.org/10.2214/ajr. commendations for the use of imaging in large vessel vasculitis in clinical practice.
08.2166 Ann Rheum Dis 2018;77:636–43. https://doi.org/10.1136/annrheumdis-2017-212649
167. Pennell DJ, Sechtem UP, Higgins CB, Manning W, Pohost G, Rademakers F, et al. 189. Forsythe RO, Dweck MR, McBride OMB, Vesey AT, Semple SI, Shah ASV, et al. (18)
Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel re- F-sodium fluoride uptake in abdominal aortic aneurysms: the SoFIA(3) study. J Am
port. J Cardiovasc Magn Reson 2004;6:727–65. https://doi.org/10.1081/jcmr- Coll Cardiol 2018;71:513–23. https://doi.org/10.1016/j.jacc.2017.11.053
200038581 190. Roque A, Pizzi MN. (18)F-FDG PET/CT: not only a promise for complex scenarios-
168. Yoshioka K, Tanaka R. MRI and MRA of aortic disease. Ann Vasc Dis 2010;3:196–201. let’s talk about aortic grafts. J Nucl Cardiol 2022;29:2949–51. https://doi.org/10.1007/
https://doi.org/10.3400/avd.sasdi10003 s12350-021-02888-0
169. Fadel BM, Mohty D, Kazzi BE, Alamro B, Arshi F, Mustafa M, et al. Ultrasound imaging of 191. Roque A, Pizzi MN, Fernández-Hidalgo N, Permanyer E, Cuellar-Calabria H,
the abdominal aorta: a comprehensive review. J Am Soc Echocardiogr 2021;34:1119–36. Romero-Farina G, et al. Morpho-metabolic post-surgical patterns of non-infected
https://doi.org/10.1016/j.echo.2021.06.012 prosthetic heart valves by [18F]FDG PET/CTA: ‘normality’ is a possible diagnosis.
170. Bhave NM, Nienaber CA, Clough RE, Eagle KA. Multimodality imaging of thoracic aor- Eur Heart J Cardiovasc Imaging 2020;21:24–33. https://doi.org/10.1093/ehjci/jez222
tic diseases in adults. JACC Cardiovasc Imaging 2018;11:902–19. https://doi.org/10.1016/ 192. Pizzi MN, Roque A, Cuéllar-Calabria H, Fernández-Hidalgo N, Ferreira-González I,
j.jcmg.2018.03.009 González-Alujas MT, et al. (18)F-FDG-PET/CTA of prosthetic cardiac valves and valve-
171. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality tube grafts: infective versus inflammatory patterns. JACC Cardiovasc Imaging 2016;9:
imaging of diseases of the thoracic aorta in adults: from the American Society of 1224–7. https://doi.org/10.1016/j.jcmg.2016.05.013
Echocardiography and the European Association of Cardiovascular Imaging: endorsed 193. Pizzi MN, Roque A, Fernández-Hidalgo N, Cuéllar-Calabria H, Ferreira-González I,
by the Society of Cardiovascular Computed Tomography and Society for Gonzàlez-Alujas MT, et al. Improving the diagnosis of infective endocarditis in pros-
Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119–82. https:// thetic valves and intracardiac devices with 18F-fluordeoxyglucose positron emission
doi.org/10.1016/j.echo.2014.11.015 tomography/computed tomography angiography: initial results at an infective endocar-
172. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ditis referral center. Circulation 2015;132:1113–26. https://doi.org/10.1161/
ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering circulationaha.115.015316
acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The 194. Teraa M, Hazenberg CE, Houben IB, Trimarchi S, van Herwaarden JA. Important issues
task force for the diagnosis and treatment of aortic diseases of the European Society of regarding planning and sizing for emergent TEVAR. J Cardiovasc Surg (Torino) 2020;61:
Cardiology (ESC). Eur Heart J 2014;35:2873–926. https://doi.org/10.1093/eurheartj/ 708–12. https://doi.org/10.23736/S0021-9509.20.11571-4
ehu281 195. Lindholt JS, Sogaard R. Population screening and intervention for vascular disease in
173. Bossone E, Czerny M, Lerakis S, Rodríguez-Palomares J, Kukar N, Ranieri B, et al. Danish men (VIVA): a randomised controlled trial. Lancet 2017;390:2256–65.
Imaging and biomarkers in acute aortic syndromes: diagnostic and prognostic implica- https://doi.org/10.1016/S0140-6736(17)32250-X
tions. Curr Probl Cardiol 2021;46:100654. https://doi.org/10.1016/j.cpcardiol.2020. 196. Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk
100654 factors in cardiovascular disease risk assessment: updated evidence report and system-
174. Bossone E, LaBounty TM, Eagle KA. Acute aortic syndromes: diagnosis and manage- atic review for the US preventive services task force. JAMA 2018;320:281–97. https://
ment, an update. Eur Heart J 2018;39:739–49d. https://doi.org/10.1093/eurheartj/ doi.org/10.1001/jama.2018.4242
ehx319 197. Normahani P, Burgess L, Norrie J, Epstein DM, Kandiyil N, Saratzis A, et al. Study
175. Vardhanabhuti V, Nicol E, Morgan-Hughes G, Roobottom CA, Roditi G, Hamilton protocol for a multicentre comparative diagnostic accuracy study of tools to establish
MCK, et al. Recommendations for accurate CT diagnosis of suspected acute aortic the presence and severity of peripheral arterial disease in people with diabetes melli-
syndrome (AAS)—on behalf of the British Society of Cardiovascular Imaging (BSCI)/ tus: the DM PAD study. BMJ Open 2022;12:e066950. https://doi.org/10.1136/
British Society of Cardiovascular CT (BSCCT). Br J Radiol 2016;89:20150705. bmjopen-2022-066950
https://doi.org/10.1259/bjr.20150705 198. Ueshima D, Barioli A, Nai Fovino L, D’Amico G, Fabris T, Brener SJ, et al. The impact of
176. Carstensen M, Keer D, Rempel J, Jeon P, Barrett B. Prevalence of risk factors for pre-existing peripheral artery disease on transcatheter aortic valve implantation out-
contrast-induced nephrotoxicity in outpatients undergoing intravenous comes: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2020;95:
contrast-enhanced computed tomography studies. Can Assoc Radiol J 2012;63: 993–1000. https://doi.org/10.1002/ccd.28335
177–82. https://doi.org/10.1016/j.carj.2010.12.004 199. de Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O’Leary DH, et al.
177. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation expos- Prevalence of asymptomatic carotid artery stenosis in the general population: an indi-
ure. N Engl J Med 2007;357:2277–84. https://doi.org/10.1056/NEJMra072149 vidual participant data meta-analysis. Stroke 2010;41:1294–7. https://doi.org/10.1161/
178. Barra L, Kanji T, Malette J, Pagnoux C. Imaging modalities for the diagnosis and disease STROKEAHA.110.581058
activity assessment of Takayasu’s arteritis: a systematic review and meta-analysis. 200. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al.
Autoimmun Rev 2018;17:175–87. https://doi.org/10.1016/j.autrev.2017.11.021 Screening for asymptomatic carotid artery stenosis: US preventive services task force
179. Dyverfeldt P, Bissell M, Barker AJ, Bolger AF, Carlhäll C-J, Ebbers T, et al. 4D flow car- recommendation statement. JAMA 2021;325:476–81. https://doi.org/10.1001/jama.
diovascular magnetic resonance consensus statement. J Cardiovasc Magn Reson 2015; 2020.26988
17:72. https://doi.org/10.1186/s12968-015-0174-5 201. AbuRahma AF, Avgerinos ED, Chang RW, Darling RC, Duncan AA, Forbes TL, et al.
180. Rodriguez-Palomares JF. Genetics of bicuspid aortic valve: ready for clinical use? Heart Society for Vascular Surgery clinical practice guidelines for management of extracranial
2022;108:1078–9. https://doi.org/10.1136/heartjnl-2021-320742 cerebrovascular disease. J Vasc Surg 2022;75:4S–22S. https://doi.org/10.1016/j.jvs.2021.
181. Guala A, Teixido-Tura G, Dux-Santoy L, Granato C, Ruiz-Muñoz A, Valente F, et al. 04.073
Decreased rotational flow and circumferential wall shear stress as early markers of 202. Howard DPJ, Gaziano L, Rothwell PM. Risk of stroke in relation to degree of asymp-
descending aorta dilation in Marfan syndrome: a 4D flow CMR study. J Cardiovasc tomatic carotid stenosis: a population-based cohort study, systematic review, and
Magn Reson 2019;21:63. https://doi.org/10.1186/s12968-019-0572-1 meta-analysis. Lancet Neurol 2021;20:193–202. https://doi.org/10.1016/s1474-
182. Horowitz MJ, Kupsky DF, El-Said HG, Alshawabkeh L, Kligerman SJ, Hsiao A. 4D flow 4422(20)30484-1
MRI quantification of congenital shunts: comparison to invasive catheterization. Radiol 203. Paraskevas KI, Spence JD, Mikhailidis DP, Antignani PL, Gloviczki P, Eckstein H-H, et al.
Cardiothorac Imaging 2021;3:e200446. https://doi.org/10.1148/ryct.2021200446 Why do guidelines recommend screening for abdominal aortic aneurysms, but not for
183. Rizk J. 4D flow MRI applications in congenital heart disease. Eur Radiol 2021;31: asymptomatic carotid stenosis? A plea for a randomized controlled trial. Int J Cardiol
1160–74. https://doi.org/10.1007/s00330-020-07210-z 2023;371:406–12. https://doi.org/10.1016/j.ijcard.2022.09.045
184. Gupta SK, Ya’qoub L, Wimmer AP, Fisher S, Saeed IM. Safety and clinical impact of MRI 204. Kobo O, Saada M, von Birgelen C, Tonino PAL, Íñiguez-Romo A, Fröbert O, et al.
in patients with non-MRI-conditional cardiac devices. Radiol Cardiothorac Imaging 2020; Impact of multisite artery disease on clinical outcomes after percutaneous coronary
2:e200086. https://doi.org/10.1148/ryct.2020200086 intervention: an analysis from the e-Ultimaster registry. Eur Heart J Qual Care Clin
185. Munawar DA, Chan JEZ, Emami M, Kadhim K, Khokhar K, O’Shea C, et al. Magnetic Outcomes 2023;9:417–26. https://doi.org/10.1093/ehjqcco/qcac043
resonance imaging in non-conditional pacemakers and implantable cardioverter- 205. Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS
defibrillators: a systematic review and meta-analysis. Europace 2020;22:288–98. trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin
https://doi.org/10.1093/europace/euz343 in patients with chronic vascular disease. Circulation 2020;142:40–8. https://doi.org/10.
186. Nienaber CA. The role of imaging in acute aortic syndromes. Eur Heart J Cardiovasc 1161/CIRCULATIONAHA.120.046048
Imaging 2013;14:15–23. https://doi.org/10.1093/ehjci/jes215 206. Del Giorno R, Reveilhac M, Stauffer I, Berthoud M, Mazzolai L, Depairon M, et al. A
187. van der Geest KSM, Treglia G, Glaudemans A, Brouwer E, Sandovici M, Jamar F, et al. new score for improving cardiovascular risk prediction and prevention. Nutr Metab
Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vascu- Cardiovasc Dis 2023;33:1546–55. https://doi.org/10.1016/j.numecd.2023.04.019
litis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021;48: 207. Mehta A, Rigdon J, Tattersall MC, German CA, Barringer TA, Joshi PH, et al.
3886–902. https://doi.org/10.1007/s00259-021-05362-8 Association of carotid artery plaque with cardiovascular events and incident coronary
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 131 ---
3668 E S C G u id e l in e s
artery calcium in individuals with absent coronary calcification: the MESA. Circ 229. Sprynger M, Willems M, Van Damme H, Drieghe B, Wautrecht JC, Moonen M.
Cardiovasc Imaging 2021;14:e011701. https://doi.org/10.1161/circimaging.120.011701 Screening program of abdominal aortic aneurysm. Angiology 2019;70:407–13. https://
208. Gepner AD, Young R, Delaney JA, Budoff MJ, Polak JF, Blaha MJ, et al. Comparison of doi.org/10.1177/0003319718824940
carotid plaque score and coronary artery calcium score for predicting cardiovascular 230. Larsson E, Granath F, Swedenborg J, Hultgren R. A population-based case-control
disease events: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2017;6: study of the familial risk of abdominal aortic aneurysm. J Vasc Surg 2009;49:47–50; dis-
e005179. https://doi.org/10.1161/jaha.116.005179 cussion 51. https://doi.org/10.1016/j.jvs.2008.08.012
209. Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, 231. Linné A, Forsberg J, Lindström D, Ideskog E, Hultgren R. Age at detection of abdominal
Jiménez-Borreguero LJ, et al. Femoral and carotid subclinical atherosclerosis associ- aortic aneurysms in siblings of patients with abdominal aortic aneurysms. J Vasc Surg
ation with risk factors and coronary calcium: the AWHS study. J Am Coll Cardiol 2016;63:883–7. https://doi.org/10.1016/j.jvs.2015.10.057
2016;67:1263–74. https://doi.org/10.1016/j.jacc.2015.12.056 232. Aboyans V, Bataille V, Bliscaux P, Ederhy S, Filliol D, Honton B, et al. Effectiveness of
210. Jacobowitz GR, Rockman CB, Gagne PJ, Adelman MA, Lamparello PJ, Landis R, et al. screening for abdominal aortic aneurysm during echocardiography. Am J Cardiol
A model for predicting occult carotid artery stenosis: screening is justified in a se- 2014;114:1100–4. https://doi.org/10.1016/j.amjcard.2014.07.024
lected population. J Vasc Surg 2003;38:705–9. https://doi.org/10.1016/s0741- 233. Hicks CW, Al-Qunaibet A, Ding N, Kwak L, Folsom AR, Tanaka H, et al. Symptomatic
5214(03)00730-4 and asymptomatic peripheral artery disease and the risk of abdominal aortic aneurysm:
211. Rockman CB, Jacobowitz GR, Gagne PJ, Adelman MA, Lamparello PJ, Landis R, et al. the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2021;333:32–8.
Focused screening for occult carotid artery disease: patients with known heart disease https://doi.org/10.1016/j.atherosclerosis.2021.08.016
are at high risk. J Vasc Surg 2004;39:44–50. https://doi.org/10.1016/j.jvs.2003.07.008 234. Benson RA, Poole R, Murray S, Moxey P, Loftus IM. Screening results from a large
212. Yuo TH, Sidaoui J, Marone LK, Makaroun MS, Chaer RA. Revascularization of asymp- United Kingdom abdominal aortic aneurysm screening center in the context of opti-
tomatic carotid stenosis is not appropriate in patients on dialysis. J Vasc Surg 2015;61: mizing United Kingdom National Abdominal Aortic Aneurysm Screening Programme
670–4. https://doi.org/10.1016/j.jvs.2014.10.002 protocols. J Vasc Surg 2016;63:301–4. https://doi.org/10.1016/j.jvs.2015.08.091
213. Ramos MJ, González-Fajardo JA, Vaquero-Puerta C, Vallina-Victorero M, 235. Sciria CT, Osorio B, Wang J, Lu DY, Amin N, Vohra A, et al. Sex-based disparities in
Vicente-Santiago M, Vaquero-Lorenzo F, et al. Asymptomatic carotid stenosis in pa- outcomes with abdominal aortic aneurysms. Am J Cardiol 2021;155:135–48. https://
tients with intermittent claudication: epidemiological study. J Cardiovasc Surg (Torino) doi.org/10.1016/j.amjcard.2021.06.023
236. Carter JL, Morris DR, Sherliker P, Clack R, Lam KBH, Halliday A, et al. Sex-specific as-
2011;52:761–8 .
214. Aboyans V, Lacroix P, Guilloux J, Rollé F, Le Guyader A, Cautrès M, et al. A predictive sociations of vascular risk factors with abdominal aortic aneurysm: findings from 1.5
million women and 0.8 million men in the United States and United Kingdom. J Am
model for screening cerebrovascular disease in patient undergoing coronary artery by-
Heart Assoc 2020;9:e014748. https://doi.org/10.1161/JAHA.119.014748
pass grafting. Interact Cardiovasc Thorac Surg 2005;4:90–5. https://doi.org/10.1510/icvts.
237. Wanhainen A, Lundkvist J, Bergqvist D, Bjorck M. Cost-effectiveness of screening wo-
2004.092262
men for abdominal aortic aneurysm. J Vasc Surg 2006;43:908–14; discussion 914.
215. Cornily JC, Le Saux D, Vinsonneau U, Bezon E, Le Ven F, Le Gal G, et al. Assessment of
https://doi.org/10.1016/j.jvs.2005.12.064
carotid artery stenosis before coronary artery bypass surgery. Is it always necessary?
238. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to
Arch Cardiovasc Dis 2011;104:77–83. https://doi.org/10.1016/j.acvd.2010.11.008
the Mediterranean diet on health: an updated systematic review and meta-analysis. Am
216. Johansson EP, Wester P. Carotid bruits as predictor for carotid stenoses detected by
J Clin Nutr 2010;92:1189–96. https://doi.org/10.3945/ajcn.2010.29673
ultrasonography: an observational study. BMC Neurol 2008;8:23. https://doi.org/10.
239. Mente A, Dehghan M, Rangarajan S, O’Donnell M, Hu W, Dagenais G, et al. Diet, car-
1186/1471-2377-8-23
diovascular disease, and mortality in 80 countries. Eur Heart J 2023;44:2560–79.
217. Carmody BJ, Arora S, Avena R, Curry KM, Simpkins J, Cosby K, et al. Accelerated ca-
https://doi.org/10.1093/eurheartj/ehad269
rotid artery disease after high-dose head and neck radiotherapy: is there a role for rou-
240. Wan D, Dehghan M, de Souza RJ, Ramasundarahettige C, Eikelboom JW, Bosch J, et al.
tine carotid duplex surveillance? J Vasc Surg 1999;30:1045–51. https://doi.org/10.1016/
Dietary intake and cardiovascular outcomes in patients with chronic vascular disease:
s0741-5214(99)70042-x
insights from the COMPASS trial cohort. Eur J Prev Cardiol 2023;30:709–18. https://doi.
218. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and
org/10.1093/eurjpc/zwad062
national prevalence and risk factors for peripheral artery disease in 2015: an updated
241. Adegbola A, Behrendt CA, Zyriax BC, Windler E, Kreutzburg T. The impact of nutri-
systematic review and analysis. Lancet Glob Health 2019;7:e1020–30. https://doi.org/10.
tion on the development and progression of peripheral artery disease: a systematic re-
1016/s2214-109x(19)30255-4
view. Clin Nutr 2022;41:49–70. https://doi.org/10.1016/j.clnu.2021.11.005
219. Campia U, Gerhard-Herman M, Piazza G, Goldhaber SZ. Peripheral artery disease:
242. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/
past, present, and future. Am J Med 2019;132:1133–41. https://doi.org/10.1016/j.
EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce car-
amjmed.2019.04.043
diovascular risk. Eur Heart J 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455
220. Søgaard R, Lindholt JS. Cost-effectiveness of population-based vascular disease screen-
243. Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee B-C, et al. Benefit of tar-
ing and intervention in men from the Viborg Vascular (VIVA) trial. Br J Surg 2018;105:
geting a LDL (low-density lipoprotein) cholesterol <70 mg/dL during 5 years after is-
1283–93. https://doi.org/10.1002/bjs.10872
chemic stroke. Stroke 2020;51:1231–9. https://doi.org/10.1161/strokeaha.119.028718
221. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneur- 244. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral ar-
ysms: single centre randomised controlled trial. BMJ 2005;330:750. https://doi.org/
terial disease of the lower limb. Cochrane Database Syst Rev 2007;4:CD000123. https://
10.1136/bmj.38369.620162.82 doi.org/10.1002/14651858.CD000123.pub2
222. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, et al. 245. Heart Protection Study Collaborative Group. Randomized trial of the effects of
Population based randomised controlled trial on impact of screening on mortality cholesterol-lowering with simvastatin on peripheral vascular and other major vascular
from abdominal aortic aneurysm. BMJ 2004;329:1259. https://doi.org/10.1136/bmj. outcomes in 20,536 people with peripheral arterial disease and other high-risk condi-
38272.478438.55 tions. J Vasc Surg 2007;45:645–54; discussion 653–644. https://doi.org/10.1016/j.jvs.
223. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, et al. The multicentre 2006.12.054
aneurysm screening study (MASS) into the effect of abdominal aortic aneurysm 246. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and
screening on mortality in men: a randomised controlled trial. Lancet 2002;360: safety of cholesterol-lowering treatment: prospective meta-analysis of data from
1531–9. https://doi.org/10.1016/s0140-6736(02)11522-4 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78.
224. Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on the incidence of https://doi.org/10.1016/S0140-6736(05)67394-1
ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. 247. Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park J-G, et al.
Br J Surg 1995;82:1066–70. https://doi.org/10.1002/bjs.1800820821 Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis
225. Duncan A, Maslen C, Gibson C, Hartshorne T, Farooqi A, Saratzis A, et al. Ultrasound of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018;6:934–43. https://doi.org/10.
screening for abdominal aortic aneurysm in high-risk women. Br J Surg 2021;108: 1016/s2213-8587(18)30290-0
1192–8. https://doi.org/10.1093/bjs/znab220 248. Yu E, Malik VS, Hu FB. Cardiovascular disease prevention by diet modification: JACC
226. Lindholt JS, Sogaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. health promotion series. J Am Coll Cardiol 2018;72:914–26. https://doi.org/10.1016/j.
Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl jacc.2018.02.085
J Med 2022;387:1385–94. https://doi.org/10.1056/NEJMoa2208681 249. López-Laguna N, Martínez-González MA, Toledo E, Babio N, Sorlí JV, Ros E, et al. Risk
227. Howard DP, Banerjee A, Fairhead JF, Handa A, Silver LE, Rothwell PM. of peripheral artery disease according to a healthy lifestyle score: the PREDIMED
Population-based study of incidence of acute abdominal aortic aneurysms with pro- study. Atherosclerosis 2018;275:133–40. https://doi.org/10.1016/j.atherosclerosis.
jected impact of screening strategy. J Am Heart Assoc 2015;4:e001926. https://doi. 2018.05.049
org/10.1161/JAHA.115.001926 250. Kaluza J, Stackelberg O, Harris HR, Akesson A, Björck M, Wolk A. Mediterranean diet
228. Howard DP, Banerjee A, Fairhead JF, Handa A, Silver LE, Rothwell PM. Age-specific is associated with reduced risk of abdominal aortic aneurysm in smokers: results of
incidence, risk factors and outcome of acute abdominal aortic aneurysms in a defined two prospective cohort studies. Eur J Vasc Endovasc Surg 2021;62:284–93. https://
population. Br J Surg 2015;102:907–15. https://doi.org/10.1002/bjs.9838 doi.org/10.1016/j.ejvs.2021.04.017
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 132 ---
ESC Guidelines 3669
251. Liu L, Yang Y. Nutritional management mode of early cardiac rehabilitation in patients 273. Abbott AJ, Reibel YG, Arnett MC, Marka N, Drake MA. Oral and systemic health im-
with Stanford type A aortic dissection. Comput Math Methods Med 2022;2022: plications of electronic cigarette usage as compared to conventional tobacco cigar-
2124636. https://doi.org/10.1155/2022/2124636 ettes: a review of the literature. J Dent Hyg 2023;97:21–35.
252. Lauret GJ, Fokkenrood HJ, Bendermacher BL, Scheltinga MR, Teijink JA. Physical activ- 274. Hamann SL, Kungskulniti N, Charoenca N, Kasemsup V, Ruangkanchanasetr S,
ity monitoring in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2014; Jongkhajornpong P. Electronic cigarette harms: aggregate evidence shows damage to
47:656–63. https://doi.org/10.1016/j.ejvs.2014.03.001 biological systems. Int J Environ Res Public Health 2023;20:6808. https://doi.org/10.
253. Gardner AW, Addison O, Katzel LI, Montgomery PS, Prior SJ, Serra MC, et al. 3390/ijerph20196808
Association between physical activity and mortality in patients with claudication. 275. Kavousi M, Pisinger C, Barthelemy JC, De Smedt D, Koskinas K, Marques-Vidal P, et al.
Med Sci Sports Exerc 2021;53:732–9. https://doi.org/10.1249/mss.0000000000002526 Electronic cigarettes and health with special focus on cardiovascular effects: position
254. Gardner AW, Montgomery PS, Parker DE. Physical activity is a predictor of all-cause paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev
mortality in patients with intermittent claudication. J Vasc Surg 2008;47:117–22. https:// Cardiol 2021;28:1552–66. https://doi.org/10.1177/2047487320941993
doi.org/10.1016/j.jvs.2007.09.033 276. Goldman RE, Parker DR, Eaton CB, Borkan JM, Gramling R, Cover RT, et al. Patients’
255. Gardner AW, Montgomery PS, Wang M, Shen B, Zhang S, Pomilla WA. Association perceptions of cholesterol, cardiovascular disease risk, and risk communication strat-
egies. Ann Fam Med 2006;4:205–12. https://doi.org/10.1370/afm.534
between meeting physical activity time-intensity guidelines with ambulation, quality
277. Howarth M, Lister C. Social prescribing in cardiology: rediscovering the nature within
of life, and inflammation in claudication. J Cardiopulm Rehabil Prev 2022;42:E82–9.
us. Br J Card Nurs 2019;14:1–9. https://doi.org/10.12968/bjca.2019.0036
https://doi.org/10.1097/hcr.0000000000000686
278. Nichols LO, Martindale-Adams J, Burns R, Graney MJ, Zuber J. Translation of a demen-
256. Thijssen CGE, Bons LR, Gökalp AL, Van Kimmenade RRJ, Mokhles MM, Pelliccia A,
tia caregiver support program in a health care system—REACH VA. Arch Intern Med
et al. Exercise and sports participation in patients with thoracic aortic disease: a review.
2011;171:353–9. https://doi.org/10.1001/archinternmed.2010.548
Expert Rev Cardiovasc Ther 2019;17:251–66. https://doi.org/10.1080/14779072.2019.
279. Martire LM, Schulz R, Keefe FJ, Rudy TE, Starz TW. Couple-oriented education and
1585807
support intervention for osteoarthritis: effects on spouses’ support and responses
257. Delsart P, Maldonado-Kauffmann P, Bic M, Boudghene-Stambouli F, Sobocinski J,
to patient pain. Fam Syst Health 2008;26:185–95. https://doi.org/10.1037/1091-7527.
Juthier F, et al. Post aortic dissection: gap between activity recommendation and
26.2.185
real life patients aerobic capacities. Int J Cardiol 2016;219:271–6. https://doi.org/10.
280. Morris SM, King C, Turner M, Payne S. Family carers providing support to a person
1016/j.ijcard.2016.06.026
dying in the home setting: a narrative literature review. Palliat Med 2015;29:487–95.
258. Chaddha A, Eagle KA, Braverman AC, Kline-Rogers E, Hirsch AT, Brook R, et al.
https://doi.org/10.1177/0269216314565706
Exercise and physical activity for the post-aortic dissection patient: the clinician’s con- 281. Ventura AD, Burney S, Brooker J, Fletcher J, Ricciardelli L. Home-based palliative care:
undrum. Clin Cardiol 2015;38:647–51. https://doi.org/10.1002/clc.22481 a systematic literature review of the self-reported unmet needs of patients and carers.
259. Chaddha A, Kline-Rogers E, Woznicki EM, Brook R, Housholder-Hughes S, Braverman Palliat Med 2014;28:391–402. https://doi.org/10.1177/0269216313511141
AC, et al. Cardiology patient page. Activity recommendations for postaortic dissection 282. Reynolds CF, III, Jeste DV, Sachdev PS, Blazer DG. Mental health care for older adults:
patients. Circulation 2014;130:e140–2. https://doi.org/10.1161/circulationaha.113. recent advances and new directions in clinical practice and research. World Psychiatry
005819 2022;21:336–63. https://doi.org/10.1002/wps.20996
260. Katsiki N, Papadopoulou SK, Fachantidou AI, Mikhailidis DP. Smoking and vascular risk: 283. Katch H. The role of self-efficacy in cardiovascular disease self-management: a review
are all forms of smoking harmful to all types of vascular disease? Public Health 2013; of effective programs. Patient Intelligence 2010;2:33–4. doi: https://doi.org/10.2147/PI.
127:435–41. https://doi.org/10.1016/j.puhe.2012.12.021 S12624]
261. Wu CW, Chuang HY, Watanabe K, Wu P-S, Pan H-C, Wang C-L, et al. Association 284. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, et al. The REduction of
between secondhand smoke and peripheral arterial disease: a meta-analysis of cross- Atherothrombosis for Continued Health (REACH) registry: an international, pro-
sectional studies. Int Arch Occup Environ Health 2022;95:1091–101. https://doi.org/10. spective, observational investigation in subjects at risk for atherothrombotic events–
1007/s00420-022-01837-9 study design. Am Heart J 2006;151:786.e1–10. https://doi.org/10.1016/j.ahj.2005.11.
262. Sode BF, Nordestgaard BG, Gronbaek M, Dahl M. Tobacco smoking and aortic aneur- 004
ysm: two population-based studies. Int J Cardiol 2013;167:2271–7. https://doi.org/10. 285. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifesta-
1016/j.ijcard.2012.06.003 tions of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15:
263. Altobelli E, Rapacchietta L, Profeta VF, Fagnano R. Risk factors for abdominal aortic 773–81. https://doi.org/10.1023/a:1007621514757
aneurysm in population-based studies: a systematic review and meta-analysis. Int J 286. Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJA, Steyerberg EW, Ridker PM,
Environ Res Public Health 2018;15:2805. https://doi.org/10.3390/ijerph15122805 et al. Development and validation of a prediction rule for recurrent vascular events
264. Lederle FA, Nelson DB, Joseph AM. Smokers’ relative risk for aortic aneurysm com- based on a cohort study of patients with arterial disease: the SMART risk score.
pared with other smoking-related diseases: a systematic review. J Vasc Surg 2003;38: Heart 2013;99:866–72. https://doi.org/10.1136/heartjnl-2013-303640
329–34. https://doi.org/10.1016/s0741-5214(03)00136-8 287. Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D’Agostino RB, Massaro JM,
265. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and et al. Estimated life expectancy without recurrent cardiovascular events in patients
risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control with vascular disease: the SMART-REACH model. J Am Heart Assoc 2018;7:
e009217. https://doi.org/10.1161/JAHA.118.009217
study. Lancet 2006;368:647–58. https://doi.org/10.1016/S0140-6736(06)69249-0
288. Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of 266. Mahtta D, Ramsey D, Krittanawong C, Al Rifai M, Khurram N, Samad Z, et al.
recurrent atherosclerotic cardiovascular event risk in patients with established cardio- Recreational substance use among patients with premature atherosclerotic cardiovas-
vascular disease: the updated SMART2 algorithm. Eur Heart J 2022;43:1715–27.
cular disease. Heart 2021;107:650–6. https://doi.org/10.1136/heartjnl-2020-318119
https://doi.org/10.1093/eurheartj/ehac056
267. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The ef-
289. van Trier TJ, Snaterse M, Boekholdt SM, Scholte Op Reimer WJM, Hageman SHJ,
fects of a smoking cessation intervention on 14.5-year mortality: a randomized clin-
Visseren FLJ, et al. Validation of systematic coronary risk evaluation 2 (SCORE2)
ical trial. Ann Intern Med 2005;142:233–9. https://doi.org/10.7326/0003-4819-142-
and SCORE2-older persons in the EPIC Norfolk prospective population cohort. Eur
4-200502150-00005
J Prev Cardiol 2024;31:182–9. https://doi.org/10.1093/eurjpc/zwad318
268. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, et al. Efficacy and safety
290. Wan D, Li V, Banfield L, Azab S, de Souza RJ, Anand SS, et al. Diet and nutrition in per-
of smoking cessation interventions in patients with cardiovascular disease: a network
ipheral artery disease: a systematic review. Can J Cardiol 2022;38:672–80. https://doi.
meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes 2017;10:
org/10.1016/j.cjca.2022.01.021
e002458. https://doi.org/10.1161/CIRCOUTCOMES.115.002458
291. Sesso HD, Rist PM, Aragaki AK, Rautiainen S, Johnson LG, Friedenberg G, et al.
269. Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman
Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa
L, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial.
Syst Rev 2023;5:CD006103. https://doi.org/10.1002/14651858.CD006103.pub8 Am J Clin Nutr 2022;115:1501–10. https://doi.org/10.1093/ajcn/nqac056
270. Rose JJ, Krishnan-Sarin S, Exil VJ, Hamburg NM, Fetterman JL, Ichinose F, et al. 292. Bondonno NP, Murray K, Cassidy A, Bondonno CP, Lewis JR, Croft KD, et al. Higher
Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific habitual flavonoid intakes are associated with a lower risk of peripheral artery disease
statement from the American Heart Association. Circulation 2023;148:703–28. hospitalizations. Am J Clin Nutr 2021;113:187–99. https://doi.org/10.1093/ajcn/
https://doi.org/10.1161/CIR.0000000000001160 nqaa300
271. Lindson N, Butler AR, McRobbie H, Bullen C, Hajek P, Begh R, et al. Electronic cigar- 293. Bapir M, Untracht GR, Cooke D, McVey JH, Skene SS, Campagnolo P, et al. Cocoa fla-
ettes for smoking cessation. Cochrane Database Syst Rev 2024;1:CD010216. https://doi. vanol consumption improves lower extremity endothelial function in healthy indivi-
org/10.1002/14651858.CD010216.pub8 duals and people with type 2 diabetes. Food Funct 2022;13:10439–48. https://doi.
272. Travis N, Knoll M, Cadham CJ, Cook S, Warner KE, Fleischer NL, et al. Health effects of org/10.1039/d2fo02017c
electronic cigarettes: an umbrella review and methodological considerations. Int J 294. Fassora M, Calanca L, Jaques C, Mazzolai L, Kayser B, Lanzi S. Intensity-dependent
Environ Res Public Health 2022;19:9054. https://doi.org/10.3390/ijerph19159054 effects of exercise therapy on walking performance and aerobic fitness in
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 133 ---
3670 E S C G u id e l in e s
symptomatic patients with lower-extremity peripheral artery disease: a systematic 314. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease.
review and meta-analysis. Vasc Med 2022;27:158–70. https://doi.org/10.1177/ Cochrane Database Syst Rev 2013;9:CD005508. https://doi.org/10.1002/14651858.
1358863x211034577 CD005508.pub3
295. O’Connor EA, Evans CV, Rushkin MC, Redmond N, Lin JS. Behavioral counseling to 315. Kray JE, Dombrovskiy VY, Vogel TR. Use of angiotensin-converting enzyme inhibitors
promote a healthy diet and physical activity for cardiovascular disease prevention in and freedom from amputation after lower extremity revascularization. Vasc Health
adults with cardiovascular risk factors: updated evidence report and systematic review Risk Manag 2017;13:269–74. https://doi.org/10.2147/vhrm.S137698
for the US preventive services task force. JAMA 2020;324:2076–94. https://doi.org/10. 316. Høgh A, Lindholt JS, Nielsen H, Jensen LP, Johnsen SP. Use of angiotensin-converting
1001/jama.2020.17108 enzyme inhibitors and cardiovascular outcomes following primary vascular surgery: a
296. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, et al. nationwide propensity score matched follow-up study. Vasc Endovascular Surg 2012;
Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev 2021;4: 46:515–23. https://doi.org/10.1177/1538574412455229
CD010216. https://doi.org/10.1002/14651858.CD010216.pub5 317. Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting
297. Krabbe B, Espinola-Klein C, Malyar N, Brodmann M, Mazzolai L, Belch JJF, et al. Health enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major
effects of e-cigarettes and their use for smoking cessation from a vascular perspective. adverse cardiovascular events among patients with critical limb ischemia. Vasc Med
Vasa 2023;52:81–5. https://doi.org/10.1024/0301-1526/a001056 2015;20:237–44. https://doi.org/10.1177/1358863x15574321
298. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al. 318. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in
American College of Sports Medicine position stand. Quantity and quality of exercise older persons with prior myocardial infarction and symptomatic peripheral arterial
for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor disease. Am J Cardiol 2001;87:1284–6. https://doi.org/10.1016/s0002-9149(01)
fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports 01521-1
Exerc 2011;43:1334–59. https://doi.org/10.1249/MSS.0b013e318213fefb 319. Soga Y, Iida O, Takahara M, Hirano K, Suzuki K, Kawasaki D. Beta-blocker treatment
299. Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt C-A, Bellmunt-Montoya S, does not worsen critical limb ischemia in patients receiving endovascular therapy.
et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2023 clinical J Atheroscler Thromb 2015;22:481–9. https://doi.org/10.5551/jat.27359
practice guidelines on antithrombotic therapy for vascular diseases. Eur J Vasc 320. Carey RM, Wright JT, Jr, Taler SJ, Whelton PK. Guideline-driven management of
Endovasc Surg 2023;65:627–89. https://doi.org/10.1016/j.ejvs.2023.03.042 hypertension: an evidence-based update. Circ Res 2021;128:827–46. https://doi.org/
300. McEvoy JW, Touyz RM, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, et al. 10.1161/circresaha.121.318083
2024 ESC Guidelines for the management of elevated blood pressure and hyperten- 321. Evans KL, Tuttle KR, Folt DA, Dawson T, Haller ST, Brewster PS, et al. Use of
sion. Eur Heart J 2024. https://doi.org/10.1093/eurheartj/ehae178 renin-angiotensin inhibitors in people with renal artery stenosis. Clin J Am Soc
301. Blood Pressure Lowering Treatment Trialists’ Collaboration. Age-stratified and Nephrol 2014;9:1199–206. https://doi.org/10.2215/cjn.11611113
blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for 322. Hackam DG, Duong-Hua ML, Mamdani M, Li Ping, Tobe SW, Spence JD, et al.
the prevention of cardiovascular disease and death: an individual participant-level Angiotensin inhibition in renovascular disease: a population-based cohort study. Am
data meta-analysis. Lancet 2021;398:1053–64. https://doi.org/10.1016/S0140- Heart J 2008;156:549–55. https://doi.org/10.1016/j.ahj.2008.05.013
6736(21)01921-8 323. Solomon SD, Rice MM, Jablonski KA, Jose P, Domanski M, Sabatine M, et al. Renal func-
302. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood tion and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients
pressure lowering for prevention of cardiovascular disease and death: a systematic re- with chronic stable coronary disease in the Prevention of Events with ACE inhibition
view and meta-analysis. Lancet 2016;387:957–67. https://doi.org/10.1016/s0140- (PEACE) trial. Circulation 2006;114:26–31. https://doi.org/10.1161/circulationaha.105.
6736(15)01225-8 592733
303. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow 324. Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM, et al. Stenting
GM, et al. Intensive vs standard blood pressure control and cardiovascular disease out- and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014;370:
comes in adults aged ≥75 years: a randomized clinical trial. JAMA 2016;315:2673–82. 13–22. https://doi.org/10.1056/NEJMoa1310753
https://doi.org/10.1001/jama.2016.7050 325. Mayr NP, Hapfelmeier A, Martin K, Kurz A, van der Starre P, Babik B, et al. Comparison
304. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure of sedation and general anaesthesia for transcatheter aortic valve implantation on
control in older patients with hypertension. N Engl J Med 2021;385:1268–79. https:// cerebral oxygen saturation and neurocognitive outcomedagger. Br J Anaesth 2016;
doi.org/10.1056/NEJMoa2111437 116:90–9. https://doi.org/10.1093/bja/aev294
305. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on out- 326. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for
come incidence in hypertension. 1. Overview, meta-analyses, and meta-regression abdominal aortic aneurysms in a population-based study: the Tromsø study. Am J
analyses of randomized trials. J Hypertens 2014;32:2285–95. https://doi.org/10.1097/ Epidemiol 2001;154:236–44. https://doi.org/10.1093/aje/154.3.236
hjh.0000000000000378 327. Vogel TR, Dombrovskiy VY, Galiñanes EL, Kruse RL. Preoperative statins and limb
306. Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A ran- salvage after lower extremity revascularization in the Medicare population. Circ
domized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; Cardiovasc Interv 2013;6:694–700. https://doi.org/10.1161/circinterventions.113.
373:2103–16. https://doi.org/10.1056/NEJMoa1511939 000274
307. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an 328. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S, et al. Statin therapy
angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high- and long-term adverse limb outcomes in patients with peripheral artery disease: in-
risk patients. N Engl J Med 2000;342:145–53. https://doi.org/10.1056/ sights from the REACH registry. Eur Heart J 2014;35:2864–72. https://doi.org/10.
nejm200001203420301 1093/eurheartj/ehu080
308. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, 329. Pastori D, Farcomeni A, Milanese A, Del Sole F, Menichelli D, Hiatt WR, et al. Statins
et al. Outcomes among hypertensive patients with concomitant peripheral and coron- and major adverse limb events in patients with peripheral artery disease: a systematic
ary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. review and meta-analysis. Thromb Haemost 2020;120:866–75. https://doi.org/10.1055/
Hypertension 2010;55:48–53. https://doi.org/10.1161/hypertensionaha.109.142240 s-0040-1709711
309. Fudim M, Hopley CW, Huang Z, Kavanagh S, Rockhold FW, Baumgartner I, et al. 330. Su Z, Guo J, Gu Y. Pharmacotherapy in clinical trials for abdominal aortic aneurysms: a
Association of hypertension and arterial blood pressure on limb and cardiovascular systematic review and meta-analysis. Clin Appl Thromb Hemost 2022;28:
outcomes in symptomatic peripheral artery disease: the EUCLID trial. Circ 10760296221120423. https://doi.org/10.1177/10760296221120423
Cardiovasc Qual Outcomes 2020;13:e006512. https://doi.org/10.1161/circoutcomes. 331. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al.
120.006512 Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med
310. Thomas Manapurathe D, Krishna SM, Dewdney B, Moxon JV, Biros E, Golledge J, Effect 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489
of blood pressure lowering medications on leg ischemia in peripheral artery disease 332. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, et al.
patients: a meta-analysis of randomised controlled trials. PLoS One 2017;12: Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a
e0178713. https://doi.org/10.1371/journal.pone.0178713 secondary prevention population. Circulation 2016;134:1419–29. https://doi.org/10.
311. Lu Y, Ballew SH, Tanaka H, Szklo M, Heiss G, Coresh J, et al. 2017 ACC/AHA blood 1161/CIRCULATIONAHA.116.021314
pressure classification and incident peripheral artery disease: the Atherosclerosis Risk 333. Clavijo LC, Caro J, Choi J, Caro JA, Tun H, Rowe V, et al. The addition of evolocumab
in Communities (ARIC) study. Eur J Prev Cardiol 2020;27:51–9. https://doi.org/10.1177/ to maximal tolerated statin therapy improves walking performance in patients with
2047487319865378 peripheral arterial disease and intermittent claudication (Evol-PAD study).
312. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, Cardiovasc Revasc Med 2023;55:1–5. https://doi.org/10.1016/j.carrev.2023.04.020
or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. 334. Cholesterol Treatment Trialists Collaboration; Fulcher J, O’Connell R, Voysey M,
https://doi.org/10.1056/NEJMoa0801317 Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among
313. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al. Impact of ramipril men and women: meta-analysis of individual data from 174,000 participants in 27 ran-
in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J domised trials. Lancet 2015;385:1397–405. https://doi.org/10.1016/S0140-6736(14)
2004;25:17–24. https://doi.org/10.1016/j.ehj.2003.10.033 61368-4
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 134 ---
ESC Guidelines 3671
335. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, et al. 357. Pinchbeck JL, Moxon JV, Rowbotham SE, Bourke M, Lazzaroni S, Morton SK, et al.
Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coron- Randomized placebo-controlled trial assessing the effect of 24-week fenofibrate ther-
ary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol 2016;67:353–61. https://doi.org/ apy on circulating markers of abdominal aortic aneurysm: outcomes from the FAME-2
10.1016/j.jacc.2015.10.077 trial. J Am Heart Assoc 2018;7:e009866. https://doi.org/10.1161/JAHA.118.009866
336. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. 358. Lamb YN. Inclisiran: first approval. Drugs 2021;81:389–95. https://doi.org/10.1007/
Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J s40265-021-01473-6
Med 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664 359. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and
337. Westin GG, Armstrong EJ, Bang H, Yeo K-K, Anderson D, Dawson DL, et al. efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med 2019;380:
Association between statin medications and mortality, major adverse cardiovascular 1022–32. https://doi.org/10.1056/NEJMoa1803917
event, and amputation-free survival in patients with critical limb ischemia. J Am Coll 360. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy
Cardiol 2014;63:682–90. https://doi.org/10.1016/j.jacc.2013.09.073 and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with
338. Belch JJF, Brodmann M, Baumgartner I, Binder CJ, Casula M, Heiss C, et al. hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis 2018;
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. 277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002
Vasa 2021;50:401–11. https://doi.org/10.1024/0301-1526/a000969 361. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic
339. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;
Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: 388:1353–64. https://doi.org/10.1056/NEJMoa2215024
a systematic review and meta-analysis of robust randomised controlled studies. Eur J 362. Balling M, Afzal S, Davey Smith G, Varbo A, Langsted A, Kamstrup PR, et al. Elevated
Vasc Endovasc Surg 2009;38:463–74. https://doi.org/10.1016/j.ejvs.2009.06.002 LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol 2023;81:136–52. https://
340. Flint AC, Conell C, Ren X, Kamel H, Chan SL, Rao VA, et al. Statin adherence is asso- doi.org/10.1016/j.jacc.2022.10.019
ciated with reduced recurrent stroke risk in patients with or without atrial fibrillation. 363. Gao JW, Hao QY, Gao M, Zhang K, Li X-Z, Wang J-F, et al. Triglyceride-glucose index
Stroke 2017;48:1788–94. https://doi.org/10.1161/strokeaha.117.017343 in the development of peripheral artery disease: findings from the Atherosclerosis Risk
341. Merwick Á, Albers GW, Arsava EM, Ay H, Calvet D, Coutts SB, et al. Reduction in early in Communities (ARIC) study. Cardiovasc Diabetol 2021;20:126. https://doi.org/10.
stroke risk in carotid stenosis with transient ischemic attack associated with statin 1186/s12933-021-01319-1
treatment. Stroke 2013;44:2814–20. https://doi.org/10.1161/strokeaha.113.001576 364. Britton KA, Mukamal KJ, Ix JH, Siscovick DS, Newman AB, de Boer IH, et al. Insulin re-
342. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and sistance and incident peripheral artery disease in the cardiovascular health study. Vasc
updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453–63. Med 2012;17:85–93. https://doi.org/10.1177/1358863X11436195
https://doi.org/10.1016/s1474-4422(09)70058-4 365. Pande RL, Perlstein TS, Beckman JA, Creager MA. Association of insulin resistance and
343. Amarenco P, Bogousslavsky J, Callahan A, III, Goldstein LB, Hennerici M, Rudolph AE, inflammation with peripheral arterial disease: the National Health and Nutrition
et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med Examination Survey, 1999 to 2004. Circulation 2008;118:33–41. https://doi.org/10.
2006;355:549–59. https://doi.org/10.1056/NEJMoa061894 1161/CIRCULATIONAHA.107.721878
344. Hackam DG, Wu F, Li P, Austin PC, Tobe SW, Mamdani MM, et al. Statins and reno- 366. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovas-
vascular disease in the elderly: a population-based cohort study. Eur Heart J 2011;32: cular disease and stroke. Cochrane Database Syst Rev 2015;10:CD009580. https://doi.
598–610. https://doi.org/10.1093/eurheartj/ehq452 org/10.1002/14651858.CD009580.pub2
345. Peng M, Dong H, Jiang X, Che W, Zou Y, Zhang Y, et al. A randomized unblinded trial 367. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arter-
to compare effects of intensive versus conventional lipid-lowering therapy in patients ial disease: randomised controlled trial. BMJ 2002;325:1139. https://doi.org/10.1136/
undergoing renal artery stenting. J Cardiol 2019;74:443–50. https://doi.org/10.1016/j. bmj.325.7373.1139
jjcc.2019.04.010 368. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al.
346. Vashist A, Heller EN, Brown EJ, Jr, Alhaddad IA. Renal artery stenosis: a cardiovascular Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J
perspective. Am Heart J 2002;143:559–64. https://doi.org/10.1067/mhj.2002.120769 Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792
347. Pan Z, Cui H, Wu N, Zhang H. Effect of statin therapy on abdominal aortic aneurysm 369. Bhatt DS, Steg PG, Miller M, Brinton E, Jacobson T, Tardif J-C, et al. Abstract 10627:
growth rate and mortality: a systematic review and meta-analysis. Ann Vasc Surg 2020; benefits of icosapent ethyl in patients with prior peripheral artery disease:
67:503–10. https://doi.org/10.1016/j.avsg.2020.03.036 REDUCE-IT PAD. Circulation 2021;144:A10627. https://doi.org/10.1161/circ.144.
348. Salata K, Syed M, Hussain MA, de Mestral C, Greco E, Mamdani M, et al. Statins reduce suppl_1.10627
abdominal aortic aneurysm growth, rupture, and perioperative mortality: a systematic 370. Kobayashi Y, Fujikawa T, Haruna A, Kawano R, Ozawa M, Haze T, et al. Omega-3 fatty
review and meta-analysis. J Am Heart Assoc 2018;7:e008657. https://doi.org/10.1161/ acids reduce remnant-like lipoprotein cholesterol and improve the ankle-brachial in-
jaha.118.008657 dex of hemodialysis patients with dyslipidemia: a pilot study. Medicina (Kaunas)
349. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of statin therapy on ab- 2024;60:75. https://doi.org/10.3390/medicina60010075
dominal aortic aneurysm growth: a meta-analysis and meta-regression of observational 371. Dopheide JF, Veit J, Ramadani H, Adam L, Papac L, Vonbank A, et al. Adherence to sta-
comparative studies. Eur J Vasc Endovasc Surg 2012;44:287–92. https://doi.org/10.1016/ tin therapy favours survival of patients with symptomatic peripheral artery disease. Eur
j.ejvs.2012.06.021 Heart J Cardiovasc Pharmacother 2021;7:263–70. https://doi.org/10.1093/ehjcvp/
350. Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic pvz081
aneurysms. Am J Cardiol 2013;112:1240–5. https://doi.org/10.1016/j.amjcard.2013.05. 372. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, et al.
081 Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in pa-
351. Jovin IS, Duggal M, Ebisu K, Paek H, Oprea AD, Tranquilli M, et al. Comparison of the tients with peripheral artery disease: insights from the FOURIER trial (further cardio-
effect on long-term outcomes in patients with thoracic aortic aneurysms of taking ver- vascular outcomes research with PCSK9 inhibition in subjects with elevated risk).
sus not taking a statin drug. Am J Cardiol 2012;109:1050–4. https://doi.org/10.1016/j. Circulation 2018;137:338–50. https://doi.org/10.1161/circulationaha.117.032235
amjcard.2011.11.038 373. Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al. Effect of evo-
352. Skovbo Kristensen JS, Krasniqi L, Obel LM, Kavaliunaite E, Liisberg M, Lindholt JS. locumab on acute arterial events across all vascular territories: results from the
Exploring drug repurposing for treatment of abdominal aortic aneurysms: a systematic FOURIER trial. Eur Heart J 2021;42:4821–9. https://doi.org/10.1093/eurheartj/
review and meta-analysis. Eur J Vasc Endovasc Surg 2024;67:570–82. https://doi.org/10. ehab604
1016/j.ejvs.2023.11.037 374. Marx N, Federici M, Schutt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC
353. Rahman MN, Khan JA, Mazari FA, Mockford K, McCollum PT, Chetter IC. A rando- Guidelines for the management of cardiovascular disease in patients with diabetes. Eur
mized placebo controlled trial of the effect of preoperative statin use on matrix me- Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192
talloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and 375. Lazzarini PA, Cramb SM, Golledge J, Morton JI, Magliano DJ, Van Netten JJ. Global
peak wall stress in patients undergoing elective open repair of abdominal aortic aneur- trends in the incidence of hospital admissions for diabetes-related foot disease and am-
ysm. Ann Vasc Surg 2011;25:32–8. https://doi.org/10.1016/j.avsg.2010.06.006 putations: a review of national rates in the 21st century. Diabetologia 2023;66:267–87.
354. Periard D, Guessous I, Mazzolai L, Haesler E, Monney P, Hayoz D. Reduction of small https://doi.org/10.1007/s00125-022-05845-9
infrarenal abdominal aortic aneurysm expansion rate by statins. Vasa 2012;41:35–42. 376. Armstrong PA. Visceral duplex scanning: evaluation before and after artery interven-
https://doi.org/10.1024/0301-1526/a000161 tion for chronic mesenteric ischemia. Perspect Vasc Surg Endovasc Ther 2007;19:
355. Angeloni E, Vitaterna A, Pirelli M, Refice S. Effects of statin therapy on ascending aorta 386–92; discussion 393–384. https://doi.org/10.1177/1531003507311802
aneurysms growth: a propensity-matched analysis. Int J Cardiol 2015;191:52–5. https:// 377. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116:
doi.org/10.1016/j.ijcard.2015.05.001 1509–26. https://doi.org/10.1161/CIRCRESAHA.116.303849
356. Rowbotham SE, Krishna SM, Moran CS, Golledge J. Fenofibrate and telmisartan in the 378. McGurnaghan SJ, McKeigue PM, Read SH, Franzen S, Svensson A-M, Colombo M, et al.
management of abdominal aortic aneurysm. Curr Drug Targets 2018;19:1241–6. https:// Development and validation of a cardiovascular risk prediction model in type 1 dia-
doi.org/10.2174/1389450119666171227224655 betes. Diabetologia 2021;64:2001–11. https://doi.org/10.1007/s00125-021-05478-4
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 135 ---
3672 E S C G u id e l in e s
379. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl 399. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in
J Med 2017;376:2367–75. https://doi.org/10.1056/NEJMra1615439 patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:
380. Malyar NM, Freisinger E, Meyborg M, Lüders F, Gebauer K, Reinecke H, et al. 117–28. https://doi.org/10.1056/NEJMoa2030183
Amputations and mortality in in-hospital treated patients with peripheral artery dis- 400. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in
ease and diabetic foot syndrome. J Diabetes Complications 2016;30:1117–22. https:// patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129–39.
doi.org/10.1016/j.jdiacomp.2016.03.033 https://doi.org/10.1056/NEJMoa2030186
381. Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA, et al. 401. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. https://doi.
peripheral artery disease. Diabetes Obes Metab 2022;24:1288–99. https://doi.org/10. org/10.1056/NEJMoa1812389
1111/dom.14700 402. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin,
382. Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:
Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes 2117–28. https://doi.org/10.1056/NEJMoa1504720
mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. 403. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al.
Circulation 2018;137:405–7. https://doi.org/10.1161/circulationaha.117.032031 Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in pa-
383. American Diabetes Association. Standards of care in diabetes–2023 abridged for pri- tients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
mary care providers. Clin Diabetes 2022;41:4–31. https://doi.org/10.2337/cd23-as01 Lancet Diabetes Endocrinol 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21)
384. Sattar N, McGuire DK. Prevention of CV outcomes in antihyperglycaemic 00203-5
drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start 404. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD,
or not to start with metformin. Eur Heart J 2021;42:2574–6. https://doi.org/10. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N
1093/eurheartj/ehaa879 Engl J Med 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269
385. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. 405. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.
Canagliflozin for primary and secondary prevention of cardiovascular events: results Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-
from the CANVAS program (canagliflozin cardiovascular assessment study). blind, randomised placebo-controlled trial. Lancet 2019;394:121–30. https://doi.org/
Circulation 2018;137:323–34. https://doi.org/10.1161/CIRCULATIONAHA.117. 10.1016/S0140-6736(19)31149-3
032038 406. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al.
386. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 311–22. https://doi.org/10.1056/NEJMoa1603827
2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925 407. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide
387. Goldenberg RM, Cheng AYY, Fitzpatrick T, Gilbert JD, Verma S, Hopyan JJ. Benefits of and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;
GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 dia- 375:1834–44. https://doi.org/10.1056/NEJMoa1607141
betes: a call to action for neurologists. Stroke 2022;53:1813–22. https://doi.org/10. 408. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and
1161/STROKEAHA.121.038151 mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes
388. Malhotra K, Katsanos AH, Lambadiari V, Goyal N, Palaiodimou L, Kosmidou M, et al. Endocrinol 2019;7:385–96. https://doi.org/10.1016/S2213-8587(18)30315-2
GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and 409. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper ME, Colagiuri S, et al. Association of
meta-analysis. J Neurol 2020;267:2117–22. https://doi.org/10.1007/s00415-020- HbA1c levels with vascular complications and death in patients with type 2 diabetes:
09813-4 evidence of glycaemic thresholds. Diabetologia 2012;55:636–43. https://doi.org/10.
389. Tsai WH, Chuang SM, Liu SC, Lee C-C, Chien M-N, Leung C-H, et al. Effects of 1007/s00125-011-2404-1
SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a sys- 410. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function
tematic review and meta-analysis. Sci Rep 2021;11:15364. https://doi.org/10.1038/ of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;
s41598-021-94945-4 375:481–9. https://doi.org/10.1016/S0140-6736(09)61969-3
390. Effect of intensive blood-glucose control with metformin on complications in over- 411. Control G, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al.
weight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study Intensive glucose control and macrovascular outcomes in type 2 diabetes.
(UKPDS) Group. Lancet 1998;352:854–65 . Diabetologia 2009;52:2288–98. https://doi.org/10.1007/s00125-009-1470-0
391. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJM, et al. Long-term ef- 412. Caturano A, Galiero R, Pafundi PC, Cesaro A, Vetrano E, Palmiero G, et al. Does a
fects of metformin on metabolism and microvascular and macrovascular disease in pa- strict glycemic control during acute coronary syndrome play a cardioprotective effect?
tients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616–25. https://doi.org/ Pathophysiology and clinical evidence. Diabetes Res Clin Pract 2021;178:108959.
10.1001/archinternmed.2009.20 https://doi.org/10.1016/j.diabres.2021.108959
392. Tan S, Goudot G, Arnoux A, Tran Y, Maissoro H, Poenou G, et al. Occurrence of ma- 413. Soehnlein O, Libby P. Targeting inflammation in atherosclerosis—from experimental
jor local lower limb events in type 2 diabetic patients with lower extremity arterial dis- insights to the clinic. Nat Rev Drug Discov 2021;20:589–610. https://doi.org/10.1038/
ease: impact of metformin. Ann Vasc Surg 2023;90:153–61. https://doi.org/10.1016/j. s41573-021-00198-1
avsg.2022.09.064 414. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.
393. Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, et al. Similar car- Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J
diovascular outcomes in patients with diabetes and established or high risk for coron- Med 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914
ary vascular disease treated with dulaglutide with and without baseline metformin. Eur 415. Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dubé M-P, Blondeau L, et al.
Heart J 2021;42:2565–73. https://doi.org/10.1093/eurheartj/ehaa777 Colchicine for secondary prevention of cardiovascular disease: a systematic review
394. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects and meta-analysis of randomized controlled trials. Can J Cardiol 2021;37:776–85.
of intensive glucose control on microvascular outcomes in patients with type 2 dia- https://doi.org/10.1016/j.cjca.2020.10.006
betes: a meta-analysis of individual participant data from randomised controlled trials. 416. Antonopoulos AS, Papanikolaou E, Vogiatzi G, Oikonomou E, Tousoulis D.
Lancet Diabetes Endocrinol 2017;5:431–7. https://doi.org/10.1016/S2213-8587(17) Anti-inflammatory agents in peripheral arterial disease. Curr Opin Pharmacol 2018;
30104-3 39:1–8. https://doi.org/10.1016/j.coph.2017.11.001
395. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood 417. Mills JL, Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al.
glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J The Society for Vascular Surgery lower extremity threatened limb classification sys-
Med 2008;358:2560–72. https://doi.org/10.1056/NEJMoa0802987 tem: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc
396. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with Surg 2014;59:220–34.e1–2. https://doi.org/10.1016/j.jvs.2013.08.003
sulphonylureas or insulin compared with conventional treatment and risk of complica- 418. Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UKA, Criqui MH,
tions in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53. https:// Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol
doi.org/10.1016/S0140-6736(98)07019-6 2017;14:156–70. https://doi.org/10.1038/nrcardio.2016.179
397. Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, 419. Diehm C, Allenberg JR, Pittrow D, Mahn M, Tepohl G, Haberl RL, et al. Mortality and
Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes vascular morbidity in older adults with asymptomatic versus symptomatic peripheral
on the development and progression of long-term complications in insulin-dependent artery disease. Circulation 2009;120:2053–61. https://doi.org/10.1161/circulationaha.
diabetes mellitus. N Engl J Med 1993;329:977–86. https://doi.org/10.1056/ 109.865600
NEJM199309303291401 420. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg
398. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. symptoms in peripheral arterial disease: associated clinical characteristics and function-
Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients al impairment. JAMA 2001;286:1599–606. https://doi.org/10.1001/jama.286.13.1599
with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–58. https://doi.org/10. 421. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E,
1001/jamacardio.2020.4511 et al. A population-based study of peripheral arterial disease prevalence with special
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 136 ---
ESC Guidelines 3673
focus on critical limb ischemia and sex differences. J Vasc Surg 2007;45:1185–91. of cardiovascular events. Eur J Prev Cardiol 2014;21:310–20. https://doi.org/10.1177/
https://doi.org/10.1016/j.jvs.2007.02.004 2047487313516564
422. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, et al. 443. Wang FM, Yang C, Ballew SH, Kalbaugh CA, Meyer ML, Tanaka H, et al. Ankle-brachial
Inter-society consensus for the management of peripheral arterial disease (TASC II). index and subsequent risk of incident and recurrent cardiovascular events in older
Eur J Vasc Endovasc Surg 2007;33:S1–75. https://doi.org/10.1016/j.ejvs.2006.09.024 adults: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2021;
423. Buso G, Aboyans V, Mazzolai L. Lower extremity artery disease in patients with type 2 336:39–47. https://doi.org/10.1016/j.atherosclerosis.2021.09.028
diabetes. Eur J Prev Cardiol 2019;26:114–24. https://doi.org/10.1177/20474873198 444. Cull DL, Manos G, Hartley MC, Taylor SM, Langan EM, Eidt JF, et al. An early validation
80044 of the Society for Vascular Surgery lower extremity threatened limb classification sys-
424. Porras CP, Bots ML, Teraa M, van Doorn S, Vernooij RWM. Differences in symptom tem. J Vasc Surg 2014;60:1535–42. https://doi.org/10.1016/j.jvs.2014.08.107
presentation in women and men with confirmed lower limb peripheral artery disease: 445. Liette MD, Crisologo PA, Masadeh S, Yang SH, Bergmann CB, Caldwell CC, et al. A
a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2022;63:602–12. prospective analysis of the SVS WIfI classification system to stratify immediate and
https://doi.org/10.1016/j.ejvs.2021.12.039 1-year patient outcomes. J Foot Ankle Surg 2023;62:661–5. https://doi.org/10.1053/j.
425. Fereydooni A, Gorecka J, Dardik A. Using the epidemiology of critical limb ischemia to jfas.2023.02.003
estimate the number of patients amenable to endovascular therapy. Vasc Med 2020; 446. van Reijen NS, Ponchant K, Ubbink DT, Koelemay MJW. Editor’s choice—the prog-
25:78–87. https://doi.org/10.1177/1358863X19878271 nostic value of the WIfI classification in patients with chronic limb threatening ischae-
426. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular mia: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2019;58:362–71.
guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc https://doi.org/10.1016/j.ejvs.2019.03.040
Endovasc Surg 2019;58:S1–109.e33. https://doi.org/10.1016/j.ejvs.2019.05.006 447. Eiberg JP, Gronvall Rasmussen JB, Hansen MA, Schroeder TV. Duplex ultrasound scan-
427. Sigvant B, Lundin F, Wahlberg E. The risk of disease progression in peripheral arterial ning of peripheral arterial disease of the lower limb. Eur J Vasc Endovasc Surg 2010;40:
disease is higher than expected: a meta-analysis of mortality and disease progression in 507–12. https://doi.org/10.1016/j.ejvs.2010.06.002
peripheral arterial disease. Eur J Vasc Endovasc Surg 2016;51:395–403. https://doi.org/ 448. Met R, Bipat S, Legemate DA, Reekers JA, Koelemay MJ. Diagnostic performance of
10.1016/j.ejvs.2015.10.022 computed tomography angiography in peripheral arterial disease: a systematic review
428. Hageman SHJ, de Borst GJ, Dorresteijn JAN, Bots ML, Westerink J, Asselbergs FW, and meta-analysis. JAMA 2009;301:415–24. https://doi.org/10.1001/jama.301.4.415
et al. Cardiovascular risk factors and the risk of major adverse limb events in patients 449. Itoga NK, Kim T, Sailer AM, Fleischmann D, Mell MW. Lower extremity computed
with symptomatic cardiovascular disease. Heart 2020;106:1686–92. https://doi.org/10. tomography angiography can help predict technical success of endovascular revascu-
larization in the superficial femoral and popliteal artery. J Vasc Surg 2017;66:835–43.e1.
1136/heartjnl-2019-316088
429. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, et al. Major adverse limb https://doi.org/10.1016/j.jvs.2017.02.031
450. Selvin E, Hirsch AT. Contemporary risk factor control and walking dysfunction in in-
events and mortality in patients with peripheral artery disease: the COMPASS trial.
dividuals with peripheral arterial disease: NHANES 1999–2004. Atherosclerosis 2008;
J Am Coll Cardiol 2018;71:2306–15. https://doi.org/10.1016/j.jacc.2018.03.008
201:425–33. https://doi.org/10.1016/j.atherosclerosis.2008.02.002
430. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al.
451. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med
in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to
2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118
2004. Circulation 2011;124:17–23. https://doi.org/10.1161/circulationaha.110.003954
431. Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality
452. Krishnamurthy V, Munir K, Rectenwald JE, Mansour A, Hans S, Eliason JL, et al.
associated with atherosclerotic peripheral artery disease: a systematic review.
Contemporary outcomes with percutaneous vascular interventions for peripheral
Atherosclerosis 2020;293:94–100. https://doi.org/10.1016/j.atherosclerosis.2019.
critical limb ischemia in those with and without poly-vascular disease. Vasc Med
09.012
2014;19:491–9. https://doi.org/10.1177/1358863x14552013
432. Wijnand JGJ, van Koeverden ID, Teraa M, Spreen MI, Mali WPTM, van Overhagen H,
453. Penin-Grandes S, Lopez-Ortiz S, Maroto-Izquierdo S, Menéndez H, Pinto-Fraga J,
et al. Validation of randomized controlled trial-derived models for the prediction of
Martín-Hernández J, et al. Winners do what they fear: exercise and peripheral arterial
postintervention outcomes in chronic limb-threatening ischemia. J Vasc Surg 2020;
disease–an umbrella review. Eur J Prev Cardiol 2024;31:380–388. https://doi.org/10.
71:869–79. https://doi.org/10.1016/j.jvs.2019.06.195
1093/eurjpc/zwad261
433. Jaramillo EA, Smith EJT, Matthay ZA, Sanders KM, Hiramoto JS, Gasper WJ, et al. Racial
454. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of
and ethnic disparities in major adverse limb events persist for chronic limb threatening
claudication pain. A meta-analysis. JAMA 1995;274:975–80.
ischemia despite presenting limb threat severity after peripheral vascular intervention.
455. Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized
J Vasc Surg 2023;77:848–57.e2. https://doi.org/10.1016/j.jvs.2022.10.043
controlled trials: walking versus alternative exercise prescription as treatment for
434. Brizuela Sanz JA, Gonzalez Fajardo JA, Taylor JH, Río Solá L, Muñoz Moreno MF,
intermittent claudication. Atherosclerosis 2011;218:1–12. https://doi.org/10.1016/j.
Vaquero Puerta C, et al. Design of a new risk score in critical limb ischaemia: the
atherosclerosis.2011.04.024
ERICVA model. Eur J Vasc Endovasc Surg 2016;51:90–9. https://doi.org/10.1016/j.ejvs.
456. Fakhry F, van de Luijtgaarden KM, Bax L, den Hoed PT, Hunink MGGM, Rouwet EV,
2015.09.025
et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg
435. Kreutzburg T, Peters F, Kuchenbecker J, Marschall U, Lee R, Kriston L, et al. Editor’s 2012;56:1132–42. https://doi.org/10.1016/j.jvs.2012.04.046
choice—the GermanVasc score: a pragmatic risk score predicts five year amputation
457. Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral
free survival in patients with peripheral arterial occlusive disease. Eur J Vasc Endovasc arterial disease: a systematic review and meta-analysis. Sports Med 2015;45:231–44.
Surg 2021;61:248–56. https://doi.org/10.1016/j.ejvs.2020.11.013 https://doi.org/10.1007/s40279-014-0261-z
436. Niazi K, Khan TH, Easley KA. Diagnostic utility of the two methods of ankle brachial 458. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication.
index in the detection of peripheral arterial disease of lower extremities. Catheter Cochrane Database Syst Rev 2017;12:CD000990. https://doi.org/10.1002/14651858.
Cardiovasc Interv 2006;68:788–92. https://doi.org/10.1002/ccd.20906 CD000990.pub4
437. Crawford F, Welch K, Andras A, Chappell FM. Ankle brachial index for the diagnosis of 459. Parmenter BJ, Mavros Y, Ritti Dias R, King S, Fiatarone Singh M. Resistance training as a
lower limb peripheral arterial disease. Cochrane Database Syst Rev 2016;9:CD010680. treatment for older persons with peripheral artery disease: a systematic review and
https://doi.org/10.1002/14651858.CD010680.pub2 meta-analysis. Br J Sports Med 2020;54:452–61. https://doi.org/10.1136/bjsports-
438. Aday AW, Kinlay S, Gerhard-Herman MD. Comparison of different exercise ankle 2018-100205
pressure indices in the diagnosis of peripheral artery disease. Vasc Med 2018;23: 460. Perks J, Zaccardi F, Paterson C, Houghton JSM, Nickinson ATO, Pepper CJ, et al. Effect
541–8. https://doi.org/10.1177/1358863X18781723 of high-pain versus low-pain structured exercise on walking ability in people with inter-
439. Tehan PE, Barwick AL, Sebastian M, Chuter VH. Diagnostic accuracy of the postexer- mittent claudication: meta-analysis. Br J Surg 2022;109:686–94. https://doi.org/10.
cise ankle-brachial index for detecting peripheral artery disease in suspected claudi- 1093/bjs/znac134
cants with and without diabetes. Vasc Med 2018;23:116–25. https://doi.org/10.1177/ 461. Guidon M, McGee H. Exercise-based interventions and health-related quality of life in
1358863X17751259 intermittent claudication: a 20-year (1989–2008) review. Eur J Cardiovasc Prev Rehabil
440. Manu CA, Freedman B, Rashid H, Winkley K, Edmonds ME. Peripheral arterial disease 2010;17:140–54. https://doi.org/10.1097/HJR.0b013e3283377f08
located in the feet of patients with diabetes and foot ulceration demands a new ap- 462. Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related
proach to the assessment of ischemia. Int J Low Extrem Wounds 2022;21:397–404. quality of life in peripheral artery disease: a systematic review and meta-analysis.
https://doi.org/10.1177/1534734620947979 Vasc Med 2015;20:30–40. https://doi.org/10.1177/1358863x14559092
441. Salaun P, Desormais I, Lapébie FX, Rivière AB, Aboyans V, Lacroix P, et al. Comparison 463. Gommans LN, Fokkenrood HJ, van Dalen HC, Scheltinga MRM, Teijink JAW, Peters
of ankle pressure, systolic toe pressure, and transcutaneous oxygen pressure to pre- RJG. Safety of supervised exercise therapy in patients with intermittent claudication.
dict major amputation after 1 year in the copart cohort. Angiology 2019;70:229–36. J Vasc Surg 2015;61:512–8.e2. https://doi.org/10.1016/j.jvs.2014.08.070
https://doi.org/10.1177/0003319718793566 464. Harwood AE, Pymer S, Ibeggazene S, Ingle L, Caldow E, Birkett ST. Provision of exer-
442. Fowkes FG, Murray GD, Butcher I, Folsom AR, Hirsch AT, Couper DJ, et al. cise services in patients with peripheral artery disease in the United Kingdom. Vascular
Development and validation of an ankle brachial index risk model for the prediction 2022;30:874–81. https://doi.org/10.1177/17085381211035259
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 137 ---
3674 E S C G u id e l in e s
465. Lanzi S, Belch J, Brodmann M, Madaric J, Bura-Riviere A, Visonà A, et al. Supervised ex- placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymp-
ercise training in patients with lower extremity peripheral artery disease. Vasa 2022; tomatic peripheral arterial disease. BMJ 2008;337:a1840. https://doi.org/10.1136/bmj.
51:267–74. https://doi.org/10.1024/0301-1526/a001024 a1840
466. Gommans LN, Saarloos R, Scheltinga MR, Houterman S, de Bie RA, Fokkenrood HJP, 487. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of
et al. Editor’s choice—the effect of supervision on walking distance in patients with aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018;
intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg 2014;48:169–84. 379:1529–39. https://doi.org/10.1056/NEJMoa1804988
https://doi.org/10.1016/j.ejvs.2014.04.019 488. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised
467. Vemulapalli S, Dolor RJ, Hasselblad V, Schmit K, Banks A, Heidenfelder B, et al. trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke
Supervised vs unsupervised exercise for intermittent claudication: a systematic re- in high risk patients. BMJ 2002;324:71–86. https://doi.org/10.1136/bmj.324.7329.71
view and meta-analysis. Am Heart J 2015;169:924–37.e3. https://doi.org/10.1016/j. 489. De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C. Efficacy and
ahj.2015.03.009 safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic
468. Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. review and network meta-analysis. Curr Vasc Pharmacol 2021;19:542–55. https://doi.
Supervised exercise therapy versus home-based exercise therapy versus walking ad- org/10.2174/1570161118666200820141131
vice for intermittent claudication. Cochrane Database Syst Rev 2018;4:CD005263. 490. Willems LH, Maas D, Kramers K, Reijnen MMPJ, Riksen NP, Ten Cate H, et al.
https://doi.org/10.1002/14651858.CD005263.pub4 Antithrombotic therapy for symptomatic peripheral arterial disease: a systematic re-
469. Pymer S, Ibeggazene S, Palmer J, Tew GA, Ingle L, Smith GE, et al. An updated system- view and network meta-analysis. Drugs 2022;82:1287–302. https://doi.org/10.1007/
atic review and meta-analysis of home-based exercise programs for individuals with s40265-022-01756-6
intermittent claudication. J Vasc Surg 2021;74:2076–85.e20. https://doi.org/10.1016/j. 491. Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M,
jvs.2021.03.063 et al. Comparative efficacy and safety of different antiplatelet agents for prevention
470. Waddell A, Seed S, Broom DR, McGregor G, Birkett ST, Harwood AE. Safety of home- of major cardiovascular events and leg amputations in patients with peripheral arterial
based exercise for people with intermittent claudication: a systematic review. Vasc disease: a systematic review and network meta-analysis. PLoS One 2015;10:e0135692.
Med 2022;27:186–92. https://doi.org/10.1177/1358863x211060388 https://doi.org/10.1371/journal.pone.0135692
471. Golledge J, Singh TP, Alahakoon C, Pinchbeck J, Yip L, Moxon JV, et al. Meta-analysis of 492. Basili S, Raparelli V, Vestri A, Di Tanna GL, Violi F. Comparison of efficacy of antiplate-
clinical trials examining the benefit of structured home exercise in patients with per- let treatments for patients with claudication. A meta-analysis. Thromb Haemost 2010;
ipheral artery disease. Br J Surg 2019;106:319–31. https://doi.org/10.1002/bjs.11101 103:766–73. https://doi.org/10.1160/th09-09-0635
472. Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. 493. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin
Sports Med 2004;34:983–1003. https://doi.org/10.2165/00007256-200434140-00004 in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet
473. Ehrman JK, Gardner AW, Salisbury D, Lui K, Treat-Jacobson D. Supervised exercise 1996;348:1329–39. https://doi.org/10.1016/s0140-6736(96)09457-3
therapy for symptomatic peripheral artery disease: a review of current experience 494. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovas-
and practice-based recommendations. J Cardiopulm Rehabil Prev 2023;43:15–21. cular events in patients with peripheral artery disease: a meta-analysis of randomized
https://doi.org/10.1097/hcr.0000000000000723 trials. JAMA 2009;301:1909–19. https://doi.org/10.1001/jama.2009.623
474. McDermott MM, Spring B, Tian L, Treat-Jacobson D, Ferrucci L, Lloyd-Jones D, et al. 495. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, et al. Ticagrelor ver-
Effect of low-intensity vs high-intensity home-based walking exercise on walk distance sus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017;376:
in patients with peripheral artery disease: the LITE randomized clinical trial. JAMA 2021; 32–40. https://doi.org/10.1056/NEJMoa1611688
325:1266–76. https://doi.org/10.1001/jama.2021.2536 496. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and
475. Jansen SC, Abaraogu UO, Lauret GJ, Fakhry F, Fokkenrood HJP, Teijink JAW. Modes of aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J
exercise training for intermittent claudication. Cochrane Database Syst Rev 2020;8: Med 2006;354:1706–17. https://doi.org/10.1056/NEJMoa060989
CD009638. https://doi.org/10.1002/14651858.CD009638.pub3 497. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with
476. Gardner AW, Parker DE, Montgomery PS, Blevins SM. Diabetic women are poor re- prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the
sponders to exercise rehabilitation in the treatment of claudication. J Vasc Surg 2014; CHARISMA trial. J Am Coll Cardiol 2007;49:1982–8. https://doi.org/10.1016/j.jacc.
59:1036–43. https://doi.org/10.1016/j.jvs.2013.10.058 2007.03.025
477. Gommans LN, Scheltinga MR, van Sambeek MR, Maas AHEM, Bendermacher BLW, 498. Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al.
Teijink JAW. Gender differences following supervised exercise therapy in patients Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral ar-
with intermittent claudication. J Vasc Surg 2015;62:681–8. https://doi.org/10.1016/j. tery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol
jvs.2015.03.076 2021;6:21–9. https://doi.org/10.1001/jamacardio.2020.4390
478. Dipnarine K, Barak S, Martinez CA, Carmeli E, Stopka CB. Pain-free treadmill exercise 499. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban
for patients with intermittent claudication: are there gender differences? Vascular 2016; with or without aspirin in patients with stable peripheral or carotid artery disease: an
24:304–14. https://doi.org/10.1177/1708538115592800 international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:
479. Gardner AW, Parker DE, Montgomery PS. Sex-specific predictors of improved walk- 219–29. https://doi.org/10.1016/s0140-6736(17)32409-1
ing with step-monitored, home-based exercise in peripheral artery disease. Vasc Med 500. Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et al. Twelve-month
2015;20:424–31. https://doi.org/10.1177/1358863x15596237 results of a randomized trial comparing mono with dual antiplatelet therapy in endo-
480. Ney B, Lanzi S, Calanca L, Mazzolai L. Multimodal supervised exercise training is effect- vascularly treated patients with peripheral artery disease. J Endovasc Ther 2013;20:
ive in improving long term walking performance in patients with symptomatic lower 699–706. https://doi.org/10.1583/13-4275mr.1
extremity peripheral artery disease. J Clin Med 2021;10:2057.https://doi.org/10.3390/ 501. Tsai SY, Li YS, Lee CH, Cha S-W, Wang Y-C, Su T-W, et al. Mono or dual antiplatelet
jcm10102057 therapy for treating patients with peripheral artery disease after lower extremity re-
481. Lanzi S, Pousaz A, Calanca L, Mazzolai L. Sex-based differences in supervised exercise vascularization: a systematic review and meta-analysis. Pharmaceuticals (Basel) 2022;
therapy outcomes for symptomatic peripheral artery disease. Vasc Med 2023;28: 15:596. https://doi.org/10.3390/ph15050596
147–9. https://doi.org/10.1177/1358863x221149454 502. Thott O, Granath F, Malmstedt J, Wahlgren CM. Editor’s choice—dual antiplatelet
482. Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JAW, Hoffmann WH, et al. therapy improves outcome in diabetic patients undergoing endovascular femoropopli-
Endovascular revascularization and supervised exercise for peripheral artery disease teal stenting for critical limb ischaemia. Eur J Vasc Endovasc Surg 2017;53:403–10.
and intermittent claudication: a randomized clinical trial. JAMA 2015;314:1936–44. https://doi.org/10.1016/j.ejvs.2016.12.014
https://doi.org/10.1001/jama.2015.14851 503. Cho S, Lee YJ, Ko YG, Kang TS, Lim S-H, Hong S-J, et al. Optimal strategy for antiplate-
483. Pandey A, Banerjee S, Ngo C, Mody P, Marso SP, Brilakis ES, et al. Comparative efficacy let therapy after endovascular revascularization for lower extremity peripheral artery
of endovascular revascularization versus supervised exercise training in patients with disease. JACC Cardiovasc Interv 2019;12:2359–70. https://doi.org/10.1016/j.jcin.2019.08.
intermittent claudication: meta-analysis of randomized controlled trials. JACC 006
Cardiovasc Interv 2017;10:712–24. https://doi.org/10.1016/j.jcin.2017.01.027 504. Ipema J, Welling RHA, Bakker OJ, Bokkers RPH, de Vries J-PPM, Ünlü Ç. Short-term
484. Dorn A, Dorweiler B, Ahmad W, Mylonas S, Becker I, Majd P. Low and high clinical outcomes of single versus dual antiplatelet therapy after infrainguinal endovas-
ankle-brachial index are both associated with mortality in German nursing home resi- cular treatment for peripheral arterial disease. J Clin Med 2020;9:3515. https://doi.org/
dents–the five-year follow-up of the ‘allo-study’ Cohort. J Clin Med 2023;12:4411. 10.3390/jcm9113515
https://doi.org/10.3390/jcm12134411 505. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al.
485. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for pre- Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020;
vention of cardiovascular events in a general population screened for a low ankle bra- 382:1994–2004. https://doi.org/10.1056/NEJMoa2000052
chial index: a randomized controlled trial. JAMA 2010;303:841–8. https://doi.org/10. 506. Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, et al. Rivaroxaban
1001/jama.2010.221 and aspirin in peripheral artery disease lower extremity revascularization: impact of
486. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of concomitant clopidogrel on efficacy and safety. Circulation 2020;142:2219–30.
progression of arterial disease and diabetes (POPADAD) trial: factorial randomised https://doi.org/10.1161/circulationaha.120.050465
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 138 ---
ESC Guidelines 3675
507. Duff S, Mafilios MS, Bhounsule P, Hasegawa JT. The burden of critical limb ischemia: a treatment of peripheral arterial diseases, in collaboration with the European Society
review of recent literature. Vasc Health Risk Manag 2019;15:187–208. https://doi.org/ for Vascular Surgery (ESVS): Endorsed by: the European Stroke Organisation (ESO),
10.2147/VHRM.S209241 The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of
508. Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al. Warfarin im- the European Society of Cardiology (ESC) and of the European Society for Vascular
proves the outcome of infrainguinal vein bypass grafting at high risk for failure. Surgery (ESVS). Eur Heart J 2018;39:e35–41. https://doi.org/10.1093/eurheartj/ehx499
J Vasc Surg 1998;28:446–57. https://doi.org/10.1016/s0741-5214(98)70130-2 530. McQuade K, Gable D, Pearl G, Theune B, Black S. Four-year randomized prospective
509. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic
(the Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet femoral-popliteal bypass in the treatment of superficial femoral artery occlusive dis-
2000;355:346–51. https://doi.org/10.1016/S0140-6736(99)07199-8 ease. J Vasc Surg 2010;52:584–91.e7. https://doi.org/10.1016/j.jvs.2010.03.071
510. Belch JJ, Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al. Results of the 531. Bosiers M, Deloose K, Callaert J, Moreels N, Keirse K, Verbist J, et al. Results of the
randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal
for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010;52:825–33.e2. lesions. J Vasc Surg 2011;54:1042–50. https://doi.org/10.1016/j.jvs.2011.03.272
https://doi.org/10.1016/j.jvs.2010.04.027 532. Farhan S, Enzmann FK, Bjorkman P, Kamran H, Zhang Z, Sartori S, et al.
511. Brumberg RS, Back MR, Armstrong PA, Cuthbertson D, Shames ML, Johnson BL, et al. Revascularization strategies for patients with femoropopliteal peripheral artery dis-
The relative importance of graft surveillance and warfarin therapy in infrainguinal pros- ease. J Am Coll Cardiol 2023;81:358–70. https://doi.org/10.1016/j.jacc.2022.10.036
thetic bypass failure. J Vasc Surg 2007;46:1160–6. https://doi.org/10.1016/j.jvs.2007.07. 533. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death follow-
046 ing application of paclitaxel-coated balloons and stents in the femoropopliteal artery of
512. Van Gelder IC, Kotecha D, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, et al. the leg: a systematic review and meta-analysis of randomized controlled trials. J Am
2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024. Heart Assoc 2018;7:e011245. https://doi.org/10.1161/jaha.118.011245
https://doi.org/10.1093/eurheartj/ehae176 534. Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Peña C, et al. Safety of
513. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease.
responsiveness to clopidogrel treatment after peripheral endovascular procedures: JACC Cardiovasc Interv 2019;12:2515–24. https://doi.org/10.1016/j.jcin.2019.08.025
the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high 535. Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall U, et al. Mortality
platelet reactivity. J Am Coll Cardiol 2013;61:2428–34. https://doi.org/10.1016/j.jacc. after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis.
2013.03.036 Eur Heart J 2020;41:3732–9. https://doi.org/10.1093/eurheartj/ehz698
514. Busch L, Stern M, Dannenberg L, Mourikis P, Gröne M, Özaslan G, et al. Impact of high 536. Lyden SP, Brodmann M, Parikh SA, Krishnan P, Schroeder H, Werner M, et al.
on-treatment platelet reactivity after angioplasty in patients with peripheral arterial
Four-year patient-level pooled mortality analysis of the ILLUMENATE US pivotal
disease. Platelets 2021;32:391–7. https://doi.org/10.1080/09537104.2020.1742314
and EU randomized controlled trials. J Vasc Surg 2022;75:600–7. https://doi.org/10.
515. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin
1016/j.jvs.2021.07.244
and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev
537. Secemsky EA, Song Y, Schermerhorn M, Yeh RW. Update from the longitudinal as-
2014;5:CD001999. https://doi.org/10.1002/14651858.CD001999.pub2
sessment of safety of femoropopliteal endovascular treatment with paclitaxel-coated
516. Bagger JP, Helligsoe P, Randsbaek F, Kimose HH, Jensen BS. Effect of verapamil in inter-
devices among medicare beneficiaries: the SAFE-PAD study. Circ Cardiovasc Interv
mittent claudication. A randomized, double-blind, placebo-controlled, cross-over
2022;15:e012074. https://doi.org/10.1161/circinterventions.122.012074
study after individual dose-response assessment. Circulation 1997;95:411–4. https://
538. Nordanstig J, James S, Andersson M, Andersson M, Danielsson P, Gillgren P, et al.
doi.org/10.1161/01.cir.95.2.411
Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med
517. Gargiulo G, Giugliano G, Brevetti L, Sannino A, Schiattarella GG, Serino F, et al. Use of
2020;383:2538–46. https://doi.org/10.1056/NEJMoa2005206
statins in lower extremity artery disease: a review. BMC Surg 2012;12:S15. https://doi.
539. Fashandi AZ, Mehaffey JH, Hawkins RB, Kron IL, Upchurch GR, Robinson WP. Major
org/10.1186/1471-2482-12-s1-s15
adverse limb events and major adverse cardiac events after contemporary lower ex-
518. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin
tremity bypass and infrainguinal endovascular intervention in patients with claudica-
use and leg functioning in patients with and without lower-extremity peripheral arter-
tion. J Vasc Surg 2018;68:1817–23. https://doi.org/10.1016/j.jvs.2018.06.193
ial disease. Circulation 2003;107:757–61. https://doi.org/10.1161/01.cir.0000050380.
540. Koelemay MJW, van Reijen NS, van Dieren S, Frans FA, Vermeulen EJG, Buscher HCJL,
64025.07
et al. Editor’s choice—randomised clinical trial of supervised exercise therapy vs. en-
519. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database
dovascular revascularisation for intermittent claudication caused by iliac artery ob-
Syst Rev 2013;4:CD000986. https://doi.org/10.1002/14651858.CD000986.pub3
struction: the SUPER study. Eur J Vasc Endovasc Surg 2022;63:421–9. https://doi.org/
520. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic re-
10.1016/j.ejvs.2021.09.042
view of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treat-
541. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, et al. Fate of the
ment of intermittent claudication. Br J Surg 2012;99:1630–8. https://doi.org/10.1002/
patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989;30:
bjs.8895
50–7.
521. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for
542. Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. intermittent claudication. Cochrane Database Syst Rev 2014;10:CD003748. https://doi.
Fate in intermittent claudication: outcome and risk factors. BMJ 1986;293:1137–40.
org/10.1002/14651858.CD003748.pub4
522. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with periph- https://doi.org/10.1136/bmj.293.6555.1137
eral artery disease: the CASTLE study (cilostazol: a study in long-term effects). J Vasc 543. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, nat-
Surg 2008;47:330–6. https://doi.org/10.1016/j.jvs.2007.10.009 ural history and cardiovascular events in symptomatic and asymptomatic peripheral
523. Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al. Cilostazol reduces angio- arterial disease in the general population. Int J Epidemiol 1996;25:1172–81. https://
graphic restenosis after endovascular therapy for femoropopliteal lesions in the suffi- doi.org/10.1093/ije/25.6.1172
cient treatment of peripheral intervention by cilostazol study. Circulation 2013;127: 544. Bloor K. Natural history of arteriosclerosis of the lower extremities: Hunterian lecture
2307–15. https://doi.org/10.1161/circulationaha.112.000711 delivered at the Royal College of Surgeons of England on 22nd April 1960. Ann R Coll
524. de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent Surg Engl 1961;28:36–52.
claudication. Cochrane Database Syst Rev 2012;12:Cd001368. https://doi.org/10.1002/ 545. Goode SD, Cleveland TJ, Gaines PA, Collaborators S. Randomized clinical trial of
14651858.CD001368.pub4 stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br
525. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking dis- J Surg 2013;100:1148–53. https://doi.org/10.1002/bjs.9197
tance in patients with intermittent claudication. Ann Cardiol Angeiol 2001;50:175–82. 546. Hajibandeh S, Hajibandeh S, Antoniou SA, Torella F, Antoniou GA. Covered vs uncov-
https://doi.org/10.1016/s0003-3928(01)00016-6 ered stents for aortoiliac and femoropopliteal arterial disease: a systematic review and
526. Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent clau- meta-analysis. J Endovasc Ther 2016;23:442–52. https://doi.org/10.1177/
dication. Cochrane Database Syst Rev 2020;10:Cd005262. https://doi.org/10.1002/ 1526602816643834
14651858.CD005262.pub4 547. Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, et al.
527. Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Stokmans RA, Broos PPHL, Self-expanding versus balloon-expandable stents for iliac artery occlusive disease:
et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2013; the randomized ICE trial. JACC Cardiovasc Interv 2017;10:1694–704. https://doi.org/
6:Cd006888. https://doi.org/10.1002/14651858.CD006888.pub3 10.1016/j.jcin.2017.05.015
528. Premaratne S, Newman J, Hobbs S, Garnham A, Wall M. Meta-analysis of direct sur- 548. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angio-
gical versus endovascular revascularization for aortoiliac occlusive disease. J Vasc Surg plasty and stent placement for aortoiliac occlusive disease. Radiology 1997;204:87–96.
2020;72:726–37. https://doi.org/10.1016/j.jvs.2019.12.035 https://doi.org/10.1148/radiology.204.1.9205227
529. Aboyans V, Björck M, Brodmann M, Collet J-P, Czerny M, De Carlo M, et al. Questions 549. Committee TS, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, et al. An update
and answers on diagnosis and management of patients with peripheral arterial dis- on methods for revascularization and expansion of the TASC lesion classification to
eases: a companion document of the 2017 ESC Guidelines for the diagnosis and include below-the-knee arteries: a supplement to the inter-society consensus for
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 139 ---
3676 E S C G u id e l in e s
the management of peripheral arterial disease (TASC II). J Endovasc Ther 2015;22: diabetic foot. Diabetes Metab Res Rev 2012;28:142–62. https://doi.org/10.1002/dmrr.
663–77. https://doi.org/10.1177/1526602815592206 2247
550. Boc V, Kozak M, Erzen B, Božič Mijovski M, Boc A, Blinc A. Prognostic factors for re- 570. Peters EJG, Lipsky BA, Senneville É, Abbas ZG, Aragón-Sánchez J, Diggle M, et al.
stenosis of superficial femoral artery after endovascular treatment. J Clin Med 2023;12: Interventions in the management of infection in the foot in diabetes: a systematic re-
6343. https://doi.org/10.3390/jcm12196343 view. Diabetes Metab Res Rev 2020;36:e3282. https://doi.org/10.1002/dmrr.3282
551. Alves-Cabratosa L, Comas-Cufi M, Ponjoan A, Garcia-Gil M, Martí-Lluch R, Blanch J, 571. Dumville JC, Lipsky BA, Hoey C, Cruciani M, Fiscon M, Xia J. Topical antimicrobial
et al. Levels of ankle-brachial index and the risk of diabetes mellitus complications. agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev
BMJ Open Diabetes Res Care 2020;8:e000977. https://doi.org/10.1136/bmjdrc-2019- 2017;6:CD011038. https://doi.org/10.1002/14651858.CD011038.pub2
000977 572. Luo Y, Li L, Zhao P, Yang C, Zhang J. Effectiveness of silver dressings in the treatment of
552. Heiss C, Olinic DM, Belch JJF, Brodmann M, Mazzolai L, Stanek A, et al. Management of diabetic foot ulcers: a systematic review and meta-analysis. J Wound Care 2022;31:
chronic peripheral artery disease patients with indication for endovascular revascular- 979–86. https://doi.org/10.12968/jowc.2022.31.11.979
ization. Vasa 2022;51:121–37. https://doi.org/10.1024/0301-1526/a000998 573. Shu H, Xia Z, Qin X, Wang X, Lu W, Luo Q, et al. The clinical efficacy of collagen dress-
553. Hajibandeh S, Hajibandeh S, Shah S, Child E, Antoniou GA, Torella F. Prognostic sig- ing on chronic wounds: a meta-analysis of 11 randomized controlled trials. Front Surg
nificance of ankle brachial pressure index: a systematic review and meta-analysis. 2022;9:978407. https://doi.org/10.3389/fsurg.2022.978407
Vascular 2017;25:208–24. https://doi.org/10.1177/1708538116658392 574. Zhang F, Chen Z, Su F, Zhang T. Comparison of topical honey and povidone iodine-
554. Meza-Torres B, Cunningham SG, Heiss C, Joy M, Feher M, Leese GP, et al. Adherence based dressings for wound healing: a systematic review and meta-analysis. J Wound
to general diabetes and foot care processes, with prompt referral, are associated with Care 2021;30:S28–s36. https://doi.org/10.12968/jowc.2021.30.Sup4.S28
amputation-free survival in people with type 2 diabetes and foot ulcers: a Scottish na- 575. Yin XL, Hu L, Li T, Zou Y, Li HL. A meta-analysis on the efficacy of vacuum sealing
tional registry analysis. J Diabetes Res 2022;2022:7414258. https://doi.org/10.1155/ drainage combined with autologous platelet-rich plasma in the treatment of grade 2
2022/7414258 and grade 3 diabetic foot ulcers. Int Wound J 2022;20:1033–41. https://doi.org/10.
555. Shishehbor MH, White CJ, Gray BH, Menard MT, Lookstein R, Rosenfield K, et al. 1111/iwj.13956
Critical limb ischemia: an expert statement. J Am Coll Cardiol 2016;68:2002–15. 576. Lim K, Lim X, Hong Q, Yong E, Chandrasekar S, Tan GWL, et al. Use of home negative
https://doi.org/10.1016/j.jacc.2016.04.071 pressure wound therapy in peripheral artery disease and diabetic limb salvage. Int
556. Misra S, Shishehbor MH, Takahashi EA, Aronow HD, Brewster LP, Bunte MC, et al. Wound J 2020;17:531–9. https://doi.org/10.1111/iwj.13307
Perfusion assessment in critical limb ischemia: principles for understanding and the de- 577. Uddin A, Russell D, Game F, Santos D, Siddle HJ. The effectiveness of systemic antibio-
velopment of evidence and evaluation of devices: a scientific statement from the tics for osteomyelitis of the foot in adults with diabetes mellitus: a systematic review
American Heart Association. Circulation 2019;140:e657–72. https://doi.org/10.1161/ protocol. J Foot Ankle Res 2022;15:48. https://doi.org/10.1186/s13047-022-00554-3
cir.0000000000000708 578. O’Meara S, Nelson EA, Golder S, Dalton JE, Craig D, Iglesias C. Systematic review of
557. Sukul D, Grey SF, Henke PK, Gurm HS, Grossman PM. Heterogeneity of ankle-brachial methods to diagnose infection in foot ulcers in diabetes. Diabet Med 2006;23:341–7.
indices in patients undergoing revascularization for critical limb ischemia. JACC https://doi.org/10.1111/j.1464-5491.2006.01830.x
Cardiovasc Interv 2017;10:2307–16. https://doi.org/10.1016/j.jcin.2017.08.026 579. Nelson A, Wright-Hughes A, Backhouse MR, Lipsky BA, Nixon J, Bhogal MS, et al.
558. Shishehbor MH, Hammad TA, Zeller T, Baumgartner I, Scheinert D, Rocha-Singh KJ. CODIFI (concordance in diabetic foot ulcer infection): a cross-sectional study of
An analysis of IN.PACT DEEP randomized trial on the limitations of the societal guide- wound swab versus tissue sampling in infected diabetic foot ulcers in England. BMJ
lines–recommended hemodynamic parameters to diagnose critical limb ischemia. Open 2018;8:e019437. https://doi.org/10.1136/bmjopen-2017-019437
J Vasc Surg 2016;63:1311–7. https://doi.org/10.1016/j.jvs.2015.11.042 580. Gardner SE, Frantz RA. Wound bioburden and infection-related complications in
559. Randhawa MS, Reed GW, Grafmiller K, Gornik HL, Shishehbor MH. Prevalence of tib- diabetic foot ulcers. Biol Res Nurs 2008;10:44–53. https://doi.org/10.1177/
ial artery and pedal arch patency by angiography in patients with critical limb ischemia 1099800408319056
and noncompressible ankle brachial index. Circ Cardiovasc Interv 2017;10:e004605. 581. Selva Olid A, Solà I, Barajas-Nava LA, Gianneo OD, Bonfill Cosp X, Lipsky BA. Systemic
https://doi.org/10.1161/CIRCINTERVENTIONS.116.004605 antibiotics for treating diabetic foot infections. Cochrane Database Syst Rev 2015;9:
560. Mustapha JA, Saab FA, Martinsen BJ, Pena CS, Zeller T, Driver VR, et al. Digital subtrac- CD009061. https://doi.org/10.1002/14651858.CD009061.pub2
tion angiography prior to an amputation for critical limb ischemia (CLI): an expert rec- 582. Patton D, Avsar P, Sayeh A, Budri A, O’Connor T, Walsh S, et al. A meta-review of the
ommendation statement from the CLI global society to optimize limb salvage. impact of compression therapy on venous leg ulcer healing. Int Wound J 2023;20:
J Endovasc Ther 2020;27:540–6. https://doi.org/10.1177/1526602820928590 430–47. https://doi.org/10.1111/iwj.13891
561. Menke J, Larsen J. Meta-analysis: accuracy of contrast-enhanced magnetic resonance 583. Lazzarini PA, Armstrong DG, Crews RT, Gooday C, Jarl G, Kirketerp-Moller K, et al.
angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern Effectiveness of offloading interventions for people with diabetes-related foot ulcers: a
Med 2010;153:325–34. https://doi.org/10.7326/0003-4819-153-5-201009070-00007 systematic review and meta-analysis. Diabetes Metab Res Rev 2024;40:e3650. https://
562. Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Luders F, et al. doi.org/10.1002/dmrr.3650
Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack 584. Elraiyah T, Prutsky G, Domecq JP, Tsapas A, Nabhan M, Frykberg RG, et al. A system-
of guideline adherence. Eur Heart J 2015;36:932–8. https://doi.org/10.1093/ atic review and meta-analysis of off-loading methods for diabetic foot ulcers. J Vasc Surg
eurheartj/ehv006 2016;63:59S–68S.e2. https://doi.org/10.1016/j.jvs.2015.10.006
563. Hess CN, Wang TY, Weleski Fu J, Gundrum J, Allen LaPointe NM, Rogers RK, et al. 585. Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical
Long-term outcomes and associations with major adverse limb events after peripheral limb ischemia. J Endovasc Ther 2009;16:Ii31–62. https://doi.org/10.1583/08-2657.1
artery revascularization. J Am Coll Cardiol 2020;75:498–508. https://doi.org/10.1016/j. 586. Manzi M, Palena L, Cester G. Endovascular techniques for limb salvage in diabetics with
jacc.2019.11.050 crural and pedal disease. J Cardiovasc Surg 2011;52:485–92.
564. Bradbury AW, Adam DJ, Bell J, Forbes JF, Fowkes FGR, Gillespie I, et al. Bypass versus 587. Dominguez A, III, Bahadorani J, Reeves R, Mahmud E, Patel M. Endovascular therapy for
angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to critical limb ischemia. Expert Rev Cardiovasc Ther 2015;13:429–44. https://doi.org/10.
facilitate clinical decision making. J Vasc Surg 2010;51:52s–68s. https://doi.org/10.1016/j. 1586/14779072.2015.1019472
jvs.2010.01.077 588. Abu Dabrh AM, Steffen MW, Undavalli C, Asi N, Wang Z, Elamin MB, et al. The natural
565. Meltzer AJ, Graham A, Connolly PH, Meltzer EC, Karwowski JK, Bush HL, et al. The history of untreated severe or critical limb ischemia. J Vasc Surg 2015;62:1642–51.e3.
comprehensive risk assessment for bypass (CRAB) facilitates efficient perioperative https://doi.org/10.1016/j.jvs.2015.07.065
risk assessment for patients with critical limb ischemia. J Vasc Surg 2013;57:1186–95. 589. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus
https://doi.org/10.1016/j.jvs.2012.09.083 angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled
566. van Netten JJ, Fortington LV, Hinchliffe RJ, Hijmans JM. Early post-operative mortality trial. Lancet 2005;366:1925–34. https://doi.org/10.1016/s0140-6736(05)67704-5
after major lower limb amputation: a systematic review of population and regional 590. Bradbury AW, Moakes CA, Popplewell M, Meecham L, Bate GR, Kelly L, et al. A vein
based studies. Eur J Vasc Endovasc Surg 2016;51:248–57. https://doi.org/10.1016/j. bypass first versus a best endovascular treatment first revascularisation strategy for pa-
ejvs.2015.10.001 tients with chronic limb threatening ischaemia who required an infra-popliteal, with or
567. Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, et al. Surgery without an additional more proximal infra-inguinal revascularisation procedure to re-
or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med 2022; store limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.
387:2305–16. https://doi.org/10.1056/NEJMoa2207899 Lancet 2023;401:1798–809. https://doi.org/10.1016/S0140-6736(23)00462-2
568. Meza-Torres B, Carinci F, Heiss C, Joy M, de Lusignan S. Health service organisation 591. Popplewell MA, Davies H, Jarrett H, Bate G, Grant M, Patel S, et al. Bypass versus angio
impact on lower extremity amputations in people with type 2 diabetes with foot ul- plasty in severe ischaemia of the leg—2 (BASIL-2) trial: study protocol for a rando-
cers: systematic review and meta-analysis. Acta Diabetol 2021;58:735–47. https://doi. mised controlled trial. Trials 2016;17:11. https://doi.org/10.1186/s13063-015-1114-2
org/10.1007/s00592-020-01662-x 592. Patel K, Liu Y, Etaee F, Patel C, Monteleone P, Patel M, et al. Differences between pa-
569. Peters EJ, Lipsky BA, Berendt AR, Embil JM, Lavery LA, Senneville E, et al. A systematic tients with intermittent claudication and critical limb ischemia undergoing endovascu-
review of the effectiveness of interventions in the management of infection in the lar intervention: insights from the excellence in peripheral artery disease registry. Circ
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 140 ---
ESC Guidelines 3677
Cardiovasc Interv 2021;14:e010635. https://doi.org/10.1161/CIRCINTERVENTIONS. 614. Zhang J, Xu X, Kong J, Xu R, Fan X, Chen J, et al. Systematic review and meta-analysis of
121.010635 drug-eluting balloon and stent for infrapopliteal artery revascularization. Vasc
593. Almasri J, Adusumalli J, Asi N, Lakis S, Alsawas M, Prokop LJ, et al. A systematic review Endovascular Surg 2017;51:72–83. https://doi.org/10.1177/1538574416689426
and meta-analysis of revascularization outcomes of infrainguinal chronic limb- 615. Matsuoka EK, Hasebe T, Ishii R, Miyazaki N, Soejima K, Iwasaki K. Comparative per-
threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S110–s119. https://doi.org/10. formance analysis of interventional devices for the treatment of ischemic disease in
1016/j.ejvs.2019.04.013 below-the-knee lesions: a systematic review and meta-analysis. Cardiovasc Interv Ther
594. Söder HK, Manninen HI, Jaakkola P, Matsi PJ, Räsänen HT, Kaukanen E, et al. 2022;37:145–57. https://doi.org/10.1007/s12928-021-00758-7
Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: 616. Fong KY, Xin L, Ng J, Loh SEK, Ng JJ, Choong AMTL. A systematic review and
angiographic and clinical results. J Vasc Interv Radiol 2000;11:1021–31. https://doi.org/ meta-analysis of sirolimus-eluting stents for treatment of below-the-knee arterial dis-
10.1016/s1051-0443(07)61332-3 ease. J Vasc Surg 2023;77:1264–73.e3. https://doi.org/10.1016/j.jvs.2022.09.022
595. Balmer H, Mahler F, Do DD, Triller J, Baumgartner I. Balloon angioplasty in chronic 617. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic
critical limb ischemia: factors affecting clinical and angiographic outcome. J Endovasc critical leg ischaemia. Cochrane Database Syst Rev 2013;2:CD004001. https://doi.org/
Ther 2002;9:403–10. https://doi.org/10.1177/152660280200900403 10.1002/14651858.CD004001.pub3
596. Kudo T, Chandra FA, Kwun WH, Haas BT, Ahn SS. Changing pattern of surgical revas- 618. Asimakidou E, Matis GK. Spinal cord stimulation in the treatment of peripheral vascular
cularization for critical limb ischemia over 12 years: endovascular vs. open bypass sur- disease: a systematic review—revival of a promising therapeutic option? Br J Neurosurg
gery. J Vasc Surg 2006;44:304–13. https://doi.org/10.1016/j.jvs.2006.03.040 2022;36:555–63. https://doi.org/10.1080/02688697.2021.1884189
597. Kim KG, Meshkin DH, Tirrell AR, Bekeny JC, Tefera EA, Fan KL, et al. A systematic re- 619. Nicoloff AD, Taylor LM, Jr, Sexton GJ, Schuff RA, Edwards JM, Yeager RA, et al.
view and meta-analysis of endovascular angiosomal revascularization in the setting of Relationship between site of initial symptoms and subsequent progression of disease
collateral vessels. J Vasc Surg 2021;74:1406–16.e3. https://doi.org/10.1016/j.jvs.2021. in a prospective study of atherosclerosis progression in patients receiving long-term
04.026 treatment for symptomatic peripheral arterial disease. J Vasc Surg 2002;35:38–46; dis-
598. Shishehbor MH, Powell RJ, Montero-Baker MF, Dua A, Martínez-Trabal JL, Bunte MC, cussion 46–37.
et al. Transcatheter arterialization of deep veins in chronic limb-threatening ischemia. 620. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International preva-
N Engl J Med 2023;388:1171–80. https://doi.org/10.1056/NEJMoa2212754 lence, recognition, and treatment of cardiovascular risk factors in outpatients with
599. Salem M, Hosny MS, Francia F, Sallam M, Saratzis A, Saha P, et al. Management of ex-
atherothrombosis. JAMA 2006;295:180–9. https://doi.org/10.1001/jama.295.2.180
tensive aorto-iliac disease: a systematic review and meta-analysis of 9319 patients. 621. Wilson YG, Davies AH, Currie IC, Morgan M, McGrath C, Baird RN, et al. Vein graft
Cardiovasc Intervent Radiol 2021;44:1518–35. https://doi.org/10.1007/s00270-021-
stenosis: incidence and intervention. Eur J Vasc Endovasc Surg 1996;11:164–9. https://
02785-6
doi.org/10.1016/s1078-5884(96)80046-3
600. Bekken JA, Vroegindeweij D, Vos JA, de Vries J-PPM, Lardenoije JWHP, Petri B-J, et al.
622. Armstrong PA, Bandyk DF, Wilson JS, Shames ML, Johnson BL, Back MR. Optimizing
Editor’s choice—two year results of the randomised DISCOVER trial comparing cov-
infrainguinal arm vein bypass patency with duplex ultrasound surveillance and endovas-
ered versus bare metal stents in the common iliac artery. Eur J Vasc Endovasc Surg 2023;
cular therapy. J Vasc Surg 2004;40:724–31; discussion 730–721. https://doi.org/10.
65:359–68. https://doi.org/10.1016/j.ejvs.2022.11.008
1016/j.jvs.2004.07.037
601. Jongkind V, Akkersdijk GJ, Yeung KK, Wisselink W. A systematic review of endovascu-
623. Pulli R, Dorigo W, Fargion A, Innocenti AA, Pratesi G, Marek J, et al. Early and long-
lar treatment of extensive aortoiliac occlusive disease. J Vasc Surg 2010;52:1376–83.
term comparison of endovascular treatment of iliac artery occlusions and stenosis.
https://doi.org/10.1016/j.jvs.2010.04.080
J Vasc Surg 2011;53:92–8. https://doi.org/10.1016/j.jvs.2010.08.034
602. Ye W, Liu CW, Ricco JB, Mani K, Zeng R, Jiang J. Early and late outcomes of percutan-
624. Lo RC, Darling J, Bensley RP, Giles KA, Dahlberg SE, Hamdan AD, et al. Outcomes fol-
eous treatment of TransAtlantic inter-society consensus class C and D aorto-iliac le-
lowing infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg 2013;57:
sions. J Vasc Surg 2011;53:1728–37. https://doi.org/10.1016/j.jvs.2011.02.005
1455–64; discussion 1463–1454. https://doi.org/10.1016/j.jvs.2012.10.109
603. Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, et al. BRAVISSIMO:
625. Rodway AD, Hanna L, Harris J, Jarrett R, Allan C, Pazos Casal F, et al. Prognostic and
12-month results from a large scale prospective trial. J Cardiovasc Surg 2013;54:
predictive value of ultrasound-based estimated ankle brachial pressure index at early
235–53.
follow-up after endovascular revascularization of chronic limb-threatening ischaemia:
604. Danczyk RC, Mitchell EL, Petersen BD, Edwards J, Liem TK, Landry GJ, et al. Outcomes
a prospective, single-centre, service evaluation. EClinicalMedicine 2024;68:102410.
of open operation for aortoiliac occlusive disease after failed endovascular therapy.
https://doi.org/10.1016/j.eclinm.2023.102410
Arch Surg 2012;147:841–5. https://doi.org/10.1001/archsurg.2012.1649
626. Poursina O, Elizondo-Adamchik H, Montero-Baker M, Pallister ZS, Mills JL, Chung J.
605. Fereydooni A, Zhou B, Xu Y, Deng Y, Dardik A, Ochoa Chaar CI. Rapid increase in
Safety and efficacy of an endovascular-first approach to acute limb ischemia. J Vasc
hybrid surgery for the treatment of peripheral artery disease in the vascular quality ini-
Surg 2021;73:1741–9. https://doi.org/10.1016/j.jvs.2020.10.002
tiative database. J Vasc Surg 2020;72:977–86.e1. https://doi.org/10.1016/j.jvs.2019.11.
627. Hawkins KE, Valentine RJ, Duke JM, Wang Q, Reed AB. Ankle-brachial index use in
041
peripheral vascular interventions for claudication. J Vasc Surg 2022;76:196–201. 606. Zeller T, Baumgartner I, Scheinert D, Brodmann M, Bosiers M, Micari A, et al.
https://doi.org/10.1016/j.jvs.2022.02.049
Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial re-
628. Armstrong EJ, Chen DC, Westin GG, Singh S, McCoach CE, Bang H, et al. Adherence
vascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP
to guideline-recommended therapy is associated with decreased major adverse car-
randomized trial. J Am Coll Cardiol 2014;64:1568–76. https://doi.org/10.1016/j.jacc.
diovascular events and major adverse limb events among patients with peripheral ar-
2014.06.1198
607. Zeller T, Micari A, Scheinert D, Baumgartner I, Bosiers M, Vermassen FEG, et al. The terial disease. J Am Heart Assoc 2014;3:e000697. https://doi.org/10.1161/jaha.113.
IN.PACT DEEP clinical drug-coated balloon trial: 5-year outcomes. JACC Cardiovasc 000697
Interv 2020;13:431–43. https://doi.org/10.1016/j.jcin.2019.10.059 629. Araujo ST, Moreno DH, Cacione DG. Percutaneous thrombectomy or
608. Brizzi V, Caradu C, Berard X, Sassoust G, Midy D, Ducasse E. Six-year multicenter ex- ultrasound-accelerated thrombolysis for initial management of acute limb ischaemia.
perience of standard endovascular treatment of critical limb ischemia in the era of Cochrane Database Syst Rev 2022;1:CD013486. https://doi.org/10.1002/14651858.
drug-eluting devices. J Cardiovasc Surg 2018;59:707–15. https://doi.org/10.23736/ CD013486.pub2
S0021-9509.16.09737-8 630. Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, Katsaros I, Jawaid O, Jonnalagadda
609. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and AK, et al. Statin therapy for reduction of cardiovascular and limb-related events in crit-
nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24: ical limb ischemia: a systematic review and meta-analysis. Vasc Med 2020;25:106–17.
1433–7. https://doi.org/10.2337/diacare.24.8.1433 https://doi.org/10.1177/1358863x19894055
610. Ozkan U, Oguzkurt L, Tercan F. Atherosclerotic risk factors and segmental distribu- 631. Londero LS, Nørgaard B, Houlind K. Patient delay is the main cause of treatment delay
tion in symptomatic peripheral artery disease. J Vasc Interv Radiol 2009;20:437–41. in acute limb ischemia: an investigation of pre- and in-hospital time delay. World J Emerg
https://doi.org/10.1016/j.jvir.2009.01.010 Surg 2014;9:56. https://doi.org/10.1186/1749-7922-9-56
611. Todd KE, Jr, Ahanchi SS, Maurer CA, Kim JH, Chipman CR, Panneton JM. Atherectomy 632. Duval S, Keo HH, Oldenburg NC, Baumgartner I, Jaff MR, Peacock JM, et al. The impact
offers no benefits over balloon angioplasty in tibial interventions for critical limb ische- of prolonged lower limb ischemia on amputation, mortality, and functional status: the
mia. J Vasc Surg 2013;58:941–8. https://doi.org/10.1016/j.jvs.2013.04.024 FRIENDS registry. Am Heart J 2014;168:577–87. https://doi.org/10.1016/j.ahj.2014.06.
612. Teichgraber U, Lehmann T, Thieme M, Wahl K-U, Stelzner C, Bormann A, et al. 013
Drug-coated balloon angioplasty of infrapopliteal lesions in patients with critical limb 633. Kulezic A, Macek M, Acosta S. Inadequacies of physical examination in patients with
ischaemia: 1-year results of the APOLLO trial. Cardiovasc Intervent Radiol 2019;42: acute lower limb ischemia are associated with dreadful consequences. Ann Vasc Surg
1380–90. https://doi.org/10.1007/s00270-019-02279-6 2022;82:190–6. https://doi.org/10.1016/j.avsg.2021.10.067
613. Yang X, Lu X, Ye K, Li X, Qin J, Jiang M. Systematic review and meta-analysis of balloon 634. Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syn-
angioplasty versus primary stenting in the infrapopliteal disease. Vasc Endovascular Surg drome: a review. Cardiovasc Surg 2002;10:620–30. https://doi.org/10.1016/s0967-
2014;48:18–26. https://doi.org/10.1177/1538574413510626 2109(02)00070-4
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 141 ---
3678 E S C G u id e l in e s
635. Jivegård L, Bergqvist D, Holm J. When is urgent revascularization unnecessary for acute 658. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al.
lower limb ischaemia? Eur J Vasc Endovasc Surg 1995;9:448–53. https://doi.org/10.1016/ Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011).
s1078-5884(05)80014-0 An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk
636. Crawford JD, Perrone KH, Jung E, Mitchell EL, Landry GJ, Moneta GL, et al. Arterial symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim,
duplex for diagnosis of peripheral arterial emboli. J Vasc Surg 2016;64:1351–6. Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc
https://doi.org/10.1016/j.jvs.2016.04.005 Dis 2012;34:290–6. https://doi.org/10.1159/000343145
637. Hemingway J, Emanuels D, Aarabi S, Quiroga E, Tran N, Starnes B, et al. Safety of trans- 659. Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, et al.
fer, type of procedure, and factors predictive of limb salvage in a modern series of Recommendations for the assessment of carotid arterial plaque by ultrasound for
acute limb ischemia. J Vasc Surg 2019;69:1174–9. https://doi.org/10.1016/j.jvs.2018. the characterization of atherosclerosis and evaluation of cardiovascular risk: from
08.174 the American Society of Echocardiography. J Am Soc Echocardiogr 2020;33:917–33.
638. Currie IS, Wakelin SJ, Lee AJ, Chalmers RT. Plasma creatine kinase indicates major am- https://doi.org/10.1016/j.echo.2020.04.021
putation or limb preservation in acute lower limb ischemia. J Vasc Surg 2007;45:733–9. 660. Barnett HJM, Taylor DW, Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, et al.
https://doi.org/10.1016/j.jvs.2006.12.050 Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade
639. Brow TD, Kakkar VV, Das SK. The significance of creatine kinase in cardiac patients carotid stenosis. N Engl J Med 1991;325:445–53. https://doi.org/10.1056/
with acute limb ischaemia. J Cardiovasc Surg 1999;40:637–44. nejm199108153250701
640. Adiseshiah M, Round JM, Jones DA. Reperfusion injury in skeletal muscle: a prospective 661. Gornik HL, Rundek T, Gardener H, Benenati JF, Dahiya N, Hamburg NM, et al.
study in patients with acute limb ischaemia and claudicants treated by revasculariza- Optimization of duplex velocity criteria for diagnosis of internal carotid artery (ICA)
tion. Br J Surg 2005;79:1026–9. https://doi.org/10.1002/bjs.1800791013 stenosis: a report of the Intersocietal Accreditation Commission (IAC) Vascular
641. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Testing Division Carotid Diagnostic Criteria Committee. Vasc Med 2021;26:515–25.
Recommended standards for reports dealing with lower extremity ischemia: revised https://doi.org/10.1177/1358863X211011253
version. J Vasc Surg 1997;26:517–38. https://doi.org/10.1016/s0741-5214(97)70045-4 662. Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI, et al. Carotid
642. Ontario Health. Mechanical thrombectomy for acute and subacute blocked arteries artery stenosis: grayscale and Doppler ultrasound diagnosis—Society of Radiologists in
and veins in the lower limbs: a health technology assessment. Ont Health Technol ultrasound consensus conference. Ultrasound Q 2003;19:190–8. https://doi.org/10.
Assess Ser 2023;23:1–244. 1097/00013644-200312000-00005
643. Gong M, He X, Zhao B, Kong J, Gu J, Chen G, et al. Endovascular revascularization 663. Rustempasic N, Gengo M. Assesment of carotid stenosis with CT angiography and col-
strategies using catheter-based thrombectomy versus conventional catheter-directed or Doppler ultrasonography. Med Arch 2019;73:321–5. https://doi.org/10.5455/
thrombolysis for acute limb ischemia. Thromb J 2021;19:96. https://doi.org/10.1186/ medarh.2019.73.321-325
s12959-021-00349-9 664. Clezar CN, Flumignan CD, Cassola N, Nakano LCU, Trevisani VFM, Flumignan RLG.
644. Doelare SAN, Koedam TWA, Ebben HP, Tournoij E, Hoksbergen AWJ, Yeung KK, Pharmacological interventions for asymptomatic carotid stenosis. Cochrane Database
et al. Catheter directed thrombolysis for not immediately threatening acute limb is- Syst Rev 2023;8:CD013573. https://doi.org/10.1002/14651858.CD013573.pub2
chaemia: systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2023;65: 665. Côté R, Battista RN, Abrahamowicz M, Langlois Y, Bourque F, Mackey A. Lack of effect
537–45. https://doi.org/10.1016/j.ejvs.2022.12.030 of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrow-
645. Veenstra EB, van der Laan MJ, Zeebregts CJ, de Heide E-J, Kater M, Bokkers RPH. A ing. The asymptomatic cervical bruit study group. Ann Intern Med 1995;123:649–55.
systematic review and meta-analysis of endovascular and surgical revascularization https://doi.org/10.7326/0003-4819-123-9-199511010-00002
techniques in acute limb ischemia. J Vasc Surg 2020;71:654–68.e3. https://doi.org/10. 666. Aboyans V, Bauersachs R, Mazzolai L, Brodmann M, Palomares JFR, Debus S, et al.
1016/j.jvs.2019.05.031 Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consen-
646. Kolte D, Kennedy KF, Shishehbor MH, Mamdani ST, Stangenberg L, Hyder ON, et al. sus document from the ESC working group on aorta and peripheral vascular diseases,
Endovascular versus surgical revascularization for acute limb ischemia: a propensity- the ESC working group on thrombosis, and the ESC working group on cardiovascular
score matched analysis. Circ Cardiovasc Interv 2020;13:e008150. https://doi.org/10. pharmacotherapy. Eur Heart J 2021;42:4013–24. https://doi.org/10.1093/eurheartj/
1161/CIRCINTERVENTIONS.119.008150 ehab390
647. Grip O, Wanhainen A, Michaelsson K, Lindhagen L, Bjorck M. Open or endovascular 667. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and
revascularization in the treatment of acute lower limb ischaemia. Br J Surg 2018;105: aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215–25.
1598–606. https://doi.org/10.1002/bjs.10954 https://doi.org/10.1056/NEJMoa1800410
648. Darwood R, Berridge DC, Kessel DO, Robertson I, Forster R. Surgery versus thromb- 668. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in
olysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev 2018; acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–9. https://
8:CD002784. https://doi.org/10.1002/14651858.CD002784.pub3 doi.org/10.1056/NEJMoa1215340
649. Schrijver AM, van Leersum M, Fioole B, Reijnen MMPJ, Hoksbergen AWJ, Vahl AC, 669. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assess-
et al. Dutch randomized trial comparing standard catheter-directed thrombolysis ment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a
and ultrasound-accelerated thrombolysis for arterial thromboembolic infrainguinal randomised controlled pilot trial. Lancet Neurol 2007;6:961–9. https://doi.org/10.1016/
disease (DUET). J Endovasc Ther 2015;22:87–95. https://doi.org/10.1177/ S1474-4422(07)70250-8
1526602814566578 670. Murphy SJX, Naylor AR, Ricco JB, Sillesen H, Kakkos S, Halliday A, et al. Optimal anti-
650. Juneja A, Garuthara M, Talathi S, Rao A, Landis G, Etkin Y. Predictors of poor out- platelet therapy in moderate to severe asymptomatic and symptomatic carotid sten-
comes after lower extremity revascularization for acute limb ischemia. Vascular osis: a comprehensive review of the literature. Eur J Vasc Endovasc Surg 2019;57:
2024;32:632–9. https://doi.org/10.1177/17085381231154290 199–211. https://doi.org/10.1016/j.ejvs.2018.09.018
651. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. Surgery 1998; 671. King A, Shipley M, Markus H, Investigators A. The effect of medical treatments on
124:336–41; discussion 341–332. https://doi.org/10.1016/S0039-6060(98)70139-4 stroke risk in asymptomatic carotid stenosis. Stroke 2013;44:542–6. https://doi.org/
652. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: 10.1161/STROKEAHA.112.673608
American College of Chest Physicians evidence-based clinical practice guidelines (8th 672. Endarterectomy for asymptomatic carotid artery stenosis. Executive committee for
edition). Chest 2008;133:815s–43s. https://doi.org/10.1378/chest.08-0686 the asymptomatic carotid atherosclerosis study. JAMA 1995;273:1421–8.
653. Hess CN, Debus ES, Nehler MR, Anand SS, Patel MR, Szarek M, et al. Reduction in 673. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al. Prevention of disabling
acute limb ischemia with rivaroxaban versus placebo in peripheral artery disease after and fatal strokes by successful carotid endarterectomy in patients without recent
lower extremity revascularization: insights from VOYAGER PAD. Circulation 2021; neurological symptoms: randomised controlled trial. Lancet 2004;363:1491–502.
144:1831–41. https://doi.org/10.1161/circulationaha.121.055146 https://doi.org/10.1016/s0140-6736(04)16146-1
654. Jivegård L, Holm J, Bergqvist D, Björck CG, Björkman H, Brunius U, et al. Acute lower 674. Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, et al. 10-year stroke
limb ischemia: failure of anticoagulant treatment to improve one-month results of ar- prevention after successful carotid endarterectomy for asymptomatic stenosis
terial thromboembolectomy. A prospective randomized multi-center study. Surgery (ACST-1): a multicentre randomised trial. Lancet 2010;376:1074–84. https://doi.org/
1991;109:610–6. 10.1016/s0140-6736(10)61197-x
655. Jivegård L, Holm J, Scherstén T. Arterial thromboembolectomy—should anticoagu- 675. Rothwell PM, Goldstein LB. Carotid endarterectomy for asymptomatic carotid sten-
lants be administered? Acta Chir Scand 1986;152:493–7. osis: asymptomatic carotid surgery trial. Stroke 2004;35:2425–7. https://doi.org/10.
656. Campbell WB, Ridler BM, Szymanska TH. Two-year follow-up after acute thrombo- 1161/01.STR.0000141706.50170.a7
embolic limb ischaemia: the importance of anticoagulation. Eur J Vasc Endovasc Surg 676. Hadar N, Raman G, Moorthy D, O’Donnell TF, Thaler DE, Feldmann E, et al.
2000;19:169–73. https://doi.org/10.1053/ejvs.1999.0999 Asymptomatic carotid artery stenosis treated with medical therapy alone: temporal
657. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. trends and implications for risk assessment and the design of future studies.
Heart disease and stroke statistics–2018 update: a report from the American Cerebrovasc Dis 2014;38:163–73. https://doi.org/10.1159/000365206
Heart Association. Circulation 2018;137:e67–492. https://doi.org/10.1161/cir. 677. Reiff T, Eckstein HH, Mansmann U, Jansen O, Fraedrich G, Mudra H, et al. Angioplasty
0000000000000558 in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 142 ---
ESC Guidelines 3679
treatment: one-year interim results of SPACE-2. Int J Stroke 2020;15:638–49. https:// (ACAS). ACAS Investigators. Stroke 2000;31:2330–4. https://doi.org/10.1161/01.str.
doi.org/10.1177/1747493019833017 31.10.2330
678. Naylor AR, Schroeder TV, Sillesen H. Clinical and imaging features associated with an 698. Kamtchum-Tatuene J, Noubiap JJ, Wilman AH, Saqqur M, Shuaib A, Jickling GC.
increased risk of late stroke in patients with asymptomatic carotid disease. Eur J Vasc Prevalence of high-risk plaques and risk of stroke in patients with asymptomatic ca-
Endovasc Surg 2014;48:633–40. https://doi.org/10.1016/j.ejvs.2014.08.017 rotid stenosis: a meta-analysis. JAMA Neurol 2020;77:1524–35. https://doi.org/10.
679. Paraskevas KI, Brown MM, Lal BK, Myrcha P, Lyden SP, Schneider PA, et al. Recent ad- 1001/jamaneurol.2020.2658
vances and controversial issues in the optimal management of asymptomatic carotid 699. Saratzis A, Naylor R. 30 day outcomes after carotid interventions: an updated
stenosis. J Vasc Surg 2024;79:695–703. https://doi.org/10.1016/j.jvs.2023.11.004 meta-analysis of randomised controlled trials in asymptomatic patients. Eur J Vasc
680. Naylor R, Rantner B, Ancetti S, de Borst GJ, De Carlo M, Halliday A, et al. Editor’s Endovasc Surg 2022;63:157–8. https://doi.org/10.1016/j.ejvs.2021.10.029
choice—European Society for Vascular Surgery (ESVS) 2023 clinical practice guide- 700. Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, et al.
lines on the management of atherosclerotic carotid and vertebral artery disease. Eur Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic
J Vasc Endovasc Surg 2023;65:7–111. https://doi.org/10.1016/j.ejvs.2022.04.011 attack of atherosclerotic origin. Stroke 2020;51:3504–13. https://doi.org/10.1161/
681. Kashyap VS, Schneider PA, Foteh M, Motaganahalli R, Shah R, Eckstein H-H, et al. Early strokeaha.120.032239
outcomes in the ROADSTER 2 study of transcarotid artery revascularization in pa- 701. Halliday A, Bulbulia R, Bonati LH, Chester J, Cradduck-Bamford A, Peto R, et al. Second
tients with significant carotid artery disease. Stroke 2020;51:2620–9. https://doi.org/ asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid ar-
10.1161/strokeaha.120.030550 tery stenting versus carotid endarterectomy. Lancet 2021;398:1065–73. https://doi.
682. Nicolaides AN, Kakkos SK, Griffin M, Sabetai M, Dhanjil S, Tegos T, et al. Severity of org/10.1016/s0140-6736(21)01910-3
asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: re- 702. Rosenfield K, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, et al.
sults from the ACSRS study. Eur J Vasc Endovasc Surg 2005;30:275–84. https://doi.org/ Randomized trial of stent versus surgery for asymptomatic carotid stenosis. N Engl J
10.1016/j.ejvs.2005.04.031 Med 2016;374:1011–20. https://doi.org/10.1056/NEJMoa1515706
683. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic 703. Brott TG, Howard G, Roubin GS, Meschia JF, Mackey A, Brooks W, et al. Long-term
stroke in population-based incidence studies. Neurology 2004;62:569–73. https://doi. results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med
org/10.1212/01.wnl.0000110311.09970.83 2016;374:1021–31. https://doi.org/10.1056/NEJMoa1505215
684. Kakkos SK, Sabetai M, Tegos T, Stevens J, Thomas D, Griffin M, et al. Silent embolic 704. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, et al. Protected
infarcts on computed tomography brain scans and risk of ipsilateral hemispheric events carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med
in patients with asymptomatic internal carotid artery stenosis. J Vasc Surg 2009;49: 2004;351:1493–501. https://doi.org/10.1056/NEJMoa040127
902–9. https://doi.org/10.1016/j.jvs.2008.10.059 705. Karpenko A, Bugurov S, Ignatenko P, Starodubtsev V, Popova I, Malinowski K, et al.
685. Kakkos SK, Nicolaides AN, Charalambous I, Thomas D, Giannopoulos A, Naylor AR, Randomized controlled trial of conventional versus micronet-covered stent in carotid
et al. Predictors and clinical significance of progression or regression of asymptomatic artery revascularization. JACC Cardiovasc Interv 2021;14:2377–87. https://doi.org/10.
carotid stenosis. J Vasc Surg 2014;59:956–67.e1. https://doi.org/10.1016/j.jvs.2013.10. 1016/j.jcin.2021.08.005
073 706. Karpenko A, Bugurov S, Ignatenko P, Starodubtsev V, Popova I, Malinowski K, et al.
686. Markus HS, King A, Shipley M, Topakian R, Cullinane M, Reihill S, et al. Asymptomatic Randomized controlled trial of conventional versus micronet-covered stent in carotid
embolisation for prediction of stroke in the Asymptomatic Carotid Emboli Study artery revascularization: 12-month outcomes. JACC Cardiovasc Interv 2023;16:878–80.
(ACES): a prospective observational study. Lancet Neurol 2010;9:663–71. https://doi. https://doi.org/10.1016/j.jcin.2023.01.369
org/10.1016/s1474-4422(10)70120-4 707. Columbo JA, Martinez-Camblor P, Stone DH, Goodney PP, O’Malley AJ. Procedural
687. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral safety comparison between transcarotid artery revascularization, carotid endarterec-
ischemia. Stroke 1977;8:301–14. https://doi.org/10.1161/01.str.8.3.301 tomy, and carotid stenting: perioperative and 1-year rates of stroke or death. J Am
688. King A, Serena J, Bornstein NM, Markus HS. Does impaired cerebrovascular reactivity Heart Assoc 2022;11:e024964. https://doi.org/10.1161/jaha.121.024964
predict stroke risk in asymptomatic carotid stenosis? A prospective substudy of the 708. de Borst GJ. Transcarotid artery revascularization. Br J Surg 2023;110:127–8. https://
asymptomatic carotid emboli study. Stroke 2011;42:1550–5. https://doi.org/10.1161/ doi.org/10.1093/bjs/znac421
strokeaha.110.609057 709. Hawkins BM, Kennedy KF, Aronow HD, Nguyen LL, White CJ, Rosenfield K, et al.
689. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and Hospital variation in carotid stenting outcomes. JACC Cardiovasc Interv 2015;8:
safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of ath- 858–63. https://doi.org/10.1016/j.jcin.2015.01.026
erosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, 710. Paraskevas KI, Kalmykov EL, Naylor AR. Stroke/death rates following carotid artery
controlled trial. Lancet Neurol 2017;16:301–10. https://doi.org/10.1016/s1474- stenting and carotid endarterectomy in contemporary administrative dataset regis-
4422(17)30038-8 tries: a systematic review. Eur J Vasc Endovasc Surg 2016;51:3–12. https://doi.org/10.
690. Kakkos SK, Griffin MB, Nicolaides AN, Kyriacou E, Sabetai MM, Tegos T, et al. The size 1016/j.ejvs.2015.07.032
of juxtaluminal hypoechoic area in ultrasound images of asymptomatic carotid plaques 711. Brott TG, Hobson RW, II, Howard G, Roubin GS, Clark WM, Brooks W, et al. Stenting
predicts the occurrence of stroke. J Vasc Surg 2013;57:609–18.e1; discussion 617–608. versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010;
https://doi.org/10.1016/j.jvs.2012.09.045 363:11–23. https://doi.org/10.1056/NEJMoa0912321
691. Gupta A, Kesavabhotla K, Baradaran H, Kamel H, Pandya A, Giambrone AE, et al. 712. Sacco RL, Diener HC, Yusuf S, Cotton D, Ôunpuu S, Lawton WA, et al. Aspirin and
Plaque echolucency and stroke risk in asymptomatic carotid stenosis: a systematic re- extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J
view and meta-analysis. Stroke 2015;46:91–7. https://doi.org/10.1161/strokeaha.114. Med 2008;359:1238–51. https://doi.org/10.1056/NEJMoa0805002
006091 713. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral antic-
692. Palacio S, Hart RG, Pearce LA, Anderson DC, Sharma M, Birnbaum LA, et al. Effect of oagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a rando-
addition of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized mised controlled trial. Lancet Neurol 2007;6:115–24. https://doi.org/10.1016/s1474-
trials. Int J Stroke 2015;10:686–91. https://doi.org/10.1111/ijs.12050 4422(06)70685-8
693. Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, et al. Carotid 714. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet
plaque MRI and stroke risk: a systematic review and meta-analysis. Stroke 2013;44: therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using
3071–7. https://doi.org/10.1161/strokeaha.113.002551 Doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli
694. Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus in symptomatic carotid stenosis (CARESS) trial. Circulation 2005;111:2233–40. https://
aspirin versus aspirin alone for reducing embolisation in patients with acute symptom- doi.org/10.1161/01.Cir.0000163561.90680.1c
atic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, 715. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al.
blinded-endpoint trial. Lancet Neurol 2010;9:489–97. https://doi.org/10.1016/s1474- Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med
4422(10)70060-0 2020;383:207–17. https://doi.org/10.1056/NEJMoa1916870
695. Karlöf E, Buckler A, Liljeqvist ML, Lengquist M, Kronqvist M, Toonsi MA, et al. Carotid 716. Wang Y, Pan Y, Li H, Amarenco P, Denison H, Evans SR, et al. Efficacy and safety of
plaque phenotyping by correlating plaque morphology from computed tomography ticagrelor and aspirin in patients with moderate ischemic stroke: an exploratory ana-
angiography with transcriptional profiling. Eur J Vasc Endovasc Surg 2021;62:716–26. lysis of the THALES randomized clinical trial. JAMA Neurol 2021;78:1091–8. https://doi.
https://doi.org/10.1016/j.ejvs.2021.07.011 org/10.1001/jamaneurol.2021.2440
696. Silver FL, Mackey A, Clark WM, Brooks W, Timaran CH, Chiu D, et al. Safety of stent- 717. Messas E, Goudot G, Halliday A, Sitruk J, Mirault T, Khider L, et al. Management of ca-
ing and endarterectomy by symptomatic status in the Carotid Revascularization rotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a
Endarterectomy Versus Stenting Trial (CREST). Stroke 2011;42:675–80. https://doi. critical review. Eur Heart J Suppl 2020;22:M35–42. https://doi.org/10.1093/eurheartj/
org/10.1161/strokeaha.110.610212 suaa162
697. Baker WH, Howard VJ, Howard G, Toole JF. Effect of contralateral occlusion on long- 718. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, et al. Analysis
term efficacy of endarterectomy in the asymptomatic carotid atherosclerosis study of pooled data from the randomised controlled trials of endarterectomy for
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 143 ---
3680 E S C G u id e l in e s
symptomatic carotid stenosis. Lancet 2003;361:107–16. https://doi.org/10.1016/ 739. Kieffer E, Praquin B, Chiche L, Koskas F, Bahnini A. Distal vertebral artery reconstruc-
s0140-6736(03)12228-3 tion: long-term outcome. J Vasc Surg 2002;36:549–54. https://doi.org/10.1067/mva.
719. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final 2002.126092
results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351: 740. Berguer R, Flynn LM, Kline RA, Caplan L. Surgical reconstruction of the extracranial
1379–87. https://doi.org/10.1016/S0140-6736(97)09292-1 vertebral artery: management and outcome. J Vasc Surg 2000;31:9–18. https://doi.
720. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, et al. Carotid end- org/10.1016/s0741-5214(00)70063-2
arterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. 741. Markus HS, Harshfield EL, Compter A, Kuker W, Kappelle LJ, Clifton A, et al. Stenting
Veterans affairs cooperative studies program 309 trialist group. JAMA 1991;266: for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data
3289–94. analysis. Lancet Neurol 2019;18:666–73. https://doi.org/10.1016/s1474-4422(19)
721. Naylor AR, Sillesen H, Schroeder TV. Clinical and imaging features associated with an 30149-8
increased risk of early and late stroke in patients with symptomatic carotid disease. Eur 742. Hanel RA, Brasiliense LB, Spetzler RF. Microsurgical revascularization of proximal ver-
J Vasc Endovasc Surg 2015;49:513–23. https://doi.org/10.1016/j.ejvs.2015.01.011 tebral artery: a single-center, single-operator analysis. Neurosurgery 2009;64:1043–51;
722. Tsantilas P, Kuehnl A, König T, Breitkreuz T, Kallmayer M, Knappich C, et al. Short time discussion 1051. https://doi.org/10.1227/01.Neu.0000347099.17437.64
interval between neurologic event and carotid surgery is not associated with an in- 743. Asiddao CB, Donegan JH, Whitesell RC, Kalbfleisch JH. Factors associated with peri-
creased procedural risk. Stroke 2016;47:2783–90. https://doi.org/10.1161/strokeaha. operative complications during carotid endarterectomy. Anesth Analg 1982;61:631–7.
116.014058 744. Obeid T, Arhuidese I, Gaidry A, Qazi U, Abularrage C, Goodney P, et al. Beta-blocker
723. Loftus IM, Paraskevas KI, Johal A, Waton S, Heikkila K, Naylor AR, et al. Editor’s choice use is associated with lower stroke and death after carotid artery stenting. J Vasc Surg
—delays to surgery and procedural risks following carotid endarterectomy in the UK 2016;63:363–9. https://doi.org/10.1016/j.jvs.2015.08.108
national vascular registry. Eur J Vasc Endovasc Surg 2016;52:438–43. https://doi.org/10. 745. Abou-Chebl A, Reginelli J, Bajzer CT, Yadav JS. Intensive treatment of hypertension
1016/j.ejvs.2016.05.031 decreases the risk of hyperperfusion and intracerebral hemorrhage following carotid
724. Strömberg S, Gelin J, Osterberg T, Bergström GML, Karlström L, Österberg K, et al. artery stenting. Catheter Cardiovasc Interv 2007;69:690–6. https://doi.org/10.1002/ccd.
Very urgent carotid endarterectomy confers increased procedural risk. Stroke 2012; 20693
43:1331–5. https://doi.org/10.1161/strokeaha.111.639344 746. Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid
725. Bush CK, Kurimella D, Cross LJ, Conner KR, Martin-Schild D, He J, et al. Endovascular prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized
treatment with stent-retriever devices for acute ischemic stroke: a meta-analysis of trial. Stroke 1993;24:1125–8. https://doi.org/10.1161/01.str.24.8.1125
randomized controlled trials. PLoS One 2016;11:e0147287. https://doi.org/10.1371/ 747. Kretschmer G, Pratschner T, Prager M, Wenzi E, Polterauer P, Schemper M, et al.
journal.pone.0147287
Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy.
726. Savardekar AR, Narayan V, Patra DP, Spetzler RF, Sun H. Timing of carotid endarter-
Analysis of the clinical series followed by a controlled trial. Ann Surg 1990;211:
ectomy for symptomatic carotid stenosis: a snapshot of current trends and systematic
317–22. https://doi.org/10.1097/00000658-199003000-00002
review of literature on changing paradigm towards early surgery. Neurosurgery 2019;
748. Dalainas I, Nano G, Bianchi P, Stegher S, Malacrida G, Tealdi DG. Dual antiplatelet re-
85:E214–25. https://doi.org/10.1093/neuros/nyy557
gime versus acetyl-acetic acid for carotid artery stenting. Cardiovasc Intervent Radiol
727. Hill MD, Brooks W, Mackey A, Clark WM, Meschia JF, Morrish WF, et al. Stroke after
2006;29:519–21. https://doi.org/10.1007/s00270-005-5288-y
carotid stenting and endarterectomy in the carotid revascularization endarterectomy
749. AbuRahma AF, Avgerinos ED, Chang RW, Darling RC, Duncan AA, Forbes TL, et al.
versus stenting trial (CREST). Circulation 2012;126:3054–61. https://doi.org/10.1161/
The Society for Vascular Surgery implementation document for management of extra-
circulationaha.112.120030
cranial cerebrovascular disease. J Vasc Surg 2022;75:26s–98s. https://doi.org/10.1016/j.
728. Blackshear JL, Cutlip DE, Roubin GS, Hill MD, Leimgruber PP, Begg RJ, et al. Myocardial
jvs.2021.04.074
infarction after carotid stenting and endarterectomy: results from the carotid revascu-
750. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor’s choice—
larization endarterectomy versus stenting trial. Circulation 2011;123:2571–8. https://
management of atherosclerotic carotid and vertebral artery disease: 2017 clinical prac-
doi.org/10.1161/circulationaha.110.008250
tice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc
729. Howard G, Roubin GS, Jansen O, Hendrikse J, Halliday A, Fraedrich G, et al.
Surg 2018;55:3–81. https://doi.org/10.1016/j.ejvs.2017.06.021
Association between age and risk of stroke or death from carotid endarterectomy
751. Ghamraoui AK, Chang H, Maldonado TS, Ricotta JJ, II. Clopidogrel versus ticagrelor for
and carotid stenting: a meta-analysis of pooled patient data from four randomised
antiplatelet therapy in transcarotid artery revascularization in the Society for Vascular
trials. Lancet 2016;387:1305–11. https://doi.org/10.1016/s0140-6736(15)01309-4
Surgery vascular quality initiative. J Vasc Surg 2022;75:1652–60. https://doi.org/10.
730. Alamowitch S, Eliasziw M, Algra A, Meldrum H, Barnett HJ. Risk, causes, and preven-
1016/j.jvs.2021.11.060
tion of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery
752. Marcaccio CL, Patel PB, Liang P, Rastogi V, Stangenberg L, Jim J, et al. Efficacy and safety
stenosis. Lancet 2001;357:1154–60. https://doi.org/10.1016/s0140-6736(00)04332-4
of perioperative dual antiplatelet therapy with ticagrelor versus clopidogrel in carotid
731. Bonati LH, Lyrer P, Ederle J, Featherstone R, Brown MM. Percutaneous transluminal
artery stenting. J Vasc Surg 2022;75:1293–303.e8. https://doi.org/10.1016/j.jvs.2021.09.
balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst
045
Rev 2012;9:CD000515. https://doi.org/10.1002/14651858.CD000515.pub4
753. Ghamraoui AK, Ricotta JJ, II. Outcomes and strategy of tailored antiplatelet therapy 732. Economopoulos KP, Sergentanis TN, Tsivgoulis G, Mariolis AD, Stefanadis C. Carotid
with ticagrelor in patients undergoing transcarotid artery revascularization. J Vasc
artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of
short-term and long-term outcomes. Stroke 2011;42:687–92. https://doi.org/10. Surg 2021;73:132–41. https://doi.org/10.1016/j.jvs.2020.04.518
1161/strokeaha.110.606079 754. Zierler RE, Jordan WD, Lal BK, Mussa F, Leers S, Fulton J, et al. The Society for Vascular
733. Bonati LH, Dobson J, Featherstone RL, Ederle J, van der Worp HB, de Borst GJ, et al. Surgery practice guidelines on follow-up after vascular surgery arterial procedures. J
Long-term outcomes after stenting versus endarterectomy for treatment of symp- Vasc Surg 2018;68:256–84. https://doi.org/10.1016/j.jvs.2018.04.018
tomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised 755. Cheun TJ, Jayakumar L, Sheehan MK, Sideman MJK, Pounds LL, Davies MG. Outcomes
trial. Lancet 2015;385:529–38. https://doi.org/10.1016/s0140-6736(14)61184-3 of upper extremity interventions for chronic critical ischemia. J Vasc Surg 2019;69:
734. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for 120–8.e2. https://doi.org/10.1016/j.jvs.2018.04.056
symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. 756. Awad El-Karim G, Kennedy SA, Ferraresi R, Addas JAK, Oreopoulos GD, Jaberi A, et al.
Lancet 2004;363:915–24. https://doi.org/10.1016/s0140-6736(04)15785-1 Percutaneous transluminal angioplasty for below-the-elbow critical hand ischemia: a
735. Rantner B, Kollerits B, Roubin GS, Ringleb PA, Jansen O, Howard G, et al. Early end- systematic review. J Endovasc Ther 2022;29:468–77. https://doi.org/10.1177/
arterectomy carries a lower procedural risk than early stenting in patients with symp- 15266028211050309
tomatic stenosis of the internal carotid artery: results from 4 randomized controlled 757. Raimbeau A, Pistorius MA, Goueffic Y, Connault J, Plissonneau-Duquene P, Maurel B,
trials. Stroke 2017;48:1580–7. https://doi.org/10.1161/strokeaha.116.016233 et al. Digital ischaemia aetiologies and mid-term follow-up: a cohort study of 323 pa-
736. Schermerhorn ML, Fokkema M, Goodney P, Dillavou ED, Jim J, Kenwood CT, et al. The tients. Medicine 2021;100:e25659. https://doi.org/10.1097/md.0000000000025659
impact of centers for medicare and medicaid services high-risk criteria on outcome 758. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of a differ-
after carotid endarterectomy and carotid artery stenting in the SVS vascular registry. ence in systolic blood pressure between arms with vascular disease and mortality: a
J Vasc Surg 2013;57:1318–24. https://doi.org/10.1016/j.jvs.2012.10.107 systematic review and meta-analysis. Lancet 2012;379:905–14. https://doi.org/10.
737. Schermerhorn ML, Liang P, Eldrup-Jorgensen J, Cronenwett JL, Nolan BW, Kashyap 1016/s0140-6736(11)61710-8
VS, et al. Association of transcarotid artery revascularization vs transfemoral carotid 759. Aboyans V, Kamineni A, Allison MA, McDermott MM, Crouse JR, Ni H, et al. The epi-
artery stenting with stroke or death among patients with carotid artery stenosis. demiology of subclavian stenosis and its association with markers of subclinical athero-
JAMA 2019;322:2313–22. https://doi.org/10.1001/jama.2019.18441 sclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2010;211:
738. Pineau S, Fajardo A, Saqib NU, Tanaka A, Motaganahalli RL, Keyhani A, et al. 266–70. https://doi.org/10.1016/j.atherosclerosis.2010.01.013
Transcarotid revascularization timing and early postoperative outcomes in symptom- 760. Labropoulos N, Nandivada P, Bekelis K. Prevalence and impact of the subclavian steal
atic patients. Vasc Endovascular Surg 2023;57:344–9. https://doi.org/10.1177/ syndrome. Ann Surg 2010;252:166–70. https://doi.org/10.1097/SLA.
15385744221146678 0b013e3181e3375a
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 144 ---
ESC Guidelines 3681
761. Zhang J, Wang L, Chen Y, Wang S, Xing Y, Cui L. Color Doppler ultrasonography for 784. Aboyans V, Desormais I, Magne J, Morange G, Mohty D, Lacroix P. Renal artery sten-
the evaluation of subclavian artery stenosis. Front Neurol 2022;13:804039. https://doi. osis in patients with peripheral artery disease: prevalence, risk factors and long-term
org/10.3389/fneur.2022.804039 prognosis. Eur J Vasc Endovasc Surg 2017;53:380–5. https://doi.org/10.1016/j.ejvs.
762. Harper C, Cardullo PA, Weyman AK, Patterson RB. Transcranial Doppler ultrasonog- 2016.10.029
raphy of the basilar artery in patients with retrograde vertebral artery flow. J Vasc Surg 785. Safian RD. Renal artery stenosis. Prog Cardiovasc Dis 2021;65:60–70. https://doi.org/10.
2008;48:859–64. https://doi.org/10.1016/j.jvs.2008.05.057 1016/j.pcad.2021.03.003
763. Chidambaram PK, Swaminathan RK, Ganesan P, Mayavan M. Segmental comparison of 786. Messerli FH, Bangalore S, Makani H, Rimoldi SF, Allemann Y, White CJ, et al. Flash pul-
peripheral arteries by Doppler ultrasound and CT angiography. J Clin Diagn Res 2016; monary oedema and bilateral renal artery stenosis: the pickering syndrome. Eur Heart J
10:TC12–16. https://doi.org/10.7860/JCDR/2016/17191.7242 2011;32:2231–5. https://doi.org/10.1093/eurheartj/ehr056
764. Tsao TF, Cheng KL, Shen CY, Wu M-C, Huang H-H, Su C-H, et al. Diagnostic perform- 787. Zeller T, Bonvini RF, Sixt S. Color-coded duplex ultrasound for diagnosis of renal ar-
ance of combined contrast-enhanced magnetic resonance angiography and phase- tery stenosis and as follow-up examination after revascularization. Catheter Cardiovasc
contrast magnetic resonance imaging in suspected subclavian steal syndrome. Can Interv 2008;71:995–9. https://doi.org/10.1002/ccd.21525
Assoc Radiol J 2016;67:190–201. https://doi.org/10.1016/j.carj.2015.08.007 788. Prince M, Tafur JD, White CJ. When and how should we revascularize patients with
765. Klitfod L, Jensen LP. Treatment of chronic upper limb ischaemia is safe and results are atherosclerotic renal artery stenosis? JACC Cardiovasc Interv 2019;12:505–17. https://
good. Dan Med J 2014;61:A4859. doi.org/10.1016/j.jcin.2018.10.023
766. Duran M, Grotemeyer D, Danch MA, Grabitz K, Schelzig H, Sagban TA. Subclavian ca- 789. AbuRahma AF, Yacoub M. Renal imaging: duplex ultrasound, computed tomography
rotid transposition: immediate and long-term outcomes of 126 surgical reconstruc- angiography, magnetic resonance angiography, and angiography. Semin Vasc Surg
tions. Ann Vasc Surg 2015;29:397–403. https://doi.org/10.1016/j.avsg.2014.09.030 2013;26:134–43. https://doi.org/10.1053/j.semvascsurg.2014.06.001
767. Daniel VT, Madenci AL, Nguyen LL, Eslami MH, Kalish JA, Farber A, et al. 790. Staub D, Canevascini R, Huegli RW, Aschwanden M, Thalhammer C, Imfeld S, et al.
Contemporary comparison of supra-aortic trunk surgical reconstructions for occlu- Best duplex-sonographic criteria for the assessment of renal artery stenosis—correl-
sive disease. J Vasc Surg 2014;59:1577–82, 1582.e1–2. https://doi.org/10.1016/j.jvs. ation with intra-arterial pressure gradient. Ultraschall Med 2007;28:45–51. https://doi.
2013.12.017 org/10.1055/s-2007-962881
768. Burihan E, Soma F, Iared W. Angioplasty versus stenting for subclavian artery stenosis. 791. Williams GJ, Macaskill P, Chan SF, Karplus TE, Yung W, Hodson EM, et al. Comparative
Cochrane Database Syst Rev 2011;10:CD008461. https://doi.org/10.1002/14651858. accuracy of renal duplex sonographic parameters in the diagnosis of renal artery sten-
CD008461.pub2 osis: paired and unpaired analysis. AJR Am J Roentgenol 2007;188:798–811. https://doi.
769. Hüttl K, Nemes B, Simonffy A, Entz L, Bérczi V. Angioplasty of the innominate artery in
org/10.2214/ajr.06.0355
89 patients: experience over 19 years. Cardiovasc Intervent Radiol 2002;25:109–14. 792. Parikh SA, Shishehbor MH, Gray BH, White CJ, Jaff MR. SCAI expert consensus state-
https://doi.org/10.1007/s00270-001-0074-y
ment for renal artery stenting appropriate use. Catheter Cardiovasc Interv 2014;84:
770. Modarai B, Ali T, Dourado R, Reidy JF, Taylor PR, Burnand KG. Comparison of extra-
1163–71. https://doi.org/10.1002/ccd.25559
anatomic bypass grafting with angioplasty for atherosclerotic disease of the
793. Caps MT, Perissinotto C, Zierler RE, Polissar NL, Bergelin RO, Tullis MJ, et al.
supra-aortic trunks. Br J Surg 2004;91:1453–7. https://doi.org/10.1002/bjs.4751
Prospective study of atherosclerotic disease progression in the renal artery.
771. Song L, Zhang J, Li J, Gu Y, Yu H, Chen B, et al. Endovascular stenting vs. extrathoracic
Circulation 1998;98:2866–72. https://doi.org/10.1161/01.cir.98.25.2866
surgical bypass for symptomatic subclavian steal syndrome. J Endovasc Ther 2012;19:
794. Amighi J, Schlager O, Haumer M, Dick P, Mlekusch W, Loewe C, et al. Renal artery
44–51. https://doi.org/10.1583/11-3692.1
stenosis predicts adverse cardiovascular and renal outcome in patients with peripheral
772. Owens LV, Tinsley EA, Jr, Criado E, Burnham SJ, Keagy BA. Extrathoracic reconstruc-
artery disease. Eur J Clin Invest 2009;39:784–92. https://doi.org/10.1111/j.1365-2362.
tion of arterial occlusive disease involving the supraaortic trunks. J Vasc Surg 1995;22:
2009.02180.x
217–21; discussion 221–2. https://doi.org/10.1016/s0741-5214(95)70133-8
795. Fatica RA, Port FK, Young EW. Incidence trends and mortality in end-stage renal dis-
773. Huijben M, Meershoek AJA, de Borst GJ, Toorop RJ. Long-term outcome of
ease attributed to renovascular disease in the United States. Am J Kidney Dis 2001;37:
axillo-axillary bypass in patients with subclavian or innominate artery stenosis. Ann
1184–90. https://doi.org/10.1053/ajkd.2001.24521
Vasc Surg 2021;73:321–8. https://doi.org/10.1016/j.avsg.2020.10.029
796. Ritchie J, Green D, Alderson HV, Chrysochou C, Vassallo D, Sinha S, et al. Associations
774. Lee AD, Agarwal S, Sadhu D. A 7-year experience with thoracoscopic sympathectomy
of antiplatelet therapy and beta blockade with patient outcomes in atherosclerotic re-
for critical upper limb ischemia. World J Surg 2006;30:1644–7. https://doi.org/10.1007/
novascular disease. J Am Soc Hypertens 2016;10:149–58.e3. https://doi.org/10.1016/j.
s00268-005-0559-y
jash.2015.12.002
775. Schillinger M, Haumer M, Schillinger S, Mlekusch W, Ahmadi R, Minar E. Outcome of
797. Raman G, Adam GP, Halladay CW, Langberg VN, Azodo IA, Balk EM. Comparative
conservative versus interventional treatment of subclavian artery stenosis. J Endovasc
effectiveness of management strategies for renal artery stenosis: an updated system-
Ther 2002;9:139–46. https://doi.org/10.1177/152660280200900201
atic review. Ann Intern Med 2016;165:635–49. https://doi.org/10.7326/M16-1053
776. Ahmed AT, Mohammed K, Chehab M, Brinjikji W, Hassan Murad M, Cloft H, et al.
798. Bhalla V, Textor SC, Beckman JA, Casanegra AI, Cooper CJ, Kim ESH, et al. Comparing percutaneous transluminal angioplasty and stent placement for treatment
Revascularization for renovascular disease: a scientific statement from the American
of subclavian arterial occlusive disease: a systematic review and meta-analysis.
Heart Association. Hypertension 2022;79:e128–43. https://doi.org/10.1161/hyp.
Cardiovasc Intervent Radiol 2016;39:652–67. https://doi.org/10.1007/s00270-015-
0000000000000217
1250-9
799. Piaggio D, Bracale U, Pecchia L, Di Taranto MD, Sodo M, Bracale UM. Endovascular
777. Che W, Dong H, Jiang X, Peng M, Zou Y, Song L, et al. Subclavian artery stenting for
treatment versus medical therapy for hypertensive patients with renal artery stenosis:
coronary-subclavian steal syndrome. Catheter Cardiovasc Interv 2017;89:601–8. https://
doi.org/10.1002/ccd.26902 an updated systematic review. Ann Vasc Surg 2019;61:445–54. https://doi.org/10.1016/
778. Hamdan R, Guilleminot P, Leclercq T, Monin A. Coronary-subclavian steal syndrome j.avsg.2019.04.050
causing myocardial infarction after arteriovenous fistula creation: a case report. ESC 800. Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, et al. Revascularization ver-
Heart Fail 2023;10:2084–9. https://doi.org/10.1002/ehf2.14341 sus medical therapy for renal-artery stenosis. N Engl J Med 2009;361:1953–62. https://
779. Che WQ, Dong H, Jiang XJ, Peng M, Zou Y, Qian H, et al. Stenting for left subclavian doi.org/10.1056/NEJMoa0905368
artery stenosis in patients scheduled for left internal mammary artery-coronary artery 801. Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, et al. Stent placement
bypass grafting. Catheter Cardiovasc Interv 2016;87:579–88. https://doi.org/10.1002/ in patients with atherosclerotic renal artery stenosis and impaired renal function: a ran-
ccd.26477 domized trial. Ann Intern Med 2009;150:840–8, w150–1. https://doi.org/10.7326/0003-
780. Muller AM, Bertram J, Bradaric C, Koppara T, Cassese S, Xhepa E, et al. Frequency of 4819-150-12-200906160-00119
subclavian artery stenosis in patients with mammarian artery coronary bypass and sus- 802. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, et al.
pected coronary artery disease progression. Clin Res Cardiol 2023;112:1204–11. Randomised comparison of percutaneous angioplasty vs continued medical therapy
https://doi.org/10.1007/s00392-022-02113-z for hypertensive patients with atheromatous renal artery stenosis. Scottish and
781. Angle JF, Matsumoto AH, McGraw JK, Spinosa DJ, Hagspiel KD, Leung DA, et al. Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998;12:
Percutaneous angioplasty and stenting of left subclavian artery stenosis in patients 329–35. https://doi.org/10.1038/sj.jhh.1000599
with left internal mammary-coronary bypass grafts: clinical experience and long-term 803. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FHM, Deinum J, Postma CT, et al. The
follow-up. Vasc Endovascular Surg 2003;37:89–97. https://doi.org/10.1177/ effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis.
153857440303700202 Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med
782. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431–42. https:// 2000;342:1007–14. https://doi.org/10.1056/nejm200004063421403
doi.org/10.1056/nejm200102083440607 804. Plouin PF, Chatellier G, Darné B, Raynaud A. Blood pressure outcome of angioplasty in
783. Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, et al. Prevalence atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique
of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002;36: Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998;31:823–9.
443–51. https://doi.org/10.1067/mva.2002.127351 https://doi.org/10.1161/01.hyp.31.3.823
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 145 ---
3682 E S C G u id e l in e s
805. Abela R, Ivanova S, Lidder S, Morris R, Hamilton G. An analysis comparing open surgical 826. Lehtimäki TT, Kärkkäinen JM, Saari P, Manninen H, Paajanen H, Vanninen R. Detecting
and endovascular treatment of atherosclerotic renal artery stenosis. Eur J Vasc acute mesenteric ischemia in CT of the acute abdomen is dependent on clinical suspi-
Endovasc Surg 2009;38:666–75. https://doi.org/10.1016/j.ejvs.2009.08.002 cion: review of 95 consecutive patients. Eur J Radiol 2015;84:2444–53. https://doi.org/
806. Balzer KM, Pfeiffer T, Rossbach S, Voiculescu A, Mödder U, Godehardt E, et al. 10.1016/j.ejrad.2015.09.006
Prospective randomized trial of operative vs interventional treatment for renal artery 827. Kirkpatrick ID, Kroeker MA, Greenberg HM. Biphasic CT with mesenteric CT angiog-
ostial occlusive disease (RAOOD). J Vasc Surg 2009;49:667–75; discussion 674–665. raphy in the evaluation of acute mesenteric ischemia: initial experience. Radiology 2003;
https://doi.org/10.1016/j.jvs.2008.10.006 229:91–8. https://doi.org/10.1148/radiol.2291020991
807. Mohler ER, III, Gornik HL, Gerhard-Herman M, Misra S, Olin JW, Zierler RE. ACCF/ 828. Oliva IB, Davarpanah AH, Rybicki FJ, Desjardins B, Flamm SD, Francois CJ, et al. ACR
ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS/SVU [corrected] 2012 ap- appropriateness Criteria ® imaging of mesenteric ischemia. Abdom Imaging 2013;38:
propriate use criteria for peripheral vascular ultrasound and physiological testing 714–9. https://doi.org/10.1007/s00261-012-9975-2
part I: arterial ultrasound and physiological testing: a report of the American 829. Salsano G, Salsano A, Sportelli E, Petrocelli F, Dahmane M, Spinella G, et al. What is the
College of Cardiology Foundation appropriate use criteria task force, American best revascularization strategy for acute occlusive arterial mesenteric ischemia: sys-
College of Radiology, American Institute of Ultrasound in Medicine, American tematic review and meta-analysis. Cardiovasc Intervent Radiol 2018;41:27–36. https://
Society of Echocardiography, American Society of Nephrology, Intersocietal doi.org/10.1007/s00270-017-1749-3
Commission for the Accreditation of Vascular Laboratories, Society for 830. El Farargy M, Abdel Hadi A, Abou Eisha M, Bashaeb K, Antoniou GA. Systematic review
Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed and meta-analysis of endovascular treatment for acute mesenteric ischaemia. Vascular
Tomography, Society for Interventional Radiology, Society for Vascular Medicine, 2017;25:430–8. https://doi.org/10.1177/1708538116689353
Society for Vascular Surgery, [corrected] and Society for Vascular Ultrasound. [cor- 831. Kärkkäinen JM, Acosta S. Acute mesenteric ischemia (part II)—vascular and endovas-
rected]. J Am Coll Cardiol 2012;60:242–76. https://doi.org/10.1016/j.jacc.2012.02.009 cular surgical approaches. Best Pract Res Clin Gastroenterol 2017;31:27–38. https://doi.
808. Davies MG, Saad WA, Bismuth JX, Peden EK, Naoum JJ, Lumsden AB. Outcomes of org/10.1016/j.bpg.2016.11.003
832. Wyers MC, Powell RJ, Nolan BW, Cronenwett JL. Retrograde mesenteric stenting
endoluminal reintervention for restenosis after percutaneous renal angioplasty and
during laparotomy for acute occlusive mesenteric ischemia. J Vasc Surg 2007;45:
stenting. J Vasc Surg 2009;49:946–52. https://doi.org/10.1016/j.jvs.2008.11.039
269–75. https://doi.org/10.1016/j.jvs.2006.10.047
809. Hicks CW, Clark TWI, Cooper CJ, de Bhailís ÁM, De Carlo M, Green D, et al.
833. Tilsed JV, Casamassima A, Kurihara H, Mariani D, Martinez I, Pereira J, et al. ESTES
Atherosclerotic renovascular disease: A KDIGO (kidney disease: improving global out-
guidelines: acute mesenteric ischaemia. Eur J Trauma Emerg Surg 2016;42:253–70.
comes) controversies conference. Am J Kidney Dis 2022;79:289–301. https://doi.org/
https://doi.org/10.1007/s00068-016-0634-0
10.1053/j.ajkd.2021.06.025
834. Tallarita T, Oderich GS, Gloviczki P, Duncan AA, Kalra M, Cha S, et al. Patient survival
810. Johansen KL, Garimella PS, Hicks CW, Kalra PA, Kelly DM, Martens S, et al. Central and
after open and endovascular mesenteric revascularization for chronic mesenteric is-
peripheral arterial diseases in chronic kidney disease: conclusions from a kidney dis-
chemia. J Vasc Surg 2013;57:747–55; discussion 754–745. https://doi.org/10.1016/j.
ease: improving global outcomes (KDIGO) controversies conference. Kidney Int
jvs.2012.09.047
2021;100:35–48. https://doi.org/10.1016/j.kint.2021.04.029
835. Alahdab F, Arwani R, Pasha AK, Razouki ZA, Prokop LJ, Huber TS, et al. A systematic
811. Pappaccogli M, Robberechts T, Lengele JP, Van der Niepen P, Sarafidis P, Rabbia F, et al.
review and meta-analysis of endovascular versus open surgical revascularization for
Endovascular versus medical management of atherosclerotic renovascular disease: up-
chronic mesenteric ischemia. J Vasc Surg 2018;67:1598–605. https://doi.org/10.1016/
date and emerging concepts. Hypertension 2023;80:1150–61. https://doi.org/10.1161/
j.jvs.2017.12.046
HYPERTENSIONAHA.122.17965
836. Mensink PB, Moons LM, Kuipers EJ. Chronic gastrointestinal ischaemia: shifting para-
812. Tian Y, Yuan B, Zhang N, Huang Z. Outcomes following the endovascular treatment of
digms. Gut 2011;60:722–37. https://doi.org/10.1136/gut.2009.199695
renal artery stenosis caused by fibromuscular dysplasia: a systematic review and
837. Roobottom CA, Dubbins PA. Significant disease of the celiac and superior mesenteric
meta-analysis. Ann Vasc Surg 2022;78:362–72. https://doi.org/10.1016/j.avsg.2021.06.
arteries in asymptomatic patients: predictive value of Doppler sonography. AJR Am J
042
Roentgenol 1993;161:985–8. https://doi.org/10.2214/ajr.161.5.8273642
813. Persu A, Giavarini A, Touzé E, Januszewicz A, Sapoval M, Azizi M, et al. European con-
838. Høyer C, Christensen MH, Sandermann J, Leusink R, Abrahamsen J. Chronic mesen-
sensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens 2014;
teric ischaemia: the importance of the individual mesenteric artery. Clin Physiol Funct
32:1367–78. https://doi.org/10.1097/hjh.0000000000000213
Imaging 2022;42:15–22. https://doi.org/10.1111/cpf.12730
814. Zeller T, Krankenberg H, Erglis A, Blessing E, Fuss T, Scheinert D, et al. A randomized,
839. Mensink PB, van Petersen AS, Geelkerken RH, Otte JA, Huisman AB, Kolkman JJ, et al.
multi-center, prospective study comparing best medical treatment versus best medical
Clinical significance of splanchnic artery stenosis. Br J Surg 2006;93:1377–82. https://
treatment plus renal artery stenting in patients with hemodynamically relevant athero-
doi.org/10.1002/bjs.5481
sclerotic renal artery stenosis (RADAR)—one-year results of a pre-maturely termi- 840. van Noord D, Mensink PB, de Knegt RJ, Ouwendijk M, Francke J, van Vuuren AJ, et al.
nated study. Trials 2017;18:380. https://doi.org/10.1186/s13063-017-2126-x Serum markers and intestinal mucosal injury in chronic gastrointestinal ischemia. Dig
815. Tamme K, Reintam Blaser A, Laisaar KT, Mändul M, Kals J, Forbes A, et al. Incidence and Dis Sci 2011;56:506–12. https://doi.org/10.1007/s10620-010-1303-5
outcomes of acute mesenteric ischaemia: a systematic review and meta-analysis. BMJ 841. Mensink PB, Hol L, Borghuis-Koertshuis N, Geelkerken RH, Huisman AB,
Open 2022;12:e062846. https://doi.org/10.1136/bmjopen-2022-062846 Doelman CJA, et al. Transient postprandial ischemia is associated with increased
816. Acosta S. Epidemiology of mesenteric vascular disease: clinical implications. Semin Vasc intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia.
Surg 2010;23:4–8. https://doi.org/10.1053/j.semvascsurg.2009.12.001 Eur J Gastroenterol Hepatol 2009;21:278–82. https://doi.org/10.1097/MEG.
817. Acosta S, Ogren M, Sternby NH, Bergqvist D, Björck M. Incidence of acute thrombo- 0b013e32832183a7
embolic occlusion of the superior mesenteric artery—a population-based study. Eur J 842. van Noord D, Kolkman JJ. Functional testing in the diagnosis of chronic mesenteric is-
Vasc Endovasc Surg 2004;27:145–50. https://doi.org/10.1016/j.ejvs.2003.11.003 chemia. Best Pract Res Clin Gastroenterol 2017;31:59–68. https://doi.org/10.1016/j.bpg.
818. Carver TW, Vora RS, Taneja A. Mesenteric ischemia. Crit Care Clin 2016;32:155–71. 2016.12.002
https://doi.org/10.1016/j.ccc.2015.11.001 843. van Petersen AS, Meerwaldt R, Kolkman JJ, Huisman AB, van der Palen J, van Bockel JH,
819. Klass AA. Embolectomy in acute mesenteric occlusion. Ann Surg 1951;134:913–7. et al. The influence of respiration on criteria for transabdominal duplex examination of
https://doi.org/10.1097/00000658-195111000-00016 the splanchnic arteries in patients with suspected chronic splanchnic ischemia. J Vasc
820. Acosta S, Björck M. Acute thrombo-embolic occlusion of the superior mesenteric ar- Surg 2013;57:1603–11, 1611.e1–10. https://doi.org/10.1016/j.jvs.2012.11.120
tery: a prospective study in a well defined population. Eur J Vasc Endovasc Surg 2003;26: 844. Zwolak RM, Fillinger MF, Walsh DB, LaBombard FA, Musson A, Darling CE, et al.
179–83. https://doi.org/10.1053/ejvs.2002.1893 Mesenteric and celiac duplex scanning: a validation study. J Vasc Surg 1998;27:
821. Kärkkäinen JM, Acosta S. Acute mesenteric ischemia (part I)—incidence, etiologies, 1078–88; discussion 1088. https://doi.org/10.1016/s0741-5214(98)60010-0
and how to improve early diagnosis. Best Pract Res Clin Gastroenterol 2017;31: 845. Schaefer PJ, Pfarr J, Trentmann J, Wulff A, Langer C, Siggelkow M, et al. Comparison of
15–25. https://doi.org/10.1016/j.bpg.2016.10.018 noninvasive imaging modalities for stenosis grading in mesenteric arteries. Rofo 2013;
822. Kärkkäinen JM. Acute mesenteric ischemia: a challenge for the acute care surgeon. 185:628–34. https://doi.org/10.1055/s-0033-1335212
Scand J Surg 2021;110:150–8. https://doi.org/10.1177/14574969211007590 846. Cademartiri F, Palumbo A, Maffei E, Martini C, Malagò R, Belgrano M, et al. Noninvasive
823. Powell A, Armstrong P. Plasma biomarkers for early diagnosis of acute intestinal ische- evaluation of the celiac trunk and superior mesenteric artery with multislice CT in pa-
mia. Semin Vasc Surg 2014;27:170–5. https://doi.org/10.1053/j.semvascsurg.2015.01. tients with chronic mesenteric ischaemia. Radiol Med 2008;113:1135–42. https://doi.
008 org/10.1007/s11547-008-0330-1
824. Block T, Nilsson TK, Björck M, Acosta S. Diagnostic accuracy of plasma biomarkers for 847. Pecoraro F, Rancic Z, Lachat M, Mayer D, Amann-Vesti B, Pfammatter T, et al. Chronic
intestinal ischaemia. Scand J Clin Lab Invest 2008;68:242–8. https://doi.org/10.1080/ mesenteric ischemia: critical review and guidelines for management. Ann Vasc Surg
00365510701646264 2013;27:113–22. https://doi.org/10.1016/j.avsg.2012.05.012
825. Kougias P, Lau D, El Sayed HF, Zhou W, Huynh TT, Lin PH. Determinants of mortality 848. Gupta PK, Horan SM, Turaga KK, Miller WJ, Pipinos II. Chronic mesenteric ischemia:
and treatment outcome following surgical interventions for acute mesenteric ischemia. endovascular versus open revascularization. J Endovasc Ther 2010;17:540–9. https://
J Vasc Surg 2007;46:467–74. https://doi.org/10.1016/j.jvs.2007.04.045 doi.org/10.1583/09-2935.1
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 146 ---
ESC Guidelines 3683
849. Huber TS, Björck M, Chandra A, Clouse WD, Dalsing MC, Oderich GS, et al. Chronic evaluation of Marfan syndrome. Genet Med 2013;15:528–32. https://doi.org/10.
mesenteric ischemia: clinical practice guidelines from the society for vascular surgery. 1038/gim.2012.172
J Vasc Surg 2021;73:87s–115s. https://doi.org/10.1016/j.jvs.2020.10.029 871. Davies RR, Gallo A, Coady MA, Tellides G, Botta DM, Burke B, et al. Novel measure-
850. Fernández-Friera L, Fuster V, López-Melgar B, Oliva B, Sánchez-González J, Macías A, ment of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac
et al. Vascular inflammation in subclinical atherosclerosis detected by hybrid PET/MRI. Surg 2006;81:169–77. https://doi.org/10.1016/j.athoracsur.2005.06.026
J Am Coll Cardiol 2019;73:1371–82. https://doi.org/10.1016/j.jacc.2018.12.075 872. Hannawa KK, Eliason JL, Upchurch GR, Jr. Gender differences in abdominal aortic an-
851. Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, et al. eurysms. Vascular 2009;17:30–9. https://doi.org/10.2310/6670.2008.00092
Prevalence of potential risk factors for stroke assessed by transesophageal echocardi- 873. Boczar KE, Cheung K, Boodhwani M, Beauchesne L, Dennie C, Nagpal S, et al. Sex dif-
ography and carotid ultrasonography: the SPARC study. Stroke prevention: assess- ferences in thoracic aortic aneurysm growth. Hypertension 2019;73:190–6. https://doi.
ment of risk in a community. Mayo Clin Proc 1999;74:862–9. https://doi.org/10.4065/ org/10.1161/hypertensionaha.118.11851
74.9.862 874. Hultgren R, Larsson E, Wahlgren CM, Swedenborg J. Female and elderly abdominal
852. Russo C, Jin Z, Rundek T, Homma S, Sacco RL, Di Tullio MR. Atherosclerotic disease of aortic aneurysm patients more commonly have concurrent thoracic aortic aneurysm.
the proximal aorta and the risk of vascular events in a population-based cohort: the Ann Vasc Surg 2012;26:918–23. https://doi.org/10.1016/j.avsg.2012.01.023
Aortic Plaques and Risk of Ischemic Stroke (APRIS) study. Stroke 2009;40:2313–8. 875. Chaer RA, Vasoncelos R, Marone LK, Al-Khoury G, Rhee RY, Cho JS, et al.
https://doi.org/10.1161/strokeaha.109.548313 Synchronous and metachronous thoracic aneurysms in patients with abdominal aortic
853. Oyama N, Gona P, Salton CJ, Chuang ML, Jhaveri RR, Blease SJ, et al. Differential impact aneurysms. J Vasc Surg 2012;56:1261–5. https://doi.org/10.1016/j.jvs.2012.04.056
of age, sex, and hypertension on aortic atherosclerosis: the Framingham heart study. 876. Olsen PS, Schroeder T, Agerskov K, Agerskov K, Røder O, Sørensen S, et al. Surgery
Arterioscler Thromb Vasc Biol 2008;28:155–9. https://doi.org/10.1161/atvbaha.107. for abdominal aortic aneurysms. A survey of 656 patients. J Cardiovasc Surg 1991;32:
153544 636–42.
854. Montgomery DH, Ververis JJ, McGorisk G, Frohwein S, Martin RP, Taylor WR. Natural 877. Tuveson V, Löfdahl HE, Hultgren R. Patients with abdominal aortic aneurysm have a
history of severe atheromatous disease of the thoracic aorta: a transesophageal echo- high prevalence of popliteal artery aneurysms. Vasc Med 2016;21:369–75. https://
cardiographic study. J Am Coll Cardiol 1996;27:95–101. https://doi.org/10.1016/0735- doi.org/10.1177/1358863x16648404
1097(95)00431-9 878. Brunkwall J, Hauksson H, Bengtsson H, Bergqvist D, Takolander R, Bergentz S-E.
855. Amarenco P, Cohen A, Hommel M, Moulin T, Leys D, Bousser M-G. Atherosclerotic Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occur-
disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med rence. J Vasc Surg 1989;10:381–4. https://doi.org/10.1067/mva.1989.13733
1996;334:1216–21. https://doi.org/10.1056/nejm199605093341902 879. Bickerstaff LK, Pairolero PC, Hollier LH, Melton LJ, Van Peenen HJ, Cherry KJ, et al.
856. Fujimoto S, Yasaka M, Otsubo R, Oe H, Nagatsuka K, Minematsu K. Aortic arch ath- Thoracic aortic aneurysms: a population-based study. Surgery 1982;92:1103–8.
erosclerotic lesions and the recurrence of ischemic stroke. Stroke 2004;35:1426–9. 880. Coady MA, Rizzo JA, Goldstein LJ, Elefteriades JA. Natural history, pathogenesis, and
https://doi.org/10.1161/01.STR.0000127788.32550.d4 etiology of thoracic aortic aneurysms and dissections. Cardiol Clin 1999;17:615–35; vii.
857. Koren MJ, Bryant B, Hilton TC. Atherosclerotic disease of the aortic arch and the risk https://doi.org/10.1016/s0733-8651(05)70105-3
of ischemic stroke. N Engl J Med 1995;332:1237–8. author reply 1237-1238. https:// 881. Diwan A, Sarkar R, Stanley JC, Zelenock GB, Wakefield TW. Incidence of femoral and
doi.org/10.1056/NEJM199505043321815 popliteal artery aneurysms in patients with abdominal aortic aneurysms. J Vasc Surg
858. Meissner I, Khandheria BK, Sheps SG, Schwartz GL, Wiebers DO, Whisnant JP, et al. 2000;31:863–9. https://doi.org/10.1067/mva.2000.105955
Atherosclerosis of the aorta: risk factor, risk marker, or innocent bystander? A pro- 882. Brown LC, Thompson SG, Greenhalgh RM, Powell JT. Incidence of cardiovascular
spective population-based transesophageal echocardiography study. J Am Coll Cardiol events and death after open or endovascular repair of abdominal aortic aneurysm in
2004;44:1018–24. https://doi.org/10.1016/j.jacc.2004.05.075 the randomized EVAR trial 1. Br J Surg 2011;98:935–42. https://doi.org/10.1002/bjs.
859. Mitusch R, Doherty C, Wucherpfennig H, Memmesheimer C, Tepe C, Stierle U, et al. 7485
Vascular events during follow-up in patients with aortic arch atherosclerosis. Stroke 883. Hammo S, Grannas D, Wahlgren CM. High risk of early and late cardiovascular events
1997;28:36–9. https://doi.org/10.1161/01.str.28.1.36 after endovascular aortic aneurysm repair. Ann Vasc Surg 2022;86:320–7. https://doi.
860. Tunick PA, Rosenzweig BP, Katz ES, Freedberg RS, Perez JL, Kronzon I. High risk for org/10.1016/j.avsg.2022.04.028
vascular events in patients with protruding aortic atheromas: a prospective study. 884. Kuzmik GA, Sang AX, Elefteriades JA. Natural history of thoracic aortic aneurysms.
J Am Coll Cardiol 1994;23:1085–90. https://doi.org/10.1016/0735-1097(94)90595-9 J Vasc Surg 2012;56:565–71. https://doi.org/10.1016/j.jvs.2012.04.053
861. Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S. Aortic arch plaques and risk 885. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dis-
of recurrent stroke and death. Circulation 2009;119:2376–82. https://doi.org/10.1161/ section: increasing prevalence and improved outcomes reported in a nationwide
circulationaha.108.811935 population-based study of more than 14,000 cases from 1987 to 2002. Circulation
862. Tunick PA, Nayar AC, Goodkin GM, Mirchandani S, Francescone S, Rosenzweig BP, 2006;114:2611–8. https://doi.org/10.1161/circulationaha.106.630400
et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients 886. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, et al. 2010 ACCF/
with severe thoracic aortic plaque. Am J Cardiol 2002;90:1320–5. https://doi.org/10. AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and man-
1016/s0002-9149(02)02870-9 agement of patients with thoracic aortic disease: a report of the American College of
863. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin Cardiology Foundation/American Heart Association task force on practice guidelines,
and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or American Association for Thoracic Surgery, American College of Radiology, American
transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, Stroke Association, Society of Cardiovascular Anesthesiologists, Society for
placebo-controlled trial. Lancet 2004;364:331–7. https://doi.org/10.1016/s0140- Cardiovascular Angiography and Interventions, Society of Interventional Radiology,
6736(04)16721-4 Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010;
864. Bowdish ME, Weaver FA, Liebman HA, Rowe VL, Hood DB. Anticoagulation is an ef- 121:e266–369. https://doi.org/10.1161/CIR.0b013e3181d4739e
fective treatment for aortic mural thrombi. J Vasc Surg 2002;36:713–9. 887. Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic
865. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill aneurysm and dissection. J Am Coll Cardiol 2014;64:1725–39. https://doi.org/10.1016/j.
D, et al. 2021 Guideline for the prevention of stroke in patients with stroke and jacc.2014.08.025
transient ischemic attack: a guideline from the American Heart Association/ 888. Caruana M, Baars MJ, Bashiardes E, Benke K, Björck E, Codreanu A, et al. HTAD pa-
American Stroke Association. Stroke 2021;52:e364–467. https://doi.org/10.1161/ tient pathway: strategy for diagnostic work-up of patients and families with (suspected)
str.0000000000000375 heritable thoracic aortic diseases (HTAD). A statement from the HTAD working
866. Amarenco P, Davis S, Jones EF, Cohen AA, Heiss W-D, Kaste M, et al. Clopidogrel plus group of VASCERN. Eur J Med Genet 2023;66:104673. https://doi.org/10.1016/j.
aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014;45: ejmg.2022.104673
1248–57. https://doi.org/10.1161/strokeaha.113.004251 889. Patel HJ, Deeb GM. Ascending and arch aorta: pathology, natural history, and treat-
867. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of ment. Circulation 2008;118:188–95. https://doi.org/10.1161/circulationaha.107.
clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 690933
367:817–25. https://doi.org/10.1056/NEJMoa1204133 890. Boodhwani M, de Kerchove L, Glineur D, Poncelet A, Rubay J, Astarci P, et al.
868. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al. A comparison of Repair-oriented classification of aortic insufficiency: impact on surgical techniques
two LDL cholesterol targets after ischemic stroke. N Engl J Med 2020;382:9. https:// and clinical outcomes. J Thorac Cardiovasc Surg 2009;137:286–94. https://doi.org/10.
doi.org/10.1056/NEJMoa1910355 1016/j.jtcvs.2008.08.054
869. Devereux RB, de Simone G, Arnett DK, Best LG, Boerwinkle E, Howard BV, et al. 891. Ganapathi AM, Ranney DN, Peterson MD, Lindsay ME, Patel HJ, Pyeritz RE, et al.
Normal limits in relation to age, body size and gender of two-dimensional echocardio- Location of aortic enlargement and risk of type A dissection at smaller diameters.
graphic aortic root dimensions in persons ≥15 years of age. Am J Cardiol 2012;110: J Am Coll Cardiol 2022;79:1890–7. https://doi.org/10.1016/j.jacc.2022.02.053
1189–94. https://doi.org/10.1016/j.amjcard.2012.05.063 892. Kalogerakos PD, Zafar MA, Li Y, Mukherjee SK, Ziganshin BA, Rizzo JA, et al. Root dila-
870. van Kimmenade RR, Kempers M, de Boer MJ, Loeys BL, Timmermans J. A clinical ap- tation is more malignant than ascending aortic dilation. J Am Heart Assoc 2021;10:
praisal of different Z-score equations for aortic root assessment in the diagnostic e020645. https://doi.org/10.1161/jaha.120.020645
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 147 ---
3684 E S C G u id e l in e s
893. Della Corte A, Bancone C, Buonocore M, Dialetto G, Covino FE, Manduca S, et al. 917. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneur-
Pattern of ascending aortic dimensions predicts the growth rate of the aorta in pa- ysms: a 7-year prospective study: the Tromsø study, 1994–2001. Circulation 2009;119:
tients with bicuspid aortic valve. JACC Cardiovasc Imaging 2013;6:1301–10. https:// 2202–8. https://doi.org/10.1161/circulationaha.108.817619
doi.org/10.1016/j.jcmg.2013.07.009 918. Jahangir E, Lipworth L, Edwards TL, Kabagambe EK, Mumma MT, Mensah GA, et al.
894. Kim JB, Spotnitz M, Lindsay ME, MacGillivray TE, Isselbacher EM, Sundt TM. Risk of aor- Smoking, sex, risk factors and abdominal aortic aneurysms: a prospective study of
tic dissection in the moderately dilated ascending aorta. J Am Coll Cardiol 2016;68: 18 782 persons aged above 65 years in the southern community cohort study.
1209–19. https://doi.org/10.1016/j.jacc.2016.06.025 J Epidemiol Community Health 2015;69:481–8. https://doi.org/10.1136/jech-2014-
895. Saeyeldin A, Zafar MA, Velasquez CA, Ip K, Gryaznov A, Brownstein AJ, et al. Natural 204920
history of aortic root aneurysms in Marfan syndrome. Ann Cardiothorac Surg 2017;6: 919. Strachan DP. Predictors of death from aortic aneurysm among middle-aged men: the
625–32. https://doi.org/10.21037/acs.2017.11.10 Whitehall study. Br J Surg 2005;78:401–4. https://doi.org/10.1002/bjs.1800780407
896. Cheung K, Boodhwani M, Chan KL, Beauchesne L, Dick A, Coutinho T. Thoracic aortic 920. Wanhainen A, Bergqvist D, Boman K, Nilsson TK, Rutegård J, Björck M. Risk factors
aneurysm growth: role of sex and aneurysm etiology. J Am Heart Assoc 2017;6: associated with abdominal aortic aneurysm: a population-based study with historical
and current data. J Vasc Surg 2005;41:390–6. https://doi.org/10.1016/j.jvs.2005.01.002
e003792. https://doi.org/10.1161/jaha.116.003792
921. Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, et al.
897. Nataf P, Lansac E. Dilation of the thoracic aorta: medical and surgical management.
Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 mil-
Heart 2006;92:1345–52. https://doi.org/10.1136/hrt.2005.074781
lion individuals. J Vasc Surg 2010;52:539–48. https://doi.org/10.1016/j.jvs.2010.05.090
898. Yiu RS, Cheng SW. Natural history and risk factors for rupture of thoracic aortic arch
922. Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z. Diabetes and
aneurysms. J Vasc Surg 2016;63:1189–94. https://doi.org/10.1016/j.jvs.2015.12.043
aortic aneurysm: current state of the art. Cardiovasc Res 2018;114:1702–13. https://
899. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the
doi.org/10.1093/cvr/cvy174
appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac
923. Avdic T, Franzén S, Zarrouk M, Acosta S, Nilsson P, Gottsäter A, et al. Reduced long-
Cardiovasc Surg 1997;113:476–91; discussion 489–491. https://doi.org/10.1016/
term risk of aortic aneurysm and aortic dissection among individuals with type 2 dia-
s0022-5223(97)70360-x
betes mellitus: a nationwide observational study. J Am Heart Assoc 2018;7:e007618.
900. Safi HJ, Winnerkvist A, Miller CC, III, Iliopoulos DC, Reardon MJ, Espada R, et al. Effect
https://doi.org/10.1161/jaha.117.007618
of extended cross-clamp time during thoracoabdominal aortic aneurysm repair. Ann
924. Nordness MJ, Baxter BT, Matsumura J, Terrin M, Zhang K, Ye F, et al. The effect of
Thorac Surg 1998;66:1204–8. https://doi.org/10.1016/s0003-4975(98)00781-4
diabetes on abdominal aortic aneurysm growth over 2 years. J Vasc Surg 2022;75:
901. Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005;111:
1211–22.e1. https://doi.org/10.1016/j.jvs.2021.10.019
816–28. https://doi.org/10.1161/01.Cir.0000154569.08857.7a 925. Yusuf K, Murat B, Unal A, Ulku K, Taylan K, Ozerdem O, et al. Inflammatory abdominal
902. Zafar MA, Chen JF, Wu J, Li Y, Papanikolaou D, Abdelbaky M, et al. Natural history of aortic aneurysm: predictors of long-term outcome in a case-control study. Surgery
descending thoracic and thoracoabdominal aortic aneurysms. J Thorac Cardiovasc Surg 2007;141:83–9. https://doi.org/10.1016/j.surg.2006.04.007
2021;161:498–511.e1. https://doi.org/10.1016/j.jtcvs.2019.10.125 926. Oliver-Williams C, Sweeting MJ, Turton G, Parkin D, Cooper D, Rodd C, et al. Lessons
903. Oladokun D, Patterson BO, Sobocinski J, Karthikesalingam A, Loftus I, Thompson MM, learned about prevalence and growth rates of abdominal aortic aneurysms from a
et al. Systematic review of the growth rates and influencing factors in thoracic aortic 25-year ultrasound population screening programme. Br J Surg 2018;105:68–74.
aneurysms. Eur J Vasc Endovasc Surg 2016;51:674–81. https://doi.org/10.1016/j.ejvs. https://doi.org/10.1002/bjs.10715
2016.01.017 927. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic
904. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture aneurysm presence and progression. Circulation 2008;118:2382–92. https://doi.org/10.
or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann 1161/circulationaha.108.802074
Thorac Surg 2002;73:17–28; discussion 27–18. https://doi.org/10.1016/s0003-4975(01) 928. Vermeulen JJM, Meijer M, de Vries FBG, Reijnen MMPJ, Holewijn S, Thijssen DHJ, et al.
03236-2 A systematic review summarizing local vascular characteristics of aneurysm wall to
905. Verloes A, Sakalihasan N, Koulischer L, Limet R. Aneurysms of the abdominal aorta: predict for progression and rupture risk of abdominal aortic aneurysms. J Vasc Surg
familial and genetic aspects in three hundred thirteen pedigrees. J Vasc Surg 1995; 2023;77:288–98.e2. https://doi.org/10.1016/j.jvs.2022.07.008
21:646–55. https://doi.org/10.1016/s0741-5214(95)70196-6 929. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT. Abdominal aortic
906. Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, et al. Systematic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004;
review and meta-analysis of the growth and rupture rates of small abdominal aortic 110:16–21. https://doi.org/10.1161/01.Cir.0000133279.07468.9f
aneurysms: implications for surveillance intervals and their cost-effectiveness. Health 930. Malayala SV, Raza A, Vanaparthy R. Gender-based differences in abdominal aortic an-
Technol Assess 2013;17:1–118. https://doi.org/10.3310/hta17410 eurysm rupture: a retrospective study. J Clin Med Res 2020;12:794–802. https://doi.
907. Sakalihasan N, Defraigne JO, Kerstenne MA, Cheramy-Bien J-P, Smelser DT, Tromp G, org/10.14740/jocmr4376
et al. Family members of patients with abdominal aortic aneurysms are at increased risk 931. Skibba AA, Evans JR, Hopkins SP, Yoon HR, Katras T, Kalbfleisch JH, et al.
for aneurysms: analysis of 618 probands and their families from the Liege AAA family Reconsidering gender relative to risk of rupture in the contemporary management
of abdominal aortic aneurysms. J Vasc Surg 2015;62:1429–36. https://doi.org/10.
study. Ann Vasc Surg 2014;28:787–97. https://doi.org/10.1016/j.avsg.2013.11.005
908. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultra- 1016/j.jvs.2015.07.079
932. Catalano O, Siani A. Ruptured abdominal aortic aneurysm: categorization of sono-
sound surveillance. UK small aneurysm trial participants. Ann Surg 1999;230:289–96;
graphic findings and report of 3 new signs. J Ultrasound Med 2005;24:1077–83. discussion 296–287. https://doi.org/10.1097/00000658-199909000-00002
https://doi.org/10.7863/jum.2005.24.8.1077 909. Mani K, Wanhainen A. Accurate and reproducible diameter measurement is essential
933. Schermerhorn ML, Bensley RP, Giles KA, Hurks R, O’Malley AJ, Cotterill P, et al.
in surveillance and treatment of thoracic aortic aneurysms. Eur J Vasc Endovasc Surg
Changes in abdominal aortic aneurysm rupture and short-term mortality,
2014;47:27. https://doi.org/10.1016/j.ejvs.2013.10.004
1995-2008: a retrospective observational study. Ann Surg 2012;256:651–8. https://
910. Isselbacher EM, Preventza O, Hamilton Black J, III, Augoustides JG, Beck AW, Bolen
doi.org/10.1097/SLA.0b013e31826b4f91
MA, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic dis-
934. Rakita D, Newatia A, Hines JJ, Siegel DN, Friedman B. Spectrum of CT findings in rup-
ease: a report of the American Heart Association/American College of Cardiology
ture and impending rupture of abdominal aortic aneurysms. Radiographics 2007;27:
joint committee on clinical practice guidelines. Circulation 2022;146:e334-482.
497–507. https://doi.org/10.1148/rg.272065026
https://doi.org/10.1161/cir.0000000000001106
935. Schwartz SA, Taljanovic MS, Smyth S, O’Brien MJ, Rogers LF. CT findings of rupture,
911. Booher AM, Eagle KA. Diagnosis and management issues in thoracic aortic aneurysm.
impending rupture, and contained rupture of abdominal aortic aneurysms. AJR Am J
Am Heart J 2011;162:38–46.e1. https://doi.org/10.1016/j.ahj.2011.04.010 Roentgenol 2007;188:W57–62. https://doi.org/10.2214/ajr.05.1554
912. Wang TKM, Desai MY. Thoracic aortic aneurysm: optimal surveillance and treatment. 936. Tomee SM, Bulder RMA, Meijer CA, van Berkum I, Hinnen J-W, Schoones JW, et al.
Cleve Clin J Med 2020;87:557–68. https://doi.org/10.3949/ccjm.87a.19140-1 Excess mortality for abdominal aortic aneurysms and the potential of strict implemen-
913. Roberts DA. Magnetic resonance imaging of thoracic aortic aneurysm and dissection. tation of cardiovascular risk management: a multifaceted study integrating
Semin Roentgenol 2001;36:295–308. https://doi.org/10.1053/sroe.2001.26938 meta-analysis, national registry, and PHAST and TEDY trial data. Eur J Vasc Endovasc
914. Rajiah P. CT and MRI in the evaluation of thoracic aortic diseases. Int J Vasc Med 2013; Surg 2023;65:348–57. https://doi.org/10.1016/j.ejvs.2022.11.019
2013:797189. https://doi.org/10.1155/2013/797189 937. Freiberg MS, Arnold AM, Newman AB, Edwards MS, Kraemer KL, Kuller LH.
915. Lin FY, Devereux RB, Roman MJ, Meng J, Jow VM, Jacobs A, et al. Assessment of the Abdominal aortic aneurysms, increasing infrarenal aortic diameter, and risk of total
thoracic aorta by multidetector computed tomography: age- and sex-specific refer- mortality and incident cardiovascular disease events: 10-year follow-up data from
ence values in adults without evident cardiovascular disease. J Cardiovasc Comput the cardiovascular health study. Circulation 2008;117:1010–7. https://doi.org/10.
Tomogr 2008;2:298–308. https://doi.org/10.1016/j.jcct.2008.08.002 1161/circulationaha.107.720219
916. McPhee JT, Hill JS, Eslami MH. The impact of gender on presentation, therapy, and 938. Bown MJ, Sweeting MJ, Brown LC, Powell JT, Thompson SG. Surveillance intervals for
mortality of abdominal aortic aneurysm in the United States, 2001–2004. J Vasc Surg small abdominal aortic aneurysms: a meta-analysis. JAMA 2013;309:806–13. https://doi.
2007;45:891–9. https://doi.org/10.1016/j.jvs.2007.01.043 org/10.1001/jama.2013.950
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 148 ---
ESC Guidelines 3685
939. Dugas A, Therasse E, Kauffmann C, Tang A, Elkouri S, Nozza A, et al. Reproducibility of 962. Lee H, Cho YH, Sung K, Kim WS, Park K-H, Jeong DS, et al. Clinical outcomes of root
abdominal aortic aneurysm diameter measurement and growth evaluation on axial and reimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac
multiplanar computed tomography reformations. Cardiovasc Intervent Radiol 2012;35: Surg 2018;106:539–47. https://doi.org/10.1016/j.athoracsur.2018.02.057
779–87. https://doi.org/10.1007/s00270-011-0259-y 963. Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D, Rubay J, et al.
940. Kontopodis N, Metaxa E, Gionis M, Papaharilaou Y, Ioannou CV. Discrepancies in de- Long-term experience with valve-sparing reimplantation technique for the treatment
termination of abdominal aortic aneurysms maximum diameter and growth rate, using of aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:14–23.
axial and orhtogonal computed tomography measurements. Eur J Radiol 2013;82: https://doi.org/10.1016/j.jtcvs.2018.10.155
1398–403. https://doi.org/10.1016/j.ejrad.2013.04.031 964. Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S, et al.
941. Foo FJ, Hammond CJ, Goldstone AR, Abuhamdiah M, Rashid ST, West RM, et al. Early and late results after David vs Bentall procedure: a propensity matched analysis.
Agreement between computed tomography and ultrasound on abdominal aortic an- Ann Thorac Surg 2020;110:120–6. https://doi.org/10.1016/j.athoracsur.2019.10.020
eurysms and implications on clinical decisions. Eur J Vasc Endovasc Surg 2011;42: 965. Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, et al.
608–14. https://doi.org/10.1016/j.ejvs.2011.07.003 Valve-sparing root replacement versus composite valve grafting in aortic root dilation:
942. Zhu C, Tian B, Leach JR, Liu Q, Lu J, Chen L, et al. Non-contrast 3D black blood MRI for
a meta-analysis. Ann Thorac Surg 2020;110:296–306. https://doi.org/10.1016/j.
abdominal aortic aneurysm surveillance: comparison with CT angiography. Eur Radiol
athoracsur.2019.11.054
2017;27:1787–94. https://doi.org/10.1007/s00330-016-4559-0
966. Leyh RG, Fischer S, Kallenbach K, Kofidis T, Pethig K, Harringer W, et al. High failure
943. Sakalihasan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne J-O, Nchimi A, et al.
rate after valve-sparing aortic root replacement using the “remodeling technique” in
Abdominal aortic aneurysms. Nat Rev Dis Primers 2018;4:34. https://doi.org/10.1038/
acute type A aortic dissection. Circulation 2002;106:I229–33.
s41572-018-0030-7
967. Schäfers H, Fries R, Langer F, Nikoloudakis N, Graeter T, Grundmann U.
944. Wemmelund H, Jørgensen TM, Høgh A, Behr-Rasmussen C, Johnsen SP, Lindholt JS,
Valve-preserving replacement of the ascending aorta: remodeling versus reimplanta-
et al. Low-dose aspirin and rupture of abdominal aortic aneurysm. J Vasc Surg 2017;65:
tion. J Thorac Cardiovasc Surg 1998;116:990–6. https://doi.org/10.1016/s0022-
616–5.e4. https://doi.org/10.1016/j.jvs.2016.04.061
5223(98)70051-0
945. Wanhainen A, Mani K, Kullberg J, Svensjö S, Bersztel A, Karlsson L, et al. The effect of
968. Rahnavardi M, Yan TD, Bannon PG, Wilson MK. Aortic valve-sparing operations in
ticagrelor on growth of small abdominal aortic aneurysms–a randomized controlled
aortic root aneurysms: remodeling or reimplantation? Interact Cardiovasc Thorac Surg
trial. Cardiovasc Res 2020;116:450–6. https://doi.org/10.1093/cvr/cvz133
2011;13:189–97. https://doi.org/10.1510/icvts.2011.267401
946. Golledge J, Thanigaimani S, Powell JT, Tsao PS. Pathogenesis and management of ab-
969. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/
dominal aortic aneurysm. Eur Heart J 2023;44:2682–97. https://doi.org/10.1093/
eurheartj/ehad386 EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:
947. Sweeting MJ, Thompson SG, Brown LC, Powell JT, Collaborators R. Meta-analysis of 561–632. https://doi.org/10.1093/eurheartj/ehab395
individual patient data to examine factors affecting growth and rupture of small ab- 970. Mok CK, Boey J, Wang R, Chan TK, Cheung KL, Lee PK, et al. Warfarin versus
dominal aortic aneurysms. Br J Surg 2012;99:655–65. https://doi.org/10.1002/bjs.8707 dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart
948. Golledge J, Moxon J, Pinchbeck J, Anderson G, Rowbotham S, Jenkins J, et al. valve thromboembolism: a prospective randomized clinical trial. Circulation 1985;72:
Association between metformin prescription and growth rates of abdominal aortic an- 1059–63. https://doi.org/10.1161/01.cir.72.5.1059
eurysms. Br J Surg 2017;104:1486–93. https://doi.org/10.1002/bjs.10587 971. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications
949. Thanigaimani S, Singh TP, Unosson J, Phie J, Moxon J, Wanhainen A, et al. Editor’s in patients with mechanical heart valve prostheses. Circulation 1994;89:635–41. https://
choice—association between metformin prescription and abdominal aortic aneurysm doi.org/10.1161/01.cir.89.2.635
growth and clinical events: a systematic review and meta-analysis. Eur J Vasc Endovasc 972. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, et al. Early an-
Surg 2021;62:747–56. https://doi.org/10.1016/j.ejvs.2021.06.013 ticoagulation of bioprosthetic aortic valves in older patients: results from the Society of
950. Wong KHF, Zlatanovic P, Bosanquet DC, Saratzis A, Kakkos SK, Aboyans V, et al. Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012;
Antithrombotic therapy for aortic aneurysms: a systematic review and meta-analysis. 60:971–7. https://doi.org/10.1016/j.jacc.2012.05.029
Eur J Vasc Endovasc Surg 2022;64:544–56. https://doi.org/10.1016/j.ejvs.2022.07.008 973. Rafiq S, Steinbrüchel DA, Lilleør NB, Møller CH, Lund JT, Thiis JJ, et al. Antithrombotic
951. Newton ER, Akerman AW, Strassle PD, Kibbe MR. Association of fluoroquinolone use therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a rando-
with short-term risk of development of aortic aneurysm. JAMA Surg 2021;156:264–72. mized controlled trial. Thromb Res 2017;150:104–10. https://doi.org/10.1016/j.
https://doi.org/10.1001/jamasurg.2020.6165 thromres.2016.11.021
952. Wee I, Chin B, Syn N, Lee KS, Ng JJ, Choong AMTL. The association between fluor- 974. Czerny M, Rylski B, Della Corte A, Krüger T. Decision-making to perform elective sur-
oquinolones and aortic dissection and aortic aneurysms: a systematic review and gery for patients with proximal thoracic aortic pathology: a European perspective.
meta-analysis. Sci Rep 2021;11:11073. https://doi.org/10.1038/s41598-021-90692-8 J Thorac Cardiovasc Surg 2022;163:2025–30. https://doi.org/10.1016/j.jtcvs.2021.01.141
953. Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic an- 975. Vorp DA, Schiro BJ, Ehrlich MP, Juvonen TS, Ergin MA, Griffith BP. Effect of aneurysm
eurysm and dissection: nationwide cohort study. BMJ 2018;360:k678. https://doi. on the tensile strength and biomechanical behavior of the ascending thoracic aorta.
org/10.1136/bmj.k678 Ann Thorac Surg 2003;75:1210–4. https://doi.org/10.1016/s0003-4975(02)04711-2
954. Garg M, Venugopalan V, Vouri SM, Diaby V, Iovine NM, Park H, et al. Oral fluoroqui- 976. Della Corte A, Lo Presti F, Saade W, Rubino AS, Palmieri L, Patanè F, et al. Acute type
nolones and risk of aortic aneurysm or dissection: a nationwide population-based pro- A aortic dissection in bicuspid versus tricuspid aortic valve patients: focus on geomet-
pensity score-matched cohort study. Pharmacotherapy 2023;43:883–93. https://doi. rical features of the aorta. Eur J Cardiothorac Surg 2023;63:ezac576. https://doi.org/10.
org/10.1002/phar.2841 1093/ejcts/ezac576
955. Fatima K, Uzair SU, Salman A, Jawed A, Husain MA, Shah MG, et al. Fluoroquinolones
977. Mullan CW, Mori M, Bin Mahmood SU, Yousef S, Mangi AA, Elefteriades JA, et al.
and the risk of aortic aneurysm or aortic dissection: an updated systematic review and
Incidence and characteristics of hospitalization for proximal aortic surgery for acute
meta-analysis including 53,651,283 patients. Minerva Cardiol Angiol 2023;71:485–93.
syndromes and for aneurysms in the USA from 2005 to 2014. Eur J Cardiothorac
https://doi.org/10.23736/S2724-5683.22.06124-5
Surg 2020;58:583–9. https://doi.org/10.1093/ejcts/ezaa067
956. LeMaire SA, Zhang L, Luo W, Ren P, Azares AR, Wang Y, et al. Effect of ciprofloxacin
978. Williams JB, Peterson ED, Zhao Y, O’Brien SM, Andersen ND, Miller DC, et al.
on susceptibility to aortic dissection and rupture in mice. JAMA Surg 2018;153:
Contemporary results for proximal aortic replacement in North America. J Am Coll
e181804. https://doi.org/10.1001/jamasurg.2018.1804
Cardiol 2012;60:1156–62. https://doi.org/10.1016/j.jacc.2012.06.023
957. Brown JP, Wing K, Leyrat C, Evans SJ, Mansfield KE, Wong AYS, et al. Association be-
979. Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, et al. Elective
tween fluoroquinolone use and hospitalization with aortic aneurysm or aortic dissec-
aortic root replacement in North America: analysis of STS adult cardiac surgery data-
tion. JAMA Cardiol 2023;8:865. https://doi.org/10.1001/jamacardio.2023.2418
base. Ann Thorac Surg 2019;107:1307–12. https://doi.org/10.1016/j.athoracsur.2018.
958. Gopalakrishnan C, Bykov K, Fischer MA, Connolly JG, Gagne JJ, Fralick M. Association
of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern 12.039
Med 2020;180:1596–605. https://doi.org/10.1001/jamainternmed.2020.4199 980. Mori M, Shioda K, Wang X, Mangi AA, Yun JJ, Darr U, et al. Perioperative risk profiles
959. Lee CC, Lee MT, Chen YS, Lee S-H, Chen Y-S, Chen S-C, et al. Risk of aortic dissection and volume-outcome relationships in proximal thoracic aortic surgery. Ann Thorac Surg
and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med 2015; 2018;106:1095–104. https://doi.org/10.1016/j.athoracsur.2018.05.081
175:1839–47. https://doi.org/10.1001/jamainternmed.2015.5389 981. Wojnarski CM, Svensson LG, Roselli EE, Idrees JJ, Lowry AM, Ehrlinger J, et al. Aortic
960. Huh K, Kang M, Jung J. Lack of association between fluoroquinolone and aortic aneur- dissection in patients with bicuspid aortic valve-associated aneurysms. Ann Thorac Surg
ysm or dissection. Eur Heart J 2023;44:4476–84. https://doi.org/10.1093/eurheartj/ 2015;100:1666–73; discussion 1673–74. https://doi.org/10.1016/j.athoracsur.2015.04.
ehad627 126
961. Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, et al. Survival and re- 982. Wu J, Zafar MA, Liu Y, Chen JF, Li Y, Ziganshin BA, et al. Fate of the unoperated as-
operation pattern after 20 years of experience with aortic valve-sparing root replace- cending thoracic aortic aneurysm: three-decade experience from the Aortic
ment in patients with tricuspid and bicuspid valves. J Thorac Cardiovasc Surg 2018;155: Institute at Yale University. Eur Heart J 2023;44:4579–88. https://doi.org/10.1093/
1403–11.e1. https://doi.org/10.1016/j.jtcvs.2017.12.039 eurheartj/ehad148
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 149 ---
3686 E S C G u id e l in e s
983. Ziganshin BA, Zafar MA, Elefteriades JA. Descending threshold for ascending aortic an- 1003.Chen JF, Zafar MA, Wu J, Li Y, Rizzo JA, Papanikolaou D, et al. Increased virulence of
eurysmectomy: is it time for a “left-shift” in guidelines? J Thorac Cardiovasc Surg 2019; descending thoracic and thoracoabdominal aortic aneurysms in women. Ann Thorac
157:37–42. https://doi.org/10.1016/j.jtcvs.2018.07.114 Surg 2021;112:45–52. https://doi.org/10.1016/j.athoracsur.2020.08.026
984. Rylski B, Branchetti E, Bavaria JE, Vallabhajosyula P, Szeto WY, Milewski RK, et al. 1004.Lobato AC, Puech-Leão P. Predictive factors for rupture of thoracoabdominal aortic
Modeling of predissection aortic size in acute type A dissection: more than 90% fail aneurysm. J Vasc Surg 1998;27:446–53. https://doi.org/10.1016/s0741-5214(98)
to meet the guidelines for elective ascending replacement. J Thorac Cardiovasc Surg 70319-2
2014;148:944–8.e1. https://doi.org/10.1016/j.jtcvs.2014.05.050 1005.Harris DG, Olson SL, Panthofer AM, Matsumura JS, DiMusto PD. A frailty-based risk
985. Mansour AM, Peterss S, Zafar MA, Rizzo JA, Fang H, Charilaou P, et al. Prevention of score predicts morbidity and mortality after elective endovascular repair of descend-
aortic dissection suggests a diameter shift to a lower aortic size threshold for interven- ing thoracic aortic aneurysms. Ann Vasc Surg 2020;67:90–9. https://doi.org/10.1016/j.
tion. Cardiology 2018;139:139–46. https://doi.org/10.1159/000481930 avsg.2019.10.090
986. Masri A, Kalahasti V, Alkharabsheh S, Svensson LG, Sabik JF, Roselli EE, et al. 1006.Goodney PP, Travis L, Lucas FL, Fillinger MF, Goodman DC, Cronenwett JL, et al.
Characteristics and long-term outcomes of contemporary patients with bicuspid aor- Survival after open versus endovascular thoracic aortic aneurysm repair in an obser-
vational study of the Medicare population. Circulation 2011;124:2661–9. https://doi.
tic valves. J Thorac Cardiovasc Surg 2016;151:1650–9.e1. https://doi.org/10.1016/j.jtcvs.
org/10.1161/circulationaha.111.033944
2015.12.019
1007.Grausgruber W, Scharfen E. Problems of the fight against zoonoses in Austria. Wien
987. Winkler A, Puiu P, Krombholz-Reindl P, Vötsch A, Steindl J, Neuner M, et al. Impact of
Tierarztl Monatsschr 1968;55:625–36.
concomitant replacement of the ascending aorta in patients undergoing aortic valve
1008.Chiu P, Goldstone AB, Schaffer JM, Lingala B, Miller DC, Mitchell RS, et al.
replacement on operative morbidity and mortality. Eur J Cardiothorac Surg 2022;61:
Endovascular versus open repair of intact descending thoracic aortic aneurysms.
587–93. https://doi.org/10.1093/ejcts/ezab420
J Am Coll Cardiol 2019;73:643–51. https://doi.org/10.1016/j.jacc.2018.10.086
988. Peterss S, Charilaou P, Dumfarth J, Li Y, Bhandari R, Tranquilli M, et al. Aortic valve
1009.Fairman RM, Criado F, Farber M, Kwolek C, Mehta M, White R, et al. Pivotal results of
disease with ascending aortic aneurysm: impact of concomitant root-sparing (supra-
the medtronic vascular talent thoracic stent graft system: the VALOR trial. J Vasc Surg
coronary) aortic replacement in nonsyndromic patients. J Thorac Cardiovasc Surg
2008;48:546–54.e2. https://doi.org/10.1016/j.jvs.2008.03.061
2016;152:791–8.e1. https://doi.org/10.1016/j.jtcvs.2016.05.020
1010.Matsumura JS, Cambria RP, Dake MD, Moore RD, Svensson LG, Snyder S.
989. Lim JY, Jung SH, Kim JB, Kim DK, Chung CH, Song H, et al. Concomitant replacement
International controlled clinical trial of thoracic endovascular aneurysm repair with
of the dilated ascending aorta during aortic valve replacement; does it increase the
the Zenith TX2 endovascular graft: 1-year results. J Vasc Surg 2008;47:247–57; dis-
perioperative morbidity and mortality risks? J Card Surg 2013;28:285–90. https://doi.
cussion 257. https://doi.org/10.1016/j.jvs.2007.10.032
org/10.1111/jocs.12111 1011.Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of 2286 thoracoabdominal
990. Idrees JJ, Roselli EE, Lowry AM, Reside JM, Javadikasgari H, Johnson DJ, et al. Outcomes aortic aneurysms. Ann Thorac Surg 2007;83:S862–4; discussion S890–862. https://doi.
after elective proximal aortic replacement: a matched comparison of isolated versus org/10.1016/j.athoracsur.2006.10.088
multicomponent operations. Ann Thorac Surg 2016;101:2185–92. https://doi.org/10. 1012.Coselli JS, Green SY, Price MD, Hash JA, Ouyang Y, Volguina IV, et al. Results of open
1016/j.athoracsur.2015.12.026 surgical repair in patients with Marfan syndrome and distal aortic dissection. Ann
991. Idrees JJ, Roselli EE, Blackstone EH, Lowry AM, Soltesz EG, Johnston DR, et al. Risk of Thorac Surg 2016;101:2193–201. https://doi.org/10.1016/j.athoracsur.2015.11.008
adding prophylactic aorta replacement to a cardiac operation. J Thorac Cardiovasc Surg 1013.Tong MZ, Eagleton MJ, Roselli EE, Blackstone EH, Xiang F, Ibrahim M, et al. Outcomes
2020;159:1669–78.e10. https://doi.org/10.1016/j.jtcvs.2019.05.001 of open versus endovascular repair of descending thoracic and thoracoabdominal
992. Grabenwöger M, Alfonso F, Bachet J, Bonser R, Czerny M, Eggebrecht H, et al. aortic aneurysms. Ann Thorac Surg 2022;113:1144–52. https://doi.org/10.1016/j.
Thoracic Endovascular Aortic Repair (TEVAR) for the treatment of aortic diseases: athoracsur.2021.04.100
a position statement from the European Association for Cardio-Thoracic Surgery 1014.Goldstein LJ, Davies RR, Rizzo JA, Davila JJ, Cooperberg MR, Shaw RK, et al. Stroke in
(EACTS) and the European Society of Cardiology (ESC), in collaboration with the surgery of the thoracic aorta: incidence, impact, etiology, and prevention. J Thorac
European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Cardiovasc Surg 2001;122:935–45. https://doi.org/10.1067/mtc.2001.117276
Heart J 2012;33:1558–63. https://doi.org/10.1093/eurheartj/ehs074 1015.Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ. Experience with 1509 pa-
993. Eggebrecht H, Thompson M, Rousseau H, Czerny M, Lönn L, Mehta RH, et al. tients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993;17:357–
Retrograde ascending aortic dissection during or after thoracic aortic stent graft place- 68; discussion 368–70.
ment: insight from the European registry on endovascular aortic repair complications. 1016.Schermerhorn ML, Giles KA, Hamdan AD, Dalhberg SE, Hagberg R, Pomposelli F.
Circulation 2009;120:S276–281. https://doi.org/10.1161/circulationaha.108.835926 Population-based outcomes of open descending thoracic aortic aneurysm repair.
994. Zerwes S, Leissner G, Gosslau Y, Jakob R, Bruijnen H-K, Oertl F, et al. Clinical out- J Vasc Surg 2008;48:821–7. https://doi.org/10.1016/j.jvs.2008.05.022
comes in hybrid repair procedures for pathologies involving the aortic arch. Vascular 1017.Yamauchi T, Takano H, Nishimura M, Matsumiya G, Sawa Y. Paraplegia and parapar-
2015;23:9–16. https://doi.org/10.1177/1708538114525608 esis after descending thoracic aortic aneurysm repair: a risk factor analysis. Ann Thorac
995. Czerny M, Weigang E, Sodeck G, Schmidli J, Antona C, Gelpi G, et al. Targeting landing Cardiovasc Surg 2006;12:179–83.
zone 0 by total arch rerouting and TEVAR: midterm results of a transcontinental regis- 1018.Patel VI, Mukhopadhyay S, Ergul E, Aranson N, Conrad MF, LaMuraglia GM, et al.
Impact of hospital volume and type on outcomes of open and endovascular repair
try. Ann Thorac Surg 2012;94:84–9. https://doi.org/10.1016/j.athoracsur.2012.03.024
of descending thoracic aneurysms in the United States Medicare population. J Vasc
996. Chiesa R, Melissano G, Tshomba Y, Civilini E, Marone EM, Bertoglio L, et al. Ten years
Surg 2013;58:346–54. https://doi.org/10.1016/j.jvs.2013.01.035 of endovascular aortic arch repair. J Endovasc Ther 2010;17:1–11. https://doi.org/10.
1019.Cheng D, Martin J, Shennib H, Dunning J, Muneretto C, Schueler S, et al. Endovascular
1583/09-2884.1
aortic repair versus open surgical repair for descending thoracic aortic disease a sys-
997. Shrestha M, Bachet J, Bavaria J, Carrel TP, De Paulis R, Di Bartolomeo R, et al. Current
tematic review and meta-analysis of comparative studies. J Am Coll Cardiol 2010;55:
status and recommendations for use of the frozen elephant trunk technique: a position
986–1001. https://doi.org/10.1016/j.jacc.2009.11.047
paper by the vascular domain of EACTS. Eur J Cardiothorac Surg 2015;47:759–69.
1020.Harky A, Kai Chan JS, Ming Wong CH, Bashir M. Open versus endovascular repair of
https://doi.org/10.1093/ejcts/ezv085
descending thoracic aortic aneurysm disease: a systematic review and meta-analysis.
998. Czerny M, Schmidli J, Adler S, van den Berg JC, Bertoglio L, Carrel T, et al. Current
Ann Vasc Surg 2019;54:304–15.e5. https://doi.org/10.1016/j.avsg.2018.05.043
options and recommendations for the treatment of thoracic aortic pathologies involv-
1021.Ranney DN, Cox ML, Yerokun BA, Benrashid E, McCann RL, Hughes GC. Long-term
ing the aortic arch: an expert consensus document of the European Association for
results of endovascular repair for descending thoracic aortic aneurysms. J Vasc Surg
Cardio-Thoracic Surgery (EACTS) and the European Society for Vascular Surgery
2018;67:363–8. https://doi.org/10.1016/j.jvs.2017.06.094
(ESVS). Eur J Cardiothorac Surg 2019;55:133–62. https://doi.org/10.1093/ejcts/ezy313 1022.Biancari F, Mariscalco G, Mariani S, Saari P, Satta J, Juvonen T. Endovascular treatment
999. Abjigitova D, Veen KM, van Tussenbroek G, Mokhles MM, Bekkers JA, Takkenberg JJM, of degenerative aneurysms involving only the descending thoracic aorta: systematic
et al. Cerebral protection in aortic arch surgery: systematic review and meta-analysis. review and meta-analysis. J Endovasc Ther 2016;23:387–92. https://doi.org/10.1177/
Interact Cardiovasc Thorac Surg 2022;35:ivac270. https://doi.org/10.1093/icvts/ivac128 1526602815626560
1000. Malaisrie SC, Duncan BF, Mehta CK, Badiwala MV, Rinewalt D, Kruse J, et al. The add- 1023.Mousa AY, Morcos R, Broce M, Bates MC, AbuRahma AF. New preoperative spinal
ition of hemiarch replacement to aortic root surgery does not affect safety. J Thorac cord ischemia risk stratification model for patients undergoing thoracic endovascular
Cardiovasc Surg 2015;150:118–24.e2. https://doi.org/10.1016/j.jtcvs.2015.03.020 aortic repair. Vasc Endovascular Surg 2020;54:487–96. https://doi.org/10.1177/
1001. Borger MA, Fedak PWM, Stephens EH, Gleason TG, Girdauskas E, Ikonomidis JS, 1538574420929135
et al. The American Association for Thoracic Surgery consensus guidelines on bicus- 1024.Walsh SR, Tang TY, Sadat U, Naik J, Gaunt ME, Boyle JR, et al. Endovascular stenting
pid aortic valve-related aortopathy: full online-only version. J Thorac Cardiovasc Surg versus open surgery for thoracic aortic disease: systematic review and meta-analysis
2018;156:e41–74. https://doi.org/10.1016/j.jtcvs.2018.02.115 of perioperative results. J Vasc Surg 2008;47:1094–8.e3. https://doi.org/10.1016/j.jvs.
1002. Kim JB, Kim K, Lindsay ME, MacGillivray T, Isselbacher EM, Cambria RP, et al. Risk of 2007.09.062
rupture or dissection in descending thoracic aortic aneurysm. Circulation 2015;132: 1025.Kotelis D, Geisbüsch P, Hinz U, Hyhlik-Dürr A, von Tengg-Kobligk H, Allenberg JR,
1620–9. https://doi.org/10.1161/circulationaha.114.015177 et al. Short and midterm results after left subclavian artery coverage during
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 150 ---
ESC Guidelines 3687
endovascular repair of the thoracic aorta. J Vasc Surg 2009;50:1285–92. https://doi. 1046.Rigberg DA, McGory ML, Zingmond DS, Maggard MA, Agustin M, Lawrence PF, et al.
org/10.1016/j.jvs.2009.07.106 Thirty-day mortality statistics underestimate the risk of repair of thoracoabdominal
1026. Cooper DG, Walsh SR, Sadat U, Noorani A, Hayes PD, Boyle JR, et al. Neurological aortic aneurysms: a statewide experience. J Vasc Surg 2006;43:217–22; discussion
complications after left subclavian artery coverage during thoracic endovascular aor- 223. https://doi.org/10.1016/j.jvs.2005.10.070
tic repair: a systematic review and meta-analysis. J Vasc Surg 2009;49:1594–601. 1047.Pomy BJ, Rosenfeld ES, Lala S, Lee KB, Sparks AD, Amdur RL, et al. Fenestrated en-
https://doi.org/10.1016/j.jvs.2008.12.075 dovascular aneurysm repair affords fewer renal complications than open surgical re-
1027. Buth J, Harris PL, Hobo R, van Eps R, Cuypers P, Duijm L, et al. Neurologic complica- pair for juxtarenal abdominal aortic aneurysms in patients with chronic renal
tions associated with endovascular repair of thoracic aortic pathology: incidence and insufficiency. Ann Vasc Surg 2021;75:349–57. https://doi.org/10.1016/j.avsg.2021.03.
risk factors. a study from the European Collaborators on Stent/Graft Techniques for 026
Aortic Aneurysm Repair (EUROSTAR) registry. J Vasc Surg 2007;46:1103–10; discus- 1048.Varkevisser RRB, O’Donnell TFX, Swerdlow NJ, Liang P, Li C, Ultee KHJ, et al.
sion 1110–1. https://doi.org/10.1016/j.jvs.2007.08.020 Fenestrated endovascular aneurysm repair is associated with lower perioperative
1028. Teixeira PG, Woo K, Beck AW, Scali ST, Weaver FA. Association of left subclavian morbidity and mortality compared with open repair for complex abdominal aortic
artery coverage without revascularization and spinal cord ischemia in patients under- aneurysms. J Vasc Surg 2019;69:1670–8. https://doi.org/10.1016/j.jvs.2018.08.192
going thoracic endovascular aortic repair: a Vascular Quality Initiative® analysis. 1049.Gallitto E, Faggioli G, Melissano G, Fargion A, Isernia G, Lenti M, et al. Preoperative
Vascular 2017;25:587–97. https://doi.org/10.1177/1708538116681910 and postoperative predictors of clinical outcome of fenestrated and branched endo-
1029. Chen X, Wang J, Premaratne S, Zhao J, Zhang WW. Meta-analysis of the outcomes of vascular repair for complex abdominal and thoracoabdominal aortic aneurysms in an
revascularization after intentional coverage of the left subclavian artery for thoracic Italian multicenter registry. J Vasc Surg 2021;74:1795–806.e6. https://doi.org/10.1016/
endovascular aortic repair. J Vasc Surg 2019;70:1330–40. https://doi.org/10.1016/j.jvs. j.jvs.2021.04.072
2019.03.022 1050.Silverberg D, Bar-Dayan A, Hater H, Khaitovich B, Halak M. Short-term outcomes
1030. Banno H, Ikeda S, Kawai Y, Meshii K, Takahashi N, Sugimoto M, et al. Early and mid- of inner branches for endovascular repair of complex abdominal and thoracoab-
term outcomes of celiac artery coverage during thoracic endovascular aortic repair. dominal aortic aneurysms. Vascular 2021;29:644–51. https://doi.org/10.1177/
J Vasc Surg 2020;72:1552–7. https://doi.org/10.1016/j.jvs.2020.02.025 1708538120977279
1031. Argyriou C, Spiliopoulos S, Katsanos K, Papatheodorou N, Lazarides MK, Georgiadis 1051.Hu Z, Li Y, Peng R, Liu J, Jia X, Liu X, et al. Multibranched stent-grafts for the treat-
GS. Safety and efficacy of intentional celiac artery coverage in endovascular manage- ment of thoracoabdominal aortic aneurysms: a systematic review and meta-analysis.
ment of thoracoabdominal aortic diseases: a systematic review and meta-analysis.
J Endovasc Ther 2016;23:626–33. https://doi.org/10.1177/1526602816647723
J Endovasc Ther 2022;29:646–58. https://doi.org/10.1177/15266028211059451
1052.Simonte G, Isernia G, Gatta E, Neri E, Parlani G, Candeloro L, et al. Inner branched
1032. Hanna L, Lam K, Agbeko AE, Amoako JK, Ashrafian H, Sounderajah V, et al. Coverage
complex aortic repair outcomes from a national multicenter registry using the E-xtra
of the coeliac artery during thoracic endovascular aortic repair: a systematic review
design platform. J Vasc Surg 2023;77:338–46. https://doi.org/10.1016/j.jvs.2022.08.
and meta-analysis. Eur J Vasc Endovasc Surg 2022;63:828–37. https://doi.org/10.1016/j.
034
ejvs.2022.02.026
1053.Gallitto E, Faggioli G, Pini R, Logiacco A, Mascoli C, Fenelli C, et al. Proximal aortic
1033. Cambria RA, Gloviczki P, Stanson AW, Cherry KJ, Bower TC, Hallett JW, et al.
coverage and clinical results of the endovascular repair of juxta-/para-renal and
Outcome and expansion rate of 57 thoracoabdominal aortic aneurysms managed
type IV thoracoabdominal aneurysm with custom-made fenestrated endografts.
nonoperatively. Am J Surg 1995;170:213–7. https://doi.org/10.1016/s0002-9610(99)
Ann Vasc Surg 2021;73:397–406. https://doi.org/10.1016/j.avsg.2020.12.008
80289-x
1054.Sultan S, Concannon J, Veerasingam D, Tawfick W, McHugh P, Jordan F, et al.
1034. Elefteriades JA. Natural history of thoracic aortic aneurysms: indications for surgery,
Endovascular versus conventional open surgical repair for thoracoabdominal aortic
and surgical versus nonsurgical risks. Ann Thorac Surg 2002;74:S1877–80; discussion
aneurysms. Cochrane Database Syst Rev 2022;4:CD012926. https://doi.org/10.1002/
S1892–8. https://doi.org/10.1016/s0003-4975(02)04147-4
14651858.CD012926.pub2
1035. Girardi LN, Ohmes LB, Lau C, Di Franco A, Gambardella I, Elsayed M, et al. Open
1055.Kölbel T, Spanos K, Jama K, Behrendt CA, Panuccio G, Eleshra A, et al. Early out-
repair of descending thoracic and thoracoabdominal aortic aneurysms in patients
comes of the t-Branch off-the-shelf multi-branched stent graft in 542 patients for
with preoperative renal failure. Eur J Cardiothorac Surg 2017;51:971–7. https://doi.
elective and urgent aortic pathologies: a retrospective observational study. J Vasc
org/10.1093/ejcts/ezx007
Surg 2021;74:1817–24. https://doi.org/10.1016/j.jvs.2021.05.041
1036. LeMaire SA, Miller CC, III, Conklin LD, Schmittling ZC, Köksoy C, Coselli JS, et al. A
1056.Oderich GS, Ribeiro M, Hofer J, Wigham J, Cha S, Chini J, et al. Prospective, nonran-
new predictive model for adverse outcomes after elective thoracoabdominal aortic
domized study to evaluate endovascular repair of pararenal and thoracoabdominal
aneurysm repair. Ann Thorac Surg 2001;71:1233–8. https://doi.org/10.1016/s0003-
aortic aneurysms using fenestrated-branched endografts based on supraceliac sealing
4975(00)02678-3
zones. J Vasc Surg 2017;65:1249–59.e10. https://doi.org/10.1016/j.jvs.2016.09.038
1037. Suzuki S, Davis CA, III, Miller CC, III, Huynh TT, Estrera AL, Porat EE, et al. Cardiac
1057.Oderich GS, Tenorio ER, Mendes BC, Lima GBB, Marcondes GB, Saqib N, et al.
function predicts mortality following thoracoabdominal and descending thoracic aor-
Midterm outcomes of a prospective, nonrandomized study to evaluate endovascular
tic aneurysm repair. Eur J Cardiothorac Surg 2003;24:119–24; discussion 124. https://
repair of complex aortic aneurysms using fenestrated-branched endografts. Ann Surg
doi.org/10.1016/s1010-7940(03)00170-2
2021;274:491–9. https://doi.org/10.1097/sla.0000000000004982 1038. Mohebali J, Carvalho S, Lancaster RT, Ergul EA, Conrad MF, Clouse WD, et al. Use of
1058.Konstantinou N, Antonopoulos CN, Jerkku T, Banafsche R, Kölbel T, Fiorucci B, et al.
extracorporeal bypass is associated with improved outcomes in open thoracic and
thoracoabdominal aortic aneurysm repair. J Vasc Surg 2018;68:941–7. https://doi. Systematic review and meta-analysis of published studies on endovascular repair of
org/10.1016/j.jvs.2017.12.072 thoracoabdominal aortic aneurysms with the t-Branch off-the-shelf multibranched
1039. Coselli JS, LeMaire SA, Preventza O, de la Cruz KI, Cooley DA, Price MD, et al. endograft. J Vasc Surg 2020;72:716–25.e1. https://doi.org/10.1016/j.jvs.2020.01.049
Outcomes of 3309 thoracoabdominal aortic aneurysm repairs. J Thorac Cardiovasc 1059.Ellahi A, Shaikh FN, Kashif H, Khan H, Ali E, Nasim B, et al. Effectiveness of endovas-
Surg 2016;151:1323–38. https://doi.org/10.1016/j.jtcvs.2015.12.050 cular repair versus open surgery for the treatment of thoracoabdominal aneurysm: a
1040. Drinkwater SL, Goebells A, Haydar A, Bourke P, Brown L, Hamady M, et al.. The in- systematic review and meta analysis. Ann Med Surg 2022;81:104477. https://doi.org/
cidence of spinal cord ischaemia following thoracic and thoracoabdominal aortic en- 10.1016/j.amsu.2022.104477
dovascular intervention. Eur J Vasc Endovasc Surg 2010;40:729–35. https://doi.org/10. 1060.Hongku K, Sonesson B, Bjorses K, Holst J, Resch T, Dias NV, et al. Mid-term
1016/j.ejvs.2010.08.013 Outcomes of Endovascular Repair of Ruptured Thoraco-abdominal Aortic
1041. Bicknell CD, Riga CV, Wolfe JH. Prevention of paraplegia during thoracoabdominal Aneurysms with Off the Shelf Branched Stent Grafts. Eur J Vasc Endovasc Surg
aortic aneurysm repair. Eur J Vasc Endovasc Surg 2009;37:654–60. https://doi.org/ 2018;55:377–84. https://doi.org/10.1016/j.ejvs.2017.11.021
10.1016/j.ejvs.2009.02.008 1061.Youssef M, Deglise S, Szopinski P, Jost-Philipp S, Jomha A, Vahl CF, et al. A multicenter
1042. Von Aspern K, Luehr M, Mohr FW, Etz CD. Spinal cord protection in open- and en- experience with a new fenestrated-branched device for endovascular repair of thor-
dovascular thoracoabdominal aortic aneurysm repair: critical review of current con- acoabdominal aortic aneurysms. J Endovasc Ther 2018;25:209–19. https://doi.org/10.
cepts and future perspectives. J Cardiovasc Surg (Torino) 2015;56:745–9. 1177/1526602817752147
1043. Hsu CC, Kwan GN, van Driel ML, Rophael JA. Distal aortic perfusion during thora- 1062.Ouzounian M, Tadros RO, Svensson LG, Lyden SP, Oderich GS, Coselli JS
coabdominal aneurysm repair for prevention of paraplegia. Cochrane Database Syst Thoracoabdominal aortic disease and repair: JACC focus seminar, part 3. J Am Coll
Rev 2012;3:CD008197. https://doi.org/10.1002/14651858.CD008197.pub2 Cardiol 2022;80:845–56. https://doi.org/10.1016/j.jacc.2021.05.056
1044. Bischoff MS, Di Luozzo G, Griepp EB, Griepp RB. Spinal cord preservation in thora- 1063.Hofmann Bowman MA, Eagle KA, Milewicz DM. Update on clinical trials of losartan
coabdominal aneurysm repair. Perspect Vasc Surg Endovasc Ther 2011;23:214–22. with and without β-blockers to block aneurysm growth in patients with Marfan syn-
https://doi.org/10.1177/1531003511400622 drome: a review. JAMA Cardiol 2019;4:702–7. https://doi.org/10.1001/jamacardio.
1045. Cowan JA, Jr, Dimick JB, Henke PK, Huber TS, Stanley JC, Upchurch GR. Surgical 2019.1176
treatment of intact thoracoabdominal aortic aneurysms in the United States: hospital 1064.Mortality results for randomised controlled trial of early elective surgery or ultra-
and surgeon volume-related outcomes. J Vasc Surg 2003;37:1169–74. https://doi.org/ sonographic surveillance for small abdominal aortic aneurysms. The UK Small
10.1016/s0741-5214(03)00085-5 Aneurysm Trial Participants. Lancet 1998;352:1649–55.
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 151 ---
3688 E S C G u id e l in e s
1065. Powell JT, Brady AR, Brown LC, Fowkes FG, Greenhalgh RM, Ruckley CV, et al. patients treated outside of instructions for use criteria. Cardiovasc Intervent Radiol
Long-term outcomes of immediate repair compared with surveillance of small ab- 2022;45:1765–73. https://doi.org/10.1007/s00270-022-03297-7
dominal aortic aneurysms. N Engl J Med 2002;346:1445–52. https://doi.org/10. 1086.Charbonneau P, Hongku K, Herman CR, Habib M, Girsowicz E, Doonan RJ, et al.
1056/NEJMoa013527 Long-term survival after endovascular and open repair in patients with anatomy out-
1066. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, et al. side instructions for use criteria for endovascular aneurysm repair. J Vasc Surg 2019;
Immediate repair compared with surveillance of small abdominal aortic aneurysms. 70:1823–30. https://doi.org/10.1016/j.jvs.2019.01.081
N Engl J Med 2002;346:1437–44. https://doi.org/10.1056/NEJMoa012573 1087.O’Donnell TFX, McElroy IE, Boitano LT, Mohebali J, Lamuraglia GM, Kwolek CJ, et al.
1067. Shirasu T, Takagi H, Yasuhara J, Kuno T, Kent KC, Clouse WD. Smaller size is more Comparison of treatment options for aortic necks outside standard endovascular an-
suitable for pharmacotherapy among undersized abdominal aortic aneurysm: a sys- eurysm repair instructions for use. J Vasc Surg 2021;74:1548–57. https://doi.org/10.
tematic review and meta-analysis. Vasc Med 2022;27:261–8. https://doi.org/10. 1016/j.jvs.2021.04.052
1177/1358863x211061603 1088.Antoniou GA, Juszczak MT, Nasr H, Narlawar R, Antoniou SA, Matsagkas M, et al.
1068. Ouriel K, Clair DG, Kent KC, Zarins CK. Endovascular repair compared with surveil- Prognosis review and time-to-event data meta-analysis of endovascular aneurysm re-
lance for patients with small abdominal aortic aneurysms. J Vasc Surg 2010;51:1081–7. pair outside versus within instructions for use of aortic endograft devices. J Vasc Surg
https://doi.org/10.1016/j.jvs.2009.10.113 2020;71:1415–31.e15. https://doi.org/10.1016/j.jvs.2019.08.247
1069. Golledge J, Parr A, Boult M, Maddern G, Fitridge R. The outcome of endovascular re- 1089.Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK, Bernhard VM, et al.
pair of small abdominal aortic aneurysms. Ann Surg 2007;245:326–33. https://doi.org/ Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002;35:
10.1097/01.sla.0000253965.95368.52 1048–60. https://doi.org/10.1067/mva.2002.123763
1070. Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic ab- 1090.Falster MO, Garland SK, Jorm LR, Beiles CB, Freeman AJ, Sedrakyan A, et al. Editor’s
dominal aortic aneurysms. Cochrane Database Syst Rev 2015;2:CD001835. https:// choice—comparison of outcomes for major contemporary endograft devices used
doi.org/10.1002/14651858.CD001835.pub4 for endovascular repair of intact abdominal aortic aneurysms. Eur J Vasc Endovasc
1071. Cao P, De Rango P, Verzini F, Parlani G, Romano L, Cieri E. Comparison of surveil- Surg 2023;65:272–80. https://doi.org/10.1016/j.ejvs.2022.11.005
lance versus aortic endografting for small aneurysm repair (CAESAR): results from a 1091.van Laarhoven C, Jorritsma NKN, Balderston J, Brinjikji W, Björck M, van
randomised trial. Eur J Vasc Endovasc Surg 2011;41:13–25. https://doi.org/10.1016/j. Herwaarden JA, et al. Systematic review of the co-prevalence of arterial aneurysms
ejvs.2010.08.026 within the vasculature. Eur J Vasc Endovasc Surg 2021;61:473–83. https://doi.org/10.
1072. Lo RC, Lu B, Fokkema MT, Conrad M, Patel VI, Fillinger M, et al. Relative importance 1016/j.ejvs.2020.10.002
1092.Hohneck A, Keese M, Ruemenapf G, Amendt K, Muertz H, Janda K, et al. Prevalence
of aneurysm diameter and body size for predicting abdominal aortic aneurysm rup-
of abdominal aortic aneurysm and associated lower extremity artery aneurysm in
ture in men and women. J Vasc Surg 2014;59:1209–16. https://doi.org/10.1016/j.jvs.
men hospitalized for suspected or known cardiopulmonary disease. BMC
2013.10.104
Cardiovasc Disord 2019;19:284. https://doi.org/10.1186/s12872-019-1265-2
1073. Bath MF, Gokani VJ, Sidloff DA, Jones LR, Choke E, Sayers RD, et al. Systematic review
1093.D’Oria M, Scali S, Mao J, Szeberin Z, Thomson I, Beiles B, et al. Association be-
of cardiovascular disease and cardiovascular death in patients with a small abdominal
tween hospital volume and failure to rescue after open or endovascular repair
aortic aneurysm. Br J Surg 2015;102:866–72. https://doi.org/10.1002/bjs.9837
of intact abdominal aortic aneurysms in the vascunet and international consortium
1074. Kristensen SD, Knuuti J. New ESC/ESA Guidelines on non-cardiac surgery: cardiovas-
of vascular registries. Ann Surg 2021;274:e452–9. https://doi.org/10.1097/sla.
cular assessment and management. Eur Heart J 2014;35:2344–5. https://doi.org/10.
0000000000005044
1093/eurheartj/ehu285
1094.Scali ST, Columbo JA, Suckow BD, D’Oria M, Neal D, Goodney PP, et al. Center vol-
1075. Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, et al.
ume is associated with diminished failure to rescue and improved outcomes following
Association between postoperative troponin levels and 30-day mortality among pa-
elective open abdominal aortic aneurysm repair. J Vasc Surg 2022;76:400–8.e2.
tients undergoing noncardiac surgery. JAMA 2012;307:2295–304. https://doi.org/10.
https://doi.org/10.1016/j.jvs.2021.12.076
1001/jama.2012.5502
1095.Eid MA, Barnes JA, Mehta K, Wanken Z, Columbo J, Kang R, et al. Factors associated
1076. EVAR trial participants. Endovascular aneurysm repair versus open repair in patients
with preference of choice of aortic aneurysm repair in the PReference for Open
with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet
Versus Endovascular repair of AAA (PROVE-AAA) study. J Vasc Surg 2022;76:
2005;365:2179–86. https://doi.org/10.1016/s0140-6736(05)66627-5
1556–64. https://doi.org/10.1016/j.jvs.2022.06.018
1077. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT, Jr, Matsumura JS, Kohler TR,
1096.Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M, Cohnert T, et al. Editor’s
et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm:
choice—European Society for Vascular Surgery (ESVS) 2019 clinical practice guide-
a randomized trial. JAMA 2009;302:1535–42. https://doi.org/10.1001/jama.2009.1426
lines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc
1078. Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Goueffic Y, Lermusiaux P, et al. A ran-
Endovasc Surg 2019;57:8–93. https://doi.org/10.1016/j.ejvs.2018.09.020
domized controlled trial of endovascular aneurysm repair versus open surgery for ab-
1097.Reise JA, Sheldon H, Earnshaw J, Naylor AR, Dick F, Powell JT, et al. Patient prefer-
dominal aortic aneurysms in low- to moderate-risk patients. J Vasc Surg 2011;53:
ence for surgical method of abdominal aortic aneurysm repair: postal survey. Eur J
1167–73.e1. https://doi.org/10.1016/j.jvs.2010.10.124
Vasc Endovasc Surg 2010;39:55–61. https://doi.org/10.1016/j.ejvs.2009.08.008
1079. Antoniou GA, Antoniou SA, Torella F. Editor’s choice—endovascular vs. open repair 1098.EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit
for abdominal aortic aneurysm: systematic review and meta-analysis of updated peri-
for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled
operative and long term data of randomised controlled trials. Eur J Vasc Endovasc Surg
trial. Lancet 2005;365:2187–92. https://doi.org/10.1016/s0140-6736(05)66628-7
2020;59:385–97. https://doi.org/10.1016/j.ejvs.2019.11.030 1099.Greenhalgh RM, Brown LC, Powell JT, Thompson SG, Epstein D. Endovascular repair
1080. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med 2010;
Guidelines on cardiovascular assessment and management of patients undergoing 362:1872–80. https://doi.org/10.1056/NEJMoa0911056
non-cardiac surgery. Eur Heart J 2022;43:3826–924. https://doi.org/10.1093/ 1100.Patel R, Sweeting MJ, Powell JT, Greenhalgh RM. Endovascular versus open repair of
eurheartj/ehac270 abdominal aortic aneurysm in 15-years’ follow-up of the UK endovascular aneurysm
1081. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. repair trial 1 (EVAR trial 1): a randomised controlled trial. Lancet 2016;388:2366–74.
Coronary-artery revascularization before elective major vascular surgery. N Engl J https://doi.org/10.1016/s0140-6736(16)31135-7
Med 2004;351:2795–804. https://doi.org/10.1056/NEJMoa041905 1101.Lederle FA, Kyriakides TC, Stroupe KT, Freischlag JA, Padberg FT, Matsumura JS, et al.
1082. Saida T, Mori K, Sato F, Shindo M, Takahashi H, Takahashi N, et al. Prospective intrain- Open versus endovascular repair of abdominal aortic aneurysm. N Engl J Med 2019;
dividual comparison of unenhanced magnetic resonance imaging vs 380:2126–35. https://doi.org/10.1056/NEJMoa1715955
contrast-enhanced computed tomography for the planning of endovascular abdom- 1102.Lederle FA, Freischlag JA, Kyriakides TC, Matsumura JS, Padberg FT, Kohler TR, et al.
inal aortic aneurysm repair. J Vasc Surg 2012;55:679–87. https://doi.org/10.1016/j.jvs. Long-term comparison of endovascular and open repair of abdominal aortic aneur-
2011.09.091 ysm. N Engl J Med 2012;367:1988–97. https://doi.org/10.1056/NEJMoa1207481
1083. Parker MV, O’Donnell SD, Chang AS, Johnson CA, Gillespie DL, Goff JM, et al. What 1103.Schermerhorn ML, Buck DB, O’Malley AJ, Curran T, McCallum JC, Darling J, et al.
imaging studies are necessary for abdominal aortic endograft sizing? A prospective Long-term outcomes of abdominal aortic aneurysm in the Medicare population. N
blinded study using conventional computed tomography, aortography, and three- Engl J Med 2015;373:328–38. https://doi.org/10.1056/NEJMoa1405778
dimensional computed tomography. J Vasc Surg 2005;41:199–205. https://doi.org/ 1104.Nana P, Dakis K, Brodis A, Spanos K, Kouvelos G, Eckstein H-H, et al. A systematic
10.1016/j.jvs.2004.12.010 review and meta-analysis on early mortality after abdominal aortic aneurysm repair in
1084. Schanzer A, Greenberg RK, Hevelone N, Robinson WP, Eslami MH, Goldberg RJ, females in urgent and elective settings. J Vasc Surg 2022;75:1082–8.e6. https://doi.org/
et al. Predictors of abdominal aortic aneurysm sac enlargement after endovascular 10.1016/j.jvs.2021.10.040
repair. Circulation 2011;123:2848–55. https://doi.org/10.1161/circulationaha.110. 1105.Böckler D, Power AH, Bouwman LH, van Sterkenburg S, Bosiers M, Peeters P, et al.
014902 Improvements in patient outcomes with next generation endovascular aortic repair
1085. Protto S, Hahl T, Koskinen KJA, Järvenpää V, Uurto I, Väärämäki S, et al. Endovascular devices in the ENGAGE global registry and the EVAR-1 clinical trial. J Cardiovasc Surg
repair of abdominal aortic aneurysms is a valid alternative to open repair also in 2020;61:604–9. https://doi.org/10.23736/s0021-9509.19.11021-x
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 152 ---
ESC Guidelines 3689
1106. Teijink JAW, Power AH, Böckler D, Peeters P, van Sterkenburg S, Bouwman LH, et al. 1126.Geragotellis A, Cox K, Yip HCA, Jubouri M, Williams IM, Bailey DM, et al. Renal out-
Editor’s choice—five year outcomes of the endurant stent graft for endovascular ab- comes of suprarenal vs. infrarenal endograft fixation in endovascular abdominal aortic
dominal aortic aneurysm repair in the ENGAGE registry. Eur J Vasc Endovasc Surg aneurysm repair: a narrative review. Cardiovasc Diagn Ther 2022;12:531–44. https://
2019;58:175–81. https://doi.org/10.1016/j.ejvs.2019.01.008 doi.org/10.21037/cdt-22-196
1107. Oliveira-Pinto J, Oliveira NFG, Bastos-Gonçalves FM, Hoeks S, Rijn MJV, Raa ST, et al. 1127.Verhoeven EL, Katsargyris A, Bachoo P, Larzon T, Fisher R, Ettles D, et al. Real-world
Long-term results after standard endovascular aneurysm repair with the endurant performance of the new C3 gore excluder stent-graft: 1-year results from the
and excluder stent grafts. J Vasc Surg 2020;71:64–74. https://doi.org/10.1016/j.jvs. European C3 module of the global registry for endovascular aortic treatment
2019.03.039 (GREAT). Eur J Vasc Endovasc Surg 2014;48:131–7. https://doi.org/10.1016/j.ejvs.
1108. Deery SE, Shean KE, Pothof AB, O'Donnell TFX, Dalebout BA, Darling JD, et al. 2014.04.009
Three-Year Results of the Endurant Stent Graft System Post Approval Study. Ann 1128.Torsello G, Scheinert D, Brunkwall JS, Chiesa R, Coppi G, Pratesi C. Safety and effect-
Vasc Surg 2018;50:202–8. https://doi.org/10.1016/j.avsg.2017.12.017 iveness of the INCRAFT AAA stent graft for endovascular repair of abdominal aortic
1109. Prinssen M, Verhoeven EL, Buth J, Cuypers PWM, van Sambeek MRHM, Balm R, et al. aneurysms. J Vasc Surg 2015;61:1–8. https://doi.org/10.1016/j.jvs.2014.06.007
A randomized trial comparing conventional and endovascular repair of abdominal 1129.Kontopodis N, Galanakis N, Tzartzalou I, Tavlas E, Georgakarakos E, Dimopoulos I,
aortic aneurysms. N Engl J Med 2004;351:1607–18. https://doi.org/10.1056/ et al. An update on the improvement of patient eligibility with the use of new gener-
NEJMoa042002 ation endografts for the treatment of abdominal aortic aneurysms. Expert Rev Med
1110. Dakour-Aridi H, Paracha NZ, Locham S, Nejim B, Malas MB. Assessment of failure to Devices 2020;17:1231–8. https://doi.org/10.1080/17434440.2020.1841629
rescue after abdominal aortic aneurysm repair using the National Surgical Quality 1130.Kontopodis N, Papadopoulos G, Galanakis N, Tsetis D, Ioannou CV. Improvement of
Improvement Program procedure-targeted data set. J Vasc Surg 2018;68: patient eligibility with the use of new generation endografts for the treatment of ab-
1335–44.e1. https://doi.org/10.1016/j.jvs.2018.01.059 dominal aortic aneurysms. A comparison study among currently used endografts and
1111. Scali ST, Giles KA, Kubilis P, Beck AW, Crippen CJ, Hughes SJ, et al. Impact of hospital literature review. Expert Rev Med Devices 2017;14:245–50. https://doi.org/10.1080/
volume on patient safety indicators and failure to rescue following open aortic aneur- 17434440.2017.1281738
ysm repair. J Vasc Surg 2020;71:1135–46.e4. https://doi.org/10.1016/j.jvs.2019.06.194 1131.Zlatanovic P, Mascia D, Ancetti S, Yeung KK, Graumans MJ, Jongkind V, et al. Short
1112. Ma B, Wang YN, Chen KY, Zhang Y, Pan H, Yang K. Transperitoneal versus retro- term and long term clinical outcomes of endovascular versus open repair for juxtar-
peritoneal approach for elective open abdominal aortic aneurysm repair. Cochrane
enal and pararenal abdominal aortic aneurysms using propensity score matching: re-
Database Syst Rev 2016;2:CD010373. https://doi.org/10.1002/14651858.
sults from juxta- and pararenal aortic aneurysm multicentre European study (JAMES).
CD010373.pub2
Eur J Vasc Endovasc Surg 2023;65:828–36. https://doi.org/10.1016/j.ejvs.2023.02.070
1113. Camazine M, Bath J, Singh P, Kruse RL, Vogel TR. Characteristics associated with fail-
1132.Hajibandeh S, Hajibandeh S, Antoniou SA, Child E, Torella F, Antoniou GA.
ure to rescue after open abdominal aortic aneurysm repair. J Surg Res 2023;283:
Percutaneous access for endovascular aortic aneurysm repair: a systematic
683–9. https://doi.org/10.1016/j.jss.2022.11.018
review and meta-analysis. Vascular 2016;24:638–48. https://doi.org/10.1177/
1114. Blair R, Harkin D, Johnston D, Lim A, McFetridge L, Mitchell H. Open surgery for ab-
1708538116639201
dominal aortic aneurysm: 980 consecutive patient outcomes from a high-volume
1133.Antoniou GA, Antoniou SA. Editor’s choice—percutaneous access does not confer
centre in the United Kingdom. Vasc Endovascular Surg 2023;57:463–70. https://doi.
superior clinical outcomes over cutdown access for endovascular aneurysm repair:
org/10.1177/15385744221149585
meta-analysis and trial sequential analysis of randomised controlled trials. Eur J Vasc
1115. Hoornweg LL, Storm-Versloot MN, Ubbink DT, Koelemay MJW, Legemate DA,
Endovasc Surg 2021;61:383–94. https://doi.org/10.1016/j.ejvs.2020.11.008
Balm R, et al. Meta analysis on mortality of ruptured abdominal aortic aneurysms.
1134.Cao Z, Wu W, Zhao K, Yang Yu, Jiang C, Zhu R. Safety and efficacy of totally percu-
Eur J Vasc Endovasc Surg 2008;35:558–70. https://doi.org/10.1016/j.ejvs.2007.11.019
taneous access compared with open femoral exposure for endovascular aneurysm
1116. Kontopodis N, Galanakis N, Antoniou SA, Tsetis D, Ioannou CV, Veith FJ, et al.
repair: a meta-analysis. J Endovasc Ther 2017;24:246–53. https://doi.org/10.1177/
Meta-analysis and meta-regression analysis of outcomes of endovascular and open
1526602816689679
repair for ruptured abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2020;59:
1135.Wang Q, Wu J, Ma Y, Zhu Y, Song X, Xie S, et al. Totally percutaneous versus surgical
399–410. https://doi.org/10.1016/j.ejvs.2019.12.023
cut-down femoral artery access for elective bifurcated abdominal endovascular an-
1117. Wang LJ, Locham S, Al-Nouri O, Eagleton MJ, Clouse WD, Malas MB. Endovascular
eurysm repair. Cochrane Database Syst Rev 2023;1:CD010185. https://doi.org/10.
repair of ruptured abdominal aortic aneurysm is superior to open repair: propensity-
1002/14651858.CD010185.pub4
matched analysis in the vascular quality initiative. J Vasc Surg 2020;72:498–507. https://
1136.Antoniou GA, Georgiadis GS, Antoniou SA, Neequaye S, Brennan JA, Torella F, et al.
doi.org/10.1016/j.jvs.2019.11.063
Late rupture of abdominal aortic aneurysm after previous endovascular repair: a sys-
1118. Tan TW, Eslami M, Rybin D, Doros G, Zhang WW, Farber A. Outcomes of endovas-
tematic review and meta-analysis. J Endovasc Ther 2015;22:734–44. https://doi.org/10.
cular and open surgical repair of ruptured abdominal aortic aneurysms in elderly pa-
1177/1526602815601405
tients. J Vasc Surg 2017;66:64–70. https://doi.org/10.1016/j.jvs.2016.10.119
1137.Fransen GA, Vallabhaneni SR, Sr, van Marrewijk CJ, Laheij RJF, Harris PL, Buth J. 1119. Dewulf M, Muysoms F, Vierendeels T, Huyghe M, Miserez M, Ruppert M, et al.
Prevention of incisional hernias by prophylactic mesh-augmented reinforcement of Rupture of infra-renal aortic aneurysm after endovascular repair: a series from
midline laparotomies for abdominal aortic aneurysm treatment: five-year follow-up EUROSTAR registry. Eur J Vasc Endovasc Surg 2003;26:487–93. https://doi.org/10.
of a randomized controlled trial. Ann Surg 2022;276:e217–22. https://doi.org/10. 1016/s1078-5884(03)00350-2
1097/sla.0000000000005545 1138.Marcaccio CL, Patel PB, de Guerre L, Wade JE, Rastogi V, Anjorin A, et al. Disparities
1120. Honig S, Diener H, Kölbel T, Reinpold W, Zapf A, Bibiza-Freiwald E, et al. Abdominal in 5-year outcomes and imaging surveillance following elective endovascular repair of
incision defect following AAA-surgery (AIDA): 2-year results of prophylactic onlay- abdominal aortic aneurysm by sex, race, and ethnicity. J Vasc Surg 2022;76:
mesh augmentation in a multicentre, double-blind, randomised controlled trial. 1205–15.e4. https://doi.org/10.1016/j.jvs.2022.03.886
Updates Surg 2022;74:1105–16. https://doi.org/10.1007/s13304-021-01125-0 1139.Schlösser FJ, Gusberg RJ, Dardik A, Lin PH, Verhagen HJM, Moll FL, et al. Aneurysm
1121. Indrakusuma R, Jalalzadeh H, van der Meij JE, Balm R, Koelemay MJW. Prophylactic rupture after EVAR: can the ultimate failure be predicted? Eur J Vasc Endovasc Surg
mesh reinforcement versus sutured closure to prevent incisional hernias after 2009;37:15–22. https://doi.org/10.1016/j.ejvs.2008.10.011
open abdominal aortic aneurysm repair via midline laparotomy: a systematic review 1140.Stather PW, Sidloff D, Dattani N, Choke E, Bown MJ, Sayers RD. Systematic review
and meta-analysis. Eur J Vasc Endovasc Surg 2018;56:120–8. https://doi.org/10.1016/j. and meta-analysis of the early and late outcomes of open and endovascular repair of
ejvs.2018.03.021 abdominal aortic aneurysm. Br J Surg 2013;100:863–72. https://doi.org/10.1002/bjs.
1122. van Keulen JW, de Vries JP, Dekker H, Gonçalves FB, Moll FL, Verhagen HJ, et al. 9101
One-year multicenter results of 100 abdominal aortic aneurysm patients treated 1141.Swart M, McCarthy R. Shared decision making for elective abdominal aortic aneurysm
with the endurant stent graft. J Vasc Surg 2011;54:609–15. https://doi.org/10.1016/j. surgery. Clin Med (Lond) 2019;19:473–7. https://doi.org/10.7861/clinmed.2019-0352
jvs.2011.02.053 1142.Stubenrouch FE, Peters LJ, de Mik SML, Klemm PL, Peppelenbosch AG, Schreurs
1123. Piazza M, Squizzato F, Suominen V, Grego F, Trimarchi S, Antonello M, et al. Early and SCWM, et al. Improving shared decision making in vascular surgery: a stepped wedge
long-term outcomes of endovascular aortic repair in young and low surgical risk pa- cluster randomised trial. Eur J Vasc Endovasc Surg 2022;64:73–81. https://doi.org/10.
tients in the global registry for endovascular aortic treatment. J Endovasc Ther 2022; 1016/j.ejvs.2022.04.016
29:248–57. https://doi.org/10.1177/15266028211045703 1143.Machin M, Van Herzeele I, Ubbink D, Powell JT. Shared decision making in and man-
1124. Paravastu SC, Jayarajasingam R, Cottam R, Palfreyman SJ, Michaels JA, Thomas SM. agement of intact abdominal aortic aneurysm: a scoping review of the literature. Eur J
Endovascular repair of abdominal aortic aneurysm. Cochrane Database Syst Rev Vasc Endovasc Surg 2023;65:839–49. https://doi.org/10.1016/j.ejvs.2023.01.036
2014;1:CD004178. https://doi.org/10.1002/14651858.CD004178.pub2 1144.Karthaus EG, Tong TML, Vahl A, Hamming JF. Saccular abdominal aortic aneur-
1125. Dosluoglu HH, Lall P, Blochle R, Harris LM, Dryjski ML. Ambulatory percutaneous ysms: patient characteristics, clinical presentation, treatment, and outcomes in
endovascular abdominal aortic aneurysm repair. J Vasc Surg 2014;59:58–64. https:// the Netherlands. Ann Surg 2019;270:852–8. https://doi.org/10.1097/sla.
doi.org/10.1016/j.jvs.2013.06.076 0000000000003529
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 153 ---
3690 E S C G u id e l in e s
1145. O’Donnell TF, McElroy IE, Mohebali J, Boitano LT, Lamuraglia GM, Kwolek CJ, et al. 1167.Iscan HZ, Unal EU, Akkaya B, Daglı M, Karahan M, Civelek I, et al. Color Doppler
Late type 1A endoleaks: associated factors, prognosis and management strategies. ultrasound for surveillance following EVAR as the primary tool. J Card Surg 2021;
Ann Vasc Surg 2022;80:273–82. https://doi.org/10.1016/j.avsg.2021.08.057 36:111–7. https://doi.org/10.1111/jocs.15194
1146. De Rango P, Verzini F, Parlani G, Cieri E, Simonte G, Farchioni L, et al. Safety of chron- 1168.Antoniou GA, Kontopodis N, Rogers SK, Golledge J, Forbes TL, Torella F, et al.
ic anticoagulation therapy after endovascular abdominal aneurysm repair (EVAR). Eur Editor’s choice—meta-analysis of compliance with endovascular aneurysm repair
J Vasc Endovasc Surg 2014;47:296–303. https://doi.org/10.1016/j.ejvs.2013.12.009 surveillance: the EVAR surveillance paradox. Eur J Vasc Endovasc Surg 2023;65:
1147. Rokosh RS, Wu WW, Dalman RL, Chaikof EL. Society for Vascular Surgery imple- 244–54. https://doi.org/10.1016/j.ejvs.2022.10.033
mentation of clinical practice guidelines for patients with an abdominal aortic aneur- 1169.Baderkhan H, Haller O, Wanhainen A, Björck M, Mani K. Follow-up after endovascu-
ysm. Endoleak management. J Vasc Surg 2021;74:1792–4. https://doi.org/10.1016/j.jvs. lar aortic aneurysm repair can be stratified based on first postoperative imaging. Br J
2021.04.042 Surg 2018;105:709–18. https://doi.org/10.1002/bjs.10766
1148. Jordan WD, Jr, Mehta M, Varnagy D, Moore WM, Arko FR, Joye J, et al. Results of the 1170.Png CY, Tadros RO, Faries PL, Torres MR, Kim SY, Lookstein R, et al. The effect of
ANCHOR prospective, multicenter registry of EndoAnchors for type Ia endoleaks age on post-EVAR outcomes. Ann Vasc Surg 2016;35:156–62. https://doi.org/10.
and endograft migration in patients with challenging anatomy. J Vasc Surg 2014;60: 1016/j.avsg.2016.01.022
885–92.e2. https://doi.org/10.1016/j.jvs.2014.04.063 1171.Xiong X, Wu Z, Qin X, Huang Q, Wang X, Qin J, et al. Meta-analysis suggests statins
1149. Sidloff DA, Stather PW, Choke E, Bown MJ, Sayers RD. Type II endoleak after endo- reduce mortality after abdominal aortic aneurysm repair. J Vasc Surg 2022;75:
vascular aneurysm repair. Br J Surg 2013;100:1262–70. https://doi.org/10.1002/bjs. 356–62.e4. https://doi.org/10.1016/j.jvs.2021.06.033
9181 1172.Schrimpf C, Teebken OE, Wilhelmi M. Thoracic endovascular aortic repair after iat-
1150. Daye D, Walker TG. Complications of endovascular aneurysm repair of the thoracic rogenic aortic dissection and false lumen stent grafting. Ann Thorac Surg 2015;99:
and abdominal aorta: evaluation and management. Cardiovasc Diagn Ther 2018;8: 1447–9. https://doi.org/10.1016/j.athoracsur.2014.05.101
S138–56. https://doi.org/10.21037/cdt.2017.09.17 1173.Sampson UK, Norman PE, Fowkes FG, Aboyans V, Song Y, Harrell FE, Jr, et al. Global
1151. Latson LA, Jr, DeAnda A, Jr, Ko JP. Imaging of the postsurgical thoracic aorta: a and regional burden of aortic dissection and aneurysms: mortality trends in 21 world
state-of-the-art review. J Thorac Imaging 2017;32:1–25. https://doi.org/10.1097/rti. regions, 1990 to 2010. Glob Heart 2014;9:171–80.e110. https://doi.org/10.1016/j.
0000000000000246 gheart.2013.12.010
1152. Prescott-Focht JA, Martinez-Jimenez S, Hurwitz LM, Hoang JK, Christensen JD, 1174.Clough RE, Nienaber CA. Management of acute aortic syndrome. Nat Rev Cardiol
Ghoshhajra BB, et al. Ascending thoracic aorta: postoperative imaging evaluation. 2015;12:103–14. https://doi.org/10.1038/nrcardio.2014.203
Radiographics 2013;33:73–85. https://doi.org/10.1148/rg.331125090 1175.Evangelista A, Isselbacher EM, Bossone E, Gleason TG, Eusanio MD, Sechtem U, et al.
1153. Riambau V, Böckler D, Brunkwall J, Cao P, Chiesa R, Coppi G, et al. Editor’s choice— Insights from the international registry of acute aortic dissection: a 20-year experi-
management of descending thoracic aorta diseases: clinical practice guidelines of the ence of collaborative clinical research. Circulation 2018;137:1846–60. https://doi.
European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2017;53:4–52. org/10.1161/circulationaha.117.031264
https://doi.org/10.1016/j.ejvs.2016.06.005 1176.Booher AM, Isselbacher EM, Nienaber CA, Trimarchi S, Evangelista A, Montgomery
1154. Quevedo HC, Santiago-Trinidad R, Castellanos J, Atianzar K, Anwar A, Abi Rafeh N. DG, et al. The IRAD classification system for characterizing survival after aortic dis-
Systematic review of interventions to repair ascending aortic pseudoaneurysms. section. Am J Med 2013;126:730.e19–24. https://doi.org/10.1016/j.amjmed.2013.01.
Ochsner J 2014;14:576–85. 020
1155. Mesana TG, Caus T, Gaubert J, Collart F, Ayari R, Bartoli J-M, et al. Late complications 1177.Howard C, Ponnapalli A, Shaikh S, Idhrees M, Bashir M. Non-A non-B aortic dissec-
after prosthetic replacement of the ascending aorta: what did we learn from routine tion: a literature review. J Card Surg 2021;36:1806–13. https://doi.org/10.1111/jocs.
magnetic resonance imaging follow-up? Eur J Cardiothorac Surg 2000;18:313–20. 15349
https://doi.org/10.1016/s1010-7940(00)00512-1 1178.Urbanski PP, Wagner M. Acute non-A-non-B aortic dissection: surgical or conserva-
1156. Bianco V, Kilic A, Gleason TG, Arnaoutakis GJ, Sultan I. Management of thoracic aor- tive approach? Eur J Cardiothorac Surg 2016;49:1249–54. https://doi.org/10.1093/
tic graft infections. J Card Surg 2018;33:658–65. https://doi.org/10.1111/jocs.13792 ejcts/ezv301
1157. Liisberg M, Baudier F, Akgül C, Lindholt JS. Long-term thoracic endovascular repair 1179.Carino D, Singh M, Molardi A, Agostinelli A, Goldoni M, Pacini D, et al. Non-A non-B
follow-up from 1999 to 2019: a single-center experience. Ann Vasc Surg 2022;86: aortic dissection: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2019;
399–407. https://doi.org/10.1016/j.avsg.2022.04.013 55:653–9. https://doi.org/10.1093/ejcts/ezy337
1158. Nakhaei P, Bashir M, Jubouri M, Banar S, Ilkhani S, Borzeshi EZ, et al. Aortic remod- 1180.Sievers HH, Rylski B, Czerny M, Baier ALM, Kreibich M, Siepe M, et al. Aortic dissec-
eling, distal stent-graft induced new entry and endoleak following frozen elephant tion reconsidered: type, entry site, malperfusion classification adding clarity and en-
trunk: a systematic review and meta-analysis. J Card Surg 2022;37:3848–62. https:// abling outcome prediction. Interact Cardiovasc Thorac Surg 2020;30:451–7. https://
doi.org/10.1111/jocs.16918 doi.org/10.1093/icvts/ivz281
1159. Iribarne A, Keenan J, Benrashid E, Wang H, Meza JM, Ganapathi A, et al. Imaging sur- 1181.Aboyans V, Boukhris M. Dissecting the epidemiology of aortic dissection. Eur Heart J
veillance after proximal aortic operations: is it necessary? Ann Thorac Surg 2017;103: Acute Cardiovasc Care 2021;10:710–1. https://doi.org/10.1093/ehjacc/zuab065
734–41. https://doi.org/10.1016/j.athoracsur.2016.06.085 1182.Pape LA, Awais M, Woznicki EM, Suzuki T, Trimarchi S, Evangelista A, et al.
1160. Hensley SE, Upchurch GR, Jr. Repair of abdominal aortic aneurysms: JACC focus Presentation, diagnosis, and outcomes of acute aortic dissection: 17-year trends
seminar, part 1. J Am Coll Cardiol 2022;80:821–31. https://doi.org/10.1016/j.jacc. from the international registry of acute aortic dissection. J Am Coll Cardiol 2015;66:
2022.04.066 350–8. https://doi.org/10.1016/j.jacc.2015.05.029
1161. Bastos Gonçalves F, Baderkhan H, Verhagen HJ, Wanhainen A, Björck M, Stolker RJ, 1183.Januzzi JL, Isselbacher EM, Fattori R, Cooper JV, Smith DE, Fang J, et al. Characterizing
et al. Early sac shrinkage predicts a low risk of late complications after endovascular the young patient with aortic dissection: results from the international registry of aor-
aortic aneurysm repair. Br J Surg 2014;101:802–10. https://doi.org/10.1002/bjs.9516 tic dissection (IRAD). J Am Coll Cardiol 2004;43:665–9. https://doi.org/10.1016/j.jacc.
1162. Troutman DA, Chaudry M, Dougherty MJ, Calligaro KD. Endovascular aortic aneur- 2003.08.054
ysm repair surveillance may not be necessary for the first 3 years after an initially nor- 1184.Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century:
mal duplex postoperative study. J Vasc Surg 2014;60:558–62. https://doi.org/10.1016/ coronary heart disease. Am J Med 2014;127:807–12. https://doi.org/10.1016/j.
j.jvs.2014.03.278 amjmed.2014.04.015
1163. Jean-Baptiste E, Feugier P, Cruzel C, Sarlon-Bartoli G, Reix T, Steinmetz E, et al. 1185.Bossone E, Pyeritz RE, O’Gara P, Harris KM, Braverman AC, Pape L, et al. Acute aor-
Computed tomography-aortography versus color-duplex ultrasound for surveillance tic dissection in blacks: insights from the international registry of acute aortic dissec-
of endovascular abdominal aortic aneurysm repair: a prospective multicenter tion. Am J Med 2013;126:909–15. https://doi.org/10.1016/j.amjmed.2013.04.020
diagnostic-accuracy study (the ESSEA trial). Circ Cardiovasc Imaging 2020;13: 1186.Rylski B, Hoffmann I, Beyersdorf F, Suedkamp M, Siepe M, Nitsch B, et al. Iatrogenic
e009886. https://doi.org/10.1161/circimaging.119.009886 acute aortic dissection type A: insight from the German registry for acute aortic dis-
1164. Johnsen L, Hisdal J, Jonung T, Braaten A, Pedersen G. Contrast-enhanced ultrasound section type A (GERAADA). Eur J Cardiothorac Surg 2013;44:353–9; discussion 359.
detects type II endoleaks during follow-up for endovascular aneurysm repair. J Vasc https://doi.org/10.1093/ejcts/ezt055
Surg 2020;72:1952–9. https://doi.org/10.1016/j.jvs.2020.02.020 1187.Núñez-Gil IJ, Bautista D, Cerrato E, Salinas P, Varbella F, Omedè P, et al. Incidence,
1165. George J, Tadros RO, Rao A, Png CYM, Han DK, Ilonzo N, et al. Duplex ultrasound management, and immediate- and long-term outcomes after iatrogenic aortic dissec-
can successfully identify endoleaks and renovisceral stent patency in patients under- tion during diagnostic or interventional coronary procedures. Circulation 2015;131:
going complex endovascular aneurysm repair. Vasc Endovascular Surg 2021;55:234–8. 2114–9. https://doi.org/10.1161/circulationaha.115.015334
https://doi.org/10.1177/1538574420980605 1188.Carbone A, Ranieri B, Castaldo R, Franzese M, Rega S, Cittadini A, et al. Sex differ-
1166. Smith L, Thomas N, Arnold A, Bell R, Zayed H, Tyrrell M, et al. Editor’s choice—a ences in type A acute aortic dissection: a systematic review and meta-analysis. Eur J
comparison of computed tomography angiography and colour duplex ultrasound Prev Cardiol 2023;30:1074–89. https://doi.org/10.1093/eurjpc/zwad009
surveillance post infrarenal endovascular aortic aneurysm repair: financial implica- 1189.Nienaber CA, Fattori R, Mehta RH, Richartz BM, Evangelista A, Petzsch M, et al.
tions and impact of different international surveillance guidelines. Eur J Vasc Gender-related differences in acute aortic dissection. Circulation 2004;109:
Endovasc Surg 2021;62:193–201. https://doi.org/10.1016/j.ejvs.2021.04.005 3014–21. https://doi.org/10.1161/01.Cir.0000130644.78677.2c
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 154 ---
ESC Guidelines 3691
1190. Manalo-Estrella P, Barker AE. Histopathologic findings in human aortic media asso- 1213.Tadros RO, Tang GHL, Barnes HJ, Mousavi I, Kovacic JC, Faries P, et al. Optimal treat-
ciated with pregnancy. Arch Pathol 1967;83:336–41. ment of uncomplicated type B aortic dissection: JACC review topic of the week. J Am
1191. Lempel JK, Frazier AA, Jeudy J, Kligerman SJ, Schultz R, Ninalowo HA, et al. Aortic Coll Cardiol 2019;74:1494–504. https://doi.org/10.1016/j.jacc.2019.07.063
arch dissection: a controversy of classification. Radiology 2014;271:848–55. https:// 1214.Kodama K, Nishigami K, Sakamoto T, Sawamura T, Hirayama T, Misumi H, et al. Tight
doi.org/10.1148/radiol.14131457 heart rate control reduces secondary adverse events in patients with type B acute
1192. Mussa FF, Horton JD, Moridzadeh R, Nicholson J, Trimarchi S, Eagle KA. Acute aortic aortic dissection. Circulation 2008;118:S167–70. https://doi.org/10.1161/
dissection and intramural hematoma: a systematic review. JAMA 2016;316:754–63. circulationaha.107.755801
https://doi.org/10.1001/jama.2016.10026 1215.Estrera AL, Miller CC, III, Safi HJ, Goodrick JS, Keyhani A, Porat EE, et al. Outcomes of
1193. Tsai TT, Trimarchi S, Nienaber CA. Acute aortic dissection: perspectives from the medical management of acute type B aortic dissection. Circulation 2006;114:
international registry of acute aortic dissection (IRAD). Eur J Vasc Endovasc Surg I384–389. https://doi.org/10.1161/circulationaha.105.001479
2009;37:149–59. https://doi.org/10.1016/j.ejvs.2008.11.032 1216.Nejim B, Mathlouthi A, Naazie I, Malas MB. The effect of intravenous and oral beta-
1194. Neri E, Toscano T, Papalia U, Frati G, Massetti M, Capannini G, et al. Proximal aortic blocker use in patients with type B thoracic aortic dissection. Ann Vasc Surg 2022;80:
dissection with coronary malperfusion: presentation, management, and outcome. 170–9. https://doi.org/10.1016/j.avsg.2021.07.056
J Thorac Cardiovasc Surg 2001;121:552–60. https://doi.org/10.1067/mtc.2001.112534 1217.Hameed I, Cifu AS, Vallabhajosyula P. Management of thoracic aortic dissection. JAMA
1195. Trimarchi S, Tsai T, Eagle KA, Isselbacher EM, Froehlich J, et al. Acute abdominal aor- 2023;329:756–7. https://doi.org/10.1001/jama.2023.0265
tic dissection: insight from the International Registry of Acute Aortic Dissection 1218.Fukui T. Management of acute aortic dissection and thoracic aortic rupture. J Intensive
(IRAD). J Vasc Surg 2007;46:913–9. https://doi.org/10.1016/j.jvs.2007.07.030 Care 2018;6:15. https://doi.org/10.1186/s40560-018-0287-7
1196. Gorla R, Erbel R, Kahlert P, Tsagakis K, Jakob H, Mahabadi A-A, et al. Accuracy of a 1219.Suzuki T, Mehta RH, Ince H, Nagai R, Sakomura Y, Weber F, et al. Clinical profiles and
diagnostic strategy combining aortic dissection detection risk score and D-dimer le- outcomes of acute type B aortic dissection in the current era: lessons from the inter-
vels in patients with suspected acute aortic syndrome. Eur Heart J Acute Cardiovasc national registry of aortic dissection (IRAD). Circulation 2003;108:Ii312–7. https://doi.
Care 2017;6:371–8. https://doi.org/10.1177/2048872615594497 org/10.1161/01.cir.0000087386.07204.09
1197. Strayer RJ, Shearer PL, Hermann LK. Screening, evaluation, and early management of 1220.Mehta RH, Suzuki T, Hagan PG, Bossone E, Gilon D, Llovet A, et al. Predicting death in
acute aortic dissection in the ED. Curr Cardiol Rev 2012;8:152–7. https://doi.org/10. patients with acute type a aortic dissection. Circulation 2002;105:200–6. https://doi.
2174/157340312801784970 org/10.1161/hc0202.102246
1198. Nazerian P, Mueller C, Soeiro AM, Leidel BA, Salvadeo SAT, Giachino F, et al. 1221.Mészáros I, Mórocz J, Szlávi J, Schmidt J, Tornóci L, Nagy L, et al. Epidemiology and
Diagnostic accuracy of the aortic dissection detection risk score plus D-dimer for clinicopathology of aortic dissection. Chest 2000;117:1271–8. https://doi.org/10.
acute aortic syndromes: the ADvISED prospective multicenter study. Circulation 1378/chest.117.5.1271
2018;137:250–8. https://doi.org/10.1161/circulationaha.117.029457 1222.Glower DD, Speier RH, White WD, Smith LR, Rankin JS, Wolfe WG. Management
1199. Bima P, Pivetta E, Nazerian P, Toyofuku M, Gorla R, Bossone E, et al. Systematic re- and long-term outcome of aortic dissection. Ann Surg 1991;214:31–41. https://doi.
view of aortic dissection detection risk score plus d-dimer for diagnostic rule-out of org/10.1097/00000658-199107000-00006
suspected acute aortic syndromes. Acad Emerg Med 2020;27:1013–27. https://doi. 1223.Nallamothu BK, Mehta RH, Saint S, Llovet A, Bossone E, Cooper JV, et al. Syncope in
org/10.1111/acem.13969 acute aortic dissection: diagnostic, prognostic, and clinical implications. Am J Med
1200. Rogers AM, Hermann LK, Booher AM, Nienaber CA, Williams DM, Kazerooni EA, 2002;113:468–71. https://doi.org/10.1016/s0002-9343(02)01254-8
et al. Sensitivity of the aortic dissection detection risk score, a novel guideline-based 1224.Suzuki T, Isselbacher EM, Nienaber CA, Pyeritz RE, Eagle KA, Tsai TT, et al.
tool for identification of acute aortic dissection at initial presentation: results from the Type-selective benefits of medications in treatment of acute aortic dissection
international registry of acute aortic dissection. Circulation 2011;123:2213–8. https:// (from the international registry of acute aortic dissection [IRAD]). Am J Cardiol
doi.org/10.1161/CIRCULATIONAHA.110.988568 2012;109:122–7. https://doi.org/10.1016/j.amjcard.2011.08.012
1201. Suzuki T, Distante A, Zizza A, Trimarchi S, Villani M, Salerno Uriarte JA, et al. 1225.Palmer J, Gelmann D, Engelbrecht-Wiggans E, Hollis G, Hart E, Ali A, et al. Invasive
Diagnosis of acute aortic dissection by D-dimer: the international registry of acute arterial blood pressure monitoring may aid in the medical management of hyperten-
aortic dissection substudy on biomarkers (IRAD-bio) experience. Circulation 2009; sive patients with acute aortic disease. Am J Emerg Med 2022;59:85–93. https://doi.
119:2702–7. https://doi.org/10.1161/circulationaha.108.833004 org/10.1016/j.ajem.2022.06.054
1202. Baliga RR, Nienaber CA, Bossone E, Oh JK, Isselbacher EM, Sechtem U, et al. The role 1226.Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, et al.
of imaging in aortic dissection and related syndromes. JACC Cardiovasc Imaging 2014;7: Endovascular repair of type B aortic dissection: long-term results of the randomized
406–24. https://doi.org/10.1016/j.jcmg.2013.10.015 investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 2013;6:
1203. Nazerian P, Mueller C, Vanni S, Soeiro AM, Leidel BA, Cerini G, et al. Integration of 407–16. https://doi.org/10.1161/circinterventions.113.000463
transthoracic focused cardiac ultrasound in the diagnostic algorithm for suspected 1227.Fattori R, Montgomery D, Lovato L, Kische S, Di Eusanio M, Ince H, et al. Survival after
acute aortic syndromes. Eur Heart J 2019;40:1952–60. https://doi.org/10.1093/ endovascular therapy in patients with type B aortic dissection: a report from the
eurheartj/ehz207 international registry of acute aortic dissection (IRAD). JACC Cardiovasc Interv
1204. Shiga T, Wajima Z, Apfel CC, Inoue T, Ohe Y. Diagnostic accuracy of transesophageal 2013;6:876–82. https://doi.org/10.1016/j.jcin.2013.05.003
echocardiography, helical computed tomography, and magnetic resonance imaging 1228.Durham CA, Cambria RP, Wang LJ, Ergul EA, Aranson NJ, Patel VI, et al. The natural
for suspected thoracic aortic dissection: systematic review and meta-analysis. Arch history of medically managed acute type B aortic dissection. J Vasc Surg 2015;61:
Intern Med 2006;166:1350–6. https://doi.org/10.1001/archinte.166.13.1350 1192–8. https://doi.org/10.1016/j.jvs.2014.12.038
1205. Nienaber CA, Clough RE. Management of acute aortic dissection. Lancet 2015;385: 1229.Lou X, Chen EP, Duwayri YM, Veeraswamy RK, Jordan WD, Zehner CA, et al. The
800–11. https://doi.org/10.1016/s0140-6736(14)61005-9 impact of thoracic endovascular aortic repair on long-term survival in type B aortic
1206. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC dissection. Ann Thorac Surg 2018;105:31–8. https://doi.org/10.1016/j.athoracsur.
Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 2017.06.016
44:3720–826. https://doi.org/10.1093/eurheartj/ehad191 1230.Lou X, Duwayri YM, Chen EP, Jordan WD, Forcillo J, Zehner CA, et al. Predictors of
1207. Rogers IS, Banerji D, Siegel EL, Truong QA, Ghoshhajra BB, Irlbeck T, et al. Usefulness failure of medical management in uncomplicated type B aortic dissection. Ann Thorac
of comprehensive cardiothoracic computed tomography in the evaluation of acute Surg 2019;107:493–8. https://doi.org/10.1016/j.athoracsur.2018.08.012
undifferentiated chest discomfort in the emergency department (CAPTURE). Am J 1231.Lou X, Duwayri YM, Jordan WD, Jr, Chen EP, Veeraswamy RK, Leshnower BG. The
Cardiol 2011;107:643–50. https://doi.org/10.1016/j.amjcard.2010.10.039 safety and efficacy of extended TEVAR in acute type B aortic dissection. Ann Thorac
1208. Evangelista A, Maldonado G, Gruosso D, Gutiérrez L, Granato C, Villalva N, et al. The Surg 2020;110:799–806. https://doi.org/10.1016/j.athoracsur.2019.12.036
current role of echocardiography in acute aortic syndrome. Echo Res Pract 2019;6: 1232.Hirst AE, Jr, Johns VJ, Jr, Kime SW, Jr. Dissecting aneurysm of the aorta: a review of
R53–r63. https://doi.org/10.1530/erp-18-0058 505 cases. Medicine 1958;37:217–79. https://doi.org/10.1097/00005792-195809000-
1209. Vignon P, Guéret P, Vedrinne JM, Lagrange P, Cornu E, Abrieu O, et al. Role of trans- 00003
esophageal echocardiography in the diagnosis and management of traumatic aortic 1233.Chiappini B, Schepens M, Tan E, Amore AD, Morshuis W, Dossche K, et al. Early and
disruption. Circulation 1995;92:2959–68. https://doi.org/10.1161/01.cir.92.10.2959 late outcomes of acute type A aortic dissection: analysis of risk factors in 487 con-
1210. Moral S, Avegliano G, Cuéllar H, Ballesteros E, Rodríguez-Palomares J, Teixidó G, secutive patients. Eur Heart J 2005;26:180–6. https://doi.org/10.1093/eurheartj/
et al. Usefulness of transesophageal echocardiography in the evaluation of celiac trunk ehi024
and superior mesenteric artery involvement in acute aortic dissection. J Am Soc 1234.Harris KM, Nienaber CA, Peterson MD, Woznicki EM, Braverman AC, Trimarchi S,
Echocardiogr 2021;34:327–35. https://doi.org/10.1016/j.echo.2020.12.019 et al. Early mortality in type A acute aortic dissection: insights from the international
1211. Nienaber CA, Clough RE, Sakalihasan N, Suzuki T, Gibbs R, Mussa F, et al. Aortic dis- registry of acute aortic dissection. JAMA Cardiol 2022;7:1009–15. https://doi.org/10.
section. Nat Rev Dis Primers 2016;2:16053. https://doi.org/10.1038/nrdp.2016.53 1001/jamacardio.2022.2718
1212. Vilacosta I, San Román JA, di Bartolomeo R, Eagle K, Estrera AL, Ferrera C, et al. 1235.Zhu Y, Lingala B, Baiocchi M, Tao JJ, Toro Arana V, Khoo JW, et al. Type A aortic
Acute aortic syndrome revisited: JACC state-of-the-art review. J Am Coll Cardiol dissection-experience over 5 decades: JACC historical breakthroughs in perspective.
2021;78:2106–25. https://doi.org/10.1016/j.jacc.2021.09.022 J Am Coll Cardiol 2020;76:1703–13. https://doi.org/10.1016/j.jacc.2020.07.061
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 155 ---
3692 E S C G u id e l in e s
1236. Czerny M, Siepe M, Beyersdorf F, Feisst M, Gabel M, Pilz M, et al. Prediction of mor- 1257.Goldstone AB, Chiu P, Baiocchi M, Lingala B, Lee J, Rigdon J, et al. Interfacility transfer
tality rate in acute type A dissection: the German registry for acute type A aortic dis- of medicare beneficiaries with acute type A aortic dissection and regionalization of
section score. Eur J Cardiothorac Surg 2020;58:700–6. https://doi.org/10.1093/ejcts/ care in the United States. Circulation 2019;140:1239–50. https://doi.org/10.1161/
ezaa156 circulationaha.118.038867
1237. Perko MJ, Nørgaard M, Herzog TM, Olsen PS, Schroeder TV, Pettersson G. 1258.Mosbahi S, Stak D, Gravestock I, Burgstaller JM, Steurer J, Eckstein F, et al. A systemic
Unoperated aortic aneurysm: a survey of 170 patients. Ann Thorac Surg 1995;59: review and meta-analysis: Bentall versus David procedure in acute type A aortic dis-
1204–9. https://doi.org/10.1016/0003-4975(95)00132-5 section. Eur J Cardiothorac Surg 2019;55:201–9. https://doi.org/10.1093/ejcts/ezy266
1238. Wolfe SB, Sundt TM, III, Isselbacher EM, Cameron DE, Trimarchi S, Bekeredjian R, 1259.Beckmann E, Martens A, Pertz J, Kaufeld T, Umminger J, Hanke JS, et al. Valve-sparing
et al. Survival after operative repair of acute type A aortic dissection varies according David I procedure in acute aortic type A dissection: a 20-year experience with more
to the presence and type of preoperative malperfusion. J Thorac Cardiovasc Surg 2024; than 100 patients. Eur J Cardiothorac Surg 2017;52:319–24. https://doi.org/10.1093/
168:37–49.e6. https://doi.org/10.1016/j.jtcvs.2022.09.034 ejcts/ezx170
1239. Trimarchi S, Eagle KA, Nienaber CA, Rampoldi V, Jonker FHW, De Vincentiis C, et al. 1260.Weiss G, Tsagakis K, Jakob H, Di Bartolomeo R, Pacini D, Barberio G, et al. The fro-
Role of age in acute type A aortic dissection outcome: report from the international zen elephant trunk technique for the treatment of complicated type B aortic dissec-
registry of acute aortic dissection (IRAD). J Thorac Cardiovasc Surg 2010;140:784–9. tion with involvement of the aortic arch: multicentre early experience. Eur J
https://doi.org/10.1016/j.jtcvs.2009.11.014 Cardiothorac Surg 2015;47:106–14; discussion 114. https://doi.org/10.1093/ejcts/
1240. Shrestha M, Khaladj N, Haverich A, Hagl C. Is treatment of acute type A aortic dis- ezu067
section in septuagenarians justifiable? Asian Cardiovasc Thorac Ann 2008;16:33–6. 1261.Iafrancesco M, Goebel N, Mascaro J, Franke UFW, Pacini D, Di Bartolomeo R, et al.
https://doi.org/10.1177/021849230801600109 Aortic diameter remodelling after the frozen elephant trunk technique in aortic dis-
1241. Bonser RS, Ranasinghe AM, Loubani M, Evans JD, Thalji NMA, Bachet JE, et al. section: results from an international multicentre registry. Eur J Cardiothorac Surg
Evidence, lack of evidence, controversy, and debate in the provision and performance 2017;52:310–8. https://doi.org/10.1093/ejcts/ezx131
of the surgery of acute type A aortic dissection. J Am Coll Cardiol 2011;58:2455–74. 1262.Tsagakis K, Wendt D, Dimitriou AM, Thielmann M, Shehada S-D, El Gabry M, et al.
https://doi.org/10.1016/j.jacc.2011.06.067 The frozen elephant trunk treatment is the operation of choice for all kinds of arch
1242. Subramanian S, Leontyev S, Borger MA, Trommer C, Misfeld M, Mohr FW. disease. J Cardiovasc Surg (Torino) 2018;59:540–6. https://doi.org/10.23736/s0021-
Valve-sparing root reconstruction does not compromise survival in acute type A aor- 9509.18.10597-0
tic dissection. Ann Thorac Surg 2012;94:1230–4. https://doi.org/10.1016/j.athoracsur. 1263.Widenka KJ, Kosiorowska M, Jakob H, Pacini D, Hemmer W, Grabenwoeger M, et al.
2012.04.094 Early and midterm results of frozen elephant trunk operation with Evita open stent-
1243. Urbanski PP, Hijazi H, Dinstak W, Diegeler A. Valve-sparing aortic root repair in graft in patients with Marfan syndrome: results of a multicentre study. BMC Cardiovasc
acute type A dissection: how many sinuses have to be repaired for curative surgery? Disord 2022;22:333. https://doi.org/10.1186/s12872-022-02777-5
Eur J Cardiothorac Surg 2013;44:439–43; discussion 443–4. https://doi.org/10.1093/ 1264.Jakob H, Shehada SE, Dohle D, Wendt D, El Gabry M, Schlosser T, et al. New 3-zone
ejcts/ezt042 hybrid graft: first-in-man experience in acute type I dissection. J Thorac Cardiovasc Surg
1244. Shrestha M, Baraki H, Maeding I, Fitzner S, Sarikouch S, Khaladj N, et al. Long-term 2022;163:568–74.e1. https://doi.org/10.1016/j.jtcvs.2020.04.113
results after aortic valve-sparing operation (David I). Eur J Cardiothorac Surg 2012; 1265.Tsagakis K, Osswald A, Weymann A, Demircioglu A, Schmack B, Wendt D, et al. The
41:56–61; discussion 61–2. https://doi.org/10.1016/j.ejcts.2011.04.012 frozen elephant trunk technique: impact of proximalization and the four-sites perfu-
1245. Tsagakis K, Pacini D, Di Bartolomeo R, Gorlitzer M, Weiss G, Grabenwoger M, et al. sion technique. Eur J Cardiothorac Surg 2021;61:195–203. https://doi.org/10.1093/
Multicenter early experience with extended aortic repair in acute aortic dissection: is ejcts/ezab295
simultaneous descending stent grafting justified? J Thorac Cardiovasc Surg 2010;140: 1266.Rampoldi V, Trimarchi S, Eagle KA, Nienaber CA, Oh JK, Bossone E, et al. Simple risk
S116–20; discussion S142–S146. https://doi.org/10.1016/j.jtcvs.2010.07.066 models to predict surgical mortality in acute type A aortic dissection: the internation-
1246. Tsagakis K, Pacini D, Grabenwöger M, Borger MA, Goebel N, Hemmer W, et al. al registry of acute aortic dissection score. Ann Thorac Surg 2007;83:55–61. https://doi.
Results of frozen elephant trunk from the international E-vita Open registry. Ann org/10.1016/j.athoracsur.2006.08.007
Cardiothorac Surg 2020;9:178–88. https://doi.org/10.21037/acs-2020-fet-25 1267.Lawton JS, Liu J, Kulshrestha K, Moon MR, Damiano RJ, Maniar H, et al. The impact of
1247. Beckmann E, Martens A, Kaufeld T, Natanov R, Krueger H, Rudolph L, et al. Frozen surgical strategy on survival after repair of type A aortic dissection. J Thorac Cardiovasc
elephant trunk in acute aortic type a dissection: risk analysis of concomitant root re- Surg 2015;150:294–301.e1. https://doi.org/10.1016/j.jtcvs.2015.03.023
placement. Eur J Cardiothorac Surg 2022;62:ezac051. https://doi.org/10.1093/ejcts/ 1268.Malvindi PG, Modi A, Miskolczi S, Kaarne M, Velissaris T, Barlow C, et al. Open and
ezac051 closed distal anastomosis for acute type A aortic dissection repair. Interact Cardiovasc
1248. Cruz I, Stuart B, Caldeira D, Morgado G, Gomes AC, Almeida AR, et al. Controlled Thorac Surg 2016;22:776–83. https://doi.org/10.1093/icvts/ivw044
pericardiocentesis in patients with cardiac tamponade complicating aortic dissection: 1269.Geirsson A, Shioda K, Olsson C, Ahlsson A, Gunn J, Hansson EC, et al. Differential
experience of a centre without cardiothoracic surgery. Eur Heart J Acute Cardiovasc outcomes of open and clamp-on distal anastomosis techniques in acute type A aortic
Care 2015;4:124–8. https://doi.org/10.1177/2048872614549737 dissection. J Thorac Cardiovasc Surg 2019;157:1750–8. https://doi.org/10.1016/j.jtcvs.
1249. Hayashi T, Tsukube T, Yamashita T, Haraguchi T, Matsukawa R, Kozawa S, et al. 2018.09.020
Impact of controlled pericardial drainage on critical cardiac tamponade with acute 1270.Yan Y, Xu L, Zhang H, Xu Z-Y, Ding X-Y, Wang S-W, et al. Proximal aortic repair
type A aortic dissection. Circulation 2012;126:S97–101. https://doi.org/10.1161/ versus extensive aortic repair in the treatment of acute type A aortic dissection: a
CIRCULATIONAHA.111.082685 meta-analysis. Eur J Cardiothorac Surg 2016;49:1392–401. https://doi.org/10.1093/
1250. Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, et al. ejcts/ezv351
The international registry of acute aortic dissection (IRAD): new insights into an old 1271.Poon SS, Theologou T, Harrington D, Kuduvalli M, Oo A, Field M. Hemiarch versus
disease. JAMA 2000;283:897–903. https://doi.org/10.1001/jama.283.7.897 total aortic arch replacement in acute type A dissection: a systematic review and
1251. Saczkowski R, Malas T, Mesana T, de Kerchove L, El Khoury G, Boodhwani M. Aortic meta-analysis. Ann Cardiothorac Surg 2016;5:156–73. https://doi.org/10.21037/acs.
valve preservation and repair in acute type A aortic dissection. Eur J Cardiothorac Surg 2016.05.06
2014;45:e220–226. https://doi.org/10.1093/ejcts/ezu099 1272.Hsieh WC, Kan CD, Yu HC, Aboud A, Lindner J, Henry BM, et al. Ascending aorta
1252. Hysi I, Juthier F, Fabre O, Fouquet O, Rousse N, Banfi C, et al. Aortic root surgery replacement vs. total aortic arch replacement in the treatment of acute type A dis-
improves long-term survival after acute type A aortic dissection. Int J Cardiol 2015; section: a meta-analysis. Eur Rev Med Pharmacol Sci 2019;23:9590–611. https://doi.
184:285–90. https://doi.org/10.1016/j.ijcard.2015.02.020 org/10.26355/eurrev_201911_19454
1253. Peterss S, Dumfarth J, Rizzo JA, Bonaros N, Fang H, Tranquilli M, et al. Sparing the 1273.Preventza O, Cervera R, Cooley DA, Bakaeen FG, Mohamed AS, Cheong BYC, et al.
aortic root in acute aortic dissection type A: risk reduction and restored integrity Acute type I aortic dissection: traditional versus hybrid repair with antegrade stent
of the untouched root. Eur J Cardiothorac Surg 2016;50:232–9. https://doi.org/10. delivery to the descending thoracic aorta. J Thorac Cardiovasc Surg 2014;148:
1093/ejcts/ezw012 119–25. https://doi.org/10.1016/j.jtcvs.2013.07.055
1254. Chen SK, Qiu ZH, Fang GH, Wu XJ, Chen LW. Reported outcomes after aortic valve 1274.Roselli EE, Idrees JJ, Bakaeen FG, Tong MZ, Soltesz EG, Mick S, et al. Evolution of sim-
resuspension for acute type A aortic dissection: a systematic review and plified frozen elephant trunk repair for acute DeBakey type I dissection: midterm out-
meta-analysis. Interact Cardiovasc Thorac Surg 2019;29:331–8. https://doi.org/10. comes. Ann Thorac Surg 2018;105:749–55. https://doi.org/10.1016/j.athoracsur.2017.
1093/icvts/ivz080 08.037
1255. Qiu J, Wu J, Xie E, Luo X, Chen JF, Gao W, et al. Surgical management and outcomes 1275.Berretta P, Trimarchi S, Patel HJ, Gleason TG, Eagle KA, Di Eusanio M. Malperfusion
of the aortic root in acute type A aortic dissection. Ann Thorac Surg 2020;110: syndromes in type A aortic dissection: what we have learned from IRAD. J Vis Surg
136–43. https://doi.org/10.1016/j.athoracsur.2019.10.014 2018;4:65. https://doi.org/10.21037/jovs.2018.03.13
1256. Umana-Pizano JB, Nissen AP, Sandhu HK, Miller CC, Loghin A, Safi HJ, et al. Acute 1276.Benedetto U, Mohamed H, Vitulli P, Petrou M. Axillary versus femoral arterial cannu-
type A dissection repair by high-volume vs low-volume surgeons at a high-volume lation in type A acute aortic dissection: evidence from a meta-analysis of comparative
aortic center. Ann Thorac Surg 2019;108:1330–6. https://doi.org/10.1016/j. studies and adjusted risk estimates. Eur J Cardiothorac Surg 2015;48:953–9. https://doi.
athoracsur.2019.04.040 org/10.1093/ejcts/ezv035
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 156 ---
ESC Guidelines 3693
1277. Geirsson A, Szeto WY, Pochettino A, McGarvey ML, Keane MG, Woo YJ, et al. B aortic dissection: a meta-analysis. Eur J Vasc Endovasc Surg 2020;59:794–807.
Significance of malperfusion syndromes prior to contemporary surgical repair for https://doi.org/10.1016/j.ejvs.2019.08.003
acute type A dissection: outcomes and need for additional revascularizations. Eur J 1297.Sa MP, Jacquemyn X, Van den Eynde J, Chu D, Serna-Gallegos D, Singh MJ, et al.
Cardiothorac Surg 2007;32:255–62. https://doi.org/10.1016/j.ejcts.2007.04.012 Midterm outcomes of endovascular vs. medical therapy for uncomplicated type B
1278. Yang B, Norton EL, Rosati CM, Wu X, Kim KM, Khaja MS, et al. Managing patients aortic dissection: meta-analysis of reconstructed time to event data. Eur J Vasc
with acute type A aortic dissection and mesenteric malperfusion syndrome: a Endovasc Surg 2023;66:609–19. https://doi.org/10.1016/j.ejvs.2023.07.004
20-year experience. J Thorac Cardiovasc Surg 2019;158:675–87.e4. https://doi.org/ 1298.Sa MP, Jacquemyn X, Brown JA, Ahmad D, Serna-Gallegos D, Arnaoutakis GJ, et al.
10.1016/j.jtcvs.2018.11.127 Thoracic endovascular aortic repair for hyperacute, acute, subacute and chronic
1279. Yang B, Rosati CM, Norton EL, Kim KM, Khaja MS, Dasika N, et al. Endovascular fen- type B aortic dissection: meta-analysis of reconstructed time-to-event data. Trends
estration/stenting first followed by delayed open aortic repair for acute type A aortic Cardiovasc Med 2023:S1050-1738(23)00113-5. https://doi.org/10.1016/j.tcm.2023.
dissection with malperfusion syndrome. Circulation 2018;138:2091–103. https://doi. 12.005
org/10.1161/circulationaha.118.036328 1299.Jubouri M, Al-Tawil M, Yip HCA, Bashir A, Tan SZCP, Bashir M, et al. Mid- and long-
1280. Leshnower BG, Keeling WB, Duwayri YM, Jordan WD, Jr, Chen EP. The “thoracic term outcomes of thoracic endovascular aortic repair in acute and subacute uncom-
endovascular aortic repair-first” strategy for acute type A dissection with mesenteric plicated type B aortic dissection. J Card Surg 2022;37:1328–39. https://doi.org/10.
malperfusion: initial results compared with conventional algorithms. J Thorac 1111/jocs.16349
Cardiovasc Surg 2019;158:1516–24. https://doi.org/10.1016/j.jtcvs.2019.01.116 1300.Torrent DJ, McFarland GE, Wang G, Malas M, Pearce BJ, Aucoin V, et al. Timing of
1281. Rylski B, Szeto WY, Bavaria JE, Branchetti E, Moser W, Milewski RK. Development of thoracic endovascular aortic repair for uncomplicated acute type B aortic dissection
a single endovascular device for aortic valve replacement and ascending aortic repair. and the association with complications. J Vasc Surg 2021;73:826–35. https://doi.org/
J Card Surg 2014;29:371–6. https://doi.org/10.1111/jocs.12348 10.1016/j.jvs.2020.05.073
1282. Kreibich M, Rylski B, Kondov S, Morlock J, Scheumann J, Kari FA, et al. Endovascular 1301.Schwartz SI, Durham C, Clouse WD, Patel VI, Lancaster RT, Cambria RP, et al.
treatment of acute type A aortic dissection-the Endo Bentall approach. J Vis Surg Predictors of late aortic intervention in patients with medically treated type B aortic
2018;4:69. https://doi.org/10.21037/jovs.2018.03.14 dissection. J Vasc Surg 2018;67:78–84. https://doi.org/10.1016/j.jvs.2017.05.128
1283. Brown CR, Chen Z, Khurshan F, Kreibich M, Bavaria J, Groeneveld P, et al. Outcomes 1302.Onitsuka S, Akashi H, Tayama K, Okazaki T, Ishihara K, Hiromatsu S, et al. Long-term
after thoracic endovascular aortic repair in patients with chronic kidney disease in the outcome and prognostic predictors of medically treated acute type B aortic dissec-
Medicare population. J Thorac Cardiovasc Surg 2020;159:402–13. https://doi.org/10. tions. Ann Thorac Surg 2004;78:1268–73. https://doi.org/10.1016/j.athoracsur.2004.
1016/j.jtcvs.2019.01.118 02.031
1284. Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Bossone E, et al. Role and 1303.Hughes GC, Ganapathi AM, Keenan JE, Englum BR, Hanna JM, Schechter MA, et al.
results of surgery in acute type B aortic dissection: insights from the international Thoracic endovascular aortic repair for chronic DeBakey IIIb aortic dissection. Ann
registry of acute aortic dissection (IRAD). Circulation 2006;114:I357–64. https://doi. Thorac Surg 2014;98:2092–7; discussion 2098. https://doi.org/10.1016/j.athoracsur.
org/10.1161/circulationaha.105.000620 2014.06.066
1285. Tolenaar JL, Froehlich W, Jonker FH, Upchurch GR, Rampoldi V, Tsai TT, et al. 1304.Jánosi RA, Tsagakis K, Bettin M, Kahlert P, Horacek M, Al-Rashid F, et al. Thoracic aor-
Predicting in-hospital mortality in acute type B aortic dissection: evidence from inter- tic aneurysm expansion due to late distal stent graft-induced new entry. Catheter
national registry of acute aortic dissection. Circulation 2014;130:S45–50. https://doi. Cardiovasc Interv 2015;85:E43–53. https://doi.org/10.1002/ccd.25614
org/10.1161/circulationaha.113.007117 1305.Cheng L, Xiang D, Zhang S, Zheng C, Wu X. Reintervention after thoracic endovas-
1286. Martin G, Patel N, Grant Y, Jenkins M, Gibbs R, Bicknell C. Antihypertensive medica- cular aortic repair of uncomplicated type B aortic dissection. J Clin Med 2023;12:
tion adherence in chronic type B aortic dissection is an important consideration in the 1418. https://doi.org/10.3390/jcm12041418
management debate. J Vasc Surg 2018;68:693–9.e2. https://doi.org/10.1016/j.jvs.2017. 1306.Akutsu K, Nejima J, Kiuchi K, Sasaki K, Ochi M, Tanaka K, et al. Effects of the patent
12.063 false lumen on the long-term outcome of type B acute aortic dissection. Eur J
1287. Brooke BS, Griffin CL, Glotzbach JP, Horns JJ, Patel S, Kraiss LW, et al. Predictors of Cardiothorac Surg 2004;26:359–66. https://doi.org/10.1016/j.ejcts.2004.03.026
adherence to anti-impulse therapy among patients treated for acute type-B aortic 1307.Tsai TT, Evangelista A, Nienaber CA, Myrmel T, Meinhardt G, Cooper JV, et al. Partial
dissections. Ann Vasc Surg 2021;76:95–103. https://doi.org/10.1016/j.avsg.2021.04. thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J
011 Med 2007;357:349–59. https://doi.org/10.1056/NEJMoa063232
1288. Zeeshan A, Woo EY, Bavaria JE, Fairman RM, Desai ND, Pochettino A, et al. Thoracic 1308.Dake MD, Thompson M, van Sambeek M, Vermassen F, Morales JP. DISSECT: a new
endovascular aortic repair for acute complicated type B aortic dissection: superiority mnemonic-based approach to the categorization of aortic dissection. Eur J Vasc
relative to conventional open surgical and medical therapy. J Thorac Cardiovasc Surg Endovasc Surg 2013;46:175–90. https://doi.org/10.1016/j.ejvs.2013.04.029
2010;140:S109–115; discussion S142–S146. https://doi.org/10.1016/j.jtcvs.2010.06. 1309.Wang J, Jin T, Chen B, Pan Y, Shao C. Systematic review and meta-analysis of current
024 evidence in endograft therapy vs medical treatment for uncomplicated type B aortic
1289. Steuer J, Eriksson MO, Nyman R, Björck M, Wanhainen A. Early and long-term out- dissection. J Vasc Surg 2022;76:1099–108.e3. https://doi.org/10.1016/j.jvs.2022.03.
come after thoracic endovascular aortic repair (TEVAR) for acute complicated type B 876
aortic dissection. Eur J Vasc Endovasc Surg 2011;41:318–23. https://doi.org/10.1016/j. 1310.Umaña JP, Lai DT, Mitchell RS, Moore KA, Rodriguez F, Robbins RC, et al. Is medical
ejvs.2010.11.024 therapy still the optimal treatment strategy for patients with acute type B aortic dis-
1290. Zipfel B, Czerny M, Funovics M, Coppi G, Ferro C, Rousseau H, et al. Endovascular sections? J Thorac Cardiovasc Surg 2002;124:896–910. https://doi.org/10.1067/mtc.
treatment of patients with types A and B thoracic aortic dissection using Relay thor- 2002.123131
acic stent-grafts: results from the RESTORE patient registry. J Endovasc Ther 2011;18: 1311.Umaña JP, Miller DC, Mitchell RS. What is the best treatment for patients with acute
131–43. https://doi.org/10.1583/10-3233mr.1 type B aortic dissections—medical, surgical, or endovascular stent-grafting? Ann
1291. Hanna JM, Andersen ND, Ganapathi AM, McCann RL, Hughes GC. Five-year results Thorac Surg 2002;74:S1840–3; discussion S1857–63. https://doi.org/10.1016/s0003-
for endovascular repair of acute complicated type B aortic dissection. J Vasc Surg 4975(02)04140-1
2014;59:96–106. https://doi.org/10.1016/j.jvs.2013.07.001 1312.Morello F, Santoro M, Fargion AT, Grifoni S, Nazerian P. Diagnosis and management
1292. Stelzmueller ME, Nolz R, Mahr S, Beitzke D, Wolf F, Funovics M, et al. Thoracic en- of acute aortic syndromes in the emergency department. Intern Emerg Med 2021;16:
dovascular repair for acute complicated type B aortic dissections. J Vasc Surg 2019;69: 171–81. https://doi.org/10.1007/s11739-020-02354-8
318–26. https://doi.org/10.1016/j.jvs.2018.05.234 1313.Marui A, Mochizuki T, Mitsui N, Koyama T, Kimura F, Horibe M. Toward the best
1293. Wilson-Smith AR, Muston B, Kamalanathan H, Yung A, Chen C-HJ, Sahai P, et al. treatment for uncomplicated patients with type B acute aortic dissection: a consid-
Endovascular repair of acute complicated type B aortic dissection-systematic review eration for sound surgical indication. Circulation 1999;100:II275–80. https://doi.org/
and meta-analysis of long-term survival and reintervention. Ann Cardiothorac Surg 10.1161/01.cir.100.suppl_2.ii-275
2021;10:723–30. https://doi.org/10.21037/acs-2021-taes-17 1314.Crawford ES. The diagnosis and management of aortic dissection. JAMA 1990;264:
1294. MacGillivray TE, Gleason TG, Patel HJ, Aldea GS, Bavaria JE, Beaver TM, et al. The 2537–41.
Society of Thoracic Surgeons/American Association for Thoracic Surgery clinical 1315.Hata M, Shiono M, Inoue T, Sezai A, Niino T, Negishi N, et al. Optimal treatment of
practice guidelines on the management of type B aortic dissection. J Thorac type B acute aortic dissection: long-term medical follow-up results. Ann Thorac Surg
Cardiovasc Surg 2022;163:1231–49. https://doi.org/10.1016/j.jtcvs.2021.11.091 2003;75:1781–4. https://doi.org/10.1016/s0003-4975(03)00113-9
1295. Brunkwall J, Kasprzak P, Verhoeven E, Heijmen R, Taylor P, Alric P, et al. Endovascular 1316.Oda T, Minatoya K, Sasaki H, Tanaka H, Seike Y, Itonaga T, et al. Surgical indication for
repair of acute uncomplicated aortic type B dissection promotes aortic remodelling: chronic aortic dissection in descending thoracic and thoracoabdominal aorta. Circ
1 year results of the ADSORB trial. Eur J Vasc Endovasc Surg 2014;48:285–91. https:// Cardiovasc Interv 2017;10:e004292. https://doi.org/10.1161/circinterventions.116.
doi.org/10.1016/j.ejvs.2014.05.012 004292
1296. Hossack M, Patel S, Gambardella I, Neequaye S, Antoniou GA, Torella F. 1317.Conrad MF, Chung TK, Cambria MR, Paruchuri V, Brady TJ, Cambria RP. Effect of
Endovascular vs. medical management for uncomplicated acute and sub-acute type chronic dissection on early and late outcomes after descending thoracic and
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 157 ---
3694 E S C G u id e l in e s
thoracoabdominal aneurysm repair. J Vasc Surg 2011;53:600–7; discussion 607. cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–241. https://
https://doi.org/10.1016/j.jvs.2010.09.053 doi.org/10.1093/eurheartj/ehy340
1318. Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, et al. 1338.DeMartino RR, Sen I, Huang Y, Bower TC, Oderich GS, Pochettino A, et al.
Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors deter- Population-based assessment of the incidence of aortic dissection, intramural hema-
mining immediate and long-term results of operations in 605 patients. J Vasc Surg toma, and penetrating ulcer, and its associated mortality from 1995 to 2015. Circ
1986;3:389–404. https://doi.org/10.1067/mva.1986.avs0030389 Cardiovasc Qual Outcomes 2018;11:e004689. https://doi.org/10.1161/circoutcomes.
1319. Zoli S, Etz CD, Roder F, Mueller CS, Brenner RM, Bodian CA, et al. Long-term survival 118.004689
after open repair of chronic distal aortic dissection. Ann Thorac Surg 2010;89: 1339.Evangelista A, Dominguez R, Sebastia C, Salas A, Permanyer-Miralda G, Avegliano G,
1458–66. https://doi.org/10.1016/j.athoracsur.2010.02.014 et al. Long-term follow-up of aortic intramural hematoma: predictors of outcome.
1320. Etz CD, Zoli S, Mueller CS, Bodian CA, Di Luozzo G, Lazala R, et al. Staged repair Circulation 2003;108:583–9. https://doi.org/10.1161/01.Cir.0000081776.49923.5a
significantly reduces paraplegia rate after extensive thoracoabdominal aortic aneur- 1340.Moral S, Ballesteros E, Roque M, Carrato C, Vilardell P, Brugada R, et al. Intimal dis-
ysm repair. J Thorac Cardiovasc Surg 2010;139:1464–72. https://doi.org/10.1016/j. ruption in type B aortic intramural hematoma. Does size matter? A systematic review
jtcvs.2010.02.037 and meta-analysis. Int J Cardiol 2018;269:298–303. https://doi.org/10.1016/j.ijcard.
1321. Conrad MF, Ergul EA, Patel VI, Paruchuri V, Kwolek CJ, Cambria RP. Management 2018.07.111
of diseases of the descending thoracic aorta in the endovascular era: a Medicare 1341.Moral S, Ballesteros E, Evangelista A. Conservative vs surgical treatment in type A
population study. Ann Surg 2010;252:603–10. https://doi.org/10.1097/SLA. intramural hematoma. What is new? J Card Surg 2020;35:1758–60. https://doi.org/
0b013e3181f4eaef 10.1111/jocs.14739
1322. Sobocinski J, Dias NV, Berger L, Midulla M, Hertault A, Sonesson B, et al. Endograft 1342.Ishizu K, Kaji S, Nakashima M, Kitai T, Kim K, Ehara N, et al. Focal intimal disruption
repair of complicated acute type B aortic dissections. Eur J Vasc Endovasc Surg 2013; size at multidetector CT and disease progression in type B aortic intramural hema-
45:468–74. https://doi.org/10.1016/j.ejvs.2013.01.031 toma. Radiology 2021;301:311–9. https://doi.org/10.1148/radiol.2021204385
1323. Conrad MF, Carvalho S, Ergul E, Kwolek CJ, Lancaster RT, Patel VI, et al. Late aortic 1343.Chou AS, Ziganshin BA, Charilaou P, Tranquilli M, Rizzo JA, Elefteriades JA.
remodeling persists in the stented segment after endovascular repair of acute com- Long-term behavior of aortic intramural hematomas and penetrating ulcers. J
plicated type B aortic dissection. J Vasc Surg 2015;62:600–5. https://doi.org/10.1016/j. Thorac Cardiovasc Surg 2016;151:361–72, 373.e1. https://doi.org/10.1016/j.jtcvs.
jvs.2015.03.064 2015.09.012
1324. Thrumurthy SG, Karthikesalingam A, Patterson BO, Holt PJE, Hinchliffe RJ, Loftus IM, 1344.Evangelista A, Mukherjee D, Mehta RH, O’Gara PT, Fattori R, Cooper JV, et al. Acute
et al. A systematic review of mid-term outcomes of thoracic endovascular repair intramural hematoma of the aorta: a mystery in evolution. Circulation 2005;111:
(TEVAR) of chronic type B aortic dissection. Eur J Vasc Endovasc Surg 2011;42: 1063–70. https://doi.org/10.1161/01.Cir.0000156444.26393.80
632–47. https://doi.org/10.1016/j.ejvs.2011.08.009 1345.Song JK. Update in acute aortic syndrome: intramural hematoma and incomplete dis-
1325. Boufi M, Patterson BO, Loundou AD, Boyer L, Grima MJ, Loftus IM, et al. section as new disease entities. J Cardiol 2014;64:153–61. https://doi.org/10.1016/j.
Endovascular versus open repair for chronic type B dissection treatment: a jjcc.2014.05.005
meta-analysis. Ann Thorac Surg 2019;107:1559–70. https://doi.org/10.1016/j. 1346.Song JK, Kim HS, Kang DH, Lim T-H, Song M-G, Park S-W, et al. Different clinical fea-
athoracsur.2018.10.045 tures of aortic intramural hematoma versus dissection involving the ascending aorta.
1326. Conway AM, Qato K, Mondry LR, Stoffels GJ, Giangola G, Carroccio A. Outcomes of J Am Coll Cardiol 2001;37:1604–10. https://doi.org/10.1016/s0735-1097(01)01184-6
thoracic endovascular aortic repair for chronic aortic dissections. J Vasc Surg 2018;67: 1347.Evangelista A, Maldonado G, Moral S, Teixido-Tura G, Lopez A, Cuellar H, et al.
1345–52. https://doi.org/10.1016/j.jvs.2017.08.098 Intramural hematoma and penetrating ulcer in the descending aorta: differences
1327. Tenorio ER, Oderich GS, Farber MA, Schneider DB, Timaran CH, Schanzer A, et al. and similarities. Ann Cardiothorac Surg 2019;8:456–70. https://doi.org/10.21037/acs.
Outcomes of endovascular repair of chronic postdissection compared with degen- 2019.07.05
erative thoracoabdominal aortic aneurysms using fenestrated-branched stent grafts. 1348.Wee I, Varughese RS, Syn N, Choong A. Non-operative management of type A acute
J Vasc Surg 2020;72:822–36.e9. https://doi.org/10.1016/j.jvs.2019.10.091 aortic syndromes: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg
1328. Marques De Marino P, Ibraheem A, Gafur N, Verhoeven EL, Katsargyris A. 2019;58:41–51. https://doi.org/10.1016/j.ejvs.2018.10.015
Outcomes of fenestrated and branched endovascular aortic repair for chronic post- 1349.Chow SCY, Wong RHL, Lakhani I, Wong MV, Tse G, Yu PSY, et al. Management of
dissection thoracoabdominal aortic aneurysms. J Cardiovasc Surg 2020;61:427–34. acute type A intramural hematoma: upfront surgery or individualized approach? A
https://doi.org/10.23736/s0021-9509.20.11367-3 retrospective analysis and meta-analysis. J Thorac Dis 2020;12:680–9. https://doi.
1329. Gallitto E, Faggioli G, Melissano G, Fargion A, Isernia G, Bertoglio L, et al. Fenestrated org/10.21037/jtd.2019.12.109
and branched endografts for post-dissection thoraco-abdominal aneurysms: results 1350.Evangelista A, Czerny M, Nienaber C, Schepens M, Rousseau H, Cao P, et al.
of a national multicentre study and literature review. Eur J Vasc Endovasc Surg Interdisciplinary expert consensus on management of type B intramural haematoma
2022;64:630–8. https://doi.org/10.1016/j.ejvs.2022.06.019 and penetrating aortic ulcer. Eur J Cardiothorac Surg 2015;47:209–17. https://doi.org/
1330. Geisbüsch S, Kuehnl A, Salvermoser M, Reutersberg B, Trenner M, Eckstein H-H. 10.1093/ejcts/ezu386
Editor’s choice—hospital incidence, treatment, and in hospital mortality following 1351.Sa MP, Jacquemyn X, Tasoudis P, Dufendach K, Singh MJ, de la Cruz KI, et al. Five year
open and endovascular surgery for thoraco-abdominal aortic aneurysms in results of endovascular versus medical therapy in acute type B aortic intramural
Germany from 2005 to 2014: secondary data analysis of the Nationwide German haematoma: meta-analysis of reconstructed time to event data. Eur J Vasc Endovasc
DRG microdata. Eur J Vasc Endovasc Surg 2019;57:488–98. https://doi.org/10.1016/ Surg 2024;67:584–92. https://doi.org/10.1016/j.ejvs.2023.12.024
j.ejvs.2018.10.030 1352.Moral S, Cuéllar H, Avegliano G, Ballesteros E, Salcedo MT, Ferreira-González I, et al.
1331. Genoni M, Paul M, Jenni R, Graves K, Seifert B, Turina M. Chronic beta-blocker ther- Clinical implications of focal intimal disruption in patients with type B intramural
apy improves outcome and reduces treatment costs in chronic type B aortic dissec- hematoma. J Am Coll Cardiol 2017;69:28–39. https://doi.org/10.1016/j.jacc.2016.10.
tion. Eur J Cardiothorac Surg 2001;19:606–10. https://doi.org/10.1016/s1010-7940(01) 045
00662-5 1353.Chakos A, Twindyawardhani T, Evangelista A, Maldonado G, Piffaretti G, Yan TD,
1332. Chen SW, Chan YH, Lin CP, Wu VC-C, Cheng Y-T, Chen D-Y, et al. Association of et al. Endovascular versus medical management of type B intramural hematoma: a
long-term use of antihypertensive medications with late outcomes among patients meta-analysis. Ann Cardiothorac Surg 2019;8:447–55. https://doi.org/10.21037/acs.
with aortic dissection. JAMA Netw Open 2021;4:e210469. https://doi.org/10.1001/ 2019.06.11
jamanetworkopen.2021.0469 1354.Song JK, Yim JH, Ahn JM, Kim D-H, Kang JW, Lee TY, et al. Outcomes of patients with
1333. Smedberg C, Hultgren R, Leander K, Steuer J. Pharmacological treatment in patients acute type a aortic intramural hematoma. Circulation 2009;120:2046–52. https://doi.
with aortic dissection. Open Heart 2022;9:e002082. https://doi.org/10.1136/openhrt- org/10.1161/circulationaha.109.879783
2022-002082 1355.Ahn JM, Kim H, Kwon O, Om SY, Heo R, Lee S, et al. Differential clinical features and
1334. Xiong J, Jiang B, Guo W, Wang SM, Tong XY. Endovascular stent graft placement in long-term prognosis of acute aortic syndrome according to disease entity. Eur Heart J
patients with type B aortic dissection: a meta-analysis in China. J Thorac Cardiovasc 2019;40:2727–36. https://doi.org/10.1093/eurheartj/ehz153
Surg 2009;138:865–72.e1. https://doi.org/10.1016/j.jtcvs.2009.02.005 1356.Kitamura T, Torii S, Miyamoto T, Mishima T, Ohkubo H, Fujioka S, et al.
1335. Zhu JM, Ma WG, Peterss S, Wang L-F, Qiao Z-Y, Ziganshin BA, et al. Aortic dissection Watch-and-wait strategy for type A intramural haematoma and acute aortic dissec-
in pregnancy: management strategy and outcomes. Ann Thorac Surg 2017;103: tion with thrombosed false lumen of the ascending aorta: a Japanese single-centre ex-
1199–206. https://doi.org/10.1016/j.athoracsur.2016.08.089 perience. Eur J Cardiothorac Surg 2020;58:590–7. https://doi.org/10.1093/ejcts/
1336. Yates MT, Soppa G, Smelt J, Fletcher N, van Besouw J-P, Thilaganathan B, et al. ezaa080
Perioperative management and outcomes of aortic surgery during pregnancy. J 1357.Jánosi RA, Gorla R, Tsagakis K, Kahlert P, Horacek M, Bruckschen F, et al. Thoracic
Thorac Cardiovasc Surg 2015;149:607–10. https://doi.org/10.1016/j.jtcvs.2014.10.038 endovascular repair of complicated penetrating aortic ulcer: an 11-year single-center
1337. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, experience. J Endovasc Ther 2016;23:150–9. https://doi.org/10.1177/
Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of 1526602815613790
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 158 ---
ESC Guidelines 3695
1358. Nguyen VX, Nguyen BD. PET/CT imaging of abdominal aorta with intramural hema- 1379.Meena RA, Benarroch-Gampel J, Leshnower BG, Escobar GA, Duwayri Y, Jordan
tomas, penetrating ulcer, and saccular pseudoaneurysm. Clin Nucl Med 2014;39: WD, et al. Surveillance recommendations after thoracic endovascular aortic repair
467–9. https://doi.org/10.1097/RLU.0b013e318292f152 should be based on initial indication for repair. Ann Vasc Surg 2019;57:51–9. https://
1359. Gorla R, Erbel R, Kuehl H, Kahlert P, Tsagakis K, Jakob H, et al. Prognostic value of doi.org/10.1016/j.avsg.2018.11.001
(18)F-fluorodeoxyglucose PET-CT imaging in acute aortic syndromes: comparison 1380.Giles KA, Beck AW, Lala S, Patterson S, Back M, Fatima J, et al. Implications of second-
with serological biomarkers of inflammation. Int J Cardiovasc Imaging 2015;31: ary aortic intervention after thoracic endovascular aortic repair for acute and chronic
1677–85. https://doi.org/10.1007/s10554-015-0725-8 type B dissection. J Vasc Surg 2019;69:1367–78. https://doi.org/10.1016/j.jvs.2018.07.
1360. Eggebrecht H, Plicht B, Kahlert P, Erbel R. Intramural hematoma and penetrating ul- 080
cers: indications to endovascular treatment. Eur J Vasc Endovasc Surg 2009;38:659–65. 1381.Kimura N, Itoh S, Yuri K, Adachi K, Matsumoto H, Yamaguchi A, et al. Reoperation
https://doi.org/10.1016/j.ejvs.2009.09.001 for enlargement of the distal aorta after initial surgery for acute type A aortic dissec-
1361. Salim S, Locci R, Martin G, Gibbs R, Jenkins M, Hamady M, et al. Short- and long-term tion. J Thorac Cardiovasc Surg 2015;149:S91–8.e1. https://doi.org/10.1016/j.jtcvs.2014.
outcomes in isolated penetrating aortic ulcer disease. J Vasc Surg 2020;72:84–91. 08.008
https://doi.org/10.1016/j.jvs.2019.09.039 1382.Ameli-Renani S, Das R, Morgan RA. Thoracic endovascular aortic repair for the treat-
1362. Überall MA, Elling C, Eibl C, Müller-Schwefe GHH, Lefeber C, Heine M, et al. ment of aortic dissection: post-operative imaging, complications and secondary inter-
Tapentadol prolonged release in patients with chronic low back pain: real-world ventions. Cardiovasc Intervent Radiol 2015;38:1391–404. https://doi.org/10.1007/
data from the German Pain eRegistry. Pain Manag 2022;12:211–27. https://doi.org/ s00270-015-1072-9
10.2217/pmt-2021-0058 1383.Fleischmann D, Afifi RO, Casanegra AI, Elefteriades JA, Gleason TG, Hanneman K,
1363. Ganaha F, Miller DC, Sugimoto K, Do YS, Minamiguchi H, Saito H, et al. Prognosis of et al. Imaging and surveillance of chronic aortic dissection: a scientific statement
aortic intramural hematoma with and without penetrating atherosclerotic ulcer: a from the American Heart Association. Circ Cardiovasc Imaging 2022;15:e000075.
clinical and radiological analysis. Circulation 2002;106:342–8. https://doi.org/10. https://doi.org/10.1161/hci.0000000000000075
1161/01.cir.0000022164.26075.5a 1384.Colacchio EC, Squizzato F, Piazza M, Menegolo M, Grego F, Antonello M. Clinical and
1364. DeCarlo C, Latz CA, Boitano LT, Waller HD, Kim Y, Sumpio BJ, et al. Natural history imaging predictors of disease progression in type B aortic intramural hematomas and
of penetrating atherosclerotic ulcers in aortic branch vessels. J Vasc Surg 2021;74: penetrating aortic ulcers: a systematic review. Diagnostics (Basel) 2022;12:2727.
1904–9. https://doi.org/10.1016/j.jvs.2021.06.035 https://doi.org/10.3390/diagnostics12112727
1365. Piazza M, Squizzato F, Porcellato L, Casali E, Grego F, Antonello M. Predictors of 1385.Vapnik JS, Kim JB, Isselbacher EM, Ghoshhajra BB, Cheng Y, Sundt TM, et al.
intervention in acute type B aortic penetrating ulcer and intramural hematoma. Characteristics and outcomes of ascending versus descending thoracic aortic aneur-
Semin Thorac Cardiovasc Surg 2022;36:1–10. https://doi.org/10.1053/j.semtcvs.2022. ysms. Am J Cardiol 2016;117:1683–90. https://doi.org/10.1016/j.amjcard.2016.02.048
07.009 1386.Gökalp AL, Takkenberg JJM. Decision-making in thoracic aortic aneurysm surgery-
1366. Kotsis T, Spyropoulos BG, Asaloumidis N, Christoforou P, Katseni K, clinician and patient view. Semin Thorac Cardiovasc Surg 2019;31:638–42. https://doi.
Papaconstantinou I. Penetrating atherosclerotic ulcers of the abdominal aorta: a org/10.1053/j.semtcvs.2019.05.032
case report and review of the literature. Vasc Specialist Int 2019;35:152–9. https:// 1387.Treasure T, King A, Hidalgo Lemp L, Golesworthy T, Pepper J, Takkenberg JJM.
doi.org/10.5758/vsi.2019.35.3.152 Developing a shared decision support framework for aortic root surgery in Marfan
1367. DeCarlo C, Latz CA, Boitano LT, Kim Y, Tanious A, Schwartz SI, et al. Prognostication syndrome. Heart 2018;104:480–6. https://doi.org/10.1136/heartjnl-2017-311598
of asymptomatic penetrating aortic ulcers: a modern approach. Circulation 2021;144: 1388.Jondeau G, Ropers J, Regalado E, Braverman A, Evangelista A, Teixedo G, et al.
1091–101. https://doi.org/10.1161/circulationaha.121.054710 International registry of patients carrying TGFBR1 or TGFBR2 mutations: results
1368. Demetriades D, Velmahos GC, Scalea TM, Jurkovich GJ, Karmy-Jones R, Teixeira PG, of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet 2016;9:
et al. Operative repair or endovascular stent graft in blunt traumatic thoracic aortic 548–58. https://doi.org/10.1161/circgenetics.116.001485
injuries: results of an American Association for the Surgery of Trauma Multicenter 1389.Thakker PD, Braverman AC. Cardiogenetics: genetic testing in the diagnosis and man-
Study. J Trauma 2008;64:561–70; discussion 570–1. https://doi.org/10.1097/TA. agement of patients with aortic disease. Heart 2021;107:619–26. https://doi.org/10.
0b013e3181641bb3 1136/heartjnl-2020-317036
1369. Katzenschlager R, Ugurluoglu A, Ahmadi A, Hülsmann M, Koppensteiner R, Larch E, 1390.Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al.
et al. Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med
Radiology 1995;195:463–6. https://doi.org/10.1148/radiology.195.2.7724767 2006;355:788–98. https://doi.org/10.1056/NEJMoa055695
1370. Mulder EJ, van Bockel JH, Maas J, van den Akker PJ, Hermans J. Morbidity and mor- 1391.Regalado ES, Morris SA, Braverman AC, Hostetler EM, De Backer J, Li R, et al.
tality of reconstructive surgery of noninfected false aneurysms detected long after Comparative risks of initial aortic events associated with genetic thoracic aortic dis-
aortic prosthetic reconstruction. Arch Surg 1998;133:45–9. https://doi.org/10.1001/ ease. J Am Coll Cardiol 2022;80:857–69. https://doi.org/10.1016/j.jacc.2022.05.054
archsurg.133.1.45 1392.Huguenard AL, Johnson GW, Desai RR, Osbun JW, Dacey RG, Braverman AC.
1371. Chaud GJ, Mohammadi S, Cervetti MR, Guimaron S, Sebestyen A, Dagenais F, et al. Relationship between phenotypic features in Loeys-Dietz syndrome and the pres-
Aortic pseudoaneurysm after type A aortic dissection: results of conservative man- ence of intracranial aneurysms. J Neurosurg 2022;138:1385–92. https://doi.org/10.
agement. Semin Thorac Cardiovasc Surg 2022;35:457–64. https://doi.org/10.1053/j. 3171/2022.9.Jns221373
semtcvs.2022.04.004 1393.Lopez-Sainz A, Mila L, Rodriguez-Palomares J, Limeres J, Granato C, La Mura L, et al.
1372. Richens D, Kotidis K, Neale M, Oakley C, Fails A. Rupture of the aorta following road Aortic branch aneurysms and vascular risk in patients with Marfan syndrome. J Am
traffic accidents in the United Kingdom 1992–1999. The results of the co-operative Coll Cardiol 2021;77:3005–12. https://doi.org/10.1016/j.jacc.2021.04.054
crash injury study. Eur J Cardiothorac Surg 2003;23:143–8. https://doi.org/10.1016/ 1394.Kaw A, Kaw K, Hostetler EM, Beleza-Meireles A, Smith-Collins A, Armstrong C, et al.
s1010-7940(02)00720-0 Expanding ACTA2 genotypes with corresponding phenotypes overlapping with
1373. Harky A, Bleetman D, Chan JSK, Eriksen P, Chaplin G, MacCarthy-Ofosu B, et al. A smooth muscle dysfunction syndrome. Am J Med Genet A 2022;188:2389–96.
systematic review and meta-analysis of endovascular versus open surgical repair for https://doi.org/10.1002/ajmg.a.62775
the traumatic ruptured thoracic aorta. J Vasc Surg 2020;71:270–82. https://doi.org/10. 1395.Velvin G, Wilhelmsen JE, Johansen H, Bathen T, Geirdal AO. Systematic review of
1016/j.jvs.2019.05.011 quality of life in persons with hereditary thoracic aortic aneurysm and dissection diag-
1374. Heneghan RE, Aarabi S, Quiroga E, Gunn ML, Singh N, Starnes BW. Call for a new noses. Clin Genet 2019;95:661–76. https://doi.org/10.1111/cge.13522
classification system and treatment strategy in blunt aortic injury. J Vasc Surg 2016; 1396.Mariscalco G, Debiec R, Elefteriades JA, Samani NJ, Murphy GJ. Systematic review of
64:171–6. https://doi.org/10.1016/j.jvs.2016.02.047 studies that have evaluated screening tests in relatives of patients affected by nonsyn-
1375. Januzzi JL, Sabatine MS, Eagle KA, Evangelista A, Bruckman D, Fattori R, et al. dromic thoracic aortic disease. J Am Heart Assoc 2018;7:e009302. https://doi.org/10.
Iatrogenic aortic dissection. Am J Cardiol 2002;89:623–6. https://doi.org/10.1016/ 1161/jaha.118.009302
s0002-9149(01)02312-8 1397.Cecchi AC, Boerio ML, Marin I, Pinard A, Milewicz DM. Preventing acute aortic dis-
1376. Gómez-Moreno S, Sabaté M, Jiménez-Quevedo P, Vázquez P, Alfonso F, Angiolillo sections: the power of familial screening and risk assessment. J Am Heart Assoc 2022;
DJ, et al. Iatrogenic dissection of the ascending aorta following heart catheterisation: 11:e025441. https://doi.org/10.1161/jaha.122.025441
incidence, management and outcome. EuroIntervention 2006;2:197–202. 1398.Abbasciano RG, Mariscalco G, Barwell J, Owens G, Zakkar M, Joel-David L, et al.
1377. Dunning DW, Kahn JK, Hawkins ET, O’Neill W. Iatrogenic coronary artery dissec- Evaluating the feasibility of screening relatives of patients affected by nonsyndromic
tions extending into and involving the aortic root. Catheter Cardiovasc Interv 2000; thoracic aortic diseases: the REST study. J Am Heart Assoc 2022;11:e023741.
51:387–93. https://doi.org/10.1002/1522-726x(200012)51:4<387::aid-ccd3>3.0. https://doi.org/10.1161/jaha.121.023741
co;2-b 1399.Musunuru K, Hershberger RE, Day SM, Klinedinst NJ, Landstrom AP, Parikh VN, et al.
1378. Bekkers JA, te Riele RJ, Takkenberg JJ, Bol Raap G, Hofland J, Roos-Hesselink JW, et al. Genetic testing for inherited cardiovascular diseases: a scientific statement from the
Thoracic aortic surgery: an overview of 40 years clinical practice. J Thorac Cardiovasc American Heart Association. Circ Genom Precis Med 2020;13:e000067. https://doi.
Surg 2014;147:332–43. https://doi.org/10.1016/j.jtcvs.2012.11.036 org/10.1161/hcg.0000000000000067
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 159 ---
3696 E S C G u id e l in e s
1400. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, et al. Familial 1421.Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner
thoracic aortic aneurysms and dissections—incidence, modes of inheritance, and syndrome. Circulation 2007;116:1663–70. https://doi.org/10.1161/circulationaha.106.
phenotypic patterns. Ann Thorac Surg 2006;82:1400–5. https://doi.org/10.1016/j. 685487
athoracsur.2006.04.098 1422.Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Mortality in wo-
1401. Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and men with Turner syndrome in Great Britain: a national cohort study. J Clin
dissections: a case control study. J Vasc Surg 1997;25:506–11. https://doi.org/10.1016/ Endocrinol Metab 2008;93:4735–42. https://doi.org/10.1210/jc.2008-1049
s0741-5214(97)70261-1 1423.Duijnhouwer AL, Bons LR, Timmers H, van Kimmenade RRL, Snoeren M,
1402. Robertson EN, van der Linde D, Sherrah AG, Vallely MP, Wilson M, Bannon PG, et al. Timmermans J, et al. Aortic dilatation and outcome in women with Turner syndrome.
Familial non-syndromal thoracic aortic aneurysms and dissections—incidence and Heart 2019;105:693–700. https://doi.org/10.1136/heartjnl-2018-313716
family screening outcomes. Int J Cardiol 2016;220:43–51. https://doi.org/10.1016/j. 1424.Donadille B, Tuffet S, Cholet C, Nedelcu M, Bourcigaux N, Iserin L, et al. Prevalence
ijcard.2016.06.086 and progression of aortic dilatation in adult patients with Turner syndrome: a cohort
1403. De Backer J, Bondue A, Budts W, Evangelista A, Gallego P, Jondeau G, et al. Genetic study. Eur J Endocrinol 2020;183:463–70. https://doi.org/10.1530/eje-20-0284
counselling and testing in adults with congenital heart disease: a consensus document 1425.Meccanici F, Schotte MH, Snoeren M, Bons LR, van den Hoven AT, Kardys I, et al.
of the ESC Working Group of Grown-Up Congenital Heart Disease, the ESC Aortic dilation and growth in women with Turner syndrome. Heart 2023;109:
Working Group on Aorta and Peripheral Vascular Disease and the European 102–10. https://doi.org/10.1136/heartjnl-2022-320922
Society of Human Genetics. Eur J Prev Cardiol 2020;27:1423–35. https://doi.org/10. 1426.Galian-Gay L, Rodriguez-Palomares JF. Turner syndrome and aortic complications:
1177/2047487319854552 more benign than previously thought. Heart 2022;109:82–3. https://doi.org/10.
1404. Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, et al. Clinical implica- 1136/heartjnl-2022-321330
tions of identifying pathogenic variants in individuals with thoracic aortic dissection. 1427.Silberbach M, Braverman AC, Prakash SK, Roos-Hesselink JW, Quezada E, Scurlock
Circ Genom Precis Med 2019;12:e002476. https://doi.org/10.1161/circgen.118.002476 C. Preventing aortic dissection in Turner syndrome: who faces the risk? Int J Cardiol
1405. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical validity 2023;377:44. https://doi.org/10.1016/j.ijcard.2023.01.075
of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol 2018; 1428.Prakash S, Gen TACRI, Milewicz D. Turner syndrome-specific and general population
72:605–15. https://doi.org/10.1016/j.jacc.2018.04.089 Z-scores are equivalent for most adults with Turner syndrome. Am J Med Genet A
1406. De Backer J, Jondeau G, Boileau C. Genetic testing for aortopathies: primer for the 2017;173:1094–6. https://doi.org/10.1002/ajmg.a.38100
nongeneticist. Curr Opin Cardiol 2019;34:585–93. https://doi.org/10.1097/hco. 1429.Corbitt H, Maslen C, Prakash S, Morris SA, Silberbach M. Allometric considerations
0000000000000669 when assessing aortic aneurysms in Turner syndrome: implications for activity re-
1407. Milewicz DM, Guo D, Hostetler E, Marin I, Pinard AC, Cecchi AC, et al. Update on commendations and medical decision-making. Am J Med Genet A 2018;176:277–82.
the genetic risk for thoracic aortic aneurysms and acute aortic dissections: implica- https://doi.org/10.1002/ajmg.a.38584
tions for clinical care. J Cardiovasc Surg 2021;62:203–10. https://doi.org/10.23736/ 1430.Quigley CA, Fechner PY, Geffner ME, Eugster EA, Ross JL, Habiby RL, et al.
s0021-9509.21.11816-6 Prevention of growth failure in Turner syndrome: long-term results of early growth
1408. Chou EL, Lindsay ME. The genetics of aortopathies: hereditary thoracic aortic aneur- hormone treatment in the “Toddler Turner” Cohort. Horm Res Paediatr 2021;94:
ysms and dissections. Am J Med Genet C Semin Med Genet 2020;184:136–48. https:// 18–35. https://doi.org/10.1159/000513788
doi.org/10.1002/ajmg.c.31771 1431.Klein KO, Rosenfield RL, Santen RJ, Gawlik AM, Backeljauw PF, Gravholt CH, et al.
1409. Harris SL, Lindsay ME. Role of clinical genetic testing in the management of aortopa- Estrogen replacement in Turner syndrome: literature review and practical considera-
thies. Curr Cardiol Rep 2021;23:10. https://doi.org/10.1007/s11886-020-01435-6 tions. J Clin Endocrinol Metab 2018;103:1790–803. https://doi.org/10.1210/jc.2017-
1410. Regalado ES, Guo DC, Prakash S, Bensend TA, Flynn K, Estrera A, et al. Aortic disease 02183
presentation and outcome associated with ACTA2 mutations. Circ Cardiovasc Genet 1432.Quigley CA, Wan X, Garg S, Kowal K, Cutler GB, Ross JL. Effects of low-dose estro-
2015;8:457–64. https://doi.org/10.1161/circgenetics.114.000943 gen replacement during childhood on pubertal development and gonadotropin con-
1411. Teixidó-Tura G, Franken R, Galuppo V, Gutiérrez García-Moreno L, Borregan M, centrations in patients with Turner syndrome: results of a randomized, double-blind,
Mulder BJM, et al. Heterogeneity of aortic disease severity in patients with placebo-controlled clinical trial. J Clin Endocrinol Metab 2014;99:E1754–1764. https://
Loeys-Dietz syndrome. Heart 2016;102:626–32. https://doi.org/10.1136/heartjnl- doi.org/10.1210/jc.2013-4518
2015-308535 1433.Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, et al. Growth
1412. Baudhuin LM, Kotzer KE, Lagerstedt SA. Increased frequency of FBN1 truncating and hormone treatment of early growth failure in toddlers with Turner syndrome: a ran-
splicing variants in Marfan syndrome patients with aortic events. Genet Med 2015;17: domized, controlled, multicenter trial. J Clin Endocrinol Metab 2007;92:3406–16.
177–87. https://doi.org/10.1038/gim.2014.91 https://doi.org/10.1210/jc.2006-2874
1413. Franken R, Teixido-Tura G, Brion M, Forteza A, Rodriguez-Palomares J, Gutierrez L, 1434.Stephure DK; Canadian Growth Hormone Advisory Committee. Impact of growth
et al. Relationship between fibrillin-1 genotype and severity of cardiovascular involve- hormone supplementation on adult height in Turner syndrome: results of the
ment in Marfan syndrome. Heart 2017;103:1795–9. https://doi.org/10.1136/heartjnl- Canadian randomized controlled trial. J Clin Endocrinol Metab 2005;90:3360–6.
2016-310631 https://doi.org/10.1210/jc.2004-2187
1414. Wallace SE, Regalado ES, Gong L, Janda AL, Guo D, Russo CF, et al. MYLK pathogenic 1435.Campens L, Baris L, Scott NS, Broberg CS, Bondue A, Jondeau G, et al. Pregnancy
variants aortic disease presentation, pregnancy risk, and characterization of patho- outcome in thoracic aortic disease data from the registry of pregnancy and cardiac
genic missense variants. Genet Med 2019;21:144–51. https://doi.org/10.1038/ disease. Heart 2021;107:1704–9. https://doi.org/10.1136/heartjnl-2020-318183
s41436-018-0038-0 1436.Grewal J, Valente AM, Egbe AC, Wu FM, Krieger EV, Sybert VP, et al. Cardiovascular
1415. Seike Y, Matsuda H, Ishibashi-Ueda H, Morisaki H, Morisaki T, Minatoya K, et al. outcomes of pregnancy in Turner syndrome. Heart 2021;107:61–6. https://doi.org/
Surgical outcome and histological differences between individuals with TGFBR1 10.1136/heartjnl-2020-316719
and TGFBR2 mutations in Loeys-Dietz syndrome. Ann Thorac Cardiovasc Surg 2021; 1437.Thompson T, Zieba B, Howell S, Karakash W, Davis S. A mixed methods study of
27:56–63. https://doi.org/10.5761/atcs.oa.20-00223 physical activity and quality of life in adolescents with Turner syndrome. Am J Med
1416. Arnaud P, Milleron O, Hanna N, Ropers J, Ould Ouali N, Affoune A, et al. Clinical Genet A 2020;182:386–96. https://doi.org/10.1002/ajmg.a.61439
relevance of genotype-phenotype correlations beyond vascular events in a cohort 1438.Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of
study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342:
Med 2021;23:1296–304. https://doi.org/10.1038/s41436-021-01132-x 673–80. https://doi.org/10.1056/nejm200003093421001
1417. Silberbach M, Roos-Hesselink JW, Andersen NH, Braverman AC, Brown N, Collins 1439.Byers PH, Belmont J, Black J, De Backer J, Frank M, Jeunemaitre X, et al. Diagnosis,
RT, et al. Cardiovascular health in Turner syndrome: a scientific statement from the natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med
American Heart Association. Circ Genom Precis Med 2018;11:e000048. https://doi. Genet C Semin Med Genet 2017;175:40–7. https://doi.org/10.1002/ajmg.c.31553
org/10.1161/hcg.0000000000000048 1440.Oderich GS, Panneton JM, Bower TC, Lindor NM, Cherry KJ, Noel AA, et al. The
1418. Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, et al. spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a
Clinical practice guidelines for the care of girls and women with Turner syndrome: 30-year experience. J Vasc Surg 2005;42:98–106. https://doi.org/10.1016/j.jvs.2005.
proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur 03.053
J Endocrinol 2017;177:G1–70. https://doi.org/10.1530/eje-17-0430 1441.Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, et al. Vascular
1419. van den Hoven AT, Chelu RG, Duijnhouwer AL, Demulier L, Devos D, Nieman K, Ehlers-Danlos syndrome: long-term observational study. J Am Coll Cardiol 2019;73:
et al. Partial anomalous pulmonary venous return in Turner syndrome. Eur J Radiol 1948–57. https://doi.org/10.1016/j.jacc.2019.01.058
2017;95:141–6. https://doi.org/10.1016/j.ejrad.2017.07.024 1442.Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz D, Byers PH. Survival is affected by
1420. Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicus- mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS
pid aortic valve are associated with aortic dissection in Turner syndrome: report of type IV). Genet Med 2014;16:881–8. https://doi.org/10.1038/gim.2014.72
the international Turner syndrome aortic dissection registry. Circulation 2012;126: 1443.van de Laar I, Baas AF, De Backer J, Blankenstein JD, Dulfer E, Helderman-van den
2220–6. https://doi.org/10.1161/circulationaha.111.088633 Enden ATJM, et al. Surveillance and monitoring in vascular Ehlers-Danlos syndrome
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 160 ---
ESC Guidelines 3697
in European reference network for rare vascular diseases (VASCERN). Eur J Med employed by a multi-disciplinary aortic team. Eur J Cardiothorac Surg 2024;65:
Genet 2022;65:104557. https://doi.org/10.1016/j.ejmg.2022.104557 ezae069. https://doi.org/10.1093/ejcts/ezae069
1444. Baderkhan H, Wanhainen A, Stenborg A, Stattin EL, Bjorck M. Celiprolol treatment in 1466.Czerny M, Grabenwoger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al.
patients with vascular Ehlers-Danlos syndrome. Eur J Vasc Endovasc Surg 2021;61: EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of
326–31. https://doi.org/10.1016/j.ejvs.2020.10.020 the aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/
1445. Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, et al. Effect of celi- ejcts/ezad426
prolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a 1467.Milleron O, Arnoult F, Delorme G, Detaint D, Pellenc Q, Raffoul R, et al. Pathogenic
prospective randomised, open, blinded-endpoints trial. Lancet 2010;376:1476–84. FBN1 genetic variation and aortic dissection in patients with Marfan syndrome. J Am
https://doi.org/10.1016/s0140-6736(10)60960-9 Coll Cardiol 2020;75:843–53. https://doi.org/10.1016/j.jacc.2019.12.043
1446. Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complica- 1468.Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller G-P, et al.
tions in women with vascular Ehlers-Danlos syndrome. Genet Med 2014;16:874–80. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart
https://doi.org/10.1038/gim.2014.53 J 2021;42:563–645. https://doi.org/10.1093/eurheartj/ehaa554
1447. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. 1469.Martín C, Evangelista A, Serrano-Fiz S, Villar S, Ospina V, Martínez D, et al. Aortic
The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476–85. complications in Marfan syndrome: should we anticipate preventive aortic root sur-
https://doi.org/10.1136/jmg.2009.072785 gery? Ann Thorac Surg 2020;109:1850–7. https://doi.org/10.1016/j.athoracsur.2019.
1448. Yildiz M, Nucera M, Jungi S, Heinisch PP, Mosbahi S, Becker D, et al. Outcome of 08.096
Stanford type B dissection in patients with Marfan syndrome. Eur J Cardiothorac 1470.Roman MJ, Pugh NL, Hendershot TP, Devereux RB, Dietz H, Holmes K, et al. Aortic
Surg 2023;64:ezad178. https://doi.org/10.1093/ejcts/ezad178 complications associated with pregnancy in Marfan syndrome: the NHLBI national
1449. Narula N, Devereux RB, Arbustini E, Ma X, Weinsaft JW, Girardi L, et al. Risk of type registry of genetically triggered thoracic aortic aneurysms and cardiovascular condi-
B dissection in Marfan syndrome: the Cornell aortic aneurysm registry. J Am Coll tions (GenTAC). J Am Heart Assoc 2016;5:e004052. https://doi.org/10.1161/jaha.116.
Cardiol 2023;82:2009–17. https://doi.org/10.1016/j.jacc.2023.08.055 004052
1450. Senemaud J, Gaudry M, Jouve E, Blanchard A, Milleron O, Dulac Y, et al. Primary non- 1471.Braverman AC, Mittauer E, Harris KM, Evangelista A, Pyeritz RE, Brinster D, et al.
aortic lesions are not rare in Marfan syndrome and are associated with aortic dissec- Clinical features and outcomes of pregnancy-related acute aortic dissection. JAMA
tion independently of age. J Clin Med 2023;12:2902. https://doi.org/10.3390/ Cardiol 2021;6:58–66. https://doi.org/10.1001/jamacardio.2020.4876
1472.Narula N, Devereux RB, Malonga GP, Hriljac I, Roman MJ. Pregnancy-related aortic
jcm12082902
1451. Judge DP, Rouf R, Habashi J, Dietz HC. Mitral valve disease in Marfan syndrome and complications in women with Marfan syndrome. J Am Coll Cardiol 2021;78:870–9.
https://doi.org/10.1016/j.jacc.2021.06.034
related disorders. J Cardiovasc Transl Res 2011;4:741–7. https://doi.org/10.1007/
1473.Davis MB, Arendt K, Bello NA, Brown H, Briller J, Epps K, et al. Team-based care of
s12265-011-9314-y
women with cardiovascular disease from pre-conception through pregnancy and
1452. Demolder A, Bianco L, Caruana M, Cervi E, Evangelista A, Jondeau G, et al.
postpartum: JACC focus seminar 1/5. J Am Coll Cardiol 2021;77:1763–77. https://
Arrhythmia and impaired myocardial function in heritable thoracic aortic disease:
doi.org/10.1016/j.jacc.2021.02.033
an international retrospective cohort study. Eur J Med Genet 2022;65:104503.
1474.Meijboom LJ, Vos FE, Timmermans J, Boers GH, Zwinderman AH, Mulder BJM.
https://doi.org/10.1016/j.ejmg.2022.104503
Pregnancy and aortic root growth in the Marfan syndrome: a prospective study.
1453. Pyeritz RE. Marfan syndrome: improved clinical history results in expanded natural
Eur Heart J 2005;26:914–20. https://doi.org/10.1093/eurheartj/ehi103
history. Genet Med 2019;21:1683–90. https://doi.org/10.1038/s41436-018-0399-4
1475.Kuperstein R, Cahan T, Yoeli-Ullman R, Ben Zekry S, Shinfeld A, Simchen MJ. Risk of
1454. Jondeau G, Detaint D, Tubach F, Arnoult F, Milleron O, Raoux F, et al. Aortic event
aortic dissection in pregnant patients with the Marfan syndrome. Am J Cardiol 2017;
rate in the Marfan population: a cohort study. Circulation 2012;125:226–32. https://
119:132–7. https://doi.org/10.1016/j.amjcard.2016.09.024
doi.org/10.1161/circulationaha.111.054676
1476.Roberts EA, Pistner A, Osobamiro O, Banning S, Shalhub S, Albright C, et al.
1455. Requejo-Garcia L, Martinez-Lopez R, Plana-Andani E, Medina-Badenes P,
Beta-blocker use during pregnancy correlates with less aortic root dilatation in pa-
Hernándiz-Martínez A, Torres-Blanco A, et al. Extrathoracic aneurysms in Marfan
tients with Marfan’s syndrome. Aorta (Stamford) 2023;11:63–70. https://doi.org/10.
syndrome: a systematic review of the literature. Ann Vasc Surg 2022;87:548–59.
1055/a-2072-0469
https://doi.org/10.1016/j.avsg.2022.08.005
1477.Roman MJ, Devereux RB. Aortic dissection risk in Marfan syndrome. J Am Coll Cardiol
1456. Guala A, Teixidó-Tura G, Rodríguez-Palomares J, Ruiz-Muñoz A, Dux-Santoy L,
2020;75:854–6. https://doi.org/10.1016/j.jacc.2019.12.042
Villalva N, et al. Proximal aorta longitudinal strain predicts aortic root dilation rate
1478.Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhi-
and aortic events in Marfan syndrome. Eur Heart J 2019;40:2047–55. https://doi.
bitors and angiotensin receptor antagonists. Early Hum Dev 2006;82:23–8. https://doi.
org/10.1093/eurheartj/ehz191
org/10.1016/j.earlhumdev.2005.11.001
1457. Teixido-Tura G, Redheuil A, Rodríguez-Palomares J, Gutiérrez L, Sánchez V, Forteza
1479.Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. Teratogenicity of angio-
A, et al. Aortic biomechanics by magnetic resonance: early markers of aortic disease
tensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31:
in Marfan syndrome regardless of aortic dilatation? Int J Cardiol 2014;171:56–61.
465–72. https://doi.org/10.3109/01443615.2011.579197
https://doi.org/10.1016/j.ijcard.2013.11.044 1480.Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al.
1458. Kuijpers JM, Mulder BJ. Aortopathies in adult congenital heart disease and genetic
Major congenital malformations after first-trimester exposure to ACE inhibitors. N
aortopathy syndromes: management strategies and indications for surgery. Heart Engl J Med 2006;354:2443–51. https://doi.org/10.1056/NEJMoa055202
2017;103:952–66. https://doi.org/10.1136/heartjnl-2015-308626 1481.Mas-Stachurska A, Siegert AM, Batlle M, Gorbenko del Blanco D, Meirelles T, Rubies
1459. Milewicz DM, Braverman AC, De Backer J, Morris SA, Boileau C, Maumenee IH, et al. C, et al. Cardiovascular benefits of moderate exercise training in Marfan syndrome:
Marfan syndrome. Nat Rev Dis Primers 2021;7:64. https://doi.org/10.1038/s41572- insights from an animal model. J Am Heart Assoc 2017;6:e006438. https://doi.org/10.
021-00298-7 1161/jaha.117.006438
1460. Doyle JJ, Doyle AJ, Wilson NK, Habashi JP, Bedja D, Whitworth RE, et al. A deleteri- 1482.Gibson C, Nielsen C, Alex R, Cooper K, Farney M, Gaufin D, et al. Mild aerobic ex-
ous gene-by-environment interaction imposed by calcium channel blockers in Marfan ercise blocks elastin fiber fragmentation and aortic dilatation in a mouse model of
syndrome. Elife 2015;4:e08648. https://doi.org/10.7554/eLife.08648 Marfan syndrome associated aortic aneurysm. J Appl Physiol 2017;123:147–60.
1461. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol https://doi.org/10.1152/japplphysiol.00132.2017
versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med 1483.Selamet Tierney ES, Chung S, Stauffer KJ, Brabender J, Collins RT, Folk R, et al. Can 10
2014;371:2061–71. https://doi.org/10.1056/NEJMoa1404731 000 healthy steps a day slow aortic root dilation in pediatric patients with Marfan syn-
1462. Teixido-Tura G, Forteza A, Rodríguez-Palomares J, González Mirelis J, Gutiérrez L, drome? J Am Heart Assoc 2022;11:e027598. https://doi.org/10.1161/jaha.122.027598
Sánchez V, et al. Losartan versus atenolol for prevention of aortic dilation in patients 1484.Jouini S, Milleron O, Eliahou L, Jondeau G, Vitiello D. Effects of a personalized home-
with Marfan syndrome. J Am Coll Cardiol 2018;72:1613–8. https://doi.org/10.1016/j. based training program among patients suffering from Marfan syndrome: a pilot ran-
jacc.2018.07.052 domized and controlled study. Intractable Rare Dis Res 2021;10:263–8. https://doi.org/
1463. Pitcher A, Spata E, Emberson J, Davies K, Halls H, Holland L, et al. Angiotensin recep- 10.5582/irdr.2021.01080
tor blockers and β blockers in Marfan syndrome: an individual patient data 1485.Benninghoven D, Hamann D, von Kodolitsch Y, Rybczynski M, Lechinger J, Schroeder
meta-analysis of randomised trials. Lancet 2022;400:822–31. https://doi.org/10. F, et al. Inpatient rehabilitation for adult patients with Marfan syndrome: an observa-
1016/s0140-6736(22)01534-3 tional pilot study. Orphanet J Rare Dis 2017;12:127. https://doi.org/10.1186/s13023-
1464. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, 017-0679-0
et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a ran- 1486.Fuglsang S, Heiberg J, Hjortdal VE, Laustsen S. Exercise-based cardiac rehabilitation in
domized controlled trial. Eur Heart J 2013;34:3491–500. https://doi.org/10.1093/ surgically treated type-A aortic dissection patients. Scand Cardiovasc J 2017;51:
eurheartj/eht334 99–105. https://doi.org/10.1080/14017431.2016.1257149
1465. Nucera M, Kreibich M, Yildiz M, Berger T, Kolb RK, Kondov S, et al. Endovascular aor- 1487.Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, et al. A syndrome of
tic repair in patients with Marfan and Loeys-Dietz syndrome is safe and durable when altered cardiovascular, craniofacial, neurocognitive and skeletal development caused
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 161 ---
3698 E S C G u id e l in e s
by mutations in TGFBR1 or TGFBR2. Nat Genet 2005;37:275–81. https://doi.org/10. 1508.Girdauskas E, Geist L, Disha K, Kazakbaev I, Groß T, Schulz S, et al. Genetic abnor-
1038/ng1511 malities in bicuspid aortic valve root phenotype: preliminary results. Eur J
1488. MacCarrick G, Black JH, III, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, Cardiothorac Surg 2017;52:156–62. https://doi.org/10.1093/ejcts/ezx065
Guerrerio AL, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. 1509.Mansoorshahi S, Yetman AT, Bissell MM, Kim YY, Michelena H, Hui DS, et al. Whole
Genet Med 2014;16:576–87. https://doi.org/10.1038/gim.2014.11 exome sequencing uncovers the genetic complexity of bicuspid aortic valve in families
1489. Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, et al. with early onset complications. medRxiv 2024. https://doi.org/10.1101/2024.02.07.
Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic 24302406.
aortic aneurysm. Nat Genet 2012;44:922–7. https://doi.org/10.1038/ng.2349 1510.Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ,
1490. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, et al. TGFB2 muta- et al. International consensus statement on nomenclature and classification of the
tions cause familial thoracic aortic aneurysms and dissections associated with mild congenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional
systemic features of Marfan syndrome. Nat Genet 2012;44:916–21. https://doi.org/ and research purposes. Eur J Cardiothorac Surg 2021;60:448–76. https://doi.org/10.
10.1038/ng.2348 1093/ejcts/ezab038
1491. van der Linde D, van de Laar IM, Bertoli-Avella AM, Oldenburg RA, Bekkers JA, 1511.Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med
2014;370:1920–9. https://doi.org/10.1056/NEJMra1207059
Mattace-Raso FUS, et al. Aggressive cardiovascular phenotype of
1512.Yang LT, Ye Z, Wajih Ullah M, Maleszewski JJ, Scott CG, Padang R, et al. Bicuspid aor-
aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. J Am
tic valve: long-term morbidity and mortality. Eur Heart J 2023;44:4549–62. https://doi.
Coll Cardiol 2012;60:397–403. https://doi.org/10.1016/j.jacc.2011.12.052
org/10.1093/eurheartj/ehad477
1492. Hostetler EM, Regalado ES, Guo DC, Hanna N, Arnaud P, Muiño-Mosquera L, et al.
1513.Guo MH, Appoo JJ, Saczkowski R, Smith HN, Ouzounian M, Gregory AJ, et al.
SMAD3 pathogenic variants: risk for thoracic aortic disease and associated complica-
Association of mortality and acute aortic events with ascending aortic aneurysm: a
tions from the Montalcino Aortic Consortium. J Med Genet 2019;56:252–60. https://
systematic review and meta-analysis. JAMA Netw Open 2018;1:e181281. https://doi.
doi.org/10.1136/jmedgenet-2018-105583
org/10.1001/jamanetworkopen.2018.1281
1493. Renard M, Callewaert B, Malfait F, Campens L, Sharif S, del Campo M, et al. Thoracic
1514.Dayan V, Zuasnabar A, Citro R, Bossone E, Michelena HI, Parma G, et al. Aortopathy
aortic-aneurysm and dissection in association with significant mitral valve disease
and regurgitation in bicuspid valve patients increase the risk of aortopathy in relatives.
caused by mutations in TGFB2. Int J Cardiol 2013;165:584–7. https://doi.org/10.
Int J Cardiol 2019;286:117–20. https://doi.org/10.1016/j.ijcard.2019.03.031
1016/j.ijcard.2012.09.029
1515.Galian-Gay L, Carro Hevia A, Teixido-Turà G, Rodríguez Palomares J,
1494. Bertoli-Avella AM, Gillis E, Morisaki H, Verhagen JMA, de Graaf BM, van de Beek G,
Gutiérrez-Moreno L, Maldonado G, et al. Familial clustering of bicuspid aortic valve
et al. Mutations in a TGF-beta ligand, TGFB3, cause syndromic aortic aneurysms and and its relationship with aortic dilation in first-degree relatives. Heart 2019;105:
dissections. J Am Coll Cardiol 2015;65:1324–36. https://doi.org/10.1016/j.jacc.2015.01. 603–8. https://doi.org/10.1136/heartjnl-2018-313802
040 1516.Tessler I, Leshno M, Shmueli A, Shpitzen S, Durst R, Gilon D. Cost-effectiveness ana-
1495. Marsili L, Overwater E, Hanna N, Baujat G, Baars MJH, Boileau C, et al. Phenotypic lysis of screening for first-degree relatives of patients with bicuspid aortic valve. Eur
spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first re- Heart J Qual Care Clin Outcomes 2021;7:447–57. https://doi.org/10.1093/ehjqcco/
port of a homozygous patient. Clin Genet 2020;97:723–30. https://doi.org/10.1111/ qcab047
cge.13700 1517.Girdauskas E, Rouman M, Disha K, Espinoza A, Misfeld M, Borger MA, et al. Aortic
1496. Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, et al. Mutations in dissection after previous aortic valve replacement for bicuspid aortic valve disease.
smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissec- J Am Coll Cardiol 2015;66:1409–11. https://doi.org/10.1016/j.jacc.2015.07.022
tions. Nat Genet 2007;39:1488–93. https://doi.org/10.1038/ng.2007.6 1518.Masri A, Kalahasti V, Svensson LG, Alashi A, Schoenhagen P, Roselli EE, et al. Aortic
1497. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, et al. cross-sectional area/height ratio and outcomes in patients with bicuspid aortic valve
Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, and a dilated ascending aorta. Circ Cardiovasc Imaging 2017;10:e006249. https://doi.
stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet org/10.1161/circimaging.116.006249
2009;84:617–27. https://doi.org/10.1016/j.ajhg.2009.04.007 1519.Della Corte A, Michelena HI, Citarella A, Votta E, Piatti F, Lo Presti F, et al. Risk strati-
1498. van de Laar I, Arbustini E, Loeys B, Björck E, Murphy L, Groenink M, et al. European fication in bicuspid aortic valve aortopathy: emerging evidence and future perspec-
reference network for rare vascular diseases (VASCERN) consensus statement for tives. Curr Probl Cardiol 2021;46:100428. https://doi.org/10.1016/j.cpcardiol.2019.06.
the screening and management of patients with pathogenic ACTA2 variants. 002
Orphanet J Rare Dis 2019;14:264. https://doi.org/10.1186/s13023-019-1186-2 1520.Ye Z, Lane C, Beachey JD. Clinical outcomes in patients with bicuspid aortic valves
1499. Brownstein AJ, Ziganshin BA, Kuivaniemi H, Body Simon, Bale A, Elefteriades J. Genes and ascending aorta ≥50 mm under surveillance. JACC: Advances 2023;2:100626.
associated with thoracic aortic aneurysm and dissection: an update and clinical impli- https://doi.org/10.1016/j.jacadv.2023.100626.
cations. Aorta (Stamford) 2017;5:11–20. https://doi.org/10.12945/j.aorta.2017.17.003 1521.Michelena HI, Khanna AD, Mahoney D, Margaryan E, Topilsky Y, Suri RM, et al.
1500. Bray JJH, Freer R, Pitcher A, Kharbanda R. Family screening for bicuspid aortic valve Incidence of aortic complications in patients with bicuspid aortic valves. JAMA
and aortic dilatation: a meta-analysis. Eur Heart J 2023;44:3152–64. https://doi.org/10. 2011;306:1104–12. https://doi.org/10.1001/jama.2011.1286
1093/eurheartj/ehad320 1522.Michelena HI, Desjardins VA, Avierinos JF, Russo A, Nkomo VT, Sundt TM, et al.
1501. Michelena HI, Vallabhajosyula S, Prakash SK. Nosology spectrum of the bicuspid aor- Natural history of asymptomatic patients with normally functioning or minimally dys-
functional bicuspid aortic valve in the community. Circulation 2008;117:2776–84. tic valve condition: complex-presentation valvulo-aortopathy. Circulation 2020;142:
https://doi.org/10.1161/CIRCULATIONAHA.107.740878 294–9. https://doi.org/10.1161/circulationaha.120.046892
1523.Girdauskas E, Disha K, Secknus M, Borger M, Kuntze T. Increased risk of late aortic
1502. Prakash SK, Bosse Y, Muehlschlegel JD, Michelena HI, Limongelli G, Della Corte A,
events after isolated aortic valve replacement in patients with bicuspid aortic valve
et al. A roadmap to investigate the genetic basis of bicuspid aortic valve and its com-
insufficiency versus stenosis. J Cardiovasc Surg (Torino) 2013;54:653–9.
plications: insights from the International BAVCon (Bicuspid Aortic Valve
1524.Cortenbach KRG, Yosofi B, Rodwell L, Meek J, Patel R, Prakash SK, et al. Editor’s
Consortium). J Am Coll Cardiol 2014;64:832–9. https://doi.org/10.1016/j.jacc.2014.
choice—therapeutic options and outcomes in midaortic syndrome: a systematic re-
04.073
view and meta-analysis. Eur J Vasc Endovasc Surg 2023;65:120–30. https://doi.org/10.
1503. Fulmer D, Toomer K, Guo L, Moore K, Glover J, Moore R, et al. Defects in the
1016/j.ejvs.2022.10.017
exocyst-cilia machinery cause bicuspid aortic valve disease and aortic stenosis.
1525.Teo LL, Cannell T, Babu-Narayan SV, Hughes M, Mohiaddin RH. Prevalence of asso-
Circulation 2019;140:1331–41. https://doi.org/10.1161/circulationaha.119.038376
ciated cardiovascular abnormalities in 500 patients with aortic coarctation referred
1504. Luyckx I, Kumar AA, Reyniers E, Dekeyser E, Vanderstraeten K, Vandeweyer G, et al.
for cardiovascular magnetic resonance imaging to a tertiary center. Pediatr Cardiol
Copy number variation analysis in bicuspid aortic valve-related aortopathy identifies
2011;32:1120–7. https://doi.org/10.1007/s00246-011-9981-0
TBX20 as a contributing gene. Eur J Hum Genet 2019;27:1033–43. https://doi.org/10. 1526.Spaziani G, Girolami F, Arcieri L, Calabri GB, Porcedda G, Di Filippo C, et al. Bicuspid
1038/s41431-019-0364-y aortic valve in children and adolescents: a comprehensive review. Diagnostics (Basel)
1505. Xu YJ, Di RM, Qiao Q, Li X-M, Huang R-T, Xue S, et al. GATA6 loss-of-function mu- 2022;12:1751. https://doi.org/10.3390/diagnostics12071751
tation contributes to congenital bicuspid aortic valve. Gene 2018;663:115–20. https:// 1527.Raissadati A, Nieminen H, Haukka J, Sairanen H, Jokinen E. Late causes of death after
doi.org/10.1016/j.gene.2018.04.018 pediatric cardiac surgery: a 60-year population-based study. J Am Coll Cardiol 2016;68:
1506. Gehlen J, Stundl A, Debiec R, Fontana F, Krane M, Sharipova D, et al. Elucidation of the 487–98. https://doi.org/10.1016/j.jacc.2016.05.038
genetic causes of bicuspid aortic valve disease. Cardiovasc Res 2023;119:857–66. 1528.Panzer J, Bové T, Vandekerckhove K, De Wolf D. Hypertension after coarctation re-
https://doi.org/10.1093/cvr/cvac099 pair–a systematic review. Transl Pediatr 2022;11:270–9. https://doi.org/10.21037/tp-
1507. Gago-Díaz M, Brion M, Gallego P, Calvo F, Robledo-Carmona J, Saura D, et al. The 21-418
genetic component of bicuspid aortic valve and aortic dilation. An exome-wide asso- 1529.Batlivala SP, Goldstein BH. Current transcatheter approaches for the treatment of
ciation study. J Mol Cell Cardiol 2017;102:3–9. https://doi.org/10.1016/j.yjmcc.2016. aortic coarctation in children and adults. Interv Cardiol Clin 2019;8:47–58. https://
11.012 doi.org/10.1016/j.iccl.2018.08.001
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 162 ---
ESC Guidelines 3699
1530. Egbe AC, Miranda WR, Bonnichsen CR, Warnes CA, Connolly HM. Potential bene- 1551.Steinvil A, Sadeh B, Arbel Y, Justo D, Belei A, Borenstein N, et al. Prevalence and pre-
fits of ambulatory blood pressure monitoring in coarctation of aorta. J Am Coll Cardiol dictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll
2020;75:2089–90. https://doi.org/10.1016/j.jacc.2020.02.053 Cardiol 2011;57:779–83. https://doi.org/10.1016/j.jacc.2010.09.047
1531. Luitingh TL, Lee MGY, Jones B, Kowalski R, Weskamp Aguero S, Koleff J, et al. A 1552.Ahmed B, Al-Khaffaf H. Prevalence of significant asymptomatic carotid artery disease
cross-sectional study of the prevalence of exercise-induced hypertension in child- in patients with peripheral vascular disease: a meta-analysis. Eur J Vasc Endovasc Surg
hood following repair of coarctation of the aorta. Heart Lung Circ 2019;28:792–9. 2009;37:262–71. https://doi.org/10.1016/j.ejvs.2008.10.017
https://doi.org/10.1016/j.hlc.2018.03.015 1553.Mukherjee D, Eagle KA, Kline-Rogers E, Feldman LJ, Juliard J-M, Agnelli G, et al. Impact
1532. Brown ML, Burkhart HM, Connolly HM, Dearani JA, Cetta F, Li Z, et al. Coarctation of prior peripheral arterial disease and stroke on outcomes of acute coronary syn-
of the aorta: lifelong surveillance is mandatory following surgical repair. J Am Coll dromes and effect of evidence-based therapies (from the global registry of acute cor-
Cardiol 2013;62:1020–5. https://doi.org/10.1016/j.jacc.2013.06.016 onary events). Am J Cardiol 2007;100:1–6. https://doi.org/10.1016/j.amjcard.2007.02.
1533. Somers T, Nies H, van Kimmenade RRJ, Bosboom DGH, Geuzebroek GSC, Morshuis 046
WJ. Necessity of life-long follow-up after surgery for coarctation of the aorta: a case 1554.Fowkes FG, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of athero-
thrombosis in 8891 patients with or at risk of vascular disease: results of the inter-
series of very late false aneurysm formation. Eur Heart J Case Rep 2022;6:ytac073.
national AGATHA study. Eur Heart J 2006;27:1861–7. https://doi.org/10.1093/
https://doi.org/10.1093/ehjcr/ytac073
eurheartj/ehl114
1534. Padang R, Dennis M, Semsarian C, Bannon PG, Tanous DJ, Celermajer DS, et al.
1555.Durand DJ, Perler BA, Roseborough GS, Grega MA, Borowicz LM, Baumgartner WA,
Detection of serious complications by MR imaging in asymptomatic young adults
et al. Mandatory versus selective preoperative carotid screening: a retrospective ana-
with repaired coarctation of the aorta. Heart Lung Circ 2014;23:332–8. https://doi.
lysis. Ann Thorac Surg 2004;78:159–66; discussion 159–66. https://doi.org/10.1016/j.
org/10.1016/j.hlc.2013.10.055
athoracsur.2004.02.024
1535. Bhatt AB, Lantin-Hermoso MR, Daniels CJ, Jaquiss R, Landis BJ, Marino BS, et al.
1556.Naylor AR, Mehta Z, Rothwell PM, Bell PR. Carotid artery disease and stroke during
Isolated coarctation of the aorta: current concepts and perspectives. Front
coronary artery bypass: a critical review of the literature. Eur J Vasc Endovasc Surg
Cardiovasc Med 2022;9:817866. https://doi.org/10.3389/fcvm.2022.817866
2002;23:283–94. https://doi.org/10.1053/ejvs.2002.1609
1536. Erben Y, Oderich GS, Verhagen HJM, Witsenburg M, van den Hoven AT, Debus ES,
1557.Jens S, Koelemay MJ, Reekers JA, Bipat S. Diagnostic performance of computed tom-
et al. Multicenter experience with endovascular treatment of aortic coarctation in
ography angiography and contrast-enhanced magnetic resonance angiography in pa-
adults. J Vasc Surg 2019;69:671–9.e1. https://doi.org/10.1016/j.jvs.2018.06.209
tients with critical limb ischaemia and intermittent claudication: systematic review and
1537. Meijs TA, Warmerdam EG, Slieker MG, Krings GJ, Molenschot MMC, Meijboom FJ,
meta-analysis. Eur Radiol 2013;23:3104–14. https://doi.org/10.1007/s00330-013-
et al. Medium-term systemic blood pressure after stenting of aortic coarctation: a sys- 2933-8
tematic review and meta-analysis. Heart 2019;105:1464–70. https://doi.org/10.1136/ 1558.Illuminati G, Schneider F, Greco C, Mangieri E, Schiariti M, Tanzilli G, et al. Long-term
heartjnl-2019-314965 results of a randomized controlled trial analyzing the role of systematic pre-operative
1538. Layton KF, Kallmes DF, Cloft HJ, Lindell EP, Cox VS. Bovine aortic arch variant in hu- coronary angiography before elective carotid endarterectomy in patients with
mans: clarification of a common misnomer. AJNR Am J Neuroradiol 2006;27:1541–2. asymptomatic coronary artery disease. Eur J Vasc Endovasc Surg 2015;49:366–74.
1539. Berko NS, Jain VR, Godelman A, Stein EG, Ghosh S, Haramati LB. Variants https://doi.org/10.1016/j.ejvs.2014.12.030
and anomalies of thoracic vasculature on computed tomographic angiography in 1559.Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, et al. Mortality
adults. J Comput Assist Tomogr 2009;33:523–8. https://doi.org/10.1097/RCT. benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral ar-
0b013e3181888343 tery disease. J Am Coll Cardiol 2021;78:14–23. https://doi.org/10.1016/j.jacc.2021.04.
1540. Dumfarth J, Peterss S, Kofler M, Plaikner M, Ziganshin BA, Schachner T, et al. In 083
DeBakey type I aortic dissection, bovine aortic arch is associated with arch tears 1560.Aboyans V, Lacroix P, Postil A, Guilloux J, Rollé F, Cornu E, et al. Subclinical peripheral
and stroke. Ann Thorac Surg 2017;104:2001–8. https://doi.org/10.1016/j.athoracsur. arterial disease and incompressible ankle arteries are both long-term prognostic fac-
2017.05.026 tors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2005;46:
1541. Hornick M, Moomiaie R, Mojibian H, Ziganshin B, Almuwaqqat Z, Lee ES, et al. 815–20. https://doi.org/10.1016/j.jacc.2005.05.066
‘Bovine’ aortic arch—a marker for thoracic aortic disease. Cardiology 2012;123: 1561.Rihal CS, Sutton-Tyrrell K, Guo P, Keller NM, Jandova R, Sellers MA, et al. Increased
116–24. https://doi.org/10.1159/000342071 incidence of periprocedural complications among patients with peripheral vascular
1542. Yousef S, Singh S, Alkukhun A, Alturkmani B, Mori M, Chen J, et al. Variants of the disease undergoing myocardial revascularization in the bypass angioplasty revascular-
aortic arch in adult general population and their association with thoracic aortic an- ization investigation. Circulation 1999;100:171–7. https://doi.org/10.1161/01.cir.100.
eurysm disease. J Card Surg 2021;36:2348–54. https://doi.org/10.1111/jocs.15563 2.171
1543. Tanaka A, Milner R, Ota T. Kommerell’s diverticulum in the current era: a compre- 1562.Aboyans V, Lacroix P. Indications for carotid screening in patients with coronary ar-
hensive review. Gen Thorac Cardiovasc Surg 2015;63:245–59. https://doi.org/10.1007/ tery disease. Presse Med 2009;38:977–86. https://doi.org/10.1016/j.lpm.2009.02.015
s11748-015-0521-3 1563.Collet JP, Cayla G, Ennezat PV, Leclercq F, Cuisset T, Elhadad S, et al. Systematic de-
1544. Upchurch GR, Jr, Escobar GA, Azizzadeh A, Beck AW, Conrad MF, Matsumura JS, tection of polyvascular disease combined with aggressive secondary prevention in pa-
et al. Society for Vascular Surgery clinical practice guidelines of thoracic endovascular tients presenting with severe coronary artery disease: the randomized AMERICA
aortic repair for descending thoracic aortic aneurysms. J Vasc Surg 2021;73:55s–83s. study. Int J Cardiol 2018;254:36–42. https://doi.org/10.1016/j.ijcard.2017.11.081
1564.Neufang A, Dorweiler B, Espinola-Klein C, Savvidis S, Doemland M, Schotten S, et al. https://doi.org/10.1016/j.jvs.2020.05.076
Outcomes of complex femorodistal sequential autologous vein and biologic pros- 1545. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW,
thesis composite bypass grafts. J Vasc Surg 2014;60:1543–53. https://doi.org/10.
et al. Peripheral arterial disease detection, awareness, and treatment in primary
1016/j.jvs.2014.07.103
care. JAMA 2001;286:1317–24. https://doi.org/10.1001/jama.286.11.1317
1565.Calvet D, Touzé E, Varenne O, Sablayrolles J-L, Weber S, Mas J-L. Prevalence of
1546. Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, et al.
asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS
Influence of polyvascular disease on cardiovascular event rates. Insights from the
study. Circulation 2010;121:1623–9. https://doi.org/10.1161/circulationaha.109.
REACH registry. Vasc Med 2010;15:259–65. https://doi.org/10.1177/1358863x
906958
10373299
1566.Hofmann R, Kypta A, Steinwender C, Kerschner K, Grund M, Leisch F. Coronary
1547. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Rother J, et al. Three-year
angiography in patients undergoing carotid artery stenting shows a high incidence
follow-up and event rates in the international REduction of atherothrombosis for
of significant coronary artery disease. Heart 2005;91:1438–41. https://doi.org/10.
continued health registry. Eur Heart J 2009;30:2318–26. https://doi.org/10.1093/
1136/hrt.2004.050906
eurheartj/ehp355
1567.Masabni K, Raza S, Blackstone EH, Gornik HL, Sabik JF, III. Does preoperative carotid
1548. van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, et al.
stenosis screening reduce perioperative stroke in patients undergoing coronary ar-
Identification of vascular patients at very high risk for recurrent cardiovascular events: tery bypass grafting? J Thorac Cardiovasc Surg 2015;149:1253–60. https://doi.org/10.
validation of the current ACC/AHA very high risk criteria. Eur Heart J 2017;38: 1016/j.jtcvs.2015.02.003
3211–8. https://doi.org/10.1093/eurheartj/ehx102 1568.Klarin D, Patel VI, Zhang S, Xian Y, Kosinski A, Yerokun B, et al. Concomitant carotid
1549. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, et al. Polyvascular endarterectomy and cardiac surgery does not decrease postoperative stroke rates. J
disease and long-term cardiovascular outcomes in older patients with Vasc Surg 2020;72:589–96.e3. https://doi.org/10.1016/j.jvs.2019.10.072
non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes 1569.D’Agostino RS, Svensson LG, Neumann DJ, Balkhy HH, Williamson WA, Shahian
2012;5:541–9. https://doi.org/10.1161/circoutcomes.111.964379 DM. Screening carotid ultrasonography and risk factors for stroke in coronary artery
1550. van der Meer MG, Cramer MJ, van der Graaf Y, Appelman Y, Doevendans PA, surgery patients. Ann Thorac Surg 1996;62:1714–23. https://doi.org/10.1016/s0003-
Nathoe HM. The impact of polyvascular disease on long-term outcome in percutan- 4975(96)00885-5
eous coronary intervention patients. Eur J Clin Invest 2014;44:231–9. https://doi.org/ 1570.Weissler EH, Jones WS, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, et al.
10.1111/eci.12222 Polyvascular disease: a narrative review of current evidence and a consideration of
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
--- Страница 163 ---
3700 E S C G u id e l in e s
the role of antithrombotic therapy. Atherosclerosis 2020;315:10–7. https://doi.org/10. 1585.Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical pro-
1016/j.atherosclerosis.2020.11.001 file, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.
1571. Alkhalil M, Kuzemczak M, Whitehead N, Kavvouras C, Džavík V. Meta-analysis of in- Am Heart J 2008;156:855–63, 863.e2. https://doi.org/10.1016/j.ahj.2008.06.029
tensive lipid-lowering therapy in patients with polyvascular disease. J Am Heart Assoc 1586.Olesen JB, Gislason GH, Torp-Pedersen C, Lip GY. Atrial fibrillation and vascular dis-
2021;10:e017948. https://doi.org/10.1161/jaha.120.017948 ease—a bad combination. Clin Cardiol 2012;35:15–20. https://doi.org/10.1002/clc.
1572. Ward RP, Goonewardena SN, Lammertin G, Lang RM. Comparison of the frequency 20955
of abnormal cardiac findings by echocardiography in patients with and without per- 1587.Parvar SL, Thiyagarajah A, Nerlekar N, King P, Nicholls SJ. A systematic review and
ipheral arterial disease. Am J Cardiol 2007;99:499–503. https://doi.org/10.1016/j. meta-analysis of gender differences in long-term mortality and cardiovascular events
amjcard.2006.09.102 in peripheral artery disease. J Vasc Surg 2021;73:1456–65.e7. https://doi.org/10.1016/
1573. Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The j.jvs.2020.09.039
prevalence of treatable left ventricular systolic dysfunction in patients who present 1588.Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often
with noncardiac vascular episodes: a case-control study. J Am Coll Cardiol 2002;39: overlapping clinical syndromes. Thromb Haemost 2010;104:657–63. https://doi.org/
219–24. https://doi.org/10.1016/s0735-1097(01)01725-9 10.1160/th10-05-0332
1574. Samsky MD, Hellkamp A, Hiatt WR, Fowkes FGR, Baumgartner I, Berger JS, et al. 1589.Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and pre-
Association of heart failure with outcomes among patients with peripheral artery dis- disposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol
ease: insights from EUCLID. J Am Heart Assoc 2021;10:e018684. https://doi.org/10. 1998;82:2n–9n. https://doi.org/10.1016/s0002-9149(98)00583-9
1161/jaha.120.018684 1590.Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent
1575. Kahan T. The importance of myocardial fibrosis in hypertensive heart disease. J risk factors for atrial fibrillation in a population-based cohort. The Framingham heart
Hypertens 2012;30:685–7. https://doi.org/10.1097/HJH.0b013e328350e5db study. JAMA 1994;271:840–4.
1576. O’Rourke MF, Safar ME, Dzau V. The Cardiovascular Continuum extended: aging ef- 1591.Zhu J, Tan X, Zhou JZ. Peripheral artery disease and clinical outcomes in patients with
fects on the aorta and microvasculature. Vasc Med 2010;15:461–8. https://doi.org/10. atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2021;44:1050–7.
1177/1358863x10382946 https://doi.org/10.1002/clc.23678
1577. Duscha BD, Annex BH, Green HJ, Pippen AM, Kraus WE. Deconditioning fails to ex- 1592.Olesen JB, Lip GY, Lane DA, Køber L, Hansen ML, Karasoy D, et al. Vascular disease
plain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med 2012;125:
Cardiol 2002;39:1170–4. https://doi.org/10.1016/s0735-1097(02)01740-0 826.e13–23. https://doi.org/10.1016/j.amjmed.2011.11.024
1578. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, et al. 1593.Skelding KA, Yakubov SJ, Kleiman NS, Reardon MJ, Adams DH, Huang J, et al.
Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle Transcatheter aortic valve replacement versus surgery in women at high risk for sur-
metabolism in heart failure. Circulation 1992;85:1364–73. https://doi.org/10.1161/ gical aortic valve replacement (from the CoreValve US High Risk Pivotal Trial). Am J
01.cir.85.4.1364 Cardiol 2016;118:560–6. https://doi.org/10.1016/j.amjcard.2016.05.051
1579. Hedberg P, Hammar C, Selmeryd J, Viklund J, Leppert J, Hellberg A, et al. Left ven- 1594.Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J, et al.
tricular systolic dysfunction in outpatients with peripheral atherosclerotic vascular Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J
disease: prevalence and association with location of arterial disease. Eur J Heart Fail Med 2012;366:1705–15. https://doi.org/10.1056/NEJMoa1114705
2014;16:625–32. https://doi.org/10.1002/ejhf.95 1595.Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter
1580. Sandesara PB, Hammadah M, Samman-Tahhan A, Kelli HM, O’Neal WT. Peripheral aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.
artery disease and risk of adverse outcomes in heart failure with preserved ejection N Engl J Med 2010;363:1597–607. https://doi.org/10.1056/NEJMoa1008232
fraction. Clin Cardiol 2017;40:692–6. https://doi.org/10.1002/clc.22716 1596.Reindl M, Lechner I, Holzknecht M, Tiller C, Fink P, Oberhollenzer F, et al. Cardiac
1581. Nakamura Y, Kunii H, Yoshihisa A, Takiguchi M, Shimizu T, Yamauchi H, et al. Impact magnetic resonance imaging versus computed tomography to guide transcatheter
of peripheral artery disease on prognosis in hospitalized heart failure patients. Circ J aortic valve replacement (TAVR-CMR): a randomized, open-label, non-inferiority
2015;79:785–93. https://doi.org/10.1253/circj.CJ-14-1280 trial. Circulation 2023;148:1220–30. https://doi.org/10.1161/CIRCULATIONAHA.
1582. Inglis SC, Bebchuk J, Al-Suhaim SA, Case J, Pfeffer MA, Solomon SD, et al. Peripheral 123.066498
artery disease and outcomes after myocardial infarction: an individual-patient 1597.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.
meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation devel-
VALIANT. Int J Cardiol 2013;168:1094–101. https://doi.org/10.1016/j.ijcard.2012.11. oped in collaboration with the European Association for Cardio-Thoracic Surgery
033 (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of
1583. Jones WS, Clare R, Ellis SJ, Mills JS, Fischman DL, Kraus WE, et al. Effect of peripheral the European Society of Cardiology (ESC) developed with the special contribution
arterial disease on functional and clinical outcomes in patients with heart failure (from of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;
HF-ACTION). Am J Cardiol 2011;108:380–4. https://doi.org/10.1016/j.amjcard.2011. 42:373–498. https://doi.org/10.1093/eurheartj/ehaa612
03.057 1598.Fanaroff AC, Manandhar P, Holmes DR, Cohen DJ, Harrison JK, Hughes GC, et al.
1584. van Straten AH, Firanescu C, Soliman Hamad MA, Tan MESH, ter Woorst JFJ, Peripheral artery disease and transcatheter aortic valve replacement outcomes: a re-
Martens EJ, et al. Peripheral vascular disease as a predictor of survival after coronary port from the Society of Thoracic Surgeons/American College of Cardiology
artery bypass grafting: comparison with a matched general population. Ann Thorac Transcatheter Therapy Registry. Circ Cardiovasc Interv 2017;10:e005456. https://doi.
Surg 2010;89:414–20. https://doi.org/10.1016/j.athoracsur.2009.11.036 org/10.1161/CIRCINTERVENTIONS.117.005456
Downloaded
from
https://academic.oup.com/eurheartj/article/45/36/3538/7738955
by
guest
on
22
January
2026
